<SEC-DOCUMENT>0001193125-20-026787.txt : 20200206
<SEC-HEADER>0001193125-20-026787.hdr.sgml : 20200206
<ACCEPTANCE-DATETIME>20200206161643
ACCESSION NUMBER:		0001193125-20-026787
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20200206
DATE AS OF CHANGE:		20200206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Schrodinger, Inc.
		CENTRAL INDEX KEY:			0001490978
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				954284541
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-235890
		FILM NUMBER:		20582896

	BUSINESS ADDRESS:	
		STREET 1:		120 WEST 45TH STREET
		STREET 2:		17TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		503-299-1150

	MAIL ADDRESS:	
		STREET 1:		120 WEST 45TH STREET
		STREET 2:		17TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d766269d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><I>PROSPECTUS </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4)<BR>Registration No. 333-235890 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>11,882,352 Shares </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g17h96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Common Stock </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT"><B><I>We are offering 11,882,352
shares of our common stock. This is our initial public offering and no public market currently exists for our common stock. The initial public offering price is $17.00 per share. Our common stock has been approved for listing on the Nasdaq Global
Select Market under the symbol &#147;SDGR.&#148; </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT"><B><I>We are an &#147;emerging growth
company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, as such, we may elect to comply with reduced public company reporting requirements for this prospectus and future filings. See
&#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company.&#148; </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Investing in our common
stock involves a high degree of risk. See &#147;<A HREF="#rom766269_2">Risk Factors</A>&#148; beginning on page 19 of this prospectus. </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT"><B><I>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>PER&nbsp;SHARE</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>TOTAL</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Initial public offering price</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$17.00</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$201,999,984</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Underwriting discounts and commissions (1)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$1.19</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$14,139,999</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Proceeds, before expenses, to us</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$15.81</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$187,859,985</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See &#147;Underwriters&#148; for a description of all compensation payable to the underwriters.
</I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We have granted the underwriters an option for a period of 30 days to purchase up to 1,782,352 additional shares of common
stock. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The underwriters expect to deliver the shares of common stock against payment in New York, New York on or about February 10, 2020. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>MORGAN&nbsp;STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"><I>BofA&nbsp;SECURITIES</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"><I>JEFFERIES</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I>BMO&nbsp;CAPITAL&nbsp;MARKETS</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prospectus dated February 5, 2020 </I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_3">Cautionary Note Regarding <FONT STYLE="white-space:nowrap">Forward-Looking</FONT> Statements
 and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_8">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of
 Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_12">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_13">Transactions with Related Persons</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_15">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_16">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_17">Material U.S. Federal Income and Estate Tax Considerations for <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_18">Underwriters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_21">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom766269_22">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor
the underwriters have authorized anyone to provide you with any information or to make any representation other than as contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus we may authorize
to be delivered or made available to you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy,
shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale
of shares of our common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside the United States: we have not, and the underwriters have not, done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own or have rights to trademarks, service marks, and trade names that we use in connection with the operation of our business, including
our corporate name, logos and website names. Other trademarks, service marks, and trade names appearing in this prospectus are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, and trade names
referred to in this prospectus are listed without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should
consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth in the
sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Unless the context otherwise requires, we use the terms &#147;company,&#148; &#147;we,&#148;
&#147;us&#148; and &#147;our&#148; in this prospectus to refer to Schr&ouml;dinger, Inc. and its consolidated subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are transforming the way therapeutics and materials are discovered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials
applications more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods. Our software is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories
around the world, and we are the leading provider of computational software solutions for drug discovery. We also apply our computational platform to a broad pipeline of drug discovery programs in collaboration with biopharmaceutical companies, some
of which we <FONT STYLE="white-space:nowrap">co-founded.</FONT> In addition, we are using our platform to advance a pipeline of internal, wholly-owned drug discovery programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Traditional drug discovery and development efforts have become increasingly complex, lengthy, capital-intensive, and are prone to high failure
rates. Traditional drug discovery relies upon many rounds of costly and time-consuming manual molecule design, chemical synthesis, and experimental testing. One of the primary reasons for long timelines, high costs, and high failure rates in drug
discovery is that predicting properties of molecules in advance of chemical synthesis is extremely complex and not amenable to traditional approaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past 30 years and with the concerted efforts of hundreds of our scientists and software engineers, we have developed a physics-based
computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy. This key capability enables drug discovery teams to design and selectively synthesize molecules with more optimal properties,
reducing the average time and costs required to identify a development candidate and increasing the probability that a drug discovery program will enter clinical development. Furthermore, we believe that development candidates with more optimized
property profiles will have a higher probability of success in clinical development. Additionally, since the physics underlying the properties of drug molecules and materials is the same, we have been able to extend our computational platform to
materials science applications in fields such as aerospace, energy, semiconductors, and electronic displays. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer our customers a
variety of software solutions that accelerate all stages of molecule discovery, design, and optimization. In 2018, all of the top 20 pharmaceutical companies, measured by revenue, licensed our solutions, accounting for $22.0 million, or 33%, of our
2018 revenue. The widespread adoption of our software, supported by our global team of sales, technical, and scientific personnel, has driven steady growth in our software revenue. Biopharmaceutical companies are increasingly adopting our software
at a larger scale, and we anticipate this <FONT STYLE="white-space:nowrap">scaling-up</FONT> will drive future revenue growth. Our ability to expand within our customer base is best demonstrated by the increasing number of our customers with an
annual contract value, or ACV, in excess of $100,000. We had 87, 103, and 122 such customers, which represented 79%, 75%, and 77% of our total ACV, for the years ended December&nbsp;31, 2016, 2017, and 2018, respectively. In addition, our customer
retention rate for our customers with an ACV over $100,000 was over 96% for the year ended December&nbsp;31, 2018 and each of the previous five fiscal years. We believe the growth in the number of our customers demonstrates that companies
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are increasingly recognizing the power and efficiency of our platform while the retention in this group is indicative of the continued value of our platform. See &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#151;Key Factors Affecting Our Performance&#148; for additional information regarding ACV and customer retention rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also leverage our platform and capabilities across a portfolio of collaborative and wholly-owned drug discovery programs spanning a wide
range of disease targets and indications. Our drug discovery group is comprised of a multidisciplinary team of approximately 70 experts in protein science, biochemistry, biophysics, medicinal and computational chemistry, and discovery scientists
with expertise in preclinical and early clinical development. We are currently collaborating on more than 25 drug discovery programs with more than ten different biopharmaceutical companies, including a number of companies we <FONT
STYLE="white-space:nowrap">co-founded.</FONT> These collaborations generate drug discovery revenue, including research funding payments, and discovery and development milestones, and have the potential to produce additional milestone payments,
option fees, and future royalties. Furthermore, since <FONT STYLE="white-space:nowrap">mid-2018,</FONT> we have launched five internal, wholly-owned programs. We are leveraging our computational platform with the goal of rapidly advancing the
discovery of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapies. Our current programs are focused
on discovering and developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. In the future we expect to expand into other therapeutic areas. We plan to begin to initiate investigational new drug, or IND,
-enabling studies for our programs by the first half of&nbsp;2021. While our revenue-generating collaborations are an important component of our business, our strategy is to pursue an increasing number of wholly-owned programs, and strategically
evaluate on a program-by-program basis entering into clinical development ourselves or out-licensing programs to maximize commercial opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generated revenue of $55.7&nbsp;million and $66.6&nbsp;million in 2017 and 2018, respectively, representing year-over-year growth of 20%.
We generated revenue of $49.2&nbsp;million and $59.7&nbsp;million for the nine months ended September&nbsp;30, 2018 and 2019, respectively, representing period-over-period growth of 21%. Our net loss was $17.4&nbsp;million, $28.4&nbsp;million,
$22.1&nbsp;million, and $18.5&nbsp;million for the years ended December&nbsp;31, 2017 and 2018 and the nine months ended September&nbsp;30, 2018 and 2019, respectively. For information regarding our estimated preliminary results for the three months
and year ended December 31, 2019, see &#147;&#151;Estimated Preliminary Results&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Industry Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Traditional drug discovery and development efforts have become increasingly complex, lengthy, capital-intensive, and are prone to high failure
rates. Traditional drug discovery involves experimental screening of existing libraries of molecules to find molecules with detectable activity, or &#147;hit molecules,&#148; followed by many rounds of chemical synthesis to attempt to optimize those
hit molecules to a development candidate that can be advanced into clinical development. Efforts to optimize initial hit molecules for a drug discovery project involve costly and iterative synthesis and testing of molecules seeking to identify a
molecule with the required property profile. The optimal profile has the acceptable balance of properties such as potency, selectivity, solubility, bioavailability, half-life, permeability, drug-drug interaction potential, synthesizability, and
toxicity. These properties are often inversely correlated, meaning that optimizing one property often de-optimizes others. The challenge of optimizing hit molecules is amplified by the limited number of molecules that can be feasibly tested across
these properties with traditional methods. As a result, this optimization process often fails to yield a molecule with a satisfactory property profile to be a development candidate, which is why many drug discovery programs fail to advance into
clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been many attempts to improve the efficiency of the drug discovery process by using computational
methods to predict properties of molecules. One of the primary computational methods that many companies have attempted to deploy is machine learning, often referred to as artificial intelligence, or AI. One of
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the main benefits of machine learning is its ability to rapidly process data at scale. However, machine learning on its own has significant limitations and has therefore had a limited impact on
improving the efficiency of the drug discovery process. Machine learning requires input data, referred to as a training set, to build a predictive model. This model is expected to accurately predict properties of molecules similar to the training
set, but cannot extrapolate to molecules that are not similar to the training set. Accordingly, since the number of possible molecules that could be synthesized is effectively infinite, machine learning can only cover a minuscule fraction of the
total number of molecules that could potentially be synthesized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The other primary computational method that has been attempted involves
using fundamental, &#147;first-principles&#148; physics-based methods, which require a deep and thorough understanding of the specific property to be computed. However, physics-based methods are difficult to develop and can be slow compared to
machine learning. Further, to apply such methods to design molecules that will bind with high affinity to a particular protein target, the three-dimensional structure of that protein must be generated with sufficient atomic detail to enable
application of these physics-based approaches, which is referred to as being &#147;structurally enabled,&#148; and such structures have been historically difficult to obtain. Another factor preventing computational chemistry from realizing its
promise has been limited compute speed. However, despite all of these challenges, physics-based methods have a significant advantage over machine learning in that they do not require a training set and can, in principle, compute properties for any
molecule. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the
past 30 years and with the concerted effort of hundreds of our scientists and software engineers, we have developed a computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy. We have built
our platform on a foundation of rigorous, physics-based methods, combined with the rapid data processing and scaling advantages of machine learning, that together provide a significant advantage over traditional methods. We believe that
physics-based simulation is at a strategic inflection point as a result of the increased availability of massive computing power, combined with a more sophisticated understanding of models and algorithms and the growing availability of
high-resolution protein structures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our computational platform provides the following significant technological advantages over
traditional approaches to drug discovery, all of which enable shortening timelines, decreasing costs, and increasing the probability of success of drug discovery efforts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Speed</B>. Our platform is able to evaluate molecules in hours rather than the weeks that it typically takes
to synthesize and assay molecules in the laboratory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Scale</B>. Our platform can explicitly evaluate billions of molecules per week, whereas traditionally operated
discovery projects only synthesize approximately one thousand molecules per year, thereby increasing the probability that we find a novel molecule with the desired property profile. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Quality</B>. In a peer-reviewed study, our platform was tested against traditional methods for selecting
tight-binding molecules and resulted in an eight-fold increase in the number of molecules with the desired affinity. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates the advantages in time, cost, and molecule quality of our
computational drug design approach over traditional drug discovery approaches. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g12k92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered. Our physics-based
approach and differentiated software solutions enable the discovery of novel molecules for drug development and materials applications more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods.
We license our software to biopharmaceutical and industrial companies, government laboratories, and academic institutions globally. We are also using our software and internal capabilities across a diverse portfolio of drug discovery programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategies for fulfilling our mission are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advance the science that underlies our computational platform</I></B>: We have emerged as the leader in the
field of physics-based computational drug discovery, and we believe our computational platform is far ahead of that of our nearest competitors. As of December 31, 2019, we had approximately 400 employees, roughly half of whom have Ph.D. degrees. We
intend to maintain our industry-leading position by introducing new capabilities and refining our software to further strengthen our technology and advance the science underlying our platform. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerate growth of our software business</I></B>: We have experienced steady growth in our software
revenues, achieving $59.9&nbsp;million in revenue in 2018 and $49.2&nbsp;million in revenue in the nine months ended September 30, 2019, primarily driven by broad adoption of our software solutions by the biopharmaceutical industry and the expansion
of our materials science business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Life science software business</I>: In 2018, all of the top 20 pharmaceutical companies, measured by revenue,
used our software, accounting for $22.0 million, or 33%, of our 2018 revenue, and these companies have been our customers for an average of 15 years. However, we estimate that even our very largest customers are currently purchasing only enough
software to optimally enable one or two drug discovery projects, which typically represents a small fraction of their drug discovery </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
projects. Our ability to expand within our customer base is best demonstrated by the increasing number of our customers with an ACV of over $100,000. We had 87, 103, and 122 such customers for
the years ended December&nbsp;31, 2016, 2017, and 2018, respectively. In addition, we had eight, nine, and 11 customers for the years ended December&nbsp;31, 2016, 2017, and 2018, respectively, with an ACV of over $1.0&nbsp;million. We intend to
leverage our existing relationships with our customers to drive larger-scale adoption of our solutions. Further, we believe there remains a large opportunity for growth as there are thousands of biopharmaceutical companies that could benefit from
our solutions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Materials science software business</I>: Beyond drug discovery, our solutions can be leveraged for broad
application to address industrial challenges in molecule design, including in the fields of aerospace, energy, semiconductors and electronic displays. We intend to continue growing this business through increased brand awareness and a <FONT
STYLE="white-space:nowrap">build-out</FONT> of industry-specific functionality. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerate growth of our drug discovery business</I></B>: We also apply our computational platform across a
diversified portfolio of more than 30 drug discovery programs through collaborations with companies we have <FONT STYLE="white-space:nowrap">co-founded,</FONT> with biopharmaceutical companies, and through our own internal efforts on wholly-owned
programs. Our collaborations generate revenues through research funding, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical milestones as well as the potential for option fees, commercial milestones, and future royalties. We also
benefit from equity positions in our <FONT STYLE="white-space:nowrap">co-founded</FONT> companies. Our drug discovery group comprises approximately 70 scientists, including biologists, medicinal chemists, biochemists, crystallographers, drug
metabolism and pharmacokinetics scientists, and pharmacologists. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are actively working with our collaborators to discover novel therapies. We also intend to add new
collaborations that offer scientific synergies and favorable economic terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We plan to progress our existing wholly-owned programs and continue to add new programs that leverage our
computational platform. As we progress these programs, we will strategically evaluate on a program-by-program basis entering into clinical development ourselves or out-licensing programs to maximize commercial opportunities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leverage the synergies between our businesses</I></B>: We believe that there are significant synergies
within our business. We leverage the feedback that we receive from our software customers, collaborators, and internal drug discovery experts to improve the functionality of our platform, which we believe supports increased customer adoption of our
solutions and more rapid advancement of our collaborative and wholly-owned drug discovery programs. In addition, the success of our collaborators in advancing drug discovery programs provides significant validation of our platform and approach,
which we believe increases the attractiveness of our platform to customers, helps us establish new collaborations, and validates the potential of our own internal drug discovery programs. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g46q96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Central to our ability to pursue these distinct lines of business is a firewall policy consisting of a set
of well-established protocols and technology measures designed to ensure that the intellectual property of our software customers and drug discovery collaborators remains confidential and segregated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Software Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are the leading
provider of computational software solutions for drug discovery to the biopharmaceutical industry. In 2018, all of the top 20 pharmaceutical companies measured by revenue were our customers, accounting for $22.0 million, or 33%, of our 2018 revenue.
Additionally, in 2018, our software was used by researchers around the world at more than 1,250 academic institutions. The widespread adoption of our software is supported by an approximately <FONT STYLE="white-space:nowrap">130-person</FONT> global
team of sales, technical, and scientific personnel. Our direct sales operations span across the United States, Europe, Japan and India, and we have sales distributors in other important markets, including China and South Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a diverse and large existing customer base, ranging from startup biotechnology companies to the largest global pharmaceutical
companies as well as an increasing number of materials science customers. Our ten largest software customers represented approximately 24% of our software revenue in 2018, and no single software customer represented more than 5% of our revenue. We
continue to expand our customer base as we promote the education and recognition of the potential of our computational platform across industries. As of December&nbsp;31, 2018, we had approximately 1,150 active customers, which we define as the
number of customers who had an ACV of at least $1,000 in a given fiscal year, and the figure below shows the growth in the number of our active customers since 2013. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g58d70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there is significant opportunity to expand the adoption of our platform within our growing
customer base. Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate that this <FONT STYLE="white-space:nowrap">scaling-up</FONT> will drive future revenue growth. Our ability to expand within our
customer base is best demonstrated by the increasing number of our customers with an ACV over $100,000. We had 87, 103, and 122 of such customers for the years ended December&nbsp;31, 2016, 2017, and 2018, respectively. In addition, for the year
ended December&nbsp;31, 2018, we had 11 customers with ACV of $1.0&nbsp;million or more, up from nine and eight customers as of December&nbsp;31, 2017 and 2016, respectively. We believe biopharmaceutical companies are increasingly recognizing and
applying the power and efficiency of our platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we believe our sales and marketing approach and the quality of our
software solutions help us cultivate longstanding relationships and reoccurring sales. This is demonstrated by the length of our key relationships, with the average tenure of our 10 largest customers in 2018 being over 17 years. Furthermore, our
ability to expand our customer relationships over time is exemplified by our ability to retain our customers with an ACV over $100,000. For the year ended December&nbsp;31, 2018 and for each of the previous five fiscal years, our year-over-year
customer retention rate for our customers with an ACV over $100,000 was over 96%. We believe the continued expansion of our customer base coupled with our ability to expand our customers&#146; use of our software will continue to drive revenue
growth. The figure below shows the different ways in which we are accelerating our growth. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g59x67.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer our customers a variety of software solutions that accelerate all stages of
molecule discovery, design, and optimization, pursuant to agreements with terms typically for one year. Certain of our key software solutions are highlighted below, along with the particular stage of drug discovery in which they are employed: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g30a18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also sell software licenses to customers engaged in molecule design for industrial purposes. The
software solutions for our materials science customers leverage much of the same technology as our software for biopharmaceutical companies. We are focused on leveraging our technology to transform the way new materials are discovered, and we
believe that materials science companies are only beginning to recognize the potential of computational methods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Drug Discovery Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are using our computational platform in both collaborative and wholly-owned drug discovery programs. Our drug discovery group is comprised
of a team of approximately 70 experts in protein science, biochemistry, biophysics, medicinal and computational chemistry, and discovery scientists with expertise in preclinical and early clinical development. Many of our scientists have decades of
biopharmaceutical industry experience across multiple disciplines and areas of expertise and deploy our computational platform across an array of disease targets and indications. Our differentiated, physics-based platform empowers our integrated
team of experts to design better molecules, in shorter timeframes, and at a lower cost than traditional drug design. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the last
decade, leveraging our platform and expertise, we have steadily grown our portfolio of collaborations. We have entered into a number of collaborations with biopharmaceutical companies under which our collaborators are pursuing research in a number
of therapeutics areas, including without limitation, various programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immune-oncology, cardiopulmonary disease and tuberculosis. Our
current collaborators include Ajax Pharmaceuticals, Inc., Bright Angel Therapeutics Inc., Faxian Therapeutics, LLC, Morphic Holding, Inc., Nimbus Therapeutics, LLC, Ono Pharmaceuticals Co., LTD., Petra Pharma Corp., Sanofi S.A., ShouTi Inc., Sun
Pharma Advanced Research Company Ltd., TB Alliance and Takeda Pharmaceuticals Company Limited, or Takeda. With the exception of Takeda, where we retain all intellectual property rights until Takeda exercises its option to acquire a program, all of
the programs being pursued under these collaborations are fully owned and controlled by each respective collaborator. Our opportunity to receive potential revenues from any of these programs is generally limited to research funding payments,
development, regulatory, and commercial milestones, option fees to license projects and royalties on commercial sales, if any. We are not responsible for advancing their preclinical or clinical development or their commercialization, if approved.
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through access to the maximum potential scale of our computational platform and our drug
discovery and software development teams, our collaborators receive the following key benefits: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Immediate utilization of our platform</B>: Ability to immediately and efficiently leverage the full benefits
of our computational platform, without the need for training or <FONT STYLE="white-space:nowrap">ramp-up</FONT> time, thereby enabling accelerated drug discovery. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Access to massive compute power</B>: Ability to run our computational software on one of the largest graphical
processing unit, or GPU, clusters dedicated to drug design in the industry, thereby avoiding the time and cost needed to build this infrastructure on their own. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Early access to cutting-edge functionality</B>: Real-time access to emerging solutions as they are being
developed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Target exclusivity</B>: Under our collaboration agreements, we agree to design drugs for a particular protein
target or targets using our computational platform and knowhow exclusively for the collaborator. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received
equity consideration from certain of our collaborators and also have rights under our collaboration agreements to various payments on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">collaborator-by-collaborator</FONT></FONT>
agreement basis, including research funding payments, discovery, development, and commercial milestones, potential option fees to license projects, and potential royalties in the single-digit range. Under certain of our collaboration agreements, we
are also eligible to receive a percentage of our collaborators&#146; sublicense revenue. We are currently eligible to receive potential milestones across our current collaborations, including research funding upon the achievement of specified <FONT
STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, and commercial milestones. However, because these collaborations are not under our control, we cannot predict whether or when we might achieve any event-based increases in research funding
payments, milestone payments, royalty or other payments under these collaborations or estimate the full amount of such payments, and we may never receive any such payments. For a further discussion of the risks we face with respect to receipt of any
of these payments, please refer to &#147;Risk Factors&#151;Risks Related to Drug Discovery&#151;We may never realize return on our investment of resources and cash in our drug discovery collaborations.&#148; As our collaboration strategy has
evolved, we are seeking to take more direct control and responsibility for all aspects of a drug discovery project and own a higher percentage of the value generated in the completed programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, since <FONT STYLE="white-space:nowrap">mid-2018,</FONT> we have launched a total of five internal, wholly-owned programs. We are
leveraging our computational platform with the aim of rapidly advancing the discovery of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics. Our first cohort of internal programs is focused on discovering and developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. Our
selection of targets is based on an extensive analysis of human targets and drug discovery programs. We analyze targets using automated methods at scale. The key steps we take in prioritizing programs involve structural and modeling enablement,
evaluation of therapeutic potential, identification of unsolved design challenges, and assessment of potential value of pathways and mechanisms. We have identified a large number of protein targets that we believe are amenable to our computational
platform, which creates a large and growing inventory of targets that we can potentially advance into discovery programs. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of our internal, wholly-owned drug discovery programs: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g26l52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first two drug discovery programs are focused on targets that mediate DNA repair, cell cycle
regulation, replication stress responses, and apoptosis, or programmed cell death. Numerous structurally-enabled targets exist within cellular machinery that mediate these functions, including the targets of our programs, cell division cycle
7-related protein kinase, or CDC7, and Wee1 protein kinase. Our next three drug discovery programs are focused on genetically-defined cancers. Alterations in the DNA sequence of a cancer cell genome, including mutations, genomic amplification, and
rearrangements are responsible for the initiation and progression of most cancers. We have not initiated IND-enabling studies for any of our internal, wholly-owned drug discovery programs. We expect to begin to initiate IND-enabling studies in our
programs by the first half of 2021, first in oncology and then potentially in other areas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to pursue an increasing number
of wholly-owned programs, and strategically evaluate on a program-by-program basis entering into clinical development ourselves or out-licensing programs to maximize commercial opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Estimated Preliminary Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth
below are certain estimated preliminary results for the three months and year ended December 31, 2019. We have provided ranges, rather than specific amounts, because these results are preliminary and subject to change. These ranges are based on the
information currently available to us as of the date of this prospectus. Our actual financial results for the three months and year ended December 31, 2019 are not yet available, and our closing procedures for the three months and year ended
December 31, 2019 are not yet completed. We have also set forth below other estimated data relating to our business performance for the year ended December&nbsp;31, 2019. Our actual results may vary from the estimated preliminary results and other
data presented here and will not be finalized until after the completion of this offering. We have not identified any unusual or unique events or trends that occurred during the period that we believe will affect these estimates. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These are forward-looking statements and are not guarantees of future performance and may
differ from actual results. The estimated preliminary results below should not be viewed as a substitute for our full interim or annual financial statements prepared in accordance with GAAP. There can be no assurance that the estimated preliminary
results or other data will be realized, and estimates are subject to risks and uncertainties. Please refer to &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding Forward-Looking Statements and Industry Data.&#148; The estimated preliminary
results below should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the consolidated financial statements and the related notes for prior periods appearing at
the end of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated preliminary results below have been prepared by, and are the responsibility of, management. Our
independent registered public accounting firm, KPMG LLP, has not audited, reviewed or performed any procedures with respect to the preliminary financial results. Accordingly, KPMG LLP does not express an opinion or any other form of assurance with
respect thereto. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited&nbsp;in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited in<BR>thousands, except<BR>Other Data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Financial Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 66,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 67,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 84,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 86,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 86,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 86,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current and long term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 26,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 27,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Active customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customers with over $100,000 ACV</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customers with over $100,000 ACV as percent of total ACV</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customers with over $1,000,000 ACV</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ACV (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customers with over $100,000 ACV - retention rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the three months ended December&nbsp;31, 2019, we expect to report revenue in the range of $25.2&nbsp;million
to $26.5&nbsp;million, representing an increase of 44% to 52% compared to the three months ended December&nbsp;31, 2018. The increase in revenue was primarily driven by a 23% to 29% increase in software products and services revenue and a 126% to
137% increase in drug discovery revenue for the low and high estimated preliminary results, respectively.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the three months ended December&nbsp;31, 2019, we expect to report a loss from operations in the range of
$(8.0) million to $(7.7) million, representing a decrease in loss of 7% to 12% compared to the three months ended December&nbsp;31, 2018. The decrease in loss from operations was primarily driven by increases in our drug discovery revenues offset by
increases in selling, general, and administrative expenses as we prepared to become a public company and support our expanded operations, as well as continued increases in our research and development budget as we continue to focus on innovation.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the year ended December&nbsp;31, 2019, we expect to report revenue in the range of $84.9&nbsp;million to
$86.2&nbsp;million, representing an increase of 27% to 29% compared to the year ended December&nbsp;31, 2018. The increase in revenue was primarily driven by a 11% to 12% increase in software products and services revenue and a 175% to 182% increase
in drug discovery revenue for the low and high estimated preliminary results, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the year ended December&nbsp;31, 2019, we expect to report a loss from operations in the range of $(38.9)
million to $(38.5) million, representing an increase in loss of 39% to 38% compared to the year ended December&nbsp;31, 2018. The increase in loss from operations was primarily driven by increases in selling, general, and administrative expenses as
we prepared to become a public company and support our expanded operations, as well as continued increases in our research and development budget as we continue to focus on innovation, offset by increases in our drug discovery revenues.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more
fully in the &#147;Risk Factors&#148; section of this prospectus. These risks include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a history of significant operating losses, and we expect to incur losses over the next several years.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to increase sales of our software, or if we and our current and future collaborators are unable
to successfully develop and commercialize drug products, our revenues may be insufficient for us to achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our quarterly and annual results may fluctuate significantly, which could adversely impact the value of our
common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our existing customers do not renew their licenses, do not buy additional solutions from us, or renew at lower
prices, our business and operating results will suffer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A significant portion of our revenues are generated by sales to life sciences industry customers, and factors
that adversely affect this industry could also adversely affect our software sales. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The markets in which we participate are highly competitive, and if we do not compete effectively, our business
and operating results could be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may never realize return on our investment of resources and cash in our drug discovery collaborations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Although we believe that our computational platform has the potential to identify more promising molecules than
traditional methods and to accelerate drug discovery, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and development of commercially viable products for us or
our collaborators. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be successful in our efforts to identify or discover product candidates and may fail to capitalize on
programs, collaborations, or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As a company, we do not have any experience in clinical development and have not advanced any product candidates
into clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to comply with our obligations under our existing license agreements with Columbia University, under
any of our other intellectual property licenses, or under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property
rights that are important to our business. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain, maintain, enforce, and protect patent protection for our technology and product
candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize
our technology and product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are pursuing multiple business strategies and expect to expand our development and regulatory capabilities,
and as a result, we may encounter difficulties in managing our multiple business units and our growth, which could disrupt our operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our actual operating results may differ significantly from our guidance. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">After this offering, our executive officers, directors, and principal stockholders, if they choose to act
together, will continue to have the ability to control all matters submitted to stockholders for approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified a material weakness in our internal control over financial reporting. If we are unable to
remedy our material weakness, or if we fail to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not
effective, which could adversely impact our investors&#146; confidence and our stock price. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the state of California in August&nbsp;1990 under the name Schr&ouml;dinger, Inc. We reorganized under
the laws of the state of Delaware in May 1995. Our principal executive offices are located at 120 West 45<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, 17<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, New
York 10036, and our telephone number is <FONT STYLE="white-space:nowrap">(212)&nbsp;295-5800.</FONT> Our website address is http://www.schrodinger.com. The information contained on, or that can be accessed through, our website is not incorporated by
reference into this prospectus and you should not consider any such information to be a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may
remain an emerging growth company for up to five years or until such earlier time as we have more than $1.07&nbsp;billion in annual revenue, the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than
$700&nbsp;million or we issue more than $1&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions
from certain disclosure and other requirements that are applicable to public companies that are not emerging growth companies, including delaying auditor attestation of internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a
part and may elect to take advantage of other reduced reporting requirements in future filings. For example, we have provided only two years of audited financial statements and have not included all of the executive compensation related information
that would be required in this prospectus if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. In addition, we
have elected to avail ourselves of the extended transition period for complying with new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as private companies.<B></B> Accordingly, our
financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11,882,352 shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We have granted the underwriters an option for a period of 30 days to purchase up to 1,782,352 additional shares of our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately following this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">48,283,005 shares (or 50,065,357 shares if the underwriters exercise
their option to purchase additional shares of common stock in full)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limited common stock to be outstanding immediately following this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13,164,193 shares</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock and limited common stock to be outstanding immediately following this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">61,447,198&nbsp;shares (or 63,229,550&nbsp;shares if the underwriters
exercise their option to purchase additional shares of common stock in full)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We estimate that the net proceeds to us from this offering will be approximately $181.8 million (or approximately $209.9 million if the underwriters exercise their option to purchase additional shares in full), based on the initial
public offering price of $17.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The principal purposes of this offering are to increase our capitalization and financial flexibility, create a public market for our common stock, and facilitate our future access to the capital markets. As of the date of this
prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering. However, we currently intend to use the net proceeds from this offering to continue to advance our physics-based computational
platform and our internal drug discovery programs, as well as for general corporate purposes, including working capital, operating expenses, and capital expenditures. We may also use a portion of the net proceeds to acquire complementary businesses
or technologies, however, we do not have agreements or commitments to enter into any acquisitions at this time. See &#147;Use of Proceeds.&#148;</TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We have two classes of common stock: the voting common stock offered hereby and limited common stock. For a description of the rights of the voting common stock and limited common stock, see &#147;Description of Capital
Stock.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;SDGR&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock and our limited common stock to be outstanding immediately following
this offering is based on 36,400,653 shares of our common stock and 13,164,193 shares of our limited common stock outstanding as of December&nbsp;31, 2019, after giving effect to (i)&nbsp;the voluntary exchange of 98,406,823 shares of our preferred
stock for an aggregate of 13,164,193 shares of limited common stock and (ii)&nbsp;the automatic conversion of 226,344,686 shares of our preferred stock into an aggregate of 30,278,832 shares of common stock, in each case, upon the closing of this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately following this offering excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,943,778 shares of common stock issuable upon exercise of stock options outstanding as of December&nbsp;31, 2019
at a weighted average exercise price of $3.57 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">236,005 shares of common stock reserved for future issuance under our 2010 Stock Plan, as amended, as of
December&nbsp;31, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,645,228 additional shares of our common stock that are available for future issuance under our 2020 Equity
Incentive Plan, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2020 Equity Incentive Plan (which includes 3,687,296 shares of common stock underlying stock option awards that our
board granted under the 2020 Equity Incentive Plan upon the pricing of this offering with an exercise price per share equal to the initial public offering price per share); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">586,845 additional shares of our common stock that are available for future issuance under our 2020 Employee
Stock Purchase Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information in this prospectus assumes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of a certificate of amendment to our certificate of incorporation renaming our
&#147;non-voting common stock&#148; to &#147;limited common stock&#148; on January&nbsp;24, 2020 and effecting a one-for-7.47534 reverse stock split of our common stock that became effective on January&nbsp;24, 2020, which also resulted in a
proportional adjustment to the ratios at which our outstanding shares of preferred stock convert into common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the voluntary exchange of 98,406,823 shares of our preferred stock for an aggregate of 13,164,193 shares of our
limited common stock upon the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of 226,344,686 shares of our preferred stock into an aggregate of 30,278,832 shares of
our common stock upon the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our restated certificate of incorporation and the adoption of our amended and
restated bylaws upon the closing of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our consolidated financial data for the periods indicated. We have derived the consolidated statement of
operations data for the years ended December&nbsp;31, 2017 and 2018 from our audited consolidated financial statements appearing at the end of this prospectus. The consolidated statement of operations data for the nine months ended
September&nbsp;30, 2018 and 2019 and the consolidated balance sheet data as of September&nbsp;30, 2019 have been derived from our unaudited consolidated financial statements appearing at the end of this prospectus and have been prepared on a basis
consistent with our audited consolidated financial statements. In the opinion of management, the unaudited consolidated financial data reflects all adjustments, consisting only of normal, recurring adjustments, necessary for a fair statement of the
financial information in those statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical results are not necessarily indicative of the results that may be expected in
the future, and our interim results are not necessarily indicative of results to be expected for a full fiscal year or any other interim period. You should read the following summary consolidated financial data together with our consolidated
financial statements and the related notes appearing at the end of this prospectus and the &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
sections of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 45,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 49,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on equity investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Schr&ouml;dinger stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to Schr&ouml;dinger common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used to compute net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,608,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,771,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,730,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,969,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> net loss per share, basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> weighted average common shares outstanding basic
and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,384,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,465,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As</B><br><B>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">280,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current and long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholder&#146;s (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma consolidated balance sheet data give effect to (i)&nbsp;the voluntary exchange of 98,406,823
shares of our preferred stock for an aggregate of 13,164,193 shares of our limited common stock, and (ii)&nbsp;the automatic conversion of 226,344,686 shares of our preferred stock into an aggregate of 30,278,832 shares of our common stock, in each
case, upon the closing of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted consolidated balance sheet data give further effect to our issuance and sale of
11,882,352 shares of our common stock in this offering at the initial public offering price of $17.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below
together with all of the other information contained in this prospectus, including our consolidated financial statements and the related notes appearing at the end of this prospectus, before deciding to invest in our common stock. The risks
described below are not the only risks facing our company. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could cause our business,
prospects, operating results, and financial condition to suffer materially. In such event, the trading price of our common stock could decline, and you might lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a history of significant operating losses, and we expect to incur losses over the next several years. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a history of significant operating losses. Our net loss was $17.4&nbsp;million for the year ended December&nbsp;31, 2017 and
$28.4&nbsp;million for the year ended December&nbsp;31, 2018. Our net loss was $18.5&nbsp;million for the nine months ended September&nbsp;30, 2019. The decrease in net loss was primarily due to $10.6&nbsp;million of net unrealized gains from equity
method investments largely related to our equity interests in Morphic Holding, Inc., or Morphic. As of September&nbsp;30, 2019, we had an accumulated deficit of $98.3&nbsp;million. We anticipate that our operating expenses will increase
substantially in the foreseeable future as we continue to invest in our internal drug discovery programs, sales and marketing infrastructure, and our computational platform. We are still in the early stages of development of our own drug discovery
program, and we have not yet identified our first clinical candidate. We have no drug products licensed for commercial sale and have not generated any revenue from our own drug product sales to date. We expect to continue to incur significant
expenses and operating losses over the next several years. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to invest in and develop our computational platform and software solutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research and development efforts for our internal drug discovery programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct preclinical studies and clinical trials for any of our future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, enforce, defend, and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional software engineers, programmers, sales and marketing, and other personnel to support our software
business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, quality control, and other scientific personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial, and management information systems and personnel to support our operations as a
public company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to increase sales of our software, or if we and our current and future collaborators are unable
to successfully develop and commercialize drug products, our revenues may be insufficient for us to achieve or maintain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve and maintain profitability, we must succeed in significantly increasing our software sales, or we and our current or future
collaborators must succeed in developing, and eventually commercializing, a drug product or drug products that generate significant revenue. We currently generate revenues primarily from the sales of our software solutions and expect to continue to
derive most of our revenue from sales of our software until such time as our or our collaborators&#146; drug development and commercialization efforts are successful, if ever. As such, increasing sales of our software to existing customers and
successfully marketing our software to new customers are critical to our success. Demand for our software solutions may be affected by a number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
factors, including continued market acceptance by the biopharmaceutical industry, market adoption of our software solutions beyond the biopharmaceutical industry including for material science
applications, the ability of our platform to identify more promising molecules and accelerate and lower the costs of discovery as compared to traditional methods, timing of development and release of new offerings by our competitors, technological
change, and the rate of growth in our target markets. If we are unable to continue to meet the demands of our customers, our business operations, financial results, and growth prospects will be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Achieving success in drug development will require us or our current or future collaborators to be effective in a range of challenging
activities, including completing preclinical testing and clinical trials of product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing, and selling any products for which we or they may obtain
regulatory approval. We and most of our current drug discovery collaborators are only in the preliminary stages of most of these activities. We and they may never succeed in these activities and, even if we do, we may never generate revenues that
are significant enough to achieve profitability, or even if our collaborators do, we may not receive option fees, milestone payments, or royalties from them that are significant enough for us to achieve profitability. Because of the intense
competition in the market for our software solutions and the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict when, or if, we will be able to achieve or sustain
profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.
Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, increase sales of our software, develop a pipeline
of product candidates, enter into collaborations, or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, although we have experienced revenue growth in recent periods, we may not be able to sustain revenue growth consistent with our
recent history or at all. Our total revenues increased by 20% from $55.7&nbsp;million in the fiscal year ended December&nbsp;31, 2017 to $66.6&nbsp;million in the fiscal year ended December&nbsp;31, 2018. You should not consider our revenue growth
in recent periods as indicative of our future performance. As we grow our business, our revenue growth rates may slow in future periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
quarterly and annual results may fluctuate significantly, which could adversely impact the value of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results
of operations, including our revenues, gross margin, profitability, and cash flows, have historically varied from period to period, and we expect that they will continue to do so. As a result, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparisons of our operating results may not be meaningful, and our quarterly and annual results should not be relied upon as an indication of future performance. Our quarterly and annual
financial results may fluctuate as a result of a variety of factors, many of which are outside of our control. Factors that may cause fluctuations in our quarterly and annual financial results include, without limitation, those listed elsewhere in
this &#147;Risk Factors&#148; section and those listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customer renewal rates and the timing and terms of customer renewals, including the seasonality of customer
renewals of our <FONT STYLE="white-space:nowrap">on-premise</FONT> software arrangements, for which revenue historically has been recognized at a single point in time in the first quarter of each fiscal year; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract new customers for our software; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the addition or loss of large customers, including through acquisitions or consolidations of such customers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount and timing of operating expenses related to the maintenance and expansion of our business, operations,
and infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">network outages or security breaches; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry, and market conditions, including within the life sciences industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to collect receivables from our customers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of software purchased by our customers, including the mix of
<FONT STYLE="white-space:nowrap">on-premise</FONT> and hosted software sold during a period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in the timing of the sales of our software, which may be difficult to predict; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the pricing of our solutions and in our pricing policies or those of our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success of the introduction of new software solutions by us or our competitors or any other change
in the competitive dynamics of our industry, including consolidation among competitors, customers, or strategic collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the fair value of or receipt of distributions or proceeds on account of the equity interests we hold
in our drug discovery collaborators, such as Morphic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our drug discovery collaborators in developing and commercializing drug products for which we are
entitled to receive milestone payments or royalties and the timing of receipt of such payments, if any; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of expenses related to our drug discovery programs, the development or acquisition of technologies or
businesses and potential future charges for impairment of goodwill from acquired companies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because we
recognize revenues from our hosted software solutions ratably over the life of the contract, a significant upturn or downturn in sales of our hosted software solutions may not be reflected immediately in our operating results. We expect our hosted
software revenue to trend higher over time as our customers continue to migrate from purchasing <FONT STYLE="white-space:nowrap">on-premise</FONT> software licenses to utilizing our hosted software solutions, which will increase the difficulty of
evaluating our future financial performance. As a result of these factors, we believe that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparisons of our operating results are not a good
indication of our future performance and that our interim financial results are not necessarily indicative of results for a full year or for any subsequent interim period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we may need additional funding. If we are unable to raise additional capital on terms acceptable to us or at all or
generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, operations, and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to devote substantial financial resources to our ongoing and planned activities, including the development of drug discovery programs
and continued investment in our computational platform. We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we advance our internal drug discovery programs, initiate preclinical and
investigational new drug enabling studies and invest in the further development of our platform. In addition, if we determine to advance any of our drug discovery programs into clinical development and seek regulatory approval on our own, we expect
to incur significant additional expenses. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current drug discovery collaborators, from whom we are entitled to receive milestone payments upon achievement of various development,
regulatory, and commercial milestones as well as royalties on commercial sales, if any, under the collaboration agreements that we have entered into with them, face numerous risks in the development of drugs, including the conduct of preclinical and
clinical testing, obtaining regulatory approval, and achieving product sales. In addition, the amounts we are entitled to receive upon the achievement of such milestones tend to be smaller for near-term development milestones and increase if and as
a collaborative product candidate advances through regulatory development to commercialization and will vary depending on the level of commercial success achieved, if any. We do not anticipate receiving significant milestone payments from
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
many of our drug discovery collaborators for several years, if at all, and our drug discovery collaborators may never achieve milestones that result in significant cash payments to us.
Accordingly, we may need to obtain substantial additional capital to fund our continuing operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, we
had cash, cash equivalents, and marketable securities of $98.3&nbsp;million. We believe that the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operations
and capital expenditure requirements for at least the next 12 months. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plans may change as a result of many factors currently unknown to us. As a
result, we could deplete our capital resources sooner than we currently expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many
factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the growth of our software revenue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and extent of spending to support research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued expansion of software sales and marketing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and receipt of payments from our collaborations as well as spending to support, advance, and broaden
our internal drug discovery programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and receipt of any distributions or proceeds we may receive from our equity stakes in our <FONT
STYLE="white-space:nowrap">co-founded</FONT> companies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that we require additional financing, we may not
be able to raise such financing on terms acceptable to us or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future
operating plans. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations and invest in our computational platform, we may not be able to compete
successfully, which would harm our business, operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our
stockholders, including purchasers of our common stock in this offering, restrict our operations, or require us to relinquish rights to our technologies or drug programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be
diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making product acquisitions, making capital expenditures, or declaring dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third
parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us or agree to exploit a drug development target
exclusively for one of our collaborators when we may prefer to pursue the drug development target for ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our NOLs and
research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2018, we had federal net operating losses, or NOLs, of approximately $75.3&nbsp;million and state NOLs of approximately $41.3&nbsp;million, which, if not utilized, generally begin to expire in 2019. As of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2018, we also had federal research and development tax credit carryforwards of approximately $6.8&nbsp;million and state research and development tax credit carryforwards of
approximately $0.4 million, which, if not utilized, generally begin to expire in 2019. These NOLs and research and development tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Federal NOLs
generated after December&nbsp;31, 2017 are not subject to expiration, but the deductibility of such NOLs is limited to 80% of our taxable income in any future taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in general, under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of
state law, a corporation that undergoes an &#147;ownership change,&#148; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three year period, is subject to limitations on
its ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and research and development tax credit carryforwards to offset future taxable income. We have performed an analysis through December&nbsp;31, 2018 and determined
that such an ownership change has not occurred. However, we may experience such ownership changes in the future as a result of this offering and/or subsequent changes in our stock ownership (which may be outside our control). As a result, if, and to
the extent that, we earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations
change, our results of operations could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with
generally accepted accounting principles in the United States, or U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our
estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, as provided in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#151;Critical Accounting Policies and Significant Judgments and Estimates.&#148; The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from
other sources. Significant assumptions and estimates used in preparing our consolidated financial statements include the estimated variable consideration included in the transaction price in our contracts with customers, stock-based compensation,
and valuation of our equity investments in early-stage biotechnology companies. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our
results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts
thereof that are relevant to us. As a result of new standards, changes to existing standards and changes in their interpretation, we might be required to change our accounting policies, alter our operational policies, and implement new or enhance
existing systems so that they reflect new or amended financial reporting standards, or we may be required to restate our published financial statements. Such changes to existing standards or changes in their interpretation may have an adverse effect
on our reputation, business, financial position, and profit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Software </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our existing customers do not renew their licenses, do not buy additional solutions from us, or renew at lower prices, our business and operating
results will suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to derive a significant portion of our software revenues from renewal of existing
license agreements. As a result, maintaining the renewal rate of our existing customers and selling additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
software solutions to them is critical to our future operating results. Factors that may affect the renewal rate for our customers and our ability to sell additional solutions to them include:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price, performance, and functionality of our software solutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability, price, performance, and functionality of competing software solutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our professional services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop complementary software solutions, applications, and services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stability, performance, and security of our technological infrastructure; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business environment of our customers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We deliver our software through either (i)&nbsp;a product license that permits our customers to install the software solution directly on
their own <FONT STYLE="white-space:nowrap">in-house</FONT> hardware and use it for a specified term, or (ii)&nbsp;a subscription that allows our customers to access the cloud-based software solution for a specified term. Our customers have no
obligation to renew their product licenses or subscriptions for our software solutions after the license term expires, which is typically after one year, and many of our contracts may be terminated or reduced in scope either immediately or upon
notice. In addition, our customers may negotiate terms less advantageous to us upon renewal, which may reduce our revenues from these customers. Factors that are not within our control may contribute to a reduction in our software revenues. For
instance, our customers may reduce the number of their employees who are engaged in research and who would have use of our software, which would result in a corresponding reduction in the number of user licenses needed for some of our solutions and
thus a lower aggregate renewal fee. The loss, reduction in scope, or delay of a large contract, or the loss or delay of multiple contracts, could materially adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future operating results also depend, in part, on our ability to sell new software solutions and licenses to our existing customers. For
example, the willingness of existing customers to license our software will depend on our ability to scale and adapt our existing software solutions to meet the performance and other requirements of our customers, which we may not do successfully.
If our customers fail to renew their agreements, renew their agreements upon less favorable terms or at lower fee levels, or fail to purchase new software solutions and licenses from us, our revenues may decline and our future revenues may be
constrained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our software sales cycle can vary and be long and unpredictable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of sales of our software solutions is difficult to forecast because of the length and unpredictability of our sales cycle. We sell
our solutions primarily to biopharmaceutical companies, and our sales cycles can be as long as nine to twelve months or longer. Further, the length of time that potential customers devote to their testing and evaluation, contract negotiation, and
budgeting processes varies significantly, depending on the size of the organization and the nature of their needs. In addition, we might devote substantial time and effort to a particular unsuccessful sales effort, and as a result, we could lose
other sales opportunities or incur expenses that are not offset by an increase in revenue, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of
our revenues are generated by sales to life sciences industry customers, and factors that adversely affect this industry could also adversely affect our software sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant portion of our current software sales are to customers in the life sciences industry, in particular the biopharmaceutical
industry. Demand for our software solutions could be affected by factors that adversely affect the life sciences industry. The life sciences industry is highly regulated and competitive and has experienced periods of considerable consolidation.
Consolidation among our customers could cause us to lose customers, decrease the available market for our solutions, and adversely affect our business. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes in regulations that make investment in the life sciences industry less attractive or drug development more expensive could adversely impact the demand for our software solutions. For
these reasons and others, selling software to life sciences companies can be competitive, expensive, and time consuming, often requiring significant upfront time and expense without any assurance that we will successfully complete a software sale.
Accordingly, our operating results and our ability to efficiently provide our solutions to life sciences companies and to grow or maintain our customer base could be adversely affected as a result of factors that affect the life sciences industry
generally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also intend to continue leveraging our solutions for broad application to industrial challenges in molecule design,
including in the fields of aerospace, energy, semiconductors, and electronic displays. However, we believe the materials science industry is in the very early stages of recognizing the potential of computational methods for molecular discovery, and
there can be no assurance that the industry will adopt computational methods such as our platform. Any factor adversely affecting our ability to market our software solutions to customers outside of the life sciences industry, including in these new
fields, could increase our dependence on the life sciences industry and adversely affect the growth rate of our revenues, operating results, and business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The markets in which we participate are competitive, and if we do not compete effectively, our business and operating results could be adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall market for molecular discovery and design software is global, rapidly evolving, competitive, and subject to
changing technology and shifting customer focus. Our software solutions face competition from commercial competitors in the business of selling simulation and modeling software to biopharmaceutical companies. These competitors include BIOVIA, a
brand of Dassault Syst&egrave;mes SE, or BIOVIA; Chemical Computing Group (US) Inc.; Cresset Biomolecular Discovery Limited; OpenEye Scientific Software, Inc.; Optibrium Limited; and Simulations Plus, Inc. We also have competitors in materials
science, such as BIOVIA and Materials Design, Inc., and in enterprise software for the life sciences, such as BIOVIA; Certara USA, Inc.; and Dotmatics, Inc. In some cases, these competitors are well-established providers of these solutions and have
long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. In addition, there are academic consortia that develop physics-based simulation programs for life sciences and materials
applications. In life sciences, the most prominent academic simulation packages include AMBER, CHARMm, GROMACS, GROMOS, OpenMM, and OpenFF. These packages are primarily maintained and developed by graduate students and post-doctoral researchers,
often without the intent for commercialization. We also face competition from solutions that biopharmaceutical companies develop internally and from smaller companies that offer products and services directed at more specific markets than we target,
enabling these smaller competitors to focus a greater proportion of their efforts and resources on these markets, as well as a large number of companies that have been founded with the goal of applying machine learning technologies to drug
discovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors are able to devote greater resources to the development, promotion, and sale of their software
solutions and services. It is possible that our new focus on internal drug discovery will result in loss of management focus and resources relating to our software business, thereby resulting in decreasing revenues from our software business.
Furthermore, third parties with greater available resources and the ability to initiate or withstand substantial price competition could acquire our current or potential competitors. Our competitors may also establish cooperative relationships among
themselves or with third parties that may further enhance their product offerings or resources. If our competitors&#146; products, services, or technologies become more accepted than our solutions, if our competitors are successful in bringing their
products or services to market earlier than ours, if our competitors are able to respond more quickly and effectively to new or changing opportunities, technologies, or customer requirements, or if their products or services are more technologically
capable than ours, then our software revenues could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be required to decrease our prices or modify our
pricing practices in order to attract new customers or retain existing customers due to increased competition. Pricing pressures and increased competition could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result in reduced sales, reduced margins, losses, or a failure to maintain or improve our competitive market position, any of which could adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have invested and expect to continue to invest in research and development efforts that further enhance our computational platform. Such investments
may affect our operating results, and, if the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested and expect to continue to invest in research and development efforts that further enhance our computational platform, often in
response to our customers&#146; requirements. These investments may involve significant time, risks, and uncertainties, including the risk that the expenses associated with these investments may affect our margins and operating results and that such
investments may not generate sufficient revenues to offset liabilities assumed and expenses associated with these new investments. The software industry changes rapidly as a result of technological and product developments, which may render our
solutions less desirable. We believe that we must continue to invest a significant amount of time and resources in our platform and software solutions to maintain and improve our competitive position. If we do not achieve the benefits anticipated
from these investments, if the achievement of these benefits is delayed, or if a slowdown in general computing power impacts the rate at which we expect our physics-based simulations to increase in power and domain applicability, our revenue and
operating results may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to collect receivables from our customers, our operating results may be adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the majority of our current customers are well-established, large companies and universities, we also provide
software solutions to smaller companies. Our financial success depends upon the creditworthiness and ultimate collection of amounts due from our customers, including our smaller customers with fewer financial resources. If we are not able to collect
amounts due from our customers, we may be required to <FONT STYLE="white-space:nowrap">write-off</FONT> significant accounts receivable and recognize bad debt expenses, which could materially and adversely affect our operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Defects or disruptions in our solutions could result in diminishing demand for our solutions, a reduction in our revenues, and subject us to substantial
liability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our software business and the level of customer acceptance of our software depend upon the continuous, effective, and
reliable operation of our software and related tools and functions. Our software solutions are inherently complex and may contain defects or errors. Errors may result from our own technology or from the interface of our software solutions with
legacy systems and data, which we did not develop. The risk of errors is particularly significant when a new software solution is first introduced or when new versions or enhancements of existing software solutions are released. We have from time to
time found defects in our software, and new errors in our existing software may be detected in the future. Any errors, defects, disruptions, or other performance problems with our software could hurt our reputation and may damage our customers&#146;
businesses. If that occurs, our customers may delay or withhold payment to us, cancel their agreements with us, elect not to renew, make service credit claims, warranty claims, or other claims against us, and we could lose future sales. The
occurrence of any of these events could result in diminishing demand for our software, a reduction of our revenues, an increase in collection cycles for accounts receivable, require us to increase our warranty provisions, or incur the expense of
litigation or substantial liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely upon third-party providers of cloud-based infrastructure to host our software solutions. Any
disruption in the operations of these third-party providers, limitations on capacity, or interference with our use could adversely affect our business, financial condition, and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We outsource substantially all of the infrastructure relating to our hosted software solutions to third-party hosting services. Customers of
our hosted software solutions need to be able to access our computational platform at any time, without interruption or degradation of performance, and we provide them with service-level </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commitments with respect to uptime. Our hosted software solutions depend on protecting the virtual cloud infrastructure hosted by third-party hosting services by maintaining its configuration,
architecture, features, and interconnection specifications, as well as the information stored in these virtual data centers, which is transmitted by third-party internet service providers. Any limitation on the capacity of our third-party hosting
services could impede our ability to onboard new customers or expand the usage of our existing customers, which could adversely affect our business, financial condition, and results of operations. In addition, any incident affecting our third-party
hosting services&#146; infrastructure that may be caused by cyber-attacks, natural disasters, fire, flood, severe storm, earthquake, power loss, telecommunications failures, terrorist or other attacks, and other similar events beyond our control
could negatively affect our cloud-based solutions. A prolonged service disruption affecting our cloud-based solutions for any of the foregoing reasons would negatively impact our ability to serve our customers and could damage our reputation with
current and potential customers, expose us to liability, cause us to lose customers, or otherwise harm our business. We may also incur significant costs for using alternative equipment or taking other actions in preparation for, or in reaction to,
events that damage the third-party hosting services we use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that our service agreements with our third-party hosting
services are terminated, or there is a lapse of service, elimination of services or features that we utilize, interruption of internet service provider connectivity, or damage to such facilities, we could experience interruptions in access to our
platform as well as significant delays and additional expense in arranging or creating new facilities and services and/or <FONT STYLE="white-space:nowrap">re-architecting</FONT> our hosted software solutions for deployment on a different cloud
infrastructure service provider, which could adversely affect our business, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our security
measures are breached or unauthorized access to customer data is otherwise obtained, our solutions may be perceived as not being secure, customers may reduce the use of or stop using our solutions, and we may incur significant liabilities.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our solutions involve the collection, analysis, and storage of our customers&#146; proprietary information and sensitive
proprietary data related to the discovery efforts of our customers. As a result, unauthorized access or security breaches, as a result of third-party action, employee error, malfeasance, or otherwise could result in the loss of information,
litigation, indemnity obligations, damage to our reputation, and other liability. Because the techniques used to obtain unauthorized access or sabotage systems change frequently and generally are not identified until they are launched against a
target, we may be unable to anticipate these techniques or to implement adequate preventative measures. In addition, if our employees fail to adhere to practices we have established to maintain a firewall between our internal drug discovery team and
our teams that work with software customers, or if the technical solutions we have adopted to maintain the firewall malfunction, our customers and collaborators may lose confidence in our ability to maintain the confidentiality of their intellectual
property, we may have trouble attracting new customers and collaborators, we may be subject to breach of contract claims by our customers and collaborators, and we may suffer reputational and other harm as a result. Any or all of these issues could
adversely affect our ability to attract new customers, cause existing customers to elect to not renew their licenses, result in reputational damage or subject us to third-party lawsuits or other action or liability, which could adversely affect our
operating results. Our insurance may not be adequate to cover losses associated with such events, and in any case, such insurance may not cover all of the types of costs, expenses, and losses we could incur to respond to and remediate a security
breach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any failure to offer high-quality technical support services could adversely affect our relationships with our customers and our operating
results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our customers depend on our support organization to resolve technical issues relating to our solutions, as our software
requires expert usage to fully exploit its capabilities. Certain of our customers also rely on us to troubleshoot problems with the performance of the software, introduce new features requested for specific customer projects, inform them about the
best way to set up and analyze various types of simulations and illustrate our techniques for drug discovery using examples from publicly available data sets. We may be unable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to respond quickly enough to accommodate short-term increases in customer demand for these support services. Increased customer demand for our services, without corresponding revenues, could
increase costs and adversely affect our operating results. In addition, our sales process is highly dependent on the reputation of our solutions and business and on positive recommendations from our existing customers. Any failure to offer
high-quality technical support, or a market perception that we do not offer high-quality support, could adversely affect our reputation, our ability to sell our solutions to existing and prospective customers and our business and operating results.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our solutions utilize third party open source software, and any failure to comply with the terms of one or more of these open source software
licenses could adversely affect our business or our ability to sell our software solutions, subject us to litigation, or create potential liability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our solutions include software licensed by third parties under any one or more open source licenses, including the GNU General Public License,
or GPL, the GNU Lesser General Public License, or LGPL, the Affero General Public License, or AGPL, the BSD License, the MIT License, the Apache License, and others, and we expect to continue to incorporate open source software in our solutions in
the future. Moreover, we cannot ensure that we have effectively monitored our use of open source software or that we are in compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been
claims against companies that use open source software in their products and services asserting that the use of such open source software infringes the claimants&#146; intellectual property rights. As a result, we and our customers could be subject
to suits by third parties claiming that what we believe to be licensed open source software infringes such third parties&#146; intellectual property rights, and we may be required to indemnify our customers against such claims. Additionally, if an
author or other third party that distributes such open source software were to allege that we had not complied with the conditions of one or more of these licenses, we or our customers could be required to incur significant legal expenses defending
against such allegations and could be subject to significant damages, enjoined from the sale of our solutions that contain the open source software and required to comply with onerous conditions or restrictions on these solutions, which could
disrupt the distribution and sale of these solutions. Litigation could be costly for us to defend, have a negative effect on our business, financial condition, and results of operations, or require us to devote additional research and development
resources to change our solutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Use of open source software may entail greater risks than use of third party commercial software, as
open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities. In addition, certain open source licenses
require that source code for software programs that interact with such open source software be made available to the public at no cost and that any modifications or derivative works to such open source software continue to be licensed under the same
terms as the open source software license. The terms of various open source licenses have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated
conditions or restrictions on our ability to market our solutions. By the terms of certain open source licenses, we could be required to release the source code of our proprietary software, and to make our proprietary software available under open
source licenses, if we combine our proprietary software with open source software in a certain manner. In the event that portions of our proprietary software are determined to be subject to an open source license, we could be required to publicly
release the affected portions of our source code, <FONT STYLE="white-space:nowrap">re-engineer</FONT> all or a portion of our solutions, or otherwise be limited in the licensing of our solutions, each of which could reduce or eliminate the value of
our solutions. Disclosing our proprietary source code could allow our competitors to create similar products with lower development effort and time and ultimately could result in a loss of sales. Any of these events could create liability for us and
damage our reputation, which could have a material adverse effect on our revenue, business, results of operations, and financial condition and the market price of our shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Drug Discovery </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may never realize return on our investment of resources and cash in our drug discovery collaborations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our computational platform to provide drug discovery services to collaborators who are engaged in drug discovery and development. These
collaborators include <FONT STYLE="white-space:nowrap">start-up</FONT> companies we <FONT STYLE="white-space:nowrap">co-found,</FONT> <FONT STYLE="white-space:nowrap">pre-commercial</FONT> biotechnology companies, and large-scale pharmaceutical
companies. When we engage in drug discovery with these collaborators, we typically provide access to our platform and platform experts who assist the drug discovery collaborator in identifying molecules that have activity against one or more
specified protein targets. We historically have not received significant initial cash consideration for these services. However, we have received equity consideration in the collaborator and/or the right to receive option fees, cash milestone
payments upon the achievement of specified development, regulatory, and commercial sales milestones for the drug discovery targets, and potential royalties. From time to time, we have also made additional equity investments in our drug discovery
collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never realize return on our investment of resources and cash in our drug discovery collaborations. Clinical drug
development involves a lengthy and expensive process, with an uncertain outcome. Our drug discovery collaborators may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of any product candidates. In addition, our ability to realize return from our drug discovery collaborations is subject to the following risks: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug discovery collaborators have significant discretion in determining the amount and timing of efforts and
resources that they will apply to our collaborations and may not perform their obligations as expected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug discovery collaborators may not pursue development or commercialization of any product candidates for which
we are entitled to option fees, milestone payments, or royalties or may elect not to continue or renew development or commercialization programs based on results of clinical trials or other studies, changes in the collaborator&#146;s strategic focus
or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug discovery collaborators may delay clinical trials for which we are entitled to milestone payments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not have access to, or may be restricted from disclosing, certain information regarding our
collaborators&#146; product candidates being developed or commercialized and, consequently, may have limited ability to inform our stockholders about the status of, and likelihood of achieving, milestone payments or royalties under such
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug discovery collaborators could independently develop, or develop with third parties, products that compete
directly or indirectly with any product candidates and products for which we are entitled to milestone payments or royalties if the collaborator believes that the competitive products are more likely to be successfully developed or can be
commercialized under terms that are more economically attractive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates discovered in drug discovery collaborations with us may be viewed by our collaborators as
competitive with their own product candidates or products, which may cause our collaborators to cease to devote resources to the commercialization of any such product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">existing drug discovery collaborators and potential future drug discovery collaborators may begin to perceive us
to be a competitor more generally, particularly as we advance our internal drug discovery programs, and therefore may be unwilling to continue existing collaborations with us or to enter into new collaborations with us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a drug discovery collaborator may fail to comply with applicable regulatory requirements regarding the
development, manufacture, distribution, or marketing of a product candidate or product, which may impact our ability to receive milestone payments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with drug discovery collaborators, including disagreements over intellectual property or
proprietary rights, contract interpretation, or the preferred course of development, might cause delays or terminations of the research, development, or commercialization of product candidates for which we are eligible to receive milestone payments,
or might result in litigation or arbitration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug discovery collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual
property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our or their intellectual property or proprietary information or expose
us and them to potential litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug discovery collaborators may infringe, misappropriate, or otherwise violate the intellectual property or
proprietary rights of third parties, which may expose us to litigation and potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug discovery collaborations may be terminated prior to our receipt of any significant value from the
collaboration. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug discovery collaborations may not lead to development or commercialization of product candidates
that results in our receipt of option fees, milestone payments, or royalties in a timely manner, or at all. If any drug discovery collaborations that we enter into do not result in the successful development and commercialization of drug products
that result in option fees, milestone payments, or royalties to us, we may not receive return on the resources we have invested in the drug discovery collaboration. Moreover, even if a drug discovery collaboration initially leads to the achievement
of milestones that result in payments to us, it may not continue to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may never realize return on our equity investments in our drug
discovery collaborators. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never realize a return on our equity investments in our drug discovery collaborators. None of the
drug discovery collaborators in which we hold equity generate revenue from commercial sales of drug products. They are therefore dependent on the availability of capital on favorable terms to continue their operations. In addition, if the drug
discovery collaborators in which we hold equity raise additional capital, our ownership interest in and degree of control over these drug discovery collaborators will be diluted, unless we have sufficient resources and choose to invest in them
further or successfully negotiate contractual anti-dilution protections for our equity investment. The financial success of our equity investment in any collaborator will likely be dependent on a liquidity event, such as a public offering,
acquisition, or other favorable market event reflecting appreciation in the value of the equity we hold. The capital markets for public offerings and acquisitions are dynamic, and the likelihood of liquidity events for the companies in which we hold
equity interests could significantly worsen. Further, valuations of privately held companies are inherently complex due to the lack of readily available market data. If we determine that any of our investments in such companies have experienced a
decline in value, we may be required to record an impairment, which could negatively impact our financial results. The fair value of our equity interests in public companies, such as Morphic, may fluctuate significantly in future periods since we
determine the fair value of such equity interests based on the market value of such companies&#146; common stock as of a given reporting date. All of the equity we hold in our drug discovery collaborators is subject to a risk of partial or total
loss of our investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our drug discovery collaborators have significant discretion in determining when to make announcements, if any, about the
status of our collaborations, including about clinical developments and timelines for advancing collaborative programs, and the price of our common stock may decline as a result of announcements of unexpected results or developments. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug discovery collaborators have significant discretion in determining when to make announcements about the status of our collaborations,
including about preclinical and clinical developments and timelines for advancing the collaborative programs. While as a general matter we intend to periodically report on the status of our collaborations, our drug discovery collaborators, and in
particular, our privately-held collaborators, may wish </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to report such information more or less frequently than we intend to or may not wish to report such information at all. The price of our common stock may decline as a result of the public
announcement of unexpected results or developments in our collaborations, or as a result of our collaborators withholding such information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Although we believe that our computational platform has the potential to identify more promising molecules than traditional methods and to accelerate
drug discovery, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and development of commercially viable products for us or our collaborators. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our scientific approach focuses on using our platform technology to conduct &#147;computational assays&#148; that leverage our deep
understanding of physics-based modeling and theoretical chemistry to design molecules and predict their key properties without conducting time-consuming and expensive physical experiments. Our computational platform underpins our software solutions,
our drug discovery collaborations and our own internal drug discovery programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the results of certain of our drug discovery
collaborators suggest that our platform is capable of accelerating drug discovery and identifying high quality product candidates, these results do not assure future success for our drug discovery collaborators or for us with our internal drug
discovery programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we or our drug discovery collaborators are able to develop product candidates that demonstrate potential in
preclinical studies, we or they may not succeed in demonstrating safety and efficacy of product candidates in human clinical trials. For example, in collaboration with us, Nimbus Therapeutics, LLC, or Nimbus, was able to identify a unique series of
acetyl-CoA carboxylase, or ACC, allosteric protein-protein interaction inhibitors with favorable pharmaceutical properties that inhibit the activity of the ACC enzyme. Nimbus achieved proof of concept in a Phase 1b clinical trial of its ACC
inhibitor, firsocostat, and later sold the program to Gilead Sciences, Inc., or Gilead Sciences, in a transaction valued at approximately $1.2 billion, comprised of an upfront payment and earn outs. Of this amount, $601.3 million has been paid to
Nimbus to date, and we received a total of $46.0 million in cash distributions in 2016 and 2017. In December 2019, Gilead Sciences announced topline results from its Phase 2 clinical trial which included firsocostat, both as a monotherapy and in
combination with other investigational therapies for advanced fibrosis due to nonalcoholic steatohepatitis, in which the primary endpoint was not met. Moreover, preclinical and clinical data are often susceptible to varying interpretations and
analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to identify or discover product candidates and may fail to capitalize on programs, collaborations, or product
candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research
programs to identify new product candidates require substantial technical, financial, and human resources. As an organization, we have not yet developed any product candidates, and we may fail to identify potential product candidates for clinical
development. Similarly, a key element of our business plan is to expand the use of our computational platform through an increase in software sales and drug discovery collaborations. A failure to demonstrate the utility of our platform by
successfully using it ourselves to discover internal product candidates could harm our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited
resources, we focus our research programs on protein targets where we believe our computational assays are a good substitute for experimental assays, where we believe it is theoretically possible to discover a molecule with properties that are
required for the molecule to become a drug and where we believe there is a meaningful commercial opportunity, among other factors. Currently, the focus of our internal drug discovery programs is in the area of oncology. We may forego or delay
pursuit of opportunities with certain programs, collaborations, or product candidates or for indications that later prove to have greater commercial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential. However, the development of any product candidate we pursue may ultimately prove to be unsuccessful or less successful than another potential product candidate that we might have
chosen to pursue on a more aggressive basis with our capital resources. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic
collaboration, partnership, licensing, or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal
resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on
contract research organizations to synthesize any molecules with therapeutic potential that we discover. If such organizations do not meet our supply requirements, development of any product candidate we may develop may be delayed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to rely on third parties to synthesize any molecules with therapeutic potential that we discover. Reliance on third parties may
expose us to different risks than if we were to synthesize molecules ourselves. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or synthesize molecules in accordance with regulatory
requirements, if there are disagreements between us and such parties or if such parties are unable to expand capacities, we may not be able to fulfill, or may be delayed in producing sufficient product candidates to meet, our supply requirements.
These facilities may also be affected by natural disasters, such as floods or fire, or geopolitical developments, or such facilities could face production issues, such as contamination or regulatory concerns following a regulatory inspection of such
facility. In such instances, we may need to locate an appropriate replacement third-party facility and establish a contractual relationship, which may not be readily available or on acceptable terms, which would cause additional delay and increased
expense, and may have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any third party may also encounter shortages in the raw materials
or active pharmaceutical ingredient, or API, necessary to synthesize any molecule we may discover in the quantities needed for preclinical studies or clinical trials, as a result of capacity constraints or delays or disruptions in the market for the
raw materials or API. Even if raw materials or API are available, we may be unable to obtain sufficient quantities at an acceptable cost or quality. The failure by us or the third parties to obtain the raw materials or API necessary to synthesize
sufficient quantities of any molecule we may discover could delay, prevent, or impair our development efforts and may have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to establish or maintain collaborations to develop and commercialize any of the product candidates we discover internally, we may
have to alter our development and commercialization plans for those product candidates and our business could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet identified any product candidates or advanced any of our drug discovery programs past the discovery stage and into preclinical
studies or human clinical trials. We expect to rely on future collaborators for the development and potential commercialization of product candidates we discover internally when we believe it will help maximize the commercial value of the product
candidate. We face significant competition in seeking appropriate collaborators for these activities, and a number of more established companies may also be pursuing such collaborations. These established companies may have a competitive advantage
over us due to their size, financial resources, and greater clinical development and commercialization expertise. Whether we reach a definitive agreement for such collaborations will depend, among other things, upon our assessment of the
collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of preclinical studies and
clinical trials, the likelihood of approval by the U.S. Food and Drug Administration, or FDA, or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of
manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard
to the merits of the challenge, and industry and market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a
collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among
large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to reach
agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, or
increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and
additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may
not be able to further develop any product candidates or bring them to market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a company, we do not have any experience in clinical development
and have not advanced any product candidates into clinical development. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We only began conducting our own internal drug discovery
efforts in mid-2018. As a company, we do not have any experience in clinical development and have not advanced any product candidates into clinical development. Our lack of experience in conducting clinical development activities may adversely
impact the likelihood that we will be successful in advancing our programs. Further, any predictions you make about the future success or viability of our internal drug discovery programs may not be as accurate as they could be if we had a history
of conducting clinical trials and developing our own product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as our internal drug discovery business grows, we
may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. Our internal drug discovery business may need to transition to a business capable of supporting clinical development activities. We may not
be successful in such a transition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we and any future collaborators are unable to successfully complete clinical development, obtain regulatory
approval for, or commercialize any product candidates, or experience delays in doing so, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our and any future collaborators&#146; development and commercialization programs will depend on several factors, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of necessary preclinical studies to enable the initiation of clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment of patients in, and the completion of, the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance by the FDA or other regulatory agencies of regulatory filings for any product candidates we and our
future collaborators may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanding and maintaining a workforce of experienced scientists and others to continue to develop any product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining intellectual property protection and regulatory exclusivity for any product candidates
we and our future collaborators may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with third-party manufacturers for, or establishing, clinical and commercial manufacturing
capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing, and distribution capabilities for drug products and successfully launching
commercial sales, if and when approved; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of any product candidates we and our future collaborators may develop, if and when approved, by
patients, the medical community, and third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining coverage, adequate pricing, and adequate reimbursement from third-party payors,
including government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients&#146; willingness to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of coverage and/or adequate reimbursement from third-party payors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile following receipt of any regulatory approvals.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of these factors are beyond our control, including clinical outcomes, the regulatory review process, potential
threats to our intellectual property rights, and the manufacturing, marketing, and sales efforts of any future collaborator. Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. If we or our future
collaborators are unable to develop, receive marketing approval for, and successfully commercialize any product candidates, or if we or they experience delays as a result of any of these factors or otherwise, we may need to spend significant
additional time and resources, which would adversely affect our business, prospects, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Our Operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Doing business internationally creates operational and financial risks for our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our fiscal year ended December&nbsp;31, 2018, sales to customers outside of the United States accounted for approximately 46% of our total
revenues. Operating in international markets requires significant resources and management attention and subjects us to regulatory, economic, and political risks that are different from those in the United States. We have limited operating
experience in some international markets, and we cannot assure you that our expansion efforts into other international markets will be successful. Our experience in the United States and other international markets in which we already have a
presence may not be relevant to our ability to expand in other markets. Our international expansion efforts may not be successful in creating further demand for our solutions outside of the United States or in effectively selling our solutions in
the international markets we enter. In addition, we face risks in doing business internationally that could adversely affect our business, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to localize and adapt our solutions for specific countries, including translation into foreign
languages; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">data privacy laws which require that customer data be stored and processed in a designated territory or handled
in a manner that differs significantly from how we typically handle customer data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in staffing and managing foreign operations, including employee laws and regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different pricing environments, longer sales cycles, and longer accounts receivable payment cycles and
collections issues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new and different sources of competition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">weaker protection for intellectual property and other legal rights than in the United States and practical
difficulties in enforcing intellectual property and other rights outside of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laws and business practices favoring local competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance challenges related to the complexity of multiple, conflicting, and changing governmental laws and
regulations, including employment, tax, reimbursement and pricing, privacy and data protection, and anti-bribery laws and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased financial accounting and reporting burdens and complexities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the transfer of funds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export
licensing requirements, trade embargoes, and other trade barriers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in social, political, and economic conditions or in laws, regulations, and policies governing foreign
trade, manufacturing, development, and investment both domestically as well as in the other countries and jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse tax consequences, including the potential for required withholding taxes; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unstable regional and economic political conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our international agreements may provide for payment denominated in local currencies and our local operating costs are denominated in local
currencies. Therefore, fluctuations in the value of the U.S. dollar and foreign currencies may impact our operating results when translated into U.S. dollars. We do not currently engage in currency hedging activities to limit the risk of exchange
rate fluctuations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European
Union, commonly referred to as Brexit. The United Kingdom and the European Union have agreed to a withdrawal agreement, which is expected to be approved by the U.K. Parliament. It is expected that the United Kingdom will formally leave the European
Union on or before January 31, 2020. Under the withdrawal agreement, the United Kingdom will be subject to a transitional period until December 31, 2020 (extendable up to two years), during which E.U. rules will continue to apply. Formal trade
negotiations are not possible until the United Kingdom has become a &#147;third country&#148; on January 31, 2020. The U.K. Prime Minister has indicated that the United Kingdom will not seek to extend the transitional period beyond the end of 2020.
If no trade agreement has been reached before the end of the transitional period this may cause significant market and economic disruption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
fail to manage our technical operations infrastructure, our existing customers, and our internal drug discovery team, may experience service outages, and our new customers may experience delays in the deployment of our solutions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have experienced significant growth in the number of users and data that our operations infrastructure supports. We seek to maintain
sufficient excess capacity in our operations infrastructure to meet the needs of all of our customers and to support our internal drug discovery programs. We also seek to maintain excess capacity to facilitate the rapid provision of new customer
deployments and the expansion of existing customer deployments. In addition, we need to properly manage our technological operations infrastructure in order to support version control, changes in hardware and software parameters and the evolution of
our solutions. However, the provision of new hosting infrastructure requires adequate lead-time. We have experienced, and may in the future experience, website disruptions, outages, and other performance problems. These types of problems may be
caused by a variety of factors, including infrastructure changes, human or software errors, viruses, security attacks, fraud, spikes in usage, and denial of service issues. In some instances, we may not be able to identify the cause or causes of
these performance problems within an acceptable period of time. If we do not accurately predict our infrastructure requirements, our existing customers may experience service outages that may subject us to financial penalties, financial liabilities,
and customer losses. If our operations infrastructure fails to keep pace with increased sales and usage, customers and our internal drug discovery team may experience delays in the deployment of our solutions as we seek to obtain additional
capacity, which could adversely affect our reputation and adversely affect our revenues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our international operations subject us to potentially
adverse tax consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We report our taxable income in various jurisdictions worldwide based upon our business operations in
those jurisdictions. These jurisdictions include Germany, Japan, and India. The international nature and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
organization of our business activities are subject to complex transfer pricing regulations administered by taxing authorities in various jurisdictions. The relevant taxing authorities may
disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a disagreement were to occur, and our position were not sustained, we could be required to pay additional taxes, interest, and penalties,
which could result in <FONT STYLE="white-space:nowrap">one-time</FONT> tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value added, or similar taxes,
and we could be subject to tax liabilities with respect to past or future sales, which could adversely affect our results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not collect sales and use, value added, and similar taxes in all jurisdictions in which we have sales, based on our belief that such
taxes are not applicable or that we are not required to collect such taxes with respect to the jurisdiction. Sales and use, value added, and similar tax laws and rates vary greatly by jurisdiction. Certain jurisdictions in which we do not collect
such taxes may assert that such taxes are applicable, which could result in tax assessments, penalties, and interest, and we may be required to collect such taxes in the future. Such tax assessments, penalties, and interest or future requirements
may adversely affect our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unanticipated changes in our effective tax rate could harm our future results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to income taxes in the United States and various foreign jurisdictions, and our domestic and international tax liabilities are
subject to the allocation of expenses in differing jurisdictions. Forecasting our estimated annual effective tax rate is complex and subject to uncertainty, and there may be material differences between our forecasted and actual tax rates. Our
effective tax rate could be adversely affected by changes in the mix of earnings and losses in countries with differing statutory tax rates, certain <FONT STYLE="white-space:nowrap">non-deductible</FONT> expenses as a result of acquisitions, the
valuation of deferred tax assets and liabilities, and changes in federal, state, or international tax laws and accounting principles. Increases in our effective tax rate would reduce our profitability or in some cases increase our losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to income tax audits by many tax jurisdictions throughout the world. Although we believe our income tax
liabilities are reasonably estimated and accounted for in accordance with applicable laws and principles, an adverse resolution of one or more uncertain tax positions in any period could have a material impact on the results of operations for that
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire other companies or technologies, which could divert our management&#146;s attention, result in additional dilution to our
stockholders, and otherwise disrupt our operations and adversely affect our operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future seek to
acquire or invest in businesses, solutions, or technologies that we believe could complement or expand our solutions, enhance our technical capabilities, or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the
attention of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have limited experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate
the acquired personnel, operations, and technologies successfully, effectively manage the combined business following the acquisition or preserve the operational synergies between our business units that we believe currently exist. We cannot assure
you that following any acquisition we would achieve the expected synergies to justify the transaction, due to a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to integrate or benefit from acquired technologies or services in a profitable manner;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated costs or liabilities associated with the acquisition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incurrence of acquisition-related costs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty integrating the accounting systems, operations, and personnel of the acquired business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the
acquired business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty converting the customers of the acquired business onto our solutions and contract terms, including
disparities in the revenues, licensing, support, or professional services model of the acquired company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management&#146;s attention from other business concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse effects to our existing business relationships with business partners and customers as a result of the
acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential loss of key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">use of resources that are needed in other parts of our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">use of substantial portions of our available cash to consummate the acquisition. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible
assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results based on this impairment assessment process, which could
adversely affect our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquisitions could also result in dilutive issuances of equity securities or the incurrence
of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business, and financial position may suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operations may be interrupted by the occurrence of a natural disaster or other catastrophic event at our primary facilities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are primarily conducted at our facilities in New York, New York and Portland, Oregon and our internal hosting facility located
in Clifton, New Jersey. The occurrence of natural disasters or other catastrophic events could disrupt our operations. Any natural disaster or catastrophic event in our facilities or the areas in which they are located could have a significant
negative impact on our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations under our existing license agreements with Columbia University, under any of our other intellectual property
licenses, or under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a number of license agreements pursuant to which we have been granted exclusive and
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> worldwide licenses to certain patents, software code, and software programs to, among other things, reproduce, use, execute, copy, operate, sublicense, and distribute the licensed technology in
connection with the marketing and sale of our software solutions and to develop improvements thereto.&nbsp;In particular, the technology that we license from Columbia University pursuant to our license agreements with them are used in and
incorporated into a number of our software solutions which we market and license to our customers. For further information regarding our license agreements with Columbia University, see &#147;Business&#151;License Agreements with Columbia
University.&#148; Our license agreements with Columbia University and other licensors impose, and we expect that future licenses will impose, specified royalty and other obligations on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements with
them and might therefore terminate the license agreements, thereby </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delaying our ability to market and sell our existing software solutions and develop and commercialize new software solutions that utilize technology covered by these license agreements.&nbsp;If
these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors could market, products and technologies similar to ours.&nbsp;This could have
a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may
arise regarding intellectual property subject to a licensing agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights under any collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our current or future licensors and us and our collaborators; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, license agreements are complex, and certain provisions in such agreements may be susceptible to multiple
interpretations.&nbsp;The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our
financial or other obligations under the relevant agreement.&nbsp;For example, our counterparties have in the past and may in the future dispute the amounts owed to them pursuant to payment obligations. If disputes over intellectual property that we
have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may experience delays in the development and commercialization of new software solutions and in our ability to market and
sell existing software solutions, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our obligations under our existing or future drug discovery collaboration agreements may limit our intellectual property rights that are important to
our business. Further, if we fail to comply with our obligations under our existing or future collaboration agreements, or otherwise experience disruptions to our business relationships with our prior, current, or future collaborators, we could lose
intellectual property rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to collaboration agreements with biopharmaceutical
companies, pursuant to which we provide drug discovery services but have no ownership rights, or only <FONT STYLE="white-space:nowrap">co-ownership</FONT> rights, to certain intellectual property generated through the collaborations. We may enter
into additional collaboration agreements in the future, pursuant to which we may have no ownership rights, or only <FONT STYLE="white-space:nowrap">co-ownership</FONT> rights, to certain intellectual property generated through the future
collaborations. If we are unable to obtain ownership or license of such intellectual property generated through our prior, current, or future collaborations and overlapping with, or related to, our own proprietary technology or product candidates,
then our business, financial condition, results of operations, and prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our existing collaboration
agreements contain certain exclusivity obligations that require us to design compounds exclusively for our collaborators with respect to certain specific targets over a specified time period. Our future collaboration agreements may grant similar
exclusivity rights to future collaborators with respect to target(s) that are the subject of such collaborations. These existing or future collaboration agreements may impose diligence obligations on us. For example, existing or future collaboration
agreements may impose the restrictions on us from pursuing the drug development targets for ourselves or for our other current or future collaborators, thereby removing our ability to develop and commercialize, or to jointly develop and
commercialize with other current or future collaborators, product candidates, and technology related to the drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development targets. In spite of our best efforts, our prior, current, or future collaborators might conclude that we have materially breached our collaboration agreements. If these collaboration
agreements are terminated, or if the underlying intellectual property, to the extent we have ownership or license of, fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market,
products and technology identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise regarding intellectual property subject to a collaboration agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of ownership or license granted under the collaboration agreement and other interpretation related
issues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and product candidates infringe on intellectual property that generated
through the collaboration to of which we do not have ownership or license under the collaboration agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assignment or sublicense of intellectual property rights and other rights under the collaboration agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the collaboration agreement and what activities satisfy those diligence
obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by us and our current or future collaborators. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
collaboration agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of
our rights to the relevant intellectual property, or increase what we believe to be our obligations under the relevant agreements, either of which could have a material adverse effect on our business, financial condition, results of operations, and
prospects. Moreover, if disputes over intellectual property that we have owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or <FONT STYLE="white-space:nowrap">in-licensed</FONT> under the collaboration agreements prevent or impair our ability
to maintain our current collaboration arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology or product candidates, which could have a material adverse effect on our
business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain, maintain, enforce, and protect patent protection
for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to
successfully develop and commercialize our technology and product candidates may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in
large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to any
proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technology and any product candidates we may develop that are
important to our business and by <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property related to our technology and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary
technology or product candidate, our business, financial condition, results of operations, and prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, defend, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also
possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing, and
prosecution of patent applications, or to maintain, enforce, and defend </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the patents, covering technology that we <FONT STYLE="white-space:nowrap">co-own</FONT> with third parties or license from third parties. Therefore, these
<FONT STYLE="white-space:nowrap">co-owned</FONT> and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and applications may not be prepared, filed, prosecuted, maintained, defended, and enforced in a manner consistent with the best
interests of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of software and biopharmaceutical companies generally is highly uncertain, involves
complex legal and factual questions, and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
countries may not protect our rights to the same extent as the laws of the United States or vice versa. With respect to both owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, we cannot predict whether the patent
applications we and our licensor are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all
third-party intellectual property rights or prior art potentially relating to our computational platform, technology, and any product candidates we may develop. In addition, publications of discoveries in the scientific literature often lag behind
the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing of the priority application, or in some cases not published at all. Therefore, neither we nor our
collaborators, or our licensor can know with certainty whether either we, our collaborators, or our licensor were the first to make the inventions claimed in the patents and patent applications we own or
<FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, or that either we, our collaborators, or our licensor were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity,
enforceability, and commercial value of our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights are highly uncertain. Moreover, our owned,
<FONT STYLE="white-space:nowrap">co-owned,</FONT> and <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending and future patent applications may not result in patents being issued that protect our technology and product candidates, in whole or
in part, or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our
owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or <FONT STYLE="white-space:nowrap">in-licensed</FONT> current or future patents and our ability to obtain, protect, maintain, defend, and enforce our patent rights, narrow the scope of our
patent protection and, more generally, could affect the value of, or narrow the scope of, our patent rights. For example, recent Supreme Court decisions have served to curtail the scope of subject matter eligible for patent protection in the United
States, and many software patents have since been invalidated on the basis that they are directed to abstract ideas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to pursue
protection based on our provisional patent applications, we will need to file Patent Cooperation Treaty applications, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> applications, and/or U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT>
patent applications prior to applicable deadlines. Even then, as highlighted above, patents may never issue from our patent applications, or the scope of any patent may not be sufficient to provide a competitive advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we, our collaborators, or our licensor may be subject to a third-party preissuance submission of prior art to the U.S. Patent and
Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, <I>inter partes</I> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse
determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights or allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to
us. If the breadth or strength of protection provided by our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or <FONT STYLE="white-space:nowrap">in-licensed</FONT> current or future patents and patent applications is threatened, regardless
of the outcome, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future technology or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be
reinterpreted after issuance. Even if our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> and <FONT STYLE="white-space:nowrap">in-licensed</FONT> current and future patent applications issue as patents, they may not issue in a form that
will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity, or
enforceability, and our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims
being narrowed, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the
duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. In
particular, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our
competitors may be able to circumvent our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or <FONT STYLE="white-space:nowrap">in-licensed</FONT> current or future patents by developing similar or alternative technologies or products in a <FONT
STYLE="white-space:nowrap">non-infringing</FONT> manner. As a result, our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> and <FONT STYLE="white-space:nowrap">in-licensed</FONT> current or future patent portfolio may not provide us with
sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to
protect our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of patent laws in the United States, including patent
reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or
defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior
art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a
patent at USPTO-administered post-grant proceedings, including post-grant review, <I>inter partes</I> review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the
first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a
first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first
to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which
could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent
positions of companies in the development and commercialization of software, biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances
and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the
federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of recent cases decided by the U.S. Supreme Court have involved questions of when claims reciting abstract ideas, laws
of nature, natural phenomena and/or natural products are eligible for a patent, regardless of whether the claimed subject matter is otherwise novel and inventive. These cases include&nbsp;Association for Molecular Pathology v.&nbsp;Myriad Genetics,
Inc., 569 U.S. 12-398 (2013)&nbsp;or Myriad; Alice Corp. v. CLS Bank International, 573 U.S. 13-298 (2014); and Mayo Collaborative Services v. Prometheus Laboratories, Inc., or Prometheus, 566 U.S. 10-1150 (2012). In response to these cases, federal
courts have held numerous patents invalid as claiming subject matter ineligible for patent protection. Moreover, the USPTO has issued guidance to the examining corps on how to apply these cases during examination. The full impact of these decisions
is not yet known. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to increasing uncertainty with regard to our ability to obtain future patents,
this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change or
be interpreted in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that may issue to us in the future. In addition, these events may adversely affect our ability to defend any patents that may issue in
procedures in the USPTO or in courts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We, our prior, existing, or future collaborators, and our existing or future licensors, may become involved
in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors and other third parties may infringe, misappropriate, or otherwise violate our, our prior, current and future collaborators&#146;,
or our current and future licensors&#146; issued patents or other intellectual property. As a result, we, our prior, current, or future collaborators, or our current or future licensor may need to file infringement, misappropriation, or other
intellectual property related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate, or otherwise
violate their intellectual property. In addition, in a patent infringement proceeding, such parties could assert that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defenses
alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or
<FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading
statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
<FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes </I>review, interference proceedings, derivation proceedings, and equivalent proceedings in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions
(e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An adverse
result in any such proceeding could put one or more of our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or <FONT STYLE="white-space:nowrap">in-licensed</FONT> current or future patents at risk of being invalidated or interpreted narrowly
and could put any of our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or <FONT STYLE="white-space:nowrap">in-licensed</FONT> current or future patent applications at risk of not yielding an issued patent. A court may also refuse to stop
the third party from using the technology at issue in a proceeding on the grounds that our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or <FONT STYLE="white-space:nowrap">in-licensed</FONT> current or future patents do not cover such
technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure
during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner and have a material adverse
impact on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference or derivation proceedings provoked by
third parties, or brought by us or by our licensor, or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the
related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct clinical trials, continue our
research programs, license necessary technology from third parties, or enter into development collaborations that would help us bring any product candidates to market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or
otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell any product
candidates we may develop and for our collaborators, customers and partners to use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is
considerable patent and other intellectual property litigation in the software, pharmaceutical, and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights
with respect to our technology and product candidates, including interference proceedings, post grant review, <I>inter partes</I> review, and derivation proceedings before the USPTO and similar proceedings in non-U.S. jurisdictions such as
oppositions before the European Patent Office. Numerous U.S. and non-U.S. issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and
pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of
success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater
resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as any product candidates near commercialization and as we gain the greater visibility associated with being
a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of all such intellectual property rights potentially relating
to our technology and product candidates and their uses, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know
with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#146;s intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent
applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies.
Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may identify may infringe. In addition, third parties may
obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by
our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may identify, any molecules formed during the manufacturing process or any
final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the
event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, pay royalties, redesign our infringing products, be forced to indemnify our
customers or collaborators or obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#146;s intellectual
property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on
commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make
substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. A finding of infringement could prevent us from commercializing
any product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign any product candidates, seek new regulatory approvals and indemnify third parties
pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims by third parties asserting that our employees, consultants, or contractors have wrongfully used or disclosed
confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we
regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our employees, consultants, and contractors were previously employed at
universities or other software or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or <FONT
STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such
individual&#146;s current or former employer. Litigation may be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our
policy to require that our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement
with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties,
or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third
party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> Even if we are successful in prosecuting
or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are
unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to
seeking patents for any product candidates and technology, we also rely on trade secrets and confidentiality agreements to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology, and other proprietary information, to
maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to
them, such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors, collaborators, and other third
parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our
trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such
breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In
addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would
have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party,
our competitive position may be materially and adversely harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect
and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition, or results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory framework for the collection, use, safeguarding, sharing, transfer, and other processing of information worldwide is rapidly
evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection,
use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data and employee data, is subject to the European Union General Data Protection Regulation, or the GDPR, which
took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing
health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality
of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR would increase our obligations with respect to any clinical trials conducted in the EEA by expanding the definition
of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to
countries outside the European Union, including the United States and, as a result, increases the scrutiny that such rules should apply to transfers of personal data from any clinical trial sites located in the EEA to the United States. The GDPR
also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20&nbsp;million
Euros, whichever is greater, and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of
the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric, or health data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR&#146;s requirements is
rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors, or consultants that process or transfer
personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such as healthcare data or other personal information, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development,
regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation, and significant fines and penalties against us, and could have a material adverse effect on
our business, financial condition, or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar privacy and data security requirements are either in place or
underway in the United States. There are a broad variety of data protection laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data
security concerns. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example,
the California Consumer Privacy Act, or CCPA, which went into effect on January&nbsp;1, 2020, is creating similar risks and obligations as those created by GDPR. Because of this, we may need to engage in additional activities (e.g., data mapping) to
identify the personal information we are collecting and the purposes for which such information is collected. In addition, we will need to ensure that our policies recognize the rights granted to consumers (as that phrase is broadly defined in the
CCPA and can include business contact information), including granting consumers the right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of the sale of their personal information. Many other states are considering similar legislation. A broad
range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with current and any future federal and state laws regarding privacy and security of personal information could expose us to fines and
penalties. We also face a threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, investigations into these issues typically require the
expenditure of significant resources and generate negative publicity, which could harm our reputation and our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We, and the collaborators
who use our computational platform, may be subject to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations. Failure to comply with such laws and
regulations, may result in substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, and the collaborators who use our computational platform, may be subject to
broadly applicable healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our software solutions and any products for which we obtain marketing
approval. Such healthcare laws and regulations include, but are not limited to, the federal health care Anti-Kickback Statute; federal civil and criminal false claims laws, such as the federal False Claims Act; the federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA; the Federal Food, Drug, and Cosmetic Act, or FDCA; the federal Physician Payments Sunshine Act; and analogous state and foreign laws and regulations, such as state anti-kickback and false claims
laws and transparency laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare
laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse
or other healthcare laws and regulations. Violations of applicable healthcare laws and regulations may result in significant civil, criminal, and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion of products from
government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements, and/or oversight if a corporate integrity agreement or similar agreement is executed to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the curtailment or restructuring of operations. In addition, violations may also result in reputational harm, diminished profits, and future earnings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws,
and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, be precluded from developing, manufacturing, and selling certain products
outside the United States or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices
Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA, and these other laws generally prohibit us, our officers, and our employees and intermediaries from
bribing, being bribed, or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. Compliance with the FCPA, in particular, is expensive and difficult, particularly
in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biopharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital
employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in
collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory
requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. If we further expand our operations outside of the United States, we will need to dedicate additional
resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to other
laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations,
economic sanctions on countries and persons, customs requirements, and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various laws, regulations, and executive orders also restrict the use and
dissemination outside of the United States, or the sharing with certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to
those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and
product candidates outside of the United States, which could limit our growth potential and increase our development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no
assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA, or other legal requirements, including Trade Control laws. If we are not in compliance with the
Bribery Act, the FCPA, and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our
business, financial condition, results of operations, and liquidity. The U.S. Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting
provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by United Kingdom, U.S., or other authorities could also have an adverse impact on our reputation, our business,
results of operations, and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, and vendors may engage in misconduct or other
improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading laws, which could cause significant liability for us and harm our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants, and vendors. Misconduct by
these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with
manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data
accurately, or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.
This could include violations of HIPAA, other U.S. federal and state law, and requirements of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, including the European Union Data Protection Directive. We are also exposed to risks in
connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in
controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance, or codes of conduct.
Furthermore, our employees may, from time to time, bring lawsuits against us for employment issues, including injury, discrimination, wage and hour disputes, sexual harassment, hostile work environment, or other employment issues. If any such
actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or
other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal information technology systems, or those of our third-party vendors, contractors, or consultants, may fail or suffer
security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our services, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially
exposing us to liability or otherwise adversely affecting our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are increasingly dependent upon information technology
systems, infrastructure, and data to operate our business. In the ordinary course of business, we collect, store, and transmit confidential information (including but not limited to intellectual property, proprietary business information, and
personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a
number of third-party vendors and other contractors and consultants who have access to our confidential information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the
implementation of security measures, given the size and complexity of our internal information technology systems and those of our third-party vendors and other contractors and consultants, and the increasing amounts of confidential information that
they maintain, our information technology systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war, and telecommunication and electrical
failures, as well as security breaches from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties
(including the deployment of harmful malware, ransomware, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social engineering, and other means to affect service reliability and threaten the
confidentiality, integrity, and availability of information), which may compromise our system infrastructure, or that of our third-party vendors and other contractors and consultants or lead to data leakage. The risk of a security breach or
disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions
from around the world have increased. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. For example, third parties have in the past
and may in the future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
illegally pirate our software and make that software publicly available on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peer-to-peer</FONT></FONT> file sharing networks or
otherwise. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates,
terrorist organizations, or hostile foreign governments or agencies. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or those of our third-party vendors and other contractors
and consultants, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of our software could be delayed. The costs related to
significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. If the information technology systems of our third-party vendors and other contractors and
consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement
protections to prevent future events of this nature from occurring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have not experienced any such system failure, accident, or
security breach to date, and believe that our data protection efforts and our investment in information technology reduce the likelihood of such incidents in the future, we cannot assure you that our data protection efforts and our investment in
information technology will prevent significant breakdowns, data leakages, breaches in our systems, or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon
our reputation, business, operations, or financial condition. For example, if such an event were to occur and cause interruptions in our operations, or those of our third-party vendors and other contractors and consultants, it could result in a
material disruption of our programs and the development of our services and technologies could be delayed. Furthermore, significant disruptions of our internal information technology systems or those of our third-party vendors and other contractors
and consultants, or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property,
proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information,
including personal information regarding our customers or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action,
and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an
adverse effect on our business. Further, sophisticated cyber attackers (including foreign adversaries engaged in industrial espionage) are skilled at adapting to existing security technology and developing new methods of gaining access to
organizations&#146; sensitive business data, which could result in the loss of sensitive information, including trade secrets. Additionally, actual, potential, or anticipated attacks may cause us to incur increasing costs, including costs to deploy
additional personnel and protection technologies, train employees, and engage third-party experts and consultants.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters
and Managing Growth </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified
personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the research and development, clinical, financial, operational, scientific, software
engineering, and other business expertise of our executive officers, as well as the other principal members of our management, scientific, clinical, and software engineering teams. Although we have entered into employment agreements with our
executive officers, each of them may terminate their employment with us at any time. We do not maintain &#147;key person&#148; insurance for any of our executives or other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of the services of our executive officers or other key employees could impede the achievement of our development and sales goals in
our software business and the achievement of our research, development, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization objectives in our drug discovery business. In either case, the loss of the services of our executive officers or other key employees could seriously harm our ability to
successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals with the breadth of skills and experience
required to successfully develop, gain regulatory approval of, and commercialize products in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and
retaining qualified scientific, clinical, manufacturing, accounting, legal, and sales and marketing personnel, as well as software engineers and computational chemists, will also be critical to our success. In the technology industry, there is
substantial and continuous competition for engineers with high levels of expertise in designing, developing, and managing software and related services, as well as competition for sales executives, data scientists, and operations personnel.
Competition to hire these individuals is intense, and we may be unable to hire, train, retain, or motivate these key personnel on acceptable terms given the competition among numerous biopharmaceutical and technology companies for similar personnel.
We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors to assist us in formulating our research and development and
commercialization strategy and advancing our computational platform. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their
availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited and our business would be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are pursuing multiple business strategies and expect to expand our development and regulatory capabilities, and as a result, we may encounter
difficulties in managing our multiple business units and our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, we are
pursuing multiple business strategies simultaneously, including activities in research and development, software sales, and collaborative and internal drug discovery. We believe pursuing these multiple business strategies offers financial and
operational synergies, but these diversified operations place increased demands on our limited resources. Furthermore, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the
areas of drug development, clinical and regulatory affairs. To manage our multiple business units and anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and
continue to recruit and train additional qualified personnel. Due to our limited financial resources and our management team&#146;s limited attention and limited experience in managing a company with such anticipated growth, we may not be able to
effectively manage our multiple business units and the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business
development resources. In addition, in order to meet our obligations as a public company and to support our anticipated long-term growth, we will need to increase our general and administrative capabilities. Our management, personnel, and systems
may not be adequate to support this future growth. Any inability to manage our multiple business units and growth could delay the execution of our business plans or disrupt our operations and the synergies we believe currently exist between our
business units. In addition, adverse developments in one of these business units may disrupt these synergies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering,
Ownership of Our Common Stock, and Our Status as a Public Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock was
determined through negotiations with the underwriters. Although our common stock has been approved for listing on the Nasdaq Global Select Market, or Nasdaq, an active trading market for our shares may never develop or be sustained following this
offering. If an active market for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our common stock does not develop, it may be difficult for you to sell the shares you purchase in this offering without depressing the market price of our common stock, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common stock is substantially higher than the pro forma as adjusted net tangible book value per share
of our common stock after this offering. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this
offering. Based on the initial public offering price of $17.00 per share, you will experience immediate dilution of $12.34 per share if you purchase shares of our common stock in this offering. To the extent outstanding options are exercised, you
will incur further dilution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After this offering, our executive officers, directors, and principal stockholders, if they choose to act together,
will continue to have the ability to control all matters submitted to stockholders for approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this
offering, our executive officers and directors and our stockholders who beneficially owned more than 5% of our outstanding common stock before this offering will, in the aggregate, beneficially own shares representing approximately 53.1% of our
common stock and all of our limited common stock, or, if the holder of our limited common stock exercises its right to exchange each share of its limited common stock for one share of our common stock, approximately 63.1% of our common stock. As a
result, if these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together,
would control the election of directors and approval of any merger, consolidation, or sale of all or substantially all of our assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This concentration of ownership control may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, defer, or prevent a change in control; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entrench our management and board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or prevent a merger, consolidation, takeover, or other business combination involving us that other
stockholders may desire. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This concentration of ownership may also adversely affect the market price of our common
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our
common stock in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. If you purchase shares of our common stock in this
offering, you may not be able to resell those shares at or above the initial public offering price. The initial public offering price for the shares of our common stock will be determined by negotiations between us and the representatives of the
underwriters and may not be indicative of the market price of our common stock following the offering. Similarly, we cannot assure you that the market price following this offering will equal or exceed prices in privately negotiated transactions of
our shares that have occurred from time to time before this offering. The market price for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our investment in, and the success of, our software solutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our research and development efforts for our internal drug discovery programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation and progress of preclinical studies and clinical trials for any product candidates that we may
develop; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of or developments in preclinical studies and clinical trials of any product candidates we may develop or
those of our competitors or potential collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our drug discovery collaborators and any milestone or other payments we receive from such
collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or the financial results of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of common stock by us, our executive officers, directors or principal stockholders, or others, or the
anticipation of such sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the biopharmaceutical sector; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry, and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, following periods of volatility in the market price of a company&#146;s securities, securities class-action litigation has often
been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments
of substantial damages or fines, damage to our reputation, or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#146;s attention and
resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our actual operating results may differ significantly from our guidance. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may release guidance in our quarterly earnings conference calls, quarterly earnings releases, or otherwise, regarding our
future performance that represents our management&#146;s estimates as of the date of release. This guidance, which would include forward-looking statements, would be based on projections prepared by our management. Neither our registered public
accountants nor any other independent expert or outside party would compile or examine the projections. Accordingly, no such person would express any opinion or any other form of assurance with respect to the projections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Projections are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to
significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. The principal reason
that we would release guidance is to provide a basis for our management to discuss our business outlook with analysts and investors. We do not accept any responsibility for any projections or reports published by any such third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying any guidance furnished by
us will not materialize or will vary significantly from actual results. Accordingly, our guidance would be only an estimate of what management believes is realizable as of the date of release. Actual results may vary from our guidance and the
variations may be material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our collaborators may not achieve projected discovery and development milestones and other anticipated key
events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we expect that we will make public statements regarding the expected timing of certain milestones and key events, such as
the commencement and completion of preclinical and IND-enabling studies in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our internal drug discovery programs as well developments and milestones under our collaborations. Morphic has also made public statements regarding its expectations for the development of
programs under collaboration with us and they and other collaborators may in the future make additional statements about their goals and expectations for collaborations with us. The actual timing of these events can vary dramatically due to a number
of factors such as delays or failures in our or our current and future collaborators&#146; drug discovery and development programs, the amount of time, effort, and resources committed by us and our current and future collaborators, and the numerous
uncertainties inherent in the development of drugs. As a result, there can be no assurance that our or our current and future collaborators&#146; programs will advance or be completed in the time frames we or they announce or expect. If we or any
collaborators fail to achieve one or more of these milestones or other key events as planned, our business could be materially adversely affected and the price of our common stock could decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our
business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market
price and trading volume for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our business. We do not have control over these analysts. We do not currently have, and may never
obtain, research coverage by industry or financial analysts. If no, or few, analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our
business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provides more favorable relative recommendations about our competitors, the price of our stock could decline. If one or more of
these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that
do not improve our results of operations or enhance the value of our common stock or in ways that our stockholders may not agree with. You will not have the opportunity as part of your investment decision to assess whether the net proceeds are being
used appropriately. Investors in this offering will need to rely upon the judgment of our management with respect to the use of proceeds. The failure by our management to apply these funds effectively could harm our business, financial condition,
results of operations, and prospectus and could cause the price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash
dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings to fund the development and expansion of our business. Any determination to pay dividends in the future will be at the discretion of
our board of directors. As a result, capital appreciation of our common stock, if any, will be your sole source of gain for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of
our common stock to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common
stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock, impair our ability to raise capital through the sale of additional
equity securities, and make it more difficult for you to sell your common stock at a time and price that you deem appropriate. After this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering, we will have outstanding 48,283,005 shares of common stock and 13,164,193 shares of limited common stock based on the number of shares of common stock and limited common stock
outstanding as of December 31, 2019, after giving effect to (i) the voluntary exchange of 98,406,823 shares of preferred stock for an aggregate of 13,164,193 shares of limited common stock and (ii) the automatic conversion of 226,344,686 shares of
our preferred stock into an aggregate of 30,278,832 shares of common stock. This includes the 11,882,352 shares of common stock that we are selling in this offering, which may be resold in the public market immediately without restriction, unless
purchased by our affiliates. The remaining 36,400,653 shares of our common stock and 13,164,193 shares of our limited common stock are currently restricted as a result of securities laws or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements,
but will become eligible to be sold at various times after the offering as described in the section of this prospectus titled &#147;Shares Eligible for Future Sale&#148;. The representatives of the underwriters may release some or all of the shares
of common stock subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time in their sole discretion and without notice, which would allow for earlier sales of shares in the public market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, beginning 180 days after the completion of this offering, holders of an aggregate of 30,278,832 shares of our common stock and an
aggregate of 13,164,193 shares of our limited common stock will have rights, subject to specified conditions, to require us to file registration statements covering their shares, or to include their shares in registration statements that we may file
for ourselves or other stockholders. We also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to
volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the &#147;Underwriters&#148; section of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock
less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; or EGC, as defined in the Jumpstart Our Business
Startups Act of 2012, or the JOBS Act. We may remain an EGC until the end of the fiscal year in which the fifth anniversary of this offering occurs, although if the market value of our common stock that is held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of any June&nbsp;30 before that time or if we have annual gross revenues of $1.07&nbsp;billion or more in any fiscal year, we would cease to be an EGC as of
December&nbsp;31 of the applicable year. We also would cease to be an EGC if we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. For so long as we remain an EGC, we are
permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements in this prospectus, in addition to any
required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken advantage of reduced reporting
obligations in this prospectus. In particular, in this prospectus we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an
EGC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict whether investors will find our common stock less attractive if we rely on
these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards
applicable to public companies until those standards would otherwise apply to private companies. We have elected to take advantage of such extended transition period, which means that when a standard is issued or revised and it has different
application dates for public or private companies, we may adopt the new or revised standard at the time private companies adopt the new or revised standard and may do so until such time that we either irrevocably elect to &#147;opt out&#148; of such
extended transition period or no longer qualify as an EGC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our
management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
public company, and particularly after we are no longer an EGC, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. The Exchange Act, Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street
Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and
financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time and resources to these compliance initiatives, potentially at the expense of other business concerns, which
could harm our business, financial condition, results of operations, and prospects. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees
to meet public company internal control and financial reporting requirements, and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us
to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of
such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and
governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified a material weakness in our internal control over financial reporting. If we are unable to remedy our material weakness, or if we fail
to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which could adversely impact our
investors&#146; confidence and our stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we were a private company and had limited accounting and
financial reporting personnel and other resources with which to address our internal controls and related procedures. In connection with the audit of our consolidated financial statements for the years ended December&nbsp;31, 2017 and 2018, we and
our independent registered public accounting firm identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting,
such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness related to our controls to review equity method
investee financial information at a level of precision that would identify material misstatements in our financial statements, which was due to a deficiency in the design of entity-level controls. As a result of the material weakness, we failed to
timely detect and correct a $3.4&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
undervaluation of an equity method investment. The accompanying financial statements were previously corrected to reflect the impact of this adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of implementing measures designed to improve our internal control over financial reporting to remediate this material
weaknesses. For example, we have increased communication with our equity investee companies to ensure timely receipt of relevant financial information; we have instructed our material investees to provide quarterly U.S. GAAP financial statements;
and we have implemented completeness and accuracy controls surrounding the financial data received from investees. We expect to incur additional costs to remediate this material weakness, primarily external consulting fees. We cannot assure you that
the measures we have taken to date, together with any measures we may take in the future, will be sufficient to remediate the control deficiency that led to the material weakness in our internal control over financial reporting or to avoid potential
future material weaknesses. In addition, neither our management nor an independent registered public accounting firm has ever performed an evaluation of our internal control over financial reporting in accordance with the provisions of the
Sarbanes-Oxley Act because no such evaluation has been required. Had we or our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the
Sarbanes-Oxley Act, additional material weaknesses may have been identified. If we are unable to successfully remediate our existing or any future material weakness in our internal control over financial reporting, or if we identify any additional
material weakness, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock
exchange listing requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result. We also could become subject to investigations by Nasdaq, the SEC, or other regulatory authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a result of becoming a public company, we will be obligated to develop and maintain proper and effective internal controls over financial reporting.
Any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, we will be required to furnish a report by our management on our internal control over
financial reporting beginning with our second filing of an Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> with the SEC after we become a public company. This assessment will need to include disclosure of any material
weaknesses identified by our management in our internal control over financial reporting. However, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting
until our first annual report required to be filed with the SEC following the date we are no longer an EGC. At such time as we are required to obtain auditor attestation, if we then have a material weakness, we would receive an adverse opinion
regarding our internal control over financial reporting from our independent registered accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve compliance with
Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate
internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting,
continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. During our
evaluation of our internal control, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you
that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately
report our financial condition, or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or
significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in
our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will become subject to certain reporting requirements of the Securities Exchange Act of 1934, as amended,
or the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management,
recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple
error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control
system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter
documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our certificate of incorporation and our bylaws that will become effective upon the closing of this offering may
discourage, delay, or prevent a merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could
also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members
of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other
things, these provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that only one of three classes of directors is elected each year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by
our stockholders by written consent, except in limited circumstances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings to the board of directors or to the secretary at the request of the
holders of at least 25% of the outstanding shares of our common stock and limited common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to
institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation
Law, or the DGCL, which prohibits a person who owns in excess of 15% of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding
voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our certificate of incorporation that will become effective upon
the closing of this offering designates the state courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the
company and our directors, officers, and employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation that will become effective upon the closing
of this offering provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal
district court for the District of Delaware) will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our
directors, officers, employees or stockholders to our company or our stockholders, (3)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State
of Delaware or (4)&nbsp;any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. These choice
of forum provisions will not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Exchange Act or any other claim for which federal courts have exclusive jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This exclusive forum provision may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find
favorable for disputes with us or our directors, officers, or employees, which may discourage such lawsuits against us and our directors, officers, and employees. Alternatively, if a court were to find the choice of forum provision contained in our
certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition, and
operating results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_3"></A>CAUTIONARY NOTE REGARDING
<FONT STYLE="white-space:nowrap">FORWARD-LOOKING</FONT> STATEMENTS AND INDUSTRY DATA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains <FONT
STYLE="white-space:nowrap">forward-looking</FONT> statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this prospectus, including statements regarding our strategy,
future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements. The words &#147;anticipate,&#148;
&#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148;
&#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; or the negative of these words or other similar expressions are intended to identify <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements,
although not all <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements contain these identifying words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">forward-looking</FONT> statements in this prospectus include, among other things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages of our physics-based computational platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategic plans to accelerate the growth of our software business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development efforts for our internal drug discovery programs and our computational platform;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, and results of our internal drug discovery programs or the drug discovery
programs of our collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to discover and develop product candidates and to maximize their commercial potential by advancing such
product candidates ourselves or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to leverage the synergies between our businesses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, the ability to submit applications for and the ability to obtain and maintain regulatory approvals
for any product candidates we or one of our collaborators may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our drug discovery collaborations and our estimates or expectations regarding any milestone or other payments we
may receive from such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with
our cash, cash equivalents, and marketable securities and proceeds of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages of our drug discovery programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our software solutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and clinical utility of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the potential market opportunity for our software solutions and any product candidate we
or any of our collaborators may in the future develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our marketing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify technologies with significant commercial potential that are consistent with our
commercial objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations related to the use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations related to the key drivers of our performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding revenue, timing of revenue, gross margin, expenses and loss from operations including our
preliminary estimates for the three months and year ended December&nbsp;31, 2019 and quarterly trends, and our estimates of other data relating to business performance for the year ended December 31, 2019; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and expectations regarding developments and projections relating to our competitors and
any competing products, technologies, or therapies that are or become available; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish collaborations or obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on key personnel and our ability to identify, recruit, and retain skilled personnel; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors
in the cautionary statements included in this prospectus, particularly in the &#147;Risk Factors&#148; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Moreover, we
operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements
contained in this prospectus. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration
statement of which this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this prospectus are made as of the date of
this prospectus, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be
read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and
studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this prospectus involves a number of assumptions and limitations, and you are cautioned not to give undue weight to
such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such
information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a
small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our issuance and sale of 11,882,352 shares of our common stock in this offering will be approximately
$181.8&nbsp;million, or approximately $209.9&nbsp;million if the underwriters exercise in full their option to purchase additional shares of our common stock, based on the initial public offering price of $17.00 per share, after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to
increase our capitalization and financial flexibility, create a public market for our common stock, and facilitate our future access to the capital markets. As of the date of this prospectus, we cannot specify with certainty all of the particular
uses for the net proceeds to us from this offering. However, we currently intend to use the net proceeds from this offering to continue to advance our physics-based computational platform and our internal drug discovery programs, as well as for
general corporate purposes, including working capital, operating expenses, and capital expenditures. We may also use a portion of the net proceeds to acquire complementary businesses or technologies, however, we do not have agreements or commitments
to enter into any acquisitions at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have broad discretion over how to use the net proceeds to us from this offering.
Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including <FONT STYLE="white-space:nowrap">short-term,</FONT>
<FONT STYLE="white-space:nowrap">investment-grade,</FONT> <FONT STYLE="white-space:nowrap">interest-bearing</FONT> instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock or our limited common stock. We currently intend to retain all available
funds and any future earnings to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of
our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem
relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents, and marketable securities and our capitalization as of September&nbsp;30, 2019:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the voluntary exchange of 98,406,823 shares of our preferred
stock for an aggregate of 13,164,193 shares of our limited common stock, (ii)&nbsp;the automatic conversion of 226,344,686 shares of our preferred stock into an aggregate of 30,278,832 shares of our common stock, and (iii)&nbsp;the filing and
effectiveness of our restated certificate of incorporation, in each case, upon the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of 11,882,352 shares of our
common stock in this offering at the initial public offering price of $17.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the information in this table together with our consolidated financial statements and the related notes appearing at the end
of this prospectus and the &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:8pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>As of September&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Actual</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Pro Forma</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Pro&nbsp;Forma</B></FONT><br><FONT STYLE="font-family:Times New Roman; "><B>As&nbsp;Adjusted</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman; "><B>(in thousands, except share and per share<BR>data)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">98,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">98,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">280,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series E convertible preferred stock, $0.01 par value per share; 77,150,132 shares authorized,
73,795,777 shares issued and outstanding, actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">109,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series D convertible preferred stock, $0.01 par value per share; 39,540,611 shares authorized,
39,540,611 shares issued and outstanding, actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">22,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series C convertible preferred stock, $0.01 par value per share; 47,242,235 shares authorized,
47,242,235 shares issued and outstanding, actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">19,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series B convertible preferred stock, $0.01 par value per share; 29,468,101 shares authorized,
29,468,101 shares issued and outstanding, actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">9,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series A convertible preferred stock, $0.01 par value per share; 134,704,785 shares authorized,
134,704,785 shares issued and outstanding, actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">30,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">191,580</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stockholder&#146;s (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Preferred stock, $0.01 par value per share; no shares authorized, issued or outstanding, actual;
10,000,000 shares authorized, no shares issued or outstanding pro&nbsp;forma and pro&nbsp;forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, $0.01 par value per share; 425,000,000 shares authorized, 6,071,496 shares issued and
outstanding, actual; 500,000,000 shares authorized, pro forma and pro forma as adjusted; 36,350,328 shares issued and outstanding, pro forma; 48,232,680 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-voting</FONT> common stock, $0.01 par value per share;
146,199,885 shares authorized, no shares issued and outstanding, actual; no shares authorized, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Limited common stock, $0.01 par value per share; no shares authorized, issued or outstanding,
actual; 100,000,000 shares authorized, pro forma and pro forma as adjusted; 13,164,193 shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">10,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">202,095</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">383,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(98,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(98,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(98,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity of Schr&ouml;dinger stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(87,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">104,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">286,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">104,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">104,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">286,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above does not include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,899,396<B> </B>shares of common stock issuable upon the exercise of stock options outstanding as of
September&nbsp;30, 2019, at a weighted average exercise price of $3.35 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">330,716<B> </B>shares of common stock available for future issuance under our 2010 Stock Plan, as amended, as of
September&nbsp;30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,645,228 additional shares of our common stock that are available for future issuance under our 2020 Equity
Incentive Plan, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2020 Equity Incentive Plan (which includes 3,687,296 shares of common stock underlying stock option awards that our
board granted under the 2020 Equity Incentive Plan upon the pricing of this offering with an exercise price per share equal to the initial public offering price per share); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">586,845 additional shares of our common stock that are available for future issuance under our 2020 Employee
Stock Purchase Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) as of September&nbsp;30, 2019 was $(87.2) million, or $(14.37) per share of common stock. Our
historical net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities and the carrying value of our preferred stock, which is not included within stockholders&#146; (deficit) equity. Historical net
tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by the 6,071,496 shares of common stock outstanding as of September&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of September&nbsp;30, 2019 was $104.3&nbsp;million, or $2.11 per share of common stock. Pro forma net
tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to (i)&nbsp;the voluntary exchange of 98,406,823 shares of our preferred stock for an aggregate of 13,164,193 shares of our
limited common stock and (ii)&nbsp;the automatic conversion of 226,344,686 shares of our preferred stock into an aggregate of 30,278,832 shares of our common stock, in each case, upon the closing of this offering. Pro forma net tangible book value
per share represents pro forma net tangible book value divided by the total number of shares of common stock and limited common stock outstanding as of September&nbsp;30, 2019, after giving effect to the pro forma adjustments described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to our issuance and sale of 11,882,352 shares of our common stock in this offering at the initial public offering
price of $17.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September&nbsp;30, 2019 would have been $286.1&nbsp;million, or
$4.66 per share. This represents an immediate increase in pro forma as adjusted net tangible book value per share of $2.55 to existing stockholders and immediate dilution of $12.34 in pro forma as adjusted net tangible book value per share to new
investors purchasing shares of common stock in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per
share paid by new investors. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
purchasing shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase additional shares of our common stock, our pro
forma as adjusted net tangible book value per share after this offering would be $4.97, representing an immediate increase in pro forma as adjusted net tangible book value per share of $2.87 to existing stockholders and immediate dilution in pro
forma as adjusted net tangible book value per share of $12.03 to new investors purchasing shares of common stock in this offering, based on the initial public offering price of $17.00 per share, after deducting underwriting discounts and commissions
and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of September&nbsp;30, 2019, on the pro forma as
adjusted basis described above, the total number of shares of common stock and limited common stock purchased from us on an as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
converted to common stock basis, the total consideration paid or to be paid and the weighted average price per share paid or to be paid by existing stockholders and by new investors in this
offering at the initial public offering price of $17.00 per share, before deducting underwriting discounts and commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing shares of common stock in this
offering will pay an average price per share substantially higher than our existing stockholders paid. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Price</B><br><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,514,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">197,319,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors purchasing shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,882,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,999,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,396,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">399,318,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this
offering. If the underwriters exercise in full their option to purchase additional shares of our common stock, the number of shares of our common stock and our limited common stock held by existing stockholders would be reduced to 78.4% of the total
number of shares of our common stock and limited common stock outstanding after this offering, and the number of shares of common stock held by new investors purchasing shares of common stock in this offering would be increased to 21.6% of the total
number of shares of our common stock and our limited common stock outstanding after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tables and discussion above are
based on the number of shares of our common stock and our limited common stock outstanding as of September&nbsp;30, 2019, and exclude: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,899,396<B> </B>shares of common stock issuable upon the exercise of stock options outstanding as of
September&nbsp;30, 2019, at a weighted average exercise price of $3.35 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">330,716<B> </B>shares of common stock available for future issuance as of September&nbsp;30, 2019 under our 2010
Stock Plan, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,645,228 additional shares of our common stock that are available for future issuance under our 2020 Equity
Incentive Plan, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2020 Equity Incentive Plan (which includes 3,687,296 shares of common stock underlying stock option awards that our
board granted under the 2020 Equity Incentive Plan upon the pricing of this offering with an exercise price per share equal to the initial public offering price per share); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">586,845 additional shares of our common stock that are available for future issuance under our 2020 Employee
Stock Purchase Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that outstanding stock options are exercised, new stock options are issued, or we
issue additional shares of common stock in the future, there will be further dilution to our stockholders, including investors purchasing shares of common stock in this offering. In addition, we may choose to raise additional capital because of
market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of
these securities could result in further dilution to our stockholders, including investors purchasing shares of common stock in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_8"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth our selected consolidated financial data for the periods indicated. We have derived the consolidated statement
of operations data for the years ended December&nbsp;31, 2017 and 2018 and the consolidated balance sheet data as of December&nbsp;31, 2017 and 2018 from our audited consolidated financial statements appearing at the end of this prospectus. The
consolidated statement of operations data for the nine months ended September&nbsp;30, 2018 and 2019 and the consolidated balance sheet data as of September&nbsp;30, 2019 have been derived from our unaudited consolidated financial statements
appearing at the end of this prospectus and have been prepared on a basis consistent with our audited consolidated financial statements. In the opinion of management, the unaudited consolidated financial data reflects all adjustments, consisting
only of normal, recurring adjustments, necessary for a fair statement of the financial information in those statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical
results are not necessarily indicative of the results that may be expected in the future, and our interim results are not necessarily indicative of results to be expected for a full fiscal year or any other interim period. You should read the
following selected consolidated financial data together with our consolidated financial statements and the related notes appearing at the end of this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; section of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 45,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 49,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gain on equity investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss attributable to Schr&ouml;dinger stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss per share attributable to Schr&ouml;dinger common stockholders, basic and diluted</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted average common shares used to compute net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,608,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,771,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,730,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,969,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> net loss per share, basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> weighted average common shares outstanding basic
and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,384,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,465,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current and long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of
operations together with the &#147;Selected Consolidated Financial Data&#148; section of this prospectus and our consolidated financial statements and related notes appearing at the end of this prospectus. Some of the information contained in this
discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a
result of many factors, including those factors set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in
the following discussion and analysis. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are transforming the way therapeutics and materials are discovered. Our differentiated, physics-based software platform enables discovery of
high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods. Our software is used by biopharmaceutical and industrial
companies, academic institutions, and government laboratories around the world, and we are the leading provider of computational software solutions for drug discovery. We also apply our computational platform to a broad pipeline of drug discovery
programs in collaboration with biopharmaceutical companies, some of which we <FONT STYLE="white-space:nowrap">co-founded.</FONT> In addition, we are using our platform to advance a pipeline of internal, wholly-owned drug discovery programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our founding, we have been primarily focused on developing our computational platform, which is capable of predicting critical
properties of molecules with a high degree of accuracy. We have devoted substantially all of our resources to introducing new capabilities and refining our software, conducting research and development activities, recruiting skilled personnel, and
providing general and administrative support for these operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are using our computational platform in both collaborative and
wholly-owned drug discovery programs. Over the last decade, we have entered into a number of collaborations with biopharmaceutical companies that have provided us with significant income and have the potential to produce additional milestone
payments, option fees, and future royalties. Furthermore, since <FONT STYLE="white-space:nowrap">mid-2018,</FONT> we have launched five internal, wholly-owned programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generate revenues from sales of our software solutions and from research funding and milestone payments from our drug discovery
collaborations, which we have used to support our research and development and other operating expenses. In addition, since inception we have raised gross proceeds of $192.6&nbsp;million from sales of our convertible preferred stock as well as
amounts received from our equity investment in Nimbus Therapeutics, LLC, or Nimbus, which we <FONT STYLE="white-space:nowrap">co-founded</FONT> in 2009. In late 2018 and early 2019, we issued and sold an aggregate of 73,795,777 shares of Series E
convertible preferred stock at $1.4906 per share, for $110.0&nbsp;million in gross proceeds. In 2016, Nimbus sold its <FONT STYLE="white-space:nowrap">Acetyl-CoA</FONT> carboxylase, or ACC, inhibitor, firsocostat, to Gilead Sciences, Inc., or Gilead
Sciences, in a transaction valued at approximately $1.2&nbsp;billion, comprised of an upfront payment and&nbsp;earn outs that are tied to the achievement of specified development and regulatory milestones. Of this amount, $601.3&nbsp;million has
been paid to Nimbus to date, and we received a total of $46.0&nbsp;million in cash distributions in 2016 and 2017.&nbsp;We are eligible to receive up to $46 million in future cash distributions on the remaining approximately $600&nbsp;million of
earn outs, if and when such earn outs are achieved. However, the likelihood and timing of such payments, if any, are not possible for us to predict as the achievement of the development and regulatory milestones under the transaction agreement is
uncertain and outside of our control. In December 2019, Gilead Sciences announced topline results from its Phase 2 clinical trial which included firsocostat, both as a monotherapy and in combination with other investigational therapies, in which the
primary endpoint was not met. Gilead Sciences announced that it was continuing to analyze the data from the trial and determine next steps. We do not know how this development will affect Nimbus&#146; right to receive future earnout payments from
Gilead Sciences or our right to receive cash distributions from Nimbus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
However, if Gilead Sciences determined not to continue to advance the development of firsocostat, then we would not expect to receive any additional distributions from Nimbus on account of this
program. Additionally, even if Nimbus were to receive any further earnout payments from Gilead Sciences, any distribution to us as an investor in Nimbus would need to be approved by the board of directors of Nimbus.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently conduct our operations through two reportable segments: software and drug discovery.&nbsp;The software segment is focused on
selling our software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries.&nbsp;The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and
clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our software
segment generates revenue from software product licenses, hosted software subscriptions, software maintenance, and professional services. The revenue we generate through our software solutions from each of our customers varies largely depending on
the number of software licenses our customers purchase from us. The licenses that our customers purchase from us provide them the ability to perform a certain number of calculations used in the design of molecules for drug discovery or materials
science. We deliver our software through either (i)&nbsp;a product license that permits our customers to install the software solution directly on their own <FONT STYLE="white-space:nowrap">in-house</FONT> hardware and use it for a specified term,
or (ii)&nbsp;a subscription that allows our customers to access the cloud-based software solution for a specified term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently
generate drug discovery revenue from our collaborations, including research funding payments and discovery and development milestones. In the future, we may also derive drug discovery revenue from our collaborations from option fees, the achievement
of commercial milestones, and royalties on commercial drug sales. In addition to revenue from our collaborations, in the future we may also derive drug discovery revenue from out-licensing our internal drug discovery programs when we believe it will
help maximize the commercial potential of the program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generated revenue of $55.7&nbsp;million and $66.6&nbsp;million in 2017 and
2018, respectively, representing year-over-year growth of 20%. We generated revenue of $49.2 million and $59.7 million for the nine months ended September&nbsp;30, 2018 and 2019, respectively, representing period-over-period growth of 21%. Our net
loss was $17.4 million, $28.4 million, $22.1 million, and $18.5 million for the years ended December&nbsp;31, 2017 and 2018 and the nine months ended September&nbsp;30, 2018 and 2019, respectively. For information regarding our estimated preliminary
results for the three months and year ended December&nbsp;31, 2019, see &#147;Prospectus Summary&#151;Estimated Preliminary Results.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Factors
Affecting Our Performance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ability to drive additional revenue from our software solutions from existing customers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our large existing base of customers represents a significant opportunity for us to expand our revenue through increased utilization of our
software. The revenue that we generate through our software solutions from each of our customers varies depending on the number of licenses for each software solution that each customer purchases from us. Accordingly, we work with our customers to
improve their experience and increase the utility of our platform in order to expand the scale at which they deploy our platform in their business. Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we
anticipate that this <FONT STYLE="white-space:nowrap">scaling-up</FONT> will drive future revenue growth. Our ability to expand within our customer base is best demonstrated by the increasing number of our customers with an annual contract value, or
ACV, of over $100,000. We had 87, 103, and 122 of these customers for the years ended December&nbsp;31, 2016, 2017, and 2018, respectively. This subset of customers represented approximately 79%, 75%, and 77% of our total ACV for the years ended
December 31, 2016, 2017, and 2018, respectively. In addition, we had eight, nine, and 11 customers with an ACV of over $1.0&nbsp;million for the years ended December&nbsp;31, 2016, 2017, and 2018, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually,
we define ACV as the contract value billed during the applicable period. For </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contracts with a duration of more than one year that are billed upfront, ACV in each period represents the total billed contract value divided by the term. ACV should be viewed independently of
revenue and does not represent revenue calculated in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, on an annualized basis, as it is an operating metric that can be impacted by contract execution start
and end dates and renewal rates. ACV is not intended to be a replacement for, or forecast of, revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, another important
driver of our ability to expand our customer relationships is the retention of our customers with an ACV over $100,000. For the year ended December&nbsp;31, 2018 and for each of the previous five fiscal years, our year-over-year customer retention
for such customers was over 96%. We calculate year-over-year customer retention rate by first identifying customers with an ACV over $100,000 in the previous fiscal year, and then calculating how many of these customers were active customers in the
current fiscal year. We then divide this number by the number of customers with an ACV over $100,000 we had in the previous fiscal year to arrive at the year-over-year customer retention rate for such customers. We intend to leverage our existing
relationships with our customers to drive larger-scale adoption of our software solutions. If we are unable to continue to increase revenue from existing customers, our financial performance will be adversely impacted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ability to increase our customer base for our software solutions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we have significant opportunity to continue to increase the number of customers who use our solutions. We had 960, 1,042, and
1,150 active customers for the years ended December&nbsp;31, 2016, 2017, and 2018. We define the number of active customers as the number of customers who had an ACV of at least $1,000 in a given fiscal year. We use $1,000 as a threshold for
defining our active customers as this amount will generally exclude customers who only license our PyMOL software, which is our open-source molecular visualization system broadly available at low cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have significantly penetrated the pharmaceutical industry, with all of the top 20 pharmaceutical companies, measured by revenue,
using our software in 2018, accounting for $22.0 million, or 33%, of our 2018 revenue, our strategy is to grow our customer base. We believe there remains a large opportunity for growth as there are thousands of biopharmaceutical companies that
could benefit from our solutions. Additionally, since the physics underlying the properties of drug molecules and materials is the same, we have been able to extend our computational platform to materials science applications in fields such as
aerospace, energy, semiconductors, and electronic displays. We sell our software solutions to a growing number of materials science customers, and we believe the materials science industry is only beginning to recognize the potential of
computational methods. We continue to promote the education and recognition of our computational platform across industries. As part of our strategy, we have driven the adoption of our software by researchers, and we had more than 1,250 academic
institutions across the world using our software in 2018. We believe that by introducing the benefits of our computational software at the academic stage, we will drive brand awareness and expand the use of our platform to industries that have
historically relied on traditional methods for discovery of molecules. Our ability to continue to grow our customer base is dependent upon our ability to educate the market and support the business through investment in our sales and marketing
efforts and the ongoing enhancement of our software solutions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Advancement of our collaborations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a number of collaborations with various biopharmaceutical companies, some of which we have
<FONT STYLE="white-space:nowrap">co-founded,</FONT> to advance drug discovery. We will seek to enter into additional collaboration agreements, driven by the synergies we expect to achieve between our platform and the capabilities and expertise of
our potential collaborators. We believe that our collaborations will be a significant driver of value for us in the form of equity stakes, research fees, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, and commercial milestone
payments, and option fees, as well as royalties on any potential future sales of products, if approved. We continue to work with our current collaborators to advance existing programs through discovery research stages and initiate additional
programs. However, we do not generally exercise control over the development programs of our collaborators and often </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rely on decisions of the management of such companies with respect to clinical development and commercialization. Our ability to continue to derive value from our collaborations will be driven by
both our capability to make progress in these programs as well as whether our collaborators successfully advance such programs beyond the discovery stage. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ability to develop and expand our internal proprietary drug discovery pipeline </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are advancing our pipeline of internal drug discovery programs through extensive application of our software platform. Since launching our
first program in mid-2018, we have built a pipeline of five programs. We intend to progress our wholly-owned programs through the development candidate stage and potentially into investigational new drug-enabling studies and clinical development. As
we progress these programs, we will strategically evaluate on a program-by-program basis entering into clinical development ourselves or out-licensing programs to maximize commercial opportunities. However, we will need to devote substantial
resources to develop and expand our internal pipeline. Our ability to advance and build value in our internal drug discovery programs will impact our financial performance, especially as we increasingly shift our focus to these programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Software Products and Services Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our software business generates revenue from four sources: <FONT STYLE="white-space:nowrap">(i)&nbsp;on-premise</FONT> software license fees,
(ii)&nbsp;hosted software subscription fees, (iii)&nbsp;software maintenance fees, and (iv)&nbsp;professional services fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">On-premise</FONT> software.</I> Our <FONT STYLE="white-space:nowrap">on-premise</FONT> software license arrangements grant customers the right to use our software on their own
<FONT STYLE="white-space:nowrap">in-house</FONT> servers for a specified term, typically for one year. We recognize revenue for <FONT STYLE="white-space:nowrap">on-premise</FONT> software license fees upfront, either upon delivery of the license or
the effective date of the agreement, whichever is later. We expect our <FONT STYLE="white-space:nowrap">on-premise</FONT> software revenue to trend lower over time as customers shift from installing our software on their own <FONT
STYLE="white-space:nowrap">in-house</FONT> servers to utilizing a hosted solution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hosted software. </I>Hosted software revenue
consists primarily of fees to provide our customers with access to our hosted software platform and is recognized ratably over the term of the arrangement, which is typically one year.<I> </I>We expect our hosted software revenue to trend higher
over time as our customers continue to migrate from purchasing <FONT STYLE="white-space:nowrap">on-premise</FONT> software licenses to utilizing our hosted software solution. When a customer enters into a hosted arrangement for which revenue is
recognized over time, the amount paid upfront that is not recognized in the current period is included in deferred revenue in our statement of financial position until the period in which it is recognized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Software maintenance.</I> Software maintenance includes technical support, updates, and upgrades related to our <FONT
STYLE="white-space:nowrap">on-premise</FONT> software licenses. Software maintenance revenue is recognized ratably over the term of the arrangement. Since software maintenance activities are performed in connection with the use of our <FONT
STYLE="white-space:nowrap">on-premise</FONT> software, we expect our software maintenance revenue to trend lower over time, although it may fluctuate from period to period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Professional services.</I> Professional services, such as technical setup or installation or modeling services, where we use our software
to perform tasks such as virtual screening and homology modeling on behalf of our customers, generally are not related to the functionality of our software and are recognized as revenue when resources are consumed. Since each professional services
agreement represents a unique, ad hoc engagement, we expect our professional services revenue to fluctuate from period to period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Drug Discovery Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently generate drug discovery revenue from discovery collaboration arrangements, including research funding payments and discovery and
development milestones. We expect our drug discovery revenue to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trend higher over time as these collaboration arrangements advance and we receive additional revenue from research funding payments, the achievement of discovery, development, and commercial
milestones, option fees, and royalties on commercial drug sales. The majority of our current collaborations are in the discovery stage. Milestone payments typically increase in magnitude as a program advances. In addition to revenue from our
collaborations, in the future we may also derive drug discovery revenue from <FONT STYLE="white-space:nowrap">out-licensing</FONT> our internal drug discovery programs when we believe it will help maximize the commercial potential of the program.
However, we expect that our revenue will fluctuate from period to period due to the inherently uncertain nature of the timing of milestone achievement and our dependence on the program decisions of our collaborators. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenues </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Software products and services.</I> Cost of revenues for software includes personnel-related expenses (comprised of salaries, benefits, and
stock-based compensation) for employees directly involved in the delivery of software solutions, maintenance and professional services, royalties paid for products sold and services performed using third-party licensed software functionality, and
allocated overhead (facilities and information technology support) costs. Pursuant to various third party arrangements, we license technology that is used in our software. These arrangements require us to pay royalties based on sales volume, and
such royalty payments represented 6.4% and 7.6% of software revenues in the years ended December&nbsp;31, 2017 and 2018, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Drug discovery. </I>Costs of revenue for drug discovery includes personnel-related expenses and costs of third-party contract research
organizations, or CROs, that support discovery activities in our collaborations, royalties paid for services performed using third-party licensed software functionality, and allocated compute capacity and overhead costs. Currently, we have only one
collaboration that involves payment of CRO costs. While we have incurred costs associated with discovery efforts for this collaboration since late 2017, we expect revenues to be recognized in the future if and when milestones are achieved.
Generally, drug discovery costs of revenue for collaborations are incurred in advance of the revenue milestone achievement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Royalty
payments to third parties represented 4.8% and 5.1% of drug discovery revenues in the years ended December&nbsp;31, 2017 and 2018, respectively. We expect our drug discovery costs of revenue to trend higher over time as our discovery collaborations
advance. Personnel-related expenses for our internal discovery programs are classified within research and development expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gross Profit and Gross Margin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit represents revenue less cost of revenues. Gross margin is gross profit expressed as a percentage of revenue. Our software products
and services gross margin may fluctuate from period to period as our revenue fluctuates, and as a result of changes in sales mix between <FONT STYLE="white-space:nowrap">on-premise</FONT> and hosted software solutions. For example, the cost of
royalties due for sales of our hosted software arrangements are recognized upfront, whereas the associated revenue is recognized over the term of the underlying agreement. Currently, gross margin is not meaningful for measuring the operating results
of our drug discovery business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense accounts for a significant portion of our operating expenses. We recognize research and development expenses
as incurred. Research and development expenses consist of internal drug discovery program costs and costs incurred for continuous development of the technology and science that supports our computational platform, primarily: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel-related expenses, including salaries, benefits, bonuses, and stock-based compensation for employees
engaged in research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with third-party CROs and consultants involved in our internal discovery
programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated compute capacity and overhead (facilities and information technology support) costs.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expense to increase substantially in absolute dollars
for the foreseeable future as we continue to invest in activities related to discovery and development of our internal target candidates, in advancing our platform, and as we incur expenses associated with hiring additional personnel directly
involved in such efforts. At this time, we do not know, nor can we reasonably estimate, the nature, timing, or costs of the efforts that will be necessary to complete the development of any of our internal drug discovery programs. Since our internal
drug discovery efforts are at a very early stage, currently we do not track research and development expense on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sales and Marketing Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales and marketing expense consists primarily of personnel-related costs for our sales and marketing staff and application scientists
supporting our sales efforts, including salaries, benefits, bonuses, and stock-based compensation. Other sales and marketing costs include promotional events that promote and expand knowledge of our company and platform, including industry
conferences and events and our annual user group meetings in the United States and Europe, advertising, and allocated overhead costs. Most operating costs of our sales offices in Europe and Japan are included in sales and marketing expense. Due to
the inherent scientific complexity of our software solutions, a high level of scientific expertise is needed to support our sales and marketing efforts. We plan to increase our investment in sales and marketing over the foreseeable future to foster
the growth of our business as we aim to expand software sales to existing customers and increase our customer base. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and
Administrative Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense consists of personnel-related expenses associated with our executive,
legal, finance, human resources, information technology, and other administrative functions, including salaries, benefits, bonuses, and stock-based compensation. General and administrative expense also includes professional fees for external legal,
accounting and other consulting services, allocated overhead costs, and other general operating expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to increase the size
of our general and administrative staff to support the anticipated growth of our business. Following the completion of this offering, we expect to incur additional expenses as a result of operating as a public company, including costs to comply with
the rules and regulations applicable to companies listed on a U.S. securities exchange and costs related to compliance and reporting obligations pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In addition, as
a public company, we expect to incur increased expenses such as insurance and professional services. As a result, we expect the dollar amount of our general and administrative expense to increase for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gain on Equity Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on equity investments consists of realized gains in the form of cash distributions received from Nimbus. In 2017, we received a
$3.2&nbsp;million cash distribution from Nimbus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value gains and losses consist of adjustments to the fair values of our equity investments, including Nimbus and Morphic Holding, Inc., or
Morphic. In June 2019, Morphic became a publicly traded company and, as such, fair value is determined as the current market value of Morphic common stock as of the reporting date. Upon commencement of public trading of Morphic&#146;s common stock,
we recognized a $16.3 million fair value gain on our investment in Morphic. We subsequently remeasured the value of Morphic&#146;s common stock as of September 30, 2019 and recognized a $1.4 million loss for the three months ended September 30,
2019. Prior to Morphic&#146;s initial public offering, fair value changes for our Morphic investment were determined under the hypothetical liquidation book value, or HLBV, method. For further information regarding the HLBV method, see
&#147;&#151;Critical Accounting Policies and Significant Judgments and Estimates&#151;Valuation of Equity Investments.&#148; We expect that fair value gains and losses may fluctuate significantly in future periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists of interest earned on our cash equivalents and marketable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Expense (Benefit) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit) consists of U.S. federal and state income taxes and income taxes in certain foreign jurisdictions in which we
conduct business. We maintain a full valuation allowance on our federal and state deferred tax assets as we have concluded that it is not more likely than not that the deferred tax assets will be realized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison
of the nine months ended September&nbsp;30, 2018 and 2019 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our unaudited results of operations data
for the nine months ended September&nbsp;30, 2018 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,573</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">On-premise</FONT> software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hosted software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33)</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">On-premise</FONT> software.</I> The decrease in revenues for <FONT
STYLE="white-space:nowrap">on-premise</FONT> software was primarily attributable to a shift in sales mix from customers purchasing our software product licenses for use on their own <FONT STYLE="white-space:nowrap">in-house</FONT> servers, which is
recognized upfront at a single point in time, to accessing our software as a hosted solution, which is classified within hosted software revenue and recognized ratably over the term of the arrangement. In addition, we fully recognized the revenue
associated with several large multi-year license arrangements in the first quarter of 2018 that did not repeat in the first quarter of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hosted software.</I> The increase in revenues for hosted software was primarily due to existing customers shifting from <FONT
STYLE="white-space:nowrap">on-premise</FONT> software product licenses to hosted software subscriptions, for which revenue is recognized ratably over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Software maintenance. </I>The increase in revenues for software maintenance was primarily due to higher product sales in the second half of
2018, as compared to the prior year, which resulted in higher maintenance revenue recognized in the first nine months of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Professional services. </I>The decrease in revenues from professional services was primarily due to lower modeling services fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Drug discovery.</I> The increase in revenues for drug discovery was primarily due to the achievement of collaboration milestones. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenues </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Software products and services.</I> The increase in cost of revenues for software products and services was
attributable to increases of $1.7&nbsp;million in personnel-related expenses, $0.7&nbsp;million in compute capacity costs, and $0.1&nbsp;million in other costs of revenue. The decrease in gross margin was primarily attributable to an increase in
personnel-related expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Drug discovery.</I> The increase in cost of revenues for drug discovery was attributable
to increases of $3.3&nbsp;million in third-party CRO costs to support a collaboration, $1.5&nbsp;million in compute capacity costs, $1.3&nbsp;million in personnel-related expenses, $0.7&nbsp;million in royalties paid to third parties for use of
licensed software functionality, and $0.3&nbsp;million in other costs of revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in research and development expense was primarily due to additional CRO costs associated with the
expansion and progression of internal drug discovery programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sales and Marketing Expense </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in sales and marketing expense was primarily attributable to an increase in personnel-related
expenses due to additional employee headcount to support the expansion of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expense
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the nine months ended September&nbsp;30, 2019, we recognized a total of $3.3&nbsp;million in <FONT
STYLE="white-space:nowrap">non-comparable</FONT> costs, which consisted of $1.8&nbsp;million of costs related to a cash distribution we received from Nimbus and a $1.5&nbsp;million unconditional gift to Columbia University intended to fund a
research laboratory. The increase in general and administrative expense was also attributable to an increase of $2.8&nbsp;million in personnel-related expenses due to additional employee headcount and a $0.7&nbsp;million increase in other expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in fair value for the nine months ended September&nbsp;30, 2019 was primarily due to a
$14.9&nbsp;million gain on our equity investment in Morphic, partially offset by a $4.3&nbsp;million loss on our equity investment in Nimbus. The decrease in fair value for the nine months ended September&nbsp;30, 2018 consisted of a
$2.2&nbsp;million loss on our equity investment in Nimbus and a $0.5&nbsp;million loss on our equity investment in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Morphic. Morphic became a publicly traded company in June 2019 and, as such, we revalued our investment as of September&nbsp;30, 2019 to equal the current fair market value of Morphic common
stock. The Nimbus fair value loss was determined under the HLBV method. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in interest income was attributable to increased earnings on our investment portfolio balance,
which increased significantly year-over-year due to the investment of proceeds from our Series E preferred stock issuance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income
Taxes </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the full valuation allowance on our U.S. federal and state deferred tax assets, income tax expense
(benefit) represents our income tax obligations in certain foreign jurisdictions in which we conduct business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2017 and 2018 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations data for the years ended December&nbsp;31, 2017 and 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on equity investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">On-premise</FONT> software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hosted software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">On-premise</FONT> software.</I> The increase in revenues for <FONT
STYLE="white-space:nowrap">on-premise</FONT> software was primarily due to increases in sales of multi-year agreements and additional software products to existing customers, partially offset by a shift
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in sales mix from customers purchasing software licenses for use on their own <FONT STYLE="white-space:nowrap">in-house</FONT> servers to accessing our software as a hosted solution, which is
classified within hosted software revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hosted software.</I> The increase in revenues for hosted software was primarily due to a
$1.4&nbsp;million increase in revenues for hosted software subscriptions sold to existing customers shifting from software product licenses and a $0.2&nbsp;million increase in hosted subscriptions sold to new customers. Revenue from sales of hosted
software subscriptions is recognized ratably over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Software maintenance. </I>The increase in software maintenance revenue was
primarily attributable to post-contract support for new <FONT STYLE="white-space:nowrap">on-premise</FONT> software license arrangements.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Professional services. </I>The increase in professional services revenue was primarily attributable to new professional services contracts.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Drug discovery.</I> The increase in revenues for drug discovery was due to a $1.4&nbsp;million net increase in achievement of
collaboration milestones and a $0.5&nbsp;million increase in research funding revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenues </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Software products and services.</I> The increase in cost of revenues for software products and services was
attributable to increases of $1.3&nbsp;million in royalties paid to third parties for use of licensed software functionality, primarily due to a shift in the timing and mix of royalty-bearing product sales, $1.1&nbsp;million in personnel-related
expenses, and $0.4&nbsp;million in other costs of revenue. The decrease in gross margin was primarily attributable to a shift in the timing and mix of royalty-bearing software sales and increased personnel-related expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Drug discovery.</I> The increase in cost of revenues for drug discovery was attributable to increases of $1.6&nbsp;million in
personnel-related expenses, $2.2&nbsp;million in third-party CRO costs to support a collaboration, $0.3&nbsp;million in information compute capacity costs, and $0.7&nbsp;million in other costs of revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in research and development expense was attributable to $3.0&nbsp;million for increased compute
capacity and facilities costs, a $2.9&nbsp;million increase in personnel-related expenses due to additional employee headcount, $0.4&nbsp;million of additional CRO costs associated with the launch of a new internal drug discovery program, and a
$0.6&nbsp;million increase in other expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sales and Marketing Expense </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in sales and marketing expense was primarily attributable to an increase in personnel-related
expenses due to additional employee headcount to support the expansion of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expense
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in general and administrative expenses was attributable to increases of $1.5&nbsp;million in
personnel-related expenses due to additional employee headcount to support the growth of our business, $0.8&nbsp;million in information technology costs as we further developed our internal systems and processes, $0.8&nbsp;million in legal,
accounting and consulting fees, $0.3&nbsp;million in facilities costs for additional office space, and $0.7&nbsp;million in other expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gain on Equity Investment </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on equity investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received a $3.2&nbsp;million cash distribution from our Nimbus investment in 2017. No cash distributions
were received in 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in fair value relate primarily to decreases in our Nimbus and Morphic equity investment valuations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in interest income was attributable to earnings on our investment portfolio balance, which
increased significantly year-over-year due to the investment of proceeds from our Series E preferred stock issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Expense </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the full valuation allowance on our U.S. federal and state deferred tax assets, income tax expense
represents our income tax obligations in certain foreign jurisdictions in which we conduct business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quarterly Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our selected unaudited quarterly results of operations data for each of the seven quarters in the period ended
September&nbsp;30, 2019. The information for each of these quarters has been prepared on the same basis as our audited annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal, recurring nature
that are necessary for the fair statement of the results of operations for these periods. This data should be read in conjunction with our audited consolidated financial statements included elsewhere in this prospectus. Historical results are not
necessarily indicative of the results that may be expected for the full fiscal year or any other period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,940</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes stock-based compensation as indicated in the table located further below. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenues: </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">On-premise</FONT> software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hosted software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Revenue: </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gross Margin: </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation: </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Depreciation and Amortization: </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total depreciation and amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly Revenue Trends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">On-premise</FONT> software revenue is subject to seasonality that favors the first quarter of each year,
primarily due to the calendar year timing of customer renewals for <FONT STYLE="white-space:nowrap">on-premise</FONT> software arrangements, for which revenue is recognized at a single point in time. Hosted software revenue grew steadily in the
periods presented, as existing customers migrated from <FONT STYLE="white-space:nowrap">on-premise</FONT> licenses to hosted solutions, for which revenue is recognized over time. As a result, a substantial portion of the software products and
services revenue we reported in each period was attributable to sales we made in prior periods. Software maintenance revenue is related to <FONT STYLE="white-space:nowrap">on-premise</FONT> software sales and also is recognized ratably over the term
of the underlying agreement. Therefore, increases or decreases in customer sales, customer expansion, or renewals in a period may not be immediately reflected in revenue for the period. Our professional services arrangements are typically
project-based and, therefore, fluctuated based on individual customer needs and ongoing project support. Drug discovery revenue fluctuated from period to period based on the achievement of specific collaboration milestones, but has grown in recent
periods as our collaborations have advanced. The majority of our current collaborations are in the discovery stage. Milestone payments typically increase in magnitude as a program advances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly Deferred Revenue Trends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred revenue consists of the unearned portion of customer billings, which is recognized as revenue in accordance with our revenue
recognition policy, as well as the unearned portion of unbilled collaboration milestones that are deemed probable in advance of actual achievement. Deferred revenue balances have generally increased over the periods presented, but have fluctuated
based on the timing of sales, the shift of product mix as customers transitioned from <FONT STYLE="white-space:nowrap">on-premise</FONT> software to hosted software that is recognized over time, and the increase in the number of milestones that were
deemed probable in advance of actual achievement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly Gross Margin Trends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our software products and services gross margin experienced declines over the periods presented due to increased headcount and the timing
effect of a shift in software sales from on-premise to hosted solutions. The cost of royalties due on sales of our hosted software is recognized upfront, while the associated revenue is recognized over the term of the related agreement, which
created fluctuation in gross margin from quarter-to-quarter. Currently, gross margin is not meaningful for measuring the operating results of our drug discovery business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly Operating Expense Trends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating expenses generally increased during the periods presented due to increased headcount involved in research and development, sales and
marketing, general and administrative activities, and CRO costs related to our internal drug discovery programs. These increases in headcount across our operations have supported the overall growth and management of our business. CRO cost increases
were driven by the launch and expansion of our internal drug discovery programs. Included in general and administrative expense in the second quarter of 2019 was $3.3 million of non-comparable items. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly Other (Expense) Income Trends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other (expense) income during the periods presented consisted primarily of fair value gains and losses related to our equity investments in
Nimbus and Morphic and, to a lesser degree, interest income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segment Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize segment information for the years ended December&nbsp;31, 2017 and 2018 and the nine months ended September 30,
2018 and 2019. See Note 16 in our audited consolidated financial statements and Note&nbsp;12 in our unaudited condensed consolidated financial statements included elsewhere in this prospectus for additional information regarding our segments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Segment gross profit is derived by deducting operational expenditures, with the exception of research and development, sales and marketing,
and general and administrative activities from U.S. GAAP revenue. Operational expenditures are expenditures made that are directly attributable to the reportable segment. These expenditures are allocated to the segments based on headcount. The
reportable segment expenditures include compensation, supplies, and services from contract research organizations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain cost items are not allocated to our reportable segments. These cost items primarily
consist of compensation and general operational expenses associated with our research and development, sales and marketing, and general and administrative activities.&nbsp;These costs are incurred by both segments and, due to the integrated nature
of our software and drug discovery segments, any allocation methodology would be arbitrary and provide no meaningful analysis. Additionally, we report assets on a consolidated basis and do not allocate assets to our reportable segments for purposes
of assessing segment performance or allocating resources. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Segment revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total segment revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Segment gross profit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total segment gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unallocated (expense) income:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,621</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on equity investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically we have incurred substantial operating losses and expect to continue to incur significant operating losses for the foreseeable
future and may never become profitable. As of September&nbsp;30, 2019, we had an accumulated deficit of $98.3&nbsp;million. Our operating cash flows are impacted by the magnitude and timing of our software sales and, to a lesser degree, by the
magnitude and timing of our drug discovery milestone achievements and research funding fees. Our primary use of cash is to fund operating expenses, which consist of research and development, sales and marketing, and general and administrative
expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay operating expenses to vendors and collect amounts due from customers and collaborators, which is reflected in changes in our operating assets and
liabilities, including accounts payable, accrued expenses, prepaid expenses, deferred revenue, and accounts receivable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generate
revenues from sales of our software solutions and from research funding and milestone payments from our drug discovery collaborations, which we have used to support our research and development and other operating expenses. In addition, since
inception we have raised gross proceeds of $192.6&nbsp;million from sales of our convertible preferred stock, as well as amounts received from our equity investment in Nimbus, which we <FONT STYLE="white-space:nowrap">co-founded</FONT> in 2009. In
late 2018 and early 2019, we issued and sold an aggregate of 73,795,777 shares of Series E convertible preferred stock at $1.4906 per share, for $110.0&nbsp;million in gross proceeds. In 2016, Nimbus sold its ACC inhibitor, firsocostat, to Gilead
Sciences in a transaction valued at approximately $1.2&nbsp;billion, comprised of an upfront payment and&nbsp;earn outs that are tied to the achievement of specified development and regulatory milestones. Of this amount $601.3&nbsp;million has been
paid to Nimbus to date, and we have received a total of $46.0&nbsp;million in cash distributions to date.&nbsp;We are eligible to receive up to $46&nbsp;million in future cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distributions on the remaining approximately $600&nbsp;million of earn outs, if and when such earn outs are achieved. However, the likelihood and timing of such payments, if any, are not possible
for us to predict as the achievement of the development and regulatory milestones under the transaction agreement is uncertain and outside of our control. In December 2019, Gilead Sciences announced topline results from its Phase 2 clinical trial
which included firsocostat, both as a monotherapy and in combination with other investigational therapies, in which the primary endpoint was not met. Gilead Sciences announced that it was continuing to analyze the data from the trial and determine
next steps. We do not know how this development will affect Nimbus&#146; right to receive future earnout payments from Gilead Sciences or our right to receive cash distributions from Nimbus. However, if Gilead Sciences determined not to continue to
advance the development of firsocostat, then we would not expect to receive any additional distributions from Nimbus on account of this program. Additionally, even if Nimbus were to receive any further payments from Gilead Sciences, any distribution
to us as an investor in Nimbus would need to be approved by the board of directors of Nimbus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, we had cash,
cash equivalents, and marketable securities of $98.3&nbsp;million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view towards capital preservation and liquidity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table presents a summary of our cash flows for the periods shown: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,794</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, operating activities used approximately $15.3&nbsp;million of cash, primarily resulting from net
loss of $17.4&nbsp;million, which included a $1.6&nbsp;million <FONT STYLE="white-space:nowrap">non-cash</FONT> loss from changes in fair value of equity investments, and approximately $2.8&nbsp;million of
<FONT STYLE="white-space:nowrap">non-cash</FONT> operating expenses included in net loss, including depreciation and stock-based compensation costs. In addition, a $3.2&nbsp;million gain on equity investments included in net loss was classified as
an investing activity. Changes in our operating assets and liabilities provided cash of approximately $1.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year
ended December&nbsp;31, 2018, operating activities used approximately $23.7&nbsp;million of cash, primarily resulting from net loss of $28.4&nbsp;million, partially offset by $3.6 million of <FONT STYLE="white-space:nowrap">non-cash</FONT> operating
expenses included in net loss, including depreciation and stock-based compensation costs, and a $0.8 million non-cash loss from changes in fair value of equity investments. Changes in our operating assets and liabilities provided cash of
approximately $0.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2018, operating activities used approximately
$14.3&nbsp;million of cash, primarily resulting from net loss of $22.1&nbsp;million, which included a $2.7&nbsp;million non-cash loss from changes in fair value of equity investments, and approximately $2.5&nbsp;million of non-cash operating
expenses included in net loss, including depreciation and stock-based compensation costs. Changes in our operating assets and liabilities provided cash of approximately $2.6&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2019, operating activities used approximately $14.8&nbsp;million of cash, primarily resulting
from net loss of $18.5&nbsp;million, which included a $10.6&nbsp;million non-cash gain from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes in fair value of equity investments, and approximately $4.6&nbsp;million of non-cash operating expenses included in net loss, including depreciation and stock-based compensation costs.
Changes in our operating assets and liabilities provided cash of approximately $9.7&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, investing activities provided approximately $2.0&nbsp;million of cash, primarily attributable to
$42.0&nbsp;million of proceeds upon the maturity of marketable securities and a $3.2&nbsp;million cash distribution from an equity method investment, partially reduced by $38.9&nbsp;million used for purchases of marketable securities and
$3.7&nbsp;million used for purchases of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, investing activities
provided approximately $11.2&nbsp;million of cash, primarily attributable to $20.1&nbsp;million of proceeds upon the maturity of marketable securities, partially reduced by $5.3&nbsp;million used for purchases of property and equipment,
$3.3&nbsp;million for the purchase of additional shares of Nimbus, and $0.3&nbsp;million for the purchase of additional shares of Morphic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2018, investing activities provided approximately $10.6&nbsp;million of cash, primarily
attributable to $19.2&nbsp;million of proceeds upon the maturity of marketable securities, partially reduced by $4.9&nbsp;million used for purchases of property and equipment and $3.6&nbsp;million for the purchase of additional shares of Nimbus and
Morphic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2019, investing activities used approximately $60.2&nbsp;million of cash,
primarily for purchases of marketable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, financing activities provided approximately $1.1&nbsp;million of cash, consisting of proceeds
from issuances of our common stock to employees upon the exercise of stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018,
financing activities provided approximately $80.3&nbsp;million of cash, primarily attributable to proceeds from issuances of our Series E preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2018, financing activities provided approximately $0.9&nbsp;million of cash, consisting of
proceeds from issuances of our common stock to employees upon the exercise of stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended
September&nbsp;30, 2019, financing activities provided approximately $30.4&nbsp;million of cash, primarily attributable to proceeds from issuances of our Series&nbsp;E preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operations and capital
expenditure requirements for at least the next 12 months.&nbsp;Our future capital requirements will depend on many factors, including the growth of our software revenue, the timing and extent of spending to support research and development efforts,
the continued expansion of sales and marketing activities, the timing and receipt of milestone payments from our collaborations, as well as spending to support, advance, and broaden our internal programs. Furthermore, our capital requirements will
also change depending on the timing and receipt of any distributions we may receive from our equity stakes in our <FONT STYLE="white-space:nowrap">co-founded</FONT> companies. The potential for these distributions, and the amounts which we may be
entitled to receive, are difficult to predict due to the inherent uncertainty of the events which may trigger such distributions. In addition, with respect to our internal wholly-owned programs, as part of our strategy we may choose to pursue
licensing arrangements when we believe it will help maximize the commercial value of any such program. If we are able to successfully enter into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any licensing arrangements in the future, the potential amounts we may be entitled to and the likelihood and timing of such payments, including at what stage of discovery or development we may
choose to pursue such arrangements, is uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be required to seek additional equity or debt financing. In the event that we
require additional financing, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital or generate cash flows necessary to maintain or expand our operations and invest in our
platform, we may not be able to compete successfully, which would harm our business, operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and
Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less<BR>than</B><br><B>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More</B><br><B>than</B><br><B>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Operating lease obligations consist of our continuing rent obligations through January 2029, primarily for our
principal offices located in New York, New York and Portland, Oregon, which expire in August 2021 and August 2026, respectively. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2019, we entered into a three-year agreement with a third-party cloud provider for compute power. The agreement contains a minimum
payment obligation which totals $18 million over the three years after the date we entered into the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into agreements
in the normal course of business with CRO vendors for research and preclinical studies, professional consultants for expert advice, and other vendors for various products and services. We have not included these payments in the table of contractual
obligations above since the contracts do not contain any minimum purchase commitments and are cancelable at any time by us, generally upon 30 days prior written notice, and therefore we believe that our
<FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations under these agreements are not material. We have also agreed to pay volume-based royalties to third parties for use of software functionality under various licensing and related
agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2018, we carried forward federal and state net operating loss, or NOL, of approximately $75.3&nbsp;million and $41.3&nbsp;million, respectively, which are available to reduce future taxable income and expire between 2019 and 2038.
Utilization of post-2017 federal NOL carryforwards are limited to 80% of taxable income generated in a given year and carry forward indefinitely. As of December&nbsp;31, 2018, we also had federal and state research and development tax credit
carryforwards of approximately $6.8&nbsp;million and $0.4&nbsp;million, respectively, to offset future income taxes, which expire between 2019 and 2038. Our carryforwards are subject to review and possible adjustment by the appropriate taxing
authorities. These carryforwards that may be utilized in any future period may be subject to limitations based upon changes in the ownership of our stock in a prior or future period. We have not quantified the amount of such limitations, if any.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by Accounting Standards Codification, or ASC, Topic 740, Income Taxes, our management has evaluated the positive and negative
evidence bearing upon the realizability of our deferred tax assets, which are composed principally of NOL carryforwards and research and development credit carryforwards. Management has determined that it is more likely than not that we will not
realize the benefits of our federal and state deferred tax assets and, as a result, a valuation allowance of $19.8&nbsp;million and $27.6&nbsp;million has been established at December&nbsp;31, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and 2018, respectively. The change in the valuation allowance was $0.1&nbsp;million for the year ended December&nbsp;31, 2017 and $7.8&nbsp;million for the year ended December&nbsp;31, 2018. We
recorded income tax benefit of $0.3&nbsp;million for the nine months ended September&nbsp;30, 2019 and income tax expense of $0.1&nbsp;million for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Seasonality </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the first
quarter of each year has been our largest quarter for software products and services revenue, primarily due to the timing of customer renewals of <FONT STYLE="white-space:nowrap">on-premise</FONT> software arrangements, for which revenue is
recognized at a single point in time. Seasonality has been a less significant factor for our hosted software arrangements, for which revenue is recognized ratably over time. Seasonality has not been a factor for our drug discovery revenues.
Historical seasonality may not be indicative of future periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not have, and currently we do not have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements, as defined under the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements in accordance with U.S. GAAP. Under standards established by the Public Company Accounting Oversight Board, or PCAOB, a deficiency in internal control over financial reporting exists when the
design or operation of a control does not allow management or personnel, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. The PCAOB defines a material weakness as a deficiency, or
combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented, or detected and corrected, on a
timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the preparation of our consolidated financial statements for the fiscal years ended December 31, 2017 and 2018, we
and our independent registered public accounting firm identified a material weakness in our internal control over financial reporting related to our controls to review equity method investee financial information at a level of precision that would
identify material misstatements in our financial statements, which was due to a deficiency in the design of entity-level controls. As a result of the material weakness, we failed to timely detect and correct a $3.4 million undervaluation of an
equity method investment. The accompanying financial statements were previously corrected to reflect the impact of the adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
in the process of implementing measures designed to improve our internal control over financial reporting to remediate this material weakness. For example, we have increased communication with our equity investee companies to ensure timely receipt
of relevant financial information, instructed our material investees to provide quarterly U.S. GAAP financial statements, and implemented completeness and accuracy controls surrounding the financial data received from investees. See &#147;Risk
Factors&#151;Risks Related to this Offering, Ownership of Our Common Stock, and Our Status as a Public Company&#151;We have identified a material weakness in our internal control over financial reporting. If we are unable to remedy our material
weakness, or if we fail to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which could
adversely impact our investors&#146; confidence and our stock price.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates,
particularly because our investments, including cash equivalents and marketable securities, are in the form of U.S. Treasury and corporate securities and a money market fund that is invested in U.S. Treasury and corporate securities. Due to the
nature of these investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of this investment portfolio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also exposed to market risk related to changes in foreign currency exchange rates. We
maintain a bank account denominated in Japanese Yen to accommodate deposits of amounts due from certain customers. We also contract with certain vendors that are located outside of the United States whose invoices are denominated in foreign
currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. We do not currently hedge our foreign currency exchange rate risk. Our cash balances and outstanding vendor invoices denominated in foreign
currencies were not material as of December&nbsp;31, 2018 or September&nbsp;30, 2019, and our market risk associated with foreign currency exchange rates was deemed insignificant. An immediate 10% change in foreign exchange rates would not have a
material effect on our consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inflation generally affects us by increasing our cost of labor and target
development costs. We do not believe that inflation had a material effect on our business, financial condition, or results of operations for the year ended December&nbsp;31, 2018 or the nine months ended September&nbsp;30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses
and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions
or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the consolidated financial statements
prospectively from the date of change in estimates<B><I>.</I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail
in the notes to our consolidated financial statements appearing elsewhere in this prospectus, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and
estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers, which we adopted as of January&nbsp;1, 2017 on a full
retrospective basis. In accordance with ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services.
To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the
contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when or as we satisfy a performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our software revenue may include upfront payments for the performance of services in the future, which have both fixed and variable
consideration. At contract inception, we assess the goods or services promised within each contract that falls under the scope of ASC 606 to identify distinct performance obligations. We then recognize as revenue the amount of the transaction price
that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For a collaborative arrangement that falls within the scope of ASC 808, Collaborative Arrangements, we apply the revenue recognition model
under ASC 606 to part or all of the arrangement, when deemed appropriate. We have determined that we are the principal in arrangements where we act as a reseller, and therefore recognize revenue on a gross basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We include the unconstrained amount of estimated variable consideration in the transaction
price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re- evaluate
the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjust our estimate of the overall transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research support payments</I>: Payments by the licensees in exchange for research activities we performed on behalf of the licensee are
recognized upon performance of such activities at rates consistent with prevailing market rates. If the expectation at contract inception is such that the period between payment by the licensee and the completion of related performance obligations
will be one year or less, we assume that the contract does not have a significant financing component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone payments</I>:
Research and development or regulatory milestones in our collaboration agreements may include some, but not necessarily all, of the following types of events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical research and development work leading to selection of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of Phase 1, Phase 2, and Phase 3 clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">filing of regulatory applications for marketing approval in the United States, Europe or Japan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marketing approval in major markets, such as the United States, Europe, or Japan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achievement of certain other technical, scientific, or development criteria. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of each arrangement that includes research, development, or regulatory milestone payments, we evaluate whether the milestones
are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is
included in the transaction price. Milestone payments that are not within our control or that of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is
then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we <FONT
STYLE="white-space:nowrap">re-evaluate</FONT> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts our estimate of the overall transaction price. Any such adjustments are recorded on a
cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which may affect license, collaboration, and other revenues and earnings in the period of adjustment. The process of successfully achieving the criteria for the milestone payments is
highly uncertain. Consequently, there is a risk that we may not earn all of the milestone payments from each of our collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Royalties and</I> <I>commercial milestones</I>: For arrangements that include sales-based royalties, including commercial milestone
payments based on <FONT STYLE="white-space:nowrap">pre-specified</FONT> level of sales, we recognize revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has
been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. The process of successfully achieving the criteria for the commercial milestone
payments and sales-based royalties under our arrangements is highly uncertain. As a result, we cannot predict when we might achieve any commercial milestone or royalty payments or estimate the amount of such payments. From inception to date, we have
not recognized any royalty revenue or commercial milestone payments from any of our collaborations. We may never receive any such payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the fair value of stock option awards granted using the Black-Scholes option-pricing model, which uses as inputs the fair value of
our common stock and subjective assumptions we make as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Common Stock.</I> As our stock was not
publicly traded prior to this offering, we historically estimated the fair value of common stock as discussed in &#147;Common Stock Valuations&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term.</I> The expected term of employee stock options represents
the weighted average period that the stock options are expected to remain outstanding. The expected terms were calculated using an average of historical exercises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility.</I> As we do not have a trading history for our common stock, the selected volatility used is
representative of expected future volatility. We based expected future volatility on the historical and implied volatility of comparable publicly traded companies over a similar expected term. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Dividend Yield.</I> We have never declared or paid any cash dividends and do not presently intend to pay cash
dividends in the foreseeable future. As a result, we used an expected dividend yield of zero. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest
Rates.</I> We based the risk-free interest rate on the rate for a U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issue with a term that closely approximates the expected life of the option grant at the date nearest the option
grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any assumptions used in the Black-Scholes option-pricing model change significantly, stock-based compensation for future
awards may differ materially compared with the awards granted previously. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors, with input from management, has
estimated the price of our common stock based upon several factors, including third-party valuations and our operating results and financial performance. The valuations took into consideration several factors, including, but not limited to, prices
for our preferred stock that was sold to outside investors in arms-length transactions, and the rights, preferences, and privileges of our preferred stock and common stock; the fact that the option grants involved illiquid securities in a private
company; our stage of development and revenue growth; the state of the biopharmaceutical industry and the economy; the marketplace and major competitors; and the likelihood of achieving a liquidity event for shares of common stock underlying the
options, such as an initial public offering or sale of our company, given prevailing market conditions. These valuations were performed in accordance with the <I>American Institute of Certified Public Accountants&#146; Audit and Accounting Practice
Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third-party valuation reports estimated a
valuation of our common stock of $3.22 per share as of April&nbsp;18, 2018, $4.34 per share as of November 9, 2018, $5.31 per share as of May 31, 2019, and $11.52 per share as of October&nbsp;15, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, management considered various objective and subjective factors to determine the fair value of our common stock as of each grant
date, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices of our preferred securities sold to or exchanged between outside investors in arm&#146;s length
transactions, if any, and the rights, preferences, and privileges of our preferred securities as compared to those of our common stock, including the liquidation preferences of our preferred securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of liquidity of our equity as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of milestones with our collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation of publicly traded companies in the biotechnology sector, as well as recently completed mergers and
acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any external market conditions affecting the biotechnology industry, and trends within the biotechnology
industry; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our preferred shares and common stock, such as
an IPO, or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the software and biotechnology
industries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represent management&#146;s best estimates, which involve
inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different.
Following the completion of this offering, the fair value of our common stock will be determined based on the quoted market price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth, by grant date, the number of shares granted, per share exercise price, and per share value of stock options granted between January&nbsp;1, 2018 and January 27, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date of Stock Option Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares&nbsp;Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B><br><B>Exercise&nbsp;Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B><br><B>Fair&nbsp;Value</B><br><B>on&nbsp;Grant</B><br><B>Date&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;24, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;7, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;29, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;3, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;29, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">861,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;2, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;7, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;2, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of Equity Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have investments in a number of early stage biotechnology companies. If we determine that, for accounting purposes, we have significant
influence over the company, we value the investment using the HLBV method. The HLBV method is a balance sheet-oriented approach to equity method accounting. Under the HLBV method, we determine our share of earnings or losses by comparing our claim
on the book value at the beginning and end of each reporting period. This claim is calculated as the amount that we would receive if the investee were to liquidate all of its assets at recorded amounts, determined as of the balance sheet date in
accordance with generally accepted accounting principles, and distribute the resulting cash to creditors and investors in accordance with their respective priorities. Significant unobservable inputs used under the HLBV method include annual
financial statements of investment companies and our respective liquidation priority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations
represent management&#146;s best estimates, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our fair
value gains and losses could be materially different. A 10% increase in the net assets of our HLBV equity investments and a 10% increase in the fair value of common stock of our other equity investment holdings would result in a $1.5&nbsp;million
increase in the valuation of our equity investments as of September&nbsp;30, 2019. A 10% decrease in the net assets of our HLBV investments and a 10% decrease in the fair value of common stock of our other equity investment holdings would result in
a $1.5&nbsp;million decrease in the valuation of our equity investments as of September&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Election </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. An emerging
growth company may take advantage of reduced reporting requirements that are not otherwise applicable to public companies. These provisions include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements and only two years of related
Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements on the effectiveness of our internal
controls over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm
rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use these provisions until the last day of
our fiscal year in which the fifth anniversary of the completion of this offering occurs. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross
revenues exceed $1.07&nbsp;billion, or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this
prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than the information you receive from other public
companies in which you hold stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act provides that an emerging growth company can take advantage of an extended transition
period for complying with new or revised accounting standards, until those standards apply to private companies. We have elected to take advantage of the benefits of this extended transition period and, therefore, we will not be subject to the same
new or revised accounting standards as other public companies that are not emerging growth companies. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until the
date that we are no longer an emerging growth company or affirmatively and irrevocably opt out of the exemption provided by Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, upon issuance of a new or revised accounting standard that
applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which we will adopt the recently issued accounting standard. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
reviewed all recently issued standards and have determined that, other than as disclosed in Note 2, Significant Accounting Policies, to our consolidated financial statements appearing elsewhere in this prospectus, such standards will not have a
material impact on our financial statements or do not otherwise apply to our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are transforming the way
therapeutics and materials are discovered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our differentiated, physics-based software platform enables discovery of high-quality, novel
molecules for drug development and materials applications more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods. Our software is used by biopharmaceutical and industrial companies, academic
institutions, and government laboratories around the world, and we are the leading provider of computational software solutions for drug discovery. We also apply our computational platform to a broad pipeline of drug discovery programs in
collaboration with biopharmaceutical companies, some of which we <FONT STYLE="white-space:nowrap">co-founded.</FONT> In addition, we are using our platform to advance a pipeline of internal, wholly-owned drug discovery programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Traditional drug discovery and development efforts have become increasingly complex, lengthy, capital-intensive, and are prone to high failure
rates. Traditional drug discovery relies upon many rounds of costly and time-consuming manual molecule design, chemical synthesis, and experimental testing. One of the primary reasons for long timelines, high costs, and high failure rates in drug
discovery is that predicting properties of molecules in advance of chemical synthesis is extremely complex and not amenable to traditional approaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past 30 years and with the concerted efforts of hundreds of our scientists and software engineers, we have developed a physics-based
computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy. This key capability enables drug discovery teams to design and selectively synthesize molecules with more optimal properties,
reducing the average time and costs required to identify a development candidate and increasing the probability that a drug discovery program will enter clinical development. Furthermore, we believe that development candidates with more optimized
property profiles will have a higher probability of success in clinical development. Additionally, since the physics underlying the properties of drug molecules and materials is the same, we have been able to extend our computational platform to
materials science applications in fields such as aerospace, energy, semiconductors, and electronic displays. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer our customers a
variety of software solutions that accelerate all stages of molecule discovery, design, and optimization. In 2018, all of the top 20 pharmaceutical companies, measured by revenue, licensed our solutions, accounting for $22.0 million, or 33%, of our
2018 revenue. The widespread adoption of our software, supported by our global team of sales, technical, and scientific personnel, has driven steady growth in our software revenue. Biopharmaceutical companies are increasingly adopting our software
at a larger scale, and we anticipate this scaling-up will drive future revenue growth. Our ability to expand within our customer base is best demonstrated by the increasing number of our customers with an annual contract value, or ACV, in excess of
$100,000. We had 87, 103, and 122 such customers, which represented 79%, 75%, and 77% of our total ACV, for the years ended December 31, 2016, 2017, and 2018, respectively. In addition, our customer retention rate for our customers with an ACV over
$100,000 was over 96% for the year ended December 31, 2018 and each of the previous five fiscal years. We believe the growth in the number of our customers demonstrates that companies are increasingly recognizing the power and efficiency of our
platform while the retention in this group is indicative of the continued value of our platform. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Key Factors Affecting Our Performance&#148;
for additional information regarding ACV and customer retention rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also leverage our platform and capabilities across a portfolio
of collaborative and wholly-owned drug discovery programs spanning a wide range of disease targets and indications. Our drug discovery group is comprised of a multidisciplinary team of approximately 70 experts in protein science, biochemistry,
biophysics, medicinal and computational chemistry, and discovery scientists with expertise in preclinical and early clinical development. We are currently collaborating on more than 25 drug discovery programs with more than ten different
biopharmaceutical companies, including a number of companies we <FONT STYLE="white-space:nowrap">co-founded.</FONT> These collaborations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generate drug discovery revenue, including research funding payments, and discovery and development milestones, and have the potential to produce additional milestone payments, option fees, and
future royalties. Furthermore, since <FONT STYLE="white-space:nowrap">mid-2018,</FONT> we have launched five internal, wholly-owned programs. We are leveraging our computational platform with the goal of rapidly advancing the discovery of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapies. Our current programs are focused on discovering and
developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. In the future we expect to expand into other therapeutic areas. We plan to begin to initiate investigational new drug, or IND, -enabling studies for
our programs by the first half of 2021. While our revenue-generating collaborations are an important component of our business, our strategy is to pursue an increasing number of wholly-owned programs and strategically evaluate on a
program-by-program basis entering into clinical development ourselves or out-licensing programs to maximize commercial opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
generated revenue of $55.7&nbsp;million and $66.6&nbsp;million in 2017 and 2018, respectively, representing year-over-year growth of 20%. We generated revenue of $49.2 million and $59.7 million for the nine months ended September&nbsp;30, 2018 and
2019, respectively, representing period-over-period growth of 21%. Our net loss was $17.4 million, $28.4 million, $22.1&nbsp;million, and $18.5&nbsp;million for the years ended December 31, 2017 and 2018 and the nine months ended September&nbsp;30,
2018 and 2019, respectively. For information regarding our estimated preliminary results for the three months and year ended December&nbsp;31, 2019, see &#147;Prospectus Summary&#151;Estimated Preliminary Results.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to improve human
health and quality of life by transforming the way therapeutics and materials are discovered. Our physics-based approach and differentiated software solutions enable the discovery of novel molecules for drug development and materials applications
more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods. We license our software to biopharmaceutical and industrial companies, government laboratories, and academic institutions globally. We
are also using our software and internal capabilities across a diverse portfolio of drug discovery programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategies for
fulfilling our mission are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advance the science that underlies our computational platform: </I></B>We have emerged as the leader in the
field of physics-based computational drug discovery, and we believe our computational platform is far ahead of that of our nearest competitors. As of December 31, 2019, we had approximately 400 employees, roughly half of whom have Ph.D. degrees. We
intend to maintain our industry-leading position by introducing new capabilities and refining our software to further strengthen our technology and advance the science underlying our platform. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerate growth of our software business: </I></B>We have experienced steady growth in our software
revenues, achieving $59.9&nbsp;million in revenue in 2018 and $49.2&nbsp;million in revenue in the nine months ended September 30, 2019, primarily driven by broad adoption of our software solutions by the biopharmaceutical industry and the expansion
of our materials science business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Life science software business</I><B><I>:</I></B> In 2018, all of the top 20 pharmaceutical companies,
measured by revenue, used our software, accounting for $22.0 million, or 33%, of our 2018 revenue, and these companies have been our customers for an average of 15 years. However, we estimate that even our very largest customers are currently
purchasing only enough software to optimally enable one or two drug discovery projects, which typically represents a small fraction of their drug discovery projects. Our ability to expand within our customer base is best demonstrated by the
increasing number of our customers with an ACV of over $100,000. We had 87, 103, and 122 such customers for the years ended December&nbsp;31, 2016, 2017, and 2018, respectively. In addition, we had eight, nine, and 11 customers for the years ended
December&nbsp;31, 2016, 2017, and 2018, respectively, with an ACV of over $1.0&nbsp;million. We intend to leverage our existing relationships with our customers to drive larger-scale adoption of our solutions. Further, we believe there remains a
large opportunity for growth as there are thousands of biopharmaceutical companies that could benefit from our solutions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Materials science software business</I><B><I>:</I></B> Beyond drug discovery, our solutions can be leveraged
for broad application to address industrial challenges in molecule design, including in the fields of aerospace, energy, semiconductors and electronic displays. We intend to continue growing this business through increased brand awareness and a <FONT
STYLE="white-space:nowrap">build-out</FONT> of industry-specific functionality. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerate growth of our drug discovery business: </I></B>We also apply our computational platform across a
diversified portfolio of more than 30 drug discovery programs through collaborations with companies we have <FONT STYLE="white-space:nowrap">co-founded,</FONT> with biopharmaceutical companies, and through our own internal efforts on wholly-owned
programs. Our collaborations generate revenues through research funding, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical milestones as well as the potential for option fees, commercial milestones, and future royalties. We also
benefit from equity positions in our <FONT STYLE="white-space:nowrap">co-founded</FONT> companies. Our drug discovery group comprises approximately 70 scientists, including biologists, medicinal chemists, biochemists, crystallographers, drug
metabolism and pharmacokinetics scientists, and pharmacologists. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are actively working with our collaborators to discover novel therapies. We also intend to add new
collaborations that offer scientific synergies and favorable economic terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We plan to progress our existing wholly-owned programs and continue to add new programs that leverage our
computational platform. As we progress these programs, we will strategically evaluate on a program-by-program basis entering into clinical development ourselves or out-licensing programs to maximize commercial opportunities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leverage the synergies between our businesses: </I></B>We believe that there are significant synergies
within our business. We leverage the feedback that we receive from our software customers, collaborators, and internal drug discovery experts to improve the functionality of our platform, which we believe supports increased customer adoption of our
solutions and more rapid advancement of our collaborative and wholly-owned drug discovery programs. In addition, the success of our collaborators in advancing drug discovery programs provides significant validation of our platform and approach,
which we believe increases the attractiveness of our platform to customers, helps us establish new collaborations, and validates the potential of our own internal drug discovery programs. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g46q96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Central to our ability to pursue these distinct lines of business is a firewall policy consisting of a set
of well-established protocols and technology measures designed to ensure that the intellectual property of our software customers and drug discovery collaborators remains confidential and segregated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Industry Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Traditional drug discovery and development efforts have become increasingly complex, lengthy, capital-intensive, and are prone to high failure
rates. Traditional drug discovery involves experimental screening of existing libraries of molecules to find molecules with detectable activity, or &#147;hit molecules,&#148; followed by many rounds of chemical synthesis to attempt to optimize those
hit molecules to a development candidate that can be advanced into clinical development. Efforts to optimize initial hit molecules for a drug discovery project involve costly and iterative synthesis and testing of molecules seeking to identify a
molecule with the required property profile. The optimal profile has the acceptable balance of properties such as potency, selectivity, solubility, bioavailability, half-life, permeability, drug-drug interaction potential, synthesizability, and
toxicity. These properties are often inversely correlated, meaning that optimizing one property often de-optimizes others. The challenge of optimizing hit molecules is amplified by the limited number of molecules that can be feasibly tested across
these properties with traditional methods. As a result, this optimization process often fails to yield a molecule with a satisfactory property profile to be a development candidate, which is why many drug discovery programs fail to advance into
clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The traditional approach to drug discovery takes too long, is too prone to failure, and is too costly. Successfully
reaching an IND application filing requires on average five to six years, and the average success rates suggest two out of three projects will fail. Accounting for such failures, the average cost to complete a successful IND filing is
$35&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A typical drug discovery project only has the budget and time to synthesize and assay fewer than 10,000 molecules,
because the cost and timelines associated with interrogating a greater number of molecules is impractical. This small sampling of molecules represents a minuscule fraction of the total number of molecules that could potentially be synthesized.
Exploring such a limited number of molecules reduces the likelihood of identifying molecules with the desired property profile, which we believe leads to development candidates with higher failure rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Being able to predict molecular properties before initiating costly and time-consuming experimental synthesis would accelerate drug discovery,
reduce costs, and increase the probability of success. If it were possible to accurately predict critical properties of molecules, fewer molecules would have to be experimentally synthesized and tested. As a result, larger pools of molecules could
be analyzed allowing for more selective synthesis of molecules, leading to higher-quality molecules. In addition, with predictive computational methods, better selections of molecules would be synthesized through exploration of larger portions of
chemical space, leading to higher-quality molecules that would in turn have a higher probability of progressing through clinical development and obtaining regulatory approval for commercial sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been many attempts to improve the efficiency of the drug discovery process by using computational methods to predict properties of
molecules. One of the primary computational methods that many companies have attempted to deploy is machine learning, often referred to as artificial intelligence, or AI. One of the main benefits of machine learning is its ability to rapidly process
data at scale. However, machine learning on its own has significant limitations and has therefore had a limited impact on improving the efficiency of the drug discovery process. Machine learning requires input data, referred to as a training set, to
build a predictive model. This model is expected to accurately predict properties of molecules similar to the training set, but cannot extrapolate to molecules that are not similar to the training set. Accordingly, since the number of possible
molecules that could be synthesized is effectively infinite, machine learning can only cover a minuscule fraction of the total number of molecules that could potentially be synthesized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The other primary computational method that has been attempted involves using fundamental, &#147;first-principles&#148; physics-based methods,
which require a deep and thorough understanding of the specific property to be computed. However, physics-based methods are difficult to develop and can be slow compared to machine learning. Further, to apply such methods to design molecules that
will bind with high affinity to a particular protein target, the three-dimensional structure of that protein must be generated with sufficient atomic detail to enable application of these physics-based approaches, which is referred to as being
&#147;structurally enabled,&#148; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such structures have been historically difficult to obtain. Another factor preventing computational chemistry from realizing its promise has been limited compute speed. However, despite all of
these challenges, physics-based methods have a significant advantage over machine learning in that they do not require a training set and can, in principle, compute properties for any molecule. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past 30 years and
with the concerted effort of hundreds of our scientists and software engineers, we have developed a computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy. We have built our platform on a
foundation of rigorous, physics-based methods, combined with the rapid data processing and scaling advantages of machine learning, that together provide a significant advantage over traditional methods. We believe that physics-based simulation is at
a strategic inflection point as a result of the increased availability of massive computing power, combined with a more sophisticated understanding of models and algorithms and the growing availability of high-resolution protein structures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have demonstrated that our software platform can have a transformative impact on the drug discovery process by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the average time and cost required to identify a development candidate; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing the probability of drug discovery programs entering clinical development. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our collaborative drug discovery efforts to date, we believe that the development candidates discovered using our platform have a
higher probability of successfully progressing through clinical development than the industry average. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown below, we achieve these
outcomes by tightly integrating our predictive physics-based methods, which have a high degree of accuracy, with machine learning, which is highly scalable. In addition, our platform enables real-time collaboration on drug discovery projects to
inform decision-making and fully benefit from the predictive capabilities of our computational platform. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g35g12.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our computational platform provides the following significant technological advantages over
traditional approaches to drug discovery, all of which enable shortening timelines, decreasing costs, and increasing the probability of success of drug discovery efforts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Speed. </B>Our platform is able to evaluate molecules in hours rather than the weeks that it typically takes
to synthesize and assay molecules in the laboratory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Scale.</B> Our platform can explicitly evaluate billions of molecules per week, whereas traditionally operated
discovery projects only synthesize approximately one thousand molecules per year, thereby increasing the probability that we find a novel molecule with the desired property profile. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Quality.</B> In a peer-reviewed study, our platform was tested against traditional methods for selecting
tight-binding molecules and resulted in an eight-fold increase in the number of molecules with the desired affinity. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below compares the optimization process of drug discovery using traditional methods and our approach. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g66i18.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our computational platform includes a broad array of proprietary capabilities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Faster Lead Discovery</B>: the ability to rapidly identify potent molecules suitable to initiate <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hit-to-lead</FONT></FONT> and lead optimization efforts via solutions for virtual screening of extremely large libraries of molecules, as well as physics-based replacement of the central
core of a molecule, known as scaffold hopping, to identify novel, highly potent molecules unavailable in library collections; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Accurate Property Prediction</B>: the ability to assess key properties of drug-like molecules using
physics-based calculations with accuracy comparable to that of experimental laboratory assays, to facilitate optimization of drug properties, including drug potency, selectivity, and bioavailability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Large-Scale Molecule Exploration</B>:<B> </B>the ability to computationally ideate and explore novel,
high-quality drug-like molecules for consideration by discovery project teams utilizing computational enumeration and generative machine learning techniques that are trained and constructed to yield molecules that are synthetically feasible;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Large-Scale Molecule Evaluation</B>: the ability to scale our calculations of key drug properties to
ultra-large idea sets of over a billion molecules to enable more rapid and successful identification of high-quality drug candidate molecules via integration of next-generation machine-learning methods with our physics-based techniques, as well as
large-scale utilization of internal and cloud computing resources; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Integrated Data Management and Visualization</B>:<B> </B>the ability to generate, access, and analyze the data
derived from complex calculations integrated with assay data through a powerful and user-friendly graphical interface. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recognition of our scientific advances has come through customer adoption, and in citations of publications in peer reviewed journals. For
example, the initial paper describing our ligand-protein docking program, Glide, published in 2004 is currently the most cited paper in the history of the <I>Journal of Medicinal Chemistry</I>, a premier journal in its field. Glide continues to be
broadly used as a <FONT STYLE="white-space:nowrap">hit-finding</FONT> technology throughout the biopharmaceutical industry by our customers. We have made many similar scientific advances in fields including druggability assessment, affinity
calculation, protein structure refinement, and molecule ideation and design. These advances were achieved by our team of hundreds of Ph.D.-level scientists and software engineers with extensive input from our Scientific Advisory Board, or SAB, which
includes thought leaders in computational chemistry, physics-based simulations, statistical mechanics, and machine learning. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also
critically important to the advances we have made are the performance gains offered by using graphical processing unit, or GPU, computing and the cloud. Our platform is capable of running on all major cloud providers and taking advantage of their
combined compute power. Combining the dramatic effects of GPU and cloud computing with our integrated physics-based and machine learning technologies enables shortening timelines, decreasing costs, and increasing the probability of success of drug
discovery efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our computational platform is also applicable to new problems of interest and new fields of study. Since the
underlying physics that drives a biologic to bind to its target is no different than the physics that drives a small drug molecule to bind to a protein, we have been able to successfully apply these technologies to the discovery of biologics.
Similarly, the physics underlying the properties of materials is no different than the physics underlying the properties of drug molecules. Therefore, we have successfully applied our computational platform to materials science applications,
including in the fields of aerospace, energy, semiconductors, and electronic displays. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Software Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
transforming drug discovery and materials design by driving widespread adoption of our computational platform by biopharmaceutical and industrial companies, academic institutions, and government laboratories globally. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are the leading provider of computational software solutions for drug discovery to the
biopharmaceutical industry. In 2018, all of the top 20 pharmaceutical companies measured by revenue were our customers, accounting for $22.0 million, or 33%, of our 2018 revenue. Additionally, in 2018, our software was used by researchers around the
world at more than 1,250&nbsp;academic institutions. The widespread adoption of our software is supported by an approximately <FONT STYLE="white-space:nowrap">130-person</FONT> global team of sales, technical, and scientific personnel. Our direct
sales operations span across the United States, Europe, Japan and India, and we have sales distributors in other important markets, including China and South Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a diverse and large existing customer base, ranging from startup biotechnology companies to the largest global pharmaceutical
companies as well as an increasing number of materials science customers. Our ten largest software customers represented approximately 24% of our software revenue in 2018, and no single software customer represented more than 5% of our revenue. We
continue to expand our customer base as we promote the education and recognition of the potential of our computational platform across industries. As of December 31, 2018, we had approximately 1,150 active customers, which we define as the number of
customers who had an ACV of at least $1,000 in a given fiscal year, and the figure below shows the growth in the number of our active customers since 2013. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g58d70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there is significant opportunity to expand the adoption of our platform within our growing
customer base. Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate that this scaling-up will drive future revenue growth. Our ability to expand within our customer base is best demonstrated by the
increasing number of our customers with an ACV over $100,000. We had 87, 103, and 122 of such customers for the years ended December 31, 2016, 2017, and 2018, respectively. In addition, for the year ended December 31, 2018, we had 11 customers with
ACV of $1.0 million or more, up from nine and eight customers as of December 31, 2017 and 2016, respectively. We believe biopharmaceutical companies are increasingly recognizing and applying the power and efficiency of our platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we believe our sales and marketing approach and the quality of our software solutions help us cultivate longstanding
relationships and reoccurring sales. This is demonstrated by the length of our key relationships, with the average tenure of our 10 largest customers in 2018 being over 17 years. Furthermore, our ability to expand our customer relationships over
time is exemplified by our ability to retain our customers with an ACV over $100,000. For the year ended December 31, 2018 and for each of the previous five fiscal years, our year-over-year customer retention rate for our customers with an ACV over
$100,000 was over 96%. We believe the continued expansion of our customer base coupled with our ability to expand our customers&#146; use of our software will continue to drive revenue growth. The figure below shows the different ways in which we
are accelerating our growth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g59x67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#151;Key Factors Affecting Our Performance&#148; for additional information regarding ACV and customer retention rate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Software Solutions for Drug Discovery </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer our customers a variety of software solutions that accelerate all stages of molecule discovery, design, and optimization pursuant to
agreements with terms typically for one year. Our licenses give our customers the ability to execute a certain number of calculations across specified software solutions. Certain of our key software solutions are highlighted below, along with the
particular stage of drug discovery in which they are employed: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g30a18.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Target Identification and Validation: </B>the identification and evaluation of a protein target that might be
worthwhile to pursue as the subject of a drug discovery campaign. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>WaterMap</B> characterizes the locations and energetics of water molecules occupying the binding site of, or
solvating, a target protein. From this analysis, one can infer the druggability of a protein, as well as uncover opportunities to significantly increase binding affinity by exploiting the water structure in the binding site. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>SiteMap</B> allows binding site identification and evaluation to help locate potential protein binding sites,
including allosteric sites, and predict the approximate druggability of those sites. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Hit Discovery</B>: the identification of hit molecules. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>FEP+</B> is our free energy calculation software. In hit discovery, this software can be used to replace the
central core of earlier known tight binding molecules to identify novel, highly potent molecules unavailable in library collections. Often these molecules have much higher binding affinity and have a better property profile than typical hit
molecules. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Glide</B> is our virtual screening program that is used to screen libraries of molecules to find hit molecules
likely to bind a particular protein target in a specific conformation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>WScore</B> is our next-generation virtual screening program that utilizes a more accurate and robust
description of protein-ligand interaction solvation effects. This and other novel features enable WScore to more reliably find hit molecules for challenging protein targets when screening libraries of molecules. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Shape</B> uses the three-dimensional structure and shape of earlier known hit molecules to find new hits when
screening libraries of molecules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>AutoQSAR/DeepChem</B> uses modern machine-learning methods trained to earlier known hit molecules to find
novel hits when screening libraries of molecules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Induced fit docking</B>, or<B> IFD</B>,<B> </B>can computationally predict the binding mode of molecules to a
binding site of a protein, including predicting how the conformation of the protein binding site may reorganize upon binding the molecule. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Hit to Lead and Lead Optimization: </B>Hit to lead is the stage at which small molecule hits are evaluated and
undergo limited optimization to identify promising lead molecules. Lead optimization improves on the property profile of lead molecules by designing new analogs with improved potency, reduced <FONT STYLE="white-space:nowrap">off-target</FONT>
activities, and favorable physicochemical/metabolic properties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>FEP+</B> is our free energy calculation software. In the hit to lead and lead optimization phases of drug
discovery, FEP+ is used to predict the binding affinity of ligands to proteins with accuracy approaching that of physical experiments. It allows precise rank-ordering of large libraries of virtual molecules so that only the most potent molecules are
synthesized in a program, which can save time and reduce cost. FEP+ can also be used to calculate the binding selectivity, solubility, and mutational resistance profiles of molecules, which are key properties for the optimization of bioavailability,
toxicology, and efficacy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>AutoQSAR/DeepChem</B> uses modern machine-learning methods to produce predictive quantitative
structure-activity relationship, or QSAR, models. This allows more accurate methods, such as FEP+, to be applied at a much greater scale but with less accuracy to much larger sets of molecules than would otherwise be possible and enables predictive
QSAR models of other properties to be developed and deployed on drug discovery projects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>PathFinder</B> is an enumeration tool that enables the rapid exploration of synthetically tractable ligands.
When PathFinder is deployed in conjunction with multiparameter optimization, machine learning, and FEP+ simulations, it provides a streamlined approach to create and evaluate large sets of synthetically tractable, lead-like, potent ligands.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Software Solutions Used Throughout the Drug Discovery Process: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>LiveDesign</B> is our user-friendly enterprise informatics solution that enables interactive and collaborative
molecule design, aggregation and sharing of data, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> discovery project coordination between chemists, modelers, and biologists. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maestro</B> is our user-friendly modeling environment, which allows expert modelers to utilize our advanced
modeling solutions. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Software Solutions for Materials Science </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also sell software licenses to customers engaged in molecule design for industrial purposes. The software solutions for our materials
science customers leverage much of the same technology as our software for biopharmaceutical companies. In addition, similar to traditional drug discovery efforts, traditional approaches to discovering new molecules in these fields also suffer from
long timelines, and it can take as long as 10 to 20 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
years to bring new materials to the market. We are focused on leveraging our technology to transform the way new materials are discovered, and we believe that materials science companies are only
beginning to recognize the potential of computational methods. We are continuing to build a team of subject matter experts to further drive adoption of our computational platform in each of the following areas in which we currently operate: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>mobile electronics and displays</B>&#151;organic electronics (OLED); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>aerospace and defense</B>&#151;polymers, composites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>microelectronics</B>&#151;semiconductors, thin film processing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>oil and gas</B>&#151;catalysis, reactivity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>energy</B>&#151;alternative energy, batteries; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>consumer packaged goods</B>&#151;soft matter, formulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Drug Discovery Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Overview
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are using our computational platform in both collaborative and wholly-owned drug discovery programs. Traditional drug discovery
and development efforts have become increasingly complex, lengthy, capital-intensive, and are prone to high failure rates. Decreasing returns on investments in drug research and development have created a significant opportunity for us to leverage
our computational platform to design and discover new medicines. In drug discovery stages, our platform can reduce the time and cost required to identify a development candidate with a more optimized property profile as compared to traditional
methods. We believe that these candidates with more optimized property profiles will have a higher probability of success in clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates the advantages in time, cost, and molecule quality of our computational drug design approach over traditional
drug discovery approaches. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g12k92.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Drug Discovery Expertise </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug discovery group is comprised of a team of approximately 70 experts in protein science, biochemistry, biophysics, medicinal and
computational chemistry, and discovery scientists with expertise in preclinical and early clinical development. Many of our scientists have decades of biopharmaceutical industry experience across multiple disciplines and areas of expertise and
deploy our computational platform across an array of disease targets and indications. Our differentiated, physics-based platform empowers our integrated team of experts to design better molecules, in shorter timeframes, and at a lower cost than
traditional drug design. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Drug Discovery Collaborations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the last decade, leveraging our platform and expertise, we have steadily grown our portfolio of collaborations and have entered into more
than 25 collaborations with biopharmaceutical companies that have provided us with significant income and have the potential to produce additional milestone payments, option fees, and future royalties. These programs pursue design of clinical
candidates across a wide range of therapeutic target protein classes and indications. Many of these programs are pursuing novel molecules for targets where a low-dose small molecule inhibitor or activator with optimal drug-like properties has been
difficult to achieve or where selectivity for the target of interest has been difficult to achieve relative to other proteins. We have steadily grown our pipeline of collaborations by selectively entering into drug discovery collaborations with high
potential from a large number of opportunities. Among the key factors that we use to select collaborators are whether the targets are well-validated, have high therapeutic potential, and are amenable to the strengths of our computational platform,
and whether or not the collaborator brings complementary capabilities, all of which we believe contribute to an increased probability of success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaboration with Nimbus Therapeutics, LLC, or Nimbus, which we <FONT STYLE="white-space:nowrap">co-founded</FONT> in 2009, is an example
of the strength of our collaboration strategy and the power of our computational platform. Based on structural insights related to a novel allosteric binding site and our computational assays, Nimbus, in collaboration with us, was able to identify a
unique series of acetyl-CoA carboxylase, or ACC, allosteric protein-protein interaction inhibitors with favorable pharmaceutical properties that inhibit the activity of the ACC enzyme. Nimbus achieved proof of concept in a Phase 1b clinical trial of
its ACC inhibitor, firsocostat. In 2016, Nimbus sold the program to Gilead Sciences, Inc., or Gilead, in a transaction valued at approximately $1.2&nbsp;billion, comprised of an upfront payment and earnouts. Of this amount, $601.3&nbsp;million has
been paid to Nimbus to date, and we received a total of $46.0 million in cash distributions in 2016 and 2017. We are eligible to receive up to $46 million in future cash distributions on the remaining approximately $600 million of earn outs, if and
when such earn outs are achieved. However, the likelihood and timing of such payments, if any, are not possible for us to predict as the achievement of the development and regulatory milestones under the transaction agreement is uncertain and
outside of our control. In December 2019, Gilead announced topline results from its Phase 2 clinical trial which included firsocostat, both as a monotherapy and in combination with other investigational therapies, in which the primary endpoint was
not met. Gilead announced that it was continuing to analyze the data from the trial and determine next steps. We do not know how this development will affect Nimbus&#146; right to receive earnout payments from Gilead or our right to receive cash
distributions from Nimbus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morphic Holding, Inc., or Morphic, was founded in 2014 and leverages our computational platform, together with
unique insights into the structure and function of integrins discovered by Professor Timothy A. Springer, to develop novel therapeutics. Based on unique structure-function insights, Morphic, in collaboration with us, was able to design an oral
inhibitor of the alpha 4 beta 7 integrin, which is an established target for autoimmune diseases. The currently approved therapeutic for this target is a monoclonal antibody that is approved for intravenous administration. Morphic became a
publicly-traded company in June 2019. According to Morphic&#146;s public filings, its alpha 4 beta 7 inhibitor small molecules exhibited high potency and selectivity for alpha 4 beta 7, oral absorption, and pharmacokinetic properties in preclinical
studies. In addition, according to Morphic&#146;s public filings, it has been able to establish preclinical pharmacological proof of concept, including observed effects on T-cell trafficking similar to a comparator alpha 4 beta 7 antibody with its
alpha 4 beta 7 inhibitor small molecules. Based on these disclosed preclinical results and its on-going IND-enabling studies, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Morphic has stated that it expects to file an IND for its alpha 4 beta 7 program by the middle of 2020 and then advance the program into clinical development for the treatment of inflammatory
bowel disease, or IBD. Morphic has also disclosed that it is progressing a partnered alpha v beta 6 program toward clinical development for the treatment of idiopathic pulmonary fibrosis, or IPF. The most advanced product candidate in this program
is MORF-720, a selective oral first-in-class alpha v beta 6-specific integrin inhibitor. In preclinical models of IPF, Morphic reported that it observed that administration of its alpha v beta 6 inhibitor was associated with local inhibition of
TGF-beta, a clinically prominent pro-fibrotic cytokine. Morphic has stated that it expects to file an IND for its partnered alpha v beta 6 program in the second half of 2020. As described below, as of September 30, 2019, we have a 2.7% equity stake
in Morphic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our collaboration with Agios Pharmaceuticals, Inc. that leveraged our computational platform resulted in two
U.S. Food and Drug Administration, or FDA, approved therapies, Tibsovo (vosidenib) for the treatment of adult patients with acute myeloid leukemia (AML) who have an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test, and
IDHIFA (enasidenib), which is being marketed by Agios&#146; collaborator, Celgene Corporation, a wholly-owned subsidiary of Bristol-Myers Squibb Company, and is indicated for certain adult patients with relapsed refractory AML who have an isocitrate
dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. We do not have any financial interest, such as the right to receive royalties or other payments, with respect to either of these approved therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through access to the maximum potential scale of our computational platform and our drug
discovery and software development teams, our collaborators receive the following key benefits: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Immediate utilization of our platform:</B> Ability to immediately and efficiently leverage the full benefits
of our computational platform, without the need for training or <FONT STYLE="white-space:nowrap">ramp-up</FONT> time, thereby enabling accelerated drug discovery. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Access to massive compute power</B>: Ability to run our computational software on one of the largest GPU
clusters dedicated to drug design in the industry, thereby avoiding the time and cost needed to build this infrastructure on their own. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Early access to cutting-edge functionality</B>: Real-time access to emerging solutions as they are being
developed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Target exclusivity</B>: Under our collaboration agreements, we agree to design drugs for a particular protein
target or targets using our computational platform and knowhow exclusively for the collaborator. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Collaboration
Agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a number of collaborations with biopharmaceutical companies under which our collaborators are pursuing
research in a number of therapeutics areas, including without limitation, various programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immune-oncology, cardiopulmonary disease and
tuberculosis. Our current collaborators include Ajax Pharmaceuticals, Inc., Bright Angel Therapeutics Inc., Faxian Therapeutics, LLC, Morphic Holding, Inc., Nimbus Therapeutics, LLC, Ono Pharmaceuticals Co., LTD., Petra Pharma Corp., Sanofi S.A.,
ShouTi Inc., Sun Pharma Advanced Research Company Ltd., TB Alliance and Takeda Pharmaceuticals Company Limited, or Takeda. With the exception of Takeda, where we retain all intellectual property rights until Takeda exercises its option to acquire a
program, all of the programs being pursued under these collaborations are fully owned and controlled by each respective collaborator. Our opportunity to receive potential revenues from any of these programs is generally limited to research funding
payments, development, regulatory, and commercial milestones, option fees to license projects and royalties on commercial sales, if any. We are not responsible for advancing their preclinical or clinical development or their commercialization, if
approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Stakes</I>. We have received equity consideration in certain of our collaborators, and from time to time, we have
also made additional equity investments in certain of these collaborators. As noted above, all of these programs are fully owned and controlled by each respective collaborator, with the exception of Faxian, which is a 50/50 joint venture. The
following table presents our equity stakes in our collaborators that are greater than 1.0% on an issued and outstanding basis as of September&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ownership&nbsp;%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ajax Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bright Angel Therapeutics Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Faxian Therapeutics, LLC (JV)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morphic Holding, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nimbus Therapeutics, LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Petra Pharma Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ShouTi Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On a fully diluted unit basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Financial Rights. </I>In addition to our equity stakes in certain of our collaborators, we also have rights to various payments on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">collaborator-by-collaborator</FONT></FONT> agreement basis including research funding payments, discovery, development, and commercial milestones, potential option fees to license projects,
and potential royalties in the single-digit range. Under certain of our collaboration agreements, we are also eligible to receive a percentage of our collaborators&#146; sublicense revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figures below show the number of collaborative programs we have worked on in each given
year, as well as the amount of revenue we have generated from our collaborations through the combination of research funding payments, discovery and development milestones, and other fees for the periods presented. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g73c53.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the year ended December 31, 2019, we expect to report drug discovery revenue in the range of $18.6 million
to $19.0 million. We have provided a range, rather than a specific amount, because these results are preliminary and subject to change. See &#147;Prospectus Summary&#151;Estimated Preliminary Results&#148; for additional information.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of our collaborative programs are currently still in the discovery stages. Generally, the size of the payments we
are eligible to receive from a collaborative program increases as the program advances. As a result of the broader validation of our platform, we intend to pursue an increasing number of wholly-owned programs, and we will continue evaluating new
collaborative programs that fit our selection criteria and where the collaborator&#146;s particular expertise has the potential to create substantial value. Importantly, our current collaboration agreements typically also contemplate additional
program targets being added, allowing our collaborators to potentially increase the number of programs under our current collaboration agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, because these collaborations are not under our control, we cannot predict whether or when we might achieve any event-based increases
in research funding payments, milestone payments, royalty or other payments under these collaborations or estimate the full amount of such payments, and we may never receive any such payments. For a further discussion of the risks we face with
respect to receipt of any of these payments, please refer to &#147;Risk Factors&#151;Risks Related to Drug Discovery&#151;We may never realize return on our investment of resources and cash in our drug discovery collaborations.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>How We Work with Our Collaborators. </I>Generally, our existing collaboration agreements provide that we agree to design drugs for a
particular target or targets using our computational platform and knowhow exclusively for the collaborator. The collaborator retains the intellectual property related to any molecules developed under the collaboration. Generally, our collaborators
are not contractually required to provide us with, nor do we expect generally to receive, access to nonpublic information regarding key developments related to the advancement of these collaboration programs, such as clinical trial results,
including safety and efficacy data, regulatory communications, or commercialization plans and strategies. To the extent we do receive such information, our collaboration agreements generally require us to maintain the confidentiality of information
we receive under the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As our collaboration strategy has evolved, we are seeking to take more direct control and
responsibility for all aspects of a drug discovery project and own a higher percentage of the value generated in the completed programs. For example, under our collaboration with Takeda, after mutual agreement on the target(s) of interest, our drug
discovery group conducts all drug discovery research and pharmacology activities through the development candidate stage. Takeda has the option to acquire the program at either the lead optimization stage
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or development candidate stage and to develop and commercialize product candidate(s) from the program. Importantly, under the collaboration with Takeda, we control the drug discovery process and
retain all intellectual property rights to any product candidates that are discovered under the program until Takeda exercises its option to acquire the program. The collaboration with Takeda anticipates drug discovery research on up to six targets.
Three programs have been initiated to date in schizophrenia, oncology, and neurodegenerative disease with multiple milestone payments achieved. Two of these programs continue to advance while the program in schizophrenia is no longer an active
collaboration and all rights to this program will continue to be retained by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The program in neurodegenerative disease is focused on
the discovery of a best-in-class compound toward a protein involved in neuronal degeneration. As shown in the figures below, our lead molecule showed inhibition of the protein&#146;s activity at 100-fold lower concentrations in biochemical and cell
based assays and <I>ex vivo</I> in a preclinical neuronal injury protection assay when compared to a published benchmark molecule. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g45d14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Internal, Wholly-Owned Drug Discovery Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since <FONT STYLE="white-space:nowrap">mid-2018,</FONT> we have launched a total of five internal, wholly-owned programs. We expect to begin to
initiate <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in our programs by the first half of 2021, first in oncology and then potentially in other areas. Our strategy is to pursue an increasing number of wholly-owned programs and
strategically evaluate on a program-by-program basis entering into clinical development ourselves or out-licensing programs to maximize commercial opportunities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Our Pipeline </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are leveraging our computational platform with the aim of rapidly advancing the discovery of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics. Our first cohort of internal programs is focused on discovering and developing
inhibitors for targets in DNA damage response pathways and genetically defined cancers. The following is a summary of our internal, wholly-owned drug discovery programs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g26l52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Our Approach to Target Selection </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our selection of targets is based on an extensive analysis of human targets and drug discovery programs. We analyze targets using automated
methods at scale. The key steps we take in prioritizing programs involve: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Structural and modeling enablement</B>. We use our computational platform to analyze protein structure quality
as well as druggability of binding sites across thousands of target proteins in parallel. For a subset of high-quality structures of interest, we confirm amenability to our computational platform. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Evaluation of therapeutic potential</B>. Our selection of targets is strongly influenced by the level of
validation of the target, including analysis of human genetics and prior clinical data. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Identification of unsolved design challenges</B>. We determine whether there are property profile challenges
that could be solved by the application of our computational platform and provide a clinically meaningful differentiated, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> product opportunity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Assessment of potential value of pathways and mechanisms.</B> We evaluate industry and commercial interest as
well as the clinical utility with the aim of prioritizing programs with high commercial and therapeutic potential. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using this comprehensive analysis, we have identified a large number of protein targets that we believe are amenable to our technology. We
continue to evaluate a number of additional targets using this analysis methodology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>DNA Damage and Replication Stress Response Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first two drug discovery programs are focused on targets that mediate DNA repair, cell cycle regulation, replication stress responses, and
apoptosis, or programmed cell death. Numerous structurally-enabled targets exist within cellular machinery that mediate these functions, including the targets of our programs, cell division cycle <FONT STYLE="white-space:nowrap">7-related</FONT>
protein kinase, or CDC7, and Wee1 protein kinase. We made the decision to focus on these targets following third-party clinical success of other DNA damage response and cell cycle checkpoint inhibitors, such as
<FONT STYLE="white-space:nowrap">poly(ADP-ribose)</FONT> polymerase, or PARP, inhibitors and CDK4/6 kinase inhibitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthy cells are
programmed to respond to DNA damage through various pathways. The cell cycle is managed and regulated by several checkpoint kinases. For example, during the &#147;S phase&#148; of the cycle, checkpoint activation arrests the cell cycle and allows
the cell sufficient time to repair damaged DNA before the initiation of cell division. This process prevents the propagation of cells with aberrant DNA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rapid cell division driven by cancer-causing genes known as oncogenes and mutations in tumor suppressor genes fuels cancer cell growth. The
ability of cancer cells to sense and repair damaged DNA is impaired making them more susceptible to DNA damage and dependent on fewer repair pathways.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to achieve successful cell division, cancer cells depend on certain checkpoint kinases to repair DNA damage. This includes checkpoint
kinases usually active during the S phase. Inhibition of these kinases leaves cancer cells vulnerable to failed DNA damage repair and high levels of replication stress, failure of cell division, and cell death.&nbsp;Combining the inhibition of
multiple DNA damage response mechanisms has the potential to heighten the damage sustained by cancer cells and lead to durable efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates the impact of checkpoint inhibition on cancer cells. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g95i46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>SDGR1 Program&#151;CDC7 Kinase Inhibitors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing tight-binding, selective, novel small molecule inhibitors of CDC7 for the treatment of advanced solid tumors, including
esophageal and lung cancers and potentially brain metastases. CDC7 is a serine/threonine protein kinase that has been shown to be a required step in DNA replication initiation. CDC7 levels are high in certain adenocarcinomas, and CDC7 is thought to
be linked to these cancer cells&#146; proliferative capacity and ability to bypass normal DNA damage responses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CDC7 phosphorylates and activates the enzymes responsible for DNA replication initiation.
Disruption of CDC7 activity in cancer cells leads to delayed DNA replication, cell cycle abnormalities, and cell death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
antiproliferative potential of CDC7 inhibition was validated by a third party in Phase 1 clinical trials of a CDC7 inhibitor in which responses were observed in patients, including those with bladder and pancreatic cancer. Prior to this positive
result, existing CDC7 inhibitors were not sufficiently tight-binding, lacked selectivity, and demonstrated poor pharmacokinetic properties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to maximize the number of cancer cells in cell cycle arrest, very tight-binding inhibitors are required to achieve durable clinical
impact as monotherapy or in the context of clinical combinations. Using our computational platform, we have identified multiple tight-binding, selective, and novel CDC7 inhibitor series. We have progressed this program from conception to optimized
lead molecules in approximately ten months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the figure below, our early molecules demonstrated inhibition of a downstream
biomarker of CDC7, intratumoral phosphorylated MCM2, or pMCM2, that was used as an endpoint in recent third party clinical trials of a development-stage CDC7 inhibitor. Furthermore, one series of our molecules displayed high levels of brain
penetration in preclinical assays, which may provide an opportunity for the treatment of brain metastases in solid tumor patients. Combination of our early molecules and the Wee1 inhibitor AZD1775 (adavosertib), which is undergoing clinical trial
testing in cancer patients, showed additive anti-proliferative effect in Colo205 cells, or human colon adenocarcinoma cells. Combination of another of our molecules and olaparib, an FDA-approved PARP inhibitor marketed as LYNPARZA by AstraZeneca,
also showed additive anti-proliferative effects in H460 cells, or human non-small-cell lung cancer cells. Additive effects were also shown in combination with ceralasertib, an ataxia telangiectasia and Rad3-related, or ATR, inhibitor in Colo205
cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g50b43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>SDGR2 Program&#151;Wee1 Kinase Inhibitors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wee1 is a gatekeeper checkpoint kinase that prevents cellular progression through the cell cycle allowing time for DNA repair before cell
division takes place. We are therefore developing tight-binding, selective Wee1 inhibitors with optimized physicochemical properties that we believe will be well suited for combinations with other DNA damage response therapies such as PARP and ATR
inhibitors for the treatment of ovarian, pancreatic, breast, and lung cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wee1 acts as a negative regulator of entry into mitosis at
the G2/M transition by protecting the nucleus from CDC2, an important activator that triggers cell division. Wee1 is one of the two mechanisms known by which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
G2 checkpoint is initiated in response to DNA damage. Blockade at the G2 checkpoint is especially important, as some tumors rely on DNA repair at the G2 checkpoint. Thus, inhibition of Wee1 can
trigger massive DNA breakage and apoptosis in tumor cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Wee1 inhibitor currently being investigated in Phase 2 clinical trials by a
third party has shown clinically meaningful tumor regression with partial responses and stable disease in ovarian cancer and small cell lung carcinoma, and is being studied in combinations with chemotherapy, PARP inhibitors, and immunotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prior third party Wee1 inhibitor that has advanced to clinical trials may have <FONT STYLE="white-space:nowrap">off-target</FONT> effects
resulting from inhibition of polo-like kinase 1, or PLK1, and inactivation of a liver enzyme, CYP3A4, which is responsible for elimination of drug and drug metabolites from the body, making dosing and combinations more challenging. We believe our
computational platform can be used to identify tight-binding molecules with optimized drug-like properties that exhibit neither of these liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have identified Wee1 inhibitor lead molecules that are tight-binding and <FONT STYLE="white-space:nowrap">100-fold</FONT> more selective
for Wee1 versus PLK1, and have exhibited a favorable property profile, including no observable inactivation of CYP3A4. We were able to achieve these outcomes within the first six months of project work. As of October 30, 2019 only 192 molecules have
been synthesized from a pool of over 1&nbsp;billion computationally evaluated molecule design ideas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also pursuing <I>in vitro
</I>Wee1 and PARP inhibitor combination studies to prepare for proof of concept studies in patient-derived tumor mouse models. In addition, we have demonstrated that combining CDC7 and Wee1 inhibitors leads to additive anti-proliferative effects in
cancer cell models, which we believe may have implications for future clinical combination trials. We believe that our selective Wee1 inhibitors, with an optimized CYP3A4 profile, are well positioned for combination therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Genetically-Defined Cancers</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our next three drug discovery programs are focused on genetically-defined cancers. Alterations in the DNA sequence of a cancer cell genome,
including mutations, genomic amplification, and rearrangements are responsible for the initiation and progression of most cancers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>SDGR3 Program&#151;MALT1 Inhibitors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing novel MALT1 inhibitors for the treatment of patients with <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphoma
and chronic lymphocytic leukemia who are resistant to or have relapsed on Bruton&#146;s tyrosine kinase, or BTK, inhibitors, a currently-approved therapy for lymphoma patients. Constant activation of nuclear factor-kappa B, or <FONT
STYLE="white-space:nowrap">NF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>B, a key signaling molecule in B cells, is a hallmark of several subtypes of lymphoma. MALT1 is a protein that is downstream of BTK in the <FONT
STYLE="white-space:nowrap">NF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>B signaling pathway and when rearranged, drives lymphoma cell growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The anti-proliferative effect of covalent BTK inhibitors, such as ibrutinib and acalabrutinib, provides clinical and commercial <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> that inhibiting <FONT STYLE="white-space:nowrap">NF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>B signaling can be effective for the treatment of <FONT
STYLE="white-space:nowrap">B-cell</FONT> malignancies with elevated B-cell receptors signaling, including chronic lymphocytic leukemia, Waldenstr&ouml;m&#146;s macroglobulinemia, mantle cell lymphoma and marginal zone lymphoma. However, a common
active site mutation in patients following long-term BTK inhibitor treatment prevents covalent binding of ibrutinib and acalabrutinib to BTK leading to loss of efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Activated B-cell, or ABC, a subtype of diffuse large B-cell lymphoma, or ABC DLBCL, is the most common type of aggressive non-Hodgkin B-cell
lymphoma. ABC DLBCL is associated with a number of mutations that trigger a constitutively active NF-kB signaling pathway, which often is mediated by increased MALT1 protease activity. Among these mutations is a gain of function mutation or
amplification of MALT1, which has also been identified in ABC DLBCL patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have used our computational platform to rapidly identify novel, tight-binding MALT1
small-molecule allosteric inhibitors with drug-like properties. Furthermore, we have been able to demonstrate that our MALT1 inhibitors show additive effects when combined with BTK inhibitors in ABC DLBCL lymphoma cell lines. We achieved these
outcomes in less than four months from project initiation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In OCI-LY3 cells, which are resistant to BTK inhibitors, our current MALT1
inhibitors showed dose responsive anti-proliferative effects compared to ibrutinib, strongly suggesting the potential of our inhibitors to benefit patients with acquired resistance due to long term BTK inhibitor treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our MALT1 inhibitors demonstrated <I>in vivo</I> target engagement with decreased tumor B-cell lymphoma 10&nbsp;(BCL 10) cleavage in a mouse
model bearing OCI-LY10 cell derived tumors after oral daily dosing. Further, additive anti-proliferative effects were observed when combining our inhibitors with ibrutinib and acalabrutinib in preclinical studies of OCI-LY10 cells, which are
responsive to BTK inhibitors. Additional combination studies were conducted with a next generation BTK inhibitor, ARQ-531, a third-party investigational reversible non-covalent inhibitor of BTK that inhibits wild type and ibrutinib-resistant
BTK-C481S mutants. Our MALT1 inhibitors showed additive effects when combined with ARQ-531 in preclinical studies. This supports the potential for our MALT1 inhibitors to be combined with BTK inhibitors to treat patients with B-cell malignancies who
no longer respond to existing BTK inhibitors.<B> </B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g40x35.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g15l30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>SDGR4 <FONT STYLE="white-space:nowrap">Program&#151;HIF-2</FONT> alpha Inhibitor </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a <FONT STYLE="white-space:nowrap">HIF-2</FONT> alpha inhibitor for the treatment of renal cell carcinoma as monotherapy or
in combination with immunotherapy agents, <FONT STYLE="white-space:nowrap">PD-1</FONT> or <FONT STYLE="white-space:nowrap">PDL-1</FONT> antibodies, and potentially other indications, such as pulmonary
<FONT STYLE="white-space:nowrap">hypertension.&nbsp;HIF-2</FONT> alpha, also known as EPAS1, is one of several master regulators of intratumoral hypoxia and control hypoxia-mediated pathological processes in tumors, including angiogenesis, pH
homeostasis, cell migration/invasion, stem cell pluripotency, immune evasion, and therapy resistance. The work elucidating the underlying biology of this mechanism was awarded the 2019 Nobel Prize in Physiology and Medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In third-party studies, clinical proof of concept was recently demonstrated for the role of <FONT STYLE="white-space:nowrap">HIF-2</FONT>
alpha inhibition in patients with clear cell renal cell carcinoma, or CCRCC, caused by a germline mutation in the Von Hippel-Lindau tumor suppressor gene. We have used our computational platform to design molecules that are predicted to be
tight-binding, highly selective, orally bioavailable inhibitors of the <FONT STYLE="white-space:nowrap">HIF-2</FONT> alpha interaction with aryl hydrocarbon receptor nuclear translocator, or ARNT. We plan to continue advancing these molecules
through preclinical testing. Prolonged treatment of CCRCC patients with a HIF-2 alpha inhibitor resulted in resistance through a mutation (G323E) identified in approximately 20% of patients in a third-party Phase 1 clinical trial sub-study,
consistent with observations from pre-clinical models. In designing our molecules, we are modeling the impact of this and other potential resistance mutations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>SDGR5 Program&#151;SOS1/KRAS Inhibitor </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a SOS1/KRAS protein-protein interaction inhibitor for the treatment of KRAS-driven cancers. SOS1, or Son of <FONT
STYLE="white-space:nowrap">sevenless-1,</FONT> is involved in the activation and regulation of KRAS. Oncogenic mutant KRAS stimulates the growth of some of the most intractable tumors, such as lung, pancreatic, and colon cancer. Strategies to
disrupt the persistently active Ras pathway have focused on targeting Cys12 of the oncogenic mutant KRAS G12C with covalent inhibitors. Disruption of the SOS1/KRAS interaction has emerged as an alternative approach based on third party preclinical
data. Our initial efforts suggest that we can leverage our computational platform to identify a novel development candidate for this target to capitalize on this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> opportunity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Future Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have identified a large number of protein targets that we believe are amenable to our computational platform, which creates a large and
growing inventory of targets that we can potentially advance into discovery programs. Our drug discovery group also intends to pursue targets with strong biological validation and therapeutic potential that currently lack protein structures of
sufficient quality to permit the use of our computational platform for drug discovery. We are actively pursuing strategic alliances with collaborators that have the ability to generate high-quality protein structures for these targets, which will
enable us to initiate discovery efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genomic instability of malignant cells leads to genetic mutations that can drive resistance to
kinase inhibitors, creating the need for second and third generation drugs targeting the same disease. Our computational platform has been shown to be capable of predicting the impact that mutations in the kinase domain have on drug binding,
potency, and drug sensitivity. Use of our platform to assess and evaluate the impact of clinical mutations on drug potency can be a powerful tool for drug discovery. We believe that deploying our platform at scale with access to genomic profiling
data for patients puts us in a strong position to predict the impact of active-site resistance mutations with clinically relevant accuracy to optimize the design of molecules that are robust against common resistant mutations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Technical Details of Our Key Technologies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Calculation of key drug properties using physics-based methods </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past 30 years and with the concerted effort of hundreds of our scientists and software engineers, we have developed a physics-based
computational platform that is capable of predicting the binding affinity of a drug molecule with a high degree of accuracy. The binding affinity of a drug molecule to a target protein is the key driving force of its <I>in vivo</I> efficacy.
Specifically, when a drug binds to a target protein, the affinity with which it binds directly affects the extent to which it will modulate the function of the protein. Therefore, the ability to predict the binding affinity of a drug molecule to a
target protein with a high degree of accuracy can significantly accelerate discovery of new efficacious medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accurately calculating
the binding affinity of a drug molecule to a protein is enormously complex and requires a full characterization of all the physical contributions to the binding. These contributions include the deformation and/or rigidification of the small molecule
into the bound conformation (<FONT STYLE="FONT-FAMILY:SYMBOL">&#068;</FONT>G(1) in the figure below) and the rigidification of the protein in the bound conformation (<FONT STYLE="FONT-FAMILY:SYMBOL">&#068;</FONT>G(2)), the removal of waters
surrounding the molecule (<FONT STYLE="FONT-FAMILY:SYMBOL">&#068;</FONT>G(3)) and the removal of waters within the protein binding site (<FONT STYLE="FONT-FAMILY:SYMBOL">&#068;</FONT>G(4)), and finally the interactions achieved between the molecule
and protein when binding to form the protein-molecule complex (<FONT STYLE="FONT-FAMILY:SYMBOL">&#068;</FONT>G(5)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g46v24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed a solution to consistently assess all of these contributions to binding with a high
degree of accuracy, building on a method called &#147;free energy perturbation.&#148; Free energy perturbation perturbs, or transforms, an initial molecule into another molecule of interest and evaluates how that transformation changes binding
affinity to a particular protein target. Our solution for conducting these calculations is called FEP+. FEP+ is enabled by the following differentiated constituent technologies: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">classical molecular mechanics force field with broad coverage of drug-like molecules with a high degree of
accuracy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an automated workflow allowing for force field coverage to be extended on the fly utilizing our accurate quantum
mechanics software; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">computationally efficient molecular dynamics engine that runs on GPUs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efficient, enhanced sampling methods that allow the calculation to be converged with reduced simulation times;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">automated atom-mapping and interaction-mapping assignment; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to scale these calculations to leverage large cloud computing environments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of these constituent technologies are necessary to achieve the accuracy, scalability and applicability of our free energy perturbation
implementation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a recent peer-reviewed study including approximately 3,000 molecules across approximately 90 distinct projects, FEP+
exhibited an error profile that indicates its affinity predictions approach the accuracy of running a laboratory experiment. FEP+ is also able to perform these computations more rapidly than experimental assays. Computational assessment of a
molecule utilizing FEP+ requires approximately 24 hours of computation on a GPU or only a few hours on a computer that contains eight GPUs. In comparison, it often takes weeks to synthesize a drug-like molecule and assay its binding affinity for the
target of interest in a laboratory. As a result, our FEP+ solution can be used to explore very large numbers of molecules to identify drug candidates much more rapidly than would be possible solely using experimental approaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a peer-reviewed article published in collaboration with a large biopharmaceutical company, the ability of FEP+ to prioritize molecules for
synthesis expected to bind more tightly than an initial hit was compared with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
several other industry-standard approaches. We found that FEP+ succeeded in prioritizing the synthesis of molecules with improved binding affinity with eight times greater success than any other
technique tested. This evidence supports the essential role that FEP+ can play in advancing drug discovery programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Enumeration of
extremely large libraries of molecules </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed methods to enumerate extremely large libraries of molecules with our
PathFinder software solution, thereby allowing our software customers, our drug discovery collaborators, and our internal drug discovery team to explore a much larger portion of chemical space than is possible through manual design. The chemical
enumeration technology we have developed incorporates over a hundred known chemical reactions that can, in a fully automated fashion, computationally explore billions of alterations of a molecule of interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Scaling accurate physics-based calculations to extremely large libraries of molecules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although FEP+ calculations have been shown to be accurate, it is not possible to apply these calculations to billions of molecules given the
current availability of computing resources. To address this problem, we developed an approach that leverages the accuracy of FEP+, but allows for exploration of billions of molecules in a reasonable amount of time by leveraging machine learning. We
have succeeded in integrating our physics-based molecule scoring with highly computationally efficient modern machine-learning methods. This combined approach allows us to apply our physics-based calculations to much larger sets of molecules than
would otherwise be computationally tractable. This allows us to both increase the speed and likelihood of identifying clinically viable molecules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advances in deep learning, a type of machine learning, in the past several years have required very large data sets as input to train the
model. In a drug discovery program, the experimental data is typically sparse and expensive to procure, which is particularly problematic given that relevant drug-like chemical space is effectively infinitely large, estimated to be 10<SUP
STYLE="font-size:85%; vertical-align:top">60</SUP> molecules. For this reason, we believe that it would be extremely difficult to realize competitive advantage in a drug discovery program by using a platform exclusively based on machine learning or
deep learning. Instead, we have developed an approach to integrate physics-based and machine-learning based scoring methodologies that allows the machine learning model to interactively prioritize additional molecules for physics-based analyses,
known as active learning. Active learning retains the computational efficiency of machine learning while also taking advantage of the accuracy of the physics-based method. One can evaluate the utility of any particular prediction method with regard
to both its accuracy and its computational efficiency. Modern machine learning methods, such as deep learning, do provide a small improvement over conventional machine learning methods. However, for much of its history, conventional molecular
simulations were much less computationally efficient than machine learning but not that much more accurate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In developing FEP+, we were
able to resolve deficiencies in early attempts to develop physics-based methods. FEP+ calculations are much more accurate than either conventional machine learning or modern machine learning when scoring molecules structurally distinct from the
training set data. In addition, by integrating FEP+ with our machine learning implementation, which we refer to as AutoQSAR / DeepChem, we developed a solution that we refer to as Active Learning FEP+. Active Learning FEP+ combines the accuracy of
free energy calculations with the speed of machine learning calculations and can be used to explore up to billions of molecules within a few days. By further combining this functionality with our ability to enumerate large sets of molecules provided
by PathFinder and our ability to build and manage complex workflows utilizing cloud resources, we are able to deploy these capabilities at scale to advance projects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Active Learning FEP+ is depicted in the figure below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g33i20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEP+ is used to build a local model for a large library of molecules instead of relying on experimental
data to provide the training set for the machine learning model. That machine learning model is then used to filter the large library of molecules down to a number that is small enough to be able to prioritize with FEP+. The result is that it takes
only a few days to prioritize one billion molecules rather than one million days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Rapid identification of novel active hit
molecules suitable to initiate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hit-to-lead</FONT></FONT> and lead optimization efforts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several <FONT STYLE="white-space:nowrap">hit-finding</FONT> technologies we have developed are routinely used to identify active hit molecules
to initiate small molecule drug discovery programs. In our <FONT STYLE="white-space:nowrap">hit-finding</FONT> campaigns, we and our software customers typically utilize: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modern machine learning models trained to the <FONT STYLE="white-space:nowrap">two-dimensional</FONT> structures
of known active molecules using our software solution, AutoQSAR/DeepChem; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shape-based methods trained to the known or computationally deduced three-dimensional bioactive conformations of
known active molecules using our software solution, Shape; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">structure-based docking methods that evaluate the number and kind of interactions possible utilizing a static
atomistic representation of the experimentally determined three-dimensional structure of the target protein receptor using our software solutions, Glide and WScore; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">free energy calculations using our software solution FEP+, which provides a fully dynamic atomistic
representation of the target protein receptor. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These four approaches are complementary to each other, and their
integrated use has led to successful <FONT STYLE="white-space:nowrap">hit-finding</FONT> campaigns for dozens of protein targets in our collaborative and wholly-owned drug discovery programs. There are also numerous reports in the literature and in
patents of our software customers utilizing some combination of these approaches to identify hit molecules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AutoQSAR/DeepChem is trained
to find known active molecules in a search through a molecule library and operates solely on the <FONT STYLE="white-space:nowrap">two-dimensional</FONT> structure of the molecule. From this training process, AutoQSAR/DeepChem learns to identify
substructures in the molecules that may lead to activity. Then when applied to large libraries of molecules, these methods can identify molecules with measurable activity against the target protein. These methods are highly efficient and can be used
to screen one billion molecules in less than one day on a few hundred CPUs. However, one significant limitation is that machine learning methods cannot extrapolate into chemical space that differs from the training set and therefore, this method
tends to identify molecules similar to already known molecules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shape is used to identify molecules with a similar shape to known active molecules. It has
been shown that molecules with similar three-dimensional shapes can have similar activities. While the hit rates and computational efficiencies of Shape and AutoQSAR/DeepChem are generally comparable, the hit molecules returned by these techniques
tend to be distinct and complementary rather than redundant. This allows results from Shape to augment the AutoQSAR/DeepChem results while still being efficient for screening a large library. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glide and WScore use knowledge of three-dimensional structure of the binding site of the protein of interest, rather than the structure of
active molecules, to evaluate the likelihood of a small molecule to bind a protein target. Glide and WScore evaluate molecules based on the number and kind of contacts made between the molecule and protein. These methods are much more
computationally expensive than AutoQSAR/DeepChem or Shape, often requiring seconds to minutes of CPU computing time per molecule. However, they can be more readily applied to targets for which there is little or no earlier reported active molecules.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fourth computational method we routinely use to identify hit molecules to initiate drug discovery programs is the FEP+ solution
described above. When used in this context, FEP+ can be used to completely replace the core moiety of an earlier known molecule to yield a novel molecule with similar binding potency. This approach is much more computationally intensive than
previous methods, often ~24 GPU hours per molecules, but is also much more accurate. Utilizing this approach on multiple programs, we have been able to identify novel nanomolar or picomolar inhibitors in the first few months of project chemistry
that have property profiles typical of molecules only observed in the later <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hit-to-lead</FONT></FONT> phases of drug discovery. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Computational analysis of the energetic properties of water molecules occupying molecule binding sites in proteins </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subtle structural variations in molecules can have a profound impact on binding affinity to the protein target. The effects of these structural
variations can be explained by a detailed examination of the thermodynamics of binding, including the free energy changes resulting from displacing water molecules in the binding site. Our computational software solution WaterMap maps the locations
and energetic properties of water molecules that occupy protein binding sites, provides insight into the properties of the binding site, and quantitatively describes the water-mediated forces driving the binding of small molecules. Further, such an
analysis can be used to assess the propensity of drug-like molecules to bind to the protein target with high affinity. WaterMap presents the computed results graphically for easy visualization of the water molecules occupying a binding site and
their energetic properties. This makes interpretation of binding affinity data more intuitive and provides insights to possible design routes to improve potency and selectivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall market for
molecular discovery and design software is global, rapidly evolving, competitive, and subject to changing technology and shifting customer focus. The solutions and applications offered by our competitors vary in size, breadth, and scope. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the principal competitive factors in our market include, among other things, accuracy of computations, level of customer
satisfaction and functionality, ease of use, breadth and depth of solution and application functionality, brand awareness and reputation, modern and adaptive technology platform, integration, security, scalability and reliability of applications,
total cost, ability to innovate and respond to customer needs rapidly, and ability to integrate with legacy enterprise infrastructures and third-party applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we compete favorably on the basis of these factors and that the effort and investment required to develop a computational,
physics-based platform similar to ours will hinder new entrants that are unable to invest the necessary capital and time, and lack the breadth and depth of technical expertise required to develop competing technology. Our ability to remain
competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our software solutions face competition from commercial competitors in the business of
selling simulation and modeling software to biopharmaceutical companies. These competitors include BIOVIA, a brand of Dassault Syst&egrave;mes SE, or BIOVIA, Chemical Computing Group (US) Inc., Cresset Biomolecular Discovery Limited, OpenEye
Scientific Software, Inc., Optibrium Limited, and Simulations Plus, Inc. We also have competitors in materials science, such as BIOVIA and Materials Design, Inc., and in enterprise software for the life sciences, such as BIOVIA, Certara USA, Inc.,
and Dotmatics, Inc. In some cases, these competitors are well-established providers of these solutions and have long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. In addition,
there are academic consortia that develop physics-based simulation programs for life sciences and materials applications. In life sciences, the most prominent academic simulation packages include AMBER, CHARMm, GROMACS, GROMOS, OpenMM, and OpenFF.
These packages are primarily maintained and developed by graduate students and post-doctoral researchers, often without the intent for commercialization. We also face competition from solutions that biopharmaceutical companies develop internally,
smaller companies that offer products and services directed at more specific markets than we target, enabling these competitors to focus a greater proportion of their efforts and resources on these markets, as well as a large number of companies
that have been founded with the goal of applying machine learning technologies to drug discovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is
characterized by rapidly advancing technologies, intense competition, and strong emphasis on proprietary products. While we believe that our computational platform, technology, knowledge, experience, and scientific resources provide us with
competitive advantages, our drug discovery business faces potential competition from many sources, including major pharmaceutical, specialty biopharmaceutical companies, technology companies, academic institutions and government agencies, and public
and private research institutions. Any product candidates that we or one of our collaborators successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreements with Columbia University </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into several license agreements with Columbia University, or the Columbia License Agreements. The Columbia License Agreements
establish our rights and obligations with respect to certain patents, software code, technology, and improvements thereto that we license from Columbia University and that are used in, and integrated into, our software solutions, and our
physics-based computational platform. Our rights and obligations under, and the terms and conditions of, the Columbia License Agreements that we consider material to the operation of our business are described more fully below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2008, we entered into an amendment, or the Royalty Amendment, to certain Columbia License Agreements, including each of
the agreements described below. The Royalty Amendment simplified the royalties payable under each agreement on gross revenues generated from the use of any product which contains any code or software, or is covered by any patent, that we license
from Columbia University, or a Licensed Product, in connection with a services agreement. We also pay royalties under the Columbia License Agreements on gross revenues generated from the sale, licensing or renting of our Licensed Products, which we
calculate on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis. In the event that one or more Licensed Products are sold together with other products for a single aggregate license fee, we
have agreed to pay to Columbia University the applicable royalty on the gross revenues attributable to each Licensed Product based on the relative list prices of each product covered by such license fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of the royalties payable by us to Columbia University in connection with our services agreements, see &#147;License
Agreements with Columbia University&#151;Services Royalty Amendment&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">PS-GVB</FONT>
License Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;5, 1994, we entered into a license agreement, or the 1994 Columbia Agreement, with Columbia
University, which was amended on September&nbsp;9, 2004 and November&nbsp;1, 2008. The technology licensed under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1994 Columbia Agreement is incorporated into our Jaguar quantum mechanical program, which we market and distribute as part of our physics-based computational platform. The 1994 Columbia Agreement
grants us a worldwide, exclusive, license to the software code developed by Columbia University and incorporated into the electronic structure software program <FONT STYLE="white-space:nowrap">PS-GVB</FONT> v1.0, or the <FONT
STYLE="white-space:nowrap">PS-GVB</FONT> Code, and all improvement to the <FONT STYLE="white-space:nowrap">PS-GVB</FONT> v1.0 software program and <FONT STYLE="white-space:nowrap">PS-GVB</FONT> Code developed by Columbia University, or the <FONT
STYLE="white-space:nowrap">PS-GVB</FONT> Improvements, including all <FONT STYLE="white-space:nowrap">PS-GVB</FONT> Code and <FONT STYLE="white-space:nowrap">PS-GVB</FONT> Improvements that are incorporated into any new products, new releases, and
new versions related to the software, or the New <FONT STYLE="white-space:nowrap">PS-GVB</FONT> Module Code, in each case, to reproduce, use, execute, copy, operate, sublicense, and distribute in connection with the marketing and sale of our
products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. We may only sublicense the <FONT STYLE="white-space:nowrap">PS-GVB</FONT> Code, the <FONT STYLE="white-space:nowrap">PS-GVB</FONT>
Improvements, and the New <FONT STYLE="white-space:nowrap">PS-GVB</FONT> Module Code, or the Licensed <FONT STYLE="white-space:nowrap">PS-GVB</FONT> Software, to the extent they are incorporated into a product that is sold directly by us or that is
distributed on our behalf. Under the 1994 Columbia Agreement, Columbia University retains the right to conduct, and to permit other academic and <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions to conduct, research using the
Licensed <FONT STYLE="white-space:nowrap">PS-GVB</FONT> Software. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for entering into the 1994 Columbia Agreement, we have
agreed to pay royalties to Columbia University in the <FONT STYLE="white-space:nowrap">low-single</FONT> digit to <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentages based upon the contribution of Columbia University generated code
to the applicable <FONT STYLE="white-space:nowrap">PS-GVB</FONT> v1.0 software program on our, and our affiliates, gross revenues from the sale, licensing, or renting of the <FONT STYLE="white-space:nowrap">PS-GVB</FONT> v1.0 software program,
including any improvements and modifications thereto, regardless of whether such improvement or modification is marketed as a new version, new release, or new product, excluding any sales to Columbia University and any revenue generated under
services agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 1994 Columbia Agreement and the licenses granted thereunder may be terminated by us or Columbia University only
upon the other party&#146;s material breach of the agreement and such party&#146;s failure to cure such breach. Upon termination, any third party that has licensed the Licensed <FONT STYLE="white-space:nowrap">PS-GVB</FONT> Software from us will
retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fast Multipole RESPA License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 1998, we entered into a license agreement, or the 1998 Columbia Agreement, with Columbia University, which was amended on
September&nbsp;4, 2004, and November&nbsp;1, 2008. The 1998 Columbia Agreement grants us a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> license to the Fast Multipole RESPA code developed at Columbia University, or the RESPA
Code, which was incorporated into the IMPACT software program used in our Glide ligand-protein docking program, PrimeX protein modelling program, QSite QM/MM program, and Combglide automated library generation program, and all improvements to the
IMPACT software program, including any new versions and new releases thereof, that are developed by Columbia University, or the IMPACT Improvements, in each case, to reproduce, use, execute, copy, compile, operate, sublicense, and distribute in
connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. We may sublicense the RESPA Code and the IMPACT Improvements, or the Licensed IMPACT
Software, to the extent it is incorporated into a product that is sold directly by us or that is distributed on our behalf. Under the 1998 Columbia Agreement, Columbia University retains the right to conduct, and to permit other academic and <FONT
STYLE="white-space:nowrap">non-profit</FONT> research institutions to conduct, research using the Licensed IMPACT Software. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
consideration for entering into the 1998 Columbia Agreement, we have agreed to pay royalties to Columbia University in the <FONT STYLE="white-space:nowrap">low-single</FONT> digit to <FONT STYLE="white-space:nowrap">low-double</FONT> digit
percentages based upon the contribution of Columbia University generated code to the applicable IMPACT software program on our, and our affiliates, gross revenues from the sale, licensing, or renting of the IMPACT software program, including any
improvements and modifications thereto and any new versions and new releases thereof, excluding any sales to Columbia University and revenue generated under services agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 1998 Columbia Agreement and the licenses granted thereunder may be terminated by us or
Columbia University only upon the other party&#146;s material breach of the agreement and such party&#146;s failure to cure such breach. Upon termination, any third party that has licensed software from us subject to the 1998 Columbia Agreement will
retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software. &nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Protein Folding License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2001, we entered into a license agreement, or the 2001 Columbia Agreement, with Columbia University, which was amended on
September&nbsp;9, 2004 and November&nbsp;1, 2008. The technology licensed under the 2001 Columbia Agreement is incorporated into our Prime protein modelling program, which we market and distribute as part of our physics-based computational platform.
The 2001 Columbia Agreement grants us a worldwide, exclusive license to the protein folding code developed by Columbia University, or the Folding Code; all improvements to the Folding Code and to any of our products, software, or code that
incorporates any part of the Folding Code, including any improvements thereto and new versions or new releases thereof, that are developed by Columbia University, or the Folding Code Improvements; and the issued patent covering the Folding Code, or
the Folding Code Patent, in each case, to reproduce, use, execute, copy, compile, operate, sublicense, and distribute in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research
and backup disaster recovery. We may sublicense the Folding Code, the Folding Code Improvements and the Folding Code Patent, or the Licensed Folding Code Software, to the extent it is incorporated into a product that is sold directly by us or that
is distributed on our behalf. Under the 2001 Columbia Agreement, Columbia University retains the right to conduct, and to permit other academic and <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions to conduct, research using
the Licensed Folding Code Software. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for entering into the 2001 Columbia Agreement, we paid Columbia University a <FONT
STYLE="white-space:nowrap">one-time,</FONT> nominal license fee. In addition, we have paid royalties to Columbia University in <FONT STYLE="white-space:nowrap">low-single</FONT> digit to <FONT STYLE="white-space:nowrap">low-double</FONT> digit
percentages based upon the contribution of Columbia University generated code to the applicable product, software program, or code on our, and our affiliates, gross revenues from the sale, licensing, or renting of any commercial product, software
program, or code incorporating the Licensed Folding Code Software, excluding any sales to Columbia University and revenues generated under services agreements. Our obligation to pay any royalty under the 2001 Columbia Agreement, including any
royalty paid pursuant to the Royalty Amendment, terminated with the expiration of the last to expire patent licensed under the 2001 Columbia Agreement in January 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2001 Columbia Agreement and the licenses granted thereunder may be terminated by Columbia University only upon our material breach of the
agreement and our failure to cure such breach. Upon termination, any third party that has licensed software from us subject to the 2001 Columbia Agreement will retain the right to use such software, and we will have the perpetual right to continue
to provide support to any such third parties in connection with their use of such software. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>PLOP License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;19, 2003, we entered into a license agreement, or the 2003 Columbia Agreement, with Columbia University, which was amended on
November&nbsp;1, 2008. The technology licensed under the 2003 Columbia Agreement is incorporated into our Prime and PrimeX protein modelling programs and our Membrane Permeability model, which we market and distribute as part of our physics-based
computational platform. The 2003 Columbia Agreement grants us a worldwide, exclusive license to the protein local optimization program software code, or the PLOP Code, developed at Columbia University and the University of California and all
software code comprising improvements to the PLOP Code that are developed by Columbia University or the University of California, or the PLOP Improvements, in each case, to reproduce, use, execute, copy, compile, operate, sublicense, and distribute
in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. Pursuant to an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interinstitutional agreement between Columbia University and the University of California, the University of California granted Columbia University the sole right to license the PLOP Code and
PLOP Improvements and has agreed not to license the PLOP Code or PLOP Improvements to any third party for as long as the interinstitutional agreement remains in effect. We may sublicense the PLOP Code and PLOP Improvements to the extent they are
incorporated into a product that is sold directly by us or that is distributed on our behalf. We are restricted from distributing the PLOP Code and PLOP Improvements source code without the prior written consent of Columbia University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Columbia University and the University of California retain the right to use, and to permit other academic and
<FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions to use, the PLOP Code and PLOP Improvements for teaching and academic research purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for entering into the 2003 Columbia Agreement, we paid Columbia University a
<FONT STYLE="white-space:nowrap">one-time,</FONT> nominal license fee. In addition, we have agreed to pay royalties to Columbia University in <FONT STYLE="white-space:nowrap">low-single</FONT> digit to
<FONT STYLE="white-space:nowrap">low-double</FONT> digit percentages based upon the contribution of Columbia University generated code to the applicable product, software program, or code on our, and our affiliates, gross revenues from the sale,
licensing, leasing, or renting any commercial product, software program, or code incorporating the PLOP Code or any PLOP Improvements, excluding any sales to Columbia University or the University of California and revenues generated under services
agreements. Our obligation to pay any royalty under the 2003 Columbia Agreement, including any royalty paid pursuant to the Royalty Amendment, will terminate on June&nbsp;19, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Columbia University is responsible for the copyright registration of the PLOP Code and PLOP Improvements. We are responsible for paying all
reasonable copyright registration and attorney fees in connection with such copyright registrations. &nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2003
Columbia Agreement and the licenses granted thereunder may be terminated by us or Columbia University only upon the other party&#146;s material breach of the agreement and such party&#146;s failure to cure such breach. Upon termination, any third
party that has licensed software from us subject to the 2003 Columbia Agreement will retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of
such software. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Water Site Analysis License </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;27, 2008, we entered into a software and patent license agreement, or the 2008 Columbia Agreement, with Columbia University, which
was amended on November&nbsp;1, 2008. The 2008 Columbia Agreement grants us a worldwide license, exclusive in the field of computational chemistry software and related services, to (a)&nbsp;certain software that implements the water site analysis
method, or the Water Site Software; (b)&nbsp;all patent rights covering the Water Site Software, or the Water Site Patents; and (c)&nbsp;any products that incorporate or include the Water Site Software, or that is covered by the Water Site Patents,
or the Water Site Products, in each case, to reproduce, modify, distribute, and perform and display in connection with the development, marketing, and sale of our products and services, to conduct research using the Water Site Software, and to
conduct backup disaster recovery. Our Water Site Products include our WaterMap Core program, which we market and distribute as part of our physics-based computational platform. We are restricted from distributing the Water Site Software source code
without the prior written consent of Columbia University. Under the 2008 Columbia Agreement, Columbia University retains the right to use, and to permit other entities and individuals to use, the Water Site Software and Water Site Patents for
academic and <FONT STYLE="white-space:nowrap">non-commercial</FONT> educational purposes in the field of computational chemistry software and related services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for entering into the 2008 Columbia Agreement, we paid Columbia University a
<FONT STYLE="white-space:nowrap">one-time,</FONT> nominal license fee. In addition, we have agreed to pay royalties to Columbia University in <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentages on our, and our affiliates, gross
revenues from the sale, licensing, leasing, or renting of any Water Site Product, excluding any sales to Columbia University and revenues generated under services agreement. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
royalties under the 2008 Columbia Agreement are paid on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis and vary based on whether or not
the gross revenues are generated in countries of manufacture or sale in which the Water Site Product is covered by a Water Site Patent. In the event that there are multiple royalties payable on a single product, we are required to (i)&nbsp;pay the
higher of the two royalties, if there are no more than two royalties payable on the particular Water Site Product or (ii)&nbsp;negotiate in good faith with Columbia University on a single royalty, if there are more than two royalties payable on the
particular Water Site Product. In the event that we take action against Columbia University with respect to the validity or enforceability of any Water Site Patents, excluding any defensive actions or claims, the royalties paid under the 2008
Columbia Agreement will increase by a specified amount. Our obligation to pay any royalty under the 2008 Columbia Agreement, including any royalty paid pursuant to the Royalty Amendment, will terminate on May&nbsp;27, 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Columbia University is responsible for the prosecution and maintenance of the Water Site Patents in the jurisdictions that we specify. If we
decide to discontinue the prosecution or maintenance of any Water Site Patent in any jurisdiction, but Columbia University objects to such discontinuation, our license to use such Water Site Patent will terminate in that jurisdiction; provided that,
if we are using the Water Site Patent or Water Site Software in the jurisdiction at issue, Columbia University is obligated to discuss in good faith whether the licenses should instead be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT>
Columbia University is also responsible for the enforcement of the Water Site Patent at its own expense and in its sole judgment; provided that, if we provide Columbia University with evidence of infringement of a Water Site Patent by a third party,
and Columbia University fails to take appropriate enforcement action, we may initiate legal proceedings against the alleged infringer. We are responsible for reimbursing Columbia University for their reasonable expenses in connection with
prosecuting and maintaining the Water Site Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, the 2008 Columbia Agreement will expire on a product by
product and country by country basis upon the later of (i)&nbsp;the expiration of the last issued Water Site Patent, (ii)&nbsp;fifteen years from the date of the first commercial sale of a Water Site Product in a given country, and (iii)&nbsp;the
expiration of the Water Site Software copyright. Columbia University may terminate the 2008 Columbia Agreement if we fail to cure a material breach, become subject to a voluntary or involuntary petition for bankruptcy or any other proceeding
relating to insolvency, receivership or liquidation, or initiate any proceeding or assert any claim challenging the validity or enforceability of the Water Site Patents. Upon termination, any third party that has licensed a Water Site Product from
us will retain the right to use such product, subject to the terms of their existing license agreement with us, and we will have the right to continue to provide support to any such third parties for the duration of their license agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Services Royalty Amendment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2008, we entered into the Royalty Amendment with Columbia University, which amended and simplified our royalty obligations
under each of the Columbia License Agreements described in each of the foregoing sections. Pursuant to the Royalty Amendment, we have agreed to pay royalties to Columbia University in <FONT STYLE="white-space:nowrap">mid-single</FONT> digit
percentages on the service fees generated from services (excluding certain gross revenue, including revenue generated under agreements with Columbia University) that we, or our affiliates, perform using one or more Licensed Products under an
agreement with a third party. Upon termination of any of the Columbia License Agreements for any reason other than our material breach, we will have the right to continue to use the Licensed Products to provide services under existing third-party
service agreements, until the expiration or termination of such agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of
our business, including by seeking, maintaining, and defending patent rights, whether developed internally or jointly, or licensed from third parties. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing
technological innovation, collaboration opportunities, and <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen, and maintain our proprietary position in our field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is important to our future commercial success to obtain and maintain patent and other
proprietary protection for commercially important technology, inventions, and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business; defend and enforce our intellectual property rights, in particular our patent, trademark, and
copyright rights; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from
making, using, selling, offering to sell, or importing any products we develop may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues. We cannot
predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure
that patents will issue with respect to any patent applications that we or our licensors may file in the future, nor can we ensure that any of our owned or licensed patents or future patents will be commercially useful in protecting our software,
technology, computational platform, and any product candidates we develop. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after
issuance. As a result, we cannot guarantee that any products we develop will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold or may hold may be challenged, circumvented or invalidated by third parties.
See &#147;Risk Factors&#151;Risks Related to Our Intellectual Property&#148; for a more comprehensive description of risks related to our intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to file patent applications directed to our key software and our key programs in an effort to secure our intellectual property
positions <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-a-vis</FONT></FONT> this software and these programs. The patent portfolio for our software business includes at least 13 published patent families. As of December 31,
2019, we owned or held exclusive license rights to approximately 60 patents and patent applications, including at least six issued or allowed U.S. cases, six pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications,
nine issued or allowed <FONT STYLE="white-space:nowrap">non-U.S.</FONT> cases, including three granted European patents which have been validated among multiple individual European Patent Convention nations and four
<FONT STYLE="white-space:nowrap">non-European</FONT> patents, six pending foreign patent applications, and three pending Patent Cooperation Treaty, or PCT, applications relating to our computational platform. While we believe that the specific and
generic claims contained in our wholly-owned and licensed pending U.S., <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> and PCT applications provide protection for various aspects of our computational platform, third parties may nevertheless
challenge such claims. Any patents that are issued or that may issue from these families are expected to expire between 2026 and 2038, absent any adjustments or extensions. There are no published patent families related to our internal drug
discovery business to date, and although several of our drug discovery collaborators have filed patent applications related to our collaborations that include employees of ours as inventors, including over 100 compound patents and patent
applications since 2010, we do not own any intellectual property rights related to these inventions. As of December 31, 2019, three wholly-owned provisional applications have been filed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark
Office may be significantly narrowed before issuance, if issued at all. We expect this may be the case with respect to some of our pending patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in
which we file, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application, absent any adjustments or extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United States, the term of a patent covering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may, in certain
cases, be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five
years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a
method for manufacturing it may be extended. Similar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents we may obtain in the
future may be entitled to patent term extensions. If our use of product candidates or the product candidate itself receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the
approved use or product candidate. We also intend to seek patent term extensions in any jurisdictions where available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such
extensions should be granted, and even if granted, the length of such extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we have approximately
40 copyright registrations covering our proprietary software code, and we rely upon unpatented trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our
competitive position. However, trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any
collaborators, scientific advisors, service providers, employees, and consultants and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors, and
collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential <FONT
STYLE="white-space:nowrap">know-how</FONT> may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property,
unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or
similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. See &#147;Risk Factors&#151;Risks Related to Our
Intellectual Property&#148; for a more comprehensive description of risks related to our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also own numerous
trademarks registered in the United States and foreign jurisdictions, including &#147;Schr&#246;dinger&#148; and &#147;LiveDesign&#148;. We pursue additional trademark registrations to the extent we believe doing so would be beneficial to our
competitive position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Software Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We commercialize our software solutions in various jurisdictions around the world through our software sales organization. We have sales
operations in the United States, Europe, Japan, and India, and we also have established distribution channels in other important markets, including China and South Korea. These efforts are led by our approximately 130 person global team of sales,
technical, and scientific personnel. Our marketing strategy leverages our strong base of scientific publications to support the continued growth of our computational platform into computational chemistry markets across industries and academia
worldwide. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Drug Discovery Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not established a commercial organization or developed distribution capabilities given the current stage of development of our
internal, wholly-owned drug discovery programs. We plan to enter into agreements with biopharmaceutical companies that contribute to our ability to efficiently advance development candidates that we discover internally using our computational
platform through to commercialization. We expect to utilize a variety of types of collaboration, distribution, and other arrangements with one or more of these third parties to develop and ultimately commercialize our development candidates. Over
time, we may also create a commercial organization for drug product sales if and as we advance the development of any product candidates that we determine to commercialize ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities for the production of any product candidates, nor do we have plans to develop our own
manufacturing operations. We expect to rely on third-party contract manufacturers for all of our required raw materials, drug substance, and finished drug product for the preclinical and clinical development of any development candidates we develop
ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approvals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local level, and in other countries and jurisdictions, including the
European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution,
marketing, post-approval monitoring and reporting, and import and export of biopharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with
applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Approval and Regulation of Drugs in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, drug products are regulated under the Federal Food, Drug and Cosmetic Act, or FDCA, and applicable implementing
regulations and guidance. The failure of an applicant to comply with the applicable regulatory requirements at any time during the product development process, including <FONT STYLE="white-space:nowrap">non-clinical</FONT> testing, clinical testing,
the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval, and/or administrative or judicial sanctions. These sanctions may include, but are not limited to, the FDA&#146;s refusal
to allow an applicant to proceed with clinical trials, refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters,
adverse publicity, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil, or criminal investigations and
penalties brought by the FDA or the United States Department of Justice or other government entities, including state agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An
applicant seeking approval to market and distribute a new drug in the United States generally must satisfactorily complete each of the following steps before the product candidate will be approved by the FDA: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical testing including laboratory tests, animal studies, and formulation studies, which must be performed
in accordance with the FDA&#146;s good laboratory practice, or GLP, regulations and standards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND for human clinical testing, which must become effective before human clinical
trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board, or IRB, representing each clinical site before each
clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety, potency, and purity of
the product candidate for each proposed indication, in accordance with current good clinical practices, or GCP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of a new drug application, or NDA, for a drug product which includes not
only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labelling for one or more proposed indication(s); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of
third parties, at which the product candidate or components thereof are manufactured to assess </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
compliance with current good manufacturing practices, or cGMP, requirements and to assure that the facilities, methods, and controls are adequate to preserve the product&#146;s identity,
strength, quality, and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of any FDA audits of the <FONT STYLE="white-space:nowrap">non-clinical</FONT> and
clinical trial sites to assure compliance with GCP and the integrity of clinical data in support of the NDA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees and securing FDA approval of the NDA to allow marketing of the new drug product; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk
Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct any post- approval studies required by the FDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before an applicant begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical
testing stage, including <I>in vitro</I> and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. Preclinical tests include laboratory evaluations of product
chemistry, formulation, and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal
regulations and requirements, including GLP regulations and standards. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among
other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity and long-term toxicity studies may continue after the IND is submitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The IND and IRB Processes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their voluntary informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under
written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical
trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND is an exemption from the FDCA that
allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured
prior to interstate shipment and administration of any product candidate that is not the subject of an approved NDA. In support of a request for an IND, applicants must submit a protocol for each clinical trial, and any subsequent protocol
amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among
other things, must be submitted to the FDA as part of an IND. The FDA requires a <FONT STYLE="white-space:nowrap">30-day</FONT> waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow
the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this <FONT STYLE="white-space:nowrap">30-day</FONT> period or thereafter, the FDA may raise concerns or questions
about the conduct of the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In these cases, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial.
Clinical holds are imposed by the FDA whenever there is concern for patient safety and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be a result of new data, findings, or developments in clinical, nonclinical, and/or chemistry, manufacturing, and controls, or CMC. A clinical hold is an order issued by the FDA to the
sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a
protocol may not be allowed to proceed, while other protocols may be allowed. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following issuance of a clinical hold or partial clinical hold, a clinical trial may only resume after the FDA has so notified the sponsor.
The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the clinical trial can proceed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under
an IND, all FDA IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that such studies are conducted in accordance with GCP, including review and approval by an independent
ethics committee, or IEC, and informed consent from subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing IND requirements, an IRB representing each
institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must
review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its
institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety
monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Suspension or termination of
development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving
business objectives and/or the competitive environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about clinical trials must be submitted within specific timeframes to
the National Institutes of Health for public dissemination on its ClinicalTrials.gov website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Human Clinical Trials in Support of an
NDA </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a
qualified investigator in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are
conducted under written clinical trial protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may
also be required after approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 1</I> clinical trials are initially conducted in a limited population to test the product
candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the investigational drug
product&#146;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2</I> clinical trials are generally conducted in a limited patient population to
identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to
obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are well controlled, closely monitored and conducted in a limited patient population. A Phase 2 trial may be further subdivided to Phase 2a
and Phase 2b trials. A Phase 2a trial is typically an exploratory <FONT STYLE="white-space:nowrap">(non-pivotal)</FONT> study that has clinical efficacy, pharmacodynamics, or biological activity as the primary endpoint. A Phase 2b trial is a
definite dose range finding study with efficacy as the primary endpoint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 3</I> clinical trials proceed if the Phase 2 clinical
trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial
evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial may be designed to
deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a drug. Such Phase 3 studies are referred to as &#147;pivotal.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may approve an NDA for a product candidate but require the sponsor to conduct additional clinical trials to further
assess the product candidate&#146;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of a larger number
of patients in the intended treatment group and to further document a clinical benefit in the case of drugs approved under Accelerated Approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could
result in withdrawal of approval for products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials must be submitted at least
annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal
or <I>in vitro</I> testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase
1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that
the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in
accordance with the IRB&#146;s requirements or if the product has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical
data submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies often complete additional animal studies. They must also develop additional
information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of
consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and
tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Review and Approval of an NDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain approval to market a drug product in the United States, a marketing application must be submitted to the FDA that provides
sufficient data establishing the safety, purity, and potency of the proposed drug product for its intended indication. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or
ambiguous results as well as positive findings, together with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to
test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by independent investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity
to establish the safety, purity, and potency of the drug product to the satisfaction of the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NDA is a vehicle through which
applicants formally propose that the FDA approve a new product for marketing and sale in the United States for one or more indications. Every new <FONT STYLE="white-space:nowrap">non-biologic</FONT> drug product candidate must be the subject of an
approved NDA before it may be commercialized in the United States. Biologic License Applications, or BLAs, are submitted for approval of biologic products. Under federal law, the submission of most NDAs is subject to an application user fee. The
sponsor of an approved NDA is also subject to an annual program fee. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation, an exception from the
program fee when the program does not engage in manufacturing the drug during a particular fiscal year and a waiver for certain small businesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of the application, generally within 60 calendar days of its receipt, and strives to inform the sponsor
within 74 days whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the
additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review.
The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which the FDA
accepts the application for filing, and 90% of applications for NMEs that have been designated for Priority Review are meant to be reviewed within six months of the filing date. For applications seeking approval of products that are not NMEs, the <FONT
STYLE="white-space:nowrap">ten-month</FONT> and <FONT STYLE="white-space:nowrap">six-month</FONT> review periods run from the date that the FDA receives the application. The review process and the Prescription Drug User Fee Act, or PDUFA, goal date
may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an application, the FDA typically will inspect the facility or facilities where the product is being or will be manufactured.
These <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with an NDA submission, including component manufacturing, finished product manufacturing, and control testing laboratories. The FDA will not
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before
approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a condition of
approval, the FDA may require an applicant to develop a REMS. A REMS uses risk-minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed,
the FDA will consider the size of the population likely to use the product, the seriousness of the disease, the expected benefit of the product, the expected duration of treatment, the seriousness of known or potential adverse events, and whether
the product is a new molecular entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel product to an advisory committee or explain why such
referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that review, evaluate and provide a recommendation as to whether the application should be approved and
under what conditions. The FDA is not bound by the recommendations of an advisory committee, but the FDA considers such recommendations carefully when making decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The FDA&#146;s Decision on an NDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the FDA&#146;s evaluation of the application and accompanying information, including the results of the inspection of the
manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response
letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#146;s
satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA
approves a new product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, or require that post-approval studies, including Phase 4 clinical
trials, be conducted to further assess the drug&#146;s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution
restrictions or other risk management mechanisms, including a REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS programs can include medication guides, communication plans for health care professionals, and
elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The
FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. The FDA may require a REMS before or after approval if it becomes aware of a serious risk associated with use of the
product. The requirement for a REMS can materially affect the potential market and profitability of a product. After approval, many types of changes to the approved product, such as adding new indications, changing manufacturing processes, and
adding labeling claims, are subject to further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Patent Term Restoration and Extension
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch- Waxman Act, which permits a
patent restoration of up to five years for patent term lost during the FDA regulatory review. The restoration period granted on a patent covering a product is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective
date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term restoration cannot be used to extend
the remaining term of a patent past a total of 14 years from the product&#146;s approval date. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using
it, or a method for manufacturing it, may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only
be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Health Care Law and Regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaborators who use our platform and we, if we develop a product, may be subject to broadly applicable healthcare laws and regulations
that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our software and any products for which we obtain marketing approval. Restrictions under applicable federal and state health
care laws and regulations, include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal health care Anti-Kickback Statute, which prohibits, among other things, persons and entities from
knowingly and willfully soliciting, offering, paying, receiving, or providing remuneration, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may
be made, in whole or in part, under a federal health care program such as Medicare and Medicaid and similar state anti-kickback laws. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order
to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including the civil False Claims Act (which can be enforced
through civil whistleblower actions), and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false,
fictitious, or fraudulent or knowingly making, using or causing to made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim
including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal and state laws and regulations that protect the privacy and security of health-related or other
personal identifiable information that we may generate or receive, and that require disclosure of breaches in which such information is compromised by being lost or obtained or accessible by unauthorized persons, including, among others, laws and
regulations implemented through informed consents for clinical research studies and the privacy and security standards imposed under the Health Insurance Portability and Accountability Act, or HIPAA, for certain individually identifiable health
information of patients and health plan beneficiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing, or covering
up a material fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient
Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for
Medicare&nbsp;&amp; Medicaid Services within the United States Department of Health and Human Services, information related to certain payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as
ownership and investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to health
care items or services that are reimbursed by <FONT STYLE="white-space:nowrap">non-government</FONT> third-party payors, including private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines
and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing
expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws (such as the California Consumer Privacy Act of 2018 and the General Data Protection
Regulation, or GDPR, regarding individuals in the European Union) also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Violations of applicable healthcare laws and regulations may result in significant civil, criminal and
administrative penalties, damages, disgorgement, fines, imprisonment, and possible exclusion of products from government funded healthcare programs, such as Medicare and Medicaid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the health care laws set forth above, we may also be subject to additional federal laws, such as the U.S. Foreign Corrupt
Practices Act of 1977, as amended, which prohibits, among other things, companies and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their intermediaries from making, or offering or promising to make, improper payments to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> officials for the purpose of obtaining or retaining
business or otherwise seeking favorable treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General Data Protection Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal
health data, is subject to the GDPR which became effective on May&nbsp;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and
other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal
data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United
States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#128;20&nbsp;million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private
right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a
rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical Insurance Coverage and Health Care Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payers to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government
authorities. Thus, even if a product candidate of ours or one of our collaborators is approved, sales of the product will depend, in part, on the extent to which third-party payers, including government health programs in the United States such as
Medicare and Medicaid, commercial health insurers and managed care organizations provide coverage and establish adequate reimbursement levels for the product. The process for determining whether a payer will provide coverage for a product may be
separate from the process for setting the price or reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers are increasingly challenging the prices charged, examining the medical necessity and
reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payers may limit
coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be
considered medically necessary or cost effective. A decision by a third-party payer not to cover a product could reduce market acceptance once the product is approved and have a material adverse effect on sales, results of operations and financial
condition. Additionally, a payer&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#146;s determination to provide coverage for a product does not assure that
other payers will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payer to payer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In international markets, reimbursement and health care payment systems vary significantly by country, and many countries have instituted
price ceilings on specific products and therapies. In some countries, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and adequate reimbursement or pricing approval in some countries, we
may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
containment of health care costs also has become a priority of federal, state, and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment
programs, including price controls, restrictions on coverage, reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions
with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved products including those that we are our collaborators may develop. Coverage policies and third-party reimbursement rates may
change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be
implemented in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Review and Approval of Medicinal Products in the European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of
other countries and jurisdictions regarding quality, safety, and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales, and distribution of products. Whether or not it obtains FDA approval for a
product, an applicant will need to obtain the necessary approvals by the comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities before it can commence clinical trials or marketing of the product in those countries or
jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and
jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in
one country or jurisdiction may negatively impact the regulatory process in others. Specifically, however, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It
entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent
authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual
member states of the European Union, or EU Member States, govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member
States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be
accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, where relevant the implementing national
provisions of the individual EU Member States and further detailed in applicable guidance documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical
Trials Regulation, (EU) No 536/2014, was adopted. The Clinical Trials Regulation was published on June&nbsp;16, 2014 but is not expected to apply until 2020. The Clinical Trials Regulation will be directly applicable in all the EU Member States,
repealing the current Clinical Trials Directive 2001/20/EC and replacing any national legislation that was put in place to implement the Clinical Trials Directive. Conduct of all clinical trials performed in the European Union will continue to be
bound by currently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable provisions until the new Clinical Trials Regulation becomes applicable. The extent to which <FONT STYLE="white-space:nowrap">on-going</FONT> clinical trials will be governed by the
Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the Clinical Trials
Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The new Clinical
Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#147;EU Portal and
Database&#148;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials,
which is divided in two parts. Part I is assessed by the appointed reporting Member State, whose assessment report is submitted for review by the sponsor and all other competent authorities of all EU Member States in which an application for
authorization of a clinical trial has been submitted (Concerned Member States). Part II is assessed separately by each Concerned Member State. Strict deadlines have been established for the assessment of clinical trial applications. The role of the
relevant ethics committees in the assessment procedure will continue to be governed by the national law of the Concerned Member State. However, overall related timelines will be defined by the Clinical Trials Regulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>PRIME Designation in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the European Medicines Agency, or EMA, launched an initiative to facilitate development of product candidates in indications,
often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial
innovation reviewed under the centralized procedure. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to
sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated
marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated agency contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies are appointed
early in PRIME scheme facilitating increased understanding of the product at EMA&#146;s Committee level. A <FONT STYLE="white-space:nowrap">kick-off</FONT> meeting initiates these relationships and includes a team of multidisciplinary experts at the
EMA to provide guidance on the overall development and regulatory strategies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Marketing Authorization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain a marketing authorization for a product under European Union regulatory systems, an applicant must submit an MAA either under a
centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure, national procedure or mutual recognition procedure). A marketing authorization may be
granted only to an applicant established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in an
<FONT STYLE="white-space:nowrap">EMA-approved</FONT> Paediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted (1)&nbsp;a product-specific waiver, (2)&nbsp;a class waiver, or (3)&nbsp;a
deferral for one or more of the measures included in the PIP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single marketing
authorization by the European Commission that is valid across the European Economic Area (i.e. the European Union as well as Iceland, Liechtenstein and Norway). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for
specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products, and products with a new active substance indicated for the treatment of
certain diseases. For products with a new active substance indicated for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The
centralized procedure may at the request of the applicant also be used in certain other cases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the CHMP
is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized
procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the
CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts
such request, the time limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated
assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final opinion from the CHMP, the
European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant provisions of European Union law into account. Before arriving at a final decision on
an application for centralized authorization of a medicinal product the European Commission must consult the Standing Committee on Medicinal Products for Human Use, or the Standing Committee. The Standing Committee is composed of representatives of
the EU Member States and chaired by a <FONT STYLE="white-space:nowrap">non-voting</FONT> European Commission representative. The European Parliament also has a related &#147;droit de regard&#148;. The European Parliament&#146;s role is to ensure
that the European Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European
Commission may grant a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;marketing authorization under exceptional circumstances&#148;. Such authorization is intended for products for which the applicant can demonstrate that it is unable to
provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide
comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing
authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicant must complete an identified program of studies within a time period specified by the competent
authority, the results of which form the basis of a reassessment of the benefit/risk profile; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the medicinal product in question may be supplied on medical prescription only and may in certain cases be
administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact
that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk- benefit balance in an annual
reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of
a medicinal product under exceptional circumstances, however, follows the same rules as a &#147;normal&#148; marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which
the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Commission may also grant a <FONT STYLE="white-space:nowrap">so-called</FONT>
&#147;conditional marketing authorization&#148; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates
(including medicines designated as orphan medicinal products), if (i)&nbsp;the risk-benefit balance of the product candidate is positive, (ii)&nbsp;it is likely that the applicant will be in a position to provide the required comprehensive clinical
trial data, (iii)&nbsp;the product fulfills an unmet medical need, and (iv)&nbsp;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data
are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the
collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions
and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Union medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale,
supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible
that the national laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted a European Union marketing authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and
leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized
procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within
90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public
health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mutual
recognition procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national
marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Regulatory Data Protection in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of
data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance the centralized
authorization procedure. Data exclusivity prevents applicants for authorization of generics of these innovative products from referencing the innovator&#146;s data to assess a generic (abridged) application for a period of eight years. During an
additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic marketing authorization application can be submitted and authorized, and the innovator&#146;s data may be referenced, but no generic medicinal
product can be placed on the European Union market until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period will be extended to a maximum of 11 years if, during the first eight years of
those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the
prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests,
preclinical tests, and clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Periods of Authorization and Renewals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on
the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent
authority with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be
valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five- year period of marketing authorization. Once subsequently
definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the European Union market (in case of centralized procedure) or on
the market of the authorizing EU Member State within three years after authorization ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> sunset clause). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Brexit and the Regulatory Framework in the United Kingdom </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. The
United Kingdom and the European Union have agreed to a withdrawal agreement, which is expected to be approved by the U.K. Parliament. It is expected that the United Kingdom will formally leave the European Union on or before January 31, 2020. Under
the withdrawal agreement, the United Kingdom will be subject to a transitional period until December 31, 2020 (extendable up to two years) during which E.U. rules will continue to apply. Formal trade negotiations are not possible until the United
Kingdom has become a &#147;third country&#148; on January 31, 2020. The U.K. Prime Minister has indicated that the United Kingdom will not seek to extend the transitional period beyond the end of 2020. If no trade agreement has been reached before
the end of the transitional period this may cause significant market and economic disruption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the regulatory framework for
pharmaceutical products in the United Kingdom covering quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union
directives and regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom. It remains to be seen how, if at all, Brexit will impact regulatory
requirements for product candidates and products in the United Kingdom. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Pricing Decisions for Approved Products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be
marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or <FONT
STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health
insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability
of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many
countries in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of
the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being
erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU
Member States, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or
reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2019, we
had 392 full-time employees and 394 total employees, including a total of 200<B></B> employees with Ph.D. degrees. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship
with our employees to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal facilities consist of office space. We occupy approximately 63,000 square feet of office space in New York, New York under a
lease that currently expires in August 2021. We also occupy approximately 26,000 square feet of office space in Portland, Oregon under a lease that currently expires in August 2026, and we lease additional office space at our other office locations
around the world. We believe our facilities are adequate and suitable for our current needs and that should it be needed, suitable additional or alternative space will be available to accommodate our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we
may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age as of December 31, 2019 and position of each of our executive officers and directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ramy Farid, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and President, Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Abel, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">37</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Science</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen Akinsanya, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&amp;D</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shane Brauner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Information Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Daniel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Human Resources Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cony D&#146;Cruz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief Business Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joel Lebowitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth &#147;Patrick&#148; Lorton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Technology Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yvonne Tran</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief Legal Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J&ouml;rg Weiser </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors</I></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Lynton<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman of the Board of Directors</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard A. Friesner, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">67</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rosana Kapeller-Libermann, M.D.,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Sender<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nancy Thornberry<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy M. Wright, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">64</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Audit Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Compensation Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Nominating and Corporate Governance Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ramy
Farid, Ph.D.</I></B> has served as our president since January 2008, our chief executive officer since January 2017 and as a member of our board of directors since December 2012. Dr.&nbsp;Farid has been with our company for over 17 years and has
served as senior vice president from January 2005 to December 2007, vice president, scientific development and product management from January 2003 to December 2004 and product manager from January 2002 to December 2002. Dr.&nbsp;Farid serves on the
board of directors of multiple biotechnology companies <FONT STYLE="white-space:nowrap">co-founded</FONT> by us, and previously served on the board of directors of Morphic Holding, Inc., a biotechnology company. Prior to joining our company,
Dr.&nbsp;Farid was an assistant professor in the Chemistry Department at Rutgers University. Dr.&nbsp;Farid received a B.S. in Chemistry from the University of Rochester and a Ph.D. from the California Institute of Technology, and he was a National
Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. We believe that Dr.&nbsp;Farid&#146;s extensive knowledge of our company and current role as our president and chief
executive officer qualifies him to serve on our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Robert Abel, Ph.D.</I></B> has served as our executive vice president, science, since
January 2020. Dr.&nbsp;Abel has been with our company for over 10 years and previously served as our senior vice president, science, from April 2017 to December 2019, vice president, scientific development from January 2014 to April 2017, director
of structure-based science from January 2011 to December 2013, senior principal scientist and product manager from January 2010 to December 2010 and senior scientist from March 2009 to December 2009. Dr.&nbsp;Abel received a B.S. in Chemistry from
the University of Florida and a Ph.D. in Chemical Physics from Columbia University. In graduate school, Dr.&nbsp;Abel was a National Science Foundation Graduate Research Fellow and a Department of Homeland Security Research Fellow, and worked from
May 2005 to August 2005 at Los Alamos National Laboratory under the auspices of the DHS Research Fellowship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Karen Akinsanya,
Ph.D.</I></B> has served as our executive vice president, chief biomedical scientist, head of discovery R&amp;D since January 2020 and previously served as our senior vice president and chief biomedical scientist from April 2018 to December 2019.
Dr.&nbsp;Akinsanya spent 12 years at Merck &amp; Co., Inc., or Merck, a pharmaceutical company, where she held a variety of positions across Merck Research Labs, including associate vice president, early scientific assessment lead, business
development&nbsp;&amp; licensing from December 2013 to July 2017, collaboration lead and executive director, cardiovascular research from January 2010 to December 2013, and associate director, clinical pharmacology from October 2005 to December
2009. Prior to Merck, Dr.&nbsp;Akinsanya held a number of roles in drug discovery at Ferring Pharmaceuticals in the United Kingdom and the United States from 1997 to 2005. In 2007, Dr.&nbsp;Akinsanya founded Envision Science Group LLC, or Envision,
a translational science consulting company, where she currently serves as president. Dr.&nbsp;Akinsanya provided consulting services on behalf of Envision to companies in the pharmaceutical industry between July 2017 and April 2018.
Dr.&nbsp;Akinsanya received a B.Sc. in Biochemistry from Queen Mary College, University of London, a Ph.D. in Endocrine Physiology from the Imperial College and completed postdoctoral studies at the Ludwig Institute for Cancer Research, University
College, London. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Shane Brauner</I></B> has served as our chief information officer since January 2019. Mr.&nbsp;Brauner has been
with our company for over 10 years and previously served as our senior vice president, information systems from January 2017 to January 2019, vice president, information technology and operations from January 2015 to January 2017, executive
director, information technology and operations from January 2014 to January 2015, senior director, information technology from January 2012 to January 2014, director, information technology from January 2010 to January 2012 and manager, information
technology from February 2009 to January 2010. Prior to joining our company, Mr.&nbsp;Brauner served as a consultant, managing global grid computing support at Pfizer, Inc., or Pfizer, from June 2007 to October 2008. Mr.&nbsp;Brauner received a B.S.
in Computer Science from the University of Houston. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jennifer Daniel</I></B> has served as our senior vice president and chief human
resources officer since February 2017 and as our vice president of human resources from January 2002 to June 2009. Prior to rejoining our company in February 2017, Ms.&nbsp;Daniel served as senior vice president, human resources at Outbrain Inc., an
advertising technology company, from December 2011 to February 2017. Prior to that, Ms.&nbsp;Daniel served as senior vice president, strategic growth, at Juno Online Services, an internet service provider company, from June 1996 to October 2001.
Ms.&nbsp;Daniel received a B.A. in International Relations from American University and an M.L.A, Environmental Studies from the University of Pennsylvania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cony D&#146;Cruz</I></B> has served as our executive vice president and chief business officer since January 2016. Previously,
Mr.&nbsp;D&#146;Cruz served as our senior vice president of business development from April 2013 to December 2015. Prior to joining our company, Mr.&nbsp;D&#146;Cruz served as president of Proteros US, Inc., or Proteros, a biotechnology company,
from 2010 to March 2013. Prior to joining Proteros, Mr.&nbsp;D&#146;Cruz served as senior vice president, North America, at Evotec SE, or Evotec, a biotechnology company, from 2001 to 2010. Mr.&nbsp;D&#146;Cruz received a B.Sc. in Applied Biology
from the University of London and an M.B.A from The Open University, Milton Keynes United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Joel Lebowitz </I></B>has served
as our executive vice president and chief financial officer since November 2018. Mr.&nbsp;Lebowitz previously spent 26 years at Merck, a pharmaceutical company, where he served as global finance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lead, project management from September 2013 to December 2014, executive director, pipeline valuation and portfolio analysis from October 2011 to March 2014 and executive director, corporate
planning and management reporting from 2005 to 2011. From January 2015 to October 2018, Mr.&nbsp;Lebowitz was retired. Mr.&nbsp;Lebowitz received a B.A. in Applied Mathematics and Economics from Brown University and an M.B.A. in Finance and
International Business from Columbia Graduate School of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patrick Lorton</I></B> has served as our senior vice president
and chief technology officer since April 2017. Mr.&nbsp;Lorton has been with our company for over 13 years and previously served as our vice president of engineering from January 2016 to April 2017, director of software engineering from January 2015
to January 2016, associate director of software engineering from December 2012 to January 2015, project leader from January 2011 to December 2012 and scientific developer from September 2006 to December 2012. Prior to joining our company,
Mr.&nbsp;Lorton served as a chemistry research assistant from December 2005 to September 2006 and a computer science research assistant from August 2004 to July 2006 at Indiana University Bloomington. Mr.&nbsp;Lorton received a B.S. in Computer
Science and a B.A. in Mathematics and Chemistry from Indiana University Bloomington. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Yvonne Tran</I></B> has served as our
executive vice president and chief legal officer since April 2017, and previously served as our general counsel from April 2010 to April 2017. Prior to joining our company, Ms.&nbsp;Tran previously served as senior corporate counsel at Oracle
America, Inc., or Oracle, a technology company, from January 2008 to April 2010. Prior to joining Oracle, Ms.&nbsp;Tran served as outside legal consultant from January 2006 to January 2008 and deputy general counsel from April 2000 to January 2006
at DoubleClick, Inc., an advertising technology company since acquired by Google LLC. Ms.&nbsp;Tran received a B.A. in Molecular Biophysics and Biochemistry from Yale University and a J.D. from the University of Virginia School of Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>J&ouml;rg Weiser </I></B>has served as the executive vice president and managing director of our German office and wholly owned
subsidiary, Schr&ouml;dinger GmbH, since October 2002. Dr.&nbsp;Weiser previously served as <FONT STYLE="white-space:nowrap">co-founder</FONT> and managing director at Anterio Consult&nbsp;&amp; Research GmbH, a German consulting and research
company, from June 1999 to September 2002. Dr.&nbsp;Weiser received a doctorate in Organic Chemistry from the University of G&ouml;ttingen and was a post-doctoral fellow at Columbia University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Michael Lynton</I></B> has served as a member of our board of directors since January 2018 and chairman of our board of directors since
October 2018. He has served as a director at General Catalyst Partners, a venture capital firm, since December 2018. Mr.&nbsp;Lynton served as chief executive officer of Sony Entertainment Inc., an international entertainment company, from April
2012 to August 2017, as chairman and chief executive officer of Sony Pictures Entertainment Inc., from January 2004 to May 2017 and as chief executive officer of Sony Corporation of America, from March 2012 to August 2017. Mr.&nbsp;Lynton currently
serves as chairman of the board of directors of Snap Inc., a publicly-traded technology company, and as a member of the board of directors of Ares Management Corporation, a publicly traded, global alternative asset manager,&nbsp;and Pearson plc., a
publicly traded publishing and education company. Mr.&nbsp;Lynton also served as a member on the board of directors of Pandora Media, Inc. from August 2017 to February 2019. Mr.&nbsp;Lynton received a B.A. in History and Literature from Harvard
College and an M.B.A. from Harvard Business School. We believe that Mr.&nbsp;Lynton&#146;s public company board and management experience and his extensive business and leadership experience qualifies him to serve as chairman of our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Richard A. Friesner, Ph.D. </I></B>has served as a member of our board of directors since August 1990, when he
co-founded us. Dr.&nbsp;Friesner is currently the William P. Schweitzer professor of chemistry at Columbia University, the principal investigator of the Friesner Research Group, a research laboratory within the Department of Chemistry at Columbia
University, and he has served as a professor of chemistry at Columbia University since September 1990. Dr. Friesner is a Fellow of the American Academy of Sciences and a member of the National Academy of Sciences. Dr.&nbsp;Friesner received a B.S.
in Chemistry from the University of Chicago </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and a Ph.D. in Chemistry from the University of California, Berkeley. We believe that Dr.&nbsp;Friesner&#146;s extensive experience in theoretical chemistry and his extensive knowledge of our
company since inception, as well as his distinguished scientific record, qualifies him to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Rosana
Kapeller-Libermann, M.D., Ph.D. </I></B>has served as a member of our board of directors since January 2019. Dr.&nbsp;Kapeller-Libermann has served as president and chief executive officer of Rome Therapeutics, Inc., a therapeutics company, since
April 2019. She has also served as an entrepreneur in residence at GV, a venture capital investment arm of Alphabet Inc. since November 2018. Prior to that, Dr.&nbsp;Kapeller-Libermann served as founding chief scientific officer of Nimbus
Therapeutics, or Nimbus, a biotechnology company, from February 2010 to March 2018. Prior to joining Nimbus, she served as vice president of research at Aileron Therapeutics, Inc., a biopharmaceutical company, from August 2005 to September 2009.
Dr.&nbsp;Kapeller-Libermann received an M.D. from Universidade do Estado do Rio de Janeiro and a Ph.D. in Molecular and Cellular Physiology from Tufts University. We believe Dr.&nbsp;Kapeller-Libermann&#146;s scientific experience in the field of
drug discovery and extensive experience working with life sciences companies qualifies her to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gary
Sender</I></B> has served as a member of our board of directors since July 2019. Mr.&nbsp;Sender has served as chief financial officer of Nabriva Therapeutics plc, or Nabriva, a publicly-traded biopharmaceutical company, since May 2016. Prior to
joining Nabriva, Mr.&nbsp;Sender served as chief financial officer and executive vice president at Synergy Pharmaceuticals Inc., or Synergy, a publicly-traded biopharmaceutical company, from November 2015 to April 2016. Prior to joining Synergy,
from August 2009 to June 2015, Mr.&nbsp;Sender served as senior vice president, finance at Shire plc., or Shire, a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited. Prior to joining Shire, Mr.&nbsp;Sender served as
founding chief financial officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr.&nbsp;Sender also spent over 15 years in several leadership roles within Merck, a pharmaceutical company. Mr.&nbsp;Sender received
a B.S. in Finance from Boston University and an M.B.A. from Carnegie-Mellon University. We believe Mr.&nbsp;Sender&#146;s extensive experience in the life sciences industry, and in particular his financial acumen, qualifies him to serve on our board
of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nancy Thornberry</I></B> has served as a member of our board of directors since September 2019. Ms.&nbsp;Thornberry
has served as chief executive officer of Kallyope, Inc., a biotechnology company, since November 2015. Between August 2013 and October 2015, Ms.&nbsp;Thornberry was self-employed as a consultant to companies in the biotechnology and pharmaceutical
industries. Prior to that, Ms.&nbsp;Thornberry spent over 30 years at Merck, a pharmaceutical company, where she held a variety of positions including senior vice president and franchise head, diabetes and endocrinology, from April 2011 to July
2013, senior vice president and franchise head, diabetes and obesity, from September 2009 to April 2011, vice president, worldwide basic research head, diabetes and obesity, from February 2007 to September 2009 and executive director, metabolic
disorders, from 2004 to February 2007, among other positions. Ms.&nbsp;Thornberry received a B.S. in Chemistry and Biology from Muhlenberg College. We believe Ms.&nbsp;Thornberry&#146;s scientific background and experience in the life sciences
industry qualifies her to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Timothy M. Wright, M.D.</I></B> has served as a member of our board of
directors since April 2015. Dr.&nbsp;Wright has served as general partner at Time BioVentures, a life sciences venture capital firm, since April 2019. Prior to that, Dr.&nbsp;Wright served as chief research and development officer at Regulus
Therapeutics, Inc. or Regulus, a biopharmaceutical company, from September 2016 to March 2019. Prior to joining Regulus, Dr.&nbsp;Wright served as executive vice president, translational sciences at the California Institute for Biomedical Research,
a <FONT STYLE="white-space:nowrap">non-profit</FONT> organization, from February 2015 to August 2016. Prior to that, Dr.&nbsp;Wright held positions of increasing responsibility at Novartis Pharmaceuticals, a multinational pharmaceutical company,
from&nbsp;April 2004&nbsp;to January 2015, including deputy head of translational research, global head of translational medicine, global head of translational sciences and global head of pharma development. Dr.&nbsp;Wright currently serves as a
scientific advisor to the Bill and Melinda Gates Foundation and to the Leonard Schaeffer Center for Health Policy and Economics at University of Southern California. Dr.&nbsp;Wright received a B.A. in Biology from the University of Delaware and an
M.D. from the Johns Hopkins University School of Medicine where he also completed postdoctoral training. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
We believe Dr.&nbsp;Wright&#146;s business experience and knowledge of the life sciences industry in which we operate qualifies him to serve on our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board
Composition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the closing of this offering, our board of directors will be authorized to have seven members and will
consist of seven members. Our directors hold office until their successors have been elected and qualified or until the earlier of their death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws that will become effective upon the closing of this offering provide that the authorized number of
directors may be changed only by resolution of our board of directors. Our certificate of incorporation and bylaws will also provide that until the first date on which the Bill &amp; Melinda Gates Foundation Trust, Schrodinger Equity Holdings, LLC,
D. E. Shaw &amp; Co., L.P., D. E. Shaw Technology Development, LLC and D. E. Shaw Valence Portfolios, L.L.C. and their respective successors and affiliates cease collectively to beneficially own (directly or indirectly) more than 40% of our
outstanding shares of common stock and limited common stock, which date we refer to as the Trigger Date, any director may be removed at any time with or without cause by the affirmative vote of the holders of at least a majority of the voting power
of our outstanding shares of common stock. On and after the Trigger Date, our directors may be removed only for cause and only by the affirmative vote of the holders of at least a majority of the voting power of all outstanding shares of common
stock. Our certificate of incorporation and bylaws will also provide that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors
then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our certificate of incorporation and bylaws that will become effective upon the closing
of this offering, our board of directors will be divided into three classes, class I, class II and class III, with members of each class serving staggered three-year terms. Upon the closing of this offering, the members of the classes will be
divided as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the class I directors will be Ramy Farid and Timothy M. Wright, and their term will expire at the annual meeting
of stockholders to be held in 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the class II directors will be Michael Lynton and Nancy Thornberry, and their term will expire at the annual
meeting of stockholders to be held in 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the class III directors will be Richard A. Friesner, Rosana Kapeller-Libermann and Gary Sender, and their term
will expire at the annual meeting of stockholders to be held in 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the term of a class of
directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The classification of our board of directors may have the effect of delaying or preventing changes in our control or management. See
&#147;Description of Capital Stock&#151;Delaware Anti-Takeover Law and Certain Charter and Bylaw Provisions.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable Nasdaq rules require a majority of a listed company&#146;s board of directors to be comprised of independent directors
within one year of listing. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating, and corporate governance committees be independent. Audit committee
members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and compensation committee members must also satisfy the
independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Under applicable Nasdaq rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of directors, that person does not have a
relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an
audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory
fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT>
the board must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#146;s ability to be
independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&nbsp;the source of compensation of the director, including any consulting advisory or other compensatory fee paid by
such company to the director; and (2)&nbsp;whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, our board of directors undertook a review of the composition of our board of directors and its committees and the
independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment, and affiliations, including family relationships, our board of directors has determined that each of our
directors, with the exception of Dr.&nbsp;Farid and Dr.&nbsp;Friesner, is an &#147;independent director&#148; as defined under applicable Nasdaq rules, including, in the case of all the members of our audit committee, the independence criteria set
forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and in the case of all the members of our compensation committee, the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the
Exchange Act. In making such determination, our board of directors considered the relationships that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances that our board of
directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. Dr.&nbsp;Farid is not an independent director under
these rules because he is our president and chief executive officer, and Dr.&nbsp;Friesner is not an independent director under these rules because he has received more than $120,000 in consulting fees from us during a
<FONT STYLE="white-space:nowrap">12-month</FONT> period within the last three years. See &#147;Transactions with Related Persons&#148; for more information regarding Dr.&nbsp;Friesner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board of Directors in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a
standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their
respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures and
the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and
regulatory requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each
of which operates under a charter that has been approved by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are Gary Sender, Rosana Kapeller-Libermann and Michael Lynton. Gary Sender is the chair of the audit
committee. Our audit committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the work of our independent registered public accounting firm, including through the receipt and
consideration of reports from that firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and
quarterly financial statements and related disclosures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring our internal control over financial reporting, disclosure controls and procedures and code of business
conduct and ethics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing our risk assessment and risk management policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt and retention of accounting related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting independently with our internal auditing staff, if any, our independent registered public accounting firm
and management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving or ratifying any related person transactions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the audit committee report required by the rules of the Securities and Exchange Commission, or SEC.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services, other than <I>de minimis</I> non-audit
services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that Gary Sender is an &#147;audit committee financial expert&#148; as defined in applicable SEC rules
and that each of the members of our audit committee possesses the financial sophistication required for audit committee members under Nasdaq rules. We believe that the composition of our audit committee meets the requirements for independence under
current Nasdaq and SEC rules and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are Gary Sender, Rosana Kapeller-Libermann and Timothy M. Wright. Gary Sender is the chair of the
compensation committee. Our compensation committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or making recommendations to our board of directors with respect to, the compensation of
our chief executive officer and our other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing an evaluation of our senior executives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing and administering our cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to our board of directors with respect to director compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to our board of directors with respect to management succession planning at
the request of the board of directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis&#148; disclosure
if and to the extent then required by SEC rules; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the compensation committee report if and to the extent then required by SEC rules.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the composition of our compensation committee meets the requirements for independence under current
Nasdaq and SEC rules and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our nominating and corporate governance committee are Michael Lynton and Nancy Thornberry. Michael Lynton is the chair of the
nominating and corporate governance committee. Our nominating and corporate governance committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our board of directors the persons to be nominated for election as directors and to each of our
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to our board with respect to our board leadership structure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to our board of directors corporate governance principles; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing an annual evaluation of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the composition of our nominating and corporate governance committee meets the requirements for independence under current
Nasdaq and SEC rules and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our executive officers serves, or in the past year has served, as a member of the board of directors or compensation committee, or
other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None of the members of our compensation committee is, or
has ever been, an officer or employee of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics and Code of Conduct </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of the code on our website, www.schrodinger.com. In addition, we intend to post on our
website all disclosures that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code. Our website is not incorporated by reference into this prospectus and you should not consider any
information contained in or accessible from our website to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion relates to the compensation of Ramy Farid, our president and chief executive officer, Cony D&#146;Cruz, our executive
vice president and chief business officer, and Yvonne Tran, our executive vice president and chief legal officer for fiscal year 2019. Dr.&nbsp;Farid, Mr.&nbsp;D&#146;Cruz, and Ms. Tran are collectively referred to in this prospectus as our named
executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing to become a public company, we have begun a thorough review of all elements of our executive
compensation program, including the function and design of our equity incentive programs. We have begun, and expect to continue in the coming months, to evaluate the need for revisions to our executive compensation program to ensure that our program
is competitive with the companies with which we compete for executive talent and is appropriate for a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation awarded to, earned by or paid to each of our named executive
officers for the years ended December&nbsp;31, 2019 and 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-Equity<BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ramy Farid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">478,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,701</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">633,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I></I>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I></I>2018</TD>
<TD NOWRAP VALIGN="top"><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">464,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">821,525</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4,614</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,370,139</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cony D&#146;Cruz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,701</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President and Chief Business Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I></I>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><I></I>2018</TD>
<TD NOWRAP VALIGN="top"><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">428,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">107,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">65,722</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4,614</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">605,336</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yvonne Tran</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,118</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President and Chief Legal Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in the &#147;Bonus&#148; column reflect discretionary annual cash bonuses paid to our
executive officers for their performance in 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in the &#147;Option Awards&#148; column reflect the aggregate grant date fair value of <FONT
STYLE="white-space:nowrap">stock-based</FONT> compensation awarded during the year computed in accordance with the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 718. See Note 10 to our
consolidated financial statements appearing at the end of this prospectus regarding assumptions underlying the valuation of equity awards. These amounts reflect the accounting cost for these stock options and do not reflect the actual economic value
that may be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options or the sale of the common stock underlying such stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in the &#147;Non-Equity Incentive Plan Compensation&#148; column reflect annual cash
bonuses earned by our executive officers for their performance in 2019 under the Senior Executive Incentive Compensation Plan. For a description of the plan, see &#147;&#151;Senior Executive Incentive Compensation Plan&#148; below.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i)&nbsp;premiums of $501 paid by us during 2019 with respect to group life, accidental death and
dismemberment and long-term disability insurance policies consistent with those provided to all of our employees, and (ii)&nbsp;matching contributions of $11,200 made by us under our 401(k) plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i)&nbsp;premiums of $489 paid by us during 2018 with respect to group life, accidental death and
dismemberment and long-term disability insurance policies consistent with those provided to all of our employees, and (ii)&nbsp;matching contributions of $4,125 made by us under our 401(k) plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) premiums of $501 paid by us during 2019 with respect to group life, accidental death and
dismemberment and long-term disability insurance policies consistent with those provided to all of our employees, and (ii) matching contributions of $7,617 made by us under our 401(k) plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Base Salary.</I> In 2018, we paid Dr.&nbsp;Farid an annualized base salary of $464,000 and Mr.&nbsp;D&#146;Cruz an annualized base salary of
$428,000. In 2019, we paid Dr. Farid an annualized base salary of $478,000, Mr.&nbsp;D&#146;Cruz an annualized base salary of $443,000 and Ms. Tran an annualized base salary of $415,000. In January 2020, our board of directors set
Dr.&nbsp;Farid&#146;s 2020 annual base salary at $525,800, Mr.&nbsp;D&#146;Cruz&#146;s annual base salary at $456,000 and Ms. Tran&#146;s annual base salary at $428,000 contingent upon the closing of this offering and effective as of January&nbsp;1,
2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use base salaries to recognize the experience, skills, knowledge, and responsibilities required of all our employees, including
our named executive officers. None of our named executive officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Annual Bonus.</I> Our board of directors may, in its discretion, award bonuses to our named executive officers from time to time. Our board
of directors has approved discretionary annual cash bonuses to our named executive officers with respect to their prior year performance. With respect to 2018 performance, our board of directors awarded bonuses of $80,000 and $107,000 to
Dr.&nbsp;Farid and Mr.&nbsp;D&#146;Cruz, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, our board of directors adopted our Senior Executive Incentive
Compensation Plan. The Senior Executive Incentive Compensation Plan provides for cash bonus payments to be made to certain eligible executive officers, including named executive officers, based upon the attainment of performance targets established
by our compensation committee, which are related to financial and operational measures or objectives with respect to our company. Each executive officer who is selected to participate in the plan has a targeted bonus opportunity set for each
performance period, but payments under this plan may be higher or lower than the executive&#146;s target bonus opportunity, depending upon our performance. This plan is designed to motivate our executive officers to achieve annual goals based on
financial and operating performance objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 corporate performance goals included, but were not limited to, those related to
drug discovery and the drug discovery pipeline, software sales, collaborations, technology enhancement, corporate hiring, and this offering. Each named executive officer&#146;s individual target bonus amount for 2019, expressed as a percentage of
his or her annual base salary, was 25%. With respect to 2019 performance, our board of directors awarded cash bonuses under our Senior Executive Incentive Compensation Plan of $143,400, $132,900, and $124,500 to Dr.&nbsp;Farid, Mr. D&#146;Cruz and
Ms. Tran, respectively, which represents cash bonus awards at 30% of each named executive officer&#146;s 2019 base salary, which exceeds the target bonus percentage for each such officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a further description of the plan, see &#147;&#151;Senior Executive Incentive Compensation Plan&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Incentives.</I> Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive
officers, or any formal equity ownership guidelines applicable to them, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our
executives and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain in our employment during the vesting period.
Accordingly, our board of directors periodically reviews the equity incentive compensation of our executive officers, including our named executive officers, and from time to time may grant equity incentive awards to them in the form of stock
options which may include time-based vesting features. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2018, we granted options to purchase 334,432 and 26,754 shares of our
common stock to Dr.&nbsp;Farid and Mr.&nbsp;D&#146;Cruz, respectively, each at an exercise price of $4.34 per share, which price was equal to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fair market value of our common stock on the date of grant as determined by our board of directors. These option grants were merit-based awards, and such options vested as to 25% of the original
number of shares underlying the options on December&nbsp;31, 2019 and will vest as to an additional 2.0833% of the original number of shares underlying the options monthly thereafter. The options have a term of ten years. We did not grant option
awards to our named executive officers in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, our executives were eligible to receive equity awards under our
2002 Stock Incentive Plan, which plan is now expired, and our 2010 Stock Plan, as amended to date, or the 2010 Plan. During 2018 and 2019 (and through the effectiveness of the registration statement of which this prospectus forms a part), all stock
options were granted pursuant to our 2010 Plan. Following the closing of this offering, our employees and executives will be eligible to receive stock options and other equity-based awards pursuant to our 2020 Equity Incentive Plan, or the 2020
Plan. For a description of our 2010 Plan and our 2020 Plan, see &#147;&#151;Stock Option and Other Compensation Plans&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use
stock options to compensate our executive officers in the form of initial grants in connection with the commencement of employment and also at various times, often but not necessarily annually, if we or they have performed as expected or better than
expected. Prior to this offering, our board of directors granted stock options to our executive officers. None of our executive officers is currently party to an employment agreement that provides for the automatic award of stock options. We have
granted option awards to our executive officers with time-based vesting. The options that we have granted to our executive officers prior to November 2018 typically vest and become exercisable as to 25% of the shares underlying the option on each
anniversary of the vesting commencement date until the fourth anniversary of the vesting commencement date. The options that we have granted to our executive officers in or following November 2018 typically vest and become exercisable as to 25% of
the shares underlying the option on the first anniversary of the vesting commencement date and as to an additional 2.0833% of the original number of shares underlying the option monthly thereafter. Vesting rights cease upon termination of employment
and exercise rights for previously vested stock options cease shortly after termination of employment, though exercisability is extended in the case of death or disability. Prior to the exercise of an option, the holder has no rights as a
stockholder with respect to the shares subject to such option, including no voting rights and no right to receive dividends or dividend equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have historically granted stock options with exercise prices that are equal to the fair market value of our common stock on the date of
grant as determined by our board of directors, based on a number of objective and subjective factors. The exercise price of all stock options granted after the closing of this offering will be equal to the fair market value of shares of our common
stock on the date of grant, which will be determined by reference to the closing market price of our common stock on the date of grant. The typical term of such stock options will be ten years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at December&nbsp;31, 2019 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding all outstanding stock options held by each of our named executive officers as of
December&nbsp;31, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>securities</B><br><B>underlying</B><br><B>unexercised</B><br><B>options (#)</B><br><B>exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>securities</B><br><B>underlying</B><br><B>unexercised</B><br><B>options (#)</B><br><B>unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>exercise</B><br><B>price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>expiration</B><br><B>date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ramy Farid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,886</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/7/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,132</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/10/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,824</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/29/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cony D&#146;Cruz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,443</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/10/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,865</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,066</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/29/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yvonne Tran</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,377</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/17/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,377</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/19/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,345</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/10/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,866</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,066</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/29/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option is fully vested. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase 160,527 shares vests over four years, in equal yearly installments through
April&nbsp;1, 2020, subject to continued service. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase 334,432 shares vests over four years, with 25% of the original number of shares
underlying such option having vested on December&nbsp;31, 2019, and 2.0833% of the original number of shares underlying such option vesting thereafter in equal monthly installments through December&nbsp;31, 2022, subject to continued service.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase 133,773 shares vests over four years, in equal yearly installments through
March&nbsp;1, 2020, subject to continued service. All vested shares under this option have been exercised as of December&nbsp;31, 2019, and the unvested portion of the option vests as to 33,443 shares on March&nbsp;1, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase 11,731 shares vests over four years, in equal yearly installments through
January&nbsp;1, 2021, subject to continued service. All vested shares under this option have been exercised as of December&nbsp;31, 2019, and the unvested portion of the option vests as to 2,933 shares on January&nbsp;1, 2020 and 2,932 shares on
January&nbsp;1, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase 26,754 shares vests over four years, with 25% of the original number of shares
underlying such option having vested on December&nbsp;31, 2019, and 2.0833% of the original number of shares underlying such option vesting thereafter in equal monthly installments through December&nbsp;31, 2022, subject to continued service.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option is fully vested.</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option is fully vested.</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This option to purchase 13,377 shares vests over four years, in equal yearly installments through April
1, 2020, subject to continued service. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase 11,731 shares vests over four years, in equal yearly installments through January 1,
2021, subject to continued service. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase 26,754 shares vests over four years, with 25% of the original number of shares
underlying such option having vested on December 31, 2019, and 2.0833% of the original number of shares underlying such option vesting thereafter in equal monthly installments through December 31, 2022, subject to continued service.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with each of our named executive officers. These agreements set forth the terms of the named
executive officer&#146;s compensation, including initial base salary. Each named executive officer&#146;s salary is reviewed by our compensation committee and the board of directors on an annual or more frequent basis and is subject to change in the
discretion of our board of directors or compensation committee. Our named executive officers are eligible to participate in company-sponsored benefit programs that are generally available to all of our similarly-situated employees. Under these
agreements, each named executive officer is also eligible to receive equity awards at such times and on such terms and conditions as the board of directors may determine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreement with Ramy Farid </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an employment agreement with Ramy Farid, dated May&nbsp;11, 2010. Under the employment agreement, Dr.&nbsp;Farid is an <FONT
STYLE="white-space:nowrap">at-will</FONT> employee and his employment may be terminated by us or by him at any time, for any reason, upon 30 days&#146; written or verbal notice. In the event we elect to terminate Dr.&nbsp;Farid&#146;s employment
immediately without 30 days&#146; notice, he is entitled to continued payment of his then-current base salary and continued benefit coverage for a period of 30 days following such termination. The employment agreement provides that Dr.&nbsp;Farid
was entitled to an annualized base salary of $250,000, prorated for the period beginning May&nbsp;11, 2010 and ending on December&nbsp;31, 2010, and that Dr.&nbsp;Farid&#146;s salary may be increased or decreased thereafter in our sole discretion.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreement with Cony D&#146;Cruz </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an employment agreement with Cony D&#146;Cruz, dated April&nbsp;15, 2013. Under the employment agreement, Mr.&nbsp;D&#146;Cruz
is an <FONT STYLE="white-space:nowrap">at-will</FONT> employee and his employment may be terminated by us or by him at any time, for any reason, upon 30 days&#146; written or verbal notice. In the event we elect to terminate
Mr.&nbsp;D&#146;Cruz&#146;s employment immediately without 30 days&#146; notice, he is entitled to continued payment of his then-current base salary for a period of 30 days following such termination. The employment agreement provides that
Mr.&nbsp;D&#146;Cruz was entitled to an annualized base salary of $290,000, prorated for the period beginning April&nbsp;15, 2013 and ending on December&nbsp;31, 2013, and that Mr.&nbsp;D&#146;Cruz&#146;s salary may be increased or decreased
thereafter in our sole discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreement with Yvonne Tran </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an employment agreement with Yvonne Tran, dated April 27, 2010. Under the employment agreement, Ms. Tran is an at-will employee
and her employment may be terminated by us or by her at any time, for any reason, upon 30 days&#146; written or verbal notice. In the event we elect to terminate Ms. Tran&#146;s employment immediately without 30 days&#146; notice, she is entitled to
continued payment of her then-current base salary and continued benefit coverage for a period of 30 days following such termination. The employment agreement provides that Ms. Tran was entitled to an annualized base salary of $235,000, prorated for
the period beginning April 27, 2010 and ending on December 31, 2010, and that Ms. Tran&#146;s salary may be increased or decreased thereafter in our sole discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee <FONT STYLE="white-space:nowrap">Non-Competition,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicitation,</FONT> Confidentiality, and
Assignment of Inventions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of their employment agreements, each of our named executive officers has agreed to certain
standard <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidential information, and assignment of invention restrictions. Pursuant to their employment agreements, each of Dr.
Farid and Mr. D&#146;Cruz has agreed that we own all developments that are made, created, developed, conceived or reduced to practice by such officer, alone or with others, (i)&nbsp;in the course of employment with us, whether during regular working
hours or other hours, or (ii)&nbsp;during the period of employment with us, whether or not in the course of such employment, to the extent the same is related to our business or actual or demonstrably anticipated research or development or is made,
created, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
developed, conceived or first reduced to practice with the time, private or proprietary information, or facilities of our company, our subsidiaries or our other affiliates, which we refer to
collectively as the Schr&ouml;dinger Companies. Pursuant to Ms. Tran&#146;s employment agreement, Ms. Tran has agreed that we own all developments that are conceived, developed, made or produced by her, alone or in conjunction with others, (i) in
the course of her employment with us, or (ii) with the time, private or proprietary information, or facilities of the Schr&#246;dinger Companies. In addition, each of our named executive officers has agreed not to, during his or her employment and
for a period of one year thereafter, (i)&nbsp;solicit or encourage any customers, prospective customers, vendors, strategic partners or business associates of the Schr&ouml;dinger Companies to cease or reduce their relationship with the
Schr&ouml;dinger Companies or to refrain from establishing or expanding a relationship with Schr&ouml;dinger Companies, (ii)&nbsp;solicit or induce any employees, consultants, sales agents, contract researchers, contract programmers or other
independent agents of the Schr&ouml;dinger Companies or of certain D. E. Shaw group entities to cease employment or retention with the Schr&ouml;dinger Companies or such D. E. Shaw group entities, or (iii)&nbsp;hire or engage any employee of the
Schr&ouml;dinger Companies or of certain D. E. Shaw group entities. Each of our named executive officers has agreed not to, during the term of his or her employment, knowingly engage in any activity or business which is the same nature as, or
substantively similar to, our business or an activity or business which a Schr&ouml;dinger Company is developing and of which such named executive officer has knowledge, and to protect our confidential and proprietary information indefinitely. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Senior Executive Incentive Compensation Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, our board of directors adopted the Senior Executive Incentive Compensation Plan, or the Executive Cash Incentive Plan. The
Executive Cash Incentive Plan provides for cash bonus payments to certain eligible executive officers, including named executive officers, based upon the attainment of performance targets established by our compensation committee, which are related
to financial and operational measures or objectives with respect to our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee administers the Executive
Cash Incentive Plan, selects the eligible executive officers and may select corporate performance goals in its discretion. The 2020 corporate performance goals include, but are not limited to, those related to drug discovery deals and the internal
drug discovery pipeline, software sales, collaborations, technology enhancement, corporate hiring and retention of key employees, and this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Executive Cash Incentive Plan, each executive officer who is selected to participate in the Executive Cash Incentive Plan has a
targeted bonus opportunity set for each performance period, but payments under this plan may be higher or lower than the executive&#146;s target bonus opportunity, depending upon our performance. Bonuses paid under the Executive Cash Incentive Plan
are based upon bonus formulas that tie such bonuses to one or more performance targets relating to the corporate performance goals. The bonus formulas are adopted in each performance period by the compensation committee and communicated to each
executive officer at the beginning of each performance period. The level of achievement of the corporate performance goals will be determined by the compensation committee, in its discretion and after applying any adjustments that the committee
determines to be appropriate, at the end of each fiscal year after our financial reports have been issued. If the corporate performance goals are met, payments will be made as soon as practicable following the compensation committee&#146;s
determination of the bonus payable to each executive officer. Subject to the compensation committee&#146;s discretion to pay a <FONT STYLE="white-space:nowrap">pro-rated</FONT> bonus under limited circumstances, each executive officer must be
employed by us on the date the bonus is payable in order to be eligible to receive the bonus payment. The board of directors or the compensation committee may amend or terminate the Executive Cash Incentive Plan at any time for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Farid&#146;s individual target bonus amounts for 2020, expressed as a percentage of his annual base salary, is 60%.
Mr.&nbsp;D&#146;Cruz&#146;s individual target bonus amount for 2020, expressed as a percentage of his annual base salary, is 40%. Ms. Tran&#146;s individual target bonus amounts for 2020, expressed as a percentage of her annual base salary, is 40%.
Each individual target bonus percentage for 2020 is contingent upon the closing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Severance and Change in Control Benefits Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Severance and Change in Control Benefits Plan, which will become effective immediately following the closing of this offering and
which we refer to as the Severance Plan, provides severance benefits to certain of our executives, including our named executive officers, if their employment is terminated by us without &#147;cause&#148; or, only in connection with a &#147;change
in control&#148; of our company, they terminate employment with us for &#147;good reason&#148; (as each of those terms is defined in the Severance Plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Severance Plan, if we terminate an eligible executive&#146;s employment without cause prior to or more than 12 months following the
closing of a change in control of our company, the executive is entitled to (i) continue receiving his or her base salary for a specified period (in the case of Dr. Farid, for 12 months, in the case of Ms. Tran, for nine months and, in the case of
Mr. D&#146;Cruz, for six months) following the date of termination, (ii) company contributions to the cost of health care continuation under the Consolidated Omnibus Budget Reconciliation Act, or COBRA, for up to 12 months following the date of
termination, and (iii) the amount of any unpaid annual bonus determined by our board of directors in its discretion to be payable to the executive for any completed bonus period which ended prior to the date of such executive&#146;s termination.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Severance Plan also provides that, if, within 12 months following the closing of a change in control of our company, we terminate an
eligible executive&#146;s employment without cause or such executive terminates his or her employment with us for good reason, the executive is entitled to (i) a single lump-sum payment equal to a percentage of his or her annual base salary (in the
case of Dr. Farid, 100%, in the case of Ms. Tran, 75%, and, in the case Mr. D&#146;Cruz, 50%), (ii) a single lump sum payment in an amount equal to a percentage of his or her target annual bonus for the year in which the termination of employment
occurs or for the year in which the change in control occurs, if greater (in the case of Dr. Farid, 100%, in the case of Ms. Tran, 75%, and, in the case Mr. D&#146;Cruz, 50%), (iii) company contributions to the cost of health care continuation under
COBRA for up to 12 months following the date of termination of employment (18 months in the case of Dr. Farid), and (iv) the amount of any unpaid annual bonus determined by our board of directors to be payable to the executive for any completed
bonus period which ended prior to the date of such executive&#146;s termination. In addition, all of the executive&#146;s outstanding unvested equity awards that vest solely based on the passage of time will vest and become fully exercisable or
non-forfeitable on the date of such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any severance or other compensation payment to any of our executives
pursuant to the Severance Plan, any employment agreement or any other agreement constitutes an &#147;excess parachute payment&#148; within the meaning of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, then such executive
will receive the full amount of such severance and other payments, or a reduced amount intended to avoid the application of Sections 280G and 4999, whichever provides the executive with the highest amount on an after-tax basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All payments and benefits provided under the Severance Plan are contingent upon the execution and effectiveness of a release of claims by the
executive in our favor and continued compliance by the executive with any proprietary information and inventions, nondisclosure, non-competition, non-solicitation (or similar) agreement to which we and the executive are party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option and Other Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this section we describe our 2010 Plan, our 2020 Plan, and our 2020 Employee Stock Purchase Plan, or the 2020 ESPP. Prior to this offering,
we granted awards to eligible participants under the 2010 Plan. Following the effectiveness of the 2020 Plan, we expect to grant awards to eligible participants from time to time only under the 2020 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2010 Stock Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2010 Plan was
initially approved by our board of directors in October 2010 and by our stockholders in November 2010 and was subsequently amended in 2011, 2012, 2016, 2017, and 2018, in each case solely to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase the total number of shares reserved for issuance under the 2010 Plan. The 2010 Plan provides for the direct award or sale of shares of our common stock and for the grant of incentive
stock options and nonstatutory stock options. Our employees, directors, and consultants are eligible to receive awards or purchase shares under the 2010 Plan; however, incentive stock options may only be granted to our employees. The type of award
granted under the 2010 Plan and the terms of such award, or the terms of a sale of shares under the plan, are set forth in the applicable award or purchase agreement. Pursuant to the terms of the 2010 Plan, our board of directors (or a committee
appointed by our board of directors) administers the 2010 Plan and, subject to any limitations in the plan, selects the recipients of awards or purchasers of shares and determines: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of our common stock covered by options and the dates upon which the options become
exercisable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the type of options to be granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of options, which may not be in excess of ten years; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price of options, which must be at least equal to the fair market value of our common stock on the
date of grant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of our common stock subject to and the terms and conditions of any direct award or sale of
shares of our common stock, including conditions for forfeiture or repurchase, and the purchase price of such shares, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum number of shares of common stock authorized for issuance under the 2010 Plan is 6,964,231. Our board of directors may amend,
suspend, or terminate the 2010 Plan at any time and for any reason, except that stockholder approval may be required to comply with applicable law. Unless terminated earlier by our board of directors, the 2010 Plan will automatically terminate ten
years after the date when our board of directors approved the most recent increase in the number of shares of stock authorized for issuance under the plan that was also approved by our stockholders, which occurred on November&nbsp;9, 2018. The
termination of the 2010 Plan, or any amendment thereof, will not affect any shares of common stock or any option previously granted and outstanding thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Effect of Certain Changes in Capitalization</I></B><I>.</I> In the event of a subdivision of our outstanding stock, a stock dividend, a
combination or consolidation of our outstanding stock into a lesser number of shares, a reclassification, or any other increase or decrease in the number of issued shares of our common stock effected without receipt of consideration by us, under the
terms of the 2010 Plan, proportionate adjustments will be automatically made to each of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of our common stock available for future grants under the 2010 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of our common stock covered by each outstanding option; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price under each outstanding option. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of the declaration of an extraordinary dividend payable in a form other than shares of our common stock in an amount that has a
material effect on the fair market value of our common stock, a recapitalization, a <FONT STYLE="white-space:nowrap">spin-off,</FONT> or a similar occurrence, our board of directors, in its sole discretion, may make appropriate adjustments in one or
more of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of our common stock available for future grants under the 2010 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of our common stock covered by each outstanding option; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price under each outstanding option. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Effect of Certain Transactions</I></B><I>.</I> In the event we are a party to a merger or consolidation, outstanding options, and shares
of our common stock acquired under the 2010 Plan will be subject to the agreement of merger or consolidation, which may not treat all outstanding options in an identical manner. The agreement of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger or consolidation, without the optionee&#146;s consent, may dispose of options that are not exercisable as of the effective date of the merger or consolidation in any manner permitted by
applicable law, including the cancellation of such options without payment of any consideration. The agreement of merger or consolidation, without the optionee&#146;s consent, will provide for one or more of the following with respect to options
that are exercisable as of the effective date of the merger or consolidation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continuation of the options by us (if we are the surviving corporation); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of the options by the surviving corporation or its parent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the substitution of the options by the surviving corporation or its parent for new options;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cancellation of the options and a payment to the optionees equal to the excess, if any, of (A)&nbsp;the fair
market value of the shares of our common stock subject to such options as of the effective date of the merger or consolidation over (B)&nbsp;the exercise price of the options (which payment will be made in the form of cash, cash equivalents, or
securities of the surviving corporation or its parent with a fair market value equal to the required amount); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cancellation of the options without the payment of any consideration (any exercise of such option prior to
the closing date of the merger or consolidation may be contingent on the closing of the merger or consolidation). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the 2010 Plan, our board of directors may modify, extend, or assume outstanding options or may accept the cancellation
of outstanding options in return for the grant of new options for the same or a different number of shares of our common stock and at the same or a different exercise price. However, no modification of an option will impair the optionee&#146;s
rights or increase the optionee&#146;s obligations under the option without the consent of the optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2010 Plan contains four <FONT
STYLE="white-space:nowrap">sub-plans</FONT> that include additional terms applicable to awards or sales of shares and options to acquire shares granted to residents of each of California, India, Ireland, and the United Kingdom. The <FONT
STYLE="white-space:nowrap">sub-plan</FONT> for residents of California contains provisions that govern the treatment of options upon the optionee&#146;s termination from service other than by reason of death or disability, termination of service by
reason of disability, termination of service due to optionee&#146;s death, or leave of absence. The <FONT STYLE="white-space:nowrap">sub-plan</FONT> for residents of India contains provisions limiting the eligible recipients of awards under the plan
to employees (and excludes consultants and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors resident in India) and requires that the exercise price for options be paid in cash and not through services rendered or a promissory note. The
<FONT STYLE="white-space:nowrap">sub-plan</FONT> for residents of Ireland contains provisions stipulating that references to &#147;withholding taxes&#148; in the <FONT STYLE="white-space:nowrap">sub-plan</FONT> include all taxes, charges, levies,
and contributions in Ireland and elsewhere, including the Universal Social Charge and Pay Related Social Insurance, establishes a tax indemnity by the participant in respect of any tax liabilities of the participant associated with participation in
the <FONT STYLE="white-space:nowrap">sub-plan</FONT> and includes required data privacy provisions. The <FONT STYLE="white-space:nowrap">sub-plan</FONT> for residents of the United Kingdom contains provisions related to the counting of shares
subject to the <FONT STYLE="white-space:nowrap">sub-plan,</FONT> limits the awards granted under the <FONT STYLE="white-space:nowrap">sub-plan</FONT> to options, permits the company to require holders of options to make certain United Kingdom tax
elections in connection with the exercise of options, and permits the transferability of options solely upon the death of the holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of December&nbsp;31, 2019, there were options to purchase an aggregate of 4,943,778 <B></B>shares of our common stock outstanding under the 2010 Plan at a weighted average exercise price of $3.57<B> </B>per share and options to purchase 236,005
<B></B>shares of our common stock were available for future issuance under the 2010 Plan. No further awards will be made under the 2010 Plan, however, awards outstanding under the 2010 Plan will continue to be governed by their existing terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2020 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, our board of directors adopted and our stockholders approved the 2020 Plan, which became effective immediately prior to the
effectiveness of the registration statement for this offering. The 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan provides for the grant of incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, stock appreciation rights, restricted stock awards, restricted stock
units, and other stock-based awards. The number of shares of our common stock reserved for issuance under the 2020 Plan is the sum of: (1)&nbsp;5,645,228 shares of our common stock; plus (2)&nbsp;the number of shares (up to a maximum of 5,180,194
shares) equal to the sum of (x)&nbsp;the number of shares of our common stock reserved for issuance under the 2010 Plan that remained available for grant under the 2010 Plan immediately prior to the effectiveness of the registration statement for
this offering and (y)&nbsp;the number of shares of our common stock subject to outstanding awards granted under the 2010 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by us at their original issuance
price pursuant to a contractual repurchase right; plus (x)&nbsp;an annual increase to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2021 and continuing for each fiscal year until, and including,
the fiscal year ending December 31, 2025, by a number of shares of common stock equal to the smallest of (i) 1.5% of the sum of (A) the outstanding shares of common stock, (B) the outstanding shares of limited common stock and (C) the outstanding
stock options granted by us (which sum we refer to as the &#147;outstanding equity&#148;), calculated on the last business day of the prior fiscal year or (ii) the number of shares of common stock determined by our board of directors and (y) an
annual increase to be added on the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2026 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2030, by a number of shares
of common stock equal to the smallest of (i) 1.0% of the outstanding equity, calculated on the last business day of the prior fiscal year or (ii) the number of shares of common stock determined by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment under the 2020 Plan, no more than 5,645,228 shares of common stock may be issued as incentive stock options under the
2020 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment under the 2020 Plan, any award that is not a &#147;full-value award&#148; (as defined below) shall be
counted against the share limits set forth in the 2020 Plan as one share for each share of common stock subject to such award and any award that is a full-value award shall be counted against the share limits specified in the plan as 1.775 shares
for each one share of common stock subject to such full-value award. &#147;Full-value award&#148; means any award of restricted stock, restricted stock units or other stock-based award with a per share price or per unit purchase price lower than
100% of the fair market value per share of common stock (valued in the manner determined or approved by the board of directors) on the date of grant. To the extent a share that was subject to an award that counted as one share is returned to the
2020 Plan, each applicable share reserve will be credited with one share. To the extent that a share that was subject to an award that counts as 1.775&nbsp;shares is returned to the 2020 Plan, each applicable share reserve will be credited with
1.775&nbsp;shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the 2020 Plan to the contrary, in no event may more than 20% of the maximum number of
shares of common stock available for the granting of awards under the 2020 Plan be issued in the form of full-value awards. For purposes of this limitation, the number of shares subject to each award shall be counted on a one (1)-for-one (1) basis
and without regard to the fungible counting ratio described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum aggregate amount of cash and value (calculated based on
grant date fair value for financial reporting purposes) of awards granted in any calendar year to any individual non-employee director in his or her capacity as a non-employee director shall not exceed $750,000; provided, however, that such maximum
aggregate amount shall not exceed $1,000,000 in any calendar year for any individual non-employee director in such non-employee director&#146;s initial year of election; and provided, further, however, that fees paid by us on behalf of any
non-employee director in connection with regulatory compliance and any amounts paid to a non-employee director as reimbursement of an expense shall not count against the foregoing limit. Our board of directors may make additional exceptions to this
limit for individual non-employee directors in extraordinary circumstances, as the board may determine in its discretion, provided that the non-employee director receiving such additional compensation may not participate in the decision to award
such compensation. For the avoidance of doubt, cash and awards granted under the 2020 Plan to non-employee directors in their capacity as consultants or advisors to us are not subject to the foregoing limitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our employees, officers, directors, consultants, and advisors are eligible to receive awards
under the 2020 Plan. Incentive stock options, however, may only be granted to our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the 2020 Plan, our
board of directors (or a committee delegated by our board of directors) administers the 2020 Plan and, subject to any limitations in the 2020 Plan, selects the recipients of awards and determines: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of our common stock covered by options and the dates upon which the options become
exercisable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the type of options to be granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of options, which may not be in excess of ten years; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price of options, which must be at least equal to the fair market value of our common stock on the
date of grant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of our common stock subject to and the terms of any stock appreciation rights, restricted
stock awards, restricted stock units, or other stock-based awards, including conditions for repurchase, measurement price, issue price and repurchase price (though the measurement price of stock appreciation rights must be at least equal to the fair
market value of our common stock on the date of grant and the duration of such awards may not be in excess of ten years). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our board of directors delegates authority to one or more of our officers to grant awards under the 2020 Plan, the officers will have the
power to make awards to all of our employees, except executive officers (as such terms are defined in the 2020 Plan). Our board of directors will fix the terms of the awards to be granted by any such officer, the maximum number of shares subject to
awards that such officer may grant, and the time period in which such awards may be granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Effect of Certain Changes in
Capitalization.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Upon the occurrence of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, <FONT STYLE="white-space:nowrap">spin-off,</FONT> or
other similar change in capitalization or event, or any dividend or distribution to holders of our common stock other than an ordinary cash dividend, under the terms of the 2020 Plan, we are required to equitably adjust (or make substitute awards,
if applicable), in the manner determined by our board of directors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and class of securities available under the 2020 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the share counting rules under the 2020 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and class of securities and exercise price per share of each outstanding option;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the share and <FONT STYLE="white-space:nowrap">per-share</FONT> provisions and the measurement price of each
outstanding stock appreciation right; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares and the repurchase price per share subject to each outstanding award of restricted stock;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the share and <FONT STYLE="white-space:nowrap">per-share</FONT> related provisions and the purchase price, if
any, of each outstanding restricted stock unit award and other stock-based award. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Effect of Certain Corporate
Transactions.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In connection with a merger or other reorganization event (as defined in the 2020 Plan), our board of directors may, on such terms as our board of directors determines (except to the extent specifically
provided otherwise in an applicable award agreement or other agreement between the participant and us), take any one or more of the following actions pursuant to the 2020 Plan as to all or any (or any portion of) outstanding awards, other than
certain awards of restricted stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that outstanding awards will be assumed, or substantially equivalent awards will be substituted, by the
acquiring or succeeding corporation (or an affiliate thereof); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon written notice to a participant, provide that all of the participant&#146;s unvested awards will be
forfeited immediately prior to the consummation of the reorganization event and/or unexercised awards will terminate immediately prior to the consummation of the reorganization event unless exercised by the participant (to the extent then
exercisable) within a specified period following the date of the notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that outstanding awards will become exercisable, realizable, or deliverable, or restrictions applicable
to an award will lapse, in whole or in part, prior to or upon such reorganization event; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of a reorganization event pursuant to which holders of shares of our common stock will receive a
cash payment for each share surrendered in the reorganization event, make or provide for a cash payment to participants with respect to each award held by a participant equal to (1)&nbsp;the number of shares of our common stock subject to the vested
portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by (2)&nbsp;the excess, if any, of the cash payment for each share surrendered in the
reorganization event over the exercise, measurement, or purchase price of such award and any applicable tax withholdings, in exchange for the termination of the award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, in connection with our liquidation or dissolution, awards will convert into the right to receive
liquidation proceeds (if applicable, net of the exercise, measurement, or purchase price thereof and any applicable tax withholdings); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is not obligated under the 2020 Plan to treat all awards, all awards held by a participant, or all awards of the same
type, identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of certain restricted stock units, no assumption or substitution is permitted, and the restricted stock
units will instead be settled in accordance with the terms of the applicable restricted stock unit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of a
reorganization event, other than our liquidation or dissolution, our repurchase and other rights with respect to outstanding awards of restricted stock will continue for the benefit of the succeeding company (or any affiliate of the succeeding
company) and will, unless our board of directors determines otherwise, apply to the cash, securities, or other property which our common stock was converted into or exchanged for pursuant to the reorganization event. However, our board of directors
may provide for the termination or deemed satisfaction of such repurchase or other rights under the restricted stock award agreement or in any other agreement between a participant and us, either initially or by amendment. Upon our liquidation or
dissolution, except to the extent specifically provided to the contrary in the restricted stock award agreement or any other agreement between the participant and us, all restrictions and conditions on all restricted stock awards then outstanding
will automatically be deemed terminated or satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time, our board of directors may provide that any award under the 2020 Plan
will become immediately exercisable in full or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except with respect to certain actions requiring stockholder approval under the Internal Revenue Code or Nasdaq Stock Market rules, our board
of directors may amend, modify, or terminate any outstanding award under the 2020 Plan, including but not limited to, substituting for the award another award of the same or a different type, changing the date of exercise or realization, and
converting an incentive stock option to a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option, subject to certain participant consent requirements. However, unless our stockholders approve such action, the 2020 Plan provides that we
may not (except as otherwise permitted in connection with a change in capitalization or reorganization event): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend any outstanding stock option or stock appreciation right granted under the 2020 Plan to provide an exercise
or measurement price per share that is lower than the then-current exercise or measurement price per share of such outstanding award; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel any outstanding stock option or stock appreciation right (whether or not granted under the 2020 Plan) and
grant a new award under the 2020 Plan in substitution for the cancelled award (other than substitute awards permitted in connection with a merger or consolidation of an entity with us or our acquisition of property or stock of another entity)
covering the same or a different number of shares of our common stock and having an exercise or measurement price per share lower than the then-current exercise or measurement price per share of the cancelled award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel in exchange for a cash payment any outstanding option or stock appreciation right with an exercise or
measurement price per share above the then-current fair market value of our common stock (valued in the manner determined by (or in the manner approved by) our board of directors); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any other action that constitutes a &#147;repricing&#148; within the meaning of Nasdaq Stock Market rules or
rules of any other exchange or marketplace on which our common stock is listed or traded. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No award may be granted under
the 2020 Plan on or after February 5, 2030. Our board of directors may amend, suspend, or terminate the 2020 Plan at any time, except that stockholder approval may be required to comply with applicable law or stock market requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, our board of directors adopted and our stockholders approved the 2020 ESPP, which became effective immediately prior to the
effectiveness of the registration statement for this offering. The 2020 ESPP will be administered by our board of directors or by a committee appointed by our board of directors. The 2020 ESPP initially provides participating employees with the
opportunity to purchase up to an aggregate of 586,845 shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our employees and employees of any designated
subsidiary, as defined in the 2020 ESPP, are eligible to participate in the 2020 ESPP, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such person is customarily employed by us or a designated subsidiary for more than 20 hours a week and for more
than five months in a calendar year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such person has been employed by us or by a designated subsidiary for at least three months prior to enrolling in
the 2020 ESPP; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such person was our employee or an employee of a designated subsidiary on the first day of the applicable
offering period under the 2020 ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We retain the discretion to determine which eligible employees may participate in
an offering under applicable regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to make one or more offerings to our eligible employees to purchase stock under the
2020 ESPP beginning at such time and on such dates as our board of directors may determine, or the first business day thereafter. Each offering will consist of a <FONT STYLE="white-space:nowrap">six-month</FONT> offering period during which payroll
deductions will be made and held for the purchase of our common stock at the end of the offering period. Our board of directors or a committee designated by the board of directors may, at its discretion, choose a different period of not more than 27
months for offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each offering commencement date, each participant will be granted the right to purchase, on the last business
day of the offering period, up to a number of shares of our common stock determined by multiplying $2,083 by the number of full months in the offering period and dividing that product by the closing price of our common stock on the first day of the
offering period. No employee may be granted an option under the 2020 ESPP that permits the employee&#146;s rights to purchase shares under the 2020 ESPP and any other employee stock purchase plan of ours or of any of our subsidiaries to accrue at a
rate that exceeds $25,000 of the fair market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value of our common stock (determined as of the first day of each offering period) for each calendar year in which the option is outstanding. In addition, no employee may purchase shares of our
common stock under the 2020 ESPP that would result in the employee owning 5% or more of the total combined voting power or value of our stock or the stock of any of our subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each eligible employee may authorize up to a maximum of 15% of his or her compensation to be deducted by us during the offering period. Each
employee who continues to be a participant in the 2020 ESPP on the last business day of the offering period will be deemed to have exercised an option to purchase from us the number of whole shares of our common stock that his or her accumulated
payroll deductions on such date will pay for, not in excess of the maximum numbers set forth above. Under the terms of the 2020 ESPP, the purchase price shall be determined by our board of directors or the committee for each offering period and will
be at least 85% of the applicable closing price of our common stock. If our board of directors or the committee does not make a determination of the purchase price, the purchase price will be 85% of the lesser of the closing price of our common
stock on the first business day of the offering period or on the last business day of the offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An employee may at any time
prior to the close of business on the fifteenth business day prior to the end of an offering period (or such other number of days as is determined by us), and for any reason, permanently withdraw from participating in an offering and permanently
withdraw the balance accumulated in the employee&#146;s account. Partial withdrawals are not permitted. If an employee elects to discontinue his or her payroll deductions during an offering period but does not elect to withdraw his or her funds,
funds previously deducted will be applied to the purchase of common stock at the end of the offering period. If a participating employee&#146;s employment ends before the last business day of an offering period, no additional payroll deductions will
be taken and the balance in the employee&#146;s account will be paid to the employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to make equitable adjustments
to the extent determined by our board of directors or a committee thereof to the number and class of securities available under the 2020 ESPP, the share limitations under the 2020 ESPP, and the purchase price for an offering period under the 2020
ESPP to reflect stock splits, reverse stock splits, stock dividends, recapitalizations, combinations of shares, reclassifications of shares, spin-offs, and other similar changes in capitalization or events or any dividends or distributions to
holders of our common stock other than ordinary cash dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with a merger or other reorganization event, as defined in
the 2020 ESPP, our board of directors or a committee of our board of directors may take any one or more of the following actions as to outstanding options to purchase shares of our common stock under the 2020 ESPP on such terms as our board of
directors or committee thereof determines: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that options will be assumed, or substantially equivalent options will be substituted, by the acquiring
or succeeding corporation (or an affiliate thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon written notice to employees, provide that all outstanding options will be terminated immediately prior to
the consummation of such reorganization event and that all such outstanding options will become exercisable to the extent of accumulated payroll deductions as of a date specified by our board of directors or committee thereof in such notice, which
date shall not be less than ten days preceding the effective date of the reorganization event; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon written notice to employees, provide that all outstanding options will be cancelled as of a date prior to
the effective date of the reorganization event and that all accumulated payroll deductions will be returned to participating employees on such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of a reorganization event under the terms of which holders of our common stock will receive upon
consummation thereof a cash payment for each share surrendered in the reorganization event, change the last day of the offering period to be the date of the consummation of the reorganization event and make or provide for a cash payment to each
employee equal to (1)&nbsp;the cash payment for each share surrendered in the reorganization event times the number of shares of our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
common stock that the employee&#146;s accumulated payroll deductions as of immediately prior to the reorganization event could purchase at the applicable purchase price, where the cash payment
for each share surrendered in the reorganization event is treated as the fair market value of our common stock on the last day of the applicable offering period for purposes of determining the purchase price and where the number of shares that could
be purchased is subject to the applicable limitations under the 2020 ESPP minus (2)&nbsp;the result of multiplying such number of shares by the purchase price; and/or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, in connection with our liquidation or dissolution, options will convert into the right to receive
liquidation proceeds (net of the purchase price thereof). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may at any time, and from time to
time, amend or suspend the 2020 ESPP or any portion of the 2020 ESPP. We will obtain stockholder approval for any amendment if such approval is required by Section&nbsp;423 of the Internal Revenue Code. Further, our board of directors may not make
any amendment that would cause the 2020 ESPP to fail to comply with Section&nbsp;423 of the Internal Revenue Code. The 2020 ESPP may be terminated at any time by our board of directors. Upon termination, we will refund all amounts in the accounts of
participating employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution employee retirement plan for our employees, including our named executive officers. The plan is intended to
qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) plan so that contributions to the 401(k) plan, and income earned on such contributions, are not taxable to participants until withdrawn or distributed from the 401(k) plan
(except in the case of contributions under the 401(k) plan designated as Roth contributions). Under the 401(k) plan, each employee is fully vested in his or her deferred contributions. Vesting in our discretionary matching contributions is based on
years of service to us, with 25% vesting per year of service to us and 100% vesting at the end of the fourth year of service to us. Employee contributions are held and invested by the plan&#146;s trustee as directed by participants. Our 401(k) plan
provides that each participant can contribute up to 75% of such participant&#146;s eligible compensation <FONT STYLE="white-space:nowrap">(pre-tax</FONT> or <FONT STYLE="white-space:nowrap">post-tax</FONT> Roth contributions), up to the statutory
limit, which was $18,500 for 2018, $19,000 for 2019, and $19,500 for 2020. Participants who are at least 50 years old were also eligible to make <FONT STYLE="white-space:nowrap">&#147;catch-up&#148;</FONT> contributions of up to an additional $6,000
above the statutory limit in 2018 and 2019, and are eligible to make &#147;catch-up&#148; contributions of up to an additional $6,500 above the statutory limit in 2020. The 401(k) plan provides us with the discretion to match participant
contributions up to certain specified amounts. In 2018, we made a matching contribution equal to 1.5% of the total eligible compensation up to the 2018 annual limit of $275,000, equating to a maximum matching contribution amount of $4,125. We
provided a <FONT STYLE="white-space:nowrap">true-up</FONT> to eligible participants to ensure that our match was 1.5% of eligible compensation up to the 2018 annual limit. Effective January&nbsp;1, 2019, we began making discretionary matching
contributions to participants under our 401(k) plan equal to 50% of the participant&#146;s contribution to the 401(k) plan up to a maximum participant contribution of 8% of participant&#146;s eligible compensation for a total match of up to 4%, or
$11,200. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation, which will become effective upon the closing of this offering, limits the personal liability of directors for
breach of fiduciary duty to the maximum extent permitted by the Delaware General Corporation Law, or the DGCL, and provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty
as a director. However, these provisions do not eliminate or limit the liability of any of our directors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for voting for or assenting to unlawful payments of dividends, stock repurchases or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission, or
claim that occurred or arose prior to such amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our directors will be further limited to
the greatest extent permitted by the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our certificate of incorporation, which will become effective upon the closing of
this offering, provides that we must indemnify our directors and officers and we must advance expenses, including attorneys&#146; fees, to our directors and officers in connection with legal proceedings, subject to very limited exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers specified liabilities of our directors and officers arising out of claims based
on acts or omissions in their capacities as directors or officers. In addition, we have entered into indemnification agreements with all of our executive officers and directors. These indemnification agreements may require us, among other things, to
indemnify each such executive officer or director for some expenses, including attorneys&#146; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our
executive officers or directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their
relationships with their employers, be insured or indemnified against specified liabilities incurred in their capacities as members of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to
directors, executive officers, or persons controlling us, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they
will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director or officer when
entering into the plan, without further direction from the director or officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows all compensation to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended
December&nbsp;31, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid in<BR>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Lynton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Friesner, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy Wright, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rosana Kapeller-Libermann, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">
(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Sender <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13,306</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nancy Thornberry <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in the &#147;Option Awards&#148; column reflect the aggregate grant date fair value of
stock-based compensation awarded during the year computed in accordance with the provisions of FASB ASC&nbsp;718. See Note 10 to our consolidated financial statements appearing at the end of this prospectus
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
regarding assumptions underlying the valuation of equity awards. These amounts reflect the accounting cost for these stock options and do not reflect the actual economic value that may be
realized by the directors upon the vesting of the stock options, the exercise of the stock options or the sale of the common underlying such stock options. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2019, the aggregate number of shares of our common stock subject to outstanding option
awards for each <FONT STYLE="white-space:nowrap">non-employee</FONT> director serving during 2019 was as follows: Mr.&nbsp;Lynton, 80,263&nbsp;shares; Dr.&nbsp;Friesner, 160,527 shares; Dr.&nbsp;Wright, 0 shares; Dr. Kapeller-Libermann,
53,509&nbsp;shares; Mr. Sender, 40,131 shares; and Ms. Thornberry, 46,820 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Kapeller-Libermann joined our board of directors on January&nbsp;9, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Sender joined our board of directors on July&nbsp;22, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms. Thornberry joined our board of directors on September 13, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents consulting fees paid to Dr.&nbsp;Friesner in connection with his consulting agreement. For further
information about our consulting agreement with Dr.&nbsp;Friesner, as well our transactions with Dr.&nbsp;Freisner and his employer, Columbia University, see &#147;Transactions with Related Persons.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we paid cash fees and granted options to purchase shares of our common stock to certain of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors for their service on our board of directors. We have reimbursed our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, on an as requested basis, for reasonable travel expenses
incurred in connection with attending board of director and committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Farid, one of our directors who also serves as
our president and chief executive officer, does not receive any additional compensation for his service as a director. Dr.&nbsp;Farid is one of our named executive officers and, accordingly, the compensation that we pay to Dr.&nbsp;Farid is
discussed above under &#147;&#151;Summary Compensation Table&#148; and &#147;&#151;Narrative to Summary Compensation Table.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
January&nbsp;2020, our board of directors approved a director compensation program that became effective on the effective date of the registration statement of which this prospectus is a part. Under this director compensation program, we will pay
our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors a cash retainer for service on the board of directors and for service on each committee on which the director is a member. The chairman of the board of directors and of each
committee will receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any portion of such
quarter that the director is not serving on our board of directors and no fee under the program will be payable in respect of any period prior to the completion of this offering. The fees paid to <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors for service on the board of directors and for service on each committee of the board of directors on which the director is a member are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Member</B><br><B>Annual<BR>Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Chairman</B><br><B>Supplemental</B><br><B>Annual Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also will continue to reimburse our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for
reasonable travel and other expenses incurred in connection with attending meetings of our board of directors and any committee of our board of directors on which he or she serves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under our director compensation program, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive, upon
his or her initial election or appointment to our board of directors, an option to purchase 25,216 shares of our common stock under the 2020 Plan. Each of these options will vest as to one-third of the shares of our common stock underlying such
option on each of the first, second and third anniversaries of the grant. Further, on the date of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
first board meeting held after each annual meeting of stockholders commencing with our 2021 annual meeting of stockholders, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will
receive an option to purchase 12,909 shares of our common stock under the 2020 Plan;<B> </B>provided, however, that for a non-employee director who was initially elected to our board of directors within the 12 months preceding the annual meeting of
stockholders, the number of shares subject to such option shall be pro-rated on a monthly basis for time in service. The foregoing share numbers for initial and annual option grants to our non-employee directors are subject to adjustment in the
event of stock splits, reverse stock splits and other events. Each of these options will vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date
of grant of the award). All options issued to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors under our director compensation program will be issued at exercise prices equal to the fair market value of our common stock on the date
of grant, will vest based on continued service, and will become exercisable in full upon specified change in control events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_13"></A>TRANSACTIONS WITH RELATED PERSONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2016, we have engaged in the following transactions in which the amounts involved exceeded $120,000 and any of our
directors, executive officers or holders of more than 5% of our voting securities, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series E Preferred Stock Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From
November&nbsp;9, 2018 to May&nbsp;14, 2019, we issued and sold an aggregate of 73,795,777 shares of our Series&nbsp;E preferred stock at a price per share of $1.4906 in cash, for an aggregate purchase price of $109,999,985<I>.</I> The following
table sets forth the aggregate number of shares of our Series&nbsp;E preferred stock that we issued and sold to our holders of more than 5% of our voting securities and their affiliates in this transaction and the aggregate amount of consideration
for such shares: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;E<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bill&nbsp;&amp; Melinda Gates Foundation
Trust<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/9/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,543,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See &#147;Principal Stockholders&#148; for additional information about shares held by this entity.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Exchange Agreement with Bill&nbsp;&amp; Melinda Gates Foundation Trust </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2018, we entered into a share exchange agreement, or the Share Exchange Agreement, with the Bill&nbsp;&amp; Melinda Gates
Foundation Trust, a holder of more than 5% of our voting securities. Under the Share Exchange Agreement, the Bill&nbsp;&amp; Melinda Gates Foundation Trust had the right to elect to exchange all or any portion of its shares of our common stock
and/or our preferred stock for shares of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, at any time without the payment of additional consideration, and we had covenanted to reserve and keep available such number of duly
authorized shares of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock as shall be sufficient to permit the Bill&nbsp;&amp; Melinda Gates Foundation Trust to exchange its shares of our common stock and/or our preferred stock for
shares of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock. Under the Share Exchange Agreement, each share of preferred stock was exchangeable for a number of shares of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common
stock that equals the number of shares of common stock into which such share of preferred stock is then convertible and cash for any fractional shares. Each share of common stock was exchangeable for one share of our
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock. On January&nbsp;24, 2020, we changed the name of our non-voting common stock to limited common stock and entered into an amended and restated share exchange agreement with the Bill
&amp; Melinda Gates Foundation Trust pursuant to which we and the Bill &amp; Melinda Gates Foundation Trust have agreed that in lieu of exchanging shares of their common stock and/or preferred stock into non-voting common stock, they have the right
to exchange shares of their common stock and/or preferred stock for limited common stock. The Bill&nbsp;&amp; Melinda Gates Foundation Trust has notified us that it will exchange 98,406,823 shares of its preferred stock for an aggregate of
13,164,193 shares of our limited common stock, effective upon the closing of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Richard Friesner </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consulting Agreement with Richard Friesner </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a consulting agreement with Richard Friesner dated July&nbsp;1, 1999, as amended, pursuant to which Dr.&nbsp;Friesner provides
certain services related to enhancing, improving and further developing of our molecular modeling software. Dr.&nbsp;Friesner is one of our <FONT STYLE="white-space:nowrap">co-founders</FONT> and has been a member of our board of directors since
1990. Under the consulting agreement, we paid Dr.&nbsp;Friesner $297,800, $330,000, $347,000, and $347,000 for consulting services during 2016, 2017, 2018, and 2019, respectively. Under his consulting agreement, we have agreed to pay
Dr.&nbsp;Friesner a monthly consulting fee of $28,917 through June&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Columbia License Agreements and Royalty Payments to Columbia University and Richard Friesner
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into various license agreements with the Trustees of Columbia University, or Columbia University, pursuant to
which we license software and code from Columbia University in exchange for our obligation to make specified royalty payments to Columbia University. For a description of certain of our license agreements with Columbia University, see
&#147;Business&#151;License Agreements with Columbia University&#148;. Dr.&nbsp;Friesner, the William P. Schweitzer Professor of Chemistry at Columbia University and the principal investigator of the Friesner Research Group, a research laboratory
within the Department of Chemistry at Columbia University, and one of our <FONT STYLE="white-space:nowrap">co-founders</FONT> and a member of our board of directors, was the inventor of certain of the technologies licensed to us pursuant to certain
of our license agreements with Columbia University. Columbia University distributes a portion of the royalties we pay to it pursuant to such license agreements to Dr.&nbsp;Friesner and to Dr.&nbsp;Friesner&#146;s laboratory at Columbia University.
Columbia University distributed $80,992, $92,722, $138,047, and $265,618 to Dr.&nbsp;Friesner on account of royalties we paid to Columbia University in 2016, 2017, 2018, and 2019, respectively. Columbia University distributed $164,413, $151,966,
$218,244, and $480,280 to Dr.&nbsp;Friesner&#146;s laboratory on account of royalties we paid to Columbia University in 2016, 2017, 2018, and 2019, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gift to Columbia University for Richard Friesner&#146;s Laboratory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;31, 2019, we entered into a letter agreement with the Trustees of Columbia University in the City of New York, or the Trustees of
Columbia University, pursuant to which we agreed to provide a gift of up to $1,500,000, in five annual installments of $300,000 beginning on June&nbsp;30, 2019, to the Trustees of Columbia University to establish the Computational
Chemistry&nbsp;&amp; Pharmaceutical Sciences Research Fund at Columbia University. Such gift will be used to support Dr.&nbsp;Friesner&#146;s laboratory at Columbia University. As of the date hereof, we have provided $300,000 of the $1,500,000 gift
to the Trustees of Columbia University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with David Shaw </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Services Agreement with D. E. Shaw India Private Limited </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schr&ouml;dinger, LLC, our wholly owned subsidiary, is party to a services agreement, dated as of June&nbsp;25, 2013 and effective as of
January&nbsp;1, 2013, with D. E. Shaw India Private Limited (f/k/a D. E. Shaw India Software Private Limited), or DESIS. DESIS is wholly owned by D. E. Shaw&nbsp;&amp; Co., L.P., or DESCO LP. David E. Shaw, who is a beneficial owner of more than 5%
of our voting securities, is a limited partner of DESCO LP and the president and sole shareholder of D. E. Shaw&nbsp;&amp; Co., Inc., which is the general partner of DESCO LP. Pursuant to the services agreement, DESIS provides a number of services
to Schr&ouml;dinger, LLC, including development and maintenance of software, support for technical and scientific research projects, programming, functional testing and validation of products and support for our data entry team. Schr&ouml;dinger,
LLC paid to DESIS $1,346,742, $1,669,030, $1,790,410, and $1,808,516 for such services in 2016, 2017, 2018, and 2019, respectively. In connection with the services agreement, Schr&ouml;dinger, LLC also paid to DESCO LP $129,003, $190,067, $267,410,
and $324,162 in 2016, 2017, 2018, and 2019, respectively, for certain indirect costs and expenses, including travel-related expenses, incurred by DESCO LP in connection with DESIS&#146;s provision of services to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with D. E. Shaw Research LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Schr&ouml;dinger, LLC, our wholly owned subsidiary, has engaged in transactions with D. E. Shaw Research, LLC, or DESRES.
David E. Shaw, who is a beneficial owner of more than 5% of our voting securities, is the chief scientist and a member of DESRES and the president and sole shareholder of D. E. Shaw&nbsp;&amp; Co., II, Inc., the sole member of D. E. Shaw Technology
Development, LLC, or DESTECH, which is the managing member of DESRES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schr&ouml;dinger, LLC sold licenses to a number of our software
products to DESRES in exchange for aggregate consideration of $350,550, $243,400, and $163,456 in 2016, 2017, and 2018, respectively. From January&nbsp;1, 2019 through the date hereof, Schr&ouml;dinger, LLC sold licenses to DESRES for an aggregate
consideration of $147,328. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2013, Schr&ouml;dinger, LLC entered into a license and software
development agreement with DESRES. Pursuant to the agreement, Schr&ouml;dinger, LLC and DESRES agreed to develop and commercialize a software product, referred to as the Desmond/GPU Product, which combines certain of our software with certain DESRES
software related to molecular simulation in connection with graphic processing units, which we refer to as the GPU DESRES Software. Under the agreement, Schr&ouml;dinger, LLC and DESRES license each other&#146;s software so as to enable
(i)&nbsp;Schr&ouml;dinger, LLC and DESRES to market and distribute the Desmond/GPU Product and (ii)&nbsp;Schr&ouml;dinger, LLC to market and distribute any of our other products, or the Other Schr&ouml;dinger Products, incorporating or statically or
dynamically linking to any portion of the GPU DESRES Software. Schr&ouml;dinger, LLC pays to DESRES a royalty equal to a low double-digit percentage of annual payments received by Schr&ouml;dinger, LLC for licensing, leasing, renting or providing
maintenance on the Desmond/GPU Product and any Other Schr&ouml;dinger Product. Such royalties are calculated on a graduated basis and are payable in perpetuity. In addition, in the event Schr&ouml;dinger, LLC performs services using the Desmond/GPU
Product or Other Schr&ouml;dinger Products on behalf of or in collaboration with third parties, Schr&ouml;dinger, LLC pays to DESRES a single-digit royalty on the services fees that directly relate to such usage. Schr&ouml;dinger, LLC paid to DESRES
$569,764, $719,471, $981,500, and $1,880,209 in royalties in 2016, 2017, 2018, and 2019, respectively. To the extent DESRES were to commercially market or distribute the Desmond/GPU Product, we would be entitled to a royalty equal to a <FONT
STYLE="white-space:nowrap">mid-double</FONT> digit percentage of annual payments received by DESRES for licensing, leasing, renting or providing maintenance on the Desmond/GPU Product. Such royalties are calculated on a graduated basis and are
payable in perpetuity. DESRES does not currently commercially sell or license the Desmond/GPU Product, and as such, DESRES did not pay us any royalties from January&nbsp;1, 2016 through the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;20, 2014, Schr&ouml;dinger, LLC entered into an amended and restated license and software development agreement with DESRES.
Pursuant to the agreement, Schr&ouml;dinger, LLC and DESRES agreed to develop and commercialize a software product, or the Software Product, which combines certain of our software with certain DESRES software related to molecular simulation for
central processing units, or the DESRES Software. Under the agreement, Schr&ouml;dinger, LLC and DESRES license each other&#146;s software so as to enable (i)&nbsp;Schr&ouml;dinger, LLC and DESRES to market and distribute the Software Product, and
(ii)&nbsp;Schr&ouml;dinger, LLC to market and distribute any of our other products, or the Other Schr&ouml;dinger Software Products, incorporating or statically or dynamically linking to any portion of the DESRES Software. Schr&ouml;dinger, LLC pays
to DESRES a royalty equal to a <FONT STYLE="white-space:nowrap">low-double-digit</FONT> percentage of annual payments received by Schr&ouml;dinger, LLC for licensing, leasing, renting or providing maintenance on the Software Product and any Other
Schr&ouml;dinger Software Product. Such royalties are calculated on a graduated basis and are payable in perpetuity. In addition, in the event Schr&ouml;dinger, LLC performs services using the Software Product or Other Schr&ouml;dinger Software
Products on behalf of or in collaboration with third parties, Schr&ouml;dinger, LLC pays to DESRES a single-digit royalty on the services fees that directly relate to such usage. The royalties are graduated and are payable in perpetuity. Under the
agreement, Schr&ouml;dinger, LLC paid to DESRES $533,573, $538,050, $591,796, and $601,141 in aggregate royalties in 2016, 2017, 2018, and 2019, respectively. To the extent DESRES were to commercially market or distribute the Software Product, we
would be entitled to a royalty equal to a mid double-digit percentage of annual payments received by DESRES for licensing, leasing, renting or providing maintenance on the Software Product. Such royalties are calculated on a graduated basis and are
payable in perpetuity. DESRES does not currently commercially sell or license the Software Product, and as such, DESRES did not pay us any royalties from January&nbsp;1, 2016 through the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under both license and software development agreements, Schr&ouml;dinger, LLC provides certain maintenance and support services for end users
using the software product under unpaid <FONT STYLE="white-space:nowrap">non-commercial</FONT> licenses. In consideration of these maintenance and support services, DESRES paid to Schr&ouml;dinger, LLC $58,727, $48,586, $50,023, and $51,544 in 2016,
2017, 2018, and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Charles Ardai, the managing director of DESTECH, previously served as a member of our board of
directors. He resigned from our board of directors in October 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to an investor rights agreement with the holders of our preferred stock, including our 5% stockholders and their affiliates.
This investor rights agreement provides these holders the right, subject to certain conditions, following the completion of this offering, to demand that we file a registration statement or to request that their shares be covered by a registration
statement that we are otherwise filing. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
certificate of incorporation, which will become effective upon the closing of this offering, provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In addition, we have entered into
indemnification agreements with all of our directors and executive officers. These indemnification agreements may require us, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#146; fees,
judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered
into employment agreements with our executive officers. For more information regarding the agreements with our named executive officers, see &#147;Executive Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted written policies and procedures, which became effective upon the effectiveness of the registration statement
of which this prospectus forms a part, for the review of any transaction, arrangement, or relationship in which our company is a participant, the amount involved exceeds $120,000 and one of our executive officers, directors, director nominees, or 5%
stockholders, or their immediate family members, each of whom we refer to as a &#147;related person,&#148; has a direct or indirect material interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a related person proposes to enter into such a transaction, arrangement, or relationship, which we refer to as a &#147;related person
transaction,&#148; the related person must report the proposed related person transaction to our chief legal officer. The policy calls for the proposed related person transaction to be reviewed and, if deemed appropriate, approved by our audit
committee. Whenever practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval is not practicable, the committee will review, and, in its discretion, may ratify the related person
transaction. The policy also permits the chairman of the audit committee to review and, if deemed appropriate, approve proposed related person transactions that arise between committee meetings, subject to ratification by the committee at its next
meeting. Any related person transactions that are ongoing in nature will be reviewed annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A related person transaction reviewed
under the policy will be considered approved or ratified if it is authorized by the audit committee after full disclosure of the related person&#146;s interest in the transaction. As appropriate for the circumstances, the audit committee will review
and consider: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the related person&#146;s interest in the related person transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approximate dollar value of the amount involved in the related person transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approximate dollar value of the amount of the related person&#146;s interest in the transaction without
regard to the amount of any profit or loss; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the transaction was undertaken in the ordinary course of our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the terms of the transaction are no less favorable to us than terms that could have been reached with an
unrelated third party; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purpose, and the potential benefits to us, of the transaction; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other information regarding the related person transaction or the related person in the context of the
proposed transaction that would be material to investors in light of the circumstances of the particular transaction. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee may approve or ratify the transaction only if it determines that, under all of the circumstances, the transaction is in,
or is not inconsistent with, our best interests. Our audit committee may impose any conditions on the related person transaction that it deems appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the transactions that are excluded by the instructions to the Securities and Exchange Commission&#146;s related person
transaction disclosure rule, our board of directors has determined that the following transactions do not create a material direct or indirect interest on behalf of related persons and, therefore, are not related person transactions for purposes of
this policy: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interests arising solely from the related person&#146;s position as an executive officer of another entity,
whether or not the person is also a director of the entity, that is a participant in the transaction where the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity, the related person and
his or her immediate family members are not involved in the negotiation of the terms of the transaction and do not receive any special benefits as a result of the transaction and the amount involved in the transaction is less than the greater of
$200,000 or 5% of the annual gross revenues of the company receiving payment under the transaction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a transaction that is specifically contemplated by provisions of our certificate of incorporation or bylaws.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy provides that transactions involving compensation of executive officers shall be reviewed and approved by
our compensation committee in the manner specified in the compensation committee&#146;s charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have a written policy
regarding the review and approval of related person transactions prior to this offering. Nevertheless, with respect to such transactions, it has been the practice of our board of directors to consider the nature of and business reasons for such
transactions, how the terms of such transactions compared to those which might be obtained from unaffiliated third parties and whether such transactions were otherwise fair to and in the best interests of, or not contrary to, our best interests.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our capital stock as of December&nbsp;31, 2019 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our capital
stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The columns entitled &#147;Percentage of Shares Beneficially Owned&#151;Before Offering&#148; are based on a
total of 36,400,653&nbsp;shares of our common stock and 13,164,193 shares of our limited common stock outstanding as of December&nbsp;31, 2019, after giving effect to (i)&nbsp;the voluntary exchange of 98,406,823 shares of our preferred stock for
13,164,193 shares of limited common stock and (ii)&nbsp;the automatic conversion of 226,344,686 shares of our preferred stock into an aggregate of 30,278,832 shares of our common stock, in each case, upon the closing of this offering. The columns
entitled &#147;Percentage of Shares Beneficially Owned&#151;After Offering&#148; are based on shares of our common stock and our limited common stock to be outstanding after this offering, including the shares of our common stock that we are selling
in this offering, but not including any additional shares issuable pursuant to the underwriters&#146; option to purchase additional shares in this offering or any additional shares issuable upon exercise of outstanding options. The table below does
not reflect any potential purchases by our existing stockholders in this offering. The number and percentage of shares of our common stock beneficially owned by them after this offering will be higher than those set forth in the table below to the
extent they purchase shares in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of the
Securities and Exchange Commission and includes voting or investment power with respect to our common stock and limited common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days after
December&nbsp;31, 2019 are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any
other person. Except as otherwise noted, the persons and entities in this table have sole voting and investment power with respect to all of the shares of our common stock and limited common stock beneficially owned by them, subject to community
property laws, where applicable. Except as otherwise set forth below, the address of each beneficial owner is c/o Schr&ouml;dinger, Inc., 120 West 45<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, 17<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, New York 10036. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of Shares<BR>Beneficially Owned -<BR>Before Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of Shares<BR>Beneficially Owned -<BR>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name of <BR>Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Limited<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Limited<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Limited<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bill&nbsp;&amp; Melinda Gates Foundation Trust<SUP STYLE="font-size:85%; vertical-align:top">
(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,393,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13,164,193</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with David E. Shaw<SUP STYLE="font-size:85%; vertical-align:top">
(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,496,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ramy Farid<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">619,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yvonne Tran<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cony D&#146;Cruz<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Lynton<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard A. Friesner<SUP STYLE="font-size:85%; vertical-align:top"> (7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,980,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rosana Kapeller-Libermann <SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Sender</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nancy Thornberry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy M. Wright</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (16 persons)<SUP
STYLE="font-size:85%; vertical-align:top"> (9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,554,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 6,393,429 shares of common stock issuable upon the conversion of 47,793,062 shares of preferred
stock held by the Bill&nbsp;&amp; Melinda Gates Foundation Trust, or the Trust, and (ii) 13,164,193 shares of limited common stock to be acquired upon exchange of 98,406,823 shares of preferred stock held by the Trust. For purposes of Rule 13d-3
under the Securities Exchange Act of 1934, as amended, all shares beneficially owned by the Trust may be deemed to be beneficially owned by William H. Gates III and Melinda French Gates, as Co-Trustees of the Trust. The address of the
Bill&nbsp;&amp; Melinda Gates Foundation Trust is 2365 Carillon Point, Kirkland, Washington 98033. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 14,890,845 shares of common stock issuable upon the conversion of preferred stock held by
Schrodinger Equity Holdings, LLC, (ii)&nbsp;1,133,158 shares of common stock issuable upon the conversion of preferred stock held by D. E. Shaw&nbsp;&amp; Co., L.P., (iii)&nbsp;467,889 shares of common stock issuable upon the conversion of preferred
stock held by D. E. Shaw Valence Portfolios, L.L.C., and (iv)&nbsp;4,264 shares of common stock issuable upon the conversion of preferred stock held by D. E. Shaw Technology Development, LLC. By virtue of David E. Shaw&#146;s position as the manager
of Schrodinger Equity Holdings, LLC, and by virtue of David E. Shaw&#146;s position as president and sole shareholder of D. E. Shaw&nbsp;&amp; Co., Inc., which is the general partner of D. E. Shaw&nbsp;&amp; Co., L.P., which in turn is the
investment adviser of D. E. Shaw Valence Portfolios, L.L.C., and by virtue of David E. Shaw&#146;s position as president and sole shareholder of D.&nbsp;E. Shaw&nbsp;&amp; Co. II, Inc., which is the sole member of D. E. Shaw Technology Development,
LLC and the managing member of D.&nbsp;E. Shaw&nbsp;&amp; Co., L.L.C., which in turn is the manager of D.&nbsp;E. Shaw Valence Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of, and the shared
power to dispose or direct the disposition of, the shares held by Schrodinger Equity Holdings, LLC, D.&nbsp;E. Shaw&nbsp;&amp; Co., L.P., D.&nbsp;E. Shaw Valence Portfolios, L.L.C., and D.&nbsp;E. Shaw Technology Development, LLC. The principal
business address of Schrodinger Equity Holdings, LLC and D.&nbsp;E. Shaw Technology Development, LLC is 120 West 45<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, 39<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New
York, New York 10036; the principal business address of D. E. Shaw&nbsp;&amp; Co., L.P. and D. E. Shaw Valence Portfolios, L.L.C. is 1166 Avenue of the Americas, Ninth Floor, New York, New York 10036. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 334,432 shares of common stock held by Dr.&nbsp;Farid and (ii)&nbsp;284,823 shares of common
stock underlying options held by Dr.&nbsp;Farid that are exercisable as of December&nbsp;31, 2019 or will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 40,131 shares of common stock held by Ms. Tran and (ii)&nbsp;53,387 shares of common stock
underlying options held by Ms. Tran that are exercisable as of December&nbsp;31, 2019 or will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 41,392 shares of common stock held by Mr.&nbsp;D&#146;Cruz, (ii)&nbsp;131,689 shares of common
stock held by Cony and Pearl D&#146;Cruz Revocable Trust dated August 20, 2019, and any amendments thereto, of which Mr. D&#146;Cruz is a co-trustee, and (iii)&nbsp;10,735 shares of common stock underlying options held by Mr.&nbsp;D&#146;Cruz that
are exercisable as of December&nbsp;31, 2019 or will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 41,804 shares of common stock underlying options held by Mr.&nbsp;Lynton that are exercisable as of
December&nbsp;31, 2019 or will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,105,450 shares of common stock held by Dr.&nbsp;Friesner, (ii)&nbsp;754,925 shares of common
stock held by RF 2018 GRAT, of which Dr.&nbsp;Friesner is trustee, and (iii)&nbsp;120,395 shares of common stock underlying options held by Dr.&nbsp;Friesner that are exercisable as of December&nbsp;31, 2019 or will become exercisable within 60 days
after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 14,492 shares of common stock underlying options held by
<FONT STYLE="white-space:nowrap">Dr.&nbsp;Kapeller-Libermann</FONT> that are exercisable as of December&nbsp;31, 2019 or will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,747,131 shares of common stock and 807,108 shares of common stock underlying options that are
exercisable as of December&nbsp;31, 2019 or will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock and provisions of our certificate of incorporation and bylaws are summaries only and are
qualified by reference to the certificate of incorporation and the bylaws that will be in effect upon the closing of this offering. We have filed copies of these documents with the Securities and Exchange Commission as exhibits to our registration
statement of which this prospectus is a part. The description of the capital stock reflects changes to our capital structure that will occur upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our authorized capital stock will consist of 500,000,000 shares of our common stock, par value $0.01 per
share, 100,000,000 shares of our limited common stock, par value $0.01 per share and 10,000,000 shares of our preferred stock, par value $0.01 per share, all of which preferred stock will be undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2019, we had issued and outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,121,821<B> </B>shares of our common stock held by 267 stockholders of record; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">0 shares of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">134,704,785 shares of our Series A preferred stock held by 18 stockholders of record, convertible into 18,019,879
shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">29,468,101 shares of our Series B preferred stock held by 1 stockholder of record, convertible into 3,942,042
shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">47,242,235 shares of our Series C preferred stock held by 1 stockholder of record, convertible into 6,319,744
shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">39,540,611 shares of our Series D preferred stock held by 2 stockholders of record, convertible into 5,289,473
shares of our common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">73,795,777 shares of our Series E preferred stock held by 14 stockholders of record, convertible into 9,871,888
shares of our common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, (i)&nbsp;98,406,823 shares of our preferred stock will
be voluntarily exchanged for an aggregate of 13,164,193 shares of our limited common stock and (ii)&nbsp;226,344,686 shares of our preferred stock will automatically convert into an aggregate of 30,278,832 shares of our common stock. We will not
have any non-voting common stock authorized or outstanding upon the closing of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock and Limited Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our
common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Holders of our limited common stock are entitled to one vote for each share of
limited common stock held on all matters submitted to a vote of stockholders, except such holders of limited common stock are not entitled to vote any shares of limited common stock in any election of directors or on the removal of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At all meetings of stockholders at which directors are to be elected, other than in a contested election, when a quorum is present the
election of directors by our stockholders will be determined by majority voting, meaning each nominee will be elected to the board of directors if the votes cast &#147;for&#148; such nominee&#146;s election by the stockholders entitled to vote
exceed the votes cast &#147;against&#148; the nominee&#146;s election, with abstentions and &#147;broker non-votes&#148; not counting as votes &#147;for&#148; or &#147;against.&#148; In a contested election, when a quorum is present the election of
directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock and limited common stock are entitled to receive proportionately any dividends as may be declared by our board of
directors, subject to any preferential dividend rights of any of our outstanding preferred stock. In the event of our liquidation, dissolution or winding up, the holders of our common stock and limited common stock are entitled to receive
proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive, Subscription, Redemption and Conversion Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, subscription, redemption or conversion rights. Holders of our limited common stock have no
preemptive, subscription or redemption rights. Holders of our limited common stock have the right to convert each share of our limited common stock into one share of common stock at such holder&#146;s election. The Bill &amp; Melinda and Gates
Foundation Trust, or the Trust, is party to an amended and restated share exchange agreement with us pursuant to which the Trust is entitled to exchange each share of common stock held by the Trust into one share of limited common stock at the
Trust&#146;s election. See &#147;Transactions with Related Persons&#148; for more information with respect to this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights,
preferences and privileges of holders of our common stock and limited common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the
future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
terms of our certificate of incorporation that will become effective upon the closing of this offering, our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of
directors has the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays
associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings, and other corporate purposes, could have the effect of making it more
difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no shares of preferred stock outstanding, and we have no
present plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2019, options to purchase an aggregate of 4,943,778 shares of our common stock, at a weighted average exercise price of
$3.57 per share, were outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delaware Anti-Takeover Law and Certain Charter and Bylaw Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to
Section&nbsp;203 of the Delaware General Corporation Law, or the DGCL. Subject to certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested
stockholder&#148; for three years following the date that the person became an interested stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is approved by
our board of directors and stockholders in a prescribed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manner or the interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an interested stockholder. A &#147;business combination&#148;
includes, among other things, a merger or consolidation involving us and the &#147;interested stockholder&#148; and the sale of more than 10% of our assets. In general, an &#147;interested stockholder&#148; is any entity or person beneficially
owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. The restrictions contained in Section&nbsp;203 are not applicable to any of our existing stockholders
that will own 15% or more of our outstanding voting stock upon the closing of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board; Removal of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and our bylaws to be effective upon the closing of this offering divide our board of directors into three
classes with staggered three-year terms. In addition, our certificate of incorporation and our bylaws to be effective upon the closing of this offering provide that until the first date on which the Bill &amp; Melinda Gates Foundation Trust,
Schrodinger Equity Holdings, LLC, D. E. Shaw &amp; Co., L.P., D. E. Shaw Technology Development, LLC and D. E. Shaw Valence Portfolios, L.L.C. and their respective successors and affiliates cease collectively to beneficially own (directly or
indirectly) more than 40% of our outstanding shares of common stock and limited common stock, which date we refer to as the Trigger Date, any director may be removed at any time with or without cause by the affirmative vote of the holders of at
least a majority of the voting power of our outstanding shares of common stock. On and after the Trigger Date, our directors may be removed only for cause and only by the affirmative vote of the holders of at least a majority of the voting power of
all outstanding shares of common stock. Under our certificate of incorporation and our bylaws to be effective upon the closing of this offering, any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of
directors, may be filled only by vote of a majority of our directors then in office. Furthermore, our certificate of incorporation to be effective upon the closing of this offering provides that the authorized number of directors may be changed only
by the resolution of our board of directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more
difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Action; Special
Meeting of Stockholders; Advance Notice Requirements for Stockholder Proposals and Director Nominations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of
incorporation and our bylaws to be effective upon the closing of this offering provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of
stockholders may only be taken if it is properly brought before such meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stockholders may not take action by written consent in lieu of a meeting, except that prior to the Trigger Date,
the stockholders may act by written consent in lieu of a meeting for the sole purpose of removing a director with or without cause; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as otherwise required by law, special meetings of the stockholders can only be called by our board of
directors or by our secretary at the request of the holders of at least 25% of the outstanding shares of our common stock and limited common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws to be effective upon the closing of this offering establish an advance notice procedure for stockholder proposals to be brought
before an annual or special meeting of stockholders, including proposed nominations of candidates for election to our board of directors. Stockholders at an annual or special meeting may only consider proposals or nominations specified in the notice
of meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper
form to our secretary of the stockholder&#146;s intention to bring such business before the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The advance notice provisions in our
bylaws could have the effect of delaying stockholder actions that are favored by the holders of a majority of our outstanding voting securities. Moreover, the prohibition on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder action by written consent except as noted above could discourage a third party from making a tender offer for our common stock because even if the third party acquired a majority of
our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Forum Selection </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
certificate of incorporation to be effective upon the closing of this offering provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the
State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on our
behalf, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, other employees or stockholders to our company or our stockholders, (3)&nbsp;any action asserting a claim arising pursuant to any
provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4)&nbsp;any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each
case, as they may be amended from time to time) or governed by the internal affairs doctrine. These choice of forum provisions do not apply to suits brought to enforce any duty or liability created by the Securities Act of 1933, as amended, or the
Securities Act, or the rules and regulations thereunder, the Securities Exchange Act of 1934, as amended, or the Exchange Act, or the rules and regulations thereunder or any other claim for which the federal courts have exclusive jurisdiction.
Although our certificate of incorporation contains the choice of forum provisions described above, it is possible that a court could rule that such provisions are inapplicable for a particular claim or action or that such provisions are
unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an amended and restated investor rights agreement dated as of November&nbsp;9, 2018, as amended on January&nbsp;4, 2019
and April&nbsp;8, 2019, or the investor rights agreement, with holders of our preferred stock. Following the completion of this offering, holders of a total of 43,443,025 shares of our common stock and limited common stock will have the right to
require us to register these shares under the Securities Act, under specified circumstances as more fully described below. We refer to the shares with these registration rights as registrable securities. After registration pursuant to these rights,
the registrable securities will become freely tradable without restriction under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand and Form
<FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning after November&nbsp;9, 2023, subject to specified
limitations set forth in the investor rights agreement, at any time, the holders of at least 33% of the then outstanding registrable securities may demand that we register the registrable securities then outstanding under the Securities Act for
purposes of a public offering having an aggregate offering price to the public, net of selling expenses, of at least $10.0&nbsp;million. We are not obligated to file a registration statement pursuant to this provision on more than two occasions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, subject to specified limitations set forth in the investor rights agreement, at any time after we become eligible to file a
registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the holders of at least 10% of the then outstanding registrable securities may request that we register their registrable securities on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> for purposes of a public offering for which the anticipated aggregate offering price to the public, net of selling expenses, would be at least $1.0&nbsp;million. We are not obligated to file a registration
statement pursuant to this provision on more than one occasion in any <FONT STYLE="white-space:nowrap">12-month</FONT> period preceding the request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incidental Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, at any time after the closing of this offering, we propose to register for our own account, or for the account of one or more of our
stockholders, any of our securities under the Securities Act, the holders of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registrable securities will be entitled to notice of the registration and, subject to specified exceptions, have the right to require us to use our best efforts to register all or a portion of
the registrable securities then requested to be included in such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any registration in which the holders of
registrable securities participate pursuant to our investor rights agreement is an underwritten public offering, we have agreed to enter into an underwriting agreement in usual and customary form and use our best efforts to facilitate such offering.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
investor rights agreement, we are required to pay all registration expenses, including all registration and filing fees, exchange listing fees, printing expenses, fees and expenses, not to exceed $30,000, of one counsel selected by the selling
stockholders to represent the selling stockholders, state Blue Sky fees and expenses, and the expense of any special audits incident to or required by any such registration, but excluding underwriting discounts, selling commissions, stock transfer
taxes applicable to the sale of any registrable securities, and the fees and expenses of the selling stockholders&#146; own counsel (other than the counsel selected to represent all selling stockholders). If a registration is withdrawn at the
request of the stockholders holding a majority of the registerable securities proposed to be registered initiating the registration, then the stockholders will bear the expenses of the registration, unless the holders of a majority of the
registrable securities agree to </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">forfeit, in the case of a Form <FONT STYLE="white-space:nowrap">S-1</FONT> demand registration, their right to one
registration, or in the case of a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration, their right to request a registration for period of 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The investor rights agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling
stockholders in the event of material misstatements or omissions in the registration statement attributable to us or any violation or alleged violation whether by action or inaction by us under the Securities Act, the Exchange Act, any state
securities or Blue Sky law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities or Blue Sky law in connection with such registration statement or the qualification or compliance of the offering,
and they are obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and
Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock and our limited common stock will be Computershare Trust Company N.A.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock has been approved for listing on the Nasdaq Global Select Market under the symbol &#147;SDGR&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock, and a liquid trading market for our common stock may not develop
or be sustained after this offering. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Future sales of substantial amounts of our common
stock in the public market, including shares issued upon exercise of outstanding options, or the anticipation of these sales, could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through
sales of equity securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will have outstanding 48,283,005 shares of our common stock and
13,164,193 shares of our limited common stock, based on the 36,400,653 <B></B>shares of our common stock and the 13,164,193 shares of our limited common stock that were outstanding on December&nbsp;31, 2019, after giving effect to (i)&nbsp;the
issuance of 11,882,352 shares of our common stock in this offering, assuming no exercise by the underwriters of their option to purchase additional shares of our common stock, (ii)&nbsp;the voluntary exchange of 98,406,823 shares of our preferred
stock for an aggregate of 13,164,193 shares of our limited common stock upon the closing of this offering and (iii)&nbsp;the automatic conversion of 226,344,686 shares of our preferred stock into an aggregate of 30,278,832 shares of our common stock
upon the closing of this offering. Of these shares, all shares sold in this offering will be freely tradable without restriction under the Securities Act of 1933, as amended, or the Securities Act, unless purchased by our &#147;affiliates,&#148; as
that term is defined in Rule 144 under the Securities Act, or Rule 144. The remaining 36,400,653 shares of our common stock and 13,164,193 shares of our limited common stock will be &#147;restricted securities&#148; under Rule 144, and substantially
all of these restricted securities will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below.
These restricted securities may be sold in the public market only upon release or waiver of any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, which release or waiver may be effected with the consent of Morgan
Stanley&nbsp;&amp; Co. LLC, BofA Securities, Inc., Jefferies LLC, and BMO Capital Markets Corp. in their sole discretion at any time, and only if registered under the Securities Act or pursuant to an exemption from registration under the Securities
Act, such as the exemptions provided by Rule 144 or Rule 701 under the Securities Act, or Rule 701. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144, beginning 90 days after the date of this prospectus, any person who is not our affiliate and has held their shares
for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell those shares without restriction, subject to the availability of current public information about us. In addition, under Rule 144,
any person who is not our affiliate and has not been our affiliate at any time during the preceding three months and has held their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would
be entitled to sell an unlimited number of shares immediately upon the closing of this offering without regard to whether current public information about us is available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning 90 days after the date of this prospectus, a person who is our affiliate or who was our affiliate at any time during the preceding
three months and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to sell a number of shares within any three-month period that
does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately 482,830 shares
immediately after this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume in our common stock on the Nasdaq Global Select Market during the four calendar
weeks preceding the date of filing of a Notice of Proposed Sale of Securities Pursuant to Rule&nbsp;144 with respect to the sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 by our affiliates are also subject to manner of sale provisions and notice requirements and to the availability of
current public information about us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon waiver or expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period described below, approximately 36,400,653 shares of our common stock and 13,164,193 shares of our limited common stock will be eligible for sale under Rule&nbsp;144. We cannot estimate the number of
shares of our common stock that our existing stockholders will elect to sell under Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701, any of our employees, consultants, or advisors, other than our affiliates, who purchased shares from us in
connection with a qualified compensatory stock plan or other written agreement is eligible to resell these shares 90 days after the date of this prospectus in reliance on Rule 144, but without compliance with the various restrictions, including the
availability of public information about us and holding period and volume limitations, contained in Rule 144. Substantially all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and will become
eligible for sale upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, each of our executive officers and directors and the holders of substantially all of our outstanding equity securities have agreed
that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, BofA Securities, Inc., Jefferies LLC, and BMO Capital Markets Corp., we and they will not, subject to limited exceptions, during the period ending 180 days after the date
of this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or limited common stock beneficially owned (as such term is used in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> of the Securities Exchange Act of 1934, or the Exchange Act) or any other securities so owned convertible into or exercisable or exchangeable for common stock or limited common stock, or make any public
announcement of an intention to do any of the foregoing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the Securities and Exchange Commission relating to this offering of any
shares of common stock or any securities convertible into or exercisable or exchangeable for common stock or limited common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock or limited common stock, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction is to be settled by delivery of
common stock or such other securities, in cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These agreements are subject to certain exceptions, as described in the
section of this prospectus entitled &#147;Underwriters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning after the closing of this offering, the holders of an aggregate of 43,443,025 shares of our common stock and our limited common stock
will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. After registration
pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options and Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this offering, we intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the
Securities Act to register all of the shares of our common stock subject to outstanding options and reserved for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future options and other awards under the 2010 Plan, the 2020 Plan and the 2020 ESPP. See &#147;Executive Compensation&#151;Stock Option and Other Compensation Plans&#148; for additional
information regarding these plans. Accordingly, shares of our common stock registered under the registration statements will be available for sale in the open market, subject to Rule 144 volume limitations applicable to affiliates, and subject to
any vesting restrictions and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements applicable to these shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_17"></A>MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of material U.S. federal income and estate tax considerations relating to the ownership and disposition of
shares of our common stock acquired in this offering by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder. For purposes of this discussion, the term <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; means a beneficial owner
(other than a partnership or other pass-through entity) of our common stock that is not, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if (1)&nbsp;a U.S. court is able to exercise primary supervision over the administration of the trust and
one or more United States persons has authority to control all substantial decisions of the trust or (2)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a United States person.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address the tax treatment of partnerships or other entities or arrangements that are
classified as pass-through entities for U.S. federal income tax purposes or persons who hold shares of our common stock through partnerships or such other pass-through entities. The tax treatment of a partner in a partnership or other entity or
arrangement that is classified as a pass-through entity for U.S. federal income tax purposes generally will depend upon the status of the partner and the activities of the partnership. A partner in a partnership or other <FONT
STYLE="white-space:nowrap">pass-through</FONT> entity or arrangement that will hold our common stock should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of our common stock through a
partnership or other <FONT STYLE="white-space:nowrap">pass-through</FONT> entity, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on current
provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of
the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue Service, or the IRS, will not challenge one or more of the tax consequences described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion addresses only <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders that hold shares of our common stock as a capital
asset (generally, property held for investment) for U.S. federal income tax purposes. This discussion does not address all aspects of U.S. federal income and estate taxation that may be relevant to a particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it address any aspects of U.S. state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, the alternative minimum tax, or the Medicare tax on net investment income. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial services entities, or other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax exempt or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive shares of our common stock pursuant to the exercise of an employee stock option or
otherwise as compensation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or
other integrated investment or who have elected to, or otherwise are required to, mark securities to market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold more than 5% of our common stock, directly or indirectly (except to the extent specifically set
forth below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations organized outside of the United States, any state thereof or the District of Columbia that are
nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlled foreign corporations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">passive foreign investment companies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATION ONLY AND IS NOT, AND IS NOT INTENDED TO BE, LEGAL OR TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT
THEIR OWN TAX ADVISORS REGARDING THE U.S. FEDERAL, STATE, LOCAL, ESTATE AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> INCOME AND OTHER TAX CONSIDERATIONS OF ACQUIRING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF
ANY PROPOSED CHANGES IN APPLICABLE LAWS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed under the heading &#147;Dividend Policy&#148; above, we do not expect to pay cash dividends to holders of our common stock in the
foreseeable future. If we make distributions in respect of our common stock, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as
determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax
treatment described below under the heading &#147;Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject
to the discussions below under the headings &#147;Information Reporting and Backup Withholding&#148; and &#147;FATCA&#148;, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S.
federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common
stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed IRS Form&nbsp;W8BEN or W8BENE (or successor form) to us
and/or an applicable paying agent and satisfy applicable certification and other requirements. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may
obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends that are treated
as effectively connected with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, and, if an applicable income tax treaty so provides, that are attributable to a permanent
establishment or a fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
satisfies applicable certification and disclosure requirements (generally including provision of a properly executed IRS Form&nbsp;W8ECI (or applicable successor form) to us and/or an applicable paying agent certifying that the dividends are
effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or business within the United States). However, such U.S. effectively connected income is taxed on a net income basis at the same U.S.
federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is classified as a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation for U.S. federal income tax purposes may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower rate as may be
specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their own tax advisors regarding their entitlement to benefits under a relevant income tax treaty and the specific methods available to them to satisfy these requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income tax on gain recognized on the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s sale, exchange, or other disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct
of a trade or business in the United States, and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the
United States, in which case, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, an additional branch profits tax at a rate of 30% (or a lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s
country of residence) may also apply; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien present in the United States
for 183 days or more in the taxable year of the disposition and certain other requirements are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such lower rate as may be specified by an
applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S.-source capital losses of the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are, or have been, at any time during the five-year period preceding such disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder held no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the five-year period ending on the date of the disposition or the period that the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. If we are determined to be a &#147;U.S. real property holding corporation&#148; and the foregoing exception does not apply, then the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on its net gain derived from the disposition at the U.S. federal income tax rates applicable to United States persons (as defined in the Code). Generally, a corporation
is a &#147;U.S. real property holding corporation&#148; only if the fair market value of its &#147;U.S. real property interests&#148; (as defined in the Code and applicable regulations) equals or exceeds 50% of the sum of the fair market value of
its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a &#147;U.S. real property holding corporation&#148; for U.S.
federal income tax purposes, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rule described above.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Estate Tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our common stock that are owned or treated as owned by an individual who is not a citizen or resident of the United States (as
specially defined for U.S. federal estate tax purposes) at the time of such individual&#146;s death are considered U.S.-situs assets and will be included in the individual&#146;s gross estate for U.S. federal estate tax purposes. Such shares,
therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on
our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is
not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Generally, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will comply with such
procedures if it provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable IRS Form <FONT
STYLE="white-space:nowrap">W-8),</FONT> or otherwise meets documentary evidence requirements for establishing that it is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, or otherwise establishes an exemption. Dividends paid to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of U.S. federal income tax, as described above under the heading &#147;&#151;Distributions,&#148; will generally be exempt from U.S. backup withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> unless the holder certifies its status as a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes,
dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a
broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of information returns may be made available to the tax authorities of the country in which the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Rather, any amounts withheld under the backup withholding rules from a payment to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed
with the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FATCA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of
the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a 30% withholding tax on dividends on, and, subject to the discussion below with respect to proposed U.S. Treasury Regulations excluding gross
proceeds from such required withholding, gross proceeds from the sale or other disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; the foreign entity
undertakes certain due diligence, reporting, withholding and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; the foreign entity identifies certain of its U.S. investors, if any, or
(iii)&nbsp;the foreign entity is otherwise excepted under FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Withholding under FATCA generally applies to payments of dividends on
our common stock. While withholding under FATCA would also have applied to payments of gross proceeds from a sale or other disposition of our common stock made after December&nbsp;31, 2018, under recently proposed U.S. Treasury Regulations
withholding on payments of gross proceeds is not required. Although such regulations are not final, applicable withholding agents may rely on the proposed regulations until final regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If withholding under FATCA is required on any payment related to our common stock, investors not otherwise subject to withholding (or that
otherwise would be entitled to a reduced rate of withholding) on such payment may be required to seek a refund or credit from the IRS. An intergovernmental agreement between the United States and an applicable foreign country may modify the
requirements described in this section. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their own tax advisors regarding the possible implications of FATCA on their investment in our common stock and the entities through
which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of material U.S. federal tax considerations is for information
only. It is not, and is not intended to be, legal or tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local, estate, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income and
other tax consequences of acquiring, holding, and disposing of our common stock, including the consequences of any proposed changes in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_18"></A>UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below,
for whom Morgan Stanley&nbsp;&amp; Co. LLC, BofA Securities, Inc., Jefferies LLC, and BMO Capital Markets Corp. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares
indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,455,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,564,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,732,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BMO Capital Markets Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,128,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,882,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the
&#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146; over-allotment option described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the
cover of this prospectus and part to certain dealers. After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to 1,782,352
additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this option solely for the purpose of covering over-allotments, if
any, made in connection with the offering of the shares of common stock offered by this prospectus. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage
of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of shares of common stock listed next to the names of all underwriters in the preceding table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses
to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional 1,782,352 shares of common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201,999,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232,299,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,139,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,260,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187,859,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216,038,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are
approximately $6,100,000. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority of up to $30,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they do not intend sales to discretionary accounts to
exceed 5% of the total number of shares of common stock offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock has been approved for listing on the Nasdaq
Global Select Market under the trading symbol&nbsp;&#147;SDGR&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all of our directors and executive officers and the holders
of substantially all of our outstanding stock and stock options have agreed that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, BofA Securities, Inc., Jefferies LLC, and BMO Capital Markets Corp., on behalf of the
underwriters, we and they will not, during the period ending 180 days after the date of this prospectus, or the restricted period: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or limited common stock beneficially owned (as such term is used in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> of the Securities Exchange Act of 1934, as amended, or the Exchange Act) or any other securities so owned convertible into or exercisable or exchangeable for common stock or limited common stock, or make any
public announcement of an intention to do any of the foregoing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the SEC relating to the offering of any shares of our common stock or any
securities convertible into or exercisable or exchangeable for common stock or limited common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock or limited common stock, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction described above is to be settled by
delivery of common stock or such other securities, in cash or otherwise. In addition, we and each such person have agreed that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, BofA Securities, Inc., Jefferies LLC, and BMO
Capital Markets Corp., on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any securities
convertible into or exercisable or exchangeable for common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph do
not apply to our directors, officers, and securityholders with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions relating to shares of common stock or any other securities acquired in the offering (other than any
issuer-directed shares of common stock purchased in the offering by our officers or directors) or in open market transactions after the completion of the offering, provided that no filing under Section&nbsp;16(a) of the Exchange Act is required or
voluntarily made in connection with subsequent sales of our common stock or other securities acquired in the offering or such open market transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers or dispositions of shares of common stock or any security convertible into or exercisable or
exchangeable for common stock (a)&nbsp;as a bona fide gift, including to a charitable organization or educational institution in a transfer not involving the payment of consideration in exchange for such transfer; (b)&nbsp;to any member of the
immediate family of such person or any trust for the direct or indirect benefit of such person or the immediate family of such person in a transaction not involving a disposition for value; (c)&nbsp;to any corporation, partnership, limited liability
company or other entity all of the beneficial ownership interests of which are held by such person or the immediate family of such person; (d)&nbsp;by will, other testamentary document or intestate succession to the legal representative, heir,
beneficiary or a member of the immediate family of such person upon the death of such person; (e)&nbsp;in connection with a divorce settlement or solely by operation of law pursuant to a qualified domestic relations order; or (f)&nbsp;to general or
limited partners, members or stockholders of such person, its direct or indirect affiliates (as defined in Rule 405 promulgated under the Securities Act) or to an investment fund or other entity that controls or manages, or is under common control
with, such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
person; provided that (i)&nbsp;each transferee, donee or distributee signs and delivers a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement to the representatives; and (ii)&nbsp;no public
announcement is made and no filing under Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership of shares of our common stock, is required or voluntarily made during the restricted period (other than, in the case of a
transfer or other disposition pursuant to clause (b), (d) or (e)&nbsp;above, any Form 4 or Form 5 required to be filed under the Exchange Act if such person is subject to Section&nbsp;16 reporting with respect to us under the Exchange Act and any
such filing indicates by footnote disclosure or otherwise the nature of the transfer or disposition); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers or dispositions of shares of common stock or any security convertible into or exercisable or
exchangeable for common stock to us pursuant to any contractual arrangement in effect on the date such person entered into the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement and as disclosed to the underwriters that provides for the
repurchase of such person&#146;s common stock or other securities by us or in connection with the termination of such person&#146;s employment with or service to us; provided that no filing under Section&nbsp;16(a) of the Exchange Act reporting a
reduction in beneficial ownership of shares of our common stock is required or voluntarily made during the restricted period (other than any Form 4 or Form 5 required to be filed under the Exchange Act if such person is subject to Section&nbsp;16
reporting with respect to us under the Exchange Act and any such filing indicates by footnote disclosure or otherwise the nature of the transfer or disposition); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of outstanding shares of preferred stock described in this prospectus into shares of common stock,
provided that such shares received upon conversion are subject to the same restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise of stock options to purchase shares of common stock granted under any equity incentive plan
described in this prospectus and any related transfer to us of shares of common stock, including by way of &#147;net&#148; or &#147;cashless&#148; exercise solely to cover withholding tax obligations and any transfer to us for payment of taxes;
provided that any shares received upon exercise of such options are subject to the same restrictions, and that no filing under Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership of shares of our common stock is
required or voluntarily made during the restricted period (other than a filing on Form 4 that reports such disposition under the transaction code &#147;F&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the
Exchange Act for the transfer of shares of common stock, provided that (a)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and (b)&nbsp;to the extent a public announcement or filing under the Exchange
Act, if any, is required or voluntarily made regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the restricted period; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) transfers of shares of common stock or any securities convertible into, or exercisable or exchangeable for,
common stock pursuant to a bona fide third-party tender offer for shares of our capital stock made to all holders of our securities, merger, consolidation, or other similar transaction approved by our board of directors the result of which is that
any person (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than us, becomes the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and
<FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of more than 50% of the total voting power of our voting stock and (b)&nbsp;entry into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to
which the undersigned may agree to transfer, sell, tender or otherwise dispose of shares of common stock or such other securities in connection with a transaction described in (a), provided that in the event that such change of control transaction
is not completed, the common stock or any security convertible into or exercisable or exchangeable for common stock owned by such person will remain subject to the same restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions on transfers or other dispositions by us described above do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares to be sold in this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of shares of common stock or securities convertible into or exercisable for shares of common
stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date of this prospectus and described in this prospectus; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of shares of common stock or limited common stock upon the exchange of any security
exchangeable therefor or the conversion of any security therefor pursuant to a contractual arrangement or other right described in this prospectus, provided that each recipient of such shares executes and delivers a lock-up agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating the establishment of a trading plan on behalf of one of our shareholders, officers or directors
pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of common stock, provided that such plan does not provide for the transfer of common stock during the restricted period and, to the extent a public announcement or filing
under the Exchange Act is required of or voluntarily made by us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the
restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the grant of any options to purchase shares of common stock or other awards granted under a stock incentive plan
or stock purchase plan described in this prospectus, and the issuance by us of shares of common stock upon the exercise thereof, provided that each recipient of such grant executes and delivers a lock-up agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our filing of any registration statement on Form S-8 or a successor form relating to the shares of common stock
granted pursuant to or reserved for issuance under a stock incentive plan or stock purchase plan described in this prospectus; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of common stock or other securities issued in connection with a transaction with an unaffiliated third
party that includes a debt financing or a bona fide commercial relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements, or intellectual property license agreements) or any acquisition of assets or
acquisition of not less than a majority or controlling portion of the equity of another entity, provided that (1) the aggregate number of shares issued does not exceed 5% of the total number of outstanding shares of our common stock immediately
following the closing of this offering and (2) the recipient of any such shares during the restricted period enters into a lock-up agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC, BofA Securities, Inc., Jefferies LLC, and BMO Capital Markets Corp., in their sole discretion, may release
the common stock and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain, or otherwise
affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater
than the number of shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the open market. In determining
the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the over-allotment option. The underwriters may also sell shares in
excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are
concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the
underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or
retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or
more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long
and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or
express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this
offering, there has been no public market for our common stock. The initial public offering price was determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price were
our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain
financial and operating information of companies engaged in activities similar to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be sold only
to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions </I>or subsection 73.3(1) of the
<I>Securities Act </I>(Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the shares
must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a
<FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the
underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area which has implemented the Prospectus Regulation, or each, a Relevant Member
State, an offer to the public of any shares of our common stock may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any shares of our common stock may be made at any time under the
following exemptions under the Prospectus Regulation, if they have been implemented in that Relevant Member State: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined in the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares of our common stock shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant
to Article 3 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in
relation to any shares of our common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an
investor to decide to purchase any shares of our common stock, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each underwriter
has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000, or FSMA, received by it in connection with the issue or sale of the shares of our common stock in
circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it
in relation to the shares of our common stock in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our common stock may not be offered or sold by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), (ii) to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made
thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation, or document relating to
shares of our common stock may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the
public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares of our common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional
investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of
1948, as amended), or the FIEL has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the shares of common stock have not been, directly or indirectly, offered or
sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the
laws of Japan) or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or <FONT STYLE="white-space:nowrap">re-sale,</FONT> directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an
exemption from the registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>For Qualified Institutional Investors, or QII </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in
relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, Article <FONT STYLE="white-space:nowrap">23-13</FONT> of the
FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock.&nbsp;The shares of common stock may only be transferred to QIIs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in
relation to the shares of common stock constitutes either a &#147;small number private placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph 4, Article
<FONT STYLE="white-space:nowrap">23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock.&nbsp;The shares of
common stock may only be transferred en bloc without subdivision to a single investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our common stock may not be circulated or distributed, nor may the shares of our common stock be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or
the SFA, (ii)&nbsp;to a relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of,
any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where shares of our common stock are subscribed or purchased under Section&nbsp;275 by a
relevant person which is: (i)&nbsp;a corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited
investor; or (ii)&nbsp;a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures, and units of shares and debentures of that corporation or
the beneficiaries&#146; rights and interest in that trust shall not be transferable for 6 months after that corporation or that trust has acquired shares of our common stock under Section&nbsp;275 except: (a)&nbsp;to an institutional investor under
Section&nbsp;274 of the SFA or to a relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA; (b)&nbsp;where no consideration is given for the transfer; or
(c)&nbsp;by operation of law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other
stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or
regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. Neither this
document nor any other offering or marketing material relating to the offering, us, or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of
shares will not be supervised by, the Swiss Financial Market Supervisory Authority, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor
protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dubai
International Financial Centre </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the
Dubai Financial Services Authority, or DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has
no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The
shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this
prospectus you should consult an authorized financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wilmer Cutler Pickering Hale and Dorr LLP, Boston, Massachusetts is acting as counsel for us in connection with this offering. The validity of
the shares of common stock offered hereby is being passed upon for us by Richards, Layton &amp; Finger, P.A., Wilmington, Delaware. Cooley LLP, New York, New York, is acting as counsel for the underwriters in connection with this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Schr&ouml;dinger, Inc. and its subsidiaries as of December&nbsp;31, 2018 and 2017, and for the years
then ended, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting
and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom766269_21"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the Securities and Exchange Commission, or SEC, a registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act of 1933, as amended, with respect to the shares of common stock we are offering to sell. This prospectus, which constitutes part of the registration statement, does not include all
of the information contained in the registration statement and the exhibits, schedules, and amendments to the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and to
the exhibits and schedules to the registration statement. Statements contained in this prospectus about the contents of any contract, agreement or other document are not necessarily complete, and, in each instance, we refer you to the copy of the
contract, agreement or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference to such contract, agreement, or document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC maintains an Internet website, which is located at http://www.sec.gov, that contains reports, proxy and information statements, and
other information regarding issuers that file electronically with the SEC. You may access the registration statement of which this prospectus is a part at the SEC&#146;s Internet website. Upon completion of this offering, we will be subject to the
information reporting requirements of the Securities Exchange Act of 1934, as amended, and we will file reports, proxy statements, and other information with the SEC. We plan to fulfill our obligations with respect to such requirements by filing
periodic reports and other information with the SEC. We intend to furnish our stockholders with annual reports containing financial statements certified by an independent registered public accounting firm. Our website address is www.schrodinger.com.
The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A><A NAME="rom766269_22"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the Years Ended December&nbsp;31, 2017 and 2018 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated Financial Statements:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_3">Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_4">Consolidated Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_5">Consolidated Statements of Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_6">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_7">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the Three and Nine Months Ended September&nbsp;30, 2018 and 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Condensed Consolidated Financial Statements (Unaudited):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_8">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_9">Condensed Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_10">Condensed Consolidated Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_11">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-37</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_12">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-39</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin766269_13">Notes to the Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-40</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin766269_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schr&ouml;dinger,
Inc.: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Opinion on the Consolidated Financial Statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Schr&ouml;dinger, Inc. and subsidiaries (the Company) as of December&nbsp;31, 2018 and 2017,
the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders&#146; deficit, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2018 and 2017, and the results of its operations and its cash flows for the years then
ended, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis for Opinion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our
audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to
error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2010. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Portland, Oregon </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October 30, 2019, except for the effects of
the reverse stock split described in note 17, as to which the date is January 27, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin766269_2"></A>Consolidated Balance Sheets </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net of allowance for doubtful accounts of $50 and $237</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Stock, and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll, taxes and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, long term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, long term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E convertible preferred stock, $0.01 par value. Authorized, 67,087,074 shares; 53,669,659
shares issued and outstanding; liquidation preference of $79,999,999</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D convertible preferred stock, $0.01 par value. Authorized, 39,540,611 shares; 39,540,611
shares issued and outstanding; liquidation preference of $22,000,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred stock, $0.01 par value. Authorized, 47,242,235 shares; 47,242,235
shares issued and outstanding, liquidation preference of $20,000,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.01 par value. Authorized, 29,468,101 shares; 29,468,101
shares issued and outstanding; liquidation preference of $10,000,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.01 par value. Authorized, 134,704,785 shares; 134,704,785
shares issued and outstanding; liquidation preference of $18,185,146</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value. Authorized 415,000,000 shares; 5,460,393 and 5,906,976&nbsp;shares
issued and outstanding at December&nbsp;31, 2017 and 2018, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock, and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin766269_3"></A>Consolidated Statements of Operations </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on equity investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to Schrodinger common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used to compute net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,608,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,771,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to Schr&#246;dinger common stockholders, basic and
diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average common shares used to compute net loss per share attributable to common
stockholders, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,384,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin766269_4"></A>Consolidated Statements of Comprehensive Loss </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in market value of investments, net of tax:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin766269_5"></A>Consolidated Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share amounts) </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E preferred</B><br><B>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D preferred</B><br><B>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C preferred</B><br><B>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B preferred</B><br><B>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A preferred</B><br><B>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT></B><br><B>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>other<BR>comprehensive</B><br><B>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>stockholders&#146;</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Balance at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,279,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,987</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Balance at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,460,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Change in unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuances of Series E preferred stock, net of issuance costs of $623</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,669,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,669,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,906,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(80,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(71,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin766269_6"></A>Consolidated Statements of Cash Flows </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash revenue from equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash rent expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash investment accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bad debt expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease (increase) in assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll, taxes, and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution from equity investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from maturity of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances of Series E preferred stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow and noncash information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue related to equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin766269_7"></A>Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Description of Business </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Schr&#246;dinger, Inc. (&#147;the Company&#148;) has developed a differentiated, physics-based software platform that enables discovery of
high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, the Company believes, a higher likelihood of success compared to traditional methods. The Company sells its software solutions to
biopharmaceutical and industrial companies, academic institutions, and government laboratories. The Company also applies its computational platform to a broad pipeline of drug discovery programs in collaboration with biopharmaceutical companies,
some of which the Company co-founded. In addition, the Company uses its platform to advance a pipeline of internal, wholly-owned drug discovery programs. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Recently Adopted Accounting Pronouncements</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Financial Accounting Standards
Board (&#147;FASB&#148;) issued Accounting Standard Update (&#147;ASU&#148;) 2016-09, Compensation - Stock Compensation (Topic 718) - <I>Improvements to Employee Share-Based Payment Accounting</I>, in March 2016. ASU 2016-09 simplifies several
aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted ASU 2016-09 as of
the first quarter 2018, and the adoption did not have a material effect on the financial position, results of operations or cash flows of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Accounting Pronouncements Not Yet Adopted</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB established
Topic 842, <I>Leases</I>, by issuing ASU No.&nbsp;2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right-of-use model (&#147;ROU&#148;) that
requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12&nbsp;months. Leases will be classified as finance or operating, with classification affecting the pattern and
classification of expense recognition in the income statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As issued, ASU 2016-02 required transition under a modified retrospective
basis as of the beginning of the earliest comparative period presented; however in July 2018, the FASB issued ASU 2018-11, <I>Leases (Topic 842) Targeted Improvements</I>, which amends ASU 2016-02 to provide entities an optional transition practical
expedient that allows companies to adopt the new standard with a cumulative effect adjustment as of the beginning of the year of adoption with prior year comparative financial information and disclosures remaining as previously reported. The Company
plans to elect this practical expedient, by adopting the new standard on January&nbsp;1, 2019, and does not expect a material adjustment to retained earnings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The new standard provides a number of optional practical expedients in transition. The Company expects to elect the &#145;package of practical
expedients&#146;, which permits it not to reassess under the new standard its prior conclusions about lease identification, lease classification, and initial direct costs. The Company expects to elect all of the new standard&#146;s available
transition practical expedients. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company expects that this standard will have a material effect on its financial statements. While the
Company continues to assess all of the effects of adoption, it currently believes the most significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
effects relate to (1)&nbsp;the recognition of new ROU assets and lease liabilities on its balance sheet for its operating leases; and (2)&nbsp;providing significant new disclosures about its
leasing activities. The Company does not expect a significant change in its leasing activities between now and adoption. On adoption, the Company currently expects to recognize additional operating liabilities ranging from approximately $18,600 to
$17,600, with corresponding ROU assets ranging from approximately $16,900 to $15,900. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The new standard also provides practical expedients
for an entity&#146;s ongoing accounting. The Company currently expects to elect the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease
liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and non-lease
components for all of its leases. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In August 2017, the FASB issued ASU No.&nbsp;2017-12,&nbsp;Derivatives and Hedging (&#147;Topic
815&#148;), <I>Targeted Improvements to Accounting for Hedging Activities</I>. The new guidance better aligns an entity&#146;s risk management activities and financial reporting for hedging relationships through changes to both the designation and
measurement guidance for qualifying hedging relationships and the presentation of hedge results. The new guidance also makes certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of
hedge documentation requirements and assessing hedge effectiveness. The standard is effective for fiscal years beginning after December&nbsp;15, 2018, and early adoption is permitted. The Company does not expect this standard to have a material
impact on its consolidated financial statements and related disclosures. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(c)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Basis of Presentation and Use of Estimates</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements in conformity with U.S.&nbsp;generally accepted accounting principles (&#147;U.S. GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the useful lives of
<FONT STYLE="white-space:nowrap">long-lived</FONT> assets, the recoverability of deferred tax assets, assumptions used in the allocation of revenue, and assumptions used in testing for impairment of <FONT STYLE="white-space:nowrap">long-lived</FONT>
assets. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(d)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Principles of Consolidation</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company&#146;s consolidated financial statements
include the accounts of Schr&ouml;dinger, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The functional currency for foreign entities is the United States dollar. The Company
accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(e)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Reclassifications of Prior Year Presentation </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company reclassified $62 of
sales and marketing expenses and $47 of general and administrative expenses of stock based compensation to research and development expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(f)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Cash and Cash Equivalents and Marketable Securities </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Included in cash and cash
equivalents were cash equivalents of $3,188 and $73,211 as of December&nbsp;31, 2017 and 2018, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company
classifies all highly liquid investments with an original maturity of three&nbsp;months or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation&#146;s insured limits;
however, the Company primarily places its temporary cash with high-credit quality financial institutions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(g)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Accounts Receivable </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Accounts receivable are stated at original invoice amount
less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer&#146;s financial condition, credit history, and current economic conditions.
Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the
balance of accounts deemed uncollectible were deemed immaterial as of December&nbsp;31, 2017 and 2018. Interest is not charged on accounts receivable. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><I>(h)</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Fair Value of Financial Instruments </I></B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to
their short maturities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(i)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Property and Equipment </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost. Maintenance
and repairs are expensed as incurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Depreciation is calculated using the <FONT STYLE="white-space:nowrap">straight-line</FONT> method
over the estimated useful lives of the assets, which range from 3 to 7&nbsp;years. Amortization of leasehold improvements is calculated using the <FONT STYLE="white-space:nowrap">straight-line</FONT> method over the remaining life of the lease or
the useful life of the asset, whichever is shorter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment as discussed below under Accounting
for the Impairment of <FONT STYLE="white-space:nowrap">Long-Lived</FONT> Assets. The Company did not capitalize any interest during 2017 and 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(j)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Intangible Assets </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Intangible assets include various intangible assets acquired
through business acquisitions and asset purchases. Intangible assets are amortized using the <FONT STYLE="white-space:nowrap">straight-line</FONT> method over their estimated useful lives, which range from 5 to 10&nbsp;years, and are included in
other assets in the consolidated balance sheets. Intangible assets are reviewed for impairment as discussed below under Accounting for the Impairment of <FONT STYLE="white-space:nowrap">Long-Lived</FONT> Assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(k)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Accounting for the Impairment of <FONT STYLE="white-space:nowrap">Long-Lived</FONT> Assets </I></B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Long-lived</FONT> assets, such as property and equipment and intangible assets subject to amortization, are
reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a <FONT STYLE="white-space:nowrap">long-lived</FONT> asset or asset group be tested
for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the <FONT STYLE="white-space:nowrap">long-lived</FONT> asset or asset
group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted
market values, and <FONT STYLE="white-space:nowrap">third-party</FONT> independent appraisals, depending on the nature of the asset. No impairment was identified for the years ended December&nbsp;31, 2017 and 2018. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(l)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Revenue Recognition </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Revenue is recognized upon transfer of control of promised
products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company&#146;s performance obligations are satisfied either over time or at a
point in time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The following table illustrates the timing of the Company&#146;s revenue recognition: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services &#150; point in time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services &#150; over time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug Discovery &#150; point in time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug Discovery &#150; over time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Software Products and Services</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts that can include various combinations of licenses, products and services, some of which are distinct and are
accounted for as separate performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price basis. Revenue
is recognized net of any sale and value-added taxes collected from customers and subsequently remitted to governmental authorities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s software business derives revenue from four sources: (i)&nbsp;on-premise software license fees, (ii)&nbsp;hosted software subscription fees, (iii)&nbsp;software maintenance fees, and (iv)&nbsp;professional services fees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>On-premise software.</I>&nbsp;The Company&#146;s on-premise software license arrangements grant customers the right to use its software on
their own in-house servers for a specified term, typically for one year.&nbsp;The Company recognizes revenue for on-premise software license fees upfront, either upon delivery of the license or the effective date of the agreement, whichever is
later. In instances where the timing of delivery differs from the timing of its invoicing, the Company considers whether a significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
financing component exists. The Company has elected the practical expedient to not assess for significant financing where the term is less than one year. The Company&#146;s updates and upgrades
are not integral to maintaining the utility of the software licenses. Payments typically are received upfront annually. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Hosted
software.</I>&nbsp;Hosted software revenue consists primarily of fees to provide the Company&#146;s customers with access to its hosted software platform and is recognized ratably over the term of the arrangement.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Software maintenance.</I>&nbsp;Software maintenance includes technical support, updates, and upgrades.&nbsp;Software maintenance revenue is
considered to be a separate performance obligation and is recognized ratably over the term of the arrangement, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Professional
services.</I>&nbsp;Professional services, such as technical support and installation or assisting customers with modeling, generally are not related to the functionality of the Company&#146;s software and may be recognized as resources are consumed
or over the term of the arrangement, depending on the terms of the underlying agreement. The Company has historically estimated project status with relative accuracy. A number of internal and external factors can affect such estimates, including
labor rates, utilization and efficiency variances. Payments for services are due in advance or upon consumption of resources. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The
following table illustrates the revenue recognized from the four components of the software products and services revenue: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On-premise software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hosted software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total software products and services revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Drug Discovery</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Revenue from drug discovery and collaboration services contracts is recognized either over time, typically by using costs incurred or hours
expended to measure progress, or at a point in time based on the achievement of milestones. Payments for services are generally due upon achieving milestones stated in a contract, upfront at the start of a contract, or upon consumption of resources.
Services may at times include variable consideration and milestone payments. The Company has estimated the amount of consideration that is variable using the most likely amount method. The Company evaluates milestones on a case by case basis,
including whether there are factors outside the Company&#146;s control that could result in a significant reversal of revenue, and the likelihood and magnitude of a potential reversal. If achievement of a milestone is not considered probable, the
Company constrains (reduces) variable consideration to exclude the milestone payment until it is probable to be achieved. As of December&nbsp;31, 2017 and 2018, respectively, the Company determined that milestones totaling $0 and $3,650 were
probable to occur, and $0 and $2,622 of those milestones were recognized as revenue during 2017 and 2018, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Significant Judgments</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Significant judgments and estimates are required under Accounting Standard Codification (&#147;ASC&#148;) Topic 606, <I>Revenue from Contract
with Customers (&#147;Topic 606&#148;)</I>. Due to the complexity of certain contracts, the actual revenue recognition treatment required under Topic 606 for the Company&#146;s arrangements may be dependent on contract-specific terms and may vary in
some instances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company&#146;s contracts with customers often include promises to transfer multiple software products and/or licenses
and services, including professional services, technical support services, and rights to unspecified updates. Determining whether licenses and services are distinct performance obligations that should be accounted for separately, or are not distinct
and therefore should be accounted for together, requires significant judgment. In some arrangements, such as most of the Company&#146;s term-based software license arrangements, the Company has concluded that the licenses and associated services are
distinct from each other. In other arrangements, including collaboration services arrangements, the licenses and certain services may not be distinct from each other. The Company&#146;s time-based software arrangements may include multiple software
licenses and a right to updates or upgrades to the licensed software products, and technical support. The Company has concluded that such promised goods and services are separate distinct performance obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company is required to estimate the total consideration expected to be received from contracts with customers, including any variable
consideration. Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is allocated to each separate performance obligation on a relative stand-alone
selling price (&#147;SSP&#148;) basis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Judgment is required to determine the SSP for each distinct performance obligation. The Company
rarely licenses or sells products on a standalone basis, so the Company is required to estimate the range of SSPs for each performance obligation. In instances where the SSP is not directly observable because the Company does not sell the license,
product, or service separately, the Company determines the SSP using information that includes historical discounting practices, market conditions, cost-plus analysis, and other observable inputs. The Company typically has more than one SSP for
individual performance obligations due to the stratification of those items by classes of customers and circumstances. In these instances, the Company may use information such as the size and geographic region of the customer in determining the SSP.
Professional service revenue is recognized as costs and hours are incurred, which requires judgment in estimating project status and the costs incurred or hours expended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If a group of agreements are so closely related to each other that they are, in effect, part of a single arrangement, such agreements are
deemed to be one arrangement for revenue recognition purposes. The Company exercises significant judgment to evaluate the relevant facts and circumstances in determining whether the separate agreements should be accounted for separately or as, in
substance, a single arrangement. The Company&#146;s judgments about whether a group of contracts comprises a single arrangement can affect the allocation of consideration to the distinct performance obligations, which could have an effect on results
of operations for the periods involved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Generally, the Company has not experienced significant returns or refunds to customers. The
Company&#146;s estimates related to revenue recognition require significant judgment and the change in these estimates could have an effect on the Company&#146;s results of operations during the periods involved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Contract Balances</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition may differ from the timing of invoicing to customers and these timing differences result in receivables,
contract assets, or contract liabilities (deferred revenue) on the consolidated balance sheets. The Company records a contract asset when revenue is recognized prior to invoicing and records a deferred revenue liability when revenue is expected to
be recognized subsequent to invoicing. For the Company&#146;s time-based software agreements, customers are generally invoiced at the beginning of the arrangement for the entire term, though when the term spans multiple years the customers may be
invoiced on an annual basis. For certain drug discovery agreements that include payment plans, the Company records a receivable related to revenue recognized upon delivery because it has an unconditional right to invoice and receive payment in the
future related to those deliveries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Contract assets are presented as other receivables within the consolidated balance sheets and
primarily relate to the Company&#146;s rights to consideration for work completed but not billed on service contracts. Contract assets are transferred to receivables when the Company invoices the customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Contract balances were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">During 2017 and 2018, respectively, the Company recognized&nbsp;$9,880 and $11,297&nbsp;of revenue that was
included in deferred revenue at the end of the preceding year. All other deferred revenue activity is due to the timing of invoices in relation to the timing of revenue, as described above. The Company expects to recognize as revenue
approximately&nbsp;85%&nbsp;of its December&nbsp;31, 2018 deferred revenue balance in 2019 and the remainder thereafter. Additionally, contracted but unsatisfied performance obligations that had not yet been billed to the customer or included in
deferred revenue were&nbsp;$14,858 as of&nbsp;December 31, 2018. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Payment terms and conditions vary by contract type, although terms
typically require payment within&nbsp;30&nbsp;to&nbsp;60&nbsp;days. In instances where the timing of revenue recognition differs from that of invoicing, the Company has determined that its contracts generally do not include a significant financing
component. The primary purpose of invoicing terms is to provide customers with simplified and predictable ways of purchasing the Company&#146;s products and services, not to facilitate financing arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Deferred Sales Commissions</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company has applied the practical expedient for sales commission expense, as any compensation paid to sale representatives to obtain a
contract relates to a period of one year or less. Therefore, the Company has not capitalized any costs related to sales commissions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(m)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Warranties </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company typically warrants that its products will perform in a
manner consistent with the product specifications provided to the customer for a period of 30&nbsp;days. Historically, the Company has not been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><I>(n)</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Concentrations of Credit Risk</I></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant
customers may be performed prior to extending credit. The determination of a customer&#146;s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash, and net income. The Company maintains an
allowance for doubtful accounts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, no customer accounted for more than 10% of total accounts receivable. As of
December&nbsp;31, 2018, one customer accounted for 18% of total accounts receivable. For the year ended December&nbsp;31, 2017, one customer accounted for 11% of total revenues. For the year ended December&nbsp;31, 2018, no customer accounted for
more than 10% of total revenues. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(o)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Royalties </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Royalties represent a component of cost of revenues and consist of
royalties paid to owners of intellectual property used in or bundled with the Company&#146;s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements
are based instead on cash collections. Royalty expense was $3,489 and $4,894 for the years ended December&nbsp;31, 2017 and 2018, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(p)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Software Development Costs </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Costs to develop new software products and
substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the
establishment of technological feasibility. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(q)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Research and Development and Advertising </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Research and development and
advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2017 or 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(r)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I><FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company
calculates <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation expense utilizing fair value&#150;based methodologies and recognizes expense over the vesting period of such awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(s)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Commissions </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Commissions represent a component of sales and marketing expense and
consist of the variable compensation paid to the Company&#146;s direct sales force. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales
personnel are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order. Commission expense was $523 and $602 in 2017 and 2018, respectively. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(t)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Income Taxes </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company records deferred tax assets and liabilities for the
expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more
likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company recognizes the effect of income tax positions only if such positions are deemed &#147;more likely than not&#148; capable to be
sustained. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><I>(u)</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Comprehensive Loss </I></B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss and changes in equity related to changes in unrealized gains or losses on marketable securities. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(v)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Equity Investments </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company has entered into collaboration agreements with
Nimbus Therapeutics, LLC (&#147;Nimbus&#148;), Morphic Therapeutic, Inc. (&#147;Morphic Therapeutic&#148;), a wholly owned subsidiary of Morphic Holding, Inc. (&#147;Morphic&#148;), and Petra Pharma Corporation (&#147;Petra&#148;) to perform drug
design services in exchange for minority ownership, which are included within equity investments in the Company&#146;s consolidated balance sheets. The Company concluded that the carrying value of its equity investments in Nimbus and Morphic should
reflect its contractual rights to substantive profits. The Company further determined that the hypothetical liquidation at book value method (&#147;HLBV method&#148;) for valuing contractual rights to substantive profits provides the best
representation of its financial position. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The HLBV method is a balance sheet oriented approach to equity method accounting. Under the HLBV
method, the Company determines its share of earnings or losses by comparing its claim on the book value at the beginning and end of each reporting period. This claim is calculated as the amount that the Company would receive (or be obligated to pay)
if the investee were to liquidate all of its assets at recorded amounts, determined as of the balance sheet date in accordance with generally accepted accounting principles, and distribute the resulting cash to creditors and investors in accordance
with their respective priorities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company has concluded that its equity investment in Petra should be valued using the historical cost
method, as the Company does not exercise significant influence over Petra. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For further information regarding the Company&#146;s equity
investments, see Note 5, Fair Value Measurements and Note 12, Equity Investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><I>(w)</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Net Loss Per Share Attributable to Common Stockholders</I></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method
required for companies with participating securities. The Company considers its convertible preferred stock to be participating securities. In the event a dividend is declared or paid on common stock, holders of convertible preferred stock are
entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, basic net loss per share attributable to common stockholders is calculated by dividing the net loss
attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred
stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive
common stock equivalents outstanding for the period determined using the treasury stock method. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible
preferred stock does not have a contractual obligation to share in the Company&#146;s losses. For purposes of this calculation, convertible preferred stock and certain stock options are considered common stock equivalents but have been excluded from
the calculation of net loss per share attributable to common stockholders as their effect is anti-dilutive. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(3)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Property and Equipment</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for 2017 and 2018 was $1,644 and $2,857, respectively, and is included within cost of
revenues and research and development, sales and marketing, and general and administrative expenses within the consolidated statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(4)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Intangible Assets</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Intangible assets are included within other assets in the consolidated balance sheets. The following table presents the Company&#146;s
intangible assets and their related useful lives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Useful&nbsp;life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5&#150;10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer relationships</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademarks, logos, and website</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Intangible asset amortization expense for 2017 and 2018 was $41 and $37, respectively, and is included within
general and administrative expenses in the consolidated statements of operations. The estimated amortization expense for the year ending December&nbsp;31, 2019 is $15, at which point the intangible assets will be fully amortized. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(5)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Various inputs are used in determining the fair value of the Company&#146;s financial assets and liabilities and are summarized into the
following three broad categories: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1 &#150; quoted prices in active markets for identical securities </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2 &#150; other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk, etc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3 &#150; significant unobservable inputs, including the Company&#146;s own assumptions in determining fair value </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those
securities. Marketable securities are classified as available for sale and fair value does not differ significantly from carrying value as of December&nbsp;31, 2017 and 2018. The following table presents information about the Company&#146;s assets
and liabilities measured at fair value as of December&nbsp;31, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s assets and liabilities
measured at fair value as of December&nbsp;31, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Fair value of the Company&#146;s investments in Nimbus and Morphic, classified as Level 3 in the fair value
hierarchy, was determined under the HLBV method, as further described in Note 2, Significant Accounting Policies. Significant unobservable inputs used under the HLBV method include Nimbus&#146; and Morphic&#146;s annual financial statements and the
Company&#146;s respective liquidation priority. The following table sets forth changes in fair value of the Company&#146;s Level 3 investments: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unrealized losses arising from changes in fair value of the Company&#146;s equity investments are classified
within change in fair value in the consolidated statements of operations. There were no transfers between Level 1, Level 2, and Level 3 investments in 2017 or 2018. The conversion of investment represents the conversion of Morphic from an equity
investment to a cost investment. See Note 12, Equity Investments for further information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(6)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and Contingencies</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Leases</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company leases office space under operating leases that expire at
various dates through 2026. In addition to rent expense, the Company pays real property taxes, insurance, and repair and maintenance expenses for its office facilities. The Company recognizes rent expense on a
<FONT STYLE="white-space:nowrap">straight-line</FONT> basis over the life of the related lease, including any periods of free rent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, future minimum lease payments under noncancelable operating
leases with initial or remaining terms in excess of one&nbsp;year were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ending December&nbsp;31:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Lease expense was $3,361 and $4,703 in 2017 and 2018, respectively. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Legal Matters</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in routine
litigation arising in the ordinary course of business. While the results of such litigation cannot be predicted with certainty, management believes that the final outcome of such matters is not likely to have a material adverse effect on the
Company&#146;s financial position or results of operations or cash flows. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(7)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Income tax expense is comprised of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Components of income (loss) before income taxes by tax jurisdiction were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Reconciliation of income tax expense at the applicable statutory income tax rates to the effective rate is as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory federal income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholding tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return-to-provision adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax contingencies, net of reversals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Cuts and Jobs Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Income tax expense for the year ended December&nbsp;31, 2017 primarily related to state taxes, taxes in
foreign jurisdictions, withholding taxes, and in 2017, an alternative minimum tax credit refund under the Tax Cuts and Jobs Act of 2017 (the &#147;Tax Act&#148;). Income tax expense for the year ended December&nbsp;31, 2018 primarily related to
state taxes, and taxes in foreign jurisdictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The total change in valuation allowance for the year ended December&nbsp;31, 2018 was
$7,813, which primarily was due to the generation of net operating losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tax effects of temporary differences that give rise to significant portions of deferred
income tax assets and deferred income tax liabilities were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,603</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company had federal and state net operating loss (&#147;NOL&#148;)
carryforwards of $75,312 and $41,348, respectively. These carryforwards, with the exception of 2018 federal NOLs, will expire between 2019 and 2038 if not used by the Company to reduce income taxes payable in future periods. Utilization of post-2017
federal NOL carryforwards are limited to 80% of taxable income generated in a given year and carry forward indefinitely. As of December&nbsp;31, 2018, the Company had federal and state research and development tax credit carryforwards of $6,812 and
$418, respectively. These carryforwards will expire between 2019 and 2038 if not used by the Company to reduce income taxes payable in future periods. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Internal Revenue Code Sections 382 and 383, the utilization of net operating losses and other tax attributes may be substantially
limited due to cumulative changes in ownership greater than 50% that may have occurred or could occur during applicable testing periods. The Company has not performed an analysis for all periods to determine the possible limitation on its net
operating losses. It is possible that the Company&#146;s ability to utilize its net operating losses may be subject to an annual limitation in future periods. The annual limitation may also cause a portion of the Company&#146;s net operating loss
carryforwards to expire unused. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has not recognized a deferred tax liability for the undistributed earnings of its foreign
operations as the Company considers these earnings to be indefinitely reinvested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company classifies interest and penalties related to unrecognized tax benefits within
income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions for tax positions taken in prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reductions for tax positions taken in prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions for tax positions related to the current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company does not anticipate any significant increases or decreases in its uncertain tax positions within
the next 12&nbsp;months. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, statutes of limitations were open for all of the Company&#146;s federal and state
tax returns filed after the year ended December&nbsp;31, 2014 and 2013, respectively. Net operating loss and credit carryforwards for all years are subject to examination and adjustments for the three years following the year in which the
carryforwards are utilized. The Company is not currently undergoing any federal or state income tax examinations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Tax Act was enacted
on December&nbsp;22, 2017. The Tax Act reduces the US federal corporate tax rate from 34% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and creates new
taxes on certain foreign sourced earnings. The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. The provisional amount recorded in 2017
related to the remeasurement of the deferred tax balance was $7,174, fully offset by a reduction in the valuation allowance. The Company recorded a receivable of $26 for the alternative minimum tax credits expected to be refunded, reduced by the
estimated sequestration. The Company completed the analysis of the effects of the Tax Act in 2018, which had an insignificant impact and is included as part of the overall provision calculation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(8)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Convertible Preferred Stock</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Series&nbsp;A Convertible Preferred Stock (&#147;Series&nbsp;A Preferred Stock&#148;)</I></B> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2010, the board of directors approved the issuance of 7,255,853&nbsp;shares of Series&nbsp;A preferred stock to existing
Series&nbsp;A stockholders as payment for $2,490 in cumulative dividends in arrears. The Series&nbsp;A preferred stock was issued at $0.3432 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Also, on April&nbsp;16, 2010, the board of directors approved the issuance of 2,987,648&nbsp;shares of Series&nbsp;A preferred stock to
existing Series&nbsp;A stockholders in exchange for the termination of the right to receive future cumulative dividends. The Series&nbsp;A preferred stock was issued at $0.3432 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As the issuance of shares in the form of a stock dividend on April&nbsp;16, 2010 was greater than 25% of the shares outstanding prior to the
dividend, this qualified as a stock split effected in the form of a dividend and resulted in an increase in the outstanding shares and related par value and an equal reduction to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2010, the board of directors approved the issuance of 89,309,763&nbsp;shares
of Series&nbsp;A preferred stock to the unit holders of Schr&ouml;dinger, LLC, other than the Company in exchange for their LLC units. The exchange rate was 1.1488&nbsp;shares of Series&nbsp;A preferred stock per LLC unit. Due to the common
ownership between the units of the LLC and the equity of the Company, this was considered a transaction between entities under common control and was accounted for at historical cost. As a result of this transaction, Schr&ouml;dinger, LLC became a
wholly owned subsidiary of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In a liquidation event, excluding a public offering, holders of the Series&nbsp;A preferred stock
are entitled to receive (i)&nbsp;following all preferential distributions made to holders of the shares of Series&nbsp;C, Series&nbsp;D, and Series E preferred stock, prior to any distribution to combined common stockholders, and on a&nbsp;<I>pari
passu</I>&nbsp;basis with holders of the Series B preferred stock, an amount equal to $0.135 per share, plus any declared and unpaid dividends and (ii)&nbsp;following payment of all preferential amounts required to be paid to the holders of
preferred stock,&nbsp;a portion of any proceeds remaining for distribution to preferred and combined common stockholders, pro rata based on the number of shares held by each such holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Holders of Series&nbsp;A preferred stock are entitled to receive noncumulative dividends at a rate of $0.00675 per share, when and if approved
and declared by the board of directors. Through December&nbsp;31, 2017 and 2018, no dividends had been approved or declared by the board of directors related to the Company&#146;s Series&nbsp;A preferred stock, other than as described above. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Series&nbsp;B Convertible Preferred Stock (&#147;Series&nbsp;B Preferred Stock&#148;) </I></B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2010, the board of directors approved the issuance of 29,468,101&nbsp;shares of Series&nbsp;B preferred stock to Cascade
Investment, LLC. The Series&nbsp;B preferred stock was issued at $0.33935 per share for gross proceeds of $10,000. During 2014, such shares were transferred to the Bill&nbsp;&amp; Melinda Gates Foundation Trust (&#147;BMGFT&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In a liquidation event, excluding a public offering, holders of Series&nbsp;B preferred stock are entitled to receive (i)&nbsp;following all
preferential distributions made to holders of the shares of Series&nbsp;C, Series&nbsp;D, and Series E preferred stock, prior to any distribution to combined common stockholders, and on a&nbsp;<I>pari passu</I>&nbsp;basis with holders of the Series
A preferred stock, an amount equal to $0.33935 per share, plus any declared and unpaid dividends and (ii)&nbsp;following payment of all preferential amounts required to be paid to the holders of preferred stock, a portion of any proceeds remaining
for distribution to preferred and combined common stockholders, pro rata based on the number of shares held by each such holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Holders
of Series&nbsp;B preferred stock are entitled to receive noncumulative dividends at a rate of $0.016967 per share, when and if approved and declared by the board of directors. Through December&nbsp;31, 2017 and 2018, no dividends had been approved
or declared by the board of directors related to the Company&#146;s Series&nbsp;B preferred stock. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(c)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Series&nbsp;C Convertible Preferred Stock (&#147;Series&nbsp;C Preferred Stock&#148;) </I></B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;11, 2012, the board of directors approved the issuance of 47,242,235&nbsp;shares of Series&nbsp;C preferred stock to Cascade
Investment, LLC. The Series&nbsp;C preferred stock was issued at $0.42335 per share for gross proceeds of $20,000. During 2014, the shares were transferred to the BMGFT. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In a liquidation event, excluding a public offering, holders of Series&nbsp;C preferred stock are entitled to receive (i)&nbsp;following all
preferential distributions made to holders of the shares of Series&nbsp;E preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
stock, prior to any distribution to combined common stockholders and holders of Series&nbsp;A and Series&nbsp;B preferred stock, and on a&nbsp;<I>pari passu</I>&nbsp;basis with holders of the
Series D preferred stock, an amount equal to $0.42335 per share, plus any declared and unpaid dividends and (ii)&nbsp;following payment of all preferential amounts required to be paid to the holders of preferred stock, a portion of any proceeds
remaining for distribution to preferred and combined common stockholders, pro rata based on the number of shares held by each such holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Holders of Series&nbsp;C preferred stock are entitled to receive noncumulative dividends at a rate of $0.0211675 per share, when and if
approved and declared by the board of directors. Through December&nbsp;31, 2017 and 2018, no dividends had been approved or declared by the board of directors related to the Company&#146;s Series&nbsp;C preferred stock. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(d)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Series&nbsp;D Convertible Preferred Stock (&#147;Series&nbsp;D Preferred Stock&#148;) </I></B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On June&nbsp;15, 2015, the board of directors approved the issuance of 35,946,010&nbsp;shares of Series&nbsp;D preferred stock to the BMGFT and
3,594,601&nbsp;shares of Series&nbsp;D preferred stock to an employee. The Series&nbsp;D preferred stock was issued at $0.55639 per share for gross proceeds of $22,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In a liquidation event, excluding a public offering, holders of Series&nbsp;D preferred stock are entitled to receive (i)&nbsp;following all
preferential distributions made to holders of the shares of Series&nbsp;E preferred stock,&nbsp;prior to any distribution to combined common stockholders and holders of Series&nbsp;A and Series&nbsp;B preferred stock, and on a&nbsp;<I>pari
passu</I>&nbsp;basis with holders of the Series C preferred stock, an amount equal to $0.55639 per share, plus any declared and unpaid dividends and (ii)&nbsp;following payment of all preferential amounts required to be paid to the holders of
preferred stock, a portion of any proceeds remaining for distribution to preferred and combined common stockholders, pro rata based on the number of shares held by each such holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Holders of Series&nbsp;D preferred stock are entitled to receive noncumulative dividends at a rate of $0.0278195 per share, when and if
approved and declared by the board of directors. Through December&nbsp;31, 2017 and 2018, no dividends had been approved or declared by the board of directors related to the Company&#146;s Series&nbsp;D preferred stock. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(e)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Series&nbsp;E Convertible Preferred Stock (&#147;Series&nbsp;E Preferred Stock&#148;) </I></B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2018, the board of directors authorized 67,087,074 shares of Series E preferred stock, of which 53,669,659 were issued at
$1.4906 per share for gross proceeds of $80,000. The remaining 13,417,415 authorized shares of Series E preferred stock are available for issuance until May&nbsp;9, 2019. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In a liquidation event, excluding a public offering, holders of Series&nbsp;E preferred stock are entitled to receive (i)&nbsp;prior to any
distribution to combined common stockholders and holders of Series&nbsp;A, Series&nbsp;B, Series C and Series D preferred stock, an amount equal to $1.4906 per share, plus any declared and unpaid dividends and (ii)&nbsp;following payment of all
preferential amounts required to be paid to the holders of preferred stock,&nbsp;a portion of any proceeds remaining for distribution to preferred and combined common stockholders, pro rata based on the number of shares held by each such holder.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Holders of Series&nbsp;E preferred stock are entitled to receive noncumulative dividends at a rate of $0.07453 per share, when and if
approved and declared by the board of directors. Through December&nbsp;31, 2018 no dividends had been approved or declared by the board of directors related to the Company&#146;s Series&nbsp;E preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(f)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Convertibility of Preferred Stock</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each share of preferred stock is convertible
at any time, at the option of the holder, into a number of shares of common stock determined by dividing the original issuance price by the conversion price, in effect at the time of conversion, as defined in the Company&#146;s Amended and Restated
Certificate of Incorporation. All shares of a series&nbsp;of preferred stock shall automatically convert into common stock upon the earlier of (a)&nbsp;the Company&#146;s initial public offering with a price to the public of at least $2.98 per share
and at least $100,000 aggregate proceeds to the Company or (b)&nbsp;the date specified by written consent of the holders of a majority of the then outstanding shares of the applicable series of preferred stock. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(9)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stockholders&#146; Deficit</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Common Stock</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company had authorized
415,000,000&nbsp;shares of common stock with a par value of $0.01 per share. Holders of common stock are entitled to one vote per share, receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, receive
a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company&#146;s preferred stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such
shares. Common stock is subordinate to preferred stock with respect to dividend rights and rights upon liquidation, winding up, and dissolution of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Non-Voting Common Stock</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company has authorized 146,199,885&nbsp;shares of
non-voting common stock with a par value of $0.01 per share. Holders of non-voting common stock are entitled to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, receive a portion of the assets
available for distributions to stockholders, subject to preferential amounts owed to holders of the Company&#146;s preferred stock. As of December 31, 2017 and 2018, no non-voting common stock was outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Non-voting common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with
respect to such shares. Non-voting common stock is subordinate to preferred stock with respect to dividend rights and rights upon liquidation, winding up, and dissolutions of the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(10)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Incentive Plan</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s stock incentive plans include the 2000 Stock Incentive Plan as amended in 2002 (the&nbsp;&#147;2002 Plan&#148;) and the Company&#146;s 2010 Stock Plan (the&nbsp;&#147;2010 Plan&#148;) (together, the &#147;Plans&#148;), and provide for
the granting of incentive stock options and nonqualified stock options. Under the 2010 Plan, stock options must be granted at an exercise price not less than 100% of the fair market value per share at the grant date. Under the 2002 Plan, incentive
stock options must be granted at an exercise price not less than 100% of the fair </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
market value per share on the grant date, but there is no minimum exercise price set for nonqualified stock options. The maximum contractual term of options granted under the Plans is
10&nbsp;years, and rights to exercise options generally vest over four years with 25% of the shares underlying the option vesting at the end of each of the first four&nbsp;years. The 2002 Plan was expired during 2010. Shares issuable under options
currently outstanding under the 2002 Plan will not be available for reissuance upon cancellation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During 2017 and 2018, 1,180,827 and
446,583 options under the Plans were exercised at a total exercise price of $1,129 and $896, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option
award is determined on the date of grant using the Black Scholes Merton <FONT STYLE="white-space:nowrap">option-pricing</FONT> model. The calculation of fair value includes several assumptions that require management&#146;s judgment. The expected
terms of options granted to employees during 2017 and 2018 were calculated using an average of historical exercises. Estimated volatility for the years ended December&nbsp;31, 2017 and 2018 incorporates a calculated volatility derived from the
historical closing prices of shares of common stock of similar entities whose share prices were publicly available for the expected term of the option. The <FONT STYLE="white-space:nowrap">risk-free</FONT> interest rate is based on the
U.S.&nbsp;Treasury constant maturities in effect at the time of grant for the expected term of the option. The Company accounts for forfeitures as they occur, as such, the Company does not estimate forfeitures at the time of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Because there has been no public market for the Company&#146;s common stock, the board of directors has estimated the price of the
Company&#146;s common stock based upon several factors, including, but not limited to, <FONT STYLE="white-space:nowrap">third-party</FONT> valuations and the Company&#146;s operating and financial performance. The
<FONT STYLE="white-space:nowrap">third-party</FONT> valuations took into consideration several factors, including prices for preferred stock that were sold to outside investors in <FONT STYLE="white-space:nowrap">arms-length</FONT> transactions, and
the rights, preferences, and privileges of the preferred stock and the common stock; the fact that the option grants involved illiquid securities in a private company; the Company&#146;s stage of development and revenue growth; the state of the
industry and the economy; the marketplace and major competitors; and the likelihood of achieving a liquidity event for the shares of common stock underlying the options, such as an initial public offering or sale of the Company, given prevailing
market conditions. These valuations were performed in accordance with the <I>American Institute of Certified Public Accountants&#146; Audit and Accounting Practice Aid, Valuation of Privately Held Company Equity Securities Issued as
Compensation.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017 and 2018, respectively; there were 655,388 and 1,334,859 additional shares available for
grant under the 2010 Plan, respectively. Following are the weighted average valuation assumptions used for options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.97</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table presents classification of stock-based compensation expense within the
consolidated statements of operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stock option activity was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term&nbsp;(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, January&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,742,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,298,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(446,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(485,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,025,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable, December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,390,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of options granted during 2017 and 2018 was $1.61 and $1.65,
respectively. The intrinsic value of options exercised during 2017 and 2018 was $2,342 and $465, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2018, there was $3,372 of unrecognized compensation cost related to unvested stock options granted under the 2010 Plan, which is expected to be recognized over a weighted average period of 2.97 years. The fair value of shares vested during 2017 and
2018 was $663 and $1,176, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(11)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net Loss Per Share Attributable to Common Stockholders</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used to compute net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,608,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,771,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as
diluted net loss per share as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive
were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,571,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,613,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares subject to outstanding common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,780,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,396,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,351,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,010,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(12)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Equity Investments</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company classifies the Nimbus investment as an equity investment within its consolidated balance sheets. The Nimbus investment was received
as compensation for collaboration services provided under a separate service agreement. During 2018, the Company made cash investments in Nimbus totaling $3,347. The Company held 7.9% and 8.0% of the issued and outstanding units of Nimbus as of
December&nbsp;31, 2017 and 2018, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company provides software used by Nimbus to pursue drug discovery activities. The
Company also has the right to designate one of nine board seats and participate via the board seat in the governance of the entity. Based upon these factors, the Company&#146;s management believes that it has significant influence over the entity
and therefore accounts for the entity as an equity method investment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company provides collaboration services for Nimbus under the
terms of a master services agreement executed on May&nbsp;18, 2010, as amended. Collaboration agreements are separate from the transaction which resulted in equity ownership and related fees are paid in cash to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under the HLBV method, the Company reported losses of $1,440 and $133 on the Nimbus investment during 2017 and 2018, respectively. The carrying
value of the investment in Nimbus was $1,073 and $4,288 as of December&nbsp;31, 2017 and 2018, respectively. The Company has no obligation to fund Nimbus losses in excess of its initial investment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2016, Nimbus entered into an agreement to sell its Nimbus Apollo, Inc. (&#147;Apollo&#148;) subsidiary to a third party for $400,000, with
future potential milestones of $800,000, and the Company received $42,780 in cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
distributions related to the Apollo sale transaction.&nbsp;In 2017, the Company received an additional $3,243 cash distribution related to the Apollo sale, which is included in gain on equity
method investments within the consolidated statements of operation.&nbsp;No cash distributions were received in 2018. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The investment in
Morphic was received as compensation for collaboration services provided under a separate service agreement with Morphic Therapeutic. During 2017 and 2018, the Company made cash investments in Morphic totaling $600 and $300, respectively. The
Company held 6.91% and 3.23% of the issued and outstanding shares of Morphic&#146;s common stock as of December&nbsp;31, 2017 and 2018, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company provides software used by Morphic to pursue drug discovery activities. The Company also had the right to designate one board seat
and participated via such board seat in the governance of Morphic prior to its initial public offering. Based upon these factors, the Company&#146;s management believes that it exercised significant influence over the entity prior to November 2018,
and therefore accounted for the entity as an equity method investment. In December 2018, Morphic reorganized and the Company determined that equity method accounting was no longer appropriate. As of December&nbsp;31, 2018, the Company accounted for
the Morphic investment as a cost basis investment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company provides collaboration services for Morphic under the terms of a
collaboration agreement that was executed on June&nbsp;10, 2015. The Company performs no collaboration services that are separate from this equity transaction for which revenue was recognized during 2017 and 2018. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under the HLBV method, the Company reported losses of $201 and $679 during 2017 and 2018, respectively, on the Morphic investment. As of
December&nbsp;31, 2017 and 2018, the carrying value of the investment in Morphic was $606 and $226, respectively. The Company has no obligation to fund Morphic losses in excess of its initial investment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes the cost method to account for its investment in Petra, as the Company owns less than 20% of outstanding stock and does
not exercise significant influence over the entity. The carrying value of the Petra investment as of December&nbsp;31, 2018 was $930. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(13)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Deferred Rent Liability</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company typically leases office space for its operations under <FONT STYLE="white-space:nowrap">long-term</FONT> operating leases. Lease
terms generally range from 3 to 10&nbsp;years, with minimum lease payments escalating during the term. For accounting purposes, rent expense is recognized on a <FONT STYLE="white-space:nowrap">straight-line</FONT> basis by dividing the total minimum
rents due during the lease term by the number of months in the lease. In the early years of a lease with escalation clauses, this treatment results in rental expense recognition in excess of rents typically paid, and the creation of a <FONT
STYLE="white-space:nowrap">long-term</FONT> deferred rent liability. As a lease matures, the deferred rent liability decreases and the rental expense recognized is less than rents actually paid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Deferred rent liability reported in the consolidated balance sheets as of 2017 and 2018 was $662 and $513, respectively. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(14)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employee Benefit Plan</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company offers a 401(k) employee savings plan to its <FONT STYLE="white-space:nowrap">U.S.-based</FONT> employees. The Company makes
discretionary matching contributions equal to 100% of the first 1.5% of compensation contributed by employees. Matching contributions during 2017 and 2018 were $425 and $489, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(15)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>D. E. Shaw</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017 and 2018, companies collectively
controlled by David E. Shaw and/or affiliates of companies controlled by David E. Shaw (&#147;D. E. Shaw entities&#148;), owned 123,314,389&nbsp;shares of the issued and outstanding Series&nbsp;A Preferred stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">During 2017 and 2018, the Company licensed technology and purchased services for $2,955 and $3,704, respectively, from D. E. Shaw entities. In
addition, D. E. Shaw entities purchased certain products and services from, and provided cost reimbursements to, the Company totaling $330 and $197 in 2017 and 2018, respectively. At December&nbsp;31, 2017 and 2018, the Company had net payables of
$787 and $1,028, respectively, to D.E. Shaw entities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Board Member</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">During 2017 and 2018, the Company paid consulting fees of $330 and
$347, respectively, to a member of the board of directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(c)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Bill&nbsp;&amp; Melinda Gates Foundation</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017 and 2018,
BMGFT owned 29,468,101&nbsp;shares, 47,242,235&nbsp;shares, and 35,946,010&nbsp;shares of issued and outstanding Series&nbsp;B, Series C, and Series D Preferred stock. As of December&nbsp;31, 2018, BMGFT owned 33,543,539 shares of issued and
outstanding Series E Preferred stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">During 2017 and 2018, the Bill&nbsp;&amp; Melinda Gates Foundation, an entity under common control
of BMGFT, issued a grant under which it agreed to pay the Company directly for certain licenses and services provided to a specified group of <FONT STYLE="white-space:nowrap">third-party</FONT> organizations. Revenue recognized for services provided
by the Company were $813 and $833 in 2017 and 2018, respectively. As of December&nbsp;31, 2017 and 2018, the Company had net receivables of $220 and $207, respectively, due from the Bill&nbsp;&amp; Melinda Gates Foundation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(d)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Nimbus</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">During 2017 and 2018, the Company recognized revenue of $166 and $1,080,
respectively, from collaboration services agreements with Nimbus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(e)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Morphic</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">During 2017 and 2018, the Company recognized revenue of $943 and $248,
respectively, from a collaboration agreement with Morphic Therapeutic. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(16)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Segment Reporting</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has determined that its chief executive officer (&#147;CEO&#148;) is its chief operating decision maker (&#147;CODM&#148;). The
Company&#146;s CEO evaluates the financial performance of the Company based on two </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
reportable segments: Software and Drug Discovery. The Software segment is focused on licensing the Company&#146;s software to transform molecular discovery. The Drug Discovery segment is focused
on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The CODM reviews segment
performance and allocates resources based upon segment revenue and segment gross profit of the Software and Drug Discovery reportable segments. Segment gross profit is derived by deducting operational expenditures, with the exception of research and
development, sales and marketing, and general and administrative activities from U.S. GAAP revenue. Operational expenditures are expenditures made that are directly attributable to the reportable segment. These expenditures are allocated to the
segments based on headcount. The reportable segment expenditures include compensation, supplies, and services from contract research organizations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Certain cost items are not allocated to the Company&#146;s reportable segments. These cost items primarily consist of compensation and general
operational expenses associated with the Company&#146;s research and development, sales and marketing, and general and administrative.&nbsp;These costs are incurred by both segments and due to the integrated nature of the Company&#146;s Software and
Drug Discovery segments, any allocation methodology would be arbitrary and provide no meaningful analysis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All segment revenue is earned
in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating
resources. Presented below is the financial information with respect to the Company&#146;s reportable segments for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Segment revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total segment revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Segment gross profit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total segment gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unallocated (expense) income:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on equity investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&#214;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;31, 2017 and 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth revenues by geographic area for the years ended
December&nbsp;31, 2017 and 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Europe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Japan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rest of World</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(17)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subsequent to year end, the Company issued 20,126,118 shares of Series E preferred stock at $1.4906 per shares for gross proceeds of $30,000.
On October&nbsp;2, 2019, the Company paid $1,823 related to a cash distribution the Company received from Nimbus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the
Company&#146;s Board of Directors and stockholders approved a one-for-7.47534 reverse stock split of the Company&#146;s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the
Company&#146;s preferred stock. All share and per share amounts in the consolidated financial statements and notes thereto have been retrospectively adjusted for all periods presented to give effect to the reverse stock split and the adjustment of
the preferred stock conversion ratios. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, which will
become effective immediately prior to the date of the effectiveness of the registration statement for the Company&#146;s initial public offering.&nbsp;The 2020 Plan authorizes the award of incentive stock options, non-qualified stock options, stock
appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares of common stock reserved for issuance under the 2020 Plan equals the sum of (i) 5,645,228 shares of common stock; plus (ii) (A)
the number of shares of common stock reserved for issuance under the 2010 Plan that remain available for grant under the 2010 Plan immediately prior to the effectiveness of the registration statement and (ii) (B) the number of shares of common stock
subject to outstanding awards granted under the 2010 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; and plus
(iii) an annual increase to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2021 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2025, by a number of
shares of common stock equal to the smallest of (A) 1.5% of the sum of (a) the outstanding shares of common stock, (b) the outstanding shares of limited common stock and (c) the outstanding stock options granted by the Company (which sum is referred
to as the &#147;outstanding equity&#148;), calculated on the last business day of the prior fiscal year or (B) the number of shares of common stock determined by the board of directors and (iv) an annual increase to be added on the first day of each
fiscal year, beginning with the fiscal year ending December 31, 2026 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2030, by a number of shares of common stock equal to the smallest of (A) 1.0% of the
outstanding equity, calculated on the last business day of the prior fiscal year or (B) the number of shares of common stock determined by the board of directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company made a cash investment in Nimbus of $2,869, which increased its ownership interest in Nimbus to 8.0% on a fully
diluted basis.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin766269_8"></A>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Consolidated Balance Sheets (Unaudited) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt"><B>Assets</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts receivable, net of allowance for doubtful accounts of $50 and $50</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Right of use assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Stock, and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued payroll, taxes and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred revenue, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Lease liabilities, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred rent, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other liabilities long-term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Commitments and contingencies (Note 4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series E convertible preferred stock, $0.01 par value. Authorized, 67,087,074 and 77,150,132
shares; 53,669,659 and 73,795,777 shares issued and outstanding; liquidation preference of $80,000 and $110,000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series D convertible preferred stock, $0.01 par value. Authorized, 39,540,611 shares; 39,540,611
shares issued and outstanding; liquidation preference of $22,000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series C convertible preferred stock, $0.01 par value. Authorized, 47,242,235 shares; 47,242,235
shares issued and outstanding, liquidation preference of $20,000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series B convertible preferred stock, $0.01 par value. Authorized, 29,468,101 shares; 29,468,101
shares issued and outstanding; liquidation preference of $10,000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series A convertible preferred stock, $0.01 par value. Authorized, 134,704,785 shares; 134,704,785
shares issued and outstanding; liquidation preference of $18,185</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Preferred stock, $0.01 par value: no shares authorized, issued or outstanding, at December&nbsp;31,
2018 and September 30, 2019; 10,000,000 shares authorized, no shares issued or outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, $0.01 par value. Authorized 415,000,000 and 425,000,000 shares; 5,906,976 and
6,071,496 shares issued and outstanding at December 31, 2018 and September 30, 2019; 500,000,000 shares authorized, 36,350,328 shares issued and outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Limited common stock, $0.01 par value per share; no shares authorized, issued or outstanding, at
December 31, 2018 and September 30, 2019; 100,000,000 shares authorized, 13,164,193 shares issued and outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated other comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total stockholders&#146; equity of Schrodinger stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total liabilities, convertible preferred stock, and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin766269_9"></A>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Consolidated Statements of Operations (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Schrodinger stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to Schrodinger common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used to compute net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,848,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,003,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,730,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,969,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to Schr&#246;dinger common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average common shares used to compute net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,465,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin766269_10"></A>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Consolidated Statements of Comprehensive Loss (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in market value of investments, net of tax:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,503</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin766269_11"></A>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#146; Deficit (Unaudited) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">paid-in</FONT></B><br><B>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>other</B><br><B>comprehensive</B><br><B>loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>stockholders&#146;</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Balance at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,460,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Change in unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Balance at March&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,670,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,973</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Change in unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Balance at June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,792,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Change in unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Balance at September&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,887,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(65,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#146; Deficit (Unaudited) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:5pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B><br><B>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Limited<BR>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">paid-in</FONT></B><br><B>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>other</B><br><B>comprehensive</B><br><B>loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>stockholders&#146;</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">53,669,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">79,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">39,540,611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">22,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">47,242,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">19,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">29,468,101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">9,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">134,704,785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">30,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">5,906,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">8,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(80,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(71,560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Change in unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Issuance of Series E preferred stock, net of issuance costs of $49</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,354,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,794</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,794</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Balance&nbsp;at March&nbsp;31,&nbsp;2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,024,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,951,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86,319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Change in unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Issuance of Series E preferred stock, net of issuance costs of $58</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,771,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Balance at June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,795,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,976,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,595</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Change in unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Balance at September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,795,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,540,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,242,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,468,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,071,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(98,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Conversion of convertible preferred stock into common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73,795,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,844,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,704,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,278,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Exchange of convertible preferred stock into limited common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,696,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,072</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,242,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,468,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,164,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:Times New Roman">Pro forma balance at September&nbsp;30,&nbsp;2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,350,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,164,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(98,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin766269_12"></A>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Consolidated Statements of Cash Flows (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash revenue from equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash rent expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash marketable securities accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease (increase) in assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll, taxes, and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,794</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from maturity of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances of Series E preferred stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contribution by noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow and noncash information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions of right of use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of use assets recognized on adoption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin766269_13"></A>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Description of Business </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Schr&ouml;dinger, Inc. (&#147;the Company&#148;) has developed a differentiated, physics-based software platform that enables discovery of
high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, the Company believes, a higher likelihood of success compared to traditional methods. The Company sells its software to
biopharmaceutical and industrial companies, academic institutions, and government laboratories. The Company also applies its computational platform to a broad pipeline of drug discovery programs in collaboration with biopharmaceutical companies,
some of which the Company <FONT STYLE="white-space:nowrap">co-founded.</FONT> In addition, the Company uses its platform to advance a pipeline of internal, wholly-owned drug discovery programs. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Recently Adopted Accounting Pronouncements </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In February 2016, the Financial
Accounting Standards Board (&#147;FASB&#148;) established Topic 842, Leases, by issuing Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> which requires lessees to recognize leases <FONT
STYLE="white-space:nowrap">on-balance</FONT> sheet and disclose key information about leasing arrangements. The new standard establishes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;)
model that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification determining the pattern and
classification of expense recognition in the income statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As issued, ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> required
transition under a modified retrospective basis as of the beginning of the earliest comparative period presented; however in July 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-11,</FONT> <I>Leases (Topic 842) Targeted
Improvements</I>, which amends ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> to provide entities an optional transition practical expedient that allows companies to adopt the new standard with a cumulative effect adjustment as of the beginning
of the year of adoption with prior year comparative financial information and disclosures remaining as previously reported. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;1, 2019, the Company adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> and its associated amendments using the modified retrospective transition method by applying the new standard to all leases existing at the date
of initial application and not restating comparative periods. There were no material cumulative effect adjustments recorded to retained earnings upon adoption. Under the standard, a lessee is required to recognize a lease liability and ROU asset for
all leases. The new guidance also modified the classification criteria and requires additional disclosures to enable users of financial statements to understand the amount, timing, and uncertainty of cash flows arising from leases. Consistent with
current guidance, a lessee&#146;s recognition, measurement, and presentation of expenses and cash flows arising from a lease continues to depend primarily on its classification. The Company elected the package of practical expedients permitted under
the transition guidance, which allowed the Company to carryforward its historical lease classification, its assessment on whether a contract was or contains a lease, and its initial direct costs for any leases that existed prior to January&nbsp;1,
2019. In addition, the Company elected the short-term lease exception as a practical expedient and to combine lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On the date of adoption, the Company derecognized a deferred rent liability in the amount of $513, and recognized a ROU asset of $16,475 and a
lease liability $18,033. As of September&nbsp;30, 2019, lease liabilities in the amount of $5,493 and $10,047 are included in lease liabilities and lease liabilities, long-term, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Basis of Presentation and Use of Estimates</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements in conformity with U.S.&nbsp;generally accepted accounting principles (&#147;U.S. GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the useful lives of long-lived assets, the recoverability of
deferred tax assets, assumptions used in the allocation of revenue, and assumptions used in testing for impairment of long-lived assets. Actual results could differ from those estimates, and such differences may be material to the condensed
consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(c)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Unaudited Interim Financial Statements</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated
balance sheet as of September&nbsp;30, 2019, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&nbsp;30, 2018 and 2019, the condensed consolidated statements of convertible
preferred stock and stockholders&#146; deficit for the three and nine months ended September&nbsp;30, 2018 and 2019, the condensed consolidated statements of cash flows for the nine months ended September&nbsp;30, 2018 and 2019, and the related
interim disclosures are unaudited. In management&#146;s opinion, the accompanying unaudited condensed financial statements have been prepared in accordance with U.S. GAAP for interim financial information. These unaudited condensed consolidated
financial statements include all adjustments necessary, consisting of only normal recurring adjustments, to fairly state the financial position and the results of the Company&#146;s operations and cash flows for interim periods in accordance with
U.S. GAAP. Interim period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying condensed consolidated financial statements should be read in conjunction with
the Company&#146;s audited consolidated financial statements and notes, which are included elsewhere in this prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(d)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Principles of Consolidation</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company&#146;s condensed consolidated financial
statements include the accounts of Schr&ouml;dinger, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The functional currency for foreign entities is the United States dollar.
The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(e)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Revenue Recognition</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Revenue is recognized upon transfer of control of promised
products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company&#146;s performance obligations are satisfied either over time or at a
point in time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The following table illustrates the timing of the Company&#146;s revenue recognition: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services &#150; point in time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software products and services &#150; over time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery &#150; point in time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery &#150; over time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Software Products and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts that can include various combinations of licenses, products and services, some of which are distinct and are
accounted for as separate performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price basis. Revenue
is recognized net of any sale and value-added taxes collected from customers and subsequently remitted to governmental authorities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s software business derives revenue from four sources: <FONT STYLE="white-space:nowrap">(i)&nbsp;on-premise</FONT> software license fees, (ii)&nbsp;hosted software subscription fees, (iii)&nbsp;software maintenance fees, and
(iv)&nbsp;professional services fees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">On-premise</FONT> software.</I>&nbsp;The Company&#146;s <FONT
STYLE="white-space:nowrap">on-premise</FONT> software license arrangements grant customers the right to use its software on their own <FONT STYLE="white-space:nowrap">in-house</FONT> servers for a specified term, typically for one year.&nbsp;The
Company recognizes revenue for <FONT STYLE="white-space:nowrap">on-premise</FONT> software license fees upfront, either upon delivery of the license or the effective date of the agreement, whichever is later. In instances where the timing of
delivery differs from the timing of its invoicing, the Company considers whether a significant financing component exists. The Company has elected the practical expedient to not assess for significant financing where the term is less than one year.
The Company&#146;s updates and upgrades are not integral to maintaining the utility of the software licenses. Payments typically are received upfront annually. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Hosted software.</I>&nbsp;Hosted software revenue consists primarily of fees to provide the Company&#146;s customers with access to its
hosted software platform and is recognized ratably over the term of the arrangement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Software maintenance.</I>&nbsp;Software
maintenance includes technical support, updates, and upgrades.&nbsp;Software maintenance revenue is considered to be a separate performance obligation and is recognized ratably over the term of the arrangement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Professional services.</I>&nbsp;Professional services, such as technical support and installation or assisting customers with modeling,
generally are not related to the functionality of the Company&#146;s software and may be recognized as resources are consumed or over the term of the arrangement, depending on the terms of the underlying agreement. The Company has historically
estimated project status with relative accuracy. A number of internal and external factors can affect such estimates, including labor rates, utilization and efficiency variances. Payments for services are due in advance or upon consumption of
resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The following table illustrates the revenue recognized from the four sources of the software
products and services revenue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">On-premise</FONT> software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hosted software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total software products and services revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Drug Discovery </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company evaluates drug discovery arrangements that are material to the financial statements to determine whether the arrangement represents
a collaborative arrangement according to Accounting Standards Codification (&#147;ASC&#148;) Topic&nbsp;808, <I>Collaborative Arrangements</I> (&#147;Topic 808&#148;). For a collaborative arrangement, the Company next determines whether it
represents a contract with a customer, and if so, fees are recorded as revenue in the Company&#146;s financial statements in accordance with the Company&#146;s revenue recognition policy. The Company evaluates the risks and rewards and activities of
the parties pursuant to the contractual arrangements. Through September 30, 2019, the Company had entered into one collaboration agreement with Morphic Therapeutic, Inc. (&#147;Morphic Therapeutic&#148;), a wholly owned subsidiary of Morphic
Holding, Inc. (&#147;Morphic&#148;) that has met the definition of a contract with a customer, and has been accounted for in accordance to ASC Topic 606, <I>Revenue from Contracts with Customers </I>(&#147;Topic&nbsp;606&#148;). The Company has
recognized revenue related to this collaboration of $0.7 million and $2.2&nbsp;million for the three and nine months ended September&nbsp;30, 2019, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Revenue from drug discovery and collaboration services contracts is recognized either over time, typically by using costs incurred or hours
expended to measure progress, or at a point in time based on the achievement of milestones. Payments for services are generally due upon achieving milestones stated in a contract, upfront at the start of a contract, or upon consumption of resources.
Services may at times include variable consideration and milestone payments. The Company has estimated the amount of consideration that is variable using the most likely amount method. The Company evaluates milestones on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, including whether there are factors outside the Company&#146;s control that could result in a significant reversal of revenue, and the likelihood and
magnitude of a potential reversal. If achievement of a milestone is not considered probable, the Company constrains (reduces) variable consideration to exclude the milestone payment until it is probable to be achieved. As of September&nbsp;30, 2018
and 2019, milestones not yet achieved that were determined to be probable of achievement totaled $700 and $1,700, respectively. For the nine months ended September&nbsp;30, 2018 and 2019, $133 and $1,391, respectively, were recognized as revenue
associated with these milestones. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Significant Judgments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Significant judgments and estimates are required under Topic&nbsp;606. Due to the complexity of certain contracts, the actual revenue
recognition treatment required under Topic 606 for the Company&#146;s arrangements may be dependent on contract-specific terms and may vary in some instances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company&#146;s contracts with customers often include promises to transfer multiple
software products and/or licenses and services, including professional services, technical support services, and rights to unspecified updates. Determining whether licenses and services are distinct performance obligations that should be accounted
for separately, or are not distinct and therefore should be accounted for together, requires significant judgment. In some arrangements, such as most of the Company&#146;s term-based software license arrangements, the Company has concluded that the
licenses and associated services are distinct from each other. In other arrangements, including collaboration services arrangements, the licenses and certain services may not be distinct from each other. The Company&#146;s time-based software
arrangements may include multiple software licenses and a right to updates or upgrades to the licensed software products, and technical support. The Company has concluded that such promised goods and services are separate distinct performance
obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company is required to estimate the total consideration expected to be received from contracts with customers, including
any variable consideration. Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is allocated to each separate performance obligation on a relative
stand-alone selling price (&#147;SSP&#148;) basis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Judgment is required to determine the SSP for each distinct performance obligation. The
Company rarely licenses or sells products on a standalone basis, so the Company is required to estimate the range of SSPs for each performance obligation. In instances where the SSP is not directly observable because the Company does not sell the
license, product, or service separately, the Company determines the SSP using information that includes historical discounting practices, market conditions, cost-plus analysis, and other observable inputs. The Company typically has more than one SSP
for individual performance obligations due to the stratification of those items by classes of customers and circumstances. In these instances, the Company may use information such as the size and geographic region of the customer in determining the
SSP. Professional service revenue is recognized as costs and hours are incurred, judgement is required in estimating project status and the costs incurred or hours expended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If a group of agreements are so closely related to each other that they are, in effect, part of a single arrangement, such agreements are
deemed to be one arrangement for revenue recognition purposes. The Company exercises significant judgment to evaluate the relevant facts and circumstances in determining whether the separate agreements should be accounted for separately or as, in
substance, a single arrangement. The Company&#146;s judgments about whether a group of contracts comprises a single arrangement can affect the allocation of consideration to the distinct performance obligations, which could have an effect on results
of operations for the periods involved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Generally, the Company has not experienced significant returns or refunds to customers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company&#146;s estimates related to revenue recognition require significant judgment and the change in these estimates could have an effect
on the Company&#146;s results of operations during the periods involved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Contract Balances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition may differ from the timing of invoicing to customers and these timing differences result in receivables,
contract assets, or contract liabilities (deferred revenue) on the condensed consolidated balance sheets. The Company records a contract asset when revenue is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
recognized prior to invoicing; a deferred revenue liability is recorded when revenue is expected to be recognized subsequent to invoicing. For the Company&#146;s time-based software agreements,
customers are generally invoiced at the beginning of the arrangement for the entire term, though when the term spans multiple years the customers may be invoiced on an annual basis. For certain drug discovery agreements that include payment plans,
the Company records a receivable related to revenue recognized upon delivery because it has an unconditional right to invoice and receive payment in the future related to those deliveries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Contract assets are presented as other receivables within the condensed consolidated balance sheets and primarily relate to the Company&#146;s
rights to consideration for work completed but not billed on service contracts. Contract assets are transferred to receivables when the Company invoices the customer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Contract balances were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of</B><br><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of</B><br><B>September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&nbsp;30, 2018 and 2019, respectively, the Company recognized
$6,300, $10,438, $10,333 and $16,171 of revenue that was included in deferred revenue at the end of the preceding period. All other deferred revenue activity is due to the timing of invoices in relation to the timing of revenue, as described above.
The Company expects to recognize as revenue approximately 88% of its September&nbsp;30, 2019 deferred revenue balance in the next 12 months and the remainder thereafter. Additionally, contracted but unsatisfied performance obligations that had not
yet been billed to the customer or included in deferred revenue were $14,632 as of September&nbsp;30, 2019. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Payment terms and conditions
vary by contract type, although terms typically require payment within 30 to 60 days. In instances where the timing of revenue recognition differs from that of invoicing, the Company has determined that its contracts generally do not include a
significant financing component. The primary purpose of invoicing terms is to provide customers with simplified and predictable ways of purchasing the Company&#146;s products and services, not to facilitate financing arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Deferred Sales Commissions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company has applied the practical expedient for sales commission expense, as any compensation paid to sales representatives to obtain a
contract relates to a period of one year or less. Therefore, the Company has not capitalized any costs related to sales commissions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(f)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Concentrations of Credit Risk</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the
Company to concentrations of credit risk consist primarily of trade receivables. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company does not require customers to provide
collateral to support accounts receivable. If deemed necessary, credit reviews of significant customers may be performed prior to extending credit. The determination of a customer&#146;s ability to pay requires judgment, and failure to collect from
a customer can adversely affect revenue, cash, and net income. The Company maintains an allowance for doubtful accounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, one customer accounted for 42% of total accounts receivable.
As of December&nbsp;31, 2018, one customer accounted for 18% of total accounts receivable. For the three and nine months ended September&nbsp;30, 2018, no customer accounted for more than 10% of total revenues. For the three months ended
September&nbsp;30, 2019, one customer accounted for 10% of revenues. For the nine months ended September&nbsp;30, 2019, no customer accounted for more than 10% of total revenues. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(g)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Income Taxes</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company records deferred tax assets and liabilities for the
expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more
likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company recognizes the effect of income tax positions only if such positions are deemed &#147;more likely than not&#148; capable of being
sustained. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B><I>(h)</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Equity Investments </I></B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company has entered into collaboration agreements with Nimbus Therapeutics, LLC (&#147;Nimbus&#148;), Morphic Therapeutic, and Petra Pharma
Corporation (&#147;Petra&#148;) to perform drug design services in exchange for minority ownership, which are included within equity investments in the Company&#146;s condensed consolidated balance sheets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company has concluded that the carrying value of its equity investment in Nimbus should reflect its contractual rights to substantive
profits. The Company further determined that the hypothetical liquidation at book value method (&#147;HLBV method&#148;) for valuing contractual rights to substantive profits provides the best representation of its financial position in Nimbus.
During 2019, the Company continued to value Nimbus using the HLBV method. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The HLBV method is a balance sheet oriented approach to equity
method accounting. Under the HLBV method, the Company determines its share of earnings or losses by comparing its claim on the book value at the beginning and end of each reporting period. This claim is calculated as the amount that the Company
would receive (or be obligated to pay) if the investee were to liquidate all of its assets at recorded amounts, determined as of the balance sheet date in accordance with generally accepted accounting principles, and distribute the resulting cash to
creditors and investors in accordance with their respective priorities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Upon the completion of Morphic&#146;s initial public offering, the
Company changed the valuation methodology used to value the Morphic investment. As there is a readily available market price per share, the Company values its investment based on Morphic&#146;s common stock price as of the reporting date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company has concluded that its equity investment in Petra should be valued using the historical cost method, as the Company does not
exercise significant influence over Petra. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For further information regarding the Company&#146;s equity investments, see Note 3, Fair Value
Measurements and Note 10, Equity Investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(i)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Net Loss Per Share Attributable to Common Stockholders</I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company calculates
basic and diluted net loss per share attributable to common stockholders in conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for companies with participating securities. The Company considers its convertible
preferred stock to be participating securities. In the event a dividend is declared or paid on common stock, holders of convertible preferred stock are entitled to a share of such dividend in proportion to the holders of common stock on an <FONT
STYLE="white-space:nowrap">as-if</FONT> converted basis. Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common
stockholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock
equivalents outstanding for the period determined using the treasury stock method. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the <FONT STYLE="white-space:nowrap">two-class</FONT>
method as the convertible preferred stock does not have a contractual obligation to share in the Company&#146;s losses. For purposes of this calculation, convertible preferred stock and stock options are considered common stock equivalents but have
been excluded from the calculation of net loss per share attributable to common stockholders as their effect is anti-dilutive. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(j)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Accounting Pronouncements Not Yet Adopted </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In November 2018, the FASB issued ASU
2018-18 (&#147;ASU 2018-18&#148;), <I>Collaborative Arrangements</I> (Topic 808) clarifying the interaction between Topic 808 and Topic 606. ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should
be accounted for under Topic 606 when the counterparty is a customer. The guidance precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is
not a customer for that transaction. The guidance amends Topic 808 to refer to the unit-of-account guidance in Topic 606 and requires it to be used only when assessing whether a transaction is in the scope of Topic 606. The guidance will be
effective for the Company for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021 and has to be adopted using retrospective approach. The Company is currently evaluating the impact
of ASU 2018-18 on the consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(k)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Pro forma financial information (unaudited) </I></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Upon the completion of the
Company&#146;s initial public offering, all of the Company&#146;s outstanding shares of convertible preferred stock will automatically convert into shares of common stock. The accompanying unaudited pro forma consolidated balance sheet and
consolidated statements of convertible preferred stock and stockholders&#146; deficit as of September&nbsp;30, 2019 have been prepared to give effect to the automatic conversion of 226,344,686 shares of convertible preferred stock into 30,278,832
shares of common stock and the issuance of 13,164,193 shares of limited common stock in exchange for 98,406,823 shares of common stock, in each case at the closing of the initial public offering. The shares of common stock issuable in the initial
public offering and the proceeds expected to be received in the initial public offering are excluded from such pro forma financial information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share in the accompanying consolidated
statements of operations and comprehensive loss for the year ended December&nbsp;31, 2018 and the nine months ended September&nbsp;30, 2019 have been computed to give effect to the automatic conversion of 226,344,686 shares of convertible preferred
stock into 30,278,832 shares of common stock and the issuance of 13,164,193 shares of limited common stock in exchange for 98,406,823 shares of convertible preferred stock, in each case at the closing of the initial public offering. The unaudited
pro forma basic and diluted net loss per share for the year ended December&nbsp;31, 2018 and the nine months ended September&nbsp;30, 2019 was computed using the weighted average number of shares of common stock outstanding, including the pro forma
effect of the conversion of all outstanding shares of convertible preferred stock into shares of common stock and the conversion of all outstanding shares of limited common stock into shares of common stock, as if the Company&#146;s proposed initial
public offering had occurred on the later of January&nbsp;1, 2019 or the original issuance dates of the convertible preferred units or convertible preferred stock. The unaudited pro forma net loss per share does not include the shares expected to be
sold or related proceeds expected to be received in the proposed initial public offering. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(3)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Various inputs are used in determining the fair value of the Company&#146;s financial assets and liabilities. These inputs are summarized into
the following three broad categories: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 &#150; quoted prices in active markets for identical securities </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 &#150; other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk, etc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 &#150; significant unobservable inputs, including the Company&#146;s own assumptions in determining fair value </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those
securities. Marketable securities are classified as available for sale and fair value does not differ significantly from carrying value as of December&nbsp;31, 2018 and September&nbsp;30, 2019. The following table presents information about the
Company&#146;s assets and liabilities measured at fair value as of December&nbsp;31, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s assets and liabilities
measured at fair value as of September&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Fair value of the Company&#146;s investment in Morphic, classified as Level&nbsp;1 in the fair value
hierarchy, was determined using the market price of Morphic&#146;s common stock as of the close of trading on September 30, 2019. Under the terms of Morphic&#146;s initial public offering, the Company is restricted from selling its shares until 180
days from the offering date, or December&nbsp;24, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value of the Company&#146;s investment in Nimbus, classified as Level&nbsp;3 in the fair
value hierarchy, was determined under the HLBV method, as further described in Note 2, Significant Accounting Policies. Significant unobservable inputs used under the HLBV method include Nimbus&#146; annual financial statements and the
Company&#146;s respective liquidation priority. The following table sets forth changes in fair value of the Company&#146;s Level&nbsp;3 investments: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unrealized losses arising from changes in fair value of the Company&#146;s equity investments are classified within change in
fair value in the condensed consolidated statements of operations. During the year ended December&nbsp;31, 2018 and the nine months ended September&nbsp;30, 2019, there were no transfers between Level&nbsp;1, Level&nbsp;2 and Level&nbsp;3
investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(4)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and Contingencies </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Leases </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company leases office space under operating leases that expire at
various dates through 2029. In addition to rent expense, the Company pays real property taxes, insurance, and repair and maintenance expenses for its office facilities. The Company recognizes rent expense on a straight-line basis over the life of
the related lease, including any periods of free rent. The Company&#146;s rent expense was $1,164, $3,508, $1,388, and $3,796 for the three and nine months ended September&nbsp;30, 2018 and 2019, respectively. The variable and short term lease costs
were immaterial for the nine-month period ended September&nbsp;30, 2019. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company adopted Topic 842 as of January&nbsp;1, 2019. In
determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. At the date of adoption
of Topic 842, the Company determined lease liability amounts using a discount rate of 5.01%, which represents the Company&#146;s incremental borrowing rate. The Company determines its incremental borrowing rate for lease liability using its current
borrowing rate, adjusted for various factors including level of collateralization and lease term. Cash paid for operating lease liabilities, included in cash flow from operating activities in the condensed consolidated statements of cash flows, was
$3,761 for the nine-month period ended September&nbsp;30, 2019. As of September&nbsp;30, 2019, the remaining weighted average lease term was 4 years. Three leases expire in January 2020 with the option to extend through August 2020. The company has
concluded that these leases are likely to be extended and have included the extension terms in the calculation of the lease liability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2019, the Company entered into two new leases, which increased ROU assets and lease liabilities
by $464. ROU assets and lease liabilities were equal as no lease costs or incentives were associated with acquiring the leases. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Future
minimum lease payments as of December&nbsp;31, 2018 under noncancelable operating leases were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ending December 31:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments as of September&nbsp;30, 2019 under noncancelable operating
leases were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ending September 30:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remainder of 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Legal Matters </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in routine
litigation arising in the ordinary course of business. While the results of such litigation cannot be predicted with certainty, management believes that the final outcome of such matters is not likely to have a material adverse effect on the
Company&#146;s financial position or results of operations or cash flows. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(5)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company estimates an annual effective income tax rate based on projected results for the year and applies this rate to income before taxes
to calculate income tax expense. Any refinements made due to subsequent information that affects the estimated annual effective income tax rate are reflected as adjustments in the current period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2019, the difference between the effective rate and the statutory rate is primarily attributed to
the change in the valuation allowance against net deferred tax assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&nbsp;30, 2019, the
Company&#146;s tax benefit was $257 and $262, respectively. The Company recognizes the effect of income tax positions only if those positions are &#147;more likely than not&#148; of being sustained. As of September&nbsp;30, 2019, the Company had
$865 of unrecognized tax benefits. Interest and penalties accrued on unrecognized tax benefits are recorded as tax expense within the consolidated financial statements. The Company does not expect a significant increase or decrease to the total
amounts of unrecognized tax benefits within the next twelve months. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company and its subsidiaries file&nbsp;U.S. federal income tax
returns and various state, local and foreign income tax returns. At September&nbsp;30, 2019, the Company&#146;s statues of limitations are open for all federal and state years filed after the years ended December&nbsp;31, 2014 and 2013,
respectively.&nbsp;Net operating loss and credit carryforwards from all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under Internal
Revenue Service or state examination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Internal Revenue Code Sections 382 and 383, the utilization of net operating
losses and other tax attributes may be substantially limited due to cumulative changes in ownership greater than 50% that may have occurred or could occur during applicable testing periods. The Company has performed an analysis through
September&nbsp;30, 2019 and determined that such an ownership change has not occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Tax Cuts and Jobs Act (the &#147;Tax Act&#148;)
was enacted on December&nbsp;22, 2017. The Tax Act reduced the U.S. federal corporate tax rate from 35% to 21%, required companies to pay a <FONT STYLE="white-space:nowrap">one-time</FONT> transition tax on earnings of certain foreign subsidiaries
that were previously deferred, and created new taxes on certain foreign sourced earnings. The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally
21%. The impact was offset with the change in valuation allowance. In addition, the Company recorded a receivable related to alternative minimum tax credits of $26 in 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(6)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Convertible Preferred Stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Holders of outstanding shares of preferred stock do not have stated redemption rights; however, the rights and preferences of preferred stock
provide for a deemed liquidation of the shares in the event of a sale of all or substantially all of the Company&#146;s assets, the merger of the Company, or upon the sale of more than a majority of the voting power of the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Series E Convertible Preferred Stock (&#147;Series E Preferred Stock&#148;) </I></B> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2019, the Company issued 20,126,118 shares of Series E preferred stock for gross proceeds of
$30,000. As of September&nbsp;30, 2019, 73,795,777 shares of Series E preferred stock were outstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In a liquidation event, excluding
a public offering, holders of Series E preferred stock are entitled to receive (i)&nbsp;prior to any distribution to combined common stockholders and holders of Series A, Series B, Series C and Series D preferred stock, an amount equal to $1.4906
per share, plus any declared and unpaid dividends and (ii)&nbsp;following payment of all preferential amounts required to be paid to the holders of preferred stock, a portion of any proceeds remaining for distribution to preferred and combined
common stockholders, pro rata based on the number of shares held by each such holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Holders of Series&nbsp;E preferred stock are
entitled to receive noncumulative dividends at a rate of $0.07453 per share, when and if approved and declared by the board of directors. Through September&nbsp;30, 2019, no dividends had been approved or declared by the board of directors related
to the Company&#146;s Series&nbsp;E preferred stock. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Convertibility of Series A Preferred Stock </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each share of preferred stock is
convertible at any time, at the option of the holder, into a number of shares of common stock determined by dividing the original issuance price by the conversion price in effect at the time of the conversion, as defined in the Company&#146;s
Amended and Restated Certificate of Incorporation. All shares of a series&nbsp;of preferred stock shall automatically convert into common stock upon the earlier of (a)&nbsp;the Company&#146;s initial public offering with a price to the public of at
least $2.98 per share and at least $100,000 aggregate proceeds to the Company or (b)&nbsp;the date specified by written consent of the holders of a majority of the then outstanding shares of the applicable series of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(7)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stockholders&#146; Deficit </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Common Stock </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, the Company had authorized
425,000,000&nbsp;shares of common stock with a par value of $0.01 per share. Holders of common stock are entitled to one vote per share, receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, receive
a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company&#146;s preferred stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such
shares. Common stock is subordinate to preferred stock with respect to dividend rights and rights upon liquidation, winding up, and dissolution of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I><FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company has
authorized 146,199,885&nbsp;shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock with a par value of $0.01 per share. Holders of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are entitled to receive dividends,
if and when declared by the board of directors, and upon liquidation or dissolution, receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company&#146;s preferred stock.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-voting</FONT> common stockholders have no preemptive or other subscription rights and there are no
redemption or sinking fund provisions with respect to such shares. <FONT STYLE="white-space:nowrap">Non-voting</FONT> common stock is subordinate to preferred stock with respect to dividend rights and rights upon liquidation, winding up, and
dissolution of the Company. As of September&nbsp;30, 2019 and 2018, no <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock was outstanding. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(8)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stock-Based Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Incentive Plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s 2010 Stock Plan (the (&#147;2010 Plan&#148;) provides for the granting of incentive stock options and nonqualified stock options. Under the 2010 Plan, stock options must be granted at an exercise price not less than 100% of the fair
market value per share at the grant date. The maximum contractual term of options granted under the 2010 Plan is 10 years, and rights to exercise options generally vest over four years with 25% of the shares underlying the option vesting at the end
of the first year and ratably over the following three years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2018 and 2019, 427,509 and
164,520 stock options were exercised at a total exercise price of $864 and $425, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is
determined on the date of grant using the Black Scholes Merton option-pricing model. The calculation of fair value includes several assumptions that require management&#146;s judgment. The expected terms of options granted to employees during 2018
and 2019 were calculated using an average of historical exercises. Estimated volatility for the nine months ended September&nbsp;30, 2018 and 2019 incorporates a calculated volatility derived from the historical closing prices of shares of common
stock of similar entities whose share prices were publicly available for the expected term of the option. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
risk free interest rate is based on the U.S. Treasury constant maturities in effect at the time of grant for the expected term of the option. The Company accounts for forfeitures as they occur,
as such, the Company does not estimate forfeitures at the time of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Because there has been no public market for the Company&#146;s
common stock, the board of directors has estimated the price of the Company&#146;s common stock based upon several factors, including, but not limited to, third party valuations and the Company&#146;s operating and financial performance. The third
party valuations took into consideration several factors, including prices for preferred stock that were sold to outside investors in arm&#146;s length transactions, and the rights, preferences, and privileges of the preferred stock and the common
stock; the fact that the option grants involved illiquid securities in a private company; the Company&#146;s stage of development and revenue growth; the state of the industry and the economy; the marketplace and major competitors; and the
likelihood of achieving a liquidity event for the shares of common stock underlying the options, such as an initial public offering or sale of the Company, given prevailing market conditions. These valuations were performed in accordance with the
<I>American Institute of Certified Public Accountants&#146; Audit and Accounting Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2018 and 2019, there were 849,911 and 330,716 additional shares available for grant under the 2010 Plan, respectively.
Following are the weighted average valuation assumptions used for options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation assumptions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table presents classification of stock-based compensation expense within the condensed
consolidated statements of operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of options granted during the nine months ended September&nbsp;30,
2018 and 2019 was $1.72 and $2.55, respectively. The intrinsic value of options exercised during the nine months ended September&nbsp;30, 2018 and 2019 was $414 and $373, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, there was $5,229 of unrecognized compensation cost related to unvested stock options granted under the 2010
Plan, which is expected to be recognized over a weighted average period of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
2.93 years. The fair value of shares vested during the nine months ended September&nbsp;30, 2018 and 2019 was $1,075 and $1,112, respectively. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(9)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net Loss Per Share Attributable to Common Stockholders </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table presents the calculation of basic and diluted net loss per share attributable to common stockholders for the periods
presented (in thousands, except per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used to compute net loss per share attributable to common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,848,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,003,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,730,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,969,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as
diluted net loss per share as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive
were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,571,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,443,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,571,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,496,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued and outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,165,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,918,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,392,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,775,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,736,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,361,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,963,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,272,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(10)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Equity Investments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company classifies the Nimbus investment as an equity investment within the condensed consolidated balance sheets. The Nimbus investment
was received as compensation for collaboration services provided under a separate service agreement. The Company held 8.0% and 7.6% of the issued and outstanding units of Nimbus as of December&nbsp;31, 2018 and September&nbsp;30, 2019, respectively.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company also has the right to designate one of nine board seats, provide software used by Nimbus to pursue drug discovery activities,
and participate via the board seat in the governance of the entity. Based upon these factors, the Company&#146;s management believes that it has significant influence over the entity and therefore accounts for the entity as an equity method
investment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company provides collaboration services for Nimbus under the terms of a master services agreement executed on May&nbsp;18,
2010, as amended. Collaboration agreements are separate from the transaction which resulted in equity ownership and related fees are paid in cash to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under the HLBV method, the Company reported losses of $853, $2,191, zero, and $4,288, on the
Nimbus investment for the three and nine months ended September&nbsp;30, 2018 and 2019, respectively. The carrying value of the Nimbus investment was $4,288 and zero as of December&nbsp;31, 2018 and September&nbsp;30, 2019, respectively. The Company
has no obligation to fund Nimbus losses in excess of its initial investment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In June 2019, Morphic successfully completed an initial
public offering. The Company accounts for its investment in Morphic at fair value based on the share price of Morphic&#146;s common stock at the measurement date. The Company held 3.23% and 2.74% of the issued and outstanding shares of
Morphic&#146;s common stock as of December&nbsp;31, 2018 and September&nbsp;30, 2019, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Prior to December 2018, the Company
valued its investment in Morphic using the HLBV method. The Company reported losses of $198 and $483 during the three and nine months ended September 30, 2018, respectively. The Company reported a loss of $1,428 for the three months ended
September&nbsp;30, 2019 and gain of $14,895 for the nine months ended September&nbsp;30, 2019. As of December&nbsp;31, 2018 and September&nbsp;30, 2019, the carrying value of the investment in Morphic was $226 and $15,121, respectively. The Company
has no obligation to fund Morphic losses in excess of its initial investment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2018, the Company adopted ASU <FONT
STYLE="white-space:nowrap">2016-01,</FONT> Recognition and Measurement of Financial Assets and Liabilities, whereby the carrying values of its <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities are adjusted based on price
changes from observable transactions of identical or similar securities of the same issuer or for impairment (referred to as the measurement alternative). Any changes in carrying value are classified within other (expense) income in
the&nbsp;condensed consolidated statements of operations. As of December&nbsp;31, 2018 and September&nbsp;30, 2019, the carrying value of <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities was $930. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(11)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(a)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>D. E. Shaw </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, companies collectively controlled by
David E. Shaw and/or affiliates of companies controlled by David E. Shaw (&#147;D. E. Shaw entities&#148;) owned 123,314,389 shares of the issued and outstanding Series&nbsp;A Preferred stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&nbsp;30, 2018 and 2019, the Company licensed technology and purchased services for $859, $2,948,
$884, and $3,651, respectively, from D. E. Shaw entities. In addition, D. E. Shaw entities purchased certain products and services from, and provided cost reimbursements to, the Company totaling $128, $137, $179, and $173 for the three and nine
months ended September&nbsp;30, 2018 and 2019, respectively. At December&nbsp;31, 2018 and September&nbsp;30, 2019, the Company had net payables of $1,028 and $1,323, respectively, to D.E. Shaw entities. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(b)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Board Member </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&nbsp;30, 2018 and
2019, the Company paid consulting fees of $87, $260, $87, and $260, respectively, to a member of the board of directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(c)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Bill and Melinda Gates Foundation </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018 and
September&nbsp;30, 2019, the Bill and Melinda Gates Foundation Trust (&#147;BMGFT&#148;) owned 29,468,101 shares, 47,242,235 shares, and 35,946,010 shares of issued and outstanding Series B, Series C, and Series D Preferred stock, respectively. As
of September&nbsp;30, 2019, BMGFT owned 33,543,539 shares of issued and outstanding Series E Preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&nbsp;30, 2018 and 2019, the Bill&nbsp;&amp;
Melinda Gates Foundation, an entity under common control with BMGFT, issued a grant under which it agreed to pay the Company directly for certain licenses and services provided to a specified group of third party organizations. Revenue recognized
for services provided by the Company were $227, $471, $101, and $846 for the three and nine months ended September&nbsp;30, 2018 and 2019, respectively. As of December&nbsp;31, 2018 and September&nbsp;30, 2019, the Company had net receivables of
$207 and $86, respectively, due from the Bill&nbsp;&amp; Melinda Gates Foundation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><B><I>(d)</I></B></TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Nimbus </I></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&nbsp;30, 2018 and 2019,
the Company recognized revenue of $91, $149, $311, and $991, respectively, from collaboration services agreements with Nimbus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(12)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Segment Reporting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has determined that its chief executive officer (&#147;CEO&#148;) is its chief operating decision maker (&#147;CODM&#148;). The
Company&#146;s CEO evaluates the financial performance of the Company based on two reportable segments: Software and Drug Discovery. The Software segment is focused on licensing the Company&#146;s software to transform molecular discovery. The Drug
Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
CODM reviews segment performance and allocates resources based upon segment revenue and segment gross profit of the Software and Drug Discovery reportable segments. Segment gross profit is derived by deducting operational expenditures, with the
exception of research and development, sales and marketing, and general and administrative activities from U.S. GAAP revenue. Operational expenditures are expenditures made that are directly attributable to the reportable segment. These expenditures
are allocated to the segments based on headcount. The reportable segment expenditures include compensation, supplies, and services from contract research organizations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Certain cost items are not allocated to the Company&#146;s reportable segments. These cost items primarily consist of compensation and general
operational expenses associated with the Company&#146;s research and development, sales and marketing, and general and administrative.&nbsp;These costs are incurred by both segments and due to the integrated nature of the Company&#146;s Software and
Drug Discovery segments, any allocation methodology would be arbitrary and provide no meaningful analysis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All segment revenue is earned in the United States and there are no intersegment revenues.
Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is the financial information with respect
to the Company&#146;s reportable segments for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Segment revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total segment revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Segment gross profit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug discovery</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total segment gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unallocated (expense) income:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,621</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth revenues by geographic area for the three and nine months ended
September&nbsp;30, 2018 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Europe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Japan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rest of World</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company&#146;s Board of Directors and stockholders approved a one-for-7.47534 reverse stock split of the Company&#146;s
issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company&#146;s preferred stock. All share and per share amounts in the consolidated financial statements and notes thereto have
been retrospectively adjusted for all periods presented to give effect to the reverse stock split and the adjustment of the preferred stock conversion ratios. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHR&Ouml;DINGER, INC. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Condensed Consolidated Financial Statements (Unaudited) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the three and nine-month periods ended September&nbsp;30, 2018 and 2019 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company adopted the 2020 Equity Incentive Plan, or the 2020 Plan, which
will become effective immediately prior to the date of the effectiveness of the registration statement for the Company&#146;s initial public offering.&nbsp;The 2020 Plan authorizes the award of incentive stock options, non-qualified stock options,
stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares of common stock reserved for issuance under the 2020 Plan equals the sum of (i)&nbsp;5,645,228 shares of common stock;
plus (ii)&nbsp;(A) the number of shares of common stock reserved for issuance under the 2010 Plan that remain available for grant under the 2010 Plan immediately prior to the effectiveness of the registration statement and (ii)&nbsp;(B) the number
of shares of common stock subject to outstanding awards granted under the 2010 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by the Company at their original issuance price pursuant to a contractual
repurchase right; and plus (iii)&nbsp;an annual increase to be added on the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2021 and continuing for each fiscal year until, and including, the fiscal year ending
December&nbsp;31, 2025, by a number of shares of common stock equal to the smallest of (A)&nbsp;1.5% of the sum of (a) the outstanding shares of common stock, (b) the outstanding shares of limited common stock and (c)&nbsp;the outstanding stock
options granted by the Company (which sum is referred to as the &#147;outstanding equity&#148;), calculated on the last business day of the prior fiscal year or (B)&nbsp;the number of shares of common stock determined by the board of directors and
(iv)&nbsp;an annual increase to be added on the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2026 and continuing for each fiscal year until, and including, the fiscal year ending December&nbsp;31, 2030, by a
number of shares of common stock equal to the smallest of (A)&nbsp;1.0% of the outstanding equity, calculated on the last business day of the prior fiscal year or (B)&nbsp;the number of shares of common stock determined by the board of directors.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company made a cash investment in Nimbus of $2,869, which increased its ownership interest in Nimbus to 8.0% on a
fully diluted basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>11,882,352 Shares </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g766269g17h96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Common Stock </I></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Prospectus
</I></B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>MORGAN STANLEY </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>BofA
SECURITIES </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>JEFFERIES </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>BMO CAPITAL MARKETS </I></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until March 1, 2020 (25&nbsp;days after the date of this prospectus), all dealers that effect transactions
in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with
respect to their unsold allotments or subscriptions. </I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g766269g12k92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g12k92.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1H64&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      $#    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    0 $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,@ S
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #P     $  0/      0 !.$))300F
M   .             #^    X0DE-! T       0    >.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             #Z@  !V,          0                         !
M              =C   #Z@                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #Z@    !29VAT;&]N9P  !V,    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M ^H     4F=H=&QO;F<   =C     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !5 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M=Q),D@_:\;_2M^]+[7C?Z5OWH^Y#]Z/VHX)?NG[$R2KOS\)CRQ][&O:8<TD
MA-^TNG_]R*_\X(>]C'Z<?\8)]N?[LOL;*2K?M+I__<BO_."7[2Z?_P!R*_\
M."'O8O\ .1_QHJ]K)^Y+["G>7-8YS6[W $M;,2?W9*YMV'UNS:7]/?+XL=_E
M2V&$$?HOYG\R=_L_<_G%N_M+I_\ W(K_ ,X(S;JG5>LU[35&[?/MCQW)T<D)
M?+*,O(V@PD-XD>8>=;@]7926-PGNEVQ[?VE<!MK]-U=E#]GT+?TM+ZG,K]E2
MTNDU9=.);3DXWV8-)-8^T.R2[=JXE]K*W5^[\Q'Z;EUY-3RU]3W-L?(I?O :
MYSG5%QAON?7[U:L_FW? H@@BP;'@@@@T11[%_]'U"BEU6XN>7EYDDZ?<HW@D
M. $G;P/BBNLK88<X F-/B=K?^DA9-E=;39;M#*VESG$$P/[*'!Z>$7KIWW29
MZ\1Z:]MFMZ5O[CON5>[#SGWUV57OIK9&^D5M<'07;I<[WMW-=M1?VITS_2-_
MS'_^12_:G3/](S7N6/C_ *E,^Y2[3_Q5'G,?[\/\8--G3NLL:&_;G. C5U#7
M'S]SG[G(V-B=2K>3D7?:&$: 5"LAT_R)]K6)7_6#HF/<^BZX,MK.U[35;(//
M^C]S7-]S'_GL4#]9OJ^*K+OM#375M]0BJTEH<=K7N8*]_I[O9ZO\W]#_ $B/
MW.9'RRU_J?V)^\POYH_XS<]&TZ;#KXC1!NJM>^6U/,:%Q!EQ_>A4_P#GC]5O
M^Y;?^V;O_227_/+ZK'C+:?']#=_Z20E\/R$5PY/\1(YW&#?%#_&36XN4^MS6
M!];R/;8&R1Y[7>U5QT[JX 'VE[M' DTMDS.QT@_F2M'IG5>E]6%AZ?;7?Z1
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M+#+'-_=W6-8_Z/T%L"_JIV@XM8EP#G^K, _3LV;/S6_F[U=20XA^Z/\ G?\
M?)H]RT3E=5'_ &A;$P(N'$Q/\VK=1>ZMCK&[+"T%[ =P!CW-W:;MJFD@2#T
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MW['3$1KROEE))3__V3A"24T$(0      50    $!    #P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O
M ', : !O '  ( !# %, -@    $ .$))300B      $N34T *@    @ !P$2
M  ,    !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (
M  $Q  (    >    <@$R  (    4    D(=I  0    !    I    -  +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HQ,#HR.2 Q.3HT-CHP,0   Z !  ,    !__\  * "  0    !   '8Z #
M  0    !   #Z@         & 0,  P    $ !@   1H !0    $   $> 1L
M!0    $   $F 2@  P    $  @   @$ !     $   $N @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 3!-
M30 J    "  ' 1(  P    $      1H !0    $   !B 1L !0    $   !J
M 2@  P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $
M  "D    T    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$Y.C$P.C(Y(#$Y.C0V.C Q   #H $  P    '__P  H (
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M\!V7R]-//$_^-HB> [+Y>FGGB?\ QM$3P'9?+TT\\3_XVB)X#LOEZ:>>)_\
M&T1/ =E\O33SQ/\ XVB)X#LOEZ:>>)_\;1$\!V7R]-//$_\ C:(G@.R^7IIY
MXG_QM$3P'9?+TT\\3_XVB)X#LOEZ:>>)_P#&T1/ =E\O33SQ/_C:(G@.R^7I
MIYXG_P ;1$\!V7R]-//$_P#C:(G@.R^7IIYXG_QM$3P'9?+TT\\3_P"-HB>
M[+Y>FGGB?_&T1/ =E\O33SQ/_C:(G@.R^7IIYXG_ ,;1$\!V7R]-//$_^-HB
M> [+Y>FGGB?_ !M$3P'9?+TT\\3_ .-HB> [+Y>FGGB?_&T1/ =E\O33SQ/_
M (VB)X#LOEZ:>>)_\;1$\!V7R]-//$_^-HB> [+Y>FGGB?\ QM$3P'9?+TT\
M\3_XVB)X#LOEZ:>>)_\ &T1/ =E\O33SQ/\ XVB)X#LOEZ:>>)_\;1$\!V7R
M]-//$_\ C:(G@.R^7IIYXG_QM$3P'9?+TT\\3_XVB)X#LOEZ:>>)_P#&T1/
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MMZ:BDLN[&M1I%M:V5R9$[GXA\!.3#:&SF,L.0N^N $L&0['8$SU^=BOCQV%
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M8)(=@/I!&6R\EC*325DX\]-6*1YK%UB()[F]P<"$A-L6#EO9--.]E;T:5 E
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M9&8'?XCBBY&CVL[JR!NC]+AF<;'"=2ZU&#X<%F4;B3!A"(TT9QB.[%<-7FP
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M#1OVW/K$4E&\2^+8;::F\1''+1XS<RI9V>RVJQU9"6NPK'2,=?Q$D:3EZ(7
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MX@2CF-@1&XM=P+-6%FAQ[A]78W^'<NH$RS6[ *);N;?KRS0LVCM0>J;0HE)
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M4=G/<RF.P IL?7.JH"4DKOD^QF Q?84R%IZ]+:1X]Q[=T'C1I[.M>P]B]/;
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MSO2I!9D>B&#ILDV#179QB-+QNXQTHX48C;KV8D&2ZKIPX?.<'JKA?/.^*#7
M/0[R$%_9P*5KBG'<O4/Z-[1*^KQ^)P##G8?-=#&)C>I&D65:DY/5K=4DSE-9
M-"T0I).\1@S;THX9J65M6J_)-S1S0\[K0/G;4@EF6]L<3H:L-3UH,11L6F&Y
MZQQQ$(=<,J\!CBW<0^<%=*K02@,R_/NK?I\Z_EQL&B*?41*(E$2B)1$HB41*
M(E$2B)1$HB41=*WC4<:''\G:@ K:2E6K=B4D+<4Q1.$F32V&+5H_+)H8OWC5
MM9-.S=NX<*)(VPPLGAC;''HL1Y>8&_8U0YU$6I<$,%O2'4KPOV@!:+!#8N1&
MU@XA-&+#&4DH0:,6BS=&5Z32T2T:^86_=+FU"D/5SR6CSHUC&=W*:O4D1ZX2
ME>4G(08XSF\G[G?JZ[JKY6241*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB418?P+
M@_H6$[^W'R5=Q !-MK[<G@'8#:4S2(PXT=UD2!0$%KVS+6DC6 VD<;8$A0%!
MV2Q1*Y+N'SAS?MUF^6".)%;IGCMQ]D<$%:ND.BM.'M9 B*Q@)KHSK&$E(('+
M.';Y^X*"HB^"+Q\>17?DR3U9ZT'HN579!\YS5R6=KYJ$5(J\">.A+DJ9Y-RB
M"1>:29WKG6>NHQ%9?"81((AK=OJHH>)QJ1:]:$8ZN^B\BQN=49Y/1KU'%NT8
ML4V*;7M5[Y$5WDN.W'XS)99-"^B].E9C/0+V+3F6$M90I])9I&"+5-B0CDL.
MN@BI21@7[)%)F]$&'3P>Z:I)MUV^:.&.%B+T[$T-KJ?"1-L(O$([-X0 *A].
M;.::_@1R9:-?D!/>EG(-6+2R-G1L:(AL$V:S%L@PR%*]P-&KY@Z8X7;7(H?Q
M3XN0GB9JMUK2)&#\O>2*;S?9NPI[,+",I7L78NQ#;@[*Y;(\00P,$P=O%54!
M[9H+%,6+(2.'LDD+]HR54(N^;<5>+[(F%-,^-^A6AB. G<7CQ9MI_7J!,#&7
MZ9%%]'0K]*.X.A8)ZD8+).Q#%5 >X3*$<%F^>+US94BXN/$CBGA%F$&QXR<>
M\82*D2LO&0_'2^N+18;+%VN+%>4,(_:-V$LY$LRPQ9JFV[1,DHUQQ;YN;I6M
MA8BD6/'?C_@=A,HPT7IW"2ZT#,HYKB18ZRA6)W7\>&HJ-QP*$EK!+/XH&8(*
MJH,A8)PP8M45%$T$$\,\L;D7;ZXTOIW3B!AMJ+4^M-5MI$]P)2!OKB"1:#H'
M2*>.>";\PE&!0M,F]3P44QP=/<5U\<5,\<5+6SRM<BLNB*&QS](M@?2 3_!T
M;JGQO^9OUHJQVP8F"@O88-_J^*RB#W Q]N)5DLX$QX?+'YDHW8EQ#_,AACB"
MR&)JXN![Q7.RCE\DTP8*]V.$NY=5<[T.03I<MS+?"</;XR^7DAH$V>3T,FIO
M6]*Z*KH4+3VH?\EO2@1BU+$Y-,]F (52-8-#P-C\.I8L;?&K];EFOD[[:.D2
M[#+X_<T[&-6HU"6*5VO&M)WT&MR@XK(81>(@3-*S#P!3\:H./D(?ZZGF;)[H
M>-ZS6D 1]A8^KN)*>R1=B,S;*8"18M^JL2P$X*Y(9/,V%\&Z.2;3)[VS+%O?
M#7_HGXS:XARB5:QZ+L7AA-;-LQ;4EZ0H\IV2UJ4@SC0HTKDB7(T(SD-[$JKQ
M$-X5WL][L+MS7TD[];DW'F.#TAZG*X9M\#^QT.$3X]EC/;8L97+=NO =5[CP
M:; C8[B3:1F!VLY>Z2;SV!E+3)?0T3U$KN4M@*'EYDV7D*$3"19NYSQ=A<E#
MZG0LW/9Y8(OV.+5=DY13R26;KK96721F/2=RM]_1O^BW!X!+TBWXT:FAR$)=
M<6#F88C3B?-E/5ET(+4E*$+5:("UC#@\"B*1V+"$7Z/^.-BT:?I$V.:1X/3E
M<LTL0H\TFS?UR"BX;\8YL>L"Y\6E.O8<PSCG)IP*,;>%,G4<3Q^OH\_FT49:
MX+:TVH"Q8X2X+(CZ\K?+!72BC@8[!GUKV1=1]9PHHIFF/001[K425<9.LU&[
MC*/]!%3B63:Y)@UN'Z'#.=9<:K;^=L:I=VT7-L2F:D?,UB/X9\F9IDG*%08A
M^L3@0KV)3$9[WTQ6>2Z5;!V#\HI\JX?H/8?%O9F</'K#T QB*V#0S8,Y Z4!
M1C&,K)"3\",X#B!HE$V:5='+12@,R_/NK?I\Z_EQL&B*?41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(J
MRVV_?#8J*<#GKM@X4V;I1@HNS<+-5E&)7<L"%E&6:B&:>>30D,>.QS]OEE=%
MVQ=.&CC!1NLJGD16;1$HB41*(E$2B*&QS](M@?2 3_!T;JGQ_H;]:+$7ENJ"
MF8R1QM+:1^&/]>CXJ;DX1,:<5C!!A()2&Q%/B.0H(6=D" ]5OVT6F-16[G?9
MHY/+I-TW2K?F#T^3R^14M?&ASC5XY9XE3P]3;S84M(F+;J:NYG-1M7)4<R_8
MM6JI ]]&%,9&#9D.5EQA@>8NA/0S#0P[69JSXCG;M?DMG7S\F_*WGPUJUG.R
M+SVZ]5KE^F&M7LP+V7)V9C<E>,V!WDD*).OT,]U1)-L#"S+=^TMKS01'CR !
MG-A!E@-%,'UFMC+E!1V"8-[N%44T4NIDZQ[9CT9726S11R1L_199X%L\\I7Z
MOI-YQSWD>?DZ@LFMR2AHU:="K:8+:)Q3L9507C$' 8^USMWMT?PR2@-QW7I$
MK\RRN'6Z=C@/$N'85W2SB:)\&[1LVKEBNY7HB) .C9)X<)RG/N8+]K]6[X1G
M-IRM4)R!@.W]QRN"ZRC,R!;%)Q1XT(%IJQ!ND48]&FXNZ-FN6*R]L+N5'-K6
M5LGT62QRPMEAG:]IXF;Z6.*^D#TA[O%^%XG(<OE]W!L MW^25LPXQY.*&BX_
M =B$[7/(_1B-#HT6E%G:3.H6%_T<<BX5PC'Y#RK5P]#C-78":M3PK&@$D]/5
M);:?BL\!]S"B+J\'DS]SL[L\>C]]K*.;D*[U+;2V5!P<*9+:M3A#=N&E#.0V
M=O&TH1-(+KV1ZBV&5VZSI/K9)73PLAA:RE[J6QM*<*Q_2)>])]_F_,^,Y?&Z
MQ.#PXT(6;MU]9K%D.V+1$4GAM$D9.$AX=90[(L*+=W6;,H_E>GP>GZ/J?$N+
M;^AO6(<N??(2]DFS?  7()0*.'B=PY-X@P2Z1EW2<DG>/2#NLLZWTM-J S+\
M^ZN^GSO^7&P:(I]1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HBJ?<_P"AX?\ Y6-"_P \]=416Q1$HB41
M*(E$2B*&QS](M@?2 3_!T;JGQ_H;]:+%;DDTW- 0,OV?'][.Q(9,@#;C(??7
MT479#$RQ08%3P>R5[W4\NP:+/%'Z[M=BKGACUDL4[WOCE7-GICK^D7BN7R#F
MN3Z4;.?G0M9@:7'_ +D\$M6E&_>I9L(V=FSX]GU2N6S.V6P6L248]PXPZO%U
MOKT6FX-R/1Q>)Z7H\#=ORKWRVMMN2[([%J5.G;ORD#* X0/8- $*PPCL#B[]
M"2GY.R_<"?[/B&^HE!)?NM#:8>40$_(<&PZ+1@+<>^'*,\45R'>G!=UB+=(J
MK9B7^+[#%XX2S;J,^K;%:_UQ:WS;C_I3P.+\@])0^<9^YQ34UX J8>'FO5M5
M)5F&6VU")#QHG&0D\^U&S%K!82%.N[,Q%3D5;B>UZ.]GD.+P,G$+V3R//S9%
MM;&O?:S7LQ.\QUFNR@%[89P'&[7>N[@'.)('ZNXUFQ722T,E$2B* S+\^ZM^
MGSK^7&P:(I]1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HBU5]E(%<L487JZ4\8)C(F>6&QH?&)9"Q D 3
M3>$RDK"O-<2_KE0Q!RUL#G3(0/?=K<6:*]]1BKMM=FT?99D6R'78*1QF"1"/
MS&4NYO+!$>%,I-+WK=FS<2,^BT2L7+W9L&[5FS2>O^WK-VC=!--LVR20_IW3
MOGD13.B)1$HB41*(H;'/TBV!](!/\'1NGQ_S?K11;>4A%QO64@=EHFWG38BJ
M'CB$1>*H-V9XA)30\$-9.W3I)=!HWN^?H*JN\TL[M[)=M3Z%<4\K8%Z3=:CC
M\+U3Z&"'DX;D\_'%@6)B%7U;>UHU<NG6.<XRBKA>S:%.=B0Y.%H>(-O$C!VS
M/@&9;U>5YH:6R7CY:T+NF3:! A#YU;*HV="T<(0S&0Y?5ZY(0#&<6*\^R?WM
MY,^)/&%T-CVPD!#/2$.UNG+&D['HR)A,C,J,NWVNSB0@]'F_?FSETP10?6P=
MJ-;+,F[IHB@\327NC;%'0?H4/3R.6BSZ_HSX[PZ.\#E-,>Q4Y'I;NA9M<0TQ
MY^KD"]D6,>L,5J,;$@>)6">O 5B$"N/M'N7TL"M:?&B73\^W.42QS<=LDS+&
M'1R*(:_)L^5W.TR^H^"&Q.=>4@1-V6"A/,@)2&Q'>>Q&NN5S.E$2B* S+\^Z
MM^GSK^7&P:(I,?+=XQ#XKVCNGN-/!3M';.U=LZZJ:71VSJ*=3H[9UNGJ9>UT
M='EZ:B]K2]B,NYI.'UAJ@XD\'Q/"[^XD!]._L)V]._K_ !'Z].GEUZM?9M+V
M0O5Z3$\)[$WAXG9W]O2$I=>SNAU_B]/XS?#U54>.6WS>O]J6]'UK7VUH?(DO
MI!OJ:S3[@I_*D?F;_64\<MOF]?[4MZ/I[:T/D27T@WU-/N"G\J1^9O\ 64\<
MMOF]?[4MZ/I[:T/D27T@WU-/N"G\J1^9O]93QRV^;U_M2WH^GMK0^1)?2#?4
MT^X*?RI'YF_UE/'+;YO7^U+>CZ>VM#Y$E](-]33[@I_*D?F;_64\<MOF]?[4
MMZ/I[:T/D27T@WU-/N"G\J1^9O\ 64\<MOF]?[4MZ/I[:T/D27T@WU-/N"G\
MJ1^9O]93QRV^;U_M2WH^GMK0^1)?2#?4T^X*?RI'YF_UE/'+;YO7^U+>CZ>V
MM#Y$E](-]33[@I_*D?F;_64\<MOF]?[4MZ/I[:T/D27T@WU-/N"G\J1^9O\
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M[LT'^;PW^U$/W GN:)_CE'Z ?]\KQ?LAB5O_ $49_P!TTQ]5JK[LT'^;PO\
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MZ-%W;R,<-<;FL&$ 47A&13$@(;2).(QQ><WC%GF2<!P9WZRG*,8]929G\%3
MD"R6)FRHX,,;]6RY J^;#V*'6O;''MKMVJBW3ZW3T8]LSQZV5^BUKY56M4M7
MC1K4JUBY8(S^'7JA*<T^C=S]HA1E.71FZOT;R;S\E0]@%44C63!KAAT[RG)
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MN]@7=ZWGZ^Z&T60'1.# <K)F#)8M,6@5>*MR@S-%^F]R&N9NN6Y ^/8+=A#
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M( 4]UZE^G'(L7:!:4_ /LY[2L,(C"^]U2/2C7!;LB+V,=.\D7XF/XQV;O=?
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M&'.!1%NP)8-'!@1BZAWY11&UPIHN"I1/I@LVB'K-&+YD:SRG 4BL<[6/68P
MP!DEXL6@1HN4?=.1X5IEEG@JR]9OZ=;%L5*(ZUQR2]FI7&C IF!*M6>HU.1+
M$[1@P\%Y$$\HA-V911*6QJ>1H-,(<<%R2,R!BF0#FPSYL1&OVJE[X]=N\9J+
M-U,DE<%&Z^."F62#A)5NK;%5+/&T_6L@M@%9K%@8!HM,11S:<)P?XXR;JS]/
MXLF^*3.SOU98O;J6:%D].X M:U7)(1@&A(91SC\+2A-FDW5NDH^3=8NTFZL[
M*1_YO^[]WN_]%>WY_P";\/7\GY&^'XOA?\K6WV;\_P"?XOUKQ[7[[>]5?B_
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M>][ZXC=[WO>_EO>]_;O6E.:_XY<LZ?!]TNYTZ?\ >=I;=X=_BEQC_P /X_\
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MO;6=OG2"&%[]%K7SM?*]L;7O;*KEROGT[5ZX6(*E*N:U9--^D1  .12DD_\
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MUJY+L6+%LYK5HQ;-FP29CG/.13&*23RF0A)N\ISG)WE*4G=W=^KNNJJ]<%4
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M  _#_P"KW]WO5:>OU/7_ &,\9O7O5/7_  .V?7U3QGK^-W]OA]/&;L[>_O\
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MYQ]:('?/K7*N>>QWC9H7+@;=BL'PWFQI.4-&U-IQ'(<?"=ISC*4&E9RT*<-
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M)[6A68L82.DL1CDC>1L5 QY0W.;Q]@2UQ'5AC9Q&R:+3OM;"[C+$H7*%F_\
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MT[M,>:'U>@35)ADUZ\7T?'-1MZF8]2UXD:MN<JX8EEF7S3BA251KBA/226\
MK.$;TA,@GHW5>$JD$IC 4W!9<,?FB8/7 8X7*D(Z?>B0RA<()<XCFQDSDFG@
MP?+J)X-P2X&G:YCG"? L3O\ '[];.+L/3K5+9P:-(HP!L:AZX0CLUAF.P+!X
M>+( .YW(.+/FG.*AK=;B.B1MP$*'(*-G0#E1M6;54!Z%P1#$KYH;!BEK6"!
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M6NM7Q^:Q3"=0&+C.0!6-[7B,IV0CX8PB7GY ^D$T@8&5Q1OM;86<4DQ5I.W
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MZA9/3N521-6M5BS"<!8/UB011O&<)-^%G;RZL_D[KPLUJ]RN:K; *S6/"0C
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J$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g766269g15l30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g15l30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (-:^A 8X0DE-! 0      $T< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  536EC<F]S;V9T($]F9FEC92!5<V5R' (% !=0;W=E<E!O:6YT(%!R97-E
M;G1A=&EO;@ X0DE-!"4      ! JC9& &OOIY1=$,7XR;SP_.$))300Z
M  #U    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    ) $( 5P @ $0 5 !0 "
M,@      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))30/R       *  #_______\  #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              05   &0
M   !                          $             !D    05
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   05     %)G
M:'1L;VYG   &0     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   $%0    !29VAT;&]N9P  !D     #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M-NW>S9O]-&CV4F?]7L=S"Q^9F%KJ'8QW7N,M>7N]1V[Z=[?5VUVO^A^C0O\
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MI%;Z)U7$ZCC?H,@9%U0'VCW,<YKG;O8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( 4X"  ,!$0 "$0$#$0'_Q  >  $  @(" P$
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MYTRCH=HYB8(CHS3(!8TN@S35!"7Z8X>F\'"]FK-UHQ9ZKH[ZM4,: 8=)NO\
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MP6FUH29D-532@HB$U<&2]4E+/:L"K.WSS\ZW&V$Q46)"0&PM<4R0)LB@$YN
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M="DA2+M9$LW4GU\QTJ.:.035B1V^4CB6F2">R6_Q=DD-@6S?EZ^GKS+%(#Y
M0B,,A<I[24G;74!M+XY%CJ$OLM@)D](I[R<6S(H(O[G@!"0 *\204=X8YUOD
M?3)=1[IEKJ&^8VT3V$;]_I_;[=V_D;![66W=L"C]-G>O;FF"S:Q[5@=;D7MD
MLI:=&;-K,+C1$;D,==0F1!DUVC'9PY?/M5U729)JHSPP6;^BBJ@>O7K]R8VO
MN]NOO]/=Z8]WMQG&ON]/O[<9SG.,>OKZ8SG.?3]<\ \\ < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < H8Z+4S(8IY.NW%J*T?I$TK!:7H4EE@8I.LX9$5QQN](VYH8G4ET1<
MV\G%U:W?70H_8-VJS! BWBUDQY ,/5B6&VL<=@7S\ AEY#_\2;LC_P FQ+_M
M;'@$S> . 5E=_ SJ0W'X]0S.\S=-J$^T<F'*K1AY$69]5/;K'V"/ZF&"DK'&
M&B;G;2,.("ENL)?L,L[#*Z[M5BF1&R/1:!K]6AUZQ7;HNF:PM6P:\%K4O>>7
M&A7D0R^:KW6_'FW/(IQ;)?YD6O=HQ4DISWU,O%EE/'<<K(QGCVNY>[NM=HW!
MUN-G:5V)QY)2V271OF[U%J0W\&:9_P#'"[5Y_P Y:B__ /*&YE_Q'B_^*?"R
M\O\ )UM^/3J]=W?3\_@CS[I9_P!OS?OC?_2D/IAUMDFO>ZB!^_;'L_N0?]8>
MRA=,UO(JEU),48U9?60;J%9LT:>1 ;##GXV<$#.7P)Z37?1R-*LR+)$8L@ZW
MH<:=GIN1I4>%.$UAY.7CYML)8NL3E+(Q8W5T6*UZUVL775D7PC&,U!=K9NI<
MTD\3TUN^&0\_/[2NJ=4=IXZCR6.,IIQ]VY6VX0>[6ZY%LT]V3!_@SS/_ (X/
M:O\ _=J,_P#(;FC_ (CQ?_%/A;_V.M__ 'PR^Z6?]OS?OC?_ $Q3Q6?17O8-
M\N%XW'([&O()U>D];+0V'WLQL2BR%F&EQL7J%82(D<0>!2X5M%-96&L?5BFR
MJ4<0;[?A<BML@X?2,D[[3+XSTJW@;3-)6'P;DW8NL9&?+AZ.G<5USQ5:H0KN
MCF2R::)Y2LGFVY*6JVURQ[L>NF$YU2KC70TZV.I7Y/::A%3QJJ5ENW!<9\DK
M)2K<%%S4=I0Y-Z4^96.3BG%NX7/7*S]/NCW8[/Z9QC]5A75]QCUQ_<YSJKUM
MSC/IG]<?;&_KZ9Q]L>G%?X@TY[<_!W#32_Y;N)J_#KOR<1+?X-OIWI)EDL6U
M=VH9GUCA/]<-E<'4)C;LX[4=YXB NSN+!"$7M,(YD<JM.MNJ[V(3,D,KV!0)
MBOG<)%%G#DR\&1%-]',1!D'"XJ]*'DI&H,EQIVQ>=5KRT;3]$X4U"7"7#3EK
MNGYF7:L'5N(.WHLQ]0OQZXSK6N7=G&S%6/)JZ-K62LF"E%URK6AB^\VY>?5[
M]G;8MU=<>VHPXUS4Z:K7*N2PXJ6TI271<JBX/E?-S.RAQ ^W0I+W@>Q552#*
M>-<X1L#KT1647]OKZZJ/X+<D*22]^?3]O02IC7]<)YQZ:\Y%YW"TUO?H&JX\
M4DV].X@@GOOU2AGZ/G2DMOY8]KS-[+FWZEAV>:OY<FB3?<K<:6W5].M>17MT
MZ;\LO/9]Q'VA^Y-R6V%G,BC%6US?$=KFRYE5<F>T;960$QVDD+?X;$%Q4%M]
MA'(D\#DF2S,T!(:W3G4F+?-MT4_C942TN]:X3T?1\K!Q,O5-3T/(U+3,35L6
M&N:9[QA^[YT)650LSM(NR<R%U4X64Y-3T1NFR#3DHJ/-K8V?=D0MLKJIRHT9
M%N-8\:UPL5E+2EM5DQKKDFG&49+)_%&2:3Z[2TKOL;6-C'E(2V>F(?9;5CDB
M_JNQP)*#6$U8:;:Z+D68$XBWQ)@;=7?1%240YW(XINKOIHW.K9VU]>9U#0]1
MTZB.;*NK,TVRU4UZKIM]>?ITK);\M=F1C.?NMTDFUCYL,;(26\JHFY5E56R=
M:<J[DFW1="55J2[VHS2[2*?3GJ<X-I[29O!!P@Z13<-5T7+=;7&Z2Z"FBR*N
MF?TW353VVTWUS^[;7;.,_NSRI::;3333:::V::Z--/JFGWHV#6-X0"06K4E@
M5K&)@V@1:=QDC%/Q8ZC*<P3$#3B61YO?2/JF0";URZ"KD&3-10HAHQ=N42&R
M;K#7Y1> <RH(;(Z\K&$P65RUI.C<1 LX^O*V4:TB#<NU%Z[-!2N([H8/Z#UF
MXE)DS<^TL[U=N6RK[&&^'/RJ $<O(G_B9W=_HR)__P!@1/@$T5D4G"2K=PDF
MN@NGNBLBMIJJDLDKKG11)5/?&VBB:FFVVF^F^N==]<YUVQG&<XX!\W7EPZO=
MLJ.BO7Z4^+V2NJW N>T5=FK"ZZ,UJ_<5N]E6#V"<-,4S#;"C)837LJ/2K=5L
M8CL2D,&K<V\=)G#H34TX*&W8E;==_+H_+Y_#SZ-^1]!%5VE"+H@,=LNNS&3<
M3DS9=9BY69/11)D\8O' PR"/@RK=F8CDGCAED_ 2>,G&3 Y'#XXB$,L&1)BZ
M;)"#8/ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' .AE0/:3Q>21O4F0";2$"8!ZF1*N$"HC8L
M/<,,$QBV?7")!AEQATS5SCT3<I)[_NX!53T=Z;]@:<MNOI7= [J5% _7;J?C
MJ'7:'6%.P-#MFP[>4P22AY5;+"9@P;2&)1K,%(/H?7XA]/D!!NR["):39QJ0
M4U? 2#[_ /=7?H]7=9SQ*OF]B_CVVFM?/QSB4JQ30#'VM?V#9,HEOS:$<DN[
MO 8!7K_3+99HQ'M\O=294N.&#W:N0*[[%\D8/M1T3[/*E*?L:'E%E%(."VA4
M1LFX8<V%2.N*:MV-O['L"*5RWB]4R!G'K=#@YH#F3QB. 28%(DV4@+BF>2&K
MUZ]?8'T \ < P"6U15L^*A3LZK6 30W&]L;QTS+8='9&5 ;ZN47NNX4B8'/'
M8K;#QN@[QLQ60SARBBOC/Q4]-]0,_P" :6,];^ODBMH+?9^CZF-7A&VZ#2/6
M^5KV*O[,!M6R#AJV;B9NZ%*R0>B@V=N4$4FI%+1-%=5/3&--\XR!NG@#@'C;
M'NQG7/KZ9QZ9]/Y/W_KZ_K^G/,HJ47%]SZ/Y>*^O<#5,(HFF:VE$FF]?U=!(
M;,)HHZ5ELFC48$!CDD5>O=23S<T28-$'1#9R0TT>+9<JJ?$<::*;>NVFN<6>
M5K&KYV+C86=JNHYN'A1C'$Q<O,OR*,:,(NN"HJMG*%2A6W7!02Y8?A73H8H4
M453LLJHJKLM?-;.NN,)V/??><DE*3W??)OKU[VV]K9QC./3/WQ_)G[_]?*UI
M--/N?>O->7R?<S*<-F.8#M5-&+1LTU5WRHKJV020U44S]L[[ZI::8VVSC&,>
M[.,Y^WZ_KZMGNVY2DVWUE)OO;>RW>R6[WV6RWW>V[;;?\NG<E^G?\WU-=VU3
MT#NF+JQ><B,/-$=MWL>.LM_D)5"I#HDIH.ET'D2.OU.*RP,KOAR*.B5V[QJK
MK[<[J-U%D%;#3M3S=)R5EX-KC+D==V/-*S$S<>33LP\_&E_E9>'>ER78]RE7
M)/=*,XQG'%;35?#DMCNDU*,DW&RN:32LJG%J5=D=VXSBTT_';=$4.O(4GTK;
MPWK!.3YV65*3-%!- 7-)7*;TK]0.$W9IM3-HNT4&J+66ZN7I#2NI0DV; 9F,
M;:1C=()*V(@;)NHU[)AQC/*XDQ*,?#U:%-=VOZ+BPE&MPHKA1+6M*@Y2E/#:
MA6]1Q9.=^%;9[US6XMEL\;0Q*_X;&O"G.=F/S2CBY-DN:>\Y.:QLB6R2L6[5
M,TE"R$5!\MB2LG_C.,XQG'WQG&,XS_DS^G.'332::::W33333[FFNC3\&NC+
M0\\D&@.RW7H'V?JY]4LGG=E0&.%B@T@9?5<8  SQAL+W4<(!'SZ0QB5MOHZA
M#Y,FNDU8MGN[T8PSH^3;ZN6[D#<D:#K1Z.@0#@X;DRX0,,$+222K,G,B/JCF
M2+-0T><#6 H<N9*;HY>DUF P<S5>KK;MF+1';1!,"-_:>F+AN@=6#*IK+K:M
MU8%:,3M(DO8552:T-#9."&&!N,CF*4<MRJLB&6SQN[3.9<*EUR#5PW38*"%6
MRBSH#74V9_P5+V8W&(T^4HGL=+HU"[_#M=44 \$O*1KB(=5M_-V^^^N6 ^P'
MVH&F[7^6V7PX+/:IFCA!BT"6 =?!Y^NGE\_'Y=-MR>' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M#A#&NB**UO59(8#:[AJTQLT%OIF\!)J95$KZZ 2HX X X X X X X X X X
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MD?D87#!!1(J(^GGD="F )/< < < < < < < < < < < < < < < < < < <
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MZ_IG]^/OSG(MM+=;/;JOC]E^B-S\_BNY_(_7) X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M506-&HK!/JT)M^([%Q4W+A-P!Y,X-^>)CQFIIT'B7S< < < < < < < < <
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MU_@C?&.T;5!*/.GRI)HMEORQ;Y=W%;\K;CS>+3?79]ZW2>S,AYX)' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MP>-9N[,6,:^9]]M/547;;_\ '!<D^BCVT+5%<J3<K.<^;8X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MK@[)I--I;13?5I[K;O)&_KRC-D< < < < < < < < < < < < < < < < <
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MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X!#WM)U@EEXR*G;,JFZGE"
MW31SNPDH9.<P,-9X%>.6M%4XG.01V#FBH!%^JLDQ GHZ6:GAZX21QT:L[;F@
MBY<"3 KRL7PCQFSI',BDO[)R^4,9>OK*21&5UG!RUER"R2E24_2<S.6#8HQ>
M/Z36"R:'U P,H5;I%@ 4)/CKZ1MR3H4*CD8$@;)B7B>S6%VF;HJB]PL6?&Y+
M9LR^CR+KE65A?A:0R6W^UER5Q^7!:3OE7%<B8,>[7209*V\6;,C-@AXF#;#)
M#7N"DCP4#UZ]?(QAKXH%)O)IH>LZ;L&)$3;%GR"N3HZ+BS[HB LGO95?D*<2
M;.SP@U>1,ZA.(R=IM<4V46SI'T$9,B2=:[-ARSUZ_,+N[MM^_P"G3UX_(BJA
M_8^@6J*VMD;4UVEYC,K+Z_/^M31E+XV. QV.QB>TF)Z_S&4CUFY@NN-^0W*S
MR]7P1FV<['Y<76"I;X6R@16$[^/K^_UW/I201T;H(MT\[YT0231TRIMG??.B
M6F--<[[[????.-<9VVS]]L^N<_?/!![> . . . . . . . . . . . . . .
M . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M . . >M5%%?7V+I)K:>N-O8JGJIK[L>OIGV[XSCUQZY],^GKCUSP#C_3A_\
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M_?'WX&R\CE\ < < < < < < < < < < < < < < < < < < < < < < < <
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M0I"(BK)B,VA>"L+=""NGK)X3.S5-XKG>66Y7AE_!>PO7BS)602E:[UG;J--
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M#O)U%[-A:DJHEK7891]7<;AO7R;:*.DHE"&N;!G6&06%!XGONZ'"=^_XO?\
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MV*%:EXT]%PJ.R1O"#A"-QR&R.5X!NS(.20@H32>L1'3P[O[=_P"YZ/';Y([
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MGU]?7/ /.--,;9WQIKC?.N-<[XUQC;.N/TUSMZ>N=<?NQZ^F/W8X!^N . .
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M T6I>(P#L 9D-]Z"J</N8W'+DB%X5X14;CHW.9#O*PU<%FE92.1&B]31$K,
MZ=>_X?M_?]#,;@Z0^3J9S_MI)7T[@TT0N6%1D9#R%>]D^P77)".R8;'JF AB
M56Q ,XF.E8"HH7B,TF4NBLCED\:SXL3".VLF8:/Y+']P\OS];_T)DR>A.W4.
MIKODN)L:;3FP;8JR&.JJ3:6(6*F0LJ$5<X#61%:DV?) =8!AZ2PY&UH_2V8E
M5S*HN72DLYE*Q@\Z#UW?KY_4A_?G57S"3.6B)96O8IF^'Q"[9%=5>1&2S$%
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MY^O';U]25'CDDS"9TY;LJ&,I .'G^Y?<\HS8RN,2&&2-JW>=C["630,Q65C
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MYE&H[+X\ZR^C\J!"9(#>[(.&NSP.<8-R8QULV=I(.FV7#)T@ME!RBBX1SO\
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MQP8XUG$.=2EQ8@0J29FI6.-54WFD=@K:.C9!D).'[0N2:"L:L3XX"7O ' '
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M'GD)(L1'17MZ4)RJ8P@>PZYVZZ=RZOTDUIG'D$829WW*1_1610]'YUMC'O\
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MP;\+O"8QD>>Q_P"A_2G<@0U,KM=W^=ELX3T21/@ <K!&HO)PXR0QN1B2(&0
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MB B0.W,8U=$3#K0"JY(*["4W18FZ38Y03</W:VNZZDD&X^ . . < J1&"!A
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MT',I!%A6P@ML^>A/I*[(D_144<Y(A<BW+!_MJ]%;L%T&^Z($7*_\;/4&M)Q
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M<#G-DPUE*]A@\B*0;OGI=NP=#2>[9==B8&#R#,<?:MGS)D7$(G&I'0">8L9
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M7/KGT_SY^^?Y<_?@$).B/^ -\?Z[G=G_ 'E;%Y"_XOF_T7KYDO\ 9=_R7I?
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MU#-R*-6GD:=C:JJLJ^RRI8VI\/Y;S(J$&K+XY&2O]YONC4I8Z@H\'PUPM7#
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M38JUK&A#0G8]B+4_&9F[+S4A&"3Q$Z+@MVUP?L,LB(+DGD,+8&:Y,/1A@0+
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M@3CYN&JUO%Q3NU)Y*6<@"D]L#$3YNQ:\=Y,"V M"1X)RYJ:E)%@X+?(EP(,
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MYUU],*XVVVVSTZT?*HW>#K>IU=_+5FRJU/'7P;RH/-:7E'.CW=_?O\ E[3-
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M?=PC) Z!;ZGMH#VW^G_R[K[O\N\OHX X X X X X X X!%_M/5-@W!#X[&H
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MM4OUZA$1IR-V6U<CI%7\*.RVH'"@VK*WTKVTG)55253^+JY:B)2)JPS'78=
MK]1.M"[=V=TV:/=_FP,DZX]A.GUQ3.)RF&5R#A/8N6Q0+DP.?4^^ V?&F=H1
ML]>I,(:EKJ&"'^X-]LF3DLC*_.IQ]Y*CX/)1762S *V(@0'LU"33WN[3_;F%
MVY9D+ZXJ=I$.G9L/B*2?Y+>SZVM;2*FGPH<!O$/#ORQM:YH0:H0A/)C2LFG6
M#LBDCQ?3:"J5S,H@!] ' -4%KVI@%;D9H,S:,&%W5,X^[E44JU])!C:;R"/,
M=2N[@J*CZKC4@\:X2 R!PCE)';=TUCLC=M=%FP PJR CST0_P"OG_7=[L_[R
MEB?_ !]N 3=X!#[M9V->4&1I)BPD5/ U+)L9O%WJ5JS!2*_-C-D-<.-Q"J3=
M?9!N@X<M$B1W9%_H'<NA*6XA^F14V;U.J:=[0<]X,N!- Q-;KQ\N-G$,LJZV
MJ.%I?9SD[8NJ,I;S<)KFIAEY490AV.GY<'<Z:G5'Q I8/\#PL/+B\J,=1][O
MG3V6(XO>=;A&3WYN^48WV1:BH8URE-U[!3G5P*Z:JI!:!53WQ[M%$[JDV^F^
MOZ>NN^M29UVQZXSCUQG./MS0;X]3:>A\-)KO3UW64U\T^%SUOQ%_^VZ7_P"]
M,[_[(1_B7;2?2N_[+HEDRZY+'J]C8 Z\9HWB_P!W6N".VGSN?5M"'I-SNV^?
M&)/F:\9#Y!**-=G;Q]H<&>W!'']KL,B[(R^"-(Q= LKH6FZS;K&?'"S<A]J[
MZZ+H:1=E62VBXJ%VF84:WCVRA?DQM@XZ55O%\LW(KMT+3:\*%5+Q\EZK>XW6
MMS[6*Y-.LO>RY?PVX>.H<C:LN5L>3>)JR+9#!RQA^QZ["6(H8_)/2I2ZY,F,
M&-&+55TY(D5-ZJ;:Z,&2*6[EYOLY;ZZMTE-LKHXQE37/&/M"NDJ<?0^&I7VM
M5T16M:U:Y73?+5%5QX9A*QRFXKDC.,I;\JDFTS<D^)&FH:;I2D^D7+4\]I2?
M2.\5HL7);[;I2BWX-&H.MO8*VKDJ8'-QA/K78^KIX78/9#'+4D01MJ]'D%DM
MASX0VKJ1)CR+5KLU451R0]5FZ[5YA!)-TGG?#C:?[6]'HJPN*N'^'JM8C%V7
M1EJNHX4G79.;IDZL?1=1QGO6DNTQ\NRN3334+(SA'2P/\8UXE4=3T_1IYGXW
M;*&H9>.MG.7(G77IF76FH<N[A?)/OVB]T<Z]>QEN4U#1\G*Q_KF&3?2V+QU-
M](.PJ8P<OL7(ZIN6B.\OAE?,,NU623K?11,ZY<#F^BY;824:CG:',&;+VK74
MJOA[@?2M9SXW8\[,?3];U#.MCA]M".5=+'NT+2E"N,'R2O\ >IK'=D;71D*#
MKE&?D<75TQ>!H>FY5_;T1E"&JWSVIE9'MI<M^G8,5M#=*?;2<')35-W*ZY;C
M3N*9LLZ;2"BYQJUV],[%(?)JVF8_37.ONQOEMI, TC63SKZYURUCSC?;UTQA
M/W;ZXYF_CVNT-+/X)UV$=]I7:;E:+J=4'YRK_B.)G27A_EX4Y)]\4OQ&S_$M
M1K>V1P]J45UWLQ;M.RZX[><??*<E^/2&-)]W3=[&O%.\U ,[6;TN:*RN.S]Q
M&]Y-@&=@TH9$$VNJOIHWR*P.6-+[K-=%R"1!H-<@MF;9?.2^'&GR^<CXIJKJ
M>9DZ#Q?A:5&786ZUE\)Z]7I56<VG#3YY<<&:>594W=!PC/&Y5R/(5SC4\;XA
MQ8W=G;@ZW14JW*67=HFIPPX6;I+'E?[LX]LX\TTXJ5+C&2[7GV@]FX[*TAC3
M*BD\:-],8]VVSP1(F6-,8U]_\9\V'1^'^S]_3?VY]?MZ>OVYB_QSPHDG+5ZX
M;[=+<7.J>[6Z3C9BQE%OR:3WZ=_0R+B+1GT]]BO_ $J<F'QZ\U*V^OCT[^AK
M6K.]O5ZXA!8W"[-'N&88^1C[S#MF_16^88*^B3Q+1%NYURP)M=D7X]3?=-QL
MU6TU=-FCK19LEM9G$^GZ3.-/$./JW#&5;'ML?#XCTC4-)R\K#E*2HS\>C(QU
M*>)D*+=<GRVU34\?*JQ\JJZBOS'B'3DO]Z][TZ;;<*M3P<O!NMJ?_1Y%5=]4
M93HNCM*$NDHOFJNA5?"RJ'OM?L'T^>0M_O<4FKF10EBLV?.QTUC6)(&R]2WR
MDQ5T$F CYJN_U46VT9[)M]G&NRF_PLZXSOGE?;Q=P?J,5BO*JU><WS5:?1IF
M9JF3D60C*:6/@TX=]V1;&*E)1JJG.,5.?2,9-6VC^T.?#&8M4X<XHU71-355
MF/#,X>S-5P=3G5=MVN/5;I;KS)PM45STUMQFHIRBU'=9B [!=<QH(..B\WB(
M^-,A;!H 8 1[AH#9A4&J20QJ(:#QB;!L,19:HIL4&:>C5)MJEHAIJEC7&/5?
M''!M,(55:SA55UQC"NNNJ^$*X12C&$(1H48QBDE&,4DDDDDC3R^,,#4\K)U+
M/UR6H9N??;F9>?F7Y.7EYN3DS=U^5DY5RLNR+\BR<K;;[9SLMG*4YRE)MD-+
MG'](;0[(4S8<[O$&@>A@.2#P=-NP<3(06?,SN%6Y]Q+01^$$R)IPY249)C<_
M46WR;@,B[#IZ.T2"JE)G:CP9JN?BZU9JTK<72H2JR*X:;9D:.I9<N2*U.Z>F
MVU56Y,I0CB0OR*I6V5;XT960L/LG!G^TUG<"^S_B_@'1K<*#XMS=,S;>+H9W
M%.)Q-H%NESKEIM>BZCINIXF'IL':LGFA9CRGJ,,K)Q[7?577"G9KB!^-IQOE
M7%5=<6B^<YS\P,J2/B''NSC&/=\<7%V:N<_;'W]_KZ_?]>>Y:Q[,)-O?0(M]
M[AIJK;Z;=77B1?<5%?\ M+>TZN/(_;1Q]=6EMV67Q?Q'FU;;[[=EF9=]>W_J
M_#N(A]::/Z+P.=7<0:]B)99:A66[XD,<+.2D-%162?#34^-%-J]9QAVU&HL,
MZQY(>HNHQ20#-DD4,8&LW&])I-W ^G7YUV1K.H2IS+792L_$S]-QKTNCR]*M
MIQL7WC#B^?$5E,ITJ>/*$>E<)/Z=Q]_MLZOQ_I/#FD8NE\+\+V\)8ZTR&IX^
MFY.KY.M8:AO+^(/BFG5L?/G+-[?*LSZJXW69EN=SV2CD6*6^KB"] D:NG.TR
MEL_>P_,>(:2$('O#L-IDN*7U]CL-\@M/D!"S4KJIL/=($L)"LM'3C0@H@QV<
M*Z6>;K' =V)?11E:GJMMM;JJTK2<GB',S]1LL:C#!Q,.NY]O;DS:JC4TJVIO
MM)0KYY+YWIG^U!Q?PUGXFOZ9J7"M^JZ1=7G:?*GV9< Y>H1S<=J6+;AR7":R
M5FU7*NW&NKNKLJOKKN[6'9<\9G]8M*R3Z_U*G3&II.JDX:,3@+:0ORQ0JQC2
M>%-!PY4@;=OR#IL-2U^0&JY?/661K9I@4[<"L,EM^ZT'L%H^GK%P]2T^B./&
M%>!J^/E8NI82A*4'BY>/F)9%5E$HNI1DY0Y(P=,YT.N<N3XAXSU7VB:WJ7'&
MN*/\9XHRIZOJDXZ7CZ*[<_*VEE9%NFXM&-CX^1D6J5^3*JF,<C(LMR>:QW.R
M>]N6Y3#@#@#@#@#@#@#@$!_)/%ZKGO5J2UO88JEC,OL\T,K7KDPO>MQ5K0S;
MLW.61:-U$Y1B)>"V6T^IL21!^^6D:T&D8Z&QQO(99(QKB)ACZ>P>NG?\?(C#
MX0:_)U;U@M*O3@VG(Q(X3V,ET+E<#J2+1:,.H/,(37U7PZ6#[+S#J=HX'()S
M)I "(6&QD;*%.F).NIE MP<KDT;T"OM1+[]^O7SW[ON_7CT+DU%$T4]U5=]$
MDDM-E%%%-M=$TT]-<[;[[[[9QKIIIKC.VVVV<:ZZXSG.<8QP00,[=O69&SO&
MR_'NVS]B\[R9<-'K-=)TT=-UNE?<G=)=NX0WW1715TVQNFJGOMIOKG&VFV=<
M^O!'C]'Y?#Z_MY^!/;@D9SC'ZY]/\_ /SC;7;^YVUV_7],XS^F?3/Z9_=G[9
M_DS]N1NO-?<#;?33'KOMKKC.<8QG;;&N,YSG&,8]<YQ]\YSC&,?OSG&/USQN
MO-?<>OR;_1-_)-GZXW7FON#\X4TSGVXWTSMZ>OIC;&<^G\OIZ^OI_E_3C=>:
M[]OKY?,'Z]<?KZ_;^7D[I]SW XW7G\?IY@_.VVNN/7;;77&<XQC.V<8QG.<X
MQC'KG.,>N<YQC'\N<XQC@'Z_7]..C^/]05QW%T6,E[ND?9ZCK(:UY<C\&Q9)
MM34;;&HC(]FK%J() )DFCLF](0V2!QPU$D(U16<-R[;$A8.T"VC%=A\QU;@7
M5*^*,GC3AC7GINK68M%;T[*QU/2\VRI1A:LN=.U\(Y%5=35T*KLFG)AV_/;%
MQIAOZ=K_ !+IMSP[-5R-:X*LQ^SR_9YJ&3;B</WY,K[;K-7PK<.$GI/$M;M;
MP>(UA9^92E[CGU:IH5EVBVTU70:M'J7)TK1!PB5=;;>KR,%1\4%L6.\MJ\P
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MEWURYN=S\U-N2[]^F[WB_DU\35<S\9G76OM*UB;WMK=51%9B\BM;P <A=!H
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MRRB2FFWKKM^N,5IC,FX X X X X X X!H3L5UVAG96%"(A+#LZAI**3$+8<
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M;Y8QUQ1BNNRBDE%=(I+H8GEIM[XN)U;>_9275MOPFDDNG1)>2V71;BZW]?\
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M8/I 9,&"4CD)C<:/UPQ%($#Q@DZ9"&FRJ EBHW')KN-6N%U -Z\ < < < <
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M9JU4QPG!P\Q;Z2J.A@YW1-_H'U]>'V\#8L8\9G56(=>H)URC\?E@4!6* 1I
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2P13T',!K5F!M+@#@#@#@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g766269g17h96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g17h96.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[18X4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             *@   2           $                          0
M           $@    *@                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   *@     4F=H=&QO;F<   2     !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   "H
M     %)G:'1L;VYG   $@     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     3A"24T$#      +P0    $   "@    %P   >
M "L@   +I0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ %P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M^;_\@ADY?'PDSXN$")E"_P!9Q\7ICQQ_N<2Z&:0E<:O4"1'%'AKU>F7]YO\
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MR6]_-_E.#^HJ-:<-_*/L_1XOZS__V0 X0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !?DU-
M "H    (  P!   #     1JW   ! 0 #     01V   ! @ #    !    )X!
M!@ #     0 %   !$@ #     0 !   !%0 #     0 $   !&@ %     0
M *8!&P %     0   *X!*  #     0 "   !,0 "    '@   +8!,@ "
M%    -2':0 $     0   .@   $@  @ "  (  @ ..R*   G$  X[(H  "<0
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HQ,#HR-R P,CHP
M,#HQ,@  !)    <    $,#(R,: !  ,    !__\  * "  0    !   $@* #
M  0    !    J          & 0,  P    $ !@   1H !0    $   %N 1L
M!0    $   %V 2@  P    $  @   @$ !     $   %^ @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 8!-
M30 J    "  , 0   P    $:MP   0$  P    $$=@   0(  P    0   ">
M 08  P    $ !0   1(  P    $      14  P    $ !    1H !0    $
M  "F 1L !0    $   "N 2@  P    $  @   3$  @   !X   "V 3(  @
M !0   #4AVD !     $   #H   !(  (  @ "  (   #P     $   /
M 4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,3 Z,C<@,#(Z
M,# Z,3(   20   '    !# R,C&@ 0 #     ?__  "@ @ $     0  !("@
M P $     0   *@         !@$#  ,    !  8   $:  4    !   !;@$;
M  4    !   !=@$H  ,    !  (   (!  0    !   !?@("  0    !
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M%QHR-4%S=7B7M!@9)#E167*'MM;7\$-455AB8\'_Q  < 0 " P$! 0$
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M3L$L)F//@C'?X;Q\>#'\%.X?H+G]2YBPZE*EX.UU%0+5[UK;F11;75U2.'L
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M\B%0K>H8Z1."%S"8B*CL6I2,'-@0-TI%RA"(^3CC6@IRN62OS BF2!B&EX(
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MBH)JXF1D"F/O;&IF/VLYH&VMU'V#7UENN;\4!_%7"S^D.0']VTUTRGLK??\
M7'\5IW^GF^%X]IC[WHWSM]9GOZ.(W_S>>&FH(P/Y)#?Y4-_%4?\ ^.U_Y1G_
M .72HV%L]0_W#^_-_)G]V7YN&?08]E/O#]Z7\X_<1^?B@N918BN(7*E*2A\Y
MSQQW=C&,/-YSG.=:6;&,8QA7CG.<_3&,?EZT&BUG&L=)S('$1J; S,R,^/\
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MF"75O0+VAYB"Q6G!K7(.8^'38KLJSOXDY$=_.W'9[X_24-/_ *SK3[C3^N+
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MO?X+HV_>R[?/]MO&WCB=T#_/N]O;]<XE?M)7'_O^3_\ >IRK_O \QOXO6/\
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M:[2>#M"VOIRFC'IOUCW!N059=;L/K."=B6AK%H6T/=)E<V+,UDLIT_)325K
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M^=EA>!T]B&8O38V%G;<PS*O,K*)%N5R$+!1"K[ZG'5@)A''7TV#6LU-2\/\
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M^)&PY(RF?M*9GC2)2FNL$H4M"5QTK4D!6L!^P "!$8_-$1''I]>7'IQ4>O\
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M!:X(S(Y@1C<B(OC,SQ0W-):6R%EMR_IS!W;;Y@G6K6*I6+#2$1 98YJ"8<P
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40PX^Y8Q$Q$H8R"-$Q$J()\\?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g766269g26l52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g26l52.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[26T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )9B^EB0X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP"   "   < E  "')R,3$V,#$T' (% !]-:6-R;W-O9G0@5V]R
M9" M(%=((%)I9&5R<RYD;V-X.$))300E       0R'!C]6N3CQT6(_]8=/BR
MHCA"24T$.@      ]0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    "0!" %<
M( !$ %0 4  @ #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             $
M$0  !V<          0                         !              =G
M   $$0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   $$0    !29VAT;&]N9P  !V<    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P  !!$     4F=H=&QO
M;F<   =G     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    K.$))300,     !K[     0   *    !8   !X   I0   !K? !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8&T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@!30)> P$1  (1 0,1 ?_$ !\  0$  @,! 0$! 0         '!@@$
M!0D! P(*"__$ &T0   % P$!" H*# @*!@@' 0,$!08'  $""!$2$Q46(522
MDPD4,3=38Y'1TM,705%55G9WE+6V&"(U-CAA<765LK34(R8R4EB6L=4D)3-"
M0U>!EZ'P&2=%9G.%-&6DI;/!X?$H.4=G=(:CPO_$ !T! 0$!  ,! 0$!
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M;N[G&=?VV[MN%SW)_P#[T\+WM]9V_P"]Q_Q$\#71]5W?]SL_X:<<W=\)U_\
M2Y_U]/"][?6=O^]Q_P 1/ UT?5=W_<[/^&L_P<SCO&)D_=>6+G<7F5+6-74C
MES%B^209SN#ON_;O>KYVMG</=;B^=K9;-UC:]N[%Y7B>YN)&-OMG?1?<)@B\
MIC]\##88CBP/T]+0+@'%LY:0!E.JZ%UV7;\IX<'P?8N\FY(T0PN2P>]]\%M@
M-#]#0T=(-<YNE*<B1.2P#CF[OA.O_I<_Z^ND\+WM]9V_[W'_ !%WW@:Z/JN[
M_N=G_#3CF[OA.O\ Z7/>OIX7O;ZSM_WN/^(G@:Z/JN[_ +G9_P -..;M^%"_
M^ESWKZ>%[V^LK?\ >X_XB>!KH^J[O^YV?\-..;NV;>-"_L]WA<]L\N_T\,7K
M]9V_[W'_ !$\#W1]67?]SL_X:<<W=\*%_E[G^-SWKZ>&+U^L[?\ >X_XB>!K
MH^J[O^YV?\-..;N^%"_^ESWKZ>%[V^L[?][C_B)X&NCZKN_[G9_PTXYN[X3K
M_P"ESWKZ>%[V^L[?][C_ (B>!KH^J[O^YV?\-..;N^$Z_P#I<_Z^GA>]OK.W
M_>X_XB>!KH^J[O\ N=G_  UEC#=3F./-L%3;A6C!8=;3PQ@!E,X($+A<QANL
M! \QKXYX9=S+'*U[7MMM>VR]=G<MYWE%O>[(<6\+;$AOMUF:]C[5&<US716A
MS7-+R' @D$$$'4NJOVZKKA7->D2'=UAAQ&6&TO8]EE@-<US8;BUS7-8""" 0
M005^+T=;G*N]S%BSA6RY<!=5 @0050Z&$$'@<%QPP#PQ&MCAACC:V...-K8X
MVM:UK6M:LWQ>EYP[VO.'#O&W,8RWVIK&-M4=K6-$=X#6@/ #0!( 4& HM7+=
M-UQ+HNR)$NZPOB/L%D>][[) <YSG0&%SG.+"222222L9XYN[X3K_ +GW7/=W
MW/\ +UUWAB]?K.W_ 'N/^(NS\#W0,;LN_P"YV?;_ .GL/45]XY.^_<<S@O[?
MW6/]R_<O_EZ>&+U^L[?][C_B)X&NCZKN_5^IV?'5_%[1UKYQS=WPG7_TN?\
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M[G.=9H))+H8+B265)-2=9)*\O;+RO!MKM36VZUAK;3':T"T10 !%<   \
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MH.Z+NA,Y7]?9E*<KXO*DQI#_ ,UJ(.X@X)]D[J2_I 35_O1>W]]U/DMW,_\
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M1/%LB*%;MUTZ[I4D/O3&OCR4^AC5=^W_ *7B_P!NPO\ (1%YUW_5<+^P8_\
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M^/$6[B_D6Z?[.L?^7AK_ #V]D(A'4Q*VHYTIT0^RZUDAQH.B-)0)*9J4Y3B
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MB/5D5R*9:JH^U#27$^$PP8?U*MB/@'TJ.1_%2&B)NMPLK))1FJ*:O/9G-R<
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M;&Z,=KW$F'$:X -:)'X.M%F,8:38$6 ^RMBM+RQD3E, /B,$;0: (CW3@N8
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M.">]29!OOPY=0!2Q#IY02W* JXFP9"130Q0T6**QI-=@UDC$X8LK-W$CEBE
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M8/KHL4WD;P(W5">C75KM--OSV_:'O3>1O C=4)Z-$TV?/;]H>]-Y&\"-[O\
MDA/=V_S:2]_;6FFSYS>D@\<$WD:W^A&ZH3T:)IM^>W[0]Z;R-X$;JA/1HFFS
MY[?M#WIO(W@1O;[@0EN[^3&B:;/G-ZPF\C>!&ZH3T:)IL^>W[0]Z;R-X$;JA
M/1HFFSYS?M#WJF$ Q+Q:I86#SW?'1.RW.XRMELLDG]M]S>VW9;9[G]M?OO\
M D0'7M,RGHCU0C[%^"_PSD%UU2(/Z)^!GB^)+KR6";P-X$7J\_-7]!!P%01U
MA?@DG:CU%?.UQMFS>1=G_AY^:KI#6,9XC%63CD>HIVN+X 7D\7GYJFD-8KM
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M>][WORWO>^V]# @$DF#")))),-A))J226S))J2<4%HM   BQ    !%>  *
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M $N.4(BC@!+*>740P1Q<0=R(*%@9Q#$SQV8YYXY96M:U[5>_1A01HLA02B/
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M*(E$2B)1$HB412+4#WA9M^2*2?J:M56XC>.*CL#N/!4Y*^Y:9^;B/[*%41N
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M*I0@M)CL.. DEIZXIYI#H74I%6%@HB%B20$I+3<)(ZN<R3B1,H..=S, E"N
MM@ \FAR.Y:&&?3U]O>K[452B+[:U[WM:W=O>UK?EO1%YFK'95M/B,7E!Q9Q[
MJ/4(OC)O36NA3>EP\<.0Y()G3V"HB2B@,!Z66< 3:HDCHZPGI)QSDVLW'*J)
M1Y/05X\9P!#'LC78)[.@\%)UE29( $ZUE*E.G4O[+=E2T_70E?AF/=136E0F
MYXP:*!IT<44AEIUD%6F=-6EF,QH^;1)R*#<<2*YTILNI0LNV=Q1,22S67<EL
MPG9E @S"71O]V.1&&(5KLSSI26-#D1MJ )S79G^R6QNEEX<-*.GC6.0 FE[)
MT8HF:A!&27DVI./NU=9^<?O !5=1$T3<)$TW5)<-Y(9=P(^;3#LY22J<3<1Q
M 4J@&D]?;MNJI/<9"LC/*<AK]],5<';K4TX1S*4F13*4DMN)E**F_%S@<3KE
M!PMABL$[A+P#[-M%'0'.X%TF$I+^9..'0</)618L,&5*8C%,CN.)GM9+/WJ_
MGZI9=*Q1&[(;I%7I2<T/ITT,01XH[08[W:@8CV8@2=,*"_VBM/9%&A@X(Z<;
MR#D70D,R*JYIH(90B*8)X]M"A#W&P $]J]6.V8R4)D"9$RGZL9G 2V\5BL<]
MDTTE20LN1J%) 36N^D&/F=)2:P'HYHZ17<^VZ](C!FDE['2>"^3Y5XF$IG#;
M%XPEG\T=/40QL<%4PFAY*=DCL_W$^VK.DIITG(RPGE,&1$]>H2JN]C[LD&C*
M04^0%'"=F RP(H;T4N&2A9#>#/:A!G!3(V2#J9I%07##B';YPYF34R*<H&$9
M64D<)>'X$)JA\^$.$$T3[ZX;S@)[_8@KD:SE2<Y&1D,:9TINJK\V-1FGUZO1
M/CAFSE$3MD!6:I-]);(;,CM!>=:BRE!.(JY!W$4!+5S2H:;1Y*4TY2)K8)7-
M--$3I4V7,B #8"72,I]M\L9;4!GKU8$">J9&.Q66HJE$4 D.2=/"1(""PY'-
MM$=^K ;4*IQ)9:PR\(G@/ER'VLPBZVN8(BBE-(%\/ HI-MDAN531PW8YBYU&
M;ME%5#&+6(IZDZN-'KB3U991WTV%4)=*-L(4,LR',,L/\@XCJPWVZ&V$2[5X
M<DXD.?;[A1\<6F0<@">.A+9,YVIDE* 9>R._UX:NI*>_C^:P1(G?327;D2:Q
MK-8XE)\\)#>BU)=)L(F( T6)%Z!J!E!$5S2:"?,)Z.D):7A)(PAYLEAUH\67
MDLB:!,$R8(1"(K*_9]TS,?:@/5P-P,:^9!!P;A=G+3G/&+8-7*2R:<4;Z"W%
M@Z<*I[0+CO07 J2&*I*02.JYJY0$@;% (HN?5=#DOSO&NY>P3HD<VL-HS'R(
MWG+(=HU<KI8*&<U MX0H41!0XI770UD8^7E(X5WX94#MBT5AQEAQRC3WJUX]
M1I7M[$[='8^M;Q9M=M"%SA01NH69504.%CY;-(3\BYY4W> G"1P'(O<,RH;X
M&&)VX-CF9W>&&6^;K'&]HB[ DFIR=CG@GD"1# 2^-Q,"14 KCG?#'<87SQ #
M#ME?##[7&^5K[G'[6VRW)1%S:(M/-07?@ACXE3#]*1/7I^Y;]=C?U:+_ 'H2
MZ#NA_5(?]/#_ +D9=%7N5XY*(E$7/35(ZD'0#Y ?(N:+Y;H,2W+:]K_R@Q,+
M[;"!9VY,P\K7QRMR[-MK7KXVBSPK5"? C,#X;Q(@Y')S3^RYIJ#ENFOO M$6
MSQ&Q(3BUS3,&9E7$. YS3F#O$C5;2-)VDG22W8>Y+J)?'&QXC?.U\L,N2V_@
M7ORBE1+W^TSY<@\K[V)LRV7R_.;TNN+=L;1,XD!Y)A1I4<*^*Z7-B"5128DX
M4-/=6"\(5NAS;XL5M(D.>'\YI_::<CE@:S"RVNK7/2B)1%B3_P#O!??Q*=GU
M?4:K<1O'%1V!W'@NKB3O3Q;\G#'^K*91V)WGBC<!N'!4&HJE$2B)1$HB41*(
ME$42='X04.?)M.GTO"M:'-=YO%9/.;YW!6VLK241*(E$2B)1$HB412+4#WA9
MM^2*2?J:M56XC>.*CL#N/!4Y*^Y:9^;B/[*%41N W#@N?15*(E$2B)1$HB41
M*(H>T>_]-_Q)@W]:4ZT>:WSN*R.<[S>"N%96DHB41*(E$2B)1$HBF4L_>L5_
M/Y'Z.6*VS$[O:%A^ W^PKLY[=:DPXQF![HJHST19:$?O=RHZS(1X9+8*4KHC
M;45%+47LI%O\(3VD3/ERYAQG@+V%*) 9P?"^.0=KVR*D;UOKZ!,]55XN-_7S
MJ;B]R-MFR<5 >RZ75CSID9M2*VV1'+S(1^7TP:BYB"-1\ZX86Y-BE\M!T.:#
MCV+%7\1DMT$BB2H-YV)PUEA/<Q71#9=0SVUD95,I2G(5K-9F9RIKQV@2P$I
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MH!%#L;63Y)GH SB<.>1?%HSPKPEA.>^=-F>)3.8SD-<Y3PPP,YSETF2O,?\
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M)/M-N2(S!22M$VD'%N:?W015%%SR<J2#J4FQ@R,K15VFZDBR4NMMBXIZ^ZE
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MMR[V'R;<"X=^0,/;R[-WGMSOMM^<7G><:\8VDZ;(+"1!@@S#03B332><R=0
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M$JSH8,]]!6MB*V!-CF+N!1DY04]*)^/3IBTT/Q]20YG"7CF/6TAMQD#-^/&
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M@07>GL\!E,(S'JI'&"\03(S,(Y[%&.*$IJI4CBGE3Z01N:=[I+@0D5D<309
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M;+^Y?R4IK;T.:?:D]_V3[E\HJE$2B)1$HBQ)_P#W@OOXE.SZOJ-5N(WCBH[
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MI@;CM:>BHQWJOMLII//NI2<S#)N%1<3OA62I=EJ9EBRB>%M@$'-;TEQ54#0
M90$N3$ %L?*J!<<(J7LQ7ID<<YB4\,\YUGBDB9=)D<*@"1U]6 D<EJ>D=B*E
M-QH,L0^Y79%K98A5:;G$V3 8Z'/24]0T_1U[ @:674B[NM9"B0D>>*\746>>
M*W4S([9-%B>=DAR8FB6B10ZP1( :I3-<L0#2DM:5PEMG.G.G+#V9">16Q+Y[
M%8,MR%-*\SWI&#;9,XJ9,B9;9J+!QE"&VN3,1*M9K4'F4EQ)*:UY&45^.U,R
MH+.9 ,@,,?:ZQF *>:HI9:SI82RV <,-^= 09( 1U2G,GKGCJZY$3DOX;_8F
M$=K-MOE6X[H[0GL@QWIN:!=^DHE3#"K@X(7?\I/%Z.RX1L_EVZ+)9*1"R0J$
M5 <; \71Q2CA&5TT[B3!ND*T()(,P!E(GUC;K23LS,5I,YY89:_<HLG=AQDH
MF7R.X3/%1-T&5UNGPED"/7HH -DLF-!C-!6-)" IOH1E+UE@*/D=0'9#D9@K
M# N(0)(Z6A9-=.4CS2&VN/\ M,XB0K,"6%52)Y#;7&FN4Z3]N<E[]<OMWOE?
M9]ME?9:^5_;RO;&UK6OE?EO:UK6M>_)LMLM6%4HBUFE-MC.B<HD3@309/+&-
M)G,[\(%D+;8&X8:QW.XQSPOMRW?=W6RVRVVNTNFWMNZ/$CNANB@P^]Z+7!I&
MDX&<R#AHRE+-==>5C-N@L@AXAR?IZ1:7$Z((D ",9S))E1=][#9[W_+?,!/W
MBO0_*N#Y"_TP^%=+\G7^4#T?_P#:>PV>]_RWS 3]XI\JX/D+_3#X4^3K_*!Z
M/_\ M/8;.V_[>+7_ "$!-OY;?X3;_GVJ?*N#Y$_TP^%4=SKYUM#>EA]CU7F\
MWD]MI^!$AAR\F1DSG:V_FQ]FS(8:]N3;[6 >.S /"UL<;=V]_+6ZW1[?'=&C
M.UB'#%&0V3F&M']XXN-3D!Z"R62%8X+84(:B]TAI/=*KC(#H& %!1=[7#7*2
MB)1$HBQ)_P#W@OOXE.SZOJ-5N(WCBH[ [CP75Q)WIXM^3AC_ %93*.Q.\\4;
M@-PX*@U%4HB41*(E$2B)1$HBB3H_""ASY-IT^EX5K0YKO-XK)YS?.X*VUE:2
MB)1$HB41*(E$2B*1:@>\+-OR123]35JJW$;QQ4=@=QX*G)7W+3/S<1_90JB-
MP&X<%SZ*I1$HB41*(E$2B)1%#VCW_IO^),&_K2G6CS6^=Q61SG>;P5PK*TE$
M2B)1$HB41*(E$4 U(;+,-,O?D_C<G6\J,X?-6V8G=[0OF_ :NWYJVR(TFT_T
M1YL5Y(Y-Q-!Z(BVTW4@*..>9!<;KA3C"0MI!W /,,3(HHIILR3,8X"89Y C9
MVQSQO>V5L+Z8J 2-H_TSRVX\W=(</-9Q.<9.1D@RNYYK"8I'$I 35U%3$X^8
M151-R4"82&YU]!,@'>V U% 5#2&I6-I-\">%TCK[=LM^M20[;Y^J0 U !:ZY
M]BUTH6:<B-0LU3A,.17N@.8VJ!'3.9YO-IOON+7L#'#6#',"DT1M'0HC:K64
MU(@7+NH^WP P32Z,.13Q2UTI>T$XFM3[LY521K7=L!IURG7;JHK*+H/T@#&D
M(X+ [/S,-S!,X+$N,O\ VQI%7E=SI:NK8V6=[<+B)KSA<"D&YW#@J.+,=?6\
M1500)6/AF)I&4IXZZI+//M/MNU!9Y#&E^ M/(BD8AJ,D-CFU=*24!04"AE95
M5,9OH-Q\D1OAJ;@4U<^40$G,R8$((A,R72RPHV8H93$6^[I,X=M7!57JHB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*).*]OLAHHM_P#M
M3-GUDA?SVK0YKNCBLGG-Z>"MM96DHB41*(E$2B)1$HBQ)_\ W@OOXE.SZOJ-
M5N(WCBH[ [CP75Q)WIXN_%'#'M?\O%E,H[$[SQ1N W#@J#452B)1$HB41*(E
M$2B*).C\(*&_QQM.GTO"WFK0YKO-XK)YS?.X*VUE:2B)1$HB41*(E$2B*1:@
M>\--OR123]35JJW$;QQ4=@=QX*G)7W+3/S<1_90JB-P&X<%SZ*I1$HB41*(E
M$2B)1%#VCW_YO^),&_K2G6CS6^=Q61SG>;P5PK*TE$2B)1$HB41*(E$6O6I>
M]K,!+V_#!-^A7%6V8G=[0L/P&_WK<D=210QA Q0[[YAG?'/9CC_*MW?]);N_
MDM?W;;:PMCWX[^TMB_+A5!\'?HX^MHB<*H/@[]''UM$3A5!\'?HX^MHB<*H/
M@[]''UM$3A5!\'?HX^MHB<*H/@[]''UM$3A5!\'?HX^MHB<*H/@[]''UM$3A
M5!\'?HX^MHB<*H/@[]''UM$3A5!\'?HX^MHB<*H/@[]''UM$3A5!\'?HX^MH
MB<*H/@[]''UM$3A5!\'?HX^MHB<*H/@[]''UM$3A5!\'?HX^MHB<*H/@[]''
MUM$3A5!\'?HX^MHB<*H/@[]''UM$3A5!\'?HX^MHB<*H/@[]''UM$3A5!\'?
MHX^MHB<*H/@[]''UM$3A5!\'?HX^MHB<*H/@[]''UM$3A5!\'?HX^MHB@SE4
M4>^I.(A,0[[UC$DWVS^UPV[;N6%>YM$_)M_%:_+R5H#Q2=H]NS:,QZUDD!PU
MR/O]A5YX50?!WZ./K:RM)PJ@^#OT<?6T1.%4'P=^CCZVB)PJ@^#OT<?6T1.%
M4'P=^CCZVB)PJ@^#OT<?6T1.%4'P=^CCZVB)PJ@^#OT<?6T189)"FB9QV_\
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M:"S+!BN%+9+05W*H(88AT(<GAFK%$P8ACF:!%+8W,6N.%F%;+&^%M>9!::]
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MVVVP0E]ML,K^-ONY!X]LL;3HS+HUG:)D3,W1(8];F 8U;,S7J+IO;2(LMI<
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M(M>IATQ1-/;N9+FE=O$7HF,EGRJRPV4X$M'6&HMIDN%&J0<!E5**2>:-!*)
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MI8,%"R4H$7F<6$7<VZZ3U&HEAC0"9IALR.2*$2R]_1\T"@IM%.<S=&6N.*F
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MG/">U9U'6E?5M'VG*7(]1W\\,W\]]-FFLN54G1.SN=:P8U#(B<X"^IFZ&^W
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M;R=\&BY$,SK0+.8BV-TLQPV"","DYZTAK&<J';OIA28Z %"#*4L9S)EF1ZY
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MDLXH9M[5K^WE;\7+RUZ7N8(%MBS($[.\5('[<(Y[BN@[H&EUFA@ DB,TT_\
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5"QQW-[9WOCIIT3.4Z267-TMDE__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g766269g30a18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g30a18.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1AF4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'CP
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             #:   !W<          0
M                   !              =W   #:
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   #:     !29VAT;&]N9P
M!W<    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   V@     4F=H=&QO;F<   =W     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !) * # 2(  A$! Q$!_]T !  *_\0!/P
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M8Q_NN:?\7^*1#NHY;@>0=A'XM43_ (N^GN!#LW(VG0P*^._YBZQ)+[SF_?\
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M8/BHP49))2'5*"C))*0I(R22D.J=H,CXHJ22G__9 #A"24T$(0      50
M  $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D
M &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M      $N34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;  4
M   !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4    D(=I
M  0    !    I    -  /.'P   G$  \X?   "<0061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.3HQ,CHQ,R Q,#HP,#HU,0   Z !  ,    !
M__\  * "  0    !   '=Z #  0    !   #:          & 0,  P    $
M!@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$ !
M  $   $N @( !     $              $@    !    2     $X0DE- _T
M      @          /_A 3!-30 J    "  ' 1(  P    $      1H !0
M  $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(
M @   !0   "0AVD !     $   "D    T    \     !   #P     %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C$R.C$S(#$P.C P.C4Q
M   #H $  P    '__P  H ( !     $   =WH , !     $   -H
M  8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
M 0 "   " 0 $     0   2X" @ $     0             #P     $   /
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MA(:BI+6W)2@U0V-F9VAU>(*FI[+"Q-/_Q  = 0$  @(# 0$
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MW=/+UPM^N,CNK /I-/(5P4>J+'>F.?4Z=V;M,>-%[[.P[W=T\O7"WZXR.ZL
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MHNI2M*UI6NZM*\^LD</G"VA25?W7O*U5 ZJ\)P I58WLH>*A=)V$7&7+6*^
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M[07!/ZRN]QX_],IW#^TUXNTO:^$^\6GV>.%SU8:[]T>^J4^T%P3^LKO<>/\
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M_P -?#IY#^#CT/)[WQ/]ZIY6M.?2D?([?%N'W.W_ */OEG4?AGN4;\?3'?\
MZI,-;NC?SU^+_CZ*3Y#N#CT/)[<6Q3/_ .J_ALO4^5K3C;XSCVZ<-P_GMD.(
MZ/Q)R-<OPSG*.<W^/EE^-3?;_BCPU^-2E:V[Z?XO^>E+K:TYN_2M.FE=1Y#^
M#CT/)RV_SOB?7_M666?OJ/*UISE?$F.?_!L#,?J]1^&>Y1OQ],?Z)<,_[O\
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M#33JE*6L>?T(/R?^'+0\+.3/,10L]F,&(R1*,"6D(;)B2HZ3X.O2O?&A>1)
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M: )RG9& +-)FF+!1['Q$=$&3+$YF+QLW'91>,8+0910"Z<3.\:<JV$*,%6*
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M%XS""%X4I#H'5!R^&2&3EWB:C50PU21X9C0],:'*.':78=ABXN&Q')$G"&_
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MN6^EAY]#G&1VXS 3ANDRDI>2W*+RUF;A,)2%,J<0/"X[0;E-O!;MBR#86P4
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MZX(O^T#O_'X'7;W!Y_5#A-_L1G_@\9KQ9KT[^]3I\G3]>_S]'AKKOG\K?/\
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M]M]E/B_GE/X$RZO_ )MF?7\B^KS=&GCG"/2N&_KT7]K4>+<2O;P":.8>"/\
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M1TM]/LSZ:?%_//Y$2[V:,_[%X>_]VH\<X1Z6PW]?B_M?=3Q9B?H^=>W^RO\
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M&^YLS&M@$59MU'3B7RLD!#(ICW;M.ZQE?F'MK((!58K4E!OG;7(_U;@%-[Y
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M32C@-CC'+.^&36762:9OT565J; H0B#&!!DG!D(BYETTC;>A%195$:0M552
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M195M4J58*) OE<G,C,C6(2">7(7V95!SRJ&S&Y7<V4Q;,5Q8*-R*7NU#([%
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MJHB6-0TJY54:WA$1[==R)0>QX>YBL"%*L3;8.35M8 ;!RG:3:Y.9SV^BD)F
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M<;DV-W4T*AV)0DVR! "+(5B^<@4<C3*#"IO$7$@($7RT0O;PYT\D"HE_+R#
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M;02,@0;7!Y[$=(!VUYX3K:_V4WK<&M&-GAIF&6SXDT$7B6V(7;CM^B%A$\R
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M_;I4[=SR?E4Z5%.-W-I3>^=*<='V:4.^WYU=K#Y(A_,^VNE;D_=';\:MU_\
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MWSR:*W.CYBJSIN\:J%G9&J96KAVS=(WD445W#9>VVY.]M]WNRH5J)!OL"1L
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82E-*4TI32E-*4TI32E-*4TI32E-*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g766269g33i20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g33i20.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1DH4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      $5    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    9 $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,0 S
M "  5 !H &4 ( !" &4 <P!T       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $
M 0/      0 !.$))300F       .             #^    X0DE-! T
M  0    >.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             "00  !<4          0
M                       !              7%   "00
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   "00    !29VAT;&]N
M9P  !<4    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   D$     4F=H=&QO;F<   7%     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $,
M4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0   1H
M!0    $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R
M 3(  @   !0   "0AVD !     $   "D    T  MQL   "<0 "W&P   )Q!!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C$P.C(Y(#$Q.C(Y
M.C$P   #H $  P    '__P  H ( !     $   7%H , !     $   )!
M      8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
M     0 "   " 0 $     0   2X" @ $     0              2     $
M  !(     3A"24T#_0      "      !    _^$!,$U- "H    (  <!$@ #
M     0     !&@ %     0   &(!&P %     0   &H!*  #     0 "   !
M,0 "    '@   '(!,@ "    %    )"':0 $     0   *0   #0   #P
M  $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ
M,3 Z,CD@,3$Z,CDZ,3    .@ 0 #     ?__  "@ @ $     0  !<6@ P $
M     0   D$         !@$#  ,    !  8   $:  4    !   !'@$;  4
M   !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M,8)J=([S=NNU!"[.6[M7C5&O@H\181\JOW.K:B;(,VF/,?S7D,$K-4W3D03
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M%#4S"U.*4O*L9RK.<^?/AB\G:ZNKFY?):>:65LG)S(Y8\_/\*^BX8Q#%%$N
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MD#4Q.Z\Q]GZ'V'57ME4HF<$U.M;*UE7[32HQ/:<<S9I]9K0*151Q8_(+G:C
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MHP*LO X((K=G_*E=8O\ Z!-4_P!Q0/\ [ISH/^.O:[_RDUG_ .?N/_SK0?\
M%'LO_P"3VC__ ./MO_\ 740ZZZ+ZKI._KCNY0&OH85*"XU=21(QB%6Z0B#7A
M,(B>4/0RW&>L4TS'(RH*D-JC#$._,&U.E9*71VZU/[0]9U#LW8]G_:;HL%N/
MZ7OYIFDNM0[RZG>*V[PL76UC@:)) 2&E*]V0(4(ET^G=A-)L>T%[KAM[<+OA
M_HJQAB6.UL1';0I+<=T $-S).LKH0NV)6[P;I7S'>3GGU=U6#WB]CZ'"BSR@
MXW*ARG'&5SA84H6@C5I]K"'#+PF'/<%0W<NY])"6PW ;RVYB1*8SEO"[D48D
M;!=4]6.,_#.!^8I5+MV;!W5?0TE.C-P4^E,(2]&D.PJY&LLMV1Y+3EERR9)S
M,!'$^:<94S7W949:<N>:L^3?-M%8P##$F7XD;<_^Z>?@<BA!P"/,<XXQX^>?
MY?A\DO>3J)VW';!/[)/54'N.0=D)FD;0,?3-M1.6W%3$=<(%@DNK[+*>J,TA
MCVWY<MIQMM,96&F6D)S>:)%R1&I!P%"+@C ZG ''ITZ#%2))$)"L0-N. <<X
M],9'/0#GQSG&J&QGOLF27 LE#L5&/#E-IGCD(A(4/]SU>RI(!,2JVHBX_C"<
MI^9W-[&<K;]4A#:T25Q!+<6DBR6MU=VLP.[?#-)"V1S]Y'5C@="6&!TJAPLP
M(GMHI@0,EX@3XGQ7I^1/)\S=GJEK#<N_MG:\UY6K58F:+M"S!JH3CSZ 4CV!
MFL$Y\$=:+16Q\A\])L T&)?F$2*V;!!B#&O9=)%HL7#KJ>C/;?M*MA=V,NM3
MS6]Q;S6[QW;13NZ2HR,JS3(]P,J2,K+D ^Z:TSZ!I#W,5T+"&.:":.>!HQ(B
MK+$VY'"JPC.& ."I4X (-?HOPH<8?#B#X;26(<&,Q#BL(QY(9C1FD,L-(QCZ
M82VTA*$X_-C&,<\]^/4\G'F>3^=;L<<>5<GBE.*5%UYTEJ#9A**8V%K6EW0K
M!A)&PR%DKXXO,C0$OO24PV'YC#KC<9,B0^]AI*L(PZ\XOR]2U9SN-.[0:YI,
M3P:9JU_80R2=Z\5I=2PH\A54,C*C %BJJN[&<*!X5JK[0]&U.59M1TNQOI40
M1))=6T4[K&&9@BM(K$+N9FP.,DFH(VOTGT;;]=6VL4C56KZ;:SHEP:%M<>GC
M&9%>E276D*+1UQ(J)/OPV/>>90RXRMUQ*6L/L87EU'1:/V_[166IV5W?ZSJ]
M]9V\PEGLVOIF6Y1 3W+!W*;7;:K%@P R=K8P=#JW8C0;S3KNUL=(TFRNYXC'
M#=I8PH]NS, 95:- X9%W$!2I)XW#.1,6BM%4+KW0A]#H8_#3#.$2#1J2AO)F
MS&%-X3),&)*$XRZ^YG&41HZ<XC#XN&X<1#;+>,9T7:+M%J7:;49-1U*7<S92
M"!"1!:0 Y6"!"3M4=6;[\CDNY+&MSH.@Z?V=L([#3X\*OO33O@SW4Q #33/U
M+'&%7[L: (@"@5,W-%6ZIQ2H2N&Z@=6)$ <U#P(A#^C<ZUP" 4%.2K*$MOB3
M4QB,%,-J4XA*FX)9<AE:L,R66'OQ.9EO;)* 6E4 Y]T$;P1Y@_P!ZT^OKZ_C
MC5!W+I_<'=-1M-9K^[ZO)I]@$DH4BCQZXBH"BPPA$=CK$D7L+M#5I@3&G<M2
M89R8D7*;7E+\9Q*TI3LTM((P<(K'GWG&X^GWN!\@/A0Y!;!P/#@$@_A_/X5\
MC.WNO'8#3ADK'NNAV"(V&X](EEZK"0L/'0TUC#A'$.M2I^O(N4QVTJ5(*U+X
ME7I3A[VL(RC-MXEX78W!]YDR 1CP X& 0",8;QJ1-* H!8CGW67((;S!4^!Q
MYCP\#5=*[<V)!I JNMW,*3(-IP-9&!TW.4_*<PA#7I:K!*F#HN4.K4OX1JIS
M%92PZV\B.]A2%[&QUC5],8M8:MJ-J 1B..ZDC3CGF,/L88_LLI'IR:Q;BTM+
MI=MQ86\A88RT*<D^7&5//4$'\!7U/> ?IK:$[:NQ]Q[0-.&X-"HCU&ILAFN/
M08+Q>ZF1\RP)(3UPX30NS5T95H4"=6U.%B33=@>DSI(YK$5B;/:3M-K&O064
M.J7YO1:M(T>Y859#($W!NYCCR?=4'?D^ P,YQ-/TC3]->>2RM5MWN-G?E2Y+
MF/=LX=FP%[Q^F,D\C@5]3_.2K:4XI3BE.*4XI3BE1S-PH%.FIF)6@5,ER"$(
MCAM:HL=<US,F;#(/I]28CB9SDB1'D2?8BNQY#,5MS,AA:5U ^'UZ9^'S'IXU
M;923D<^=</[25W]?A?VK _Q__-RK</3\.>,\^&/+'/'GGFC!\C^!KS]HZ[^O
MPG[5@?\ >.,CTXZ>'KC&3\_#.!@XI@^1_ T^T==_7X3]JP/^\?T__'EGD<9Z
M^I/SQC'P.?'C/PI@^1_ T^T==_7X3]JP/^\?^/ZV>3D#/.?+G^/[#@G@X!I@
M^1_ T^TE>^[Y^$_:L#'Z?_M'UY .?'\3TQR.3^'0^/ABF#Y'\#7C[25W]?A?
MVK _Q_(R/CU\\9..>3^/3]*8/D?P->?Q;*M@<.3\7 <D172A)&%*&MP([[<A
MZ*S+PG+$V7/PU\%[$1U:XC3[DR0MG+3#4H?+.?TXX\_+'T,&I5.<GC%2CRFK
MM.*5PR,7,X?.A85A&9D.5%PO/UPC,AA;6%9QCZ^2<K\\_O<4JHUPTZYL;<76
M_<B; @.K0BMLMD:N\*5+DF9NR**Q3'H:B&)\? 9ZOO-JFN95"(I)-J2VUF.T
MM$I=6,XY/'J3\<#CH.H'&,59/&X'QY'XU1*5X6<J7J_KY04;P0.-=>NL<72M
M7MD77S<E+VQ:SO+KSONA;.? S;2N,\%!V[K\*CF:-(F.K/C34EA-E&+8]QY@
M\>@YQ\2,^GCU\/&JM_)XZG\L8_A7=6GPW;;N6USMB=@=V ++<K=L@6=O4376
MMB%$J/X,J_UJWSUW"Z]I\$M?KD=%F%*WY:;R5NQL\><DS\MA(8.! C0WV6#D
MY(SDYP/#!]0,Y'3KZ>--X'"@XQQD^.?'CIZ>?Y1C1O",E5NJ' DO9.E*_8A>
MNZ!3=97C5'5L!2+"S:=8;6H&X*KLW:<XI>[67NA"39]74MJR46KFJ#134=@O
M,=&H*2@TNO-H\_'PS^)QT_8'&13?Z?B?3&.GUUZU8JP]4NW%BME"W/-[5:V=
MWC0;AL"6 8E=>Y[VDZYKK8NO*W13%+K]+B[<@7YTJP5J\+8*;38MHF\RK#.)
M!DB8-<5%AQF"?+.<?AY_WY/A4!QC&WCCQY)&?''F?EZU663X.F"-#I5<.;HK
MMJL&N-6==:C6IMKU&DQ3#5RT'MG?FQ7S=[I"+Q"^>U"_!M[EJB5J@TX$(!E0
ML'Q=ES)S$APVT^/X=<$$=<9\/PX\ZGO/3C/GX?#S^O6LA-^%07):O'4N/:.L
M*)S^S-C;)/ ,=3(0#7 <O=JQ3ZE72^KI5!V;3=Y4:[:\$4N$S#NZMUES%RCE
MBHVT>H6/IT2J"GGCD_F>AXY],_PYIWGQ_'Y_#!/I_ #:;I*AD==4K46KB5VL
MFS"VJJ%7@)_8MM>5*LUOG ZNU5D6"S25O2G'#UH=7+-25/RI4AQ;,IR1+DN*
MQ(D#P,>7Q_0_M1.26^O.K$<IJY3BE89L8!BUZ]OE65&ES$V6F6@!F) =ALSI
M6# 2<.S&A/$7HP]J6_B3[4=V=(8AMO*0N2\TSA:TB7',?=[QRG>AS%O'W>\$
M960QYQO",KE<A2&P:I<91@.I5AQ@'D'H2"/Q!'F"*^1_?/0WMN;UU7M37VJ6
M8W6=.K!O:K7/UJ5L0=\+7X:ZDQ7[I.U-4-AM83]D)423#F#9$Z>Z2KSBR12(
MJ>EF7T\_:2YBMK*2/2K?5+GVJ*"2PL-7AL8K*V:U<27?M6NV=DEU$ERL:>R=
M^DXMY&D6>62,PR\1%HK6]W>RI%>6$=W"S37/<+J#R77>AXQ##9WLK1KAI=SR
M6Y3>P4Q;?ZU-4&W.IMF)5J ?M#S6O#VM6R=55JD00@A;1(&29,JQQ;+7'3DR
MHPBD%7NI@*'#7)EA4<F.L*!HEQ'VY"_UNW.K:;92Z%VGD%QIYN!?=F[.UUO2
M[69;LK+I]_<Z??27EI="%UFCF-G+8S!F5+@2QF(7;"-H(+\O>6*EYUVG7ENM
M-EF"P+&)HXKFT,+1,Z.&C:2.5$C!.])%>H*V3U+WCLVJUW:42E7J?1XVKA;<
MNX9@DC#HU53ED15B=O#@43<"]6D1I:/3(S8T!DS<P2<K,UV+"6\GE>TG;KLK
M:]H'[+S7TBZ[ING::+C39Y;73[O_ !FV]I00OJ\EA#J<HBDB,ZZ7+=-#+($N
M%B8.J;C1=/OC9R7<4<+6MUJ5X\,J!YH9%+I&K(MH9#%$Q5RAN%52B@Q[MT?>
M0E:-?V2PP-95"K*39BHFE0AR)=>+9;1)PTS.EMYADHSS;KN/A8$K*D8;S'4J
M,[A?H?1'8=[Z*.]UFRT&.PLK_P!HETX*MI(KVUZBQ,PS*D32=WD+N4;V39[V
M<==8)H+";59KF6W2)KUB7VB:-GD(]V,%%,A)8<!2Q/&.*E6C0C^OM:DZ[)DD
MPEY$72B%_/85L,&JG">?N33@B>R*8JXJ?6A+#\)_%AECB5D=+9A_,V,C\L-L
M2-C<Z-J>BZ/K5OJL$UO-<+IT\<,TZ3SF#VR- X.P%5,D3J%9.J]"-N:1<P7F
MJ:1<6YB,'=WV)(T6-&8V^X%E64D':Z[E81NA.-N2=O?%K'N1G8P\A?K!28@-
M$%:"]AHUN>V./@P'62[$>;BI6OL/7()?W9#^,2 Q%$"/&BO-3?E:774LS^1F
MMKMV#M;W(V0[UVZ=%(@BR-SO/R\0YQPR Y/N]2,D&PDN80DYDN$D8QH%4^\K
M D/(-/E,*D[<.)H\]=Q(W5LGZZ K6?/[SG54)O,U#@!:+@C+TQMBAT!$)#EB
MV/[.#]=V!:JT)LRWD-NJ&NLL3GAV&Y3.4-?&H2KINT>#K4 R,^QN<;<,=U_?
MG*D J!AAQN !X&<9K6:<^S1V+&-<7"@]Z&>,$VEH?NHK-G)." <$XZ8-512,
M*2[)LYDB8MXK(O%EFK'[?)U1+,W,2UICY@P"]7DO-$;K^7SEEE$MP7-?037$
M6^F/#<;YFPXU:!O\5/\ CUIS&UP)05NH>'60B+;T]Y05W<' ^]?',MX0(#FU
MNE_JGF[Y=UK_ &XW CVG*[MI+*-G0@FM-NP<Y5?;OG/USFWV7/G]_GYFIOU\
M_P _G]_-;J'_ "^^S_IEU_V\E=E8_P#(K3_U6W_[)*Q'F'657Z!'\C(?SN0_
M_P 9;9O^"6L^*M/U^7\37T0<513BE.*4XI4?VO5>O;LM;]CJ@R616W[23L-+
MP:S1V_+R],*T!'AUB@?3/EYPB;&?+Z>?ERM))(^4=E_V6(\CT'P'X#RI58]A
M=-(5FCJ9K]\(MQ<(4EL/=QC%KC,HQC/H:@'H,BOVB,YG/T5.-DK4[]<K6P]G
MZ<R4OIU^\5?Y ?PQTXZ>O6I!Q]=?+/PJEL_PK)VS+1&B[/GT,)KT-.CS?0)&
MC-CVT^MI;;[;8J?<J8+%4MIEW"\KFJ#V$DIQ+:8OPR4*D.UR7[NI C523G=R
M2OPSQGPR<]!\A)( Z#Q'F#U!Q\^GG\ZVCZ:Z^:BT$":!:OIT %C$=$><;D+?
M+6HUA'HSZSEG*.2C1/S6VE3;$B9F'%PE#,*-%CMM,HP#R[.>7?&]C]YMH"KD
M]3M4!5'@  ,"H\,> Z#RYSQ\R34S\4IQ2G%*<4IQ2G%*<4IQ2O6\RS(:6R^T
MV^RZA3;K3R$N-.(5CR4A;:\*2M"L?1258SC./IG'EQ2H3L/7C6!M:I(X3+I)
M'/K5B=0R#U99R^YGS7*F5Z-ARH&96<_^G/5TJO'YL\O)<3I]V5L>3'<,>@;(
M'RJ<GIFJ>[,Z)'C&)<X!9@-LDX2YF'&L49REEUY\O4CX^P X-A"$7<JQA&,,
M4H$WZ<_C.I\LY5E+J$H'O*K>O3G/H/+BI#$?P\A^6?S_ !S4?Z3\*768>U.;
M,WHS6[7:I"VUL5*G!8M>KD.,TI2VH%HM4.&.N&Q<8SE*I<4E)$5B6YA3;]:D
MQ\(QRQ-=/-D8"*RLK*O]M6&&#9SD$<$=""1CFJ223D^>1Z5M>" PM:%PP==$
M# 08>U[, 2'@QAHV$SZLK]J+!AM,QH[>5J4K*6FTXRI2E9QYYSG.*    ,
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M*]"J=JM)1,0,7EEO\VK!LLB8IXJ/7H@^)(;51Q;,11=Z8EN"JD*6.%!8X9L
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M?O%9BL$LL$S-'M==LFZW0!FWJ%+ H201B75E%>-:-*9 ;.[2\BV, #+''+&
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M5/L]Q*UGJ9T[J@587!0=30\',,EW@W-7(M6=%BATP0\#="!9C<!A<"/.&.,
MXX'0\DYP!\<<>>#Q5:PRMMVQ2-N:-%VHQW-+N[M5P.6DV-W:CE]K;<X.,^O>
MT.W77&R6V@'NU^T;#7Q&L.@M0[.[SNP*DE8.@KIOC95[&;7VO0HL*BQ0-,'U
MG5]-A0GI%HA6"N@"%XK.P+HX0D"R,@A'U^]4;3@-@[22H;!P2H4L >A*AE)'
M4!ESU%7$Z/;X(,ZX[Z[R.;\V%OGKEI;:-O!:6N.Q5AY19W7.DM0UZS[$*,&@
M]<KRK-#D;%+W@*-LTR#(E&@=7"R,29N,8ERE1UX']]:Z3=N[HTW4=YL]\[F]
MC)%FH/A<B.U>V!8%&M0K:>QNVC5L_E>M7U!Y6N99*JBA<VJV():&XDA^P794
M0%\Y)8@//BWG/B,8SD'K]>E205)5@5920RD$$$'!!!Y!!X(/(-3W#[';^);4
M'@BW9:XO=L:UW/U#H4/U J0NGQJY/Z_ "&OXF[-O;+HRZJ[:IE9O>O)&Q]NQ
M-OY*BZW5'Y=(J]0?BRHD@>9<_7Q_:HJFQOLWMS;472N[ZSNZW[Z[#ZNT7V_[
MU;6ZO?*PA;66@=P:MH175^D]:_8X#4H-SK=EU66W7-&V&FDC!"T7E58>M1B&
M@E+KI'CZ^CX4J0ZKMW?>]*F;T;;-P M]:CWSM7I;H\[;0>Y$;X$3=@6S:3^R
MM\XI%] ]<=#T@>%*=>Z':56S50&9<&-=ROD3;J*\HW-BS'U]9^OG2OJ;XI3B
ME:_.ZMBV49V/U"T%JS;%FTS-VMM6ZV_:%VIK()ZRQM$Z=U;9S=V&C'+(%/AQ
M[IZWV'6P))>2-D+$K(HGQFGI##;2U*TRC.R7=776G=-[<"]B=MW^U[!Z:]@M
M^G!^R %3LE/UGJ$CNG4&ONO5^)5&MT865LEKH%$V23VK<+(8GS)ML8IECA%&
MT@%LP83^?Y8_<9\LBIVMM#8.TDJ&P=I90"P!Z$@,I(Z@,">HK.=D;8NEXM*]
M%:CW/L7NIH*Q=ANG<JO7NS$JG:&+OLW3D+=':WL'KRB;!I-7! K/3IE>T/IH
M8='BVR0BFVV]$JT,DQ%.R ,!@\^0^/CR.?Q_3PIAB"0"0N,D#@9Z9/AGPSU\
M*B'4O>?O7+UGLK<87<=5V.=']3;!L;<K8FZ2-R5#2NS;O=*$(I)7\&XKK9KP
M/H<YHL(4V(3MVCK+L^YV@W5ZC-)6P::F@Y=HF/#\CY_AC^%3C@'(Y.,'@_''
M^;YGSXJX\?M&#UAL#1K-=[[[#VCUQLG:MX/=-R[:C5/-.G,ZSZT7JU7#7.O=
MS@:X$KVT0VS=F&]<L00-:B.(#V^L7"CT^60DQ9X08JFJ-7/M9V>O$2J=G:Q8
M948^ U7<+ %O5YS$K 7KWK'Q!.^,JF:XM)J80I5P%5!G6W5SKXVA-JM=.LXV
MFYM[=LM <N*8F12$G/B,8R.F.1U'Q&?'GIZ5<=7& Z%-NZ/E-AW(??#<#+J6
M ;/O#@''%30_VK[%Q>O!)V=V> UNIGNSLYO4-YL>^'X@C:FI]9:Q%RMLZB ]
M\;+UGHM$@%+'L@E)L.I[TNAD8-I9K5OUH)O$@<&FSP\8XSGUQQ\,=>3U/H,<
MT*KL5@^6.2RX  &0%P=Q+,3N+#:H50I#-N(6^^Q>Q-_IOA=Z1VS*VG?JY:]I
MSNL( INK; "M4"[:ZJ&Y=Q4478;EM!@9'S3*\1I.M#I.,>M&6H%?GD(*+$I,
M%!-+#:K=5$W?W<V'>8N\+UKSL@C7.IS?;:%0]*/VFUQ]$TK9FI>OFA*C.W#5
M*3V1L-"MM;U=:=J;:NQ4_KZP'QKC&Q0^MYHBOEX0:=/)PW]_\/PX^&<^.:J.
MX*H*X!RZDJ 6!.TD-C+*"A Y*JP?&"6SAE7WYV-W;L/1=5HNY=I5JSW&)T<T
MEC9=LUMK@)NT'!OU8W)W7["3;"-^S)BM0[2WH:IZ4H9M'P4REEC,J/9I-?RL
MLB"A5-=W#[1WL$V-K6]NX&Z=.]646OO]:*5OS.*RO<FSD===SB=3ZWU%'O<J
MA$Q9*<M S9NT ]?B5W%OV(%C5FOQ<2P(,W"(*5N7Z"$]K6#IAUKMN\;63NVU
M[YJFM;&NMA,0QP\B\4V-'5>6AL@>)BPAD'%?@6"'7F8<&*S&C1Q33+:/)'GE
M2K>\4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*X;P^!(9S&D08;\=3WQ"H[
MT9EUE4CW?>]_+2T*;R][V<N^[E/K]W\IZO5]>*5Y?'P)+B7I,*)(>2RY'2Z_
M&9=<3'=SC+K"5N(4K#+F4IRXUC/H7G&,J3GRQQ2O9\+&QA.,1F,80^J2C'LM
M^2)*\K4N0G'I_%?4IQS*G<>3BLK7G*LY4KS4KUJ@05^KUPHB_5[N%>J,RKU8
M?<0Z_A7FC/G[SK;;COG_ .4<0A:_-24YPI40[NT13-]UD;6[63O-;<"6@3<P
M5FUI>+%KNW![(%ADQT*:P=K,V$]-BY&F2@^8%,ME )&)-<;GC)&4,*:4KFZ6
MT?KO0.MQVJ]<BYT:K09MA+S'; :+6RPV.PW X1LUOL]LLMCED35EL5HL)<F8
M-EBTR3(F2YCF/-N.EEAI2I45$BKPO"XT=6'4--N84RVK#C;&<J9;7C*<X6AE
M2E*:2KS2WE6<HQC.<\4KQB'$Q*5.Q%C8FK9Q'7,PPUB4IA*O6EA4C"?=4RE7
MXV&\KRC"OKA/G]>*5X:@P8[CCS$.*R\\MUQYUJ.RVXZM_+>7EN.(0E2UO9::
MRZI6<Y<RVWE><^A/DI7\L#X$9IIF-!AQV6'5/L-,1F6FF7EX7A;S3;:$I;=7
MAQS"G$8PM6'%^><^M7FI7,XI3BE>M3+*UI=6TVMQ"7$(<4A*EH0[Z?=0E><9
M4E+GH1[B<9QA?H3ZL9]./)2O6F)%1Z<(C1TX2QB*GTLMI],7'W1D^2<>3&/+
M'DSC\GCR_F>*52SO[V#L?4?JA>ML:JJ-9M.TAY.C4G3E(-PY60=BV5LZ^5ZA
M5@.]#"RQ9%QAZ;8URY3 V=!D.QXTC_++*,N.I?']OG\NI]*D;<^\"1@]#M.<
M':<E6X#8)&.1D97.X59V'XCDN+M#P\-.Z/IU.L-C[CKUSL_<I4G$F/@-9Z2N
MNN;'L1Z<CY26'KQ>;F'I]UF4Q\L^4',BJ)9)Y>#-:5!RXJ/X5<?I%N ]V7ZM
M:IWE<ZO5J^]LC-HN55!5T9*C"!]#>O5F;U3/:9)RR+WS<AKIFL&2L]AR/&?,
M$)T@;$@07(\5I3\ZA2Z>)EUJI.Q;!JEZC[SLI$3MZ3UN?,4G2%@M5,.[ICT9
M=['ZG FAB5M6"P$0N",5$:#&?%U^;!G?;&;61CD4C+?7P^NOP(J2 -OO Y&3
MC=[IR1M.5 )XS[NY<$>]G('"<\3KJZ0H8:PB:7NBX0T4V[[%NU'K&F2=CLNE
MZ!JV_6S65QMFU04)UX?6AX6ZT*Z"!D 9.-GK/FJ'Y=,#GX8F:^RJ*Q?M)XFV
MNJ-3KR"T95[%N2^-RM7:[JMJ;UU9+)UV@[GWPFIO:AU]?[H+D#DHGG1-VK%D
MF#AKN(\ <8"CC1VOF#PB-(4J4!OB(]8#Y@K7E1;?]DV$;:57-IE]?28&EMEV
M#1(@V>V@)U_;)3CR3,ZNP*K;)T4C(&1 EAC52Q2:F:/LB9#O%*L3U9N]SVSU
MRT3MO9U?KM>V+LW5=%V-:0M<@3(8L$7N=7'FU"8;12<4)MK%0B+ E]<LA(?6
MY&=QE3;2DL-JJ;;GW0P&%X9@QW;1N.0J\%LE1C*J0I9R"QPSL!TNTWV3)QR.
MPIVTAT9RHD=>V>O:_P!M7W7E5V!K\N264*TV]UVJ&QHLZ((R)$]F7(PQ%-/#
M2I80HM\K)2X;JJ:M0.'P1 ^"*%PXP\8,AQAXZ!#91'B08,)E$:)#BQVDI:8C
M1H[;;+#+:4H::0E"$X2G&.*5S.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*54&S]KF!5D)S:W1#=RTO19^0NUMNA%XDCJN7=5Z5K BV6W9=P
M$U52,YOA /[J0+<IM;>)+D.4POMK3L<TUK#'=:A!8Z[J,?M&C:)<#9+>0+R!
M<S,RQV,UX#_X-CGP;DHP.P.C5QMUVM6*ZE>VL)[W1+"3N-7UB [X[29L<V\2
M@O>PVF,ZA+#D6X8$;RC*;8"R@TV.@F \^&4%$XK$X<2'R&I<*=#DMI=CRHLE
MA2V7V'FE)6VZVM2%ISC.,YQSC9H9;>62">-X9HG:.6*5622-T.&1T8!E92""
M" 0:ZZ*6*>*.:&1)89462.6-@\<B,,JZ.I*LK Y!!((KG<MU<IQ2G%*<4IQ2
MG%*<4IQ2JY]@^O<7L#.T+@M9EA:_IG?=3WH5KZ0R2C=]DT>O6Z'6JS+E+)P,
M!8D&UGPEQ5/Q%+J=D5>,/Q!;^,^/AJ5KMU;X0$#5%:JD0+V(/$;S5-7[^HT7
M8977T5XHNP[(U35M"Z2M+$!NY(;'B>M6EJTY3:I38TOX:QS[#9;.Z8KY$X4:
MF*5<CJ)U[[#==*S3]:; [#:UVKJ36^KZWK6@5*G]<)NH#8=FHP @0 3*6N3O
M/9K9I,< )>A2X#=?%JFSIB262#7PV8DE2L0UUT/9I!S25@);1=M$_4>\NU_8
MTI\12F8#5YVSV9)WM0P[+Q]IIRQ$?5M7V+8ZF(BI<*/FX2H,A4T(F)B(XX]?
MQ_'P_#R]:J)3G"MG"XRX."  Y/N#(8Y*C@H, LY&37.N>%):M?T<IK?6?:B=
M4*QMO0%0T!V=(+T^-,7;9 X"=V6<LEUU;9I%]88TU;KVK<.PXQATL&VN.'++
MPBX>%%-CESYKCPX'Q\/R_$8J&QN.T$+DX#,&8#P!8*H8CQ(50>N!TK-8'AFE
M@5\"P:SOYH'UA!=IJ'VSBZ!:U)!D6&5>:%7*^-$U0IM]5Y:=GT.#9*E6[B$'
MNT+YV+GBXPV0>*#8@]N$^OKC]OC4@KSN#'W2%PP7#>!.5;*]<J-I.<[ACF!J
MSX(U/K5*OU!@[0UL+&3].[?TKJ^UU?JGKBL[6KH'<S,P$?M6V-I1;%(MFW[^
M&H),M101P3,U; ?@F"Q>SAK(5GY<95 9@" Q 8;6 ) 8;@V"/$;E5L'C<H/4
M"MX@<3  B!8,7';B# PZ")'16DX2U&@#HS4.)';3CZ);9CLMMH3CZ82G&,<5
M%=CQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*KGV/IV\-
M@U1FGZ?L%0J<,LYENY&CI6PCSDD+ZDX?  '000@L9@JSEQF>;1+:(1H^<L0&
MFG'E2V^G[+WW9_3;QK[6[:]O'A&;&WMX;:6W2XYVW-R+BXB$W<MAH[<HT3MA
MI6*KW;<WVEL]=U"T%GHUQ9VB2DB]GGEN(YV@_M6]N8()#%WHR))PXD5<K&%+
M;QZ^LYV&>ZW44Q&JE:J\-5>-QDU6NQY":Y$:$%S(G+$=J<[(EOM3$P,R)KLU
M]Z3,D29+\EQ;KRU9J[5VTEMVIU"![RZO)/:;=S>73*;IS/!!-N8QA45H^\VH
ML8"(J*J   5'9B=+CLU83+:6UJGL\Z>R6RL+9!#--#M42%G8/W>YVD9F=F9G
M))-07TH#;HC@X5U>SK8;HW9P_-QK^NPA*V*(:X(%,*D/,U=DL,FQ(X,E*P\_
M.K'SKY<.E253 C\1M,@?.Z'M[/H37$E@O]*S=H-)E]AN=4N(K,1ZI%%A5-V8
M9D=IXDPL=WW'>RHH2X5R5ECT/8>#6U@COC_1D6@ZI%[;;Z;!+=F339)O>(M!
M-'(B02MEI+7O^ZC=B\#1C=')L$YYK7H=.*4XI3BE.*4XI3BE.*4XI3BE.*5@
M9W:>L:N3="V;8M%KQAA#+KPHY; (HDRW(;P['<=@SI[$EM#[2DN,J6UA+C><
M+1G*<XSS8V^CZM>1">TTO4;J!BRK-;V5S/$Q4X8"2*)D)4\, <@\&M?<:MI5
MK*T%UJ6GVTR@%HKB\MX95# ,I,<DBL RD$$C!!R*R0%80-H'-&*T;$V$2^MU
MMDH$(PRH]YQAQ33Z&IL%Y^,XMEU*FW4H<SEMQ*D+QA6,XYBW%M<VDK07=O/:
MSJ 6AN(I(95# ,I:.15<!E((R.001Q65!<6]U&)K6>&YA8D++!*DT;%3A@'C
M9E)4@@@'@C!YKN.6*O4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI7C/W9_>S_>XJ#T/P/Z5KJZT=B-%5'KG4:I9]M4$#91P^WQI
MX,K91D,G#D2;19)$=F1$>?2ZTX\Q(8=;0M.,J0ZA6,>2L<]/[5]F>T-[VIO;
MRTT74KFUEEL7CN(;29XG5+.U5F5U4@@,K D9Y!KSGLSVCT"S[.6EI=ZQIUO<
MQ)>K)!+=0I*C-=W+*&1G# E64@'&01YU8+IU_J7M'?\ X?AO^BYSFNW'_.[M
M!_[2G_45T/8S_FKH/_LVW_ZM64YRM=-3BE.*4XI3BE.*4XI3BE.*4XI3BE?-
M#XD?^J_N/_!NB_X-P>?6OV2_\R+'_P!;U+_[EOE7RU]J'_/"]_\ 067_ -M%
M\JVZ^''_ *E2G?U=N7^$<[GA_P!JO_/34?\ T%A_]G#7M'V:?\TK+_T][_\
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MV58B54,6QM-4H/>-AV/VN^9@Z#U'J^@PJZ06'M)G9UCCS)(69A*":Y\"1).
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MZ9#O])8[&/WOEL?/E^]YJSGR_3G.?SYYB7'WA_LCGXL?+]_TK NO\HO^P/\
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M+DR2%L&XBVX0)W2GP!5R222P )K!GCC=KSW;82'2+L.0]Z96!MI1[ID4VNW
MPV&$I48)R0!F^M&03E5W0P='Z?DQ&]P24L/[9[B[#U((0K.NJ$M*$:3AUHU0
M3R6L8PMZQ2)$2>52I(R6G+0MI:[NI[OZ3NQXF"SY:-6)8Z?:DDN>6;))"' ;
M//'3<V64TRQ4"0'VFZ!"+NQ_CUT/%AM4G&YQ[RG.!GFJA:RF!9_R.(+%4IK+
M&P:"](DZYELQ&VG5X)->Y;?>ARUGGGD*EI'L1Y@I^!C$U]6)S7OH18T$R#5;
M4L;GB2Z_RT30J%]CN P13D;,8&!D'S4 $8\L<BV>HLSW;%HU/^,LQ0 7*'$,
M; [..0V2-JG  K2DCZ(3_23C^]C\_.6KOZ_KBE?IJ^"-_.L>G_\ P(M?_:?>
M>*LM]XUM*7,B-RV(#DJ,B=)9D28T-;[29<B/$7';ER&(^58>=9BKEQ42'6T*
M;97)CI<4G+S>%5!'*-($8QHRHSA245G#%%9L;0SA'*@D%@C$ [3BV70.L9=1
M(ZLZH6&]E0J'95SDJI= Q P"RYZBN3RFJJPNP?Z/@_ZD6+/]?$RLX\_W_+.<
M?O9S^GD@9/U]?7B>*H?I\_X&O7RX!U\O3]SY].O0]2,5:IQD'PZY\,_L<$YZ
M]>>G@IQG'D.I^>,=.".A'Q(]:5KX\4BEM7?I1LV$_#O<Y@'9]-6^;&UR0OD*
MSX"5C=.ORMIGQV-<28]I)QPM39.G7H<)N8N,H8T:C1?F0F!*C4,..F,<#K_'
M'CX=?D,U4GWA\_TK712+AM!>X:,\$NG;F?V<E=T3@JPT<O.[ S=!M] <$+(F
MI61\+:XV=*LUE6A4T2S1=B25?A<);OF21A<]+M,DR&12/3.<^'E]>(/GTJYQ
MY#& /#[V>G'S]/SKW>%=L*V7T_U"/TS9W:K:.;3U*N)SNK/W@8W58=?0-C*E
M:U5I^96Y>TD9IHJT$7W[S'K:-4/8C6S6L95GL?S92AYV5(//&>A/S&<=1CZ.
M*A^A)QX;>1GUXZ^?UBH,[7UFUTWQ-[3L/14#L\6[1[ [#=.X$36UQZ[5RR]7
M;]H<#61@"^6P%MG-1N" 8.AB&Y\\O:95SU]8:?<'":H($D_%^;AX/4]>OC^)
MZ?AGIF@^Z.>,<D'H>,>7UU]>7XCNU*?N/:U/[!#M4[:VSI"-U<\1OIK 8':2
MO5KF5KM7.8@TP&'FUD?7RI:O.W,F*F5JLW-\?&&R,Q7922;$*,_(8'J".F",
MX'AC/S^?Z<2H(&/4'Y9_D?HU0;:/6_L!2JE=.ONP-([4L_9'L1U9\).C]8;:
M.U_9[3 IMOT4NOP-TA)NRQ@L@&UG/U\4A2C%J2:,!&TCV<%7W5PY4>0^^/IZ
M_O\ PQ4Y!Y!X&<_7AC^?2K6:VU/L=KOG5]4/:;V1&WI4O&2[#=O+;MF3KFR1
MJJ[U$M^L\L 3Z=ON"DUB> MK4F!4X-68L+TQ@O%P%D"HSV&VU .?+GGU 'U_
M?Q4'&"<\$8'Y_P!WRKZS>7CGG'CG)^ QCC^7(/'A5FG*<C.<^.3^OYCQ&><8
MP,4IR<_#/&>O@,\<9'P/7D8SU5U9K_0R3G\Z?94G/Z%(?:4E6/T92K&%8S^;
M.,9QR#Y').,^8SGPZ8X!^ Z5*_>'QJ3.6ZOTXI3BE1.5_P!,9W_?!W_5D7F)
M<?>&3_9'G_G'/'EY\>-8%U_E!_L#_K-75$GYD4=/DCH'S0A'A2GX(S$IF%DC
M,98<<BP,39&,QXF9CZ41\2G\99CY<]UW'H0KEC'CU)/.,?QY^/)],>&-]>=:
M'M/^(]VW/1]&W(]H9_8L:X]'MC]B+UKVDV;6M5C,R*;M.OBT[!'6&SS42XS$
MFK2I@0'KYLA.ERBDZ,\6=CIC2#,>X5'(\B,=3U' P./GC/Z5E-"@#8.,,!N.
M<<@GPS\<^0(QXU:?9OBCZYUQ:-;Q9%">>HVPH^AID*RG-IZGIUV(C^P+U=16
MRFO]+G+.G8NRA=5;M0ER]3@0^.T*4R;9%?/' )+#3;UYQUZ ^N<G&/7I^M4"
M'(;WN1G^RQ''KC^[UJ:.JO8K:6T=;]@KUMW7F:^]JG?/8RBU\759PNP3SU4U
M#>[/78(V%"A2<9?LD)D#\CD/29+#-C-(63@)@#IL>/'A@ 0 ?(GCID ^!.>N
M>GB.":I=%#*%/55)SX9&>OC]?&JUU7Q;*">7?@<O5KLC85=$Z?ETJAZZW1I?
M;TJ[6+>6R8^I*+KHM8*-:IE<UYL)B[$!3-K!68@J( !3E6!HJ3A1EI5)0G'.
M!GDX/&!SX9Z9Y%5=P>,'CG)*D8 &2V".1X#&>>.#Q7;Z2[WWYS=NU*'V.U\5
MU@+G=IOP"4Q@B6IA(3J8B/Z>ZRWU!"V.U5ORC645LN9G8UAJ-G??S*81+#5X
MG$%RGXPJ *>Z-I'3(P.HW$9_+RXZ\]",0(!1L^Z#XY.789P0,8&T'KXX\JQ_
M8_BX4[6NM*!MX]I@L)H]UUB*W,E=RV[J#7MJGZ\L=EL(^MYUO1K?9!MJVM=I
MU/!Q=@$*=6QK&10JPA JC$JQR'AK()U&>F/ GI\N.GZGUIW.20&R0=O"MC./
M$@' R<9\.IQXRQ,\1.(-V>?KA/1-XA:?J?9"-U8LF]EVFE+#C]GE:J'M85YF
MC8)8N4VJOQK #'E#K4-"A1 FRAN$1CQR$B%'=Y&,\D;L>)YSUZ ^/'4>1Z1W
M)P/>&2NX#YXQ^I^ Z<UCLKQ,XU:TT_V"V5UPV9K?4%HIU)NFD[K8;=K%D-LF
M+LJXUJG4$':BLFT00>F;$?5<*];'H]^+LAPM&4>/ESD5ZKFQL:=F3MW<@^]C
MG&!D^>>F>/0^-.YR=H<$Y(8 $XP,YZ<^F#SX<G%6)ZA=PZ+V[ ;!F5>.''V'
M5=R8I-V'5G85&VU4<SB-=$6L*5J.S-;EC-1MP,F%-1VW'HLB&4#G8!NOFQ ^
M<+5[U++C'XY(P>.F<CTY\O"J9(RA'D>1P0?F#T\?CC-6]Y3QZ8^6 .N<'&.H
MS\JMUBFS-X53KYHL;L2UMS)C$8$"'AQ$!M:I9P]+$I6.$MOX;<8@H?\ AW7)
M$^7Z8\6,R\YY//\ LQG^P[,]GKWM/JEOI5B41W4RSSR$!+>VC*B6=ER&D*[E
M"Q1Y=V8#W5W.MK7]?L^SFE2:G>!W1-D<,,8)>XN)%)BA# %8]VTEI'PB*">6
MVHV@\-WWWN'W7:MX.,UPX;L=<>I\"O'F2TFLU2LJ+#R[ VOPH!<8['4W(&L9
MD2G7W72#SLJ7,PY)>PXCZ=G^S+L]-H%GV?#7=O!:W2WTMU;- EW>78ADA:6Y
MDD@F# K*P1%4")0B)A%P?G2#[1==AUN[UPK;3S7-L;..WG69[:TMC-'*(K=$
MFB*X:-=S%B9"S,^7;(F;'BP=BO/'^<G4GYO/_,>V?\W^?+_X\T?^!3LQ_P#U
M#6O^GLO7_P Q^'T>-U_A@[0_Z%I!_P#@7?\ WW\*^@85*<G"QLUW"4NS($.4
MXE&,X0ER1';=7A&%94K"<*7G"<94K.,>7GG.?KSYDF01RRQC.$D=!G&<*Q49
MQ@9XYP *^BHG+Q1N< O&CG'3+*"<9R<9/')KG\MU<JD/<>[5D:-#TZ2?>@'[
M0+L-39R(=B?,ZXK98YRC@K+.?F$@XP'%9GRYLV!,.G ,<C\B*L#9ZI4)[#*E
M974+W+IG5K6<NI#F;]8@8#4>LI0!R7%&S_M/+F5.A&1A2,7ECT0#@>60>?(@
MS4\2\V['<C39</"LOX4_+Z]*QK02+CK"T0M<D=/RZ-6[W+L]DR:(':I*\CH@
M.#BQQL9BN72VN2'7 8Z.RGXN*/?E,BYA@H8*&5S'""E1)VDV3UNC]D:/#VYN
MB#K6QZ=UC;)P*#'5\SEDYF\V7ZO-P>$Q0AR7#"B*]4%OJDN?)\R'K)"<ADTK
MA/83=B@GFW=S#++MQN,:,X7.<9*@XS@_A5V.":7<8HI),8#%%+8\1G;TSSC/
MEZ5<?3&SZOL30U&V>,,A5UPI1HI"28BDXKX&*L3#<@'5M&/<Q#='#B0\@Q\P
M]W$=;,;,CUX;SY\M$$$@C!'!!X((Z@BK1!!((P1P0>"".H(JI/AY:]F:<I5;
MUP?GB'3R^OVI[5';@FYY)R>+L6Q-]6;,MJ.7BP9L;Y8W:18XG$B,/CATMV.E
MN6OXUG*U/K\!6R+BE.*5J \0?NV6ICIG0NHY,T9:UQT1;Y=&T2(4D#$GQ$/X
M!5EQ:&G/FDV'(9<F'HZLMCHSV(XUQ1%QR4,]Q^S'[/(M16#M)K21RV08MIM@
M2DBW+QN5-S= %AW,<B,J6SC,KKNE B"I-XS]HW;R33VF[/:0\D5X5"ZA>@,C
M6R2(&$%J3M/?2(RL]PIQ$C;8B926BI1K;Q'M^ZNH=4UX KNLY86GA8@,;)+!
M;'))OQ82/0V[.?CVN(R])7]<N.-1F$*5]<-IYZ!JOV3]G=7U&\U.YN]62>^G
M>XE2">T2%7D.2L:O9NRJ.@!=CX9KA],^U#7=*L+33K>UTMX;.%((WF@N6E94
M& 79+U%+'Q(11Z5L3Z+]SML=E-AVZJ7\-2!HT#3%6&$[6!AB#+<G8-B1OMR'
M")\LTN/[$YY7H0PVY[J4*]WTXRE7EWVB]@='[):98WNFW&H32W-_[*ZWDL$B
M"/V>:7<HBMH6#;HU&2S#!(QG!KTGL#VYU7M3J-Y:7\%C%';V7M*&UBGC<OW\
M46&,MS."NUV. H.<<XXJR_=N>T+ZS;#)/,3)2!\_7<W$8>VZ],D.1=H4M]EF
M.TQ)AOK6ZZA"/2S*CO92K/M/-N>E6/)(2!-&3T#KTZ]1TKU"< PR@D &-LD]
M ,'D\']#\#6A'Q7M\O=<^Z6G;?:-JU'4#%@Z[7RN#SU@T_<MT.2HRKS0"?RR
M!2J?L+7X9DD]-$DB'S>U6*:/APXJ(,6"])*9S"V,&\[#"?>5G7<0C ':O)+
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MSV<-M<1RR6EI:/+%+W<"1S0L"&B4M(6)D)=G!)&V7O\ )5NSG[F]1_W,V?\
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M%'72  +V,:;,PATHV].?=Y*GK@X' VY'H.G3Y54" "6*_P!O!P,#W<CP_(_
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M7UQY>GECC%.[]?R_G3Y=:/SP '[>(_Q9XR/+R\3U'UT_2G=^OY?SI\NM/]
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M21U"S2%+F-W$181!D#G<^!V>RMBV>GD*^$I^L;#L8R<AGBKV8<^!7*V#%5Y
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@4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g766269g35g12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g35g12.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2GR4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #W    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    * &0 <P!K '0 ;P!P "  8@!W       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #P     $  0/      0 !.$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             $
M*   !V(          0                         !              =B
M   $*                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   $*     !29VAT;&]N9P  !V(    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P  !"@     4F=H=&QO
M;F<   =B     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X
M=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI
M9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!
M;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#
M;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )
M=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O
M='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))
M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    #.$))300,     !_6     0   *    !:   !X   J,   !^Z !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !: * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$
M 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T
M<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2D
MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$
M P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#
M4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T
MMK'7N+G& /('D;FM:UVYGT"W<[:I_9&?O'_-9_Z32Q?HN^+?^HK1TE(/LC/W
MC_FL_P#2:7V1G[Q_S6?^DU7S>HWX8M?9CN]"L;AD#WL#=-[[:Z]V1[/^#JL_
ML+#ZS]=_L&0,;&QV7V>DU[RZPAH<_P![&-BMWJUOJ]]=S?\ OB)!JU.]E_8\
M.AV1E7-II9$O?Z31).UK=SV-;N>[VM4<.S!S19]FN%AI?Z=P:*W;7PVSTW.8
MQS-VU[?SEQ/UC^LEW6Z<?"HJ=2VT1DT7UU^BYCQM=G4=0L]3[+]@NJO_ $WI
M>S^=_G*O072]'SNDVULP\ ,KQ<4/--;';'.8'.:]YQ?T7L<[WUY+_4];]);_
M #B8)7(CH/S7S$80B2;G+7A'Z,/ZW]YV?LC/WC_FL_\ 2:B_'#&E[8>6ZEKF
MM@CP]K6J=+O<Y@=O8 US2>8=/M/W(EGT'? IRP&T3VTBK>VMKIC:(&I=HW\J
M;[(WN[7OM:P#Y;F.3G^C5_&O_JF(Z2D'V1G[Q_S6?^DTOLC/WC_FL_\ 2:.D
MDI!]D9^\?\UG_I-+[(S]X_YK/_2:K?MO"_:=G3 +#?2 ZYVQPK8US38RRR]S
M6T['_P TSW_SWZ/_  ;U?#@X2#(\0D""D@BK%6+^A0_9&?O'_-9_Z32^R,_>
M/^:S_P!)HZ22$'V1G[Q_S6?^DTOLC/WC_FL_])HZ8$$D R1H?(\I*0?9&?O'
M_-K_ /2:BYCJ'@M/MB?"8^DUS6^SZ/T';5:0,K@?!WY$E/\ _]#T[%^B[XM_
MZBM5^M4Y5V":\7*=AV.<&^HQH<X[YJV-+OYM^ZS?7;_@[&?Z+U*U8Q?HN^+?
M^HK1;*V6UNKL&YCQ#@>X*(-&U/"'H7UE]F4SK=<UO<;:!?D-K+@_UFU66MR<
MG8QW]"]1_P!#$]'_ +5JCC=!SW8S'9%S,>U]A=3EWBQ[LBSV-QZL;!VUOKQ:
MZZOM%C[:/??;_-?9_4?9NM^J_5,?JU PGBC!Q;*G8]S+-A%#1MOQ+\=E?ZW>
M[Z%5V0^ROT/^%_G=2]M+LFW.?OJ=Z3,=N4\@36Q_JO?C;-SF.R+;F5?S7Z7T
MJ_\ 15IV?+PQT,3U_NA4]!H7!Z=T+"PL*]W5 +7.:;,GTG6!HQF%^20^C95;
MCL=;O?Z#?YST*ZF*KT.K)R;;,FZR\$V.OQ<7T]E5C?<[&?555O=M]%OH6U^M
MZ6/L]+U/]'?S,;(+WT88<RYUE3GXYM)V-D#'=U#)<[<[)RK-GH8OZ3[/1ZES
M/TWIJG9TC/Z<[%J&*RKTGA]%K UQ9M<7,==91NR=EEM[WVU_I*/YO_2W*C[A
MTE6D?LW_ ,%B@01P>V2=N*,1D^7^]ZGM.FO#L5@;7Z;0T$ "!J-Q:&D#;L^B
MK-GT'? H'33G'!J_:  R@"+(C6"0UQV>S>]FU[]GLWH]GT'? JT-A;)'8=$1
M_HU?QK_ZIB.@'^C5_&O_ *IB.BEYGK/UE?1DOQZL#J3CCDA]N-5N!#B6;]K]
MU;Z_;^C>YU3_ /SXN;R^O=;S,C[;BW9-=%4,;50'PW;[-^0S]-55]I_365?;
M/5?Z?H^O_@[+>OZQT[K3LAMW2,DU>II8U[X8P@EX>VK8]EE=VY_VK_#_ ,U]
MELH4,C$8VRVZKU*M@+*6C8UC V;+K6>VYN/ZMGZ6_*O9]K]GZ%'+.,<>@U_E
MT1,D"P\_@CJO0LJFAS?M%_4;'7V44[?>]K:_7GTG4X]%-3K/YNOU/4LMR<E]
M7ILHK7:X5HOK]:6DO&H:9X+O<9#/^H7'W].ZC?;=F5M;<YC?LU)WAEPV_I6N
M;2?>S)8^RR[TKK?5_36TY?\ A%UG26Y0PF'+JKIN,EPK$ @GVN<R&[+'-_G&
M_OJ'%(V8U0W"N+C/&>+7?B&G^"V6Y%#[GT-L:ZVL O8""YH=]'<WY+&^MGUA
MNZ%BT74L98ZZPLBPD" US_S?ZJV6X]#+GWLK:VZP /L  <X-^CN/S7)?6CIG
M4_K"RG'R.CWBK'L>]CZLVBHDR^EO->1[+*=EW_7-BE2Y6#_C#MZODLZ7ELKI
MMNL=M%0LAS6M]1OZ7<_;8W:]_P!'\Q;W3\@WCUG..$;7$$URYY>"\U;JZSL]
M&QK]^S_J++5R6-]0NIX=WVFGH][LD-M:Q_V^DL'J,LH#G465;G[6V_Z>M=E]
M7NAYU&%7CY]8QVTBO8RN\W[VMK%3V7_H,=E;_;_@_6_1V^E_H[%#EQ6>(:GM
M_:V,.<1'!+2/<?\ >N[B9!R<9EQ8:R\3M/\ #^3^ZFRN!\'?D1T#*X'P=^12
MBZ%F_%@)!)(%#L__T?3L7Z+OBW_J*T=4_LXR<6RDN<P.+)<TP8#:G.;/\O;M
M0!TO,:!4S.M;2P#:##W?G[PYSQN_T7I[W6)P (UE2BZ:KW4OWM]!K6$G<Y^V
M9(.[:[Z/T_WU6_9N9#3]NLWM<7 [1$%@KV07>[WCU/>[_P!**)Z5G.;L?U&U
MS3 (VM$B=SM6;7>Y(PB?TA]DD'R9V](JN#7.L<VZLNLK>T"!<YIK;DNK_F[K
M*MWZ+[1ZJS!T3ZPMS/M Z@PM,.=6#:QI<UO'IA]E?I6/_,_G&4_X7U_TZT?V
M5D-MLLJSK6>HYSMIAP:'.LMV-W?NONL_ZW^C_P #C^BU?2,IFTG/M):(:8;H
M-/;[MV[WM_/33BQG]+_I*B>'8.D 0 "9(Y/BFL^@[X%!P:LBG&:S)L]6X%Q<
M\3W<7-;[OW6^U&L^@[X%(BC6Z41_HU?QK_ZIB.@?]IJ_C7_U3%6NZ=E>M9D8
MV6]EMAT8[6L [&QZ;M[?;L<Y$ '<THN@AOI98\/?)V\-D@<SV^E_:52O SV/
M#CGN<T.W$&MLENHV?N_0V>_;_@_ZZ$WIG4V5MK;U)P#6AH)K:3H'"27N<[\Y
M'AB?TA]DD?1GG?5_I6=!R*CI^X]S!,NLW%M;FL<YS[;-_P"^KU5;:JVUMG:P
M "3)@>96?9TG+L:0[/M#G/<XO;[26N:RKT]K7;/\'OWL_/2?TSJ#W2[J+X(+
M7 5M'M/TFC7V_P!?^<2$(;\0^PJL[4Z:2SZ\+J++F?KA?1L<'2UNX.(VLV#:
M6^WZ7O\ ^_IKNF9;WLLKS[:WLK:PZ2USVA[?7?6"QFYWK/W-^A_,_P"@K2X1
M^\/Q5?@Z*2SAT[-W;OM]FXF70UL2!#8:[<UO_"?F/3_8>H;6?K[MX %EGIB7
M;7NL]K-WI,W-?Z;_ &?F)<(_>'_.5?@Z"!E<#X._(JHZ=GEK0_J%A</I.#&"
M?ZH_-]J>NK+JK>W+M%SB]YK<-/9M#1NT;^=N>D0*TD"D>3__TO1K14<*WUB\
M537O],.+B(J]H]/W^[^0J0=6[=8[(S&LI((W-)G=MK]H8WU/S_\ C?>K[C8V
MDLKL%-C]CF6.$B &-L'N_/VL<A-JRP0/VBTL9$2UI+M!NWNEO\K_ ,[22UA=
M2QPL;E9(#=KGLV%X(;Z53R[:W=^EV?O?SEGJ)>HT5M<<W))+B'EK2>-CG-:P
M;O\ 2?\ "_\ HI637F!@V=187@.+I:V'.)EOYS_3;M]GL3MJR 9/4AR2-K*P
M(/E[O\Y)33+ZB0S[7FMNT:1M.Z73M]NS:Q3;DX]UKR+,K=9.TAI; 8#9LKT]
MGJ[?SOY"M5LR6O8Y_46O@^]NQ@#A_9.YJN>O1_I&_P"<$D-#%QG9#?7JS,@:
MD$/  )'?;M'^O_;:/3A/Q][SDVW-+7#8\B),.W>UH5CUZ/\ 2-_S@HV7U%A:
MQP>XB&M:9)/R24L?Z-7\:_\ JF+.S'-9DW.;=D5N<YI(K82UT-:/38^/Y/M_
ME^I_.+3>QS: T#<6;3 [[2UVG^:G&101/J-^9 24X_JXX9M&3EN:YI8&EAT#
MA#+-H8U_Z-W_ %?^C2+J:B'LOS'FT-L<UK(G=]'WN8UGTO;L6QZ]'^D;_G!+
MUZ/](W_."2G)LNH:\-??E/L;4&B&P1(9NO\ H_SFUW]C_MM1-M0L!.3F-/8%
MAU$PW=M9O_U_TJV/7HF?49/Q"7KT?Z1O^<$E..+F#<_[5E!SV;G LEK?4;M8
M]PJ;_*K>QN].,FKTW$9.:X%S7&P,^B(<[:V:]CFN_P"#:]:_K8^OO9KSJ-4O
M7H_TC/\ ."2FAB8OKUNM9F9+@X>G[_:06EONC8UWTF?YCT5W3'.DC*N:\L#'
M.!YV_G'_ #O];%:]>C_2-_S@EZ]'^D;_ )P24R8T,8U@,AH D\Z(65P/@[\B
MGZ]'^D;_ )P0KWML!V'<&-)<X:C4;0V4E/\ _]/U&D TLG]T?D0#F,.<_!94
M76555W/=H&AMKK:Z]3[MV[&L_-5BG^99_5'Y%EL/_9+G-/!P,3G_ ([J"2FS
M7U''M<]M8:\U/=6\-,P]FEC/H_F*5N;516;KVMHJ;&^RTAC6R8&][PUK5D]
MM8UG52:W.V]3RFP!)U+-6C]U4OKS=35]6\M[<<NK#&765.$!X9D8A<QSMEFU
MVW?^=_ZC!->:NM.S5]9.@6%TYN*&M <7BZLM )CW.#O:K%/6.BWW-HHS,>ZU
MQ+6LKL:]Q</I-AA=[FKQ+(Z[D6XCF]/HJJQ;76U[26&[987NLK]%NW])Z;_T
MFQOI_P S^B_1[UM?40XIZUT_T=S6_:KC6TCEOIVC>_\ .:[\U-A*9^:'#VUX
MEQ$:TE;ZS9EX55IIM>VMX:'G=[0 XEC/>[V>YS'>U(9N .+ZA/\ +;\?%5\T
MTMRBZW"=D?HVC>QN\F39^CVG]'^C]WY_^&58,P75@NZ:\$6P^MK 026NBR[C
M>ST[/?ZG^$L4HX.MK=72^W8>TO%S"&ASC!!,-&YYV_2]K3N4!G]/>YP%]9+8
MDEPC6.'?1=])5&?8G7N=^S+ ^T.:^PU#4/'Z1KG3^?\ 04?5PR]I_9EN]H!C
MTFR-W?Z7\G:EZ/%&K>^V]/AI%U3@\PV'-,Q^[M^"+59CW-+JG,L:#!+2'">8
M]JSG,Q 07=,<;'M <&L:1R6^FYWM;^:I49=5#7"C!O:"\FR&3):/3<[=+M[O
MT3*TCPUI:=72VM\!]R6UO@/N5(=2LB7860($D!H/\1N<G/4;&D XE\PTO(;(
M&YH>=O[^QSMB:IN;6^ 2VM\ J0ZG9MEV%D C4@-!C\1N_LJ3^H/;:Y@Q;WM!
M#6O:T02>^KF_H_H_I$E-O:WP"6UO@/N5)W4K!LVX=Y#V[OHZM).W:_\ =_?<
MG?U)X;+<3(<=F^-D1)+=AU^EI^;^8DIN;6^ ^Y#O$4/CP4V.+F-<1M) );X3
MV4<C^9?\$E/_U/4:"#6&]V>UP\"%0LQ,IG6,C-;6+:;\:BAH#@'!U5F5:_<'
M;?;MR:_SE9R/Y\?U?\'_ #G?G^0H_P#L0DIS>ALNP_VBW)JLK=?U#(NK'IO>
M#6\L]-^ZIKF>[:JOUT9DY_0LK'P<>[)NL8&^DVNQA<#=C.L:U[_3V_H:[G?1
M_P#4NY_[$I?^Q*!VU2-Q6]OD3/JMUK%#VT=)R\C$:XEU5S&[G.</:ZG\[TJ=
MOT'_ $WO]1;'U3Z+UZKKO3LK+Z??16VRPO<]L!C=ES6>H[^TQG^8O1?_ &(2
M_P#8A1PX>+]+CH?-NV,W'P?H>UQ&O;^7B_PO7P_R^=EE8(R2=UUK&.;M=6QT
M-(U[1^=N0V],+7$_:\@R[<9>-?N:I?\ L0E_[$*5K,/V2-FTY600?I2_Z7]?
MVIW=,<\M<[+O#FL:TEK@ 2!J[;M/TOI*7_L0E_[$)*6JZ:YK'M?E7.W'0AY;
M#1]%H_[_ /OIATPA^\9>1N//O$'Y;5+_ -B$O_8A)3%O2PUKFG*R'!W(+QH=
MS;-S(;['>S_P12?T[?8'G)O@%I+-XVDM_DEJ7_L0E_[$)*6;TP,+2,G(]K@Z
M/4T(!W;'"/SOSU=5/_V(2_\ 8A)3<25/_P!B$O\ V(24W$+((]/;^<\AK1YE
M _\ 8A2Q_P"?=_5_PG\YV_\  TE/_]DX0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !+DU-
M "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0   &H!
M*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0
M *0   #0 "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,3DZ,3 Z,C@@,C(Z,3 Z,C8   .@ 0 #     ?__  "@ @ $
M     0  !V*@ P $     0  !"@         !@$#  ,    !  8   $:  4
M   !   !'@$;  4    !   !)@$H  ,    !  (   (!  0    !   !+@("
M  0    !              !(     0   $@    !.$))30/]       (
M      #_X0$P34T *@    @ !P$2  ,    !      $:  4    !    8@$;
M  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
MD(=I  0    !    I    -    /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HQ,#HR." R,CHQ,#HR-@   Z !  ,
M   !__\  * "  0    !   '8J #  0    !   $*          & 0,  P
M  $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$
M!     $   $N @( !     $              \     !   #P     '_X4"
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MY6M#:%..*2A"$J6M:U82A"$XRI2E*5G&$I3C&<J5G.,8QC.<Y\.,91QTI&3
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M$@%D5$5!W%A]8]CFPP1F!YI!(Y#!4CC8*?<!BS%''CN'CC[CR,Z+*QV2V/\
M*(_+$ =;-Z[?DX+16N0I\&NTO5=@MM#IVT92 @GS1[$-AQ^/G"D6)\E9@:WR
MC&?806VH\DAAW#[_ %%=-0Z8Z V.YU^O67<2F)3)?C@M6==#8D$<AX"M$K0
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MW5*%293;$+%!R^W]W[21&8?8@H^0L$?-5>GQKSLHT_*STDP@)B?M?LXJX_\
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M7](P*&60YXO%F9QE>,\B-A9AZ3TRBBE=K,W[N*"<_P#Z@N#ZLTRA26B4>#R
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M0\N%)UL9+SGBY[.%###->/D9:0A.$XN_XA8DA]/HGB_[(6UJ*(Q]@)(FCF/
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M&.,9B-\?]FJ,^_X^'I1AB\9^;'AG [OAGQS\V.7(QRZ@_K_H<MR>$/'OX_U
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M$*4\-Q)Y!7@@E* #GTT[3V[A:I:INNFNM$.BVP3E&UDY1(9=;M49;LQ% UW
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MC7NJP+82.3O(:3LV$'J12QM%&C*R\K$\G'$A0DY,Z_5UY[#D2Q30=C/%]7U
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M:O-%$KN\;5FF)F-SD<QP-Z*R.\JSQ13O4_56_P!W?ADZ9U[6J:VWNP65JS2
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M^8YI8$=H_6F6+LZ\.G>FKIK?O;N7:$'L$"AW/7>I]KBZW@X*G;"N Y%^=C!
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MC) 19VNT4(UF8$_4P,\A)/XF["WE0.9@V;/8V-KC1E"ZWZ7VG:=FKJL]G9#
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MY'\-7I;BKL+U"Y/6EHK#96!43YA%24*%9S&582%5D[W1S >47GALZ#T1U/\
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MIL>?W432-PQS+^[O::B3)H[-J:*+MC77R5&KR,H[5(]:Q7DA5O?L:/E1R 6
M[CIMJO2,Q?)"<[O=Z/9XL")&7,U37LJR/@:,AHU:EPCLM'M.$,J2I:DKAJ^V
MX0\64^RX<X0ZM6']3Z?Z>N;9Y/B5\2KO_(UX!=IZ^6.6"MZ8'=$QI3(LL-*/
MN6.G2EC%JY+_ ,Q:!]18WT&AH;&PFL=;_$-E6&GW3ZO43<-#0K1$-&\L(:2,
MV)9!W+#'R&)B#F1P6;HNV2?L?=>\MC;4AM2[TN>V[-)/#::)JU6FW@GXER:=
M!DS&)X!G(,?'046]$PWF'D6 P72?97W6_36GD7KZ&YZICFV-*Y8FBVNTDV*S
M0H0Z112%/1?CDI\HBPUXXXCVQG@=X2,=WS/:Z?ZSZXWO5'4537;;Y_8VE@Z<
M,=GT(HZ]>S+7L;"5XY$:%*M5HZ]>.-@"]E@"06(R G6.\8ZFUDC7NANQN-G)
M7>S-X$YUY9(4"!@$-@QY*!)AZ/!7-^^(1$DDB/%*DGC5*],<97JX0OPG0>Z$
M22PP[&&Q6K;*&8>G(BRQRO\ \BD;*O>R>D\RVNXDGN*E2I;+]OH'K6#IC62Z
M?I?<5>HH6WMGJBT.(KERO,884JP/ZW;8:]6]7]W$W"JS"7ZRA$+;:N6OZ=,5
M+6-;'VK5]<V.C4-VZ2]FHMMB!FK4B)C43V<0V8>))FVJQ.F2"4$-"EO(PA_"
M2W%O8>=C-WHY:%OUFV:ZV2[%0EBK[*=(%:Y#42/8V$B<Q1RQ03R2^DK?4Y+]
MI(<$R[_#CJ&[?Z>32?#SJ:WT'73HZ#K*K1I60UNW'%5EOK-6Y,S]DD%@SVC&
MZB::40\H57)D@-*[*G P-AO:^W_):!%M4X/4+'1M;S,H3>G8F$DE1DFY4D$*
MFXBMSLQ[H2F2.AG1'FW#LM/9(%\'<.O\+=K96ML3)/=CFU]RL;5)%=+)"N]&
MPJ&9A&#(5)/[SLCE<([-%VMU[3WNJNG>D/B5T'-T#N/\'=3]63[#I6NU>M=M
M]/4:8E=A\C8D2Q5FV<D6OB@E$?[LI/:EC24@-Z//DL,[6QU4C6MJ4ZU41X>Y
M6AJFUVZ@$15B&IGJ".!.E19B4& #ORJY=P <IMMS F6E(1AA36<_1GPZU.TT
M?34&LVLK2R5YYOERP8%:\G9($'?]7:LS3=G('T\ #MXS=?A%5ZBI]&UZ_4E%
M];:2Y<-2A*ZR35=>T@:".5E)7N[C(P1?"*RH.0!G8_S>LZ?CC&.,8XQCC&.,
M9YH;9_E'5.IO:26T+-]4-A"UB-WP7UY$GLW6NO;*GKE'V86L'2D1J@4-\MR
M:(+:D&'7YYI\R-SET=*B$J%P_O\ O^N5X/'/_P"?RS6KNY\L=V?$[8;)H>@\
MQT7IG6T]^ 84-9J0A]5[DHBO+-M5DE%SD7[QCL"6)YV.@H]:HQ@KW$PEUS#T
MAX+]H#R& )_@>#]QX\\_W]_;*A58?4W'D?T]_P"/Z?\ XS4 #Y43Y1*2]1T6
MPT=+*4CNJ;?UMK0=6,%(4^A#>"X)C*\MMN)0O"<*6A3+*'\,D/DM"^^&;W#<
M@_8DD#W^Y_/_ #STRQ =OU'[>/L../O]_P _UYR*NQG</N5V.U?9-7;2D('\
M!IIP N7&IT+6:C.*S#F-287N^>J3<=9&,(+'8=?8%+RHM.%,+8?94MA7I%"^
M_=S[ ?;S^G_XY_GEO@?E_P"<T:TU8-I=;-CP.TM9.6@6VU),ND(BQV:P7J'?
M23'>R'>VURT2\[!G.NA2#S .'HTA'M&%/#>) *''KXC[_ !_EX_SY_+C_,_<
MYX(C3RW'/GW\G^OGD?I_3]-I[-\LQ\HD#8S8$6-HAL,.F,>9L*M6:PQAS!K*
MVRQG4D0&&G/8WVDNX]F9RIO#JO:?Z/R>'CTF4]O$G''//>WW)X '/Z<^3QX/
MC*?NV/@@_IP"/S_+_P"?R.?BH_+H=[H@(]<K4M7B2PZ2$ S6*!5(6:R/)0IN
M7DBEUR*&P.^R7AL!#@F4O(8)PX\I3S3GC50#W+)'RO/CF1^>1[>S<'R?'(Y^
MW/C!C\^&=3^053[_ ,5)'Y<CV_+SY@[IEV([S5;;LY#_ ":6I:5.[PV9%2+%
MKJ-D((GGK-4XDIN?DY!)EWM$0P$:"8\DA3HTDE9#*2T9:<PAIQ0.T)5U 502
M#SRP^Y ')_($\'_QQZ>%>!R6)/OR./\ ,?G^7C^&=IU4A?\ *.[/L^G[&V#T
MNT^.53;-7[+@9R7K\0J:1#2PLB]%X/BMI3&!$F-C*&4Z_'N-M^OZV,9RWX<]
MR6GF4H[HJ\<>!_/]?O[?E]LQ14@C<.L;%^>>0QX'\OP_T'.>O70MOV!N+2M1
MM&^-'OZ3O\\"_P#AEI^QS5=O&*[("FD"^GB9AG"X>5!/:8:D@'/!#Z!2FFBV
M&26W$8BYX(;$;0V(HIXG'UQRHLL;?HRN"I_H<DJ]FQ4F6>K/-6GC/*35Y9(9
M4/YI)&RNO\589-PH@H([0@0PX8K"<(9&%9;''91C\B&F64H;;3C^I*$XQC_5
MRL<4<*+%#&D4:#M2.-%1$ ]@J* JC]  ,\S336)'FGEDGFD/=)+,[22.Q]V=
MW+,Q_5B3E1SWEO'&,<8QQC'&,<8R*Z=^D?</]Y4K_!P/&,H-<_I![ ?6+5OX
M-:QXQE7KK\[]\?6M$?P1TYQC.?47YM3OUH[F_BU=.>1]_P#[C_M_^<9*//6,
M<8QQC'&,<8QQC'&,X\--)5E:6VTK5_I+PA.%*_X58QXY_P"//'.,Y.,9"F\-
MBV"@0E7'J0,87:;U=H.BP;\YDCW)%ES67U+E9- BFR'V V!G5H%:=:44_P"D
MSZJ,+RK$3M[TU*&NM81&S=MP4H&G[O1CDG)_>2!"&8*%)"@CN;A>1SD9M+DM
M.&$0"/YBU9BJ0M-SZ222D\/(%*L0H!(4$=QX'(YS7W5O0[7=0WK>NR]Y.^(.
MWMAP2Z[./%Q8H=2$C'W!WB6(R >R<O"W%#,M>T%FD+PPWA"$H\<YY$:WI.K5
MLW+U^1=C:OM+)822%!3#S"-9&CKOZA!*Q(G+2-PH/ !)R$UO2&OI[*]N;02[
ML]DGIVI6B582GT_2D+&3@?2!Y=CP!F3UW4^O]1[]$9@Z?6D1>R 9:=B$-10F
M#:A9()H7,@J)SAO_ #2(EA'/64VRA&!I%"LMJQ[5E.(FGT]ING^JHOD]902'
M<1V+,'96B$M"[41/5,!"_NZ]B(@D+QV3@E>/4.4K:K7ZC?*M>G6$6R2:Q$%B
M0-4LPA/4]+Q]$,RGNX4#MD!(/U'-:^SG=:1_"D_4&J!S6S!#U0T_-9%?0>4=
MY\L.Q4*/X)>PC*U8;67E&%NY^8?&4*PO/S;\=OCGO19N=#?#^&Q#=]9M=L-K
MZ,@MR62QB:CJX1Q("S,$-H@,QY$*D$2"Y;ZEA6]\C K.8Y DIX(+,#P44'SQ
M^9X\_P !DK:%ZFQ ZHS9FUHIIVP8;3)"5T[TWA8YWR^JDV50O"TO&H_\IAI:
MEH85C"E^+B?FSO@=_P .,&C>#K7K^NMKJ.<"U!J9W$];7R-PXL7.[E;%X>3]
M19(F//)=>X3[5X+)CGF@5>P!@C@>&'DLP\@ ?8'V]S^NM_=[Y1"M0T*7J;0=
M@%FK%+C*!G[?#.9<#@ GDK9=C8A]ORX=F'D_T2W6O% *<J3C.2/#".E_$SXG
M1U*<NCZ6L"6Y/&8K6RK\F.G$P*M%5=?#62#QWKRL(YX^O@#BO7_Q7UM6-]'T
MY=BMWYU,=BW6</'51N5:*-UY#6&_#]/_ $__ +O&6?I#U>SJK7EN[/;ACTC2
M[=+L<O5HJ62E3L3"IB"2S)Z1;(3YFI"08;6@9#F<.M"N+6ORN$>5.%\)/A_+
MIZTW5^]A*7I:LIUE:;GU*T#QLTEJ96'*V)QRJ \LD));AI&5;O0'2;:G6VNJ
M=S$$MFC8EJ12\%H(?29VG<'VEE ^GGRJ'SY8YMM\F;.,7+I%HJTN!"-/SM<E
M'B,MCM(R\A-EFFVL.YPGQ<QAE*$X]3*OFQX<[EH3W:BASP3Z 5N.>"RLRGW\
MGDC.@= 3"ST;T_-XYDUT);_[AR#[@<^0<WJ8CP!<J4*"&,I7CYE,#,LY5X_E
M\V6T)SGQ_K\>2_ 'L.,W  #V '\ !D([PK^DHO6EZF-GTZNF5@J#,CYY#5>C
MB9>7;F,>[FXN.P@;!94K*%%M!@,M.>LZ8^UA.<9_&Q&[2O2GU]V"]"):MBO+
M!8B5?KECF4QM&G'!+L&X3@\]W'&7Z8>&W7GK!8[$,J2Q2=J_NWC8.')XX 4C
MEB?MSSXSS&U'J3;F+KM+%?H%LK#6NYR:D:N01'X&GXM@(OSQ@V):,;\"9(<5
MQI*E!DO)4K"O(I?CCQ_*CXAP?$#ICJV2#I+1]5V$H[F:"2:K7OV)*E2.9C%,
MTM<&$2B(Q,6C/GECS]A]JZ/:]&WM%KI>H+&FDL[6&",HZU^&FDC^MI%<&1(@
MZ,"TG':2.>!G;U\E98^QM^K.ZY+L'8K/9(*)NT75]=@70#"2108R';?E21UE
M",DD,.DEL#X6]EW&5CJRE7CYLY_0#X';/J7<=*-<ZEL7Y['K)#$-DC).OIQ@
MR\^HB2-]3 $R L6!\^^?-/Q-HZ*AOOE='%52OZ7JO\JRR0EG=NW@JS)X YX4
M\>?8$9VV,#CC(],9AD=OQ\?38:0TCQS_ %^5M*4^/^WPYVG.=  >PX_AG-QC
M'&,<8QQC'&,<8R&-7?GOV,^N.$\/L!T=_P!/&,F?C&.,9&-2_2%MG^\*=_A,
M/C&2=QC'&,<8QQC'&,<8QQC'&,TRJ,5JH:Y,7O>#\>K>U/E;>)$S5[*<:17(
M:5D3V@U:\;.RU"!PTC6G06<E0S:C7DK('DWU&X*1C3JL^H@N/9W,T<.Z@DLQ
MJ^PD:,1UVED](T/5(K^A)7,9Y@Y?N++*?4##-6K/K$MO:VK)'MX)+,:O=<CT
MH'D?T_D3(1"()8.QN8>6)[A(>\,,N9]AEJ[6]U734,<$F-E%P*J5F6#=$AIK
M8$L0J+FI*+;6D5SW.:29")R6[EJ,)F6I$U+F1W"2'8C:WMA0T_5>SZ5AK^K,
ME7]C?.1LE.SNK,GR\TT:_NC\M+)-5'J,4@DLK+*7",[-Z2=H8MM<UD:_+RM"
M:O>ACBFO.2D\L0(4F&1FA!<\1M,)7!X+,<$T'UULPWM>T^RIK$_=7BG9AJ)D
MR!Y *O8&RIS!IQ"5*"<(:2C+@XPZE1\>SA'E\SF/Z+D?PU^!EJ/=V/B)\5[3
M=0=63SFU3I7IH[E33^F>4G?@-7:P@',$,)-.FG;Z:F4=R2&N2XM,OM3'W]S3
M.A[2(PH))=_P^P[N!X ]_/(S1*SV#L%\HOML'7S%.M6INN59F#R7IZ0B94>.
MLHL,<X*F;;D"0AA962DA\X]P1J,>P!MO*)<<?6C+BIS?T^I_BAMJNK"3:CI2
M"4S22JDI2PD3\"9Y&C5)K3H>*T'_ $826=B[*2> #;]5_%CJ!M6NEVG3O2.O
MM3\WK=:>*/9)5F:(68971$G-A>&JQ@>FJ,7)8@G-G=7VZE1/RAP76_5^1VZI
MH/I_)!3P0*TO,@66V;&J$BT*>\C.<+ELQ8 LB<I?]*I^46IS\=2DIZYIZ>OU
M5^OI=7&L-+5:<5TB0\A6^8C=O4/_ '2MWK)*S?4TDA8^2<Z7J;FM@Z\/3.J*
M"+0=(H)XHV#"&2WLHV1)".>)F2(2OW<,?4#'WSL:L-XJ=54TU/3@8)3Z<K'
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MUTGL8=O-N-MN;\-EK;I9DA%)K#.9"37$9/'>>>TM^ON3FI'RO_RGE#J-%O\
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MG I)$C'F'EX5E*&V717GU>9_&,:AM]A5M=*:#1U75+U.BR68@.&CE@B,$@/
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M&5>NOSOWQ]:T/_!#3G&,YM0_FU/?6EN?^KP_^EJY_P#?QY0??^/Y\_I_8_\
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M"PMHK#E)S'R9@84@*(S+["JD#*+>%D6G@UH5$RAS?G?;SAC*\/IRE;:5IO\
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MV*=F5R&HFFM>%[%N]OV87K[;FP9>#W;!6 *1:BQYS2TY#XJ\%>WSWHV2LEK
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ML7H[MEI;$=B9KEC]WZ=:143M[B\G#<@XB4=K8EUJ7$I00ZMQ,LM>2222Q+'
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MENNM,:7T[,7W0^NZ_P!AZ]"%_A-:5P%6EK<%-NR\HI!*;3'^\4K-S&O"H]M
MD%KPUG#/K8\JD8Z#USUIL=SN=Q#0WVQL=/6)D%:J+%J*H\"PQ K\K)Z1$?JA
MSZ<D8'/G@^#FOZ+2UJ-*FT]&M'L(XR)9?3B:8/W-Y]5>[R5X^I6]O'.15'=4
M]CA]6:_2F]=1X^RQN[P^\)%AL^M).Q7&>TI-KQ;US")'V5TU&I_9LI80:N7Q
M&)1"X%]J1D'$M)U9K7ZILWCL9&UK=$-HXV,=DI\R>F$J_)B$Q]X3]J]WU=@A
M,O,_=VGOS%34V%U<,'RZ"PN[%YP&CY],;5IC-W]W'=\IQX[N_M_=@<_3F+UC
M3TJ7\H19M-QAT>?U^H-R![W&1 1'KYK^X+W %T6&IDBTAOT0D.6L&Q;>C(Y'
MD;0AT4KR^=W"UY5K<1)\/JVYECDCZ@OTGZ$29UX^8T]&PMZ:Y&2>YS\J];4R
MR^Y8,O/ X%F*F[=0RTU*M0KS+OBH/)CN6$:!(6''"@RK+<50?<@_?*37FB^R
MM8V]9HFAZKO.K-+RXW8HB\52[[-UEL77$@??(^:>JA6CG0V$[%JLA9K41&SE
MC!FWHR#%8</%(PM33/J^]AONFK6HJR[#:T=KNH7Z=6E;HZS9Z[91QT)81;7>
M!V.OMQUJJR0UGA629F",G )XK7H[&*W*E>M/5I2?M SPS6:MBLS3J[1&EP/F
M(6EF(>02%(U!8>_'-UU[IKL)UYL6A-IL: 5NY872G6O76W4J)M]%B[AK.Y4X
MPF9D7 2K3+"5F3K%C5(^ZYMZ'EB2<$Q;1'D)"PT@BSL-ST]U#7W^J/4 T@?K
M79=14[LM.]+3V=*VBPQB1:T368K5;T_5@6>)%*RE>5?DIZKT]AKY:%H4/G>W
M2UM=-"DL"S5IX278J976)H9>[LD*.6YC4\%?>U[)U)V?*W/%["TGH6V:;O-P
M:T*Y;Y6-VSJBS]?#@*<Q%MS45LF@2T<F=:D]?1>)&N5F4UX#ZIK88$G&.CO+
M5A5W6[?IA--+K]UOZFZHTVWPIQ2ZG:U>H8Y+C3&&76["*7T3%L9#'9M17WX0
MN\4O<H\>;-79FXMBE0FISS#7^NZ6ZDNO98>WU$LUY%$G=77NCC>N@+!58%><
MFWMQU,V9;^OW86!H6R=M[EMFS1J^U7=8;$MM2_ :(4UM.I6PMJ!3F"K:HQB.
MB8LT$?,C-EJQ$)=%3@DUQI:H/I+JW6U-_P!/3W];J--4UCV&L;374[?STP.J
MN5$-@^O9]4RS2H[>G O[[ASVH",S-OJK,^OV,=>Q:N2VA'Z=6Q-%Z"\6H9F"
M?1'VA41E'<[?1X').8B50>S>W]RZNV5&]?H7K4=UXU)M^$@)"?ME+L8U[O-V
MI*JO4JA&"T@LY2-8UZ80Q8W7Y]D);GHL-#PXY/J9YFK?Z8T^FVFLDZ@GZFCZ
MBV^GFL1P5+M9J%"E=%JW<D>ZJ<[.S"6K!8&?CDL9F7C++5]G;NU;*Z]-:VNJ
M7(XWDFAE%B>>#TXH5$!;BK&X$O=(%)X $8/.1%K#K_V7F]FZKN.S]6[9G1:M
MI/=5&V(-MW;NK2(BP6J[T@(!%>U]":Y><"I>OIJ3#=BQY! 23&&RH]TF)8;B
ME&/R^TZ@Z9@U>UIZS::F![6[TM[7-J-/M%FKU:-YI/F-A/L5#7=A!$XE:,OV
M,4D596,H08U6ALGLU9K56RXBHW8+/S=NJ5DEGA1>RO'6^B*O(RE W:& *\H
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M=UO2H9[ZS#FINQ>^9+V\F.)B6V4-,2+V$YPRNW9ZNT6ZBOC;R2I7N=<ZB_\
M(P1S"2/IRC2FH@1/&H2,PUQ#&8UD68L6:(%OJ'J+4W:;US45&D@T=V 3R%>U
MME8GBGY=2>XB23U&+%>T#@,1SQD75;JQV6V1=CS;5![CIK$]U W5H^2O&Y]F
MZWMDA'["O#53P"JNU[6AC@E>H>2!37(Y$</@AQ(Q628^+4T L^4M]5=,ZZE$
ME2?37&K]8:7>1T=+J]E4CEU](VN_YFQLD#6=@%9/4,K< LG:\@+^GC1ZO8V9
MF>5;D(?3WJ+37+-:5Q9G,':8XZS%8X05;M[0"0IY5/I[I#L5)[(;!ZDW#K2[
MTV%H%A@^NYVMXNY"[ U<3!SMA =K80L+1F I+WNS!6QN/)GI FP.5]L(@05D
MULTO*7DQU>[TYK^K:G4J]9O?KS]1)LI:;Z_:+/!7<67::\TD?I&>IZBP1) L
MY=&8Q]B?3F1)#L;&IFUK:=:\BZYJRS+8JF*24"-0D 1N\1R]I<F7TNTJ P)\
MY+F\NN%YG-B9E]?44!$)CH1O/1*'H\NOQ3>+E87:FJBU'V=XT1[V520Y?(9>
M6O<T;_2^T&"Y?3ZD1H^I*$&N$.PO2>M_C[1[TK(EB8_)5Q9^>N=P1QWCNB[T
MY]>3QVHW!XR[VNGDLEX(5]/]@WZ *LB_OY3#Z$7!8'MX5^#Y1//)!(Y^:2ZW
M7> V@]9KS1 /=V.A>D-&,G&E5^3SBY0+MNS>JFEIDTI](^$%0F##,M8AY%/I
M)8,)PRYA%=WU+1GU@K4+TGJ?X]W>]9(TLQ?\E.*GR%ODHH[N5F[$Y,T9Y[D7
MD<THZV:*P)9H$[1H:- $F-OWT;3F>+CN)[?JCY8_0WCAFX/&F-6ZB=I-5(T%
M=QZ[N(\J-ZLU[25OK&DMD:?KEXH]DKMJFIW 99>R!Y>K3-*G1I4?VM5<EDF"
MR0/JDM%C)';5N=KJ_I;:G?T6LZ=%EZHGW=2UN]9M[-&_6L5((#(B:\PV8+L#
MQ-V"S#V/&X"%6+D0\6HV=/Y"816V*:J*C-%1LTTF@EBD=^.;(:)X)0P#&)^X
M,H+!AP!VS]1-3%:1Z\ZZUR?%2<#(Q(4K(R<#+6F-NAD')V2>E+)(16;)#P-:
MBY%H,R5>;:S'PPH8R/ 0993+""W^2]7[9-WU%LMC'+%/%+)%'%/#5DI)/%6@
MBK1RBM-/9EC+I$"?4F9V/UL$9BB[5J:AI:^O7*LC*K,R/*LS(\KM*RF5(XE;
MAG/X8P![#D#N.EG6,7M-J353?72?ZJW08"4NNTQ7]P1>T]2XC(&%V;L2U38U
MN;@$V9RPO8KD99&CW01V52)#@*VQF?66A'-TZF?I7;;4]10=54GDBIZMUT\F
MIVYDL3ZS7U86IF<UEKK\S+6,:NQ$:B0%CP"<AM8NTJ51KI-7,%:>V#<6U3[$
M2U9FD$OI^J93Z:R@E0O<2O@<^,A'KQU"WS7Y7KCK'9U.W;F"Z_[!"MR[8O<N
MFDZ/&)J2)IV%L=$K<33BMI2#UF?,;'DJY.)AW\"2LOB4GU/80]R<ZBZOT-B'
MJ/9ZNYI/7Z@USTA4_8NX_;C+;] 35[]F6XFLC6JJ$QV(3,O?%%Z4!7D'#UVH
MO1G6U;45PIKYUE]7YRF*7,/=V201I"UMC+W<-')Z9X9^Z4_>]0.D.XEKVEH:
M:VE3MHR$SKKL[G8E_L1FRM5L:+&J?MMQ%!.U/KFNE"V3*U1,S'/29MC#8L"/
M&2:?1*%R3GL]F?>='5-5OH=7<U<<.QZ9_9VOK)K-JV]:WV5&=-MLK"/7X]6&
M01I7<US^[*F)(QW>DI;>6SKWM0V&DK[,V+,IL511$/,X1JE>,B3PKIW&15D'
M+_C+<B01.H^Q&/DWG]"YUK&HVG.[*B+#:*R@ZL8<EXQ':R)ODB9)S*9'W0=G
MX= (-4T[)NOK$&9BFVU&(:"Y'2=7:YOB2F^_:<AU-?7RP5;/9:XAD/2LU"-(
MH3'ZT?\ _,9"G(B"AV:4GL)?,A=38'3IU_RZ_,R6EDEB[HN'7]K+89F<-V,#
M77NX+<\#MX[OIS*.U/6?:%ZOW:&8UU1ABXK9/1>.U%6W1)&NQ*)W9(&P+'(L
M03K!<B"XPX+7"H[#$I(-CQ;8V6PFS\*:4PC%Z5ZEU='7],0[&\R2ZWKF3;V
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MM+:=VY:M=V5I-HL#>R)J$K-O8K1=D@@LQ[E>&)$9.%(S$21F'Y-Y@O RA&W
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M>T #55'M8-0LJ-B6"R0^R##V8"#G[21&145#'Q<7[@:G6@Q@)G/M,L2(]XN
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MQ16_34,PTXVE?&,M\QU,T=.W0R[R-9DUE2MC#N4Y6F+79Q:!8;@ MAP2TS]
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MV-I_;M%LT%5SV3M5UW:M0L=4@=G5*$D!HG;E!AR8AHK:$!"*L@!"IF/( M\
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MG&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC(KIWZ1]P_P!Y4K_!P/&,H-<_I![
M?6+5OX-:QXQE7KK\[]\?6M$>/V(Z<_Z.,9S:A_-J>^M+<_\ 5X?_ $M7/_OX
M\?W[\_W_  QDI<8S7 SJ1UZ/K-IIQ>N(UVN7/9V=PV*-R?,);-V#DEDK,TVZ
MB02^$SE3'H^Z 71H?V1\L/ &!3"6G6,O-RZVZCO;-N1/0$@DFZW"KW^9E(FR
MV.$F&KE3(@""K5AA9.+E!2X"0BXJ-%$:5#N!MN82XX\VX\\ZXMC*_P#W/VJL
MU6UTQRO$OP%XN45?[2.3/V @F6MT,_5R0)AZ1=DUR#;J"*;7GGF6"6ABG EJ
M)9=]K,]=C*[9>E*%M<RMR=J'GQYFI9E$P,]5+=:*3/!!SK# T[%XF:G+0\@[
M%3(XHS4B Z0L=_##2O*EQ"5X8R,#>E_7HF%JL$'4YFO#4R)F*]!F52]7BL3*
M*S/S9MBF*Q(3D+8 Y:8KQLQ(FF>ZI4LL899#F TCI5G'&,NPO4O1P%P9NL=7
MIV-DD2 $P7%Q]ZNXE5F9R-!9C1)ZP51FP)@)^9R"PVP9(2P!;\I^.[*J-?==
M<6QF,Q71OK;$8?0-3IM]ARK6NCAB2.P+_)A0E-NH#L;8*Q7@SK*^+!0Y0I#^
M&!HQH903KJGA'&7<(6AC)$O77'5.Q)"#E+#%3K)\#5W:.T37;G;ZH[*4E]QE
MXBH6%RMS48NP5TA\=IY^,EE%,N.86I7S//8<8S"R.F77_+E??CZM.P:ZY7:W
M566JW?[Y669Z IS:&ZO%V[$)80\VEN'2TTT(3.>W&H9;;960XPVAK#&6[06E
M;+ ;3W5OW95:J%7V#MHFM1(T%49<FQ"0E4JD*#'H49.E1,+DZ:L4B-[?*J'C
MV6$C@0[65NO,.*PQF>[*ZSZBVO96KA:X:<9LGNAFO2,K5KG;Z63/UT<ETMB
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M6,F736I:WH[74#K2ID2AD- JE2$'33XK\F<=.3!\]+&EJ!$CP&UE2<D6\D8
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MA#3 [#:&FFT8PE"$)2G&,8XQE9QC'&,P._5(RS 1QL$<U$7&K2.)ZHRQ"7G
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MC"E*-L\,"TKQ5Y?!ITIEIMW/CC\C:E9\/QO#PSC.6/TR[?AALSZ'R/W[J_\
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M/$DR0@>1?0?8?#=&\/#&&59=4M6'$XQF 2^HQ)7TN%"@ ]X;SW$GG@@CC@<
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MVF@#=NN:+"ON#=DLSA-6>C!*U;285JU!1JI@VKNW)F"<IK=C#C4++*A5S^)
M9*%M/,(?0IK$$W274":@;U]?V:TP+:$KV::S&J\GI):%,V!=-=Y.%285_3;D
M%6*^<S1M:#6_D5G[K(D,158IB@E5>]HC,(_1$BH.XQ^IW >XRWQ7<GK?-WX7
M6\9LADJPR%H*H\8=BN6UNERUU"4\@JH1&Q7H%N@RME:='?8]RQ]D(/<*:6*T
MRLE.6N7)>C>I(*#;*76LM:.JEZ5/F*ANPTGX*VYM<)S?BK$,#ZTE94"D,Q"^
M<HFWUSSBLMCF1I6@5O3F]%YUYYA2R8_EWE!##L64L2K  D$90=L]N7'3]?TS
M(TQ\!@F[]EM)ZOG<R #9Z'*I>K*J,GV1D.*3@8UP7&$C&I\5C+_'2G.>7.DM
M13W$^ZCNK(RT>FMUM*_IR&,BW1KK)79B/Q(&/+(?#>Q\9YVMN:HE)H2H,^RI
M59.Y>[]U/+V2 <^S<>S?8Y0R_>[JI W<_7DMM88.SP]V5KJ=;<J]U5#5VYXD
M$Q+4)8K0BMJK,"\7(J]E!)E9<0(Y6%+%)=90MQ/N'H3JNQ1CV$.I9ZLU+]HP
M$6J/K6*7I^L9Z]4V1:G"1\.ZQ0NZ @,H8\9Y?>ZJ.9J[V@)4G^6D'IS%(IBW
M8$EE$9BC+-X4NZAC^$G( H?92/V9WAW)72=TW6L:\T34X%,-0$5$BN4*R&?@
M_;"=G638UCLE(2:.W62FX]RNN_A17HLYF+3(Q/OH'VU;NP7^FI-9T/IK":6E
M9V.]MV/7OFVMF_60V*BZNMK:]>[V.;2&06%%:S+&TICF]&3L"X$&Q%G>78C<
MGC@H0Q=E<1&.O(2DK69;$DD'</3(7T_WL:,%[D[UY)V9U;W,ZV;FM3=+UYLE
MB7L9<:?,0H,A7+=6FK3$1?AF1DZ:?9X&'C[B"&C/K$$5DJ40@=*RLY]G0MU.
ML[3HSJ32U3=V.M:&LLB0S/'8J635FD_Z<5R.K/-)3=S]*BRL7+$+^(@&2J[C
M6W)1#7LAY&5GC#1RQ"5%_$T+2QHLRK[DQ%^!Y/C,0B_E">G\Q79RWQ^X@G:E
M6R*T'-VARJWD6  -ML@Y%0H2Y4JLLAN&+/:4Q(#,.NNPV?!<PD%O/FYER_#W
MK"&Q!4DTSBW96R\%46Z#6)(ZD8EFD$2VF<((R#&S ";VA[SEE.H-0\3S+<4P
MQ&)9)3%.(U:9NQ%+F,*6[O# $F/_ +^W+2Y\I%TU9'+??VV^.[&%NC3<<1KS
M9[$U6V&F@G\S%H@W:8B7K5;<9D0G1K+.! 0)27_ :0=4V\EN\/AMUFS(%U 8
M2H&AD78ZLPV&8NHAK3_.^E9LAHW#5H'>=>/JC 92?/\ B/3@-S;(,9(D4U[0
M>( *W?+&8>^*+AEXED58SSX8Y*NS>VV@]02 D=>[F:"X56@+FZ;#TR\VV&BJ
MA)OD#1]HL$]4JW-PM=@2WA"4L2<V>"*M+#CN'/23E?(K6=);_<1O)0I(X6S)
M2"37:-.:6Y$JM)5KP7+,$UBPBNO=%"CL"P''/C,JSM:%1@L\Q7F-9BR0S2HD
M3$A99)(HWCBC8@\/(RKX/G(];[P:K?[0"=:AD2I1<C1XRPQ]O$@;@9%&628G
MF(Z.KC'LM5=C7(<F(*'FTWI,W^"V%.^ZUFH-0M*9 ]#[5>EWZE;TD6.]+7DI
MO/321*L-<RR627MB3UEF5H#0]#YL\>J$*$98_;54[,:T=Y9H%E658YF0R/($
M6/D1%>TJ0_K]_I>>TL&\924OME1*'HVC7W?6YZ;9Y6ZVN^5VO36NZ+>&,7$R
MN7&QQ2HBL:^8C9FZG%UH2*Q%SA+$4Z+[4"X9ZZQBQ2R_=WI._?WEZAH=+<JQ
M4JE"Q8@V-ZBWR:6*5:7U;6P:6*DBV7E]6!#*'[7[.T,C(GF':PP4H)[]R"5Y
MIIXXWK03CUC'-*G9%7 DG9HPG:Y"D<J3[$$WF5[]=38:(J4X9M9+@%UB3Y^&
MQ'TV_2Q[$#%3I-8DYNPQ475BY2IQ(-A#,AB9"T!Q R) 0D?#F5L.^6S%T!U;
M--;@34L'I31UYC)<H0QM8E@6U%!7EEM)%;EDKNDRQU7F;TW5B &'/MM[JD6%
MS:Y$Z-(G;#.["-',;R2(D3-#&LBLC/*$4,".?!S;]A]HIADD=>'6"&FWV7$^
M/E<:>1AQM:?'&,^"T*2K'CC&?#/SXQS3V4JS*PX9258'[$'@C^1R7!! (\@^
M0?T.<O*8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'
M&,<8QQC'&,<8QQC'&,<8QQC'&,<8R'-<_I![ ?6+5OX-:Q_+QC*O77YW[X^M
M:'_@CISC&2QQC'&,<8QQC/+MI8]:O\I0W_'9=SY$:PDW\,>THPGYM5Z[_I/8
M_1RO*O,\M/M/M"<9QGTLM9\F%8J?9?X'_4YY'NQ_A_I_\YZA'V6R&G&7D>HV
MXG*5HSG*?'&?]2DYPI.<9\,I4G.%)SC"DYQG&,\IGK(BCYLYDPML>0;"R^YD
M0&$/*R_AN1,6P0Y&CD$""-MS0R&RRLC%%'X=Q(#JSZ8^48QE21OV<)""J*)/
M64,"\?+#O()/T\_3R !R@]B3GGV)\^.?;QX)^WC^(/GS]^>,\E(+C_\ _4<V
MAV4"B/>C%Y4APA9B$V13#G61GV=#0 SF!%CY99PLQP;SMCD.J1ASPRWE6+GK
M/4N]3K"8[DQB>O@C!>4O,B L5[(8Z%8QE*&,DP)).&LISCYB"'<YQG/S_-RH
M4GSR/X%@.?\ /*#Z@?(\<??@GW\CVY]N?'/'YYD04#-"^GZJ)\[+0Z1E9,:"
M\2%X5A>3'L##C)]JSC/IJRSAICR8^8?"_P ;C@_I_4?^<IW#[ _R'^680D7;
MZ#[)ENO0SL(V-+*K.6G"\2Y$HEQ7L#$FV_Z8"!GW_50^IHAK+:?3SAS/XZL.
M#_9'_GG_ ,\CC'(\?R_/\Q]^/L?\_!XR.:?2]U3$W&V6W:_U[!.8DD$R:D19
M#UJQY$-H40$6P>2"IU64,MH)=(_HT-*RXQE"497Y!Y /GSXX(\^_')'N!Y\D
M^.//MCD>??P>/8^Y\^/S_EX^V2='@;B78WDR4- -5)+Q:F'A$23L\Z+C./8<
M+0YE 33Z\9SDA6/.VE3?E;2KU,9;]<']/ZC_ ,X+#C_X/'M_#\O/\,\$GRVN
MK%SGRI-\*"V%9J[:Y$NBQD3&@3HK!IQ<C6*X['1X=9]S3Q4FK+LFF)PZ;[N@
MLLY&$,*0MW#>.4]=;>2E/=@FU5.]0BU<=NS/;JDQ01JUIIFFOO<J15EB2'U5
M$1EMCAI(XN%YS;-' CQ0O'9LQ66LNBQPS!0PXA"%8O2E,C,S%?K"QGPK-R0#
MJ3L7Y._7=1G98;7$1K&0WE*ON3"*AM&#DE5B<D10VB)BOZZ';+)J09SSK!Q@
M47-AM)++<6!'2+0OLX[? ]!\9-ILJU:;?S;R#I&$+6DVN@LP&_3@DG,<%W<E
MHUV3QHCQ1RV*<A*1J)IX2_>YV[8=,5XIYOD8:?[0?F85;:2&"1U7F2*KQ_RZ
M%V5G2.4!>24C<+VC.Q#1&M]+U_06I8WM5IK5&M[1N.OPL:NP5.J-TH&'E[P4
MK\%Z;.J$?R^ 4>,_%!.2XA 3+=@>RR^,V,M!#'&NK][U/>ZTZE?X?=3=1;>C
MTS:LVHJ6QV3;=[%;4Q W]C5]9>R>.&1;$R021S,U-0RL7Y0]%T6BUE;4Z6?J
M"I3K'<0Q0RR5X/E?1FNN5K5W*$%>Y3&DA#)VS'[<>.:B:B!Z!57:;FAV9ZW/
M1MEFMG%TZPF/S>;#6O8(L0JH(<<7[0\V!D(E4<;YL2 A$FR_@AUQ#BG/-KJ%
M_C-NNG8>LIJ&H@EUR:/]K5HEKK3N(;5J/8A 0HEM=\435PP@F,?IA44CB8CT
MZ=$T=HVC^:L2Q6FV(KM(97FA(A1JO)![XT[7^IPS@2\]Q()SK^^6'=UF5)Z8
MW3$.,J@+N3%PUOC&&1DD%UJRQ2YB%M(KGDPY'VFMX3ZP4D.XR[E>&AR5/#H4
MUGK?_#5^W(8^J>EK2LMG5&:QKK#LY6*]3L_*6Z#_ %=LNOMEAZD# H!WO&$D
M8.NF_%<:]Y=/MHC^ZN^G%:B4("\%B(S0V%^\=B$<E9 0>"%;E1QG25N**M5V
M:@G;-?VKDS73K8Z=MRQR1) \R+/3.)$880\C#TE,XP7[SDV&F6W74NR[K/D;
M?P\RW]5ZTZG36[M;54C!'86B*VHI54@=!5K>@9Y*R%8:8:+T(.97C7LK(>2I
M0MSC_#NZV]&'8W[$-;6UYK4<W4.UG9:3EYF?T:TW9)8V$@<32B*G%8D+2,%4
M%7[>[+048V_K*HM"K8D&6:O76<%*C$/M+9]PB--$J;)JDX\VE[&6W$(4ZVI&
M5HPI"5IRI&WQLSJ.Y#&_:I:,LK%2PY*\J2I(/*\@D$CD$C-'G6..>:.*86(H
MY'6.=5:-9HU9@DHCDXD02*.\*ZJZ@\, ?&;5]1'D*[T]4&FI04E(_8'5XZ@!
M07 51ZD7*+4\R3_\3PS!#F",N_C(&SEM/E:PK*$)\/>6\_I!<8QQC.H]>D]_
M43<78ZP =.-$=@*]M;<!>PJS;K[LJJ0,Y'PY%2JL B%S&R^OK64PRT7 E'8Q
M[>PCU#G/ 5*O,Z[UO]M:"_I^G*[]9;WI^QJM.FOM5*&MN3PR3+:M3F;U(=A4
M1B4G5/P,>$'U?8:H*5^O<V4BZFA?CMW#9CFGLQQR*AAAC],J]:4CAHRWXN.6
MR;:OH;9TCL7M;L:UT^KUU_>W7O5%%@(,*?"G&8JRPE$ML5:JRZ>@$'"X4"9F
M(X,:26&,-*#L8+0(RAOTTPMK?:N/7=*:ZI<M61HNH=K>L6)*[P&:K-?J35+0
MC+R'UWAAD=HN]FB9BA=B>3GQT;+6=G9ECBC-[7U($02=_;+'%.LL9/:/W:O(
MH5N!W $]H]LP'76A>P6H;ATHM491ZW<V===80^N.W@<7D*#*IY)DC0)$ZWQ+
MQ4>4/:@(S-9/:S' J9,-SZ>&5-I=2YC/V.^Z>V]/K6I+>LTFV/4[=1ZB3Y%Y
MTN*D5^-*DH21&JO+\RA]20%(Q[\D$9BUZ%^I-I94ACF%?6#76QZX0PEFK,9D
MY0B54])@5'!8<<$>^:_5/H?N^ON#:4L,!8;MJH7<;MS1>E]J+Q6Z$_2GKX_?
MF23-)@1I#K>R8PYQKTL"Y573IP=$P2>GU'EKV"WUYH[ ;=U[%>CMGTXIF@.E
M:5F^MT45H%4W<DBJ=;(@//?_ ,RD#&%8_  CXM%=C(I21R3U%N&83?M6Q'"8
M?F#8!:DH/%A6X_#^[9_K+>X,U;+T_9=3=.?E-2[2!&"D;2M'9W:D"1'E,&/'
M5"S4T%F ?D7&DI4.:E,>6E8+V5+%3X?/_2<A==N*VVZQ^&259)7755.F-586
M1&0)<JW)#8$8)X9#ZB<2#@/_ "S,MTY:FFZG,H0?--L[4?:>XF*2N G>> 0W
MTGZ23Q_/*6@:L[-;F+Z:B;&UGK/5NNNMIE7V-F\56\YL<CL(N)H1E<K<+4:P
MW QI=0@Y0:69-LXLX4XMO ^ @U$^SLNO^MAM.F-,G63Z[9[/:;'J1;>N^1M4
M?EHM<LU];%B:W:,\B7)HFB*57KH/+=[]O<W:@J[.VVG%FM5JP:UHK'KQ3^JU
M@I7:*-(8O35H8W$G=(';D=O:.?!-\KO4S:D/\GSKCKI[JKS&RZ[>:/8YP,>8
M$Q$Y8A>PX.R9<A$LEO#!).:VPX^G'E\[YF$B8SZF<9Y8L=6:J;X@['J/UK#:
MRQ1NUH':%_6!FZ>;6PKZ)Y95%DA?R5?K]LN1ZJRFAK:[MC%B.Q!*X#CLX38K
M:<]W'D^F"?;RWC+<+UZ[&1O;-^[:\J+.F-?3VX)2Z;8LM<WO*6&A[?I9D.\"
MZZ;I*7KZ\P&V9E>0DGV*()B8V/=$=>:)D7'$DJNOU#TW)TD*.QMG=;&#3PTM
M36L:&*O?U%U)5=0F[AL 3ZF#ZRE>599I P4B,?1G@:[8KMC/6B%*N]QYK<D=
MYY8+D+(5;NI/'^[MN>WND0JJD<AG^\-:AZ+;PII&K]07.O3MJUWJ_;,=<Q]@
MN=I;N)K\ROUVTEW"N2\)HP>-<5%[!%DG15$@/K_!AV0;/+S)Y1(96W,;?KK1
MW%VFWI6*]78[34R4FU_^%J3[!+%BJE.Q%8WK2 3:]HU;M=1\R(S&GI@Q\'#J
M:.[":U2:.26O5MK,+!VLZP-'',9HG2B%/98#]I*D^F6[F[CR<[$.VFI+EM^O
MZ8CJ6. 032.RVD]GSV#SV@$-52C654G/OC+=QG!)K0F<*&"1X.$K_$1G&><\
MZ2V]/3S[J2ZTBK>Z:W6KK^G&9";=Z!8X%8#\*%@>YSX4>3FP[6I-;2DL(4F#
M94K4G<W;^Z@E[Y./S;CV7[YK5:>INSY7KIW5UR#$5W-OWMV9MFU:5A<L(V.?
M6Y&WZ]EX<R6/RWY8^09 K1^4B/>9T9QEEO"L*=3S9JO5NKBZCZ)V3S6/D]#T
MS4U5[B%RT=F*GL89DBC!_>1E[,8[U\.I)/L<BY=3:;7;NLJQ>M?V<MN#ZAP8
MWEK.A=N/I<+$WCR00.#D@WCJQ<MCV#OK''R0=;KO9K66L*32+"P2DTH20K5!
ML=>ER96,9R@AD(>5D@D+9RYA<@ HG#.4Y^?D=1ZJI:VMT#(D3V;'3.SVEV]7
M9>Q7CLWZUB%8I6Y5G:*-R#QQ'(%[LR9]5-9;?(SK&FSJU8(9 Q+!HJ\D3LZC
M@A0[+]^67GV\9@]<U'V?VG>^L^-O:QUCJ*J]6R9&<58*;>,6T[9%A31)6@14
M93HEB"B7:71R19/,Q,ASS[I[F1@(QD96!?:LYUG;]+ZJAU-^Q]GL]O;ZI2.#
MY>Y1-2/6U_GHK\LER9II1=O(T?HP/ HC'=)(6'?VY8CJ;.W8UGSE:M4BU;-)
MZD,_JM8E^7>NJPJ$0PP$/WNKDD\*G![>31QO4?9 W27K'H)^#K7X6ZVVUI6X
M7Z+Q)A*A7(:I;<:NES=9,PU[-*$$1*BG_0PCSR)3JV<YRMS.<^Y.KM:W6W4^
M_6>S\ILM1N:="7TG]83V]1\G3!3GNB59@J]W/$:@-X RBZBR-)K=?V1>M6M4
M9IU[AZ92&XL\_#<<,2G<>./J8\9)-VZX7>=MO?\ G0(F!6CL9H.GZ[UZ0Z<(
MV0?8876VPZP<Q,^9OSQ@:92>@D-E$96VXRC+V,>43&,1E/J.C!3^']=Y9P>G
M=]<V.Q41N5CKS;/7VHVAX/$KF&"<E5'(8]ON_G)FUT\DV^=5CXV-"&O7)8 M
M)'7L1'O\?2O=(@Y)/('MXS5C:?5;MG::V1KPN.-O-1*ZR:WUAK^,BNP=BU11
M]87R&H3M=OTEL"KU1(1NULR4TI)\$LPF5A20DMPDF"("Z\4QM6JZJZ2JV1L%
MD2C;7J?9;3822]/5]M>VE";8"SKX]?:M=Z:H1P?NYPJQ3+(3/$[. IB[.JVT
ML35R&GA.LKUJRIL):D-:=:YBL-/'"%:UW/\ 4A)9"@$;*HY;-DJKI_>6M]^=
M>=@15(@;;5A>J%*ZY;/=Q=0H61H4M!66)L)]G$$)!)3;(U#;)8; ,8ZR420V
ME:G1F5)<<UNUN-'LM!U%KY;T].T_5EWJ35K\C)/'?BGK2UXZKNCK\I)R5=I)
M0553P QY D8J=ZML-?82&.6(:J'76CZRHT#1RK(954J?67\2A5(/(Y]LA>F=
M6^QFF .LNSZE3Z5L._:65V3K-LU;+V\>!1(U7=FUINYQ=BI5R>CSXF-M,;'Y
MC&SV9$9#)<<>=&>T-.MYRJ:N]4].;F7J?5V[EW74-W_ANS5VL--[!CLZ7504
MY:UVDLD<TM6242F-HV)61$E[2",Q(M7L::ZVU##!8L4OVE%+5>81AHKMMYTD
MAF*,JRHH7N# !E9E[@1Y_'8;2W;?;)M0V+5])UO6N]W=<R=4"V?J_LW,U@_6
MY9-TEI2/KUXBGZ>BO[.H+481'3LI%CQ9Y9%B>F@@G1PUC&.NGMUTCJ4N:ZSN
M[.RT(V4=I]7M.F8K4>R1:4,4EFC*MSYC67VE62"*1Y$1:ZP.X9PRCSL:6VMF
M&Q%3CK7_ )9HEM5=F\35F]9W6.=##Z=JN%['90C,9#(HX7ACVQUX>8$@(,2P
MG,2D^+#Q@\Y)#,X'&D9AD)AN3.''PE&&&"S4OD-,X0G#3;B482GR^&.3V&A>
MQ.]>-HJ[32M!$Q[FCA9V,4;-Y[F1"JD\GDCG-KC#B-!(P:0(H=@. S@ ,P'V
M!/) ^V7CEG/>.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&0[KG](.__K$JW\&M9<8RJUU^=^^/
MK6B/X(Z<XQDL<8QQC'&,<8SRCZFD&XW_ "FOL,6\E:VVM/2"58;2XM7])K/6
MV,>"6VUJ5\^?R)2KYO'.?#&,\J?8?P_W.>?8M_+QS^G\SY_AY\9ZC6+8(1E:
M6ABLY;1EQ7G8*9QA&,I3G.%/"MH7\ZL8\$*4K/SYQC.,*SAP//G_ "_^<IW'
M\N/XG_X_OV]_&<15M"&;RXL?/^EGRX6YAG"EIQX_Z;C>$X5C&/'Y\XSC&/'Y
ML8X('Y_G]N/(_O\ ^/;FH8G[?E]_S_B!_?WSR+A*CI3_ "B&VG)EP0Y8BZ/D
MA1! ?M)K2FNLHK"7VBD*8RH8EI6''!?5PMST$.-J1CQ4NRSR"54$1,9 )E[E
MX!Y([>W\1/MY]O/Z9Y9G#JH0E2/,G(\'SX[??GV//''G^/'KP",&P!$JRXPI
M8@['KK4MQ'H^(Z$N?B)PO&5*0K.<86K\7'AE.<^;Y\@*W'MX8 CV\^?X_P ?
M],]<Q?B8L&3DK]//)(X(/D<>/OP3_ORG+]X9%<!L)D4AE[#KV AHXA![7@VK
MT7LR$>:IMK./]^*IAWP7G^D_T<XIV-^7^8_\Y0.OD@\@^?'\!_KG*&4REPEY
M4BZZT\0M#(BF6\-#*06\E:FEH'00O+^5)RO#[KJ4Y3C#6$8SG&15OR_+[_IE
M.\?F?X$?S/L/]^.??SE*TW+9F$/DK0AA'M3:/!2U)<%RM*VTH8PWC""%^5K+
MCBU9SA#;GD3GQ\4X:"7Y@^IVA?K$;!AR5)C/:1QP#]//V)[B01QGHD\_<*/Q
M>">0/;^!Y/OQ[<CW\YKO-:LVE)=DJOMJ/[&ST/JR)JI,3*:+:AFG(>;DG2&'
MD3#AN2T-^=IM"Q\N.1CQ3:7LX;)2I*58S.QOR_T_\Y3O7CW\_P _?C\^!_EG
MC'^4,QK9[_*"*V_:;+%QI4=?-239\46T:\5(@!Z[C%5E?EP,H(81BQ+PZX^\
M0CP7_I-^IAKQX)_Q &[_ /3WK.&AKME9N6>FYJE6Q7>HE*'UY@EL.'E%I[#5
M0X CC[0G'D\N1OO0M46]IJHDFA$W[1C?Y?LD:Q*(T#)V\+Z:HKDDL[ #R3P
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MY*"F8'4E;VS6=KV;6$_#G6'8EAB)M5?J\#;6)F@05+H4_=Y\<^-LT2T<@J,
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MC&4^5?CG&4W.21YY!YY^_P#(_;[?I_#D>WC@#[CC\_'(X]QS^OY'[<^/&9$
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MJFP:1%5TJ-K&S*=6Z'9XL27D4MJK-3K2ZE"!1SSC[A #H\*XIETMMU1)3_\
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M&>2RDY\/\I6[$Y2K*5?"(KQREYH=2<_#C6N,?TKJ5-I\<>'SYQG.?R8SC//
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MLA2AO4ZQJQV(MU-2B[DVDM:E(URO4A2:2-+X81U[@*1!Y*T4KN2@[S\\]9_
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M^+E>,8^&VOOU)J__ #)'?]GXX'Y?W_9/]<8^&VOOU*J__,D?_P!GXX_O_/\
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BZ]",RI#\96W'O#"7<5J/AVUHQAO+?DQY>,9(W&,<8S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g766269g40x35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g40x35.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2=,4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $4< 5H  QLE1QP"   "   < E  %4UI8W)O<V]F="!/9F9I8V4@57-E
M<AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX .$))300E       0W%\@
M)OL>CT)BMG1P^1W!03A"24T$.@      ]0   !     !       +<')I;G1/
M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4    "0!" %< ( !$ %0 4  @ #(       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              +C   %W
M   !                          $             !=P   +C
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   +C     %)G
M:'1L;VYG   %W     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "XP    !29VAT;&]N9P  !=P    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     @X0DE-
M! P     '+P    !    H    $\   '@  "4(   '*  &  !_]C_X@Q824-#
M7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3
M+4A0("
M         !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B
M:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0
M !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #
MU    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER
M:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M       2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q
M.38V+3(N,0
M                6%E:(        /-1  $    !%LQ865H@
M         %A96B        !OH@  ./4   .06%E:(        &*9  "WA0
M&-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                          !D
M97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(
M9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$
M '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M $P)5@!0    5Q_G;65A<P         !                         H\
M   "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H
M "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4
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M]"NL94+OM&132YI>ZN!Z=M^\/J]_TJ5'7'S6&,=SQQ_!;FB89<1D"+C*0O\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@
M   !4DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    %@   +"':0 $     0   ,@   #T "W&P   )Q  +<;    G$$%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C Z,#$Z,#D@,C,Z-30Z,C$
M36EC<F]S;V9T($]F9FEC92!5<V5R      .@ 0 #     ?__  "@ @ $
M 0  !=R@ P $     0   N,         !@$#  ,    !  8   $:  4    !
M   !0@$;  4    !   !2@$H  ,    !  (   (!  0    !   !4@("  0
M   !              !(     0   $@    !.$))30/]       (
M  #_X0%434T *@    @ " $2  ,    !      $:  4    !    ;@$;  4
M   !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[
M  (    6    L(=I  0    !    R    /0   /      0   \     !061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HP.2 R,SHU-#HR
M,0!-:6-R;W-O9G0@3V9F:6-E(%5S97(      Z !  ,    !__\  * "  0
M   !   %W* #  0    !   "XP         & 0,  P    $ !@   1H !0
M  $   %" 1L !0    $   %* 2@  P    $  @   @$ !     $   %2 @(
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M-:5^H*M[0 VP4?#8Z<79X2V0F,EZL,!C<(,TT7'$R=@!J2:<M!9""6H/DA*
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MRO25 4<(A2O7LKRW(B3US2XITP=NWI3TDJ\ 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MV%L'$8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M9?"NS%8J_P!U]'9@USL^=I3U4VM>*64PJ8_6^H/#7MG=7%JG =E\OI-G+ &
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MB3X!@*F@37X$* LEP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MJ<_3>E<[AXW(BKX^)K?_ -8>33*XZ.'LJU/M7Y23V;P;(, 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 0<[;Y9EG4+' FF+22.QT
M<2=GEQ6&R +D("H#DD1)B@)M-R-4+TRQ)1"'LWU8?(>O+TM^>M17M1T!7Z]I
M+13T-=24+K=454TCJMLSDD2>*)C6L2%CE16K&JJJX3"IC/1HNN-*U>J:>WPT
ME33T[J.::1ZU/*[KVRQL:B-Y*.1<HK<KG"8*\?[$G;_G^J=6WE_T4G\_P/D-
M?U.NH?Y?LW^:KO\ <D<_P1WK^4[7Z:O_ (<M$XYH&1<W5.KKZ3/;*_N*B8/$
MC"N8@K@H@IG) SI"TXM."9*?ZXL3:8(?D7L'HF \A[WYZ#/6S;1]5HC3S[-6
M5=/63/N-36\M3-D;'N3Q4T;68E:UV\WD%SP5,*F%Z$E31FGZG35H?;ZJ>&HE
M=6S5._3\IR:,DC@8C?NC&.WD6)57ACBF%YR)74/AJF]0678J]]>Z<B,$LS3Z
ML>YW%:?+;^H20/\ S3)^;7""#M=.^D(WJ#K&R1BD2DYX:SW 362= /81-QJ!
M_:=_-L,HKN1;<L2B>V(;<=E5ZLMOL.HY#41\A@4+?F>OH2S'4DY5-'5I<>?I
M.]/STIV[ODAFKZ U[1@]4[IHL@WLID ]N@$:NHO#(53.'WT]0A4V&NDKMN8W
MBQPJ$PJ,HY ]HA<!,_)#+4J<4CE<.B3JG<I.P%2E<VR.21:*/T?<5,+<W2/@
M6*)2F Z)5W"/0-^PCL=]O?4<I%UZ1=+F10F*,$+U$36#=GU!RI5ZVRW!BC=I
MSQ0P.Q8.?'I*S$ES<R4JDLF<Y.O/CBI_U&F<#H5M<(]'5T]P^FJ>B;7:];O[
M-0E6IY[)*_ASF5 *BIGK9\NN,!>)8YW/$I$RV=&(O+W4RPK$U7$].MU5&HI+
MD:4=IE.[:\@?CU-;=TU'=?B&0RZ(+XD$R9NAV&M8[Q;*..8RMD4#A4/9JO9R
M=HHE*8\<4FIJ[SKT5SM1.)-8!J)*^Q0^'""L/C[>D3 &41%YL<_'*_/S</)Q
M^0NJY8274W\S\^(>D%2%=T$CI>LDUW+&X2 2)3:Q$-9RYZ<2-JUIJ,]9)PN8
MC#6H(6LTW8S&X(40B Z&/)S>,SU@# & 4MG?LA9!_ _K_P"F$DP<OP/SOL+I
M,'$8 P!@# & , 8 P!@# & , @]X@LQET!YV>Y/"9([Q9]32&)I271E5C1+0
M)UCN$E24%05Y&A <6+T# A%KT@[V'?V.]ZW%FV*YW&S:*J:^U5M1;ZQE=01M
MJ:618I4CEFQ(Q'M5%P]$1%Z<<.E472MH-=66[3-34T-3-25#:BC:V:GD=%(B
M/G8US4<SCA6JJ+S93@O!37['T??1CYJ3#MR>"D&FG3%IXW(5WPAIFTLVOTV:
M4^L]9I'I;O:K1.M^CZ[[/_"^/*>+KG6"U??ZZDN_?G>_>G?/?DO*][+(LW(;
MV?ZWRJK)N\V]Q*\_OGU"E1WW[-7'OE8.]EG[ZEY1:?E.5Y%7;V>3Y1=]6\RN
MXFP5X?4VEM@<WLDCFTA=I0_'R>6)CG=Z5F+EYB=*Z#*3$C4&[V,19!>M *#O
M>_0#]CKXO+6KB;'KK<;SHFEK;K6U%?5NK[A&ZHJI'2S.9'-AC5>[BJ-1<(G0
MF<%A=GU=67'35-55U3-5U#JFL:Z:H>LDBM9.Y&M5SN*HU."9YD)MY*1NPP!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , KB\13Q#F7P
M^8S64E>JO=;-*LE^?V(A(U29)&C&H;"WH%YB@TY8SNP%05 %VBP%A"2(O90A
M;$/0M:U(&S_9_5:^JKC34]S@MOL;3P3O?-2R5/*I/))&C&)'-#N*U6;RJN]E
M%PB)SG27N]Q62*"62!\Z3R.C1&/;'N[K=[>57-=GH3"(G%>="JK^V5(%_BG3
M#_UJLG_<O_WY*7]3E<OYTT/^JZCYN_#6_P!_U+_>$WQ3,7YF=EX%RW G:#7W
M=1Z^ZFB!.%<I4,]?H()@<GU/(5!A[$UQ]T&XZ7I6UK*"6H"_EDA3^S;&6),,
M6S1Z,#H,/:YT=/H>]-LM17PW&1U#3UW+PT[Z=B-GDJ(TCW))9556\@J[V\B+
MO8W4QQVNT71EWH^^XXG0MY62+<>Y'K[3''>1$145'(O,=-5>)OS#'+G?*8LJ
M1ZJ):S2>VX@5,K)=XK'88[/M/K:91OJ5O<37\Q7H+B&ZV-<W*%B%*G3-[%(E
M;T:U%$(MKM..T)",O7/,,CED^@K!?-7/$QJPF;*+'C;=+VE6[0DJM5@4%@"D
MB0E0,QJW#%HP)I*!5HL;.:84%<$G9I?I!XS!#)XFG)#S,)Y'3+,C4>CU9O,[
MCDTL263& QV)MK[!WBD(^).D3KI:&4.K;('V]XLR,\@0QXUD)>T:EI>EK2M>
M8@7) .!/?$]Y5@3O60U$W97^NK3=8<SLMO1R8U^XPML63'5]IT_PZ@]["YHW
MD-SYSY*HBK/%%AEJYFY-T3:!.+^W29O8P^S]7Z2=D.F,3L.*QZ=022,DQADM
M9T$@B\JC3FD>6"0,;HG J;G9G=4!IZ-P;UJ8P!R94F.,*-+%H01;U@&ISW[P
M'V7<_>=S64KX$L+K6CY':B!6@< =B5-7,,G%#)>/8]!(K4^ZPF%S1PUG+KGJ
M\+A>21Q<8LB4*GQO/5HS#=KB5AHRCL)X^C#5SS]>/+T_(;)G$T.M&N^-^48!
M=Y:XJY8/SC2D0M8MT>T,F<B[%C5<1QFF8'"1M;B[MK^M#(43AI4\H79S2.9^
MAK4Z]64<%08,$GL 8 P"EP[]D+(?X(!=_3"28.7X'YWV%T>#B, 8 P!@# &
M, 8 P!@# & 5]>)G\UB1?=1"OPX7D.[=? "KYO=*V_3KS?I\GE2/]IO@E5\_
M]DT/-\)9S]O2:VF4A*SFR;X9?S5(_P#=;-/PP9EWMA?O?T?BN5S^F_7]A9C9
MEX)TOPJM]8<6!Y,1( P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M\L_;!H&TWP2K/A-#ZRPUM,I"5F-DSPR_FJQ[[KII^&#,N]L+][^C\5RN>/\
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M2C2*)>:,;^<F(,7B+".)(# & , I<._9"R'^" 7?TPDF#E^!^=]A='@XC &
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MJ[YRUZ??/E_X84YYW[0?#G5OY073UN4J3J[PGOWG2L^E<9 X(^=G4W_2S/\
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M0DZ"$_0VL6_0\Q^FXG6I>WXA'4Z/MKP;.>^J&^&J:]17-9D/DA$-6/14B4L
M$FK38=I3GHAM:"G 0Q- E.C@-J700GZ*]7O9?IBC#:OX.4_G6E]7K2^O[G$F
M.Z%K$Y\;/-2?66GOV&KQKX]Z\OVO+^?^OV_Y,KL>[QM7U)^L@4_]U+S_ +^I
MSF^ZM]Y"FQGW4C\GNK4_9]I\S/[I?[^FUG/]_:(QS_S4TUS_ !_$5W95H\M2
M>U^_K%-S?=I&_P#?[ \]+^XE_KVE./\ \PU1T<4_BZO]/;R$[Z<][.;X1/\
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MGR+&/8FB8RFMJK$_K8]7OOJH=9(!C3IE#ZYN#N<K5&#'E[=OU$K< 8 P!@#
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5E8 P!@# & , 8 P!@# & , 8!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g766269g45d14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g45d14.jpg
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M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^*
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M.)LWPS3MHES-!E1<]"[(Y>N>H56+!75-C(4N7#S]6^&J':\))_O_ ')/^O\
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M>.V-!7TUP:7;Y8*_&)I"[^OB(JA[<<BMF*89#+"UIJ"_AV?Y$W;K_P" ;?\
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MS2L$CC5G=CZ*J@L3]>P[ 9)/8#6J>>*M#+8G<1PP1O++(WHD<:EG8X[]E!.
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MYEYVX;[=\<WD#G+DO'\5XN2XK\_!H]K="4E:5?6K2'UU*%*4]KCK4V(0R<<
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M.6PU^)9!.%48\:\Q./N(2XY8[/+9\YL]2(TU858XU555C%558Y55K?*N8O\
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MJ3QV-N\&4:7@RA+ 5:O/]P1FMN=ZNR>5H=VWYMVWA7&>7WAG+9R9ZZO-?/\
M1TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--:D_C&ZJ#"=O7$
MVVFDTPR9ON'H95L>/>0\[QKRQ6"W7%',68M">+;O75.HS!VBGJ+RPKK^GN<1
MLH)..3MQ9" 4%G5@[G)M-6:,YRX<[4.PK,\WRC 9OASBKMYXW.R5"FUI+H3Z
M2_*9JAXSPP'(<MA+F[F>]LK#,XVGV$ULZAM#;(.XFM$KB'F(TU33M7^,!F^?
M'27&KXCNL[B"N)>.=W27?$<7(O<9I2]5=\>\'[#D;,66"XNXKL[ZNILC=<ZT
M6:H=0(MM%>?EW16-\!D5: $2T_?]=7.^':=!:=D7;39"M)8-8<85!P[#0C*T
MQL!<Y<\32Z^P@&/ )2.1J3AFC#EC2^J$B&*9CV-::N?TTT=--'335-.5>4>/
MM_W#<1=KU;IJFUV=!J0^:N3<A%-(\ZFR> I"M+AICD2%1F%$\F%<=7H@?S'S
MB UCC'P,&F@EEKYYX9;<%%9%:5'%F:,'NL42EHRWL"9S"P&<X&<8[ZYC<-QI
M6]ZV[P_'8CDMPSINM^J#YXJM.,SU&<8X@M?:E*BYY<8R^,8)N7U8:Z?1TTTA
MZ;05V3S>@U-O*D%3FJ2UO[.951$AKZ<&>P-E55\(B1C#R/557PB)UILSQU:\
M]J4\8JT,L\K'L%CA1I'/\E4G4[:]NL[ON>W;323J7-TO5-NJ1CUDLW;$=:!!
M_P#=+*B_SU3_ +'.W:XX*P>IT6DVFDTVFYTT(O+VDH[SW&BXB]T]7 ?:9T)9
MBS)[ P0PN82TOIU$FN/D@GOK@U']+^1\%>'IMCI6K%BY9LV=\L+N]F"?(6E/
M:C626NF7<NZ.[++,>!EX)F->/?[5]OGVF4OM"\0;-MVV;#M.T[7]GVTOX)VN
M_MW$R[]M^T6I*]3=+!2&!((IX84FJ;?&)HZ0GF5;,W4RLU<V]N/$/<1!BQN6
MLO\ F:' :D789EJ65I6*)<"^E'-G=5F".-KS&,CC.KBEE%);%'ZX_4QKDNMY
M\/;1X@6FN[5?BEH6EMUAU98^$RX_-TG3J1N  \;\D8 9';7"^ _M.\:_9I)O
MLO@S>&VA_$>SS[%NQ%6G:Z]"?)_#%N"<5[,+%FKVH0D\)9^+X9@9RZNM<#HZ
M::.FFCIIHZ::.FFCIIHZ::.FFCIIK1)\=B#@UG$7!]GR):8FNW@_*C0\X5;Z
M/(IOZ3C\FF.*WFGXSX]WW<!V]8[86H&AK^/*>YL;G4D?EFBOS2*X=UJ:# 2_
M?KC_ "TUMA[57UDG:_VWR4AQ%G3/X%X??4V1D%0,785CN/<ZX XH:@U&WH1R
M"Q5B(G@I-IKZB*61T=;J+\-L-L6TUHY[T/AQ_$*YQY]YUY"S7(O'VCQ/(^@X
MZGXY _/FQQAO&P.,XW[J./\ C>R'J)!SJA#.%-GRWQWSC81!+[FMVM0??4<@
M]Y5U59&_?[_?^VFMG/:GF=UE>Z7OA Y Y,*Y4MBS> ;6NO2\GG,=)4Y\_);*
M6HRS*[,0P!&Q4,"*-'<%-=9V2.]TY[I$1>FFM@_331TTU7(Q\FH[JJ4'T)+6
M<1<,V=\3ZO#HX]/S!J8*6@(:BL5&& 9SC+9#H]KTD8)HY&^/;)7S7-F7=$7^
M&I3:0_\ \6W($0_J(Z\P]NSGMC5.WX^^QKC*;?MKRM\NMN,XBB(]@R0T; ^?
M&;Y-JQO5CJXT=--4!^)9H=-GNU^Z7$\DV/&^OOM1F,E22UPZ$+J6:DR2DO\
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M?:=&"A'%1O/-8^&6.JM8QI3+25H98R[? >8.7.Y/FDCN.-31"=N^DS])Q[0
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M(!:I):G^$$5VL7HRLR_#6&J[C>K-(RRKT[!=8UL1P316M_PUK?\ [BKOC_\
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M_P 5I.ZW1Y/N?HCP0J+D;,66J%[;M;H<8RMPFRIC0[FVXUN[JK^K,M?G139
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M->_7D$A=2KU?_P"D.9]LMLM/A8K['9O+<%B)VDL4]D\-;O*35-41('7Q"(U
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MB[2,[9Y.2<_A=KJ&:>&A326:)(9S%!7CEG@C58UCD8*#*B1@(L;$@JJH!@*
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M659/7OJSV_9_#J&*SMU&NKU<?#M&6_#,=9Z*J 9"JD59'K $'\)RGH=8UO\
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MP1JLN/9-HK_&=*C"GQ\,M:X$Y@30336K$L)'/"QO8N7)V1 HZUJQ)CG+(61
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M<N%(*]SZZDWN"P/,<_#/#4$E!I[>$?-DZ?DJS)!E+NQM#9E#BUY.ND8DMBR
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M/:])_6YTJK_7<]RJJ_NKT5'([U?_ (E5WW^Z^5Z^AJQ/;  '8 #M\\8^GO\
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M>8]TYWJ1[X8]#8B1N5O[*J!$0>E4_P!BYB)Z?MX3K-MKV\IT_@ZX7& .E&P
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MS,DH;.#^&$/4 SV(=2/0YU!DBW#XR(P_"?=?!A,&ZWQ1E]$*%6Z?$#L?7W[
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M52PL0(Q*D9XGF#G )&!@?R)Q]UI_"[K426Q3AE66.-C\1"C,58*W E@<$9]
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MZ$PA $E.?/(L36L#%'E(E+]N.2+TR2=4FT[O-8#5^3)!%Q/)*Q>1E=_R8"L
MOL&(QQ).<@:H-DWTWFFJAFBKUROXGPS,9!(Q)5>,; J,X+$=L]_3(B:NOX#(
M'RZK)C#6/S534UI\CC$ 8 LDS3520MU@*OZ61P^ZV1?0QZ^F)7HQ66<M9XV
MI77:(QSSS1 1]3JA5Z>!'TY.Y)/$C/EQG&<W+5V#JM6T3&PD>10(PW(CR^T;
MC!/88.?0D>FF]<<HZQAA5;)!4!1#)\F$&5FZ@H^O &<V,4)I]@"^Q2&,:.(=
MZNF8I,+?3,US7N:LJ':J?!)5:=V;SNZ6IT221@2[LD4JQ\BS%AV\I[KZ=I,6
MUU.*ORF=F\SN+,P1Y&[LQC23I EB2 %['T],Z9T5O"0CEL8FQ-A268<JIA
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M((J\?"-(D6*%%C0!(U12>(')\<G;S,2=80P1UU98U(#N\C%F9BSN>3'+$_H
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M6G[J^T7:;$,VV[NGB*,,>=?=Z\FWGBP."94#(2"<85\Y([8!&D;&\1?#YMK
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M:[VY1BQGHZ.8>:%TD4C7,7^&]?2J+X<G07Z4&X0R5;"JRNC+S&>2$C(=& #
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M-U[,YC^+@KPD&RD$:RE^L598TFXEHNH'/F4$^)OMC=;M3;MJZD4-R-Y;5FT
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M&RLEE?'*^6.>2&2(V)BK)#(]6.AFE[A1,QJVZO$3T&E>! 0@F1UXM&&.0OE
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MWP._?S#TP0&[XQJI7<I!(G,^K-?,5)#=MIM'7PE3SD*'7:>CKK\.N&=.YTC
M@(;%!0H6K[<(T4;&?I:G7:[/;M7=KJO:FELV(E>E)--(TDCFE*],,[.2W(K"
MO;.!Z#TQJ_V!C]T5 3EJZR5&8\<L:DKUB[8_B8QEFP!EB3V'8Q54W=KGY22:
M*RL*R4VN,JC"*\A\+R:VR@<-8 3/8Y'/%-'D? 2._P QSQ.5CVN:OCJWKV[-
M0LT#F-G1XR0H)*."K*.0/8AB.W?OZYQJUD19 .HO(9# '(&1W![$>G[]=8<2
M(GE?]DOCSY^R^/[%3^U/Y^?O]_\ -UH=B3W[=R<9)[_/OW[_ *ZR/K[#Z#T'
MZ=S_ )Z['>?2OI_?]T^_C[HOG]_Y?Y^L0<$$>H(/]/TUYJ[6;T^9YM[?,?PK
MO.1:S):SB([87'#]A>2%-SQ5;IB!#K_$:4I!(X*+YFQ@DM<]HI9C1XII)ZNP
M:*'/ 2%R5N&[L^]V-VIU9;M+=5KQ[I7@P\\-B$LB7X%Y$SEH^*6(5PY54D7+
MJROR%E+6T[U8W2K0FM4]P2O#>C@C3K1O&>*6H55^I(@0\9HN&20)%R0V,CMD
MP&PXTYWXX.VM(//A=\;;\66FAHKBIT^7E!Y(I;;$DL*N<T?9U[8V,N&%+ 02
MR5L+/?=#Z/"]1?%-VIN.Q;C'4E87MN6'=8:\T,E:UU-LL0W4,<5F.-V;E"4!
M564L>(/MJ)XONU]Q\/;K'0G*;C0BCW2"&>.6M/U=NFBMIQBG2-VY-$48HI]P
MK Z1N9"7<%:^_P".N/L37BSYHQP%[N+[*C:.[))1JQ#.#+O@30ZA)X6LD]52
M)7M]U[F#>%B4@G?LRC?:D.X[E=E=;2\Z]&M;:M L?9CS2N\;RD-GO*[^4 MZ
MA5SV$_\ $-"INU^[(WQ4?4AVZ"X:T"@8ZBND+J\Y1B5(G:3 "\QGL)2XXWVX
MXEXLU7+W,=I;65AI0W9_A3#WU@6%->VA,4L-KLFT<+X90\KGZXIS(SG""PV%
MO.)!5D^^%-(-6;C0H;MNE3:-FCABCK2=?>[T"*ZUD7!BIF8EA):L. 60.QCA
M5VE0AP&B;GM53=]THT-G$,$5:4S;S?K1HSQQJ%,=);!Y,)Y7XL>+\EC5N60V
MJDWL6SWV0GVEYK<^M.#=PT V-%N*^H(KYI 2BXS*W'BPCB14\,44D$IXL:*I
M4K$D];Y7R]=W6I5*4+25TC61642-*9)+5@2$GD9'#.^,88E_)V'E&!KK(&IT
MK/PD%6<3-&)6M/#*XDR>)YVFY9?MDJ[9&1]-1];5@]1C* R46A(.T9I]B+;
M:6&PNP:NN<^KFI;W."G2Q43IC6_40I+$(:P,'2.4=\@4C7.MI(DCK0GC"7E9
MF#1S%I$X$KQEAP2F3EE+'NOMWU;!LNPRV%4'#+A2Q&?*>P/U SC^NG1P*4-%
MR]@I7M_[-?#@M8R5&,]1P\X/K>LWN.7RZ;U^E%3RJ^F-6JK?3SV^J6VB\!V(
MKM(WE))Z3K)VXXP?*>_?&>^JO>QG:+_<*!7+DD%O^6ROGL1Z8)^6!W]"=2)Q
MW1:CA[FEBZ3-F4&GH"A;JO\ K@XXC:YLJQV%=9206<?L.B)&=%*'[B.;/[S&
ML1RKX3#=9;'W?#-6E,;%8IH^,?4,BLHXE  X8'()R"  <^AS!OV8=RVA9*5E
M)H)5X\H#U5E(RI52A/(AAYACL%((QK<;Q=><;\L8AN*U<8T-C6,L2L?85\[X
M9QRID2>>LE+69)[*&PG_ $,]_P!V:$B=6QL^7>_U?%=T7<J-M+M;#QNZC<(9
M$&74G'Q POD>%>Y (5D'?#8(_/\ O,.\;%N;W*G4*V#'\06B3!\V%$H"85 /
M?/DQG( (UK(O^,L7R%N;F@PTH]=I 8;!NA U&?(!+KJR!S7F6E:,A+%)M@5C
M:@+6L0V?YEL<3"'/5K?INW;Q?V:D+%V!+E*PG3K,)%F7JR !!S _"[')8^2/
M!+ #.OLE/>;^U[;!:W*/J5ING'7DK3"=))90 B.W$\$;(RS-P7B3E ->_+\,
MKLZ?8=B>_ASM7-4T60[@-+C:V L6,6Q(93XS#O)L;-K&,<XZP.***E27RZ!L
MC!FJL<+%ZN_#]":E7GDLRI+/>G-N0QMR1.:@+&A[^5$"J"?S8Y>^NF\.4+-&
MG,UN83SW;,EUV5N2)U@.,49[^2-%51W[XSKT9=7^N@T=--'337YZ'XI6OY"=
M\0K/6N9Y- R6?%[>^.H;0&?=RYJ<,Q^AVRPGK4L)'+-:3'X;&150'2JX=\+V
ML>Q&K179-M^,Z5G;GM663,4BT/B590JY0S,IC7CVR'90 PU27WVYK(@M;>UJ
M=HB8V^ ^)5E]&7JLIC7 .&#L.Q]\:T.\%[E]?H3CK+N$V.NCI*N2QN0%(UD6
M;<#$^.!HSC;PN(HI[SB18A_ 5>JK^B*1TDK&+SN_4C+6CCBV"I5ZTXCCD K&
MP9&RW+IP+Q4!%8L2[_\ <N!G7*^(Z)EHI6@V"G76>40P$"'JB4CD"(J\96,!
M5/(DN!ZMY=6$,S6)[BN0<C!POS#:U5+;<B9R#84VQSQU7=DV< E<6X  J0\Z
M>U!"% .;1U*/$A?,CT& 5RR.ZY\3VO#="V^\[3%-)'MMAZLU:9'@1"\B,TBJ
MJK&6:1#-.WGX_F< +KFX[-WPO0D&_P"S)9>#;7-:U3DKR)'&6:.61XH\%&YR
M*))%5F*X)()XAI]VFYXXTG(F@P&]/T'U#0["UNG'5;JZ%,<+8WY*YV&U2<IT
M4WL43HF%BQ1M=$)-!/*^4B%&=;_"6W[A6VZON%".N(Z]..$12=5Q;:.!1/T3
MPR,SABC,V6=67MR.I?A.AN<%!-TVF"G%62K$D5:7J8M%*ZM,8W0$H3,<(Y#*
MSHR^ASIL\ID<7Y[A0;$W14!N.2V<WCZ? VM=;V!%Y3L'EN#+2WB>7GQY;AE@
MV0@0OY8L 08-M>T[UE-29M2;I/O3W8E:.UTO_41?CDA18)^2Q+%%@6'Z1C(4
MIR1F9NKP\IU(V9=SM[U)N44<L-HPJE\[E!8KQB*1FZ<4%=@EDK%Q\DJ+(DA8
M\S'Y6U1@>\XI'9#&1QUHC4<W_P"UIR$*V>1BN5/=DABR3HXYOT_]C7PC?+E\
M.16N;VTD&ZL69=PKH/\ I.WNRCT[<C<#%3[GB#V'H<Y[YJ^Z,3PW&NG?\AH'
M  ]@SVQD$8[GY# T_+R_XTY:F ()E.XPUPE954\15DXK59?014P,5=7RGD5X
M$%U2VSAX8(IIQZP\ AT7NR-#<KG.@UZ^Y[2DBIT]SIO++*8TXUK=<SN9).FL
MDC5YHN;2,%>:*5>7%>8QB%#!?VF-UY+NE9I)9BL:BM8A:>1I9%1))#'+&K$A
M!S#@'&6P-2IF=?S;QG/0V9M-7<V81"H(QS*9A%V.$7%#\@P06_J(8;W,7L(K
MV#0C63(3(X71-8&^)S6K5VJFR[E'8ACE?9+O$\HYB*[,A)DYM!,Y@LQ,X+,8
M69"P/FY9S3W*>S;JDZ+9FV&^BEBDS+%U%)Y&26K.S5[$#$9+*./KEU(.K MD
MR/&]]H<L#RJ_'3['*V<%;E=M%:W=A4R:.HD7YNTMJ4:S2L(KQ"2U2>V%K+D2
MR@BD>,@D;43GB+>X5X+;;5\6M2S&9;- Q0Q3F"50$CAE>,R+(ZJ (7EA>,GS
M%SG7,R1VMTBIW)-F2XM&Y&TMR@\=>.5:LHXB*&8PM*K2(I98FDAD0E58L3EN
M=H_ NDRW).FT&AM\F1EB^+=Q5@:S.:JGT822;2JDR@I\Z5A4YPL8S;F4HMEN
M($L,$,CT:UT3U23XOWRM=VRM#7BM):3=MOF>K8K2UFS0G%PP#J (QD, C0PO
M)EF7.<@';XT\25[.VU:]2"]\6FZ4Y)JD]&Q6DZ52032@--&L1;" J8G?)(^F
M->NTP>FXXOSLQKZ<NHMJTB096%0O;$2R-5]L@$KQ\N<&1'Z9ABA9)1R(7MEB
MD>QR.7OJ-ZKN5>.U4F6:*50V5(+)G\RR)^:-T.0Z, RL"" 1KZ72OU-RKQVJ
M4R3Q2*'RA!*DC+*Z_F1E;*E6 8$8(!TWS1!XZ4&P9; D&%G'PE4D<-BVPJQ1
M8PWB&%3R@Q5DL-DXF9@[ CBB85!(^>'$2052+5H(UK).MF%WDD:+X9>?63B
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MW6X@NM@\D4UE[YCZ@$K#$H*@*:*]#-9L3BW%_P"GUEYJD4@CFLC@I82Y8%X
M?_IA@KD?B J -:3>4C![:4NJVUY7H711U=137!%:2W136;$9/>V-J,/%+:G5
M)<KC7RE'2&3R6"CS5SG#3%=:=H#11K)3KN19,MB:))U^'2'FPBAB9F6 2J.F
M B< (P5?#!=:=N(0"3;X)#'.&DEB68&NL?HD:,Q$(E!X#@A7"Y#=PF(,AS1T
M[G?33J6PC<J^RL-E##-,GG[>U7FJ+8*]?/V8X5'.5?"(J^>KMK,:_P#.2>/'
M=@8G91^LD8>+'MD/@=]6;V4&.HDT>.YY1$J,_.1>4?\ /D=.ZGXIY&N:J>X
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MD,@.0#GOD=^_?'IGVU+N>C*Y6SEO0V%B.-H,U']9K;(V8B)MD$[T0F $O3^
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MLO33B^0O($%<$Z8NAX-H=9'/H>WO2"[L'PZ4WCJ:51N1::5SD_@5%*4,"?M
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MQTND$>1B[2=0R]P64MC"Y&6;MC66W7GLW-RJF&:-*,T4:-.Q82\U)+*"/R8
M .3Z8SKPE:])"MML6M5'O34Z)55SVM3TMM3%5SGR.1/NB*OW7RO[(BN7[VI
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MS2)2BGOFGG<KY)%8OESE_=5]+$3S_P /]O5B$XJ%50JJ.P![ ?S/I@=O;&K
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M<C.""I!]&'KJ-?2PT!%0I%*I4AF3DO$$$KC(]1D#N",C!U-FXY(R\_'-=FA
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M[?::Z?YB[NB$)-F:QD?N2(UK47PQ/[&I^[G*G[>?Y=6>W48-JJ0TJ@Q! O%
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M&L;?U[U9[MBC!8Z$KP!E^'1$F,2LDB"5@S!4/$.=8NFQMWGZ[1.N*JY?/);
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M?/V\_P!OGRB)^_\ G_?K+'^^LLC./?7-4\^%1$5?Y^E/'C]OMX_S_OX3^_\
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MI''S2U@]L1#"(8?"&DBB_.3P#002EQ1^N2&"*-9'1QL1.Q>-1*TA1.J5"-(
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M\S_;8Z2:1?2BMCA'A8^<B>5S(8((WS2R,C8YR3K$T-6(SV)8X8E&2\CA0,G
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M!62SW >21PLH/X> I1>7VR9JEJ1;LJI+8,DT!2;,30L[/F>,1@I.,^=W?B^
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MF>??5P6:)GLCFE%Q/%O5>J*KB(H)'(Q<:5^U20PV]OO1)&TG&U7$=N+@SL4
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MTP,4B?1RY/XK:J57^5]N-[D=$)/ZG(5'$GW\MF:QTC/#]9A ?KQ*JR,/QD&
M9NQ R?=U[<23CU7T/;7TN+B6-5Y'O*H[<P,DY(SE@!E2?TSJ['&O;8%G\C3\
MC\G0TU'52PNN)+S6GDBU05:Z5T8I0%4$CC[][T1GRX(8QA%D03#![=<'%/8K
MQ&Y^(Y;-N;;=K,\TN1"L%1%:>23CEEDD<JE< YR\CQJBHQ#2.5CUPNY^)C;N
MV=KVF2>:<,8(X:<22O)..[Q2S2#I0\1GF[<1#Q+$R,1%IO<E]U#,K5IB.W$0
M/C_+RB/$LM@&#7 <@Z,A[G(86I8+9TRE>:S](]?3D)8*,OMV5H4Z22-LG;?"
MK69/CO$DC;A9#\XZ4CR2[?7 _*@63'Q<J'\TEA>GR[Q1)@'4C:?"0LS#<?$D
MC;A?'_*K22RR[?54#*QK&_$3NG\<KQ\6<$HB@#5'CSCK0B4RR-+/+F>LDQ)A
M,Q1$KU7RKY)IWR/>Y5^ZN<Y5_OZ[- L0"QHB(HPJ*BJJCY * !CZ:[>-4B4)
M$BQ(O94C5451G("A0 ,?0#6(U$:GA/V\^?O]_P#/UD6SZ@'^HUGG/KW]?7U_
MF??_ ,ZPI'O5'IY\I]T\?W?S_P"#K8%'8X^1UX/7^1_R.O0E^%W_ -=QXL3^
MWC'E[_DPG_\ WK+6:>YQW _KZ_[#31_$4JY/B^=UB(OA&S<8^/*>?'_6KQ_[
M)_?_ #\^?Y>.M3@9_O\ O]]]>2*.7IZ@'O\ ,C6DIS_LGJ5?LB^5_?U2+Y2-
M43PGI1'*Q%\JY/**OV3[=88]AV_VSW_MG6O&!VP/3Y#M[_VS_EI8MR$(6M>0
MY76'T^!ARJB*U5A_AP*CF_I<YPS8O<1$\HYOW5>M,2\>H%_Y?48I_/NW_P#,
M3_7TQZZ8!CJ #"=0E/;U_-Z]_P V<9TFM(>UKV,<]K)&HU[4<K4>B.1R(]O[
M.1'-:Y$=Y3RB+^Z=;M;]*5+=DTMG6V$,:22AV 1+&_J]3WC$Q3L\/9Z9HU<^
M-J*L#XWJGZ6N3RO6B:!)HI8CV#QNA[]L,I4^O;T)QGMGO[#6F6!)8I$/8/&Z
M'O[,"/KGL>V>P]<:G_N&K"'FT&D&-CL*_3UM"X@F2OAJ#)K:LJ1PVEDB1-?&
M&A(Z?UHS)F&3PD%$N4A7N3G?#4R].Q593'+5DL!$$IE05Y92Q17..?!^W=%*
MJRH@"X&J'8)X^$U8KPEJF2,*'ZB"%GSQ# D-Q('J 0&   U$(&M , @I=/1C
M62"S-^1U$4Q(^GK8F*K&!M(]R<"QKX/U.9 < \J+PV(8V$9ORZW<M1XW,U2;
MI%O-+790]>0X[L5PCQ.W;+1/C/=D9B3JVEJ.CM-7E://=ZQ"FO)E>[$8YHQP
M,F-E4GNZ,W?76S.F6%J3-C+8C3$MD69%%]\&_P#5(OJ>J5[WH1-*UZK[R@O,
M:UOF1TJ-^ZC92.,+=B6LAP"9.+USCT\_=5!SA1($+>F,YUZ;$:Q@7(U@3&//
MQ>#^;_E'KVYA2?3&G'4<F[ET;J/0,)W>>&DEE*SFJ>7:1#2R/8V:8:;WDLJX
MQSD8CR!287._JR(]KG-6)/M5 D6:Q&WV2!PMT^,188[*X Z,J'_I=6Q@8P0"
M,6K5@I,!6NS=UDB 53]0,<3Z#^$YQIRFXK ;:5A6-LHN/;PXMCH\1L3X/HSA
MG-; [Z+JU(61Q#K#UM96W5;6-@&>Q[+,M&N].A+NXT%*WHVW*%%.;]&(B7/=
MLSTR, !,$R022Y([PH3WT):M5E9;"-;158K8KH2YQDCJ1^F<>IC#9P!A2<:C
M799A^.^ET]I5VM;I1XBY+]IY(! ,BRD*^LEK(Q8DE@B<"K'2/)(G0A7LF'5D
M#VMZMJ=J*ZAFKRK+ QQ&55@?*/.#G&<-V(QV/8]P=3*UA;(:2-U:/("X#!@0
M!R#!L'()P1@8(QZY S]!S!R9KN.\5Q/I-[IKSC/C8^\L<%BK&V*(SN3.T<S"
M+XFCK'R*.!+:D,24Q86I[LGJ=^[G>9 C57:0+AW4*Q^8'IV/H?8D=SVSG U*
M^GMIN+E+],H[;I7JN9;=1YQ;3Y@7TI;R"//8&@OOH9Y46-\OO_+*,GI]"R>M
M4;UYU%ZG2SY^/+&#C'ZXQ_+.<=];A7E:!K 7\%7$9;('F(R!Q)Y'L#W QV]=
M-KUN3U(U7-1R>ES45414]2.]*HGCRGJ1%\+_ #1%_EUGK3KC U'S.;(JI&J-
M1%_EY7PB^?NBHB?NJ_?KT_E[?F[_ ,_Y_3']_P!=>,2!D=_W_+_7_:6<#56X
M=PIX8$EB,(*=[D1D;')).L#D&]SRR:)?!+AW1M15EE:WV8U1[_'5/N4L+0"*
M241-(\8#(QR%# N>Q!QQY9."!GN.(SJIW&:&2$Q2.(W9XP"A((0N.>!D'\@;
M)';'<X&I\I['5"5B4(>Y@PL_(-2:';V%B38 @K&"]A!9D@0PSSH:Z1CGCH-
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M8]27H6I9V<S63$IDD#X\KR$%W&%]V/?) &F)D^XSD7+;--U$94F:"2K,IB+
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M7MM C@'/<+."^62*.2-TC6^I7.C7RUGJ]']5WAR.1+*K92VDC(CQF*0PND@
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MRB0V%61(8,96)5.54L1SE9?,S$!F8(@&SX"&VLTNX5XK L1R((;$<<B1PLH
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MOAL<$B(QC%5[R%5/'6+M>4.5^'E/<H/-$,9[ Y$@].Y*@9/;CK!C=0/QZ#@
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ML"01R+R(8J3Q(XG/\8';5-ONW[M?BBK[;N$-2!W"W1) 3,]=NTB12*3P8J2
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M.38)]>(]L:#SRUUEF>.0NJRAD4J ) #P'S"9QR/<]NPU@9_,V^F^M?26 O\
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MQ\GR1L;&Q_=)N7)&Q/2QGG$\>KZ&-7]FM\^&IY7[>/*^>L&(9F8*%!)(5<@
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MMDE?678Q$LDK?8;7-L99C)H/+HG(C!FOD>YRJV/W415>OI5/#OO+EF583)+
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M:#;>*1.:NSW?YFP)?7YW%ZF/4WH[B890@,"N@TEO4'2I,QS)TJ)B@Q1_7$A
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MS)=+;@_*2N-E*/\ H TQ,=<5(81 >% VBWO'BAYC94OX?JR%8Y9(S4L[Q(A
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MS&"5(ADM([&557@).6OET,/CC;X$CDI36Z&X!>G76S%9M[<O/J00M+.\;CI
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MA6:GS@Q3B98VU7^+)XN1M:69UCO26-Y<J'9[)^'VR,Y(XQUJRK%+G_ID$Q&
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ML7W61O5B^(D:GOR*USUJJM>*I<NW99*N)F"!N2ADX]BK$N<<NS$9SGMQ P!
MJ0+3NV[:O"GQ&$=W?\H4=UY,W$ ]C@$9/L,]TK/8FN@:P;D#<LQV4+F?8%UD
M3X;?13FUXI$-<YF7%.;[1[FFRPPDV\@$,0A)*QD+ZU8LM]P;D!4IS7&Y@%D_
M"KA?XC\1($1U7Y1%V)POU$M=R+-TX*UBR@=>H\0"PGURPEE"J_')R(RS=^/8
M^GK2_"00TT'=#S^/10RQBS]MD!A<I398B[ EW(^0%D(<C27BJ+&3 :P)4A]^
M.%Z^9E]QS553.URV;#!FQTU6,CIQKGFJYP&ZA1D+G."<X7 SI5ZK6;+2OR(
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MJ.K@,"&\N1CTU87C_MQY2;M5X8OVCZ7 6*B326]%Z;RJ L[.N284VK+CD&;
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M_%:XQO=CQ3R3E*2+C;EF"6YTN&U%%50SSYGT0126-I5B!QRS/_3"Q\R/D?\
M:-KE^W3^>/WZ:S56'<J0,>I!'J1CUUV?B&>.^>-3\4+N'94<>\K:S!SKQO8T
MC\EBM9>5BSNXVRPQDL!=;53 2RI*,Z&98R)5C6-6+X<BM2L6K#\3/8C@1;#'
MIO*Z_P#,  *_J._L!D@ZAFLILR6$B FP(VD=<@H,$#.#VR3Z#]?36B7_  >.
MX)7.>W@+FEK57[O=Q;MD5&JOZ4D=]#\>KQX1?*_UO/\ ;U-/(^IS\^^1\NPS
MZ?+Z?+4GB^._]O3/T&N:=N_<)Y7SP3S*UO\ )R\8[9$=Y7]D7Z)X7[=8_O\
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M1IZT9JIP].+!)::3#32$ %Y!ZM@ #O\ T [#/OY6BZ2X.6D(!DD*A3(_\1.
M ?ICL!V]M:.?B2_#_P"^?9_$)[W-ED.SCNCUF3UG=3SUILQI<UP#RM?4-_0W
M')NC/JK>IMJS)D@6598AD0E!&AD3#%CRLF@EDB>CEF"5#G\W8X[HP_L1G^>,
M?+UUL!4D@AO*O'\C>H/KW'I]?Z9&D7C/X,/=GLN()=_:<0]P>/W[= 96P\5:
M;MAYM$,FHQ8&2+HY+],W%! R9WOQ! 1@$2$$1>B60>%ZR,Y^_OUBG?\ A$VF
M[;K],,]R!3Q5R"RQ*.FY9V.%8Y  .<]L:YG=_$,VW7A2BV7<[B%4835*LDJ]
MU/YGZ? >; (ZF<9;&!@QC?\ PQ.Y7)VD599=J'?3J7>&ODL\;VE<FI5JU7^A
M9(2C*B>0CPK7N5CAX7HGI]7I7RWJ1#<WBW%U8J-6J._&.Y--U2?3#+'74*,^
M_)O?&1ZRZ]W>[D/6CV^G3.>T=R>8S$ ?QI%70(WR!=O?OWUD'_#FYQE?# /V
MA?$.!2&%&2$O[0N0[*.5ST;)ZU2"C <LL;GOA7]T5L;/UHJN1,$D\0)GG6VF
M3E_"MBVAP"1C)A<>@^F,GLV,G)'\0QABU;:Y"2/*L]I#Q[]P3$X^6,^O<D>F
MFXSX;G<L%*V:7M1[]+D5)O+@J_LVY;J3I1_6B.1YQU4<*-*]BJK'QBF,:Y/U
M,\>$64T^[,G&.E2ADQ^>6Z\J ^V(TJHY /Y@73M[ZW]7=G! I5(F]GEMR3)D
M_P#ZM((F*@XSYER#[8USTO:#WS0U5EC>-.P7O4R>(LI!I+1MEVZ<RVFLTL@7
MJ>,NENQ./ZX644<A[YQ*JK KZR)RQR$CF%PL+Z5]OD:5+FXS);NHKK"8XS'5
MJB3 ?X:%FD8,RC#2R222XR$>-"4UE7H2,\=K<)$LW(U98C&K1UZROC/0A9G(
M8@ -)(SR'OQ9 2NHEA[ ._ECU<[L:[QT3Q^R=LO-*^I?M]E_ZBOV_G_]?>QX
ML?4CMV_?;5B58^I'S_T^6I'9VM?$[AXZ)XDC[0>]=_&Y=NV_DR$G;7S9]*9=
M,_['9LC3%HY"&KY?Z?4L*O7W%B61$?U%^[JGQ:WS"@N*O#X@ !RF,!"<=QCM
MW]NWIJO.TT3?7=?A81N*Q='XL*.L8AZ1EL9*X[ 'V[9&F;7]B/Q!:<T:UJ^R
M3O. LPIHB!3Q>VKFV F":%R/CEAECQC7QR,<B*Q['-<U416JB^.M\D*S(T4J
MI)$X(9'')2I]05]#V]CVU*EA2Q&\,\0DAD!62-U!1E;.5*L"I'<]CV(R#ZZL
MO!Q)\3O2/8FO[#^Y33Z!)ZQ0==H>S+D.ZOX$K6+'!\P=;\;ER'2,:D;89II6
MD0M:J1RM]7Z>:;PKM]?M4DLU*Y$H>G7N6:\#F7UXI#*@C&<EE 8/ZD'&#S(\
M'[=5;G2>_4KE)D>C7O6H:C&7!/&**5$09)RJCBV>ZG&K9<-8_P"(-Q_R:!G*
M+L6[H*QEI<UXAVXM.VWE."N')DDC^:*7QQ\-75M+'.Y[F-EF(EC@8YI%K*Q?
M*<GO7@N.[M4T]DR3B.&1_@8Q-S9,-P7D).<LW' R%4%NZQ @:Y#?O  W&G\<
M\UCJ4U,L%2&,R,.!!08EZAEE\O<X4$]NEC.6AS=??&#O=QL$PW:]WG9_/%6!
MU8V +MIY@MZV>N%)G@"*J1+3!'5U6Z0=RN<95CCD3^YZWDR-; D5KX4\![)L
ME.NZ58A:EI].24((IPDR)UHYIEQ-+S( 8O(<8P HY$V.Q_9OLHVZG'N]8[C8
M0I<'Q&8S%/(GG#"'CD)DJBME4'8 8.JE;[LA^*AR%C:?9[3MQ[Q-E5MM2*V'
M-V'"W,Q%Q1FQP22I,_)SX^&6 ,H6+S!9!!3 ?=@CR8R'(-U] K>%]JVC;(=U
MH?<\!NS/7FKU7C3<49"2&LQ.JRM$^,K(KNA)PQ#'&NQHT=LV^R]>GMAJ.4 Z
MT=;*2H#Z=<<FXACDHY0ELL%([Z@%_P /SOZ3U-3L:[Q%7[^%3MFYI5/NGGSY
M_)7W5%7^SQTXY(.<^F<^X[?35P5;U]3G]/Z@@:Z$^'UW_(J+_@.=XR^/O]^V
M;FK]T^Z+_P#<E?V7PO66/E@'YX&O0N#G!/\ 3_\ ZUF6?83\0FWDAF/[(>\D
MHB&&,="B>VWG,@A1X6,B&']4V/D8P<2&-L(T,+(V11?H\*C6>G;+--.P>>62
M9PJH'E=G8(@"H@+$D*H&%7T4=A@:\"!1QCC5%/<A0JY).2>WJ3[GU.3G2<OP
M]_B JQ(U['N\96(OE&+VS\V*Q%_M1OY)\(O^CK#DV..3Q]<9[9_33B_R_P O
MW^OS]]>RG\*=V[]P/!_'OQ!0^:N"N9.("]4!Q,F6&Y1XPV_'Y&E<!1\K1&MS
M\.LHZB2Y<%*>#&6VM:2X=YHC9D8XF%'X_/Y8'^N=9J.P!&,'_;O^NO.%VC=F
MO?+AN\*OU%WV?]V%/FI+[DD:QLK/MZYC I)JNTIM+$D19DV-8(X6P=+#%&CW
MK&1)+"UBO>YB+R7CFB^X>%]PKP1236"U*2!88S),'BNP/RC !/)5!;([XS[Z
MY#QW2LW?"VYUZ<4DUEA7>NL4;-)S6U%^0KY@P0L,C\H[XP-=FJ^%MWJ&Z:RN
M^/.WSN,_*5_9EV_Y9U';]R>/,#*800KA$ N<8VH+6-SWL$(CB2>.%6.6)R(U
MSXM?=9HZL5?<MJN"W#&D8L5EF4.JJ!S+19D0$8+@-@G/<>@AT=WN14X:NZ['
MN"7((DC-FK!-)'*$4#F)(1U 6 RRD8Y9 8>SKY([5>_7BK%TO&W$W:QW49\R
MV$>=N=1C.UOEMQ!I,)+H1*>LN*'$*0((.L3YRBX?E)K269',CBKHQXY(NV;6
M-TN3[GNE*>PD4G"A!;F/352,O-)#..,K$$(JNSK&%SWD+XC;7L8WB[/NN];9
M/92.7AMU;<&=ECCX@M*\$W)&=LA OGX!?4OG48\'=KO??@.1L]N=;VQ?$ TX
MU=90E6E!7]O7/]8R[&]WWC!K"S-RA7^*SIZFSCI6S?-M58WJQKU7JZW/;38J
M&"ML^T_-/C(DFB#+GB.C7^'<CMZBPA4$X.=6F_;$VX;;8HT=NH59)(\16&BB
M+0MZ QQI&K*P7LKE_+^;##L=C>B"YFWHA3 ?AK]V64FO3QQ!'V/91JB7<73'
MQO@GU]<:[C<R?7&B2#CS?+R UIDD3?#BV3K&_KCZ'A#>JLL45BU"%!L_$.-P
MW>;;IX)7C>."IMYF%C;6B3FO5:[=#=@4*\L_,8?LZ\6T[AE?>I[%*$=1:]>Y
M;26^J%>-*9@8UA1E+*9 .6>^#C5 M3V3=Y=;<VLMAV<]R6GE(F&/!Y.QW:#R
MW'<F1V4;E+^NYBZR;G20O;(^(QM8^MMP2D;(PF0=S(Y>DAI3M&$@CMQ1H9(C
MM]RS.L&(F7@]>>-?*<@,@F62)D)!7D,CZ16HW98HBD%^IA"LVTW;DCQ1E/RF
M"W77\P(4H)FFKNA[IS'+467WPSN[W>$_4<?VO]SL&AD@]5A1Z/MAY]RPEJ;!
M&YTQ-3>7.(=5C*3$UGI M;$1ZDHY(BBGRL9U8UK=W;UX7:$[5@W&*S6>&RT,
M>0 D\,/XK\>^7AB8\>Y1<$BWKV;]%>%O;[+P _AV(#%:,:$@".>&$!VXY.9(
MHSA0"573GXT^'QWZQ9W4FWO9SW-4&ES]&968>SL.WKF%Q,Y)D\,A(?RP6-D>
M=X DL5K;4U/D:\^0=[)G3,A;'NL0[?-8,<TEE*TZK:<1T[4\;S0=HX>P @-@
M\1*<@<$//B')U#W0/UJP@KVK%6>19;<$<3XRN KB1EQ'E@H>(=W0-G [ZCS)
M?"R[Y] W2):=IG<T*56U)Q0$,O;]RV.AAS)&JV.(DS&B1D$3)[BCPP23J^3Q
MZO0U7)TN[G+ :YAI6'CFE5)#TG8QQ8[GB@<J5[$\@OTSVQ/N;E+7^$Z=*U*)
MIHHW*P2.8D88Y.$5BJIVY%@/YGMJ.<S\-+XB>DL):>K[(>[*&5ZHPB2TX#Y3
MH*[T-=]G$V5QF :^.-KD1?,A'A/"O3SX\]6D]Q*D1FDDE$6!E8HIIV8$>AC@
M21V]#G*D#W(U:69XX$ZTH<*,D+'!+,XRI.!''&[Y.,8XY[X]3J_?%?;9WX]J
M?&FDSG'W:7W!Z;E#33.-T-M'VI<R:&KR]>('(-6U61MYN.YJNTOT/G)/L[.#
MYH.,9@HM40]TALJ_/]Y\/CQ=N-.S?I[E6VNKQ6O$++5FMN6#/)<A25)4@X +
M'"QSS)>6,<4&N$W;P_\ \4[G!/>V^]!ML,)@KH76*6<R,CS2SQENI!&R1JD>
M.$P)<MA< T'W/9K\2/D6_+TVS[+^\R\NCE\D&$=L?,K'.3U.<UC8X<.R-D;5
M<[T,:U$:B^E$1/MUWE.A6V^!:M*)8($_*@+'!P!GODYQC)).>Q]==K1VVKM=
M9*="%:\$>.,:EOD.^6))^I).<:3L_P##>[\[J4M#.S+NUI0PA)3)YS>V?FYS
MGQQ.8QL D$>'<\DN5\C&PP,5JK]WN<UC'.3.:1H.+)#).[OQ5$(&"?=V8@*H
M&<MD_+!.I$TAB"\*[3,[!0JX&,@]V;T4#'<Y)_7(TL&=A_>G6B.!HOA^]X1T
MLD+82;NY[:.;_F9)4<YRS! P9#V HU:K6>E[R)'(U5<YGJ6--206Y'YV+/ !
MN25X O +C'&61E+R'W[< #Z#(SK0M>TSAIIBF&Y"*( *%(QAW8<I"#ZX"@'L
M,X#:C]_P]>_Q[E=_@-=XB>5\^/\ !EYJ^W[?_P!D_P"?_1XZG_I^_P"P_P M
M2RI]AZ =^PSKA_T//O\ ?^X;[P__ $9>:O\ ]D]-8\&^7]QH_P"AY]_O_<-]
MX?\ Z,O-7_[)Z:<&^7]Q_OK]!?\ "P<.<N\)?#\Y$RO,_%7)'$6H+[DME<"Y
MSD_#:? 7Q501CL(./:CU&KJZFP(K9R!2H(3HAWC23#$0LE62&1K6MH]!^@UZ
&8.FO=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g766269g46q96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g46q96.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[23L4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      $#    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    0 $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,@ S
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #P     $  0/      0 !.$))300F
M   .             #^    X0DE-! T       0    >.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             #UP   ^@          0                         !
M              /H   #UP                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #UP    !29VAT;&]N9P   ^@    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M ]<     4F=H=&QO;F<   /H     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" "= * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M2@:@/M&81(H:8V@_G7OU])O_ ((]<1U'JF?U.S?FV[V@RREOMK;_ %*_WO\
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MV]9^VO\ LK;Q?J-G/(.7DUT-[MJ!L=_G/])C?\VQ=FQC*V-KK:&,8 UK6B
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M]_Z]+C_Y[?\ ];6I7]8^BO$_:FL\GAS#_P!-K5&8D='7Q\W@F+$P/"1X)?\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0   1H !0
M  $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(
M @   !0   "0AVD !     $   "D    T  MQL   "<0 "W&P   )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C$P.C(Y(# U.C0U.C P
M   #H $  P    '__P  H ( !     $   /HH , !     $   /7
M  8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
M 0 "   " 0 $     0   2X" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!,$U- "H    (  <!$@ #
M 0     !&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "
M    '@   '(!,@ "    %    )"':0 $     0   *0   #0   #P     $
M  /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,3 Z
M,CD@,#4Z-#4Z,#    .@ 0 #     ?__  "@ @ $     0   ^B@ P $
M 0   ]<         !@$#  ,    !  8   $:  4    !   !'@$;  4    !
M   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M5>^XPND <SJNY(QQ=6@!)4J[5=R)G458&!RB1,[IA((OH=_(Q[N0"2  22;
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MNJV=LW;54B[9TU<HF(LW<METTUD%TCD425(10ABF* A2I"5I4A:4K0H%*DJ
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MJ;/=EGM">^H]@L72FSB5J/\ "%O,OVA-@4;5;(NUV39!K>RS3TZVI*;N35)
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M.V'0;]K<+18/[3:MIQN7:59T4@3"ST7[$X,4OA]\]KDN\(=4X@4 .K]BEXY
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M1XTN;G&O 'AK;K?I^L1V\_,//@V_ #QS^7GSWWXTZ7QRR+6YBQY7\;\,Q&O
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MBQ$5PE^EC"S7)E'J$K6&,%"6?J#Q7B^I.JKDU_;)6[1<JO"GR;$72.3D)K^
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MTI00IYO>#FY@W!-B!2A_B"+6C+Y-TO)U1O\ $8ZI<1<K ^B(>_08>ZE[[6J
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M%RFD9(@")C& A3&+0Q7J1,NH88GFW'5N=BE&X^B[MBKL]YQI*0NR20DJ"CH
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M)OQ\],\,@V#G;;N'G\?E\/,!V ?,0'2U]3G%O VM^]AJ<F%^7.^+</#SSIR
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M+-7DXN)TOM)".DD4DSG)R(=AJF3+$[-3#%0W&)R=$Z]+*DVEJ*BTPRMM,P7
MM*5(8396X2@DD),6Z:VFIL_1Z;3YV@=K/4FC&C2E1;J\TP@-IF9Z<8F'9!+*
MFG'&GYY94CM4I=0A"5*3J.X>98K2T%'U!GC9!K2PLPVZ<KCBYV1^F\F A9.#
M1"OOE!2<UEBT0EG#Q%$_WV[=OT&!IM_,,F2; >)NCS29AR=755+GO=?<V)I,
MA*MJ0S[PS,*]Y;!*)MQ:F$-J/\!"&RYV#;+BRN.X]MA3%2$O1F=F&VJ']Z??
M$_3'*W4YA+TZ)&:D&_NY]12Y2F&$3;KR$$3SSTPB7,^_.L,(8CR>0KZI>WD
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M;?86T@A%/+AUXQ[9Y:FF-H7&=V90_4/CG 4+<Y;,B$#CF46O>'$LK.[3*6^
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M<OGIX1+QMQV'S$.?7XCQQOQV]/.K.!?X$VX6M?P-NN;PYGCU^!N!ID\>FL3
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M@&^X@ ;_ %SZ=^-OEJ1RY Y'ZY/F!Q(L!>((.I-KZCZXP.1US#?OZ[<_#O\
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MJ;824D6!3TBC>XB(;\^?8/F/?CL&^_GY^@7S'A^>HYG!T)O:_'&<)TT\/#Y
MD@Z"UQG'&(@'/(;[?#R'S^?/8>P;^>HOC! YV-LCH/ 9TO:W&(/UT^6+G0#(
MQYXB.VVX<[!MV[[_ #X\_P ?3C<-->-KW&?CXY!Z_,0OISU/+E:VG"_#'47A
MN._ [>GGOW'U'UXW'8?EVG''//A;3PUMG&+\]8Z_ ]?7+EYQ/V^7G^'/EZ_E
M\/+5.OCP\\<>7QZ\8C6(" <CL/Z?#]O0?7;G4B^!<=/GY\3KYXB;X]<AZ..&
MIB41V 0$=_ASSOML/Z;]]N=+Z6Z9L-<_7KG%\Q4$W/(&_2W,:<+VTM#G8 'R
M[AN(<=NX\"'Y]]@XTZZ>5QI?QY<#SN8CB>N1I<W/UMH,7QC-H@/?<-_+XCWX
MY[AQZ<\>8<C4.I X#0"]LX.IT-C;RM:'0?'IIP)Z_'K$0W\^>_H'GSP(?#D1
MV[[=]4Z:=+ZVO;F#PX:G&L/5N)&+<\GH/E>,\_LW&BC?IX=+G3\!9#(EG<HG
M_P#\J23&"C_'ON._A69+)>6PIB&W&X^>?:>L*VE"0;ENFRB5="I;[MNF' ?.
M/H/]F-E3?LV6X4[HF=HJHZDVMOI2Q(2^]ULMA:;_ .V+_=:[CT/&&3HZR+G]
MK[4/VCV(+O1YJ/Q)9%,=9KITQ)2<2F6*41K\1AB"EH^,/*!*O(;*4-C1^X:N
MV$>LE$K8_(E*"R4EV1W49N>6+1) L.>0=?7SY1Y_VXE?%SA7#%H*EXAALIOH
M-14$SF%-*QU*5??S*% 2D(=6LI!L?;QG\ $'</";:OLI>W:K4Y?_ +6GI>M<
M9+$RVBV=<3!T\^8R?99=IJ91_5+A7_D<2-/^>-:+6](SB)@';XAYAZ^7?Z#5
M)%^AX'EQT]&$3 < ^@ //Z^ >NW-)03Z)/#UU/*^$2F-O\OKZV_QM4E-O'UZ
MO^]T>VQYC7(&6;0QI>-*?/7>TR _]-#5]BH\7(EXBD.\>K;ILXJ-2,8A7,K*
MN648U\9/M3Q$#%'75G9Z3IS"YF>F695A RX\H)!.2$H%BIQ>I2VVE;AL2E)L
M8XGGV9=LNON(:;&JEFWD!JI7)*05'-A&;' 7L3;!*H,ISJ/R&%835*192AXW
M%G)320&*0X(2MQDVSJ%:N"")T736'AIE !+XVLX<# 8NK:Q[4V6RMJB27;D8
M$Y/;R&C_ +FY5!2ZH'5*G76C;\30,8M.;4)22B29W[?ZK]PD]4MI(41R*E)/
M-,96<;^SNZ-\8MT$XG!M1L;U$"B,OD)N?($BHJ7;_?WM9Y-DU4';<2Q[)FB7
M<0(D0HB Z]GMM-II]1+E6F6$G_3DE>YH SC_  _9K4,_SK4>MXL#]8J3YNJ:
M<0/Z63V*;?\ A[I/_,2>L780U*IM=0(UK]2K,$V3 "IMH:!BHQ @%#PE B+)
MH@F4"E_E "E  #@.-8\[-33ZMYZ9?>5_4Z\XXK.N5J)BWJ=<6;K<6L\U+4H_
M$DQ]CZMUV415;R<!"R+=P4Q5T'T6Q=HK%,0Q#%53704(H!B'.00. @)3&*/!
MA :4/O-D*;>=01D%#BTD<<$$$9 /E$!:TD%*E C((401X$&+;[]T/])62DER
MVC .-@<N/'[R4KU>:T^:\9R'(*@3-3"%DA4#Q^+<[DX"<B1C@84D_#>Y/:K:
M*1*?=ZQ/;J;6;>>5,M6!O;LIGM46\$C!(XF.ZS5*@P1V<V]8?RK67$:W_"YO
M)S;..?,Q8/-^R'KV/,D4/,'3/D63@)_']UK=T;4C(Y_OF EQKLRTEC0S:U1K
M(LU!HR*;4\>LX?Q5I,"+DP^$OA'Q9>U[1WIV2FZ;79)MYF<E7Y54U(CLGF^V
M:4V'%2[B^R>*"K? 0Y+]X"+LG:)QYAV6G64K0\TMHNL]U:=])3O;BKH44W"@
M 49&O+-%K6$8U#2$-(1B.F^EZSY_ZC.KQF[EL?U.B#G# $R]FI+#SJPYB.K3
M<-80LB;K%&57-WB8NBF%]#I1A)(E)M#N)?!*/&JX.U$T6<<?AZ&?'Y0CL<8=
M5=*PO@O-%5BS.++GJOYSZPG%/Q"E#3Y9FT6VW=5.6G&.(<JWW:1D1C9WEDK2
MYI CP4F\+)&E!-[A$XA/[_M\HD_D/IGYQ1+%N+K9BF,R]A',6#I9*OYCP/:\
MN0\W?WM%R:-CZKZ/1E8+-5S:J5B0LK"N3^5HB4KUVCV:Q8YXI*P-X<1RCC[2
MLFG'ARZ:^NL1%69G!CV4=] ]>QC3\,U5X;!F2IJR#DC"!L@4@956D8';.7,W
M4X*SX[-_%STZ/NF<V_G1=)ILWJ!VCL3>)M,(]"4,68+ZAK?*]7L=CYFUD<.8
MJJ^%+^KC9U%8481,7&3*.7<?T.->GM\5CN?F[VJ:RNZ@\GG$[:JO*U)BUD;0
M6KNOL"$6T,L:9>DBXV/A3'5&3KIIWKINW35C+J"QC.R=-:8FD"8A<T:H.:BY
MF*9(8T:72T(V.8QVC.%3_@RDST;'+5-)NW^[8V/7KUP\X>/RQ^4>2J,$GA>R
M8CZC,3,,B6^N].72)A"6GXE2GN86W63&%TS!U#1.=\;)TY, 3@Y/'*\O&7..
MQ\V<N!@G.)ZY64'3M!-N\<3$\/C],?G\8OOZ#,<W7'U^ZE%LD-#)Y&OIL-9,
MR2\335-'JY'O]<M%LN$-%/CD*1_$TI]+ITB#.0=V]=KT*U.1($B$!]8B,E&D
M(:0BGV6+RUQIC6\7UV)?!5ZW*2B"9N =2"38Y(IB')0\;^34:,D]S%#WC@NY
M@#D+C2)!=4JDA3T:S<TRRI7]#:E NN'HVT%N'HDQCNUU>9V7V8KVT#Q&[2:7
M-S:$G_5F$-*$JP,CO3$TIEA.1WG!<@9&J\HJJLJJLLJ=5=94ZRZIQ$QU53F,
M=1101Y,90YA.<>1$1$1YUZY"4I2$I 2E("4BP 2G^5*;8L$BP& -+\ODLM:W
M7%.NJ4XMQ2EK<42I2W%FZUJ)N2I2B23:Y.;1+QP/IOQON(["/X;<".^WYB.I
MZ'IPN-/"]QP /RBB^>GPU^(MPS?%H!QP'??UX  [C\NX<CW]!X!KDVM;70D\
MM-?RZ&\1C&#GT..<]!YPWYVWY$1[>7ZB&X^OEOI8VOP%M1KC.;7L/A:)%O#!
MS?'3K@<-3QXQ,''.W.WS\^.>=]^.P?L&H/*^GZ9QBUK9N?S,4\_0B//UOMQY
M"/[_  Y]-1CU:^>('Y=<<X0^(A^^^V_';\O/3H#^5KVSK\>$(XQ  V$>0'^X
M#SZ\;ZJO?  O^W &UK<,8OJ,WJ!MQ.,X_L>-K_0XB(\=_@';X@(\]_U$1W[:
M#3/4\] 0,$YMX#2&I[M_W/A@0Y_ >P[!^(CY;<B&_H.X;\CJ.E^!OD\/0-CQ
M%L:0%L<]X<>'3-_63#GN(^7GZCZ;;[AN';]-3TMQ/RS;(%K G.IARX=1? T)
M.=3CY1L4]"D4,5TO8W W_?(FM4J;^7P[@]N$\9$?_MXFY43%-YE$NW&VO,WM
M >#VUE4MHW[HSK?+<E+A7_JWK];Q]+/8'*>Z>RG9@'\4P*K-G%O\^LSZD'F;
MMA!!XBV2,Q=WK#8W%&-N? U-]K/CJ35_V(_./0M?Z<DH)1*F^LN$,T5:VLVY
M3E$"JNDJ[E&?7 JA1,DV14%(0*HJ&D/7UCA]K32@MW15>I B0*NJ'9*1=&O'
M) 2L#:MR"A1]X0 ]W$6614-N54!(4P F)_"<F<^SN:]VVHE$7LF;8FY576[*
MGT#3BZPCEU($7O9]WLZFR+V#J'6CYH*P/-2!&HCKT?&Q8:0AI"+Z.B?H7R!U
M@VI55NLM4L3UQ\DA<[^JV]\/O@!%=2MU9NH7W,E9G#59-0PK#]WPC99.0DO?
MF.QC)+$MJ=K)/9J7 ($S47T$RLF%6QD!^84,H82H$8[[J@4(L M;=IJE59IK
M=K!R86+MLWMC([19&B 1I^)1PFV5)VO<!]..(^FJF(4K%%6:PK0? K+S2X$=
MV:S2 $*0\E8ILZ97<BZ,!0!)(PILF*6S:.:-&I"(E\]5>MU&N3)FJA,*=4+A
MIH=UB71>X;8:'=0D<3E:SWEJ4K,:_FYV8G72[,.%9T2G1"!_2A.B1SXG51)C
MRV=^KW!G3PBHWO5K3=6?[.99I2*XF69M+D? 4R0.&:*A&T,FN!R&1<SKR,;K
M$$QT#K> Q==:5I\U-Y:;[EP"XONHY8)RKEW00#@D7$:KVZ]K>P_L]0I%=JR5
MU+LRMJBT\";JCM@E20IA"@W*I6%I*')UV6;6FY0I=B(Q/9+]KIDJ6<+ML4X]
MK-0C?YB)25K5=6B<4+_XKE;,UHB(8J;<B@<DNF4>/?J!J^L4!D &8=4LXNE'
M<3KD?U:<01Y1Y0VE^USM#,N.-;*;/4^E2^4HF:LMVI3BOZ7 RRJ5E63;^17O
M0!QOF+29OK^ZN9Q<RRN8YB-*(#LA"1-;B4"@)@-L4K2&(I_+L!0$RAC^'<IC
M#N.]P32:>G 8!ZJ)4>6=XWQ?%M3;(L8U+._:!]KD\O?5M=,RP.B)*2ITH@ G
M>M9N3"L: E15NX)M'7QG7;U;12H*(9NM#GDVZ<FV@95(V^P" DD(AP/_ (\
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MX>8BK!%1TY!R+.7AI=FWD(N4CG"3MB_8NTBK-G;1RB8Z2Z"Z1RG343,8IBB
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MQ:.++6I&K-F2IV)F:1$G2J$E%L)9%RP8UR\TX\IM*DILM+RM]._9SLUH0E:
MK.XL*)%P3?\ F(S%IVOV$I>S]+JT_*3D\J8D*ILO(.4V<7)N3-+>K=(K,_/T
MRJ.2B2RY4J9,4QIE2F%-(2EU:)B69F4+:9[65PM1*0U4LUN=W*=@GG^F4)6*
MW6'<-&6&=M=SQ/3LE6$SN=D8>7CH>#KXVMFP9E+ RDC*'?L4 % &K]\:@33S
MO<;#2% /...+"BE#;;[C*;)!!4I6X2>\ +$VT$=J;V'V>H2'*E6':U4)%U>S
M-/I5+I;TG*U&?JU9V4H^TD^7I^8E)J7E)&0-5:892F1F9B9+[+?<[-Y^/*M\
M/M''4/1<12,3>J7"W2\8[KQFEN2BR7.*B+I)0K%PZ.HT;EBGBB02+A:)?E8(
M(/VQ&CM>/;"LJT2Y?>2)-V8"FG%M-NJNWO=FI2 38#\0T[POC-N$6=.QK*_:
M-0MD9B3KU$D:W6=GY'L:NF436I:3K+\HRX[OLH,H\4]NZJ4F PA#S:6W%R[9
M4II/?US%&,<F+(J8_D;W#A"72A0ESA;<K7Y-T-7N]RBZ66RUR>B&$4W^VQDQ
M+1S5U"R4$.Y9)L_;OW*;9XU)QKF7V0.U2TK?;<4VIO? WT(W]Q:5*5A20;*2
MK)%B,B+I3=CME=IW+[/35?E/N^N4*0K4C5U4^8=52ZW6)>BBI4V>E&)9OMI>
M<F9=IV3F)(XF&WD/.);=;'+,X5J\1BMY<8^/O]VD$E+(C)3]6D*VK6<<R<3<
M)"O1<!?Z\$:]L21Y2+8LIT;"I(5^+,6?BV4<WD%$':HPB;<4^$*[)I-F[(7O
M[[P4T%*6TNX1A1*0BRCA5SI%4[L)29391ZL2LMM#7)D+J3<Q/TJ8IJJ9LW-2
ME8F*=*4_:"G^[/5%/O,JRU/*J)?D9:T]+LR[;RFW5'HK[0<6TB:L.*04R!,Y
M7K<@%8>3[1Y6DJ,O>VC]&/F:\C7W,>G-DA6#_P"VQ:-H-9SN'CAH1^%<1:.0
M11K:>F'$IF"&42ZTE800LN=D02%;P.[O%.=W<MPO%OK^SVR=$GI_9$*VBG-K
MJ=,)ICE19=IJ*$Y7D/MR\U3T4]QA,Z)%A\NRR*G]Y%QY;0?%/2VX$)]&;$N)
MI&\3>$J_,WEQDZ(<6* 8W)XI"EQ_8KM6$) SV#1K)8M*Q0T)*2$6ZB(2RN+'
M(N1558R$E7F35RX184"8F0RF96AGL5;JBV-[M4-J("5%6]NJ4-X%2 D#4!1(
MO%Q.Q^Q\Q79W8:GSM=7M1)KJ$BS6GE20V?J-:I;;ZIB113!*IJ$G(S+TL[*R
M52<J$PYOEE^8D&FG%H9Z"8PU7XYU;I\DO+_Z<1V(X+)=4E5Q8A*S+^ZI1T'6
M*RN<C;[&=]'7MY,1-B!LV()X^EV=9G]G.FDLE4B:<4&T;B>V5,*9<3G=2ELE
M2UZ[UB@(*<ZK%\7CHSNP]-E7JQ4$SDX=F9;9"0VFI,VLL";G9BM)EY&F4QQ0
M:#)>EZX[-RL^&FDE4O2*BMG<*4K36BV]+-,ALS5S%2,!ER,C97+H8^&ZS-@I
M3UC.1B*\F@9U!1D?6VSMC)2)&:3U@:05=-VZ'ODG""RQDSDZ[4^ZY+K>*Y<E
M,OVH;2ET*2>[A14NQ2-XWL03BQ$9M5_9-19+;*F[*HD-KY:5F]K10/OR<J%#
M>EYV629I*G9&5EJ>A]B9F RAU@S!<;;1VB7$*64D>0E>G"K+N(6K10W:GY3N
MT%+NZ-C.]R57>RKJ:AG$0ZBXZ2?QC.*2;M\EPDA)(T!1ZTAUE+%  Q63D(RP
M1LFWY$3SHWG%!MV7:4GM7F@X$[JPH$I"B3=H@=I;>[IN+%)!M$W[,J0M4E2I
M55;HVU=;D9QVA;,U^:I3TT].R3LJY+R\T_*LRJ&FMHY)^8305/MR:U5"1[%:
M7Y>?EYANV_)==K51M3BKUJ;4L98%HSC+!.IJMUHB1MK=,0L8UHZ"*0JUIE(F
M4BXEZL=PK+HL331%4FTBW9M>]+K<=;#JTA':$J0BQN&K]PN7OWB "=-;7!!)
MUEM13:71ZLY2J7/+J0I[3,K4)\+:7*3-6;3_ .T?NPMMHWJ:S,%4K*O.*<7-
M)8,V%I;?;::I^'Q_7R'MZ>?S\]M@US$VX?7ZWSBW$"UQ;,8X.OSX'3EQ\>-K
M")@#<>._8?\ GO\ \]M3@> P<9^>-,\P;XM%7U]&VE_[QR 3COY^GE^GY_U[
MZB]C>W#3'Y#]_I"(>[_KY?U\M^?+\>^G=SKS%\9Y8Q].6-81*)1#@0#8?Q ?
M7C;U[@/?3%KX.+$'\KXSG&?#@%R#<8SJ,>>-,Q<]AWK'ZAL'%;,Z;D"0=UYK
M_*G4;3XK'62)AM_LMF3Y07,6D&W_ &0SV-V'<>XCOTIFFRDR"5M@*U#B.Z;9
MMD6)Y643;%ASVGL?[9_:'L2&F:37GYBG,V I55O4:>$#_3;;>5VLLG_Z1Y@W
MZ8C(K1/;!N2))(9,PZDX5 0!:3HL\9N4P>(-S)P<^DOX3 43"!36 0$Q0*)B
M@<3)V=W9^^6'_P#E<3<^9&Z .MCUCT10?M?G<;1M-LAO+T<FJ)/;B3D93)3R
M5$63O$@SQRD#&\2BX.)]K-TW/2%&2K^4850? !BK5^$?$*)A*!MCL+(L8Q2
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M:V.7M-IL4TM"L7H'53A(R1BXX5SE>K(*R#=H[;TB3!N77G75%M3:2LI 0E8
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MJ:9PV,0H@*;VN <\;$<1U',?$<XZS;SK)*F77&B; EM:D$A*DK )2039:4J
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MGP_+'KX?G$./,?3ZV^@^ : YQD:#>SK;7X8\(:?3U;T.@B<#!MSY#OP' \
M?0<<:DWM?GW=>M\'EX]8D9_6(^,.1[_CL'&_S_'C5./6I)M?X0CB$1'<1'Y^
M0  <[?$/7U#4VOI:P%[Z>(OQ\[>0B,FXOQTY=.M\7YB+N.GSHHSCU#.&CV @
M#UFDJJI@ZOEI2780P(&]P=12(:G*#^P+B@N19N2.1%DK_P!JTDU PG"WS53E
MI0*2I6^YP;2;YR+G) N0<G%QKPC<'L^]B&W'M 6T_*2)I-$4I/:5NIH6S+[A
M#:E*E&%6?GE[BTK0&4]DK^9]%R8SX]-70SAOIR29S+-A_&F1DR)J+WRQMFZK
MM@Z,T%L[)58\"&;UQDL*KGPBD9U+*(KB@]EG:9$P)BLY4IB;)!5N-&X[-)-B
M-[>&^;]XZ<A@8OF/>WLW]B.QWLZ;9F9>6%7V@2E*G*[46FEOM/%GLGA3&0DH
MI[#A4X0$J=F2EQ3;LTZ@) O ETY5:)DT8)XQCYM6/>IP[^38+RL:QE5&RI8]
MY(1;:0B7,DQ;.Q16=L&\K&+O&Y%&Z4@R44*Y3M\;CC']TJ^S6PGTQ91M_4.K
M9,B9@ZFLC_?BE_S=D2R+DD9@UH=M9&P1\73ZZ$13H>ON7[)DI'1B\7+O(=LP
MCF#27^RL&Q"1;]?7APB2;^ T$9$=3$0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(1TMAK=>ML2\@;1!Q-BA)!(R+V)FX]K)QSI(Y1*8B[1
MXDL@H&PCL)B")=]RB \ZJ0M;:@I"E(4-%))!^(CIS]/D*I*NR-2DY6?DGTE#
MTK.,-S$NZD@@A;3J5(5@G48X1C'S5[*C$%V4>S&*)N0Q5-K^-4D.9(]@I9UA
M$#>!./771EHE,X[E_P"BDUFC<! 48WPE]V:]2U<F&K!Y*7@/YOPK\[85G/\
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M4E+X()-_2222"2:""::***9$D44B%32223*!$TTTR !")D( %(0H 4I0 I0
M  -6LF^3DG))XQO=*4H2E"$I0A"0E*$@)2E*18)2D6 2!@   # CDTBJ&D(:
M0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"
M*)Y)Z<<%Y>\9\B8OJ5C>'*8GWNI&E83Q2G P"!)^*,QF2;>,3% KX *?90H
M<I3!V6IN98_RGEI'*]TZWT5<#R'/F8PW:/V>;$[6@G:'9FDU%T@CWI<LEF=
M((($]+%F;&%&UGA8V4+* (L*OOLC\*S9E7% O-WH;E3P>!I(?8+C"I"  !Q(
MW=%BID?'L)_"I/J 4YC 3P)B4A+HU7YE'^8VVY:]K70>ESWK@'PX<HT/7OLF
M;#SY4Y0JO6J"XK=LVXIFJR:;6!W6WDR\UG)[TZH!1-@$V2+/;?[)'.\0"RU1
MN>/;DBF F21<.)>KR2_)-B%;NF,C'%/_ #'_ /=ER$\*?B\0&4]V6X-U^65_
MFM.(.EQD>.+G&F ;\  (T]6/LD;;2N^NCUR@U="1=*'53=-F7#CNA"V9B7!R
MK\4T!8:W5NBW"P] '5U6Q-]IP[+RB0".RU>F*S/E,!2E$3%1BYIP[ !\0  &
M;$,8P"4I1,!M=QNK2*]'PG3_ #$E&FANJU[6M8: Z7UUQ4/L^^UNF ES9.8F
MTY[U/G:=/: ?RR\TIS-[#N"Y%K7R:02W3AG^#,)9;"N4F0E 1$QJ-9#IB!3'
M(/A51CE$S!XBFV\!QWX$HB E$>RF<E%Z3+1QBR\\/$VSK<^5K#$)OV9^T&1O
M[UL5M,UN@DD4:?4FR2I)(4VRM-K@VL>1'"/**XKRB@<4UL:9!1.0/$8BM*LJ
M9R@ $'<2&BP$  %$^> #WA/_ )EWK$PQ;_.;(OH%?#GP%QQM<9BU+V/VL0K=
M7LOM @@&X51ZBDBU@38RV@WDB_\ N',7Y6V(\L.S%3:XOR*Y4.)2D*A1[.H)
MA/\ ]@% D6;?Q>6V^X<AQJ/>9<"_;MC6X"K6QS'+T<Q4WL9M>Z0EO9;:)Q1*
M0 FBU$W*OPVM+G7@=(]U"]+'4A8!(6*P?D]<#^ "J+U"98([*  D$SB1:M$"
M (& 1.=0I0 0\0AQKC5/R:/Q3+0-OZP<WOH-+VUR;VXZWR3]E'M)GRD2VQ&T
MJ]ZP"G*7-2Z#?0ER80R@:Y)4!D7.D5DKGLY^KRQ&3$V,"U] ^P_:+):*O'%3
M VP[J-D99Y) ( ;DH,A$H@)1*4Y1*'676)!&CI601^%"CIC6QY<Q;&(S*F_9
MQ]K=0*2K9QNGH5_/4:I36 GB-YIN:>F-#:P:-B+$ Q<U3?9!92?G2/?,J4FM
M-Q\!E4:Y'3-L>[=SI[O2U5HD?_Q!0JSDH#SX3@  /2<V@:%^R9<6?]Y"1C0X
MN;<;6XVUS&S:-]D+:1Y255[:NCR#?=*D4V5FZD\1JI(+_P!V-()T"@IRQ%[*
M%A%YV/\ V573=5#HN;8YNF27A!*8Z,W,DA(4QRF PBG'5EO&/O=FV\)DG<P]
M*)3&WW'82VUVN3CF$;C0_P!J;D:\3XDZ>-XW+L_]EGV;4E3;M3-8VC>38J3/
MS@E),J!O=,O3FY9T).A2Y-.BQ.<XOPH6)\9XN8C'8[H=4IC4P "H5^$81R[H
M2AL!WKM!$KM\IMW5=KKJCYG'5L=?>>-W75N'_<HD>0T'D(WM0]E]G-F6#+[/
MT.ET=HVWQ3Y)B76[86!>=;0'7E6QO.K6KK%0=<47Z&D(:0AI"&D(:0AI"&D(
M:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI
M"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(
$:0C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g766269g46v24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g46v24.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1W84&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #W    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    * &0 <P!K '0 ;P!P "  8@!W       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #P     $  0/      0 !.$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MT0  !V0          0                         !              =D
M   #T0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #T0    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   ]$     4F=H=&QO
M;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    !.$))300,     !.\     0   *    !3   !X   FZ   !.@ !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !3 * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5)1?NV.V0'0=I/$]
MI5!V3U.G;Z_V5IU)FQS=/%N]ONV(@6IT4E1IR<ZX/-8QW %L;;"Z![M[7[6?
M2^AL5Y(BE*20[S>*G''#76B-K7R&G7W"6_1]JHNSL^G2]F.-K?>?6VZCF&N9
M]%__ $$A$G93I)+.^WY.UV[[,US0\G]+/M 'I/B!^>[](I-S,^R6UTT.>&ET
M"Z?ZOM#/WD> ^'VJMOI*+-^QN^-\#='$]X3NW;3MC=&D\2FJ7266,_-:"Q[\
M0.;[2XVP0[PLK#?:YO\ 74OMF>]^QGV67_0 M+G1^\!L;ZGYZ=P'P5;I))))
MJE*I=K<6 -WV.#0YP!V@-WO(W?G?N*VJF2:&UY-F0]M558#W6NX9M&[U)/T=
MB(W"CLM91Z.UV_U"YX:*W,9[I^D!L8UVYK=SU!^34USF_9V$-) .^H3'?5R
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MZ1WJ,9<ZIOI[_P#"_N(CBE(0@?5\Q']3JJ, (').$CC-PC*)X1[U<4>+YO\
M%;PRL)W6ST;]G:-K-SKW5#TS] L],[7;_<^S<]_I_I:U=R;<+IE?VCT(W.##
MZ-<G7\Y^P>RIGTK++/T:Y0=1RVC-Z8V^]F4\UOH8Y[WOL87.+O1O_,MM;93[
M?T?LK_XQ#Z5U7-KRV8G4F&OI^=8<<=/<W<-KV^^]CK2<C[/]#U_?]G].VQ-G
M,P%3G7'\E@]?ECZ5V/$,IN$-,8'N1$QQS_?G 3_[CY'NP01(3JC>;W>B,&UC
M*"PP&#<"--A9L:]NQO\ K_(9F3;BXF3E9CS:VAILV-;#@UK=SFAI%?N>[^;3
MPP-E^)BO)+Z:W$S)<T'GGD)V8N*QXL936UXX<&@$:;?I1^ZN)/U@NN]'K+WV
MBD9'Z:NMY=Z+-S=E7H,V5V.?2Q_T?4]3>AYF5U@9YOQ;'"M]KGCJ@DM;5+AL
M:V\^A7C[6N_1OK]]E7Z'_2)9"<<3+(3&,21(]N'YOE78\9R2X8U9!/J(C\HX
MOTGOTEG]!ZB>J=(QLUS2U]K?>"(ES2:WN;_(>YN]BT$ 018ZJG"4)2A(5*),
M9#M*.ZE5R,2C,9D8V0-U5@:'MF)$2K2$66![G,+8=',]D5KE8'U>&)FBVRW[
M12UK7MW@!WK_ )]I8UOI[?SJO]$M/[%B[BXLDF2=3^=H[O\ RD/(PFY-M%US
M&/LQ7FRATN&UQ!9N]KO=[7?G)?8AO]3:W=),[G]^=-WFAKJND0:-^8H1B#_5
MX6?V#%U]AU$'W.X_SD1[0S'<UO#6$#OH J_V!G9K1I'TG\?YZ**K6U>DW:&
M;1R2!Q^<45K_ /_1[_K+<>MIBH^K>0YUE4"P["W=MG^>V,^G3_A*E@OZ+U&F
MVREI9CBDONQ;*RUSK6.&ZVIM%AV_YZ[-S6NT< 8U$ZZJM?T[#R+Z\BVL.MJ(
M=6_N"--/[/M0]0-@_3]'ZLL9PJI1O3YM92_J</J@\G@[6AN?U"EU=--C397'
MJ/+A[&.=4T>G12QWN?Z:Z;I6#51BD-L?=3:XVUBT>YH<=^W_ *2M4XF-1N]&
MIM>\R_: )/\ *1DJUN[H(.3T&('#Q2XI 'T?U*$O5Z?[Z/[/3[AL!#Q#@=1'
MAM*Y/J=+NH9&9]AJ+KJJP^J@;""['?Z-;'.^EANW?I?LCOZ3_P '^F78)@UH
M)( !=JXCN8C5(@]#P^2(2C'YH">U DB/UX7A+Z>IXX;E65/VYMNUW3Z]MCV6
M&O<Y]V0[^9OM:[?736WZ'O\ YQ6*:NG[!A9SGL'5L85XYI)<2W<QKJ_6+/TN
M4VUV^VNWV8]'Z/\ ?715_5_IC!</3/Z<5^H0YP<75;S7?ZC3ZOVG])^ER-_J
M6J]113CTLHI8&55C:QH[! B1C1(Z#;3A'I_J?,O]S''()0B:CZHF),)\?S1^
M:6;^:FPHQME+&7/.38T>ZZP-#G$_R:FUUM_LL0L[IM>7B_9VN-1:]MC'1O&Y
MAW-]1C_YUG\ARN))S$39MXS]A]9^UVXU-9QJL6TY&/GRUY<' >JRK']K7W7O
M_,L_15?S?]<?1<2SJSVBUGV>6L=8;#[WUL+FDXU#6^BWWMKK?=O]6K_KB[=5
M<;IN%BW67T5!EEL[G23R=[FL#B6UM<\[]E:0O2R35]OTO%=*<2-(1C\NW'^@
M.$_-+_*?IILC(JQJ777.VUMY/QT"!3U+$NN;36XE[IVZ::>[G^I[U9L#G,(8
M8=V)_P!7(+:[1<''@#5T@@C7V[=K/=K]-)8@ZMU)N#3[2WU2"[W D-8T2^U[
M06;O]%4S?7ZV1955O6,WKV=&2XV$?9V%]@BNSVDM:WTS4VMM-FZQFSU;,NKT
M_6]7^9_25?K11;GNR*G@AU!]5I@0T5!_H>K)V58_HW9&3]I?OWV_HM_ZMZ:H
M&^E_4!?7;=-E+ [(HAS7LM.RS]I;7;&6V.]M?\O]RQ2T   1Q &4@0)?X6OZ
M*T1,AQ4:OA%77]W3])U,+ZTW.RQC-><BQX:=IAU8<[Z-#LAK,9U&0YWZ+^8R
M,7U/3_HZZFBYE]-=]9EEK0]I\G#<%PE/3,7)L-553:C8YILKQ[)W.WDXU'KG
MUO1;[;+KVT4^HRC%^U+N<2C[/CLJ<X/=JYS@-H+G$V/VM]VUNYWM40,R#QQ$
M:-0,?TX]>*/]5DR#$#'VI3-CUQR#Y)>GY9?UY>Y_@<"9)-(3I+7_TO4,G)KQ
MJO4LDR0UC&B7.<=&5L;^\Y!#NIV:AM6,W^7-KO[36&AC/^W;57ZM==18RZBD
MY-M--UM- ,;K!Z+&Q_+]*V[_ *:R;^I=<SL=KA75ABAC+KFN?%ALY%%E#HLJ
MIL^C^D_2)2F( :7(B]F3%R\\MGBC& /!ZI1CK\WR_P XZ]^;=C5MM=DXUF]V
MUC3^B#R/\&RYUMK&V?UE:9G8SL?[0YWIL!V/#]"QT[?3L'YKFN_U]-<#CLS<
MVZ^FK'!-UH]?IMC2]A+X]?)J=[<;%=4WZ._W_N+M*,:LNR&5,:^ICJF!K@'C
M=6T,L=[_ *3VU[*MW_!H8\GN"1(KAV(9.;Y4<N8 3XC*^*/[OZ0/S?\ H#;K
MS<:VP5,?+R"0""./I?2"'D95WK_9,1K7WAN^QSR0RMI.VO=L#G/?8YK_ $Z_
M9_-V?I6)J*!5:Y[:0T@:PUK?@*_3G^WN7/?M?K&(;K0W'JQ,FD7U9MS@VIV1
M;Z7MLL=8W^CU^K37C[/6]/'K1,A")E(7K7U/=BQXI99\$" :XO4>'0>FH_UO
M4[5V;FT7UXV1?BT&YP%-SIEY/^!KQ2]OZ3^7]H_ZVHX76ZK<U_3[7UOOK>:W
M.KEI#@-X]7&M_25;F_S=K'WT6?Z7])76N3ZRSJ53+Z'AF=7:]MV5M>7&G*?_
M #-@])_K^AZ+/7Q*+J_1I]3T[?4]-:'1</*?D&IQ]>OV'!R;6^G8RAEK<C*?
M;2/>U]V2UM=/K?ILBVJZ[^:3(9C/((< $>NFL?ZS8R\ECQ8#E]WBE^B =)DR
MCZ?^=_?X/U_KQO569V)58ZNRP-<V-P,Z3]'=^ZF?G8K,-V:7_J[6E^_Q \!^
M\AW8X-CW^BT]P]K&%Q@#67GZ?]E">T.S</$L:VNNMK\AK !#GL(8QH_-_1>M
MZS]O^%]+]Q21%G7;?[&G(T-/)GOZRZKU@RACHW-Q7;BXC]Q^2UVRNS_T'M8S
M_A$^SJ[0+/4HL=WHVN8V/!N1-K]S?W_1_2?Z*I75&RQE;'66.#&,!<]SC  &
MKG.*/%_5'V(X?$_:CQ,D9-/J;36X%S+*W1+7L.Q[/;[?I!&5+IK;7-MR[&>C
M]K>+6TGZ36[&5M]7_AG-9^D_<_FU=2D )$!,38%M#K5%-F!=:]H-E+'/K>0"
M6D#7D']$YOMO9_A*=[%@C#JSQF_5VCI@P\?#<VZFPN)K>_=+?4>T?]J*#[??
M=Z?_ %M=:DF2'%P_U;W'%<9?HLN+(<?'5^KAX2)2A[>2!TR^CYI</I<[H_33
MAXK&W,8+&.>:FM]WIL>9]$6EK76>UK?>HY/2L:MN_'QW6.<^7L;<^OF?>T[O
M[.U::2<)$;%CIQWXELV%N$^P>ZL%V21+6NW-+6_19[JV.K5BCIM5C9OJ?60?
M:PW/>(!W_O?G.^FM!)$S/E]2BG__T_3LO'=<QIK<&7U.WTO.H#@(AX_.KL:[
MT[/Y'_"+FLFOI.5UC[)=BVLOZE1MNL86MK86G? >UK?7NW?X5WYBZQ477]0J
MWD8;7ZN(+; WVR=N[>/YS;MW)2CQQ$=-#>O;]*+)ARG%,R%^J)CZ9<'J_0GZ
M?W)-3HGU=9TEMKC<<C(?(KN>-6-/#6@N=_;6KCT,QZ64LDM8.7&7$G5SWN_.
M>]WO>AU79;GL#Z QIG>[>#MCZ&@^EO\ ^@K"0CPCA&R,F2>69R3/%,]5+#Z[
M@8[:GNJI+W9;+J[L>J ;IJMO]DM<UN5OJ]EVW?\ I+5N*C9?U!IUPV70XFLB
MP#3W!G\XW^<VHC4$=P1]JP&I1D-X2$A_@EY[&^K-'6J<3J5E;^F7L_1W4-W'
MV4_J[&5NO].VASJZF>_;_-+J<?$QL;=Z%;:PX-!#1  8/3K8QOYE;&CV5L]B
M",K,=6US,=IW-<6Q8TB0)J$_G>K_ .!J)S.H%A->%+H.V;603^;Q_*^FFPQ<
M-U5G21NN)ES\Q/,0)$\$"?;@?5[<3^CQ?-+A^5O(63BX^57Z636VUG,.$P8V
M[F_NN]WTVH@\TZ()&H8B+W<'&ZKU)G4,3 &,Z_#>+&OSG23-;KV5L?Z;34VW
M;CL];U/3WVV+:NHJOK].YN]DAQ:>"6D/;/\ ::J@R>HL<YOV(.;)(<U[&\EW
MYI+O\_\ /2^V=2X&%NTF1:S4QV'[FY.X9<1-C4\0UCZ?!,C$Q@!$#AB(RW/N
M2_?EQ-],1((F)[A,PN+&EXAY W =CW4DU#2JZ:<?^CWO9(AQ<&NF/H\M_-0N
MH-Q:S4W(MM+GES@T$$.(:&.W-L]C*]OYG\S^E>M)))3E8C\#W>F^UNTLEY)U
M(8^QKWN9_P '_.>O_P!<56O]EN%0#[W!Q8&@AIU)]N_V^S8__P!1?SGZ3?22
M4T7=1P\8BLN>2[<_W3(&]P=_.P_;NW>G_(_F?\&CXN57E5FRL$!KBTAVAD?"
M?%'224__U/55C=<]/UZM_P!EG8Z/M&_=])GT?2_P7[^Y?-R2='?K_@[J+],]
M#V?97[/0CU'?T;=M[?3]7W^HM%?*J2$MSO\ 7=3]5+(ZOZ?VEN[[-NV-C[1O
M_>=^Y[-G[J^;$D8[]?\ !47Z%/I0[_DZ-ON_G-WT?\'^?L_XO\Q6NF^G]MJV
M_8YV'^:W[^/\#O\ ;Z?[R^<$DX['Y_JC['ZJ27RJDHTOTGU?T_M3-WV>=@_G
M_4F)=_->G[-__@B%TGT_M;=OV*??_,;]\Z?0]3V[/](OG%)2?H_I;?X*.O1^
MJDE\JI*-+]5)+Y5224_522^54DE/U4DOE5))3__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     2Y-30 J    "  ' 1(  P    $  0   1H !0    $   !B 1L !0
M  $   !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD
M!     $   "D    T  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$Y.C$P.C(X(#(Q.C0Q.C X   #H $  P    '_
M_P  H ( !     $   =DH , !     $   /1          8! P #     0 &
M   !&@ %     0   1X!&P %     0   28!*  #     0 "   " 0 $
M 0   2X" @ $     0              2     $   !(     3A"24T#_0
M    "           _^$!,$U- "H    (  <!$@ #     0     !&@ %
M 0   &(!&P %     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "
M    %    )"':0 $     0   *0   #0   #P     $   /      4%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,3 Z,C@@,C$Z-#$Z,#@
M  .@ 0 #     ?__  "@ @ $     0  !V2@ P $     0   ]$
M!@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !
M  (   (!  0    !   !+@("  0    !              /      0   \
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M 0$! 0'_P  1" $Y ET# 1$  A$! Q$!_\0 'P !  (" P$! 0$
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M JOI-HG%@@+>96C8IS*02ZP,6;'ZI"@LWE&S&21IM"]-:$P;;%(^)94):SD
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MJPKV9%:WK25W1DQCF\95HFG,8J5.U=,V:#Y0)*!!1*1*JP9N%FRK91_?]_\
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M[J^QMED**9$T&6TFNS:NOMA1CJ@15A7K14'UE%JH5LG7'S&P.+2W3DBPM_\
MB%%M@FM3;2:L"W]2M*2O'=!$QK?1-.E"1;TD"V24K]P[C81X%K!LD+K_  )Q
M7:TU-;9,/M&PLI@X*>[[X1K"F!7,7XI>W\/MLLAQ^S<SM?5C6%+VHO5+U)1-
MZX^3O(V(AHIE!KSY:E /]0Q[J#6;+SK9F:T.%MRUT631%\I&JA'2Y3R:1R,B
MO/>MTE?L[*WK!9I12TM[#H)9I7F$'U4Z;5UF#+"S_3*-3/WL4$@]R+B,@OV>
M<NXKQ58;9BG9)J#[!454,GM1FH"A!D"^Z3<CX ;M/:_XQP.>S4Y3),0?0,WJ
M/8D1M$MZJ]!K^JSOJ#(3MJE+A5)6\1,A&6",N+NEM(9G5:U<I:P/)>PQZL42
MEV!)%M(*F@PFO,=-%^R>':4)=::5F]/LNR]'#6BJ6HJ<L<L$E1;;3/9L5(H$
MB@D$IMP$L@$WL]OWF%Y1ZMA+)GC@CJDP-)*TL33JRNDS0JBQ1S/(7D4K[,@
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M,$))/DDF->23]R<D;+?GOC&,8QC&,8QC&,8QC&,8QC&,8QC&,B70?^ K2O\
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M+JB<P"(0]R)*(Q*JR".Y_CSH&-O5+B+!LFY1EBM-JU[?(F@R^X)'YG:]_P!
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MZ8K&7 GI&6+[!YAW[" $$![Z^_W_ %]@[P6/KNN;'M>YY)X/)' \^>>.?O\
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M $_U3UIH:?4O4W4>KJ[6PVVC%FIKX+T:SP5*M5PT2F.)T$DO:97?N/<%X4;
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M(_Y_Z#^_SSZXSG&,8QC&,8QC.@LT$G8XA>-,N=HJ8Z+AH[(4#F:O&R@*MUO
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M7G;3,0E.JD(W(0[M^LWC(UF@F4"(MT"?NR=^( 1!LW()S= 5-,>NLN@
M \  < #\@!\9@;N\CM)(S.[L6=W)9V9CR69CR2Q/DDGDGY/.5Q;)^*UI2!<?
M3]55^?V^Z3 ?FGT<(UZ!;'*<2BB60DFBJ[M4 #R$&S(R0 (!ZW?8!SG3GX_7
M)8XT<_M9<AK"%%>0TIKG8"J*KB/K\^Z;.FDXF@'DL6$ED2()NW21 %4[)1NB
MX],ICIE4*41!G.;?;%B#SE/EXXC(DD"A6BRL<HF54KY%F];.U6P)G 2F.H1
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M8QC&,8QC&,8QC&,_"JJ:*9UEE")))$,HHJJ<J::9" )C'.<P@4A"@ B8QA
M !$1 ,8S6W:'+WCOJ.'<2UIV;6W2J+D&24)7)%G8K \>F[Z:M(F,767.H  (
MG.IZ2*0 (JJD#&,B#6/Q'>->S+*TJA)6R4J5DG)6D2>]0R4-&R3@Y@(BBC*-
MG\@R;JKF$"HIOEFAE3"!">1Q\<8_K_?^PS?,! P 8H@8I@ 2F 0$! 0[ 0$/
M80$/<!#V$,8S5;>7-'CUQZ>EAMA78GXD,!!_"]>9N)^=2%4!] ';-@4Y8\5Q
M#I+Z@LV\_P"4'Y.S8QS_ .V: /\ XM\H,T*T'H!TZIQ5^BNY"W%:6!PT\O=P
M#-&'<,6ZPI_G!J9TN &_(+@?Y6,99SH+D!K_ )&4=&[4)XKX)+?(SD$_!-&:
MKDJ4@'/'RC4AS^!A*/J-UR&,@Z1$%43B'D!6,G#&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,B70?^ K2O^B77'_!T-C&2UC&,8QC&5[_$IY;VOA_H!I<Z!$,)
M&]W.XQU#K#Z:;*/(*NNGL;+3#R=DF::B'SQFL?#.48Y@==)%Q(.&YG J-T5D
M%<0ZVZBFZ:TK7:L2RVIIXZM?W 6BC>0.QDD \L%5&[5^"Q'/@$'8C]F3T=UO
MK7ZE1],[N_/1T>NU-S>[44W5+]RM4DKP)2INZNL3S3VHC+-V,T==)2@$A1EU
M9^%GS9Y$\C3;;C-YRM5MR%'<T,\;-Q$$PK4\3\:/)E@9JLT@TTH20:M%8YLH
MEXLF;XA%7'JN77@F0+)Z>]4;;J$;.+:M6D>E],\<L$8B9A8,P*LJ'LX3VAP0
MH/D@DY*?[8?H1Z?^CAZ'O]!1[>I!U*=W7NT-E=DOQ1OJ1KBEBO-87ZE7E^M<
M2QM))'PB&-4Y;+>+[?8/7$*G8[+\TC! ^392$F@FD=M#E7;.U6SV2]19)0C1
MR];MH=$6Y'"QY.4CDO1!%19="2LTDR&7?*BD-:\%C&O6TZ#8IPG8TQ:RWGJZ
M[C8..GK7%R$*YLJ3]W)TAM*L6MK1AD9-O&2"P-1=*"9(ZK&<5YR?800OT+#0
M+<G((V;8\6PCX52N2SE_ :XF8Z'E)]),)Y QUEEI>-3;PB(*2SMTLHDR:N$D
MA7%C)$'<D<6I;)NRE4MA('7#NSLE#BG!"^M2]1=/V4S^&F(3OJ@0'; [9F,^
M,$=TJH7\B:93J QF(J<DX:/6E4+%0;Y7%(N0E:^4'OX.??4K;%M(1^2KQWT:
MW213/91G8HM2,D'AF<&=0[E!]*,%&QO-C.NL/(9O79\JLU"6*$80$7:HRTU)
MRWKSR;6MZUAT3&TA-C(1\R]ASM9!#:[8I' 3C=DD$F8\P#56,.#=C^^,RRN[
MU8VQ9BS@*+>'L@+0TC8&2B5:CCU:*&QRE8;2CY:5LC%M+,I!Y"3+Z/-6EII1
MQ$1J[LR23A>/9/6,Q&Q<C8)NIKV58GE(RO.X:$V/<!=Q[!PN.O[/IG>M]C&2
M:;=R]72F6+S5J;Q^FT$@"!&S5H^>H/'1"L9+6M=EL=EL)5ZT@+#7E8B028.6
M<^C'@9;UV+9^BY9/8B1EHQXAZ;GY9P"#TRS5\V<H+)%(""SAC))QC&,9'U2_
MOLVI_G7!_P#+ZGXQD@XQC&,P:Z4*$NC$[>1;)'5\?R*&(4W?0#T4X"'OW]N_
M_,>L\9H(K"%)%##+GK-M=U,ZSU)7C(/)"L0#\<_[#^_C(;C./U.CCF]2';G.
M81[Z;I]!]^A WC^O]'Z??^.4::BDHY,:\_\ ZJ_G\?8_KX(^/CCC,DL^HG4L
MY"B],J@<<"1_'Y\^?((X'QY_4G-$.9.^U--62)TUK],K>4=0S:;EOEC F<I'
MZRZ3-)8Y.A*0"-Q4 !^XG 0 ?N%;%#'"O:B@ _/Z_P#;],Q:]L[FRD$MN9Y7
MX_QMSQR2>?)^_P#T'Y961NF1VQ)'A9"V3<@UC54".6;)H[733 JH^0KK&\BF
M.8P" >7L'B4 'L.^_7C^_P"_[\Y0YFU VA<- [!I4HQGWCZ+D'T$#YF=PHKX
MIRBB"8^ B8>^A6 ABB(@("(?T"QERO/OD3+Z.TO$_AAQ\C==D2B-=@UP'I1@
MF+,7LH])_ S=OXD*(?XZ@!W[XSCY_P!N1_7_ "_K_P!L\\-%+(738THG>;++
M2)U91)"0<2+YPO\ E6!)45S)J*BF!?%0!+T7H Z_3KMG/Y_]_P O[^/^>97R
M6=5WCQ8VTKKFZII6"$!A,PTQ"N@3<M'1?!4"*'0.'Z@*2R1A$IRF,4X="(9?
M>CXM1MNI:.JOW(HUF=N8^5)D* L(_)X!)^?]/TS)8.BNJ[^N?94=+=FJA2PF
M$+]I4CY4<?B_,#CR/(R<M%_%FL]JGXB+M2SI%Y(H%(=14YC,G#I-(/F"%,;]
MV<B@D4$"F#[=!]P[R3.O?3J#3:V7<ZV13#7D03Q CQ%(P57[3\%25[OD$>?S
MS#8Y)XYVJ6X)()5Y!25"CJ1]B#^?R/CCG]><O/H/X8WUK1G9(X4E&<CZJ*R1
M!*H5J^1*7UT ]C?NC>H0Y2CT!/( ^W60C-"D\91_O^@X\_;^G^7^7YWO6[&Q
MJ[4=FNQ5D(/()YY''GQ]^>/CSXY^W&=GJO2:.O99VZBT@8H.%3'72*4")J"8
MWD/D4  !_B'0#T/?\1'+70U8HS.\7"HYY91\,3R>>!_7]?T_3-NJ^MY^J-?5
M@ONUB:LBK%(Q+.@' _F_+CQ\^?T(S98     ^P9><CL#C--*KRZC).\;H1M$
M(VK6I*!09C9%"V,5\N_/L&H:ZFIRJ[@L)(Y-J5%K&5BSQC-M G:.GQK%"R4=
M/MQ!G*L2BQG<P^U-W+SNO7%K8Z(H#2_RC,S;4%KO4HSW TJCSH#2+25216@9
MZ[1B:K=Q+42)K:T.@[^9A6VQ'0HI2SEC.CG>26Q4Z3&[#J&LX6R5.W;ZJ^L*
MA*.;3]*23H4YLJK:D1V!))%:OGLN\L]KE9.7I</!L0BU:4$7/S]ABA45;J,9
M/-$O\G9;ON.ES$:S8.-;6ROL(=RR575";JEGHU<L\9+.R+!TUD$IE[9(%RW2
M.=(Q(-%Z3TRO02(QDK8QC&,QR?JT98?EE71GC5ZR$_R<C&NE63YN"G7J)E62
M'\Z2G0"=)4ITQ, & H& # QD)[MN$5QLTGLG:;%HYEY>#@S.45I%PH]>2<LL
M=./B$G2ZA@$K1-ZZ1.HDD":8)@H/CY&$V,XX_O\ O^S_ +9YVHC7FW^4TI/W
M"QRL[>K&JW7EY0[N07,UCV8"=4S:/8BJ#1@P; <4T&K9)),A!$ */N(LY\??
M[^,CB@Z_AHNTSU+F':$<U5A)21AT7)1.F68BA*JO')B81\/FVOS"A"=^ *(>
MQ0$_8,?&6&_"PN$Y!;RV-JEH]<+4R6IJUO",%4YV<9.1DK',!=M41$R:!W[9
M^9-QX>F"HH)F,!A+[,?W_3(O^)5N*:VAR!G=0-GCE.J:@A6Y20Q5C@TD[A*1
MH2:\FZ;%\2N%6K==HS9>KZ@(@54Q *90PF8_/[_W\9K5Q08ZH4<PW[3) (FJ
MD;J*R\@4"E,W$B1S'45,8Q ( *@/J',/0>XCT'8YPS!068A54<LQ(  'R23P
M  /))^V=X899I(X((Y)II75(HHT9Y9)'/"HB*"S.S$ *JEB3P 3FLO)7DEKR
MC7TDAQRO:*UAKUG([J=G8%\RPYV"_FD\!RN@=@Y5/UZ!&WFJBL"BA52F('B?
M*/36?H+J'J$TMYU+IHHZZCLUL^Q2K+L;#DJD,,K/$&6+^>012&0LJHHX+$2/
MNO1#UHUG3IZC/IOU2NL]L2FV-;)(T,! ;WY*B%KBIQY[FK]H');@9-?''XMG
M,DUY^E7Z[,KHNFD>30@9JM0<8QG8]K^\?QZ:L7&LG4?($;B*[9P@<R9R)F,8
M@^ E/(GJ1Z=ZW2Z^/J/IJ7W-294AN5O?%E:QE/;%/!/W,7@:3B-T9W:-V3@E
M20L.Z^]-*[5K4;1V$Y)#HT;$K\JRG@JR\<D<?U'/.>IK1FUJ?R!U=5MHUUBD
M1E86WJ.H]XB@JZAYEH<6\G&.3^'1UV#PBB0+%Z]4@$5*!0/T$)D _(!^_GSE
MZ5F0DHS*2."5)4D?D>..1^GQDT '7L'L >P 'Z9SG7&,9IJOR#MRW)2M5*-9
MPZFB9"RV'13JP'9/3S<CO^,I$QM)W].DRN"QI*=6JY5I&D/#@V75?[&>R\(=
MTR=58S:08S Y?=VQYO7;'D"MN[7.A-6VA\JMK"+L^KY._MIBK J^5@;)LB?;
M6F#=1Q;I#,OQ C&0*< E4XYZR9OYV;DB. %C)*G]F["GE=YS=;N,-0M?ZEFH
M.C?75]:3NS)F0F8.-8V;:%BAJ]7Y5M)R!$"6.'H=?C4V<@=C/UVVRKQA--E8
MQLFQG0<:=[;$V1,T=K='=<E8?86C'^S*M)0,2$.L[1KNUYRM-K)(,B3<Z$4:
M_:_LNLIX]64>K+5.?9V:*4=+J>HW8,9NWC&,8RF+XG^\+>WLE-X^565?0,5.
M01K9=7<>X5:.I9FN]7CHN%%PB8BH,3&:O'+Q(J@ N8K<IP,4H!C&5K7OBM,5
MNA0UYE(A-O$3Y!/%2*8E]452=&*H!RCZA3]_F\^P'O[B/VQ]O]N?Z?WYSC_3
M\_[_ /?,+D(RN26KH65(^*K8&YI**G41 I%VTA%K]M79#%$!#YMH=JN!O805
M!40ZZ*.,?[\?W_KGH T+N^=A> $+NBV&7E)FH:KL,FHNX$YG$N:JEDF<6X7.
M8!,H=^FQ:'46]P/Z@J=B ]BQ]O']_P!_V/MGFGLDJ_M\M [ M#T\K*6RS2<S
M89)<QCG7E)-$[M(3G.8XD3 3KD;)";P2(4B28  %#&<?E_7_ 'XY\_GQ^GY?
M.;GNMB\6:#H*4<; G4XG9+AP4*\B8X*&>-RE*"@-V2/DNX,4>Q,()B4OL B'
MMENV.VUNIC$VRN0U(SSV^ZX#2<>2$3^9C]OP^/S^?&:=&>GO6OJ'?;6]&=-[
M/J"U$ 9Q1KL\-8-_*UFP>V"!3YX]QP6_P@^<J?)S,W33;G:'/&[9-JH<5))M
M2R+*#%=FK/$CCJJ)2#YD9(%O GKJ)(J)>!TFZA@,H45! -@/3A/1O?=/0PVN
MH^GMGM]D\8E$FVBHWZL\J\PTJ4,TT,_NIY[O;1S-+W@AT546G]1_2CU:],YX
MY.K>B]UI*+L5ANRU38H3,."R_65_=@1O([4=T< <A3QSEV?P]/B9[+L\I2:Y
MNJ=/;*I<Y0M4^O2A4QGZC;?4*V13=2)$R*2L2^='03$7WFY;@Y25(L8 .F:.
M^M.F9.DM_:U#2&: *EFE.1P9J<W)B9N/'>I#1R<>"Z,0 #P,,JV!9@28#M)Y
M#K_Z7'@@\^?!^/Z_?/1AF*94XQC&,8QC&,8QC&,8QC&,8QC&,8QC(ET%_@)T
MK_HEUQ_P=#8QDM8QC&,8QD;;5U31MR50].V%5:W<8$7S62"&M<.WFXD[QH"I
M$ECM7  9)<B3A<B#QJH@[:** L@J!B^)J6[1I[&!JMZM#;KOP6AGC61"1\-P
MP/##_"PX8'R",OW3?5'4?1VV@WO2N[V?3^XK!EAV.IN34K2H_'N1&2%E+PR@
M 2PR!XI5'#HP\9#7'GAAH3C-+W.PZKI:->EKTYCEY@I)BPRT<S0B"N?IK&&:
M3TK)ECT&RCUZN*B'IJJ*NE  4T"HH)VW3]-Z;0O9?54Q5-LH9N)99 1'W=BJ
M)7?L52[$*O Y8_;@#-/4;UH]1_5B#1U^O>H3O(^G4M)K":&MI/&USV?J9IFH
M5*IL3RK7@5I9NYNV)?N6)V6GJ_!VF*<0=CB6$Y#NU&BKJ,DVR3QDX48/&\BR
M.JW6*9,YFKYHV=H"8H^FX024+T8@"%\R+<PZ5T[JZ<1<MY2BUUT@]DYV8?)"
MP323D)"T':*61>1*AZ02!9Y9A'N)=N\]=M(N8^/<ND57#%JHBQGTDM2ZWEUW
M;F2J$0[6?R3V6>'435#YA[)I-49<5"D5*06LV1BT^NQWB$?.';I*RS5XJ0#X
MQF3GK%>4BI2"/#1YH>:6E',M&BW)\I(+S3E9Y+*ND>O%520=.%W#HQ@[555.
M<WN8<8SKI&@4F7*^)*5:#D4Y)Q)NY!-]'MW23US,Q2,'*K.DEB'36/(0[=".
M="H4WJM4B)&]BAC&=:EJC7"4>I%A38)1FNG(IN"N697:[H99S"/)!P[>.A6>
M.WKAW6J\Y&0<N%7R:T%$*).$S1S04F,!JG70!!_^Z,0)JZLJXB5C)*'<I*N)
M,DVX.Z=&4%S)_,S:24VZ+**O"N9E%&67!2023<E8SBP^FM5P!E#1%"K3,5?E
M@.!8U)4@HLH>P5YBT CCU2%CV$!:K%!1\<4H,6$-+O(MHW18G! K&916:C6Z
M<S785F(;1#5RY!VX3;^J<RZY6Z#-(ZJRZBJQRMV35JR:)&4%)HR:MF;4B+9!
M)(C&9'C&,8R/JC_?9M3_ #K@_P#E]3\8SKMF;&CZ)'BLY7*DH9(RG9Q   OV
M >Q'^@?T_4/?],M^PO)2C[F(!X^_V^WS_9S*>E^FK/45OV($9P&"\*.23X^W
MW^1]_OFK]:YAU=Y96\,M(HJBX6!#Q\B^PF$0#_&[#W]_?_6/7VL%7J>O)9$#
M.#W'@>1_3GQ_9/Z')6W/HCNJFHDV,-9P8H_</X6 ('GX^#X^3]O]<W=B9=G,
M-4W314JA%" <OB/?91_7_P _;^/Z_KF7*P90ZGE6\@_GD!RQO!*\,JE9(V*L
M#^8YY_K\'-$.9_*EII!-"#3>$9NU69';A45 (<06\O2( ]@;KHO?0==F'W'H
M.AS_ *.Z7;=%IV0NH<JHXY'X?YCQ]_R\_'Y>><H;$RQ?)[?'Y^3S]O\ ;\P?
M&4#!MQ7D'R5L$J#_ .=?NXNO)-154\Q!&/3,T42(/D/12J"!^@$ #U ,/WR]
M]?\ 1HTFKUFTAC[ \TE2T%' #,&E@<CP!R Z'P " /D^?*G96:1U!^ " ?G]
M?^7/^?ZY)/)VU2:3-*-<,CI+0,62/,0 ]C"DF)0.7K^(>_MWWWW_ %Q-EP/Q
M_3SD-\:)-+=V^],4*6F8AFQCI^NR<\>:D46H.8Z <MWBC,GS)TB*K.!;D1!$
M#B80./L/L W5-'N)*8V$>MN24F'(LQP.\7 YY/<H/@<'SGG[L8;M[UY_4C_J
M<OO^)KQYM^[M+0%@ULQ&8NFJ)\UICX-#H5YR$<LQ9S3!C^AWA$"H.VJ??[T&
MZB9 %0Y &U9Z']/[_O\ 3/+ML[9,G44IF7:,Y&!NB$?\A)P<DT79N@?)@#9)
MRH@J4BB:K=,2@<PD#R(D ^X!EGW]Y];IMC>C'=+7JR/&/S?CA?\ 0GG_ "R1
M?2+I6MUOZE]&=+79/9I;C>5:UR0CP*R<S3>>0/Q1Q,@\^2WC\\U;<*3%H8+O
MYZ;?2*ZI"&4,NN<Y1,;HWB!1,/Y2B/L ^WB&:KU^I=]7O#<UME-!;AD9XW5O
MACR#P/CCCX/'/GYS] =3H#HG34*O3M3IS7_0QP" \PJ9&1%"]Q?YY)'/CQ^?
MZS9I"J KKJYWLY2@CKFP,D@<F]@]1^V5 R1#?KV"B(B "(@8Y>P_, YZ;7]J
M'JN#K?IWHG<W&F3JFE/VE96/X:DT9$DB'PO\K@>?L>!^$Y\S_P!HGT"U ];N
MCM#TW753U2HG:M&B]R0H[O(S!>.0B1OYX'A>>. <OO\ A,\DE&E1<:\FWXN&
M[^]27R*:JH&413>-(M- 4_(1/X@L4P>WY3>)@$0'L<G[I_JM-C.L#.#W_<GG
MR3P./]O^60QZP^@=GHNA)?A@:/Z>/W&X5@I12W<#\#X!_4$CYR_O,^S4[(]V
MS6[C<=:W:J:_MZ%!N-CK[^%@KHXBEIH*PYDDOE%9AO&H242JN_9M57"L8<)!
M K:1!JZ4!9- S=5C-2GW$F]6X:=6KK;]516L:QIW:&B'%8U;KBV5.9=:TV74
MH>O+P#"=G-G6QK&DAY*K5"=9+C#NU!6@_1'Q%VHL5C,Y'1&W;?9-.2.WMAZQ
MM3'3EO;W)*8KFJY6NW:[2$57+%!PR4K)/+_-Q-;;!)3;2TS3>%C'3:2F(5HD
MR1B&:O@@QG&U;JN5>:;T?J.=G8>)G^/5LHA+W#1SEG/JS+;6)'J]).L=J]25
M@_Q@+6E[&:&?HJ/4(\_TQVQ(]47.U8R5],U&R0Z^SKY=V9(FU;5O[FSK07S3
M)\-5JL!!PU'H]>6D&"SADX=_ARL-K--E:.G+%G9K//M&+MZT12>N6,KLY#?&
M>XWZ2ODIKVMUZW[?F*\^6C;)(4_Z<V@(N0:J'2=L$922723DG+90ADUA9D.@
M10!)ZQA*;J/MUZD:'3VGI_QKLT3]DWT_;[<;<\,O>QX9E^"%Y\^.?'G;[TS_
M &+?5?U&T$'4C-J^F-;>A6QK1NWE6W=@=0T<RUHD9X8I5/*&4JQ'#=@!&;C<
M8^:NHN4^O4]AT=.QQ$>C+J5^::6*+%LM!3B22"QF+]PW47;@4Z3E$Z+H# @J
M50H^1?<,R?1;ZAU#2%[7LYB#F-UD7M>.0 $JPY(^"""#P0<@WU6]*.J_1WJA
MNE>KH:Z7'JQWJEBI+[U2[3E=XTGA<JK<=\3JRLO*LI!S::>GH>L0<M99Z0;Q
MD'!QKN6E9)TH5-LRCF*!W+ITLH(]%3213,<1_4 Z#L1#+_!!+9FBKP1M+-/(
MD44:#EGD=@JJH_,D@9&1( ))X '))^P'R<\J?-;XS"^[8B[Z;U/K"/'5DPHE
M&*72S/7I;'*MV,@BZ+*Q,2S!)M&)G5;)JM"O5W2ATQ#UDDQ-XEV'U/H9"U 2
M;K;30["2(L(*<:&&O(R\HLDDG)E[6X]P*$!X(#98)MZJR=L,7<BG\3L2"0#P
M2J@'[>1R>.?OQF8:#3W*QUN[V'K1](C6G4*@63E&I!! 63Y(AO37,F)?$?S>
M)P'W*;L#?;H(!V>NL:G87-9;7MLTK$E>4>>"T9X[A^:NO#K^:D'+[&ZRHLBG
ME74,#_4<C-)]F7N;@KHUDY%,G30DB[.[%P1!+UED543"NLN=,B90*LHH(B<?
M+Q\0*.4L,,MB6.""-YIIG6.**-2\DDCGA41%!9F8D * 23X&=F(4<D@ ?<_;
M\S_ISEN7P:7=&EW^S-AR.R*+(7NW@UKT!2F-DC'-D9U^)6.[>OE8KYCZ@0CQ
MYX 0WH@"J3<%0+X>!AN^QZ:Z@U$8EV>GV%&(\<26:LL:>?@%BO:I/C@,0?TS
MRCGBE_DD1C^2L#_?]^?&?+XF_%79,%L]URBU9 NK/7)F(9(;,B(T"GD8A]$(
M@U0GR-?8[ABY8D13=*$ PMSH=J=)F*.63/0@\\C_ #^>/^WZ>/O\?.>>7;]Z
M4D&3>'KKF2CX*QR_C8&0%.B@B<J:CKY1)P0P 5!XLD8RC4?RF BA0\DQ,0(T
M]4MC:H]/+'69HQ;LK#-(A(/M!2Y3D<<!R #Y'(Y'GXS=W]@_H_1=3^KEV_NJ
M\%Q^FM'+L]94LI'+&UV29*PL"-PP9JZ,9(V /8Y#CM=1D<.:[%'ABCXM1\P,
M06X$*!B !?8P^W0#^O?]'\>N]:RG$:SK+_$[N?GR#_D?MSY_7\OM]G?J&EL/
M4DK]U<IVGN4&)E( [.WCM[2#QP!_EQSFTE);-8SC+";D7B6+RZTFVS-.JKUW
MZB)IEFMTT!L\<)]*NDVK)X[2 X^H)/E4Q'W+T&!='^M?7G0?K1L?3[1;BY;Z
M/ZBT=;<[[IFU8DGU5>52TIL5J\A==;::Q#!(LM81-)[ACD#H2I^5_JA^S=H>
MO_VG+G1ND*:/7W:'_$&UNT:T3'5!JK&P8X>$C/U%DPJL;$*'L'CCP<O9^"[R
MUHMPH\WQXG!7KVV(^<L%U9Q#E8%8J=@WQVIG"E><B!#"K'G#S>LE2%5 %#.$
M_,GD(;R=)=;T>IP\'MFGL(E[WK,P8.@X!>)^!W<$_B7CD?KFO?[0G[+O4_H8
MU;:BZO4725Z85X=S#"8):EENXQUK\ :18S(H_A2JY1S^$A6\&^+,XS5O.,]2
M<.&;M!H[,P=+-ETFSXB*3@[-PHD<B+LJ"X&07,W4,58J*Q3)*"0"* )#"&,9
MHW6^&]Q@H/6E3><E[S/5765[K&PXV-?Z_P!6(2<M8Z]936E\_F;,RK2$^YD+
M=(.I@+=*E>DD)I.P3@N5S'D%C&9QQ^I_O_W_ /CC,B6XDOPK2VIV&ZK@QX_K
M2!%TM5C6J4_D(N!+-)S_ . 8>^OXAQ,-Z(1VG\@TCW[&3GXZOG&"869LS08?
M)LY_OCQG*B]0W2-L=_@:SO$^NIAYM"Y;6KD=6VU=LKN3HFS8R!^L!>*?;(ER
MC\U%;(96PU3FXIR=!FU1CR.EG"<A+0&,9DVB] ?LEL5BE7#T'S)C6JWK;7I5
M9%:4DTZ5"NI6VS]EM#L\;$MC7S8>Q+;8YFUA%LDX<C")JC9@!1:. %C-F\8R
MO[G[SYI?!VB1$@\AS7+8]T.\;T:E)NP9).08@F#V9FG@$5590S$ZR*8F21.N
M\<'!LW\1!55+.^A>AKG6=V6-9?I-=3"&[<*][*7Y[(84/ >9^"?) 1?Q'GD
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M^>?'R>/S^_(SV'Z,C](;-XP0NL==7>L[+UREKU/74C+5F4:23=9-2&^G/OF
M0.91H[5%55P"3I-)8!,!_']<H=EJMEI[!J[.E8HV .1'8B:,LOQW(2.'7_\
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M=SXXYY\9X(*V=NF5TG-D<#(D6=IR15^P>%E2K* \!YZO[P' .@/ZWJ?G]0#
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MLG_T0T>],"S0OS E$H"D<%R>EYE,4I2#_)$ S67UKTGT6^J;>,((MM6*R!2
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M^X\YQH>(V#5_K+&)C*;+QSZT6BPM7DC9YN(>^G99U_.BV<,6U/F$$SLCOS-
M43D%@<%1*X\$!5%!/G.OG[<?Z?\ <9W'SNT_^[- _P#7-B_L\_\ W_'&//Z?
MZ?\ ?^_RS"G.U[%%6J6HDI5(=U<C5^M350AJY9GTF$\,_(6^/>J2SB0J\/\
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MQC&,_AC%* F,(%*4.Q,80   /N(B/L !_$<<<^!Y."0!R3P!\D^!G"+*1AS
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MKEM+[)L^T0_\AY8@GN\ <>3SW?//D\9?#K>*7C:\B+HQA77 IA\^^P H?P$
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M)RT4=>/O8+88<*Y/<@)!C$A95SB7USJV]14@T>EN7>M[LKT?^&6CE5Z5V/\
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M(!CG39BLJ0H"8Y"E]\C/?^G76/3-;ZS;:6Q%3_Q6X&CM5X^2 /=DKO((@2>
M9.U2?'/.2AT[ZD]%]4V33TV\K371SQ3F62K9DX')]J.PD9EX'DB/N8#R1FUN
M81F=8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9#VY)\U=@$GISBDV.H=)13OHI3
MB7L@&-^G?N ?;L?U[ZRBO2&.-?/ 9NTG]3_M_3[_ )>>,R3IJH+=QT [I$3O
M"^"2H\$C[_AYY/'V(/VRLO=3;84[6I"P464.WEF2*CMB"1S#ZIDRF.4AA*(]
M@<>@*(?8??WZ]\0VE>U/7>2K)[4R<O$?/!8>0#^C'^^<V&Z$VF@U^VKT=]36
MWK;#+!<7M!98W*JSISX[HQY')\CP3Y.=[PAY.,>1S!_JO>]>+';.J_JQK>3<
M)@W^O,$^T@055'KMV4G8$\P."Q/<A@/T ]^E.I)-DLFOV4?LWZ_X3W#@2K]N
M.?OP/'Y@?T&4?KWZ,5NB+57JSHZVNQZ4VZK:A:(][T9'_$5<#X0-_,/!1OG\
M)YS6;G]P/OT-'R]QT_#FL4"JFNLZ0:BJI,Q ' 3"59LF0PKM2#WXN40,/70*
ME(( (XYUMTI>F22UKQ[J\$LB\F1.//A>#W#]?M]P?)R9/V9?7SIG4V*FBZOD
M^AE#QI%9?M%:P!X'\1B DA^"CCCGRK'XRLOC;Q^L!91-U,,'!7:IBE<F%-1,
MP&[#M,2"3OR*<!\O(._OV'O[Q]TW1V>NMK/"]BM95AS)$SQM\_#<<!E ^1Y!
M^>/&;?>M'6W1_5>AEUMF+6;;4R1\I6MI#9101XD0DDQOP05:)E93QVMP#ERS
M#C^YKU&-/,F+!^9)'LS9ZU.B<YO$!\ 6236#^/YBI!U[^P>X9LSK>L.J(M8R
MB<S,L? +CD^1\CCX/Z ?U'Y?)G;]/=%T^KTBBFDI:^2<D1&02Q1^>>/<<]P3
M\@['\N<I^Y9;CMT*JI#MZRE%)$6^7!-C^_)V)A+ZA^D"'ZZZ]S]=?8>_MD$]
M3[;J6:])*(+,TLK\L_:YY//]#PH^W 'SP,^COI)TSZ27=-%^^=_K5CCA[D,L
M\*.O"\A4)D\GGGPWS^:^,@+4S?:.RY(D?%R:,<3R(4YW*+HJ9"FZ]_(J1B_E
M[_H_3,LZ5L=13+&)XS$G'XN]&'@_(\C_ +\YK=Z_ZCT<ULUJ356XKMLL?:6M
M/$69O/!!B=B1S^1_T^1=7QSX74&):FNVVK2^N,LR;>M&0#,YX^&2===@J]4*
M<';KH!'I,ORY 'H#&,'8#(TLC10,_P#,RISR./)X_3_I\_I\C2S75([^SB@7
M\$,LW 4GGA"?"EODGC[G_/\ /)0A^4D'2KX2F$,W8-DG'RK5@@)$$FJ)#>)1
M*7L *4"E#^5V8W0"(B(]C@474\45YH96X9F(\D<_/V_Z^!Q\#SFVMGT,M[3I
M:+9:ZORD=<."BDJ2%YX\#R2>!R"?OF[D+O>"FI%!FSD&[M,J)"J]J$.FJ8_7
MD7[B _?KKV^W?Z9ET6TKV"%C=7 'GDC[_8CGSP?]>?SS7G8=!;C3(\EVM)7E
M+GL'##A0?!Y(!^/(_+YYXXS9N AJY)MT95"/1*<_YN@*4  W8#Y%Z#[#_#^G
M[Y7I# W\14')\_WQ_P!/\\Q*QL-C$6K26).%Y'!)Y[?CY/Q]O[YS.2E*0I2$
M*!2E  *4 Z  #[  949:B23R3R3\D^3GZQC&,8QC&,8QC*O^7O(;D),[BA.(
MW$5*(B=G2%71NU^V;/MTW\90*N[77:,6K2/43.FM.2:B8+HJK#XMT  2)G.8
M3IXGN]AMIKJ:30^S%<:O]5;OV%[X:==G,: 1\'W)I&'*+SP%!/V\;!>F/1_I
M]K>E[7JCZL'8WNFX=LVAZ?Z4T\@K['J;<10):L,]HNOTNMI1'BQ* 2TC+&#S
MP&KMV3O+XBGPX+K4;COG9*/(72]GED8^PMWK1 B[<%/)9PG%/0;@O$/T4"++
MLP\UV;D$3-UDTS&*<N&['9]7]&6:MK;7HMUIK$RP3.L0BDA9N2!\<HW )4\E
M6[2OCQFRG1_0G[.O[2^CZ@T?IYTQL/3'U'T.LDVE"I/?:_4V56)DB,I(=4LQ
MB62*.ROM1S0F5)4:1>[+M-TLE.1?$C8#;6;WU5-LZ?DUZ<Z3-X"X&P00NXU,
M#D,'B9R"A&QA W0&4'OLOWDF^AV>FM)5;DW:$@@;GY,T)[//Z\@'-)^DK"]#
M>I.AL;^#M7ICJNF=K"1SV#7;!5L^"//9[;, 1S^'XYSPBLEUJDXDZW9(U6'L
M$&LXAY>(E$CLG\7(,E#(+HN&ZY2*HJI*$, ^9 -]A#L! 1U"D237SSU[,#K-
M&[H5<$,K*Q4\@CGY\C_49^BFE<H]5:S6[G2[""WKKM>"U7GJRI+#)%+&K*.5
M8CC@\<']1EG/P[.*EUYR/=APELL5G@M)U6 .S2LK)N!E9*VO%$R-("-DWA5$
MCM6S3UG,AZ1')FY 22 J9E $-AO1+J/J*A<CV,RBW1U,J34/K5=E^H4GMB60
M,KO$@_'V]Q"L% /&?*K]OOI'TKTVQT5KI^M4U_7FYDF?J"MJ6ACK3Z\(_%V[
M3A_APW99BB"<*CV%#F0,5[LO!<U?3?PUN-=[ME0T$^8C4X$ L=O9E:3\[.F=
MKHL4W[^PKC]049G=.$CJH@"+=BD(F^63(EXA,'6?76YV<%K;;JQ8MQU4:5*-
M52((_L%@KK^  <_B=@S!>68D<YHEZ?\ 1+]9=5:+H_76]=JIMW>CI+?V<ZUJ
MD/=RS/-,W!9RJD11CS-)VQ*06!'E66WX^5LUFO;-9HU=6F>D;"]0*J M^Y%R
MJZ,AX@(#VD"O@50H ;V^P]CFGU#K79ZS:6]G4':]ZW+/8J.28)A+*6['7QP5
MYX60?B7R?(\'[K=7?LU=#=<]!=.=#]0J\T/2^BHZG3=0U_;CVE!J-2*N+4%@
M\AHIC$'GJ2EJ\@\$!@KC9;1[S9>]+A0(F.7BJLXOD^:NU\D\LY*FY452.#21
M5^724<(LW;LGRS<WH&$P&*O_ '/KO9+I_:R[K65]C-1EH-,#Q#*W<2!\NOA3
MV,>>PLH)'G/BEZO^G^O],.N=KT?K>J:75T6L90^RHPF!(I)"S?1S+[TR?501
M]GU'MRNBNQ0-W*0+M]*_"VM:=NBK9R*NE?DZ[772<F6DU0KUVC-+LC NW^KS
M#U-F"<>50@*N&B#10[@">D90A#&-EZ/^W'_SD8^20!_\\_ ^>>?]LQOC3S->
M\PN<.P*5)7!:GZ9UTTE(C5&OXQ_]'1N3B&?C%OYV<61,@M)N_31%9A%>0H,F
MJPB0BATC*9'>AZK7>=4[2@9Q%7H1E*%?D+]4ZN4GF<^.]U'!2/SVJ>[R1XW-
M]5O0"3TN] ^A^J8-8VRWG5=R.UU=N#$TYT-.>H+.JUU9.&6I7FD8I9N<!IIH
MXXBRK*J&S?9.U:/Q]NFLHV0DE&L?M&SHTI.'!R9UZ$H\;.'#*52;',JN1%,6
MAB/#I !"HG%53HI1$,\LVX:IK+*P5K4ZUXEY +NP8C@$^?@\\? ')S4[1].;
M/?Q;J;7PM+#H=18W6PE[6,<-2N\4;]\@_"A+2J(^X_C8]H\C-I$U$UDR*I'*
MHDH4ITU"& Q#D, &*<ABB(&*8! 0$!$! >PRIRQY^\8QC&,8QC&,8QC&,8SS
MH?'LU1<I!GH_=T5'R$I3:66R5.UF9I*N$H%:>68/HR7>II ;T&BYF*S([LY0
M3(J9),YR^H7N&_5S66K%77;&%&EAJ-+%.J@L$]TJR2-Q\+RI7GCYXSZ/_P#T
M].M]!I^H.LNC]I:KT=EU'7H6]3+8=(OJFHF5)Z<;MQS+VRK*L?=RRAB >WQY
MW$;BZ3&-)6E' 3WF1",)"@JI)O'2YBIH-TD6H&6<**J& @(@0_J=]>)N\A2K
M<N1SUVUYFAMQN!$]<,LG<?Y0.WD_H5/(/P1Y(SZ>[_0=-WM1MH>L(M;?Z<LU
MI#L:VX6"6@:X4L[/[_X%[0.Y)%*M&0&5U(!'I\XQ_"TI;G7FG-S\AZE([(W
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MG55<W+2:Q.+-X.U6V36>GCH<@@DW8A&JQ[Q)VQBE!63CWI5Q628']--,Z9"
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MK;ZBKI-ZC:V!3(_3S*%3266)T05$5#]^H53_ !1\C  " >P^X^NBZIUFS_\
M#(4AF7\)CY\$C\N[\_MY/^^6_P!5O0;K;H4_O6U%-LM9-Q(+BH251N3YXY'C
M[\<>0?GG-:MW:2K=@=/SNW9&Y!\CE5511. CT8?(IS!T/Z="'\/X^^97V(WD
MHI_JJG_WR Q/80=BSSH!]EED0?Z*P'^6:@U*J52I6I-J>9!42'Z$J!"IF4(
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M^">>WPH^>?Z_^]\=4BS1,,R9G_E(H$((_J8W0>0C_K#H/_V&2JB]B*O_ *5
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M&]_8?X=9AU_1FX)(IARIY /W^_!_U_+^G/CG-D.D/52/IKZ2_KB$FB[6ECY
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M5Z>ZKTM"OK[:;'^%5V258UBCN5)V_A/[JJ&FC9EDCD+#L9>ULVKXIZ$M4/;
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M^7/_ "S'SZ^BUU2J.DTECD#HJHD#SZ_0!#KW_K[#WSS:&-_++R?OX_Z^>?\
M/\LJH-A;@':DA /SP3_V/C@?'Y_/VS-F+%O'-R-FQ (F3] #KL<[*H4<*.!^
M7_QXSPEEDF<R2,6=ODG.9G;//&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9P9
M*-CYB/>14JS;R$;(ME6;YB[2(NV=-5R"FL@NBH!B*)J$,)3%, @(#G#*&!5@
M&4C@@CD$?D1G>.22&1)8G>.2-@Z21L4=&!Y#*RD%2#\$'G(T"E7!E&J5B&M#
M)C6A24:-%U(\ZTW&1YP$A6;8WF#544$C>DW75\1*4I1,D80Z%Y_0>/'CX_\
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M7]6M1.N2.PVA4)U=FPEBE@ABFIB-U9)4SPZIP=/%!.""/F(%$I$P5'Q$P*%
M<DSIOU!FZ5T$FNJ:M9[\]Z2Y'<ML?IH8Y(HHE,<*J'E8&,_,BI_^DWD906*2
MVI@[R$($["B_)\ECRW^'Y_+_ )Y+-YX>%U9=V.NHV'91U@^9;)E+'F!P9ZJ
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M8DIR,05>-F]E9_HLWO>Y5"/CJ=K/:D[$3AS)LTXJJV!U$/7":RC=44W*#,[
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MLI5K6;+ NM:&69T4CN(BC:0J.? 8@<#G\\D$738KDC,SA ':B1ER-163!R=
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MIY'QR&(Y\@_?/Y_[$W*22'SLG/38TB8?<R,?58Z+:CV/9@](DDMT'WZ .O\
M\@Q_]Q>BX?%/TRU,0_.6[),WCX/<8%Y_,\\YR/3CK:4]USU0W$Q_Q+%0@@C/
MS_A$K'[_ )_[9R4^$6ZF(^HER:LDPH7W 95H<GJ"'7]T!%<>O+W^P_<?T#WS
M@^I'3L@X;HVG #X_@2*>WY\CN7[?WSGL/3GJ*/XZRNV"//,T?'<?OSV,/GQS
M\?\ 7/ZYXT\@(A,01N0RYB!Y)/(Z0<M'9% [\5 246. B ]#UXC]@#VPO6/2
MM@_BUWL<_P T<L2R(1]QW*H_,_XA_F!A^D.J8!^'8^^5_E>.5T<$>0?Q,?\
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M7\)(\@-X!\?'GJM5\RM@<;KN[T%SXDV<8_216>Z^WXBQ.WJ%ZB$0#IO)"S:
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M1+WJG5?7^E=3S<URZLCYU6YK5TO'/F\9K^9B_32EIB>=JE0!2&34,HJT RR
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M(20?;\>?@'^8C>+67$326LQ1>,ZFPGI\OB96>L+=*2>J+!T(J$!P50J?Y@[
M/SB'\<CC<]>=1[GNCDO2U:I\+5J,T,87\CV$$_K\<_?))TW073FF[9(Z,=JT
M.";-I%FD+#SR._N \^1^6;,I))(IE213322( %(FD0J:9"A]@*0H 4H!^@
M!F&DEB68EB?)))))_,D^3F9*JJ J@*!X  X ']!GTSC.<^*KA! .UEDT@_\
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M:"$GAY(ZS35Q*RCR%,R<_8Y1LY^*WJ+8.S3Z2YGZ!@]1FK4])Q;JV6!"-V;
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MLV97FGFD)9Y)'/+,Q/GY_P!!P,FFI4KT*M>E4B2"K5B2""&-0J1Q1J%55 X
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M<)+(*)$'T3J_0_KZDG6?2&AZYTUGZI-%JZFCW]-TXM4YH2 +#'D]\9>0>>.
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MG26<?+JJFE68M/)THT B021T;0TTL,O4%*:2[<V<DCVK=A569)&/,D(C'(B
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M /WIQ_OEJWJL^EVJK\MK[8'Z_P !_'^8\97QPPNY*CP8KUD:D(=P$C8DTB&
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MTXE3GGL5RD8 X_Q+]A_K)5UHVO:5#R$@W%HR3=)**ID\$FA1*<?,"$)T7H
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MV-UGK(NB^DVJ4.E&:QJT@E1$U<DCQDV]ANI%AC2=V2-HH(^.WL[D1V!?._\
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M.2O.Z6-N#9=IE4R0M<86DSJIUZ&KBZS(L?(*PC@(^:74?$<D=M4E#,6WI"B
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M8QC&,8QC*H&CP>*'-FR'E#?3]8<D'R#YN\/^ZCV%Q43*54#J#TD0[LY2AUY
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MQC&,8QC&,UQY0<?(3D5K"5I[PX1UA;E"2J-A2#P>0D^S$%V+I!<HE4(4%R%
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M$^>"/(\98>HH1),ZJIBD33(910YAZ*0A $QC&$?L!0 1$?X!F7 %B%4<EB
M/DDG@ ?U.:_L0H+$\!022?L .2?\AE=M=U>]Y%<IC;XN*"QM:Z>1<US5<*[
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MY&PKQH-#/VT!&!YR$TZ9D?-5G+2,;.G*+=7Y@Z0($44)7T=7L=G[OT%.>T(
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MR=J98J9SG.0#@4QS" B.-W; MW;=I4]M;-JQ8"$@]@FE>0)R  >T-QR  >/
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,&,8QC&,8QC&,9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g766269g50b43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g50b43.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Y\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'F"^=W8X0DE-! 0      %X< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP"   "   < E  "')R,3DU-C<V' (% "5-:6-R;W-O9G0@4&]W
M97)0;VEN=" M(%)I9&5R(#$Q-"YP<'1X.$))300E       0 +<@9)H5$878
MP]Z'B=%FH#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M    #@             _@   .$))30/R       *  #_______\  #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              .,   &/P
M   !                          $             !C\   .,
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   .,     %)G
M:'1L;VYG   &/P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   #C     !29VAT;&]N9P  !C\    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MLY'U>S[?1-O4LF]PS&Y+BW8P, 8ZO]"W:YS6-_T6^RO_ ()*SU!'XJJ] ?\
MN?\ I.^DJ/1\/+PL,T9=WVBSU;7-L+BYWIOL?92U[WANZQE3FL>KR*%(65E4
M8E)OR';*VEK2Z"[5[FUL]K YWTWHJS?K")Z8YNYK)MH]SB -+JG:EY:U)21F
M?E#-&/D8OI5V.<RFX6-?NVAUFXU^U[-S&*F>DTWY>14W(SZ()>=F06U@V%UA
M])C'N<W<XN^DSV)%E-?6Z0P9.\VO<YUKK74G=4]WZOZCG4-_J5KSSZE_6/ZP
M9?UIZ?CY?4;[Z+GV-LJ>X%K@VJ][-T-_-<U)3Z3;T%MCWO\ M^<QSW%WLR'
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MGU#(KV,:QVE3MQ:2?4?OI=^D?/Z38DP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M[^WZO\??_JGQ[#\8DE9M,;2V!H?60$"]6JQK<A2W-K[%J0W8QFU7*F]<-LS
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M\7;MR<=ENV[M%67)G3U+]%SA*ZU[@ LQ^\L0J@=V9B%4%B 9;@N"YCJ;E\/
M]/\ &Z^7YCD[OE\''8JC=ITV^+6,J(/HJ5H]MMC%:ZJD>VUTK1F'E2[K5-B5
M8-=J0>'6:J6&)B<%.BI"9, A%^(ME2V74^6<*9?:=C2&7$H?BRF7HTAMJ0RX
MVGW'LR\AEIVXM%6K+H064WT.+*K$/<=U9?8]B"K ]F5@58!@0/.<X/E^FN6W
M<%SW':N)YCC+SFW\=MJ:G3FN"JX6Q&^YT=+*W4M7;4Z6U,];JQQV#N75!38A
M34@W8U,G[."06R1>A1+$+?M0Z"XEM>)$L*W)5.92AMYAUY"V<.,,R([SR$-2
M&5N6TY+!9MMXVO9F??16MMV1;D.BNM@I#O4&\U'VT)[CN!962 '4FY=T[SN?
MALW4-W$[ZN#UWG/FY1\UBXKK@UR!$N*^)#/FTUUO[)99FTUULST6JD4]K^W^
MENF6NH^S=V%R8X#/,, !4<**>*D"15]M3_MFOUT<=#2U&;>DNR2Q$=%REKX#
M+SLQV/&>FLG%\MR2:3Q'&:.5NRU+=;FS7X*+?3:Q:@P?D=F+/V#,/+O>"!W(
M!/8'&XK'EY#?1CV<SQG T7"PORG,?/\ R&<(A8>M^3,');>]C!:JQ5CM[V.H
M;P3R=97U+MFD;PUK4ML:X*.F*5=Q&#->(R($X6_(B_&?BN8=@$H\68P]'EQI
M$9U+C.$*<:RMAQZ.MIYRWNQ;.-TVXM^=LFV@5F_-8]+O2UE27!':BVVHN$L7
MR].QU#'Q\NX,PK%1;;:Z[JM*5VV5+?07--XKL:OU:3:E5AJL*^59>NMBI!9%
M/<#17T=\8?=_8#MSLK0_8'7?7/3&K];#;^_*VG#VI(;'6.?4[-"K0U%(-V*:
MS7+F/G29*GY$P4XRCY:G!=A7M%,ID;!HXWBM0V8^!HY7;S/'79*M^&O35R%^
M;YBAK+!?@R\51HI-%@.723<WRNU3EL#LRL8/-S&*_5IRKR?'6VY"PTT5.BVY
MV#>*^J3IL[>7N0/ ?0]RK K+T]E?%"T?HU-950BFM]_K,D,##$.A;_T]"*5F
M5+)B10AR:'GV*07FCYD@D\\0+PH*A-;@#I9*PSA\!/N$Y&+I$K3=IZIY$]%Y
M49*\^KG^,Y#-FV6M5?<U%6FRJFA;_"DFJAK#?I+>.>MV4RCD^?P<957=;?E:
MM[!67;=DI5'<@(";K5[^7VB2/951F8A02-AE).%[+4:W8#];>IQLR%'$BE6D
M%A)Y\!.F1FWY(EPT"D2PQ54)Q>6?F R2_!E83AZ.XIM>.:KJKHITWU9M2;<]
M=KI1LKKMJ334K$5WI5<J6UK:O9PEBAU![,.XDS6Q>M'*^)=%8KW5O$L >WDI
M*MV[]NZD@_4'M,HY8E<<1'$1Q$<1'$1Q$<1'$1Q$TC6^Z3+7XKE JD.WPIT*
MK/U\K;JW5-LU?V8HT I_84#1T%:Z>HL>]+(+K5Q.N6ZF46ZJK'SF6Q*.177H
M$_)=$O/V-[EBNN]W'44EK&X6>:>UU]-*T;A$JR*K1DY*WCI'0HVE9FD"F2 V
M6FT;XJ!@^>("6 82N?&EQY)B=B2/A(E=-<>+GUZV"T7DEZ=N6I@'*M1[)5B@
MW5UYVT1/0[J/.KD,E:MI:N;!L-)>!E*Z3'YD6B%"&&6<1)X@A(1*Q';1)3\)
M]U#WAP=.'F_5\-W258<1ZVW&5^A>92D^MIU*'6U>G./4VXA#B,^:5I2K&<81
M.?W=XFG0SK=L<SJ+>79O7>MMDUZ.)EFJA8%FTE!T<Z*B&Q#K^(0>7']$\5/A
MS6?0^O/P7T>O"5^I.$2BX_Q>O#4:[=VZ_.=O]5HI\_KAKJH0SV7;#[*191.S
M=HF20A'D"^+[J(+-"IKOFUAOX4UGTN*5ZDI1+\:$\1_HYVAOR=7: [(Z_P!H
M[ 6&)6%%6KCAE1)040J,DD0QB<)A,? AJF1L._LWK_9D>E"OK\D2[?$1Q$<1
M'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$2O
M_9_K[7.T&E+CIJR3&P[%GCQ\#[+@-!.$*N1CR$*P9#1IZVFV22H"YXKW3,B,
M^F 4GQ\/?!D/-.HFOB_^$77[CL2\[0&;[M5<M$W8%MV'J?U4FOF1>LRFSKQ>
M]@;4B&83Q&&YL6)9CNR+4V!]Y)KKE1'*$QFLEWA[\F>B9U1NNNM.O/>GJO7-
M>Q#J$1.CW86FRYYRTV,\\2&ZYMG2ZJ5U]0\F3D A,O N*CWV:Z)#1YTA2GY$
M=:DM?#1-IO$1Q$<1'$1Q$<1/S.<8QYYSY?P_5_\ WGZO_7B)JPNVY>UI7N.,
M3H.8'VYUTK]>=@7NO!<!A%9#6-N$1:G1+#M V,4/Q8(IM0V6[%J)LZ1#"([L
M0C4_<XDMD>8[N6ZLMZSSC@&S<MTUGRV5<CGI%55-&P):&73R=R>GZZ7>BQ3'
M??;14'6W'Y]_5^L>"Z,^#F'X&\A9\2*]W17Q.W\G7KZ>Y/D'W:^1V\.UV:RJ
M_CND\.I;QQEF :ZQHYO#QV3;KLKNR\WZ/@<E5N_?:[8AG0-]A1DZSV?2<$P8
M/8E>U?1]AW.E5Z&^3:]:979PDW#H#]I"G(XS# RO4?)4601[@@J#F,EN35U(
M>5Y;B=V;9;Q+<>Z(N['CS7Z2M?K5CQ3EM>G)39I2TU-6N?C6NK96N\?&IF7@
M-/QP^'_PAW9NKOAGP75_675'3>L64=1<QS>7I_IVCU@^*\6\1PW$\N-!N2]L
MU_&_T7Z6LHNN&BNM5:?=T<UYV5WWUJU^;UINPCUZU?#^=! -;FP95S*>W'EI
M69Q(8JI"]#---D2,B7)R2GEKBLA.7,G2)"Y+BVFLC@^F==?#<;5BY[5EXTYB
M<V;-?F-F91?<C)=\GBP,FA[%LNL%MMKOZJ7,[^H)1L^/G5_Q/UZ>N=?0WPEX
M_E.?T6:=V_?PO5G5>[0U'CCK!IYSJQ./S)33FKIS5497SU9ZZDJK6KQK74J+
MIVAZQXK6\>N8IKN9MC<NK0#.P:K8^O8BF4_8-D[&6S$LQM29FS629)%TNFS*
MGL<6\YL"TFP#"C<^[I*61]DE5F3,WGZ.K:SU]'-<R"0%OVU:]%%S*" %>^AF
MT'O]A5K-R(P"*2%$YK1QFK/UGR77M6_)EZ@Y2IZ;ZLG2_23\%54^?/F-63I[
MF.$YGB,Z+7DI>K^EGLIO5M%5B6NSF]>WO"K[N]M:5,&[/OHRF49<Z$;#Z-W5
MV(V_V5/$2\%WX<(A>K9%A -4 IH^,]*EQ1]4UO<\,3<M,1K8AE3LE>?NX+-5
MB*<'NYT<EYU]]W*\QIOIMJ!)>M</>X9K"" ;3IU$^)[+7ZA\75@ZNY[C3GR=
M2+GUI=596U?$=/<'0R*'6RNP]-<#Q?;OY!E\:"GDH#(20ZWAT=X0.O:MJRHT
M??F[M_;L^0B?E3E+SMJVU33(,5$==8 UBF4FNOBB0RNUX$V-#16)IZ6J7F$Y
M+^#!C/L"H,SQ[:N*6K\G<GS.2X4T&_17RNM+[=8SU)KN2REZC55;I6VW/2@!
MSU.E1>QT:U\:K@#=CQU\OR7+[ME&6BB^Y.<YJBFUZU 9DHKWI6BLW<]@B]^Y
M/9>Y$UA]-?"JT->>X'8S5>[@6V=I:GTPX1&5FJ;+#54%6GY$LA'B"9I<O2:_
M6+ V2D#\O'J,T,-M02E2>5)+,SE,HDRN>=-\W?R'5_6&/Y#FN.OQW]K^8/*\
MJE_)&^Q;;3OO&H-?;MN_VPSEWL]6EO58EP+'[?UY^YJZ%Z ^''PU^)'$=5)R
MG+_$3+=HY7B\?,\G5?F;Q?2[9+,_(+INHXZU1Q?.?-]WKYM>RE/(TTU\\>#J
MIU@Z):YT(QTTTR'U9MK8]ULRSTFO@+O<'#.NJ^$9CDVILX@Y9!P](ZRGJU/9
MC/9C3IV&W50L26HDF.OH=/2&WJ)+ER<%S'4(I>I[K*+>3W/D?M:]:L3I94&O
MTWI)8>7L/%T0.Z\+W='=)\C0*>:WZ* EU%F=.1YOG="6$V+5>]7JZ]8K:BE_
M4L[5!GS^JE3F\TU7=K/IH3JACJ7UL)T94Q52F:1UF\!40CFHDU4#-2%8;5)B
MV/*CT=Y2L+4MDNK,]K.?1)_9,9Y>OHNRWW9M.1L&BBQZKL++8C8[%8ALQ2W]
M]04D>F%L)<!1Y$GW.T!**P*\MBW9:P*\UJ+X+9G3[--BIW/BKUA6"]SX@]NY
M[=Y97EJ(XB.(CB(XB.(CB(XB.(CB)H3>&[!N_C#56RAQMT3K:CM6@!8".J:[
M=).LVSPT!9UI7MFUW2%JW7$&QRLEV()D1KN+V&N4LJR-=(FZN+A#<5!$W?VF
M@42\L28MUI53M\:8#*5F7'M%=$'V)5;.21<PU7Y+)6'+;?"&)@0++*"G4J@S
MY(@6_+8=='Q%LHGSAZ!1*A(LABITJIU@O9HHQNR%*]71 4C8$5T7D17T')HV
M'&DED A*4BPR9[LC L<G$*#AB-C#7$2EWA2?BY.GGY%:U_2E\1.BK]T:?C:.
MP'_"NCOT+T?B)HWXB=AK[F*_&>POY/\ MS^OJ/$3^B]Q$<1'$1Q$<1'$1Q$<
M1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$31AXJ^T+WKW<>G7
M FP]B#Z+!U5?[1L"GZZW%V6TZU4A RV4^._O'8]AZX:/VL]!UY5H3\L(4GW\
MB)"1LSW9XV,E H],RB;RVE)4TVI*L*2IM"DJ2OUI5A2<9PI*_P#MISC/GA7V
M*QY9Q]O$3V<1*37O\8;UG_DF=POTI=-^(EV>(CB(XB.(CB)&FX=K5C1^M+?M
M>YL'I%6I(M1@VBM B%D,(@I?98<?CB1C3LEUF-EY+\Z4O#4,; ;DDB,F) B2
M9+6+MV4X,M^S2Q6C-6UMK #[*+[LQ)*JJJ/=F9E15!9F502 6ZQZJLV3D-^B
M^^C-1CXOCMW+<AHNTW)157EX[C,^O?KL+V+^]9,UUQ4,5K;MVFO2N]MZ)V^U
MQ8]M.E+SJOJC3"4:OV"/.&% NQ=V7*0F%E%'!.5QTE*D51R7/AU]P'1")&XW
M^S2<UE*Q0QF5 LNICD?Z(ZK;7LNX_@L["O16MB#=R>KV+8VLRVV"C)62J6TT
M6_-:K#Z3M1G#KIW?B^L>CNANGEZHP>MSO5&T"_A>3YCICF\/!<)QEX5>/YG@
M>+ZCXGC]/5/.<K8W^T^P8-'$<;X^IEKY#EGILXK@X_67L_NC=VN[5<Y=9U1T
MI@@_9SNG;):8TMX(.@E& 0*]UFHCX%*+2C9*4.LA\(]8#  /&CMU*5&L3,)]
MTCFU<7NMU9OZCCX6JM53B:QZ86M 175952J5=B>SFON4K!-95O'L>(<GFZRZ
MRZF'4'4W)76<7O9]/)<3R._3MW[G*V>)Y=AWJV:--K)HU+=KT5U@#*XT(A#R
M;XIECU%I'P[.PMON>JA-RJ5 UT]"I]1'5H)*8K=LLF6M=T6P 8<N+F!7/H@9
MMD,GDR/9:E A,6=(')4ZA##NX\=1C^>X]M7&4\GBQ:\^V_CGHKNINRXK!ITU
MM38CU>F<]5HL\JV05ERZE PFS[N*P;L)P:,F.S.J@9Z;LU5M%%BHU=+U4LI1
M&J\R*_$*0"54@&:Y.C.P]Z]]>ONI]>=7:$=Z&=3 ]/KT3>F\Q0RN ]U;FV'&
M"BH%YKVAT"FG!]5BE9D=Q=AWL2BS;7)?7Z0D$(3'X>(;%KXKC.(?1R&O!7A'
M)7Z-_$]+YU&8U8]=CVYK^2.<5?)8Q646C+4*MFVM5>LX\S5:7M<=ES8J$P\;
MGS9\]/8769J*J*7O"JMK5UU*J67.5_?+#W5&'BQ=T-8E'JKX;FT.L_B.6WL3
M4.O/7NI:*/T3&J1Y6!V)VI<-H0((F?:)TC<<\)9]68B6#9&UH[U3@7L64M^4
MCY;-@.MVX\2,D')L;IY[DM6)N/>VFO&ZYT>C/ES9D:O+IV:\Z'T*JR17?OT,
M"268>B+&<45>,B**PXL[$N"Q#,[L076M&(#,5'=:T'8  =B0 6;RWW\AY=GY
MG'FG.//R\\9QYX_<_P#K_P O_+B)5+4?6NRZOVM?MID=\7F^/;*<@RK;7CM8
MUZ,&DYX03$K]9G+E5^MCI\5P "ALCH[(QX?&FXQ[@BU*>RM2]8XGI[3QG*\C
MR=G.;=QY1JWU9K\W'U5-9137FS.'SY:K5-&>L5A49%L_/L#-[GKO6?Q/XOJS
MI#IKI+-\/N Z>3I1-%/#\GQ_+=2Z]6;-R&V_DN5S^CR7*ZLUJ<CR.A]3OIKT
M6Y_ZEE>JOLHLP4 @SB64F@PHNF/E:HZ2@^)/2PIS"<.*93*:=PUE>$IPO*,)
MRK"4X5G.,8\MKKNNI[FJVVKR #>G8Z>0'N/+Q([]C]._?M[]OK.0D _4 _K
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MHT:K#=IONTW$ &W1;9=80!V +V,S=@!V []@/H)=550>**JJ._LJA1[GN3V
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M64O9HT6=O5UZKG:W3JN(^MNBYWL;[E\@B@(J@:!.FO9]5D\,;JGH/3%F,QF
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M=D2'6V&&&UNO/.K2VTTTVG*W'''%YPE#:$XRI:U9PE*<94K.,8SGGA(4%F(
M ))/T 'N23]P ]R?N'O*D1['6NM6=W941$4L[NQ"JJJH)9F) 50"22 !W,J#
M?M_UK:(0=0.NVR:O9K/L!\P*FWBG'11Z%JJG \L(OFPB<F))?B1)X.)-B#JG
M%FJ0DC;38![X;P=@E(9U79SN7E*:\73_ ".77IWM=4VW%?3I3C,F?Q&_=8U;
M.B6T)8M61'_JFR_.2IH6UE[!PWP_Y/H[7LZE^)W3/)\+PO3%.3D%X3J#!LXJ
MWJKE]@MLX'IZA--=-KX]MF>_9S6BH=LG"8.27U*]MF2NS7^"ZU=3]W;7H&R;
MOLS&JD%/EM1Z7:SA;#J54L]^UQKT>V,F[!'URSC9EBM2MC$6I9F"V-8=DYIR
M =@G/I+6.:U#L9NF>*V&O4*#3FH3/1Q]:"K[6;( M5MILJ=K#:X-M9<^0[BW
MOZEA:<,U=0]6]<=0:.N-_6?5^2VWD^4W<$.+Y[=QU-*<M3\KS'(Y,U+BO#7U
M!5Y9[*<:T)?P]>2FT&M_2KS'Q/-^??%Z_=F^N&FHT.T("ZW.P>S>S'6PL^BZ
M?J4P:EXAK1I\VT\$MF_-DBWT5RK:]@/H*TJ-88E_LTD2MNH![ATWISCOROSO
M%\641AR&I,A:SU_"E;E9&TM\NR6?THI.D>3>CY5#Y@-G]0'*U7#/GNO/?M2C
M6=E\0S>'OX#R!'>PCP'L3W;[/VNTJW]SU];XHWI]K7:=KDR"L4)8KV_J6MNB
MHL2L!"9]$*!>=J#9'LHDRUV>UO-3*H'MI-#CH&F#)%;KC_RHF0=F;+U79@X+
M+CZ;X1L-AT\=AT]0\MQ^B[2.5UAK+$S"RUF%.'.PKO\ EZ!75IO-.IZU]*A*
M\/&MFBRS7I%@\+;$R46HJFBOQ"FSLONUE@)'FW=D0M6#[N6[&W.?R3CB(XB.
M(CB(XB1ULV@D-B@8P0;LK8FK7XY1@DJP:SG5F >E-,1Y3&14EZU5:W#\BY"I
M*)+[;0UJ6J1$B9;F-M)>:?1*!=3?#GV!UHO^U+M8.^O:[=,+8>V4[(@U"Y&Z
M\JOP!K3\A[%8L:#(RV2##D]$A,$T5ICFLX,X;"&1(E=&>P8=PB9=WBZ7'>V!
MRL$1IFJ"F*AI'?%1&-6BJT>VQ2%VV&?TM/KL&9'NVO[P]7 ,X/0[4,+WFAR:
MSLBIOD!<^KE'LYFQ'$2M.P.D_=O99 U,,[C",2 &UK'LW4;I'9-\-!:D6;U[
MV."ZK)1:W)K\B,%GZ[)[ T\.>^5OY%E'Z@6M<@"1/CF"UN1,C.]5>^TVHAW1
M>^2T6Q#!-=$N5Q[?VV(\68*7<>R9P_$=M@\>V56>BLVWK<_$MIE-FL>0NM;#
M1)!XT!FDU7A$S0QUI[I-OQY\?<YRUM%3UV*WL!GL#L/7N3.7K7NS[UR:E8@5
M*+HUZ/JX"W:F)V<+4ZV+"V5RBRPI@/882&HAA$R:I:+[>#-8]GP.S3&M]^62
M^JC8U?6=FW"V%M5%"";1:I[Q*TUF0 =D5:IN B5-:)ZUK<Y56-9JDFML00+<
MPE=+4B6_ZX:ZFZFTAKS79(:R((U@._$GCXIN)8(<>;)*3R$KY?/'5BE"6!KK
M\QQ\:%"5*N@*U =CUP")A!Q4%E*)-W$1Q$<1'$1Q$TJ;2BQ#7C#:GPV.,(EU
M*@TDG+.I<.R'<8(53?D&&#%EA^A+$S6ZA,;FS)MPJ$_>E, 74_"K!EX6X1 N
MP;"B;+^T%.V5?]#[#J&GEAVMEFQL"/47[!>[YK8%%)-&QDI4LQ;=8^B]1AD2
M*Q(D3A%?E#G[3&:<JTHN('F99.(B4,U?U([S5&Q7H@CML<I(@U5M70V)UPL"
M^UQR>5J%*36S[4$;=*/J*K4,;/<C09Y@@.$V2Q7:T()6B<2 LDW07$29?"?2
MXCPX.G"'7/C.ITC6$N.^A+?Q7,>ZPMSX:<Y2WZU8RKT)SG"?/TXSY8QQ$Z+/
MW1I^-H[ ?\*Z._0O1^(FC?B)V&ON8K\9["_D_P"W/Z^H\1.^1W,_!+[)?D3V
M1^:I/FM]8_V)=3?WAY;_ $&^=2^!_P#NR?"W_C]TI_KK'.C[SX+G] T<1.X5
MX5?X"^F?]]L/])]RY]J?"C^P'@?XN_\ UGLGX>?NO?\ SA>OOU]-_P#TIP<U
M@^.3^VGHO_@&R_G#'YRGX]_PET__ '#K_P!(2?7/_D^?[$_B(?\ ]Q<3_JVV
M:,^<!GZ%2T_1_P#"_P"M_P"5^E?_ #B/S<?A]_9KTU_?7/\ SF<<_="?[B'Q
M2_XF<U_HS3NVO?X)W_=K_HYY]SS\"I_-@._Y<,_QJ1_M;W/T:S_UO1_P-7^0
MLXU9_5+/X[?Y1G%<O2B=KK[GT_:"WQ^62!^8P+GRS\??X>X+^\]G^G7S?>DO
MZRU?W6?\Q3,J\?/\&/3_ .7X9^C?8_/E/K7^#L_]U#_-O-/^,/\  /%?W[K_
M -7<C.J'SF,^>IYM_P"$;_[Z?Z6.>K]1^L?SQ/Z0D+_$XG_AF/ZI'.^I^8O\
M5?YA/MY/S%_BK_,)]/*I5'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$Q.)0:+ N!784"
MEU.%?CPR*%.7>)71$:WF0T'+:H0DK9&8:#)$9#4RRJ+ F37HL=33>66D90G.
M$3+.(E'=@>(QU,U<9V%7[U>;6"-:TG"1QH<]J#;S\DY(,79O7#&=>)B4=_&S
MHT6\.9K96;K_ #8X8J<T^J>^Q%9<D)1./-GQMF[Z=4CHI4K$,OTY[8%XS!$?
M.#E8\4KL?IE.B-E0A6/#+AI^&'D8E"RT*&1@OX<BS(K$EEUI")?+SQG[,^?$
M3&C]SJ-5DA8=FM%>KTNQD$B:]%-FAHJ0=*+]/H&AV9\F.X3GKPM.4PX27Y"O
M4GR;SZD^>-?LR96I33IST/IL%.=+KJZFOM([BJD6,ILL/W(GDQ^X23X_A>8Y
M:K==Q?$\ER5/&9FV\E;@PZME?'XU/9M>Y\]5BY,RGN&OO-=0['NP[&5I[N;T
MJFC>NNSCAHZ/'&R='M<.KC95<E71TI,2$EN3'7ZD/*!9A$"+@_&FV:<X5&#
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MMNEEWGNPN9W?: EE)8/B>O=QC4N/6%SF:O3J1B[Z'LLJ-K^M""YL6#II^58
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MT2DH&.2%O.1\9D*?5E$N/J+P&>@>@;=B_P"D8W834]W2,FA4VS7_ &2VS5K
MD024PH@-P5$6"+,Q"FJBQ\R8^'?A/98:^(E7H3Y(ECCOALZLM 4K7+'O[O,<
M '!\H49#%>Z._9PPH,G,KCS($^'(N#C$J)*8<6R^P\A;;K:U(6G*<YQRSHST
M:J+LVFJN_/HJ>F^FU0]5M5BE+*[$8%61U)5E((()!F;QW([^(WXN5XO9HX_D
MN.U4;<&[):]&K'KS6+;GTY[JRKU74VHME=B$,CJ&4@B5BLO@>]# E=.F'R.^
MA30L02GK)E^T&T8 N!B)#>?Q,(S9MD:AQ(,?*,.RI,IUN.RPA;CRTMI4K&N?
MT$='_P"]GA/^;LW_ '<Z9_L\?&G_ .*?7?\ \R\I_P#<R.^OW@6];G=&ZB<W
M^K>>=X+UU45;;R [*[(^29V'D)#^EJA/R>P?*?E^3?O,Q,C?[Q^#E'M<89]&
M./Z".C_][/"?\W9O^[C_ &>/C3_\4^N__F7E?_N9="G>&%IC7M=@5&B[N[M5
M"KBLRLC:]7.Y.^! >!F;,?(3,Q!\*W,QF,RITJ3+?RVVGXLA]UU?FM:LYG\6
M''QV:O'@S48\E/EZ6?-6M--?F[6/X5H J^5CL[=A[LQ)]S.><YSW-=3<IIYO
MJ'E=_-<QM]'YOD^3TV[-NGY>BK+1ZVBYGML]+/3517Y,?&JM$'95 F(["\(3
MK#MJ8.(;/V%VYV!.$1GH8N7;^VF[#\@?$D.X??C0WB5HD+CLNO)2ZXVTI*%N
M8PK.,YQY\PN2X#A.8>JSE>*P<B]"LE+[,M5[5HY#,J-8K%58@$@>Q([R<Z8^
M(?7715&K-TCU=U#TWGW6I?LIX7E=?'U:KJD-==MZ9K:ULL2LE%9@2%/8'M*C
MWWP0.LR-U:&!T0CN7Z /O;&)[R%3^T%^^DRZQ'ILJ+0R(&!,LN#:HK6Q9 B,
M4F!V<MMLO)9(.)8=PA4;_01T?_O9X3_F[-_W?[=_\&S_ .SQ\:?_ (J=>?\
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M +7FL,XA"EQ<0G84?-KRI6?)>U;_ )I-*+4K5IW6E'0 HWHU>-2,5[A% '8
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M=&1F1NWDI['LRL._Z&4E3^L$B;'1?7IIKOJ+FNU0Z&RJVERI^GE5<E=J'_\
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M[>3GR8_K/8=S]W>;%15Z-5=1LMN]-0OJWL'M?M_;6,%4,Q^\A0/T2BD;P^K
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MU2Y*[5!_"Q%;\1-8%T[J;EB1]F(J^R-81#](U+7;-(KUFU=9HBHFTS%+K]D
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M=]FM*1\KR?I[.7XDBJKF>*Z<W:\S9FQQ$<1,&,[.UQ7;2&I!Z]U$-<K$B,Z
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MN5@KAX7(\OC0"X8H]*'D(CF4I4IB2PXCUH0O&,+0E6'[?X?K$K]8_!8Z(6X
M$JUGI%I.5^M"8H*MC"-H3(8KH>"UAB$- J4+^,'B1&L>B,R.<C)83Y_#PG.<
MYS<KMMJ;SJLLK<#L'K=D8#MV[>2D'MV]NW?MV]IX0&!# $$$$$=P0?8@@^Q!
M_ ^TJ[K+P7>J^C._ C8>M=K;<H<UWK\2<J50$]@YS&QE2!)<;2[:4'>X@O;
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MFAMH(V:E.RFF'SM+.YCQ,1D3E=Q=5O$&IVIMEVS7?B?=A;K?:U1+4<I=.D:
MZ:18]IM(L)-F :\](QI2+EAHN39C0%O8DQ\MI?RO#S?EZ\/UQ.'TGX;O=+4%
M4)5M'B_]G3N2-LLEFS,*:FT5<7FVS<]4B/$:([BK6U[-%;8C)9^,/'V2%66I
MJY<@)70K,ER.H??Z^_ZXGG:O#@[K67:^M-E_W8+M%"1K^!:(;H2)JK1HD<74
M?BL1XSDRKU>MUS5I_$-27G75[%UKL"6WG$1=?EUR7&Q,4B8[VHZ&]V+IUTW%
M44>)7OS9B[/1C #%$)Z%ZE#H-D26;3!7!?(5_5%:/0<)0\J2W,"V($6C.L(>
M&EQTU#$MJ_FTZ,=]6K)?;FTT.+*-%%CU74V+^:]=E95T8?<5(/8F4LJNI1U5
MU8$,K ,K _4%2""#]X([3#M8>"O<=9:^J-!@=YK'-BU4-'%MRY_3KI-9)4AU
M"G'Y4A9K8>F;W=IJ'I;S[K*K)<;&3::6AAXM+^$ES,I9U-U):S/9U!SCNW;R
M8\MO[MV 4=S\Q[^P ]_N 'W2V,^=0%6BE5'T J0 >_?V 7L/<D_K,P8'X$-H
M"[[N.\V^^%O=(6RIBZYD2[U6ZL3!45Z+[!J;,;I!>A%=+#L/Q0HA$675]25J
MR-2,EY$RQS\F2:9E]NKNJ7SKE;J+FC0GCXI^4M8[%6M8$.+0_<FZSR/EW<%0
MY8(@6D9,H<V#-0+"""_I5^1!\>X)\>_8^*^WZ!,1[C>"KLO8>C# <5V\NUI+
MQ++1B(\-7>L?475\QQI5N$"3Q!^RZAUCJVW.0@=5*GSCHOZ71A<QX='7/ASO
M;LL\IHZKZGS,[4]0\VC.@K9ORGL9O$6)9V5FN8H2U:]V0JS+Y(24=U;U\N:P
M /GH< ]P&J0COV([]BO8^Q/UFWZJ:![(4^KUNI".WCV1-7 !ZZ+S-T-K^3,R
M."#HPR%F7)^9M^XDYC16\OO^A'Q7<K<]*?5Z<0=MME]MM]SFRVZQ[K7;ZO98
MQ=W/;L.[,22  .Y]@)> "@*!V    ^@ '8 ?J$Y_[TG:'_6[1_\ P!K_ /ZM
MRW/9@^P*IW$H8D#9JSOV/L^5&V5I\<;I3VE:.#;)T.P;9I5?V;.^;Q33<H>N
MN:X*6NS-28ZEO-NAT9;8DJ\H[J)>7B)^9SC&,YS]F,9SG^#'U\1*777O-JNE
M[,JFM'*]L,S)M;C#48\-J<V.,CK01EPSF&QYC(RRFDU2%&0=LBZX#,(@AID.
M0SF4^_B-C4=G6?&8^1R\<U'(6OJ("W5Y+!6I%C)=V2WT[[AE11?I.>FWTZ7K
M;[1;Q':.#^!G5?.=+<OU37R'3F.GB%9K<&GE\[ZG5L]-V$O?D^9XW >6NN;!
MQB<GNQOHVY]%3+4M8=ITN^VH5=UK&V%6QB[/\[/4*J58:0<(U1@B?V3?JYK>
MLI,2IP2:6 !T6&T#WC1#Z.DI\ 0U,F1 Q20VQ!D[33=7HJ2ZHDUV+Y(61T)4
M_0E+%1U/Z&4$?A.0[L6CCM=^'6J)IS6&JY*[J-"*X )"WYK+J+1[C[55KJ?N
M;V,KR"[M"+!-TXB'KXFT+V0$UJ1M$Z4>B-S*40VW=K-K6EC!@YH<^U<VDWBG
MG8EB)M$0# L D;8(#1K)#Y;'NS%EY.(CB)3CM)H:F[A-:[)6#;<C5MCK[DB-
M4Y<0N$%%%PF[32KI=)-:64_OA%A;#T>(F(6@86Z 6VQ/EXE5]5AK]C1*PJZ2
M=*)ED&C4;>K\XO=%GY 2MOF]/F)!UVRV;5M]=="P9->E3)S.2>I0J$-M>Z:)
M5F9-JTKW5>8'#X:)E@OI'UXJ1H1('[W/0+6Q:\6L*5+W"DF[1/)7^S5<]6(<
MK%H@%HYB"53KV!7 #+0IF2;K8V17X,ET6X>AED3"JQTKZ8C)\ ;!WF')N#3F
MJ+@2"N6O64^ 6&TU1@ &%R1$R#/&0A5I/UJZ9D3@D,<<;-2KZL26AF9+T^ B
M2D$Z_P"@1O8FN[-@[Y#D3M_ME@MBJ<BSTIN=L@N2/'=G4<2VD"B#-L@*IE!!
MZPC9,M!0[-@:PH =)K%>I!J <1(_&]#>H+[\9(O<?D[+$V&D%&*U:]9"%VH#
ML&OQ*ZNMEOD 6+(E+E':M:[V+]FY&EO;'/WVQL87(<]N.1+":$U'UQT78+0=
MIFUQ)0ML(N@]$C*O%1$C6P)\E.C50##KU+S70MI##94^8&HY2TC;(;'1UI 5
M\Q&&1((N(B6<IVT==;"GV491[I7;7.I\L3#L; (G&(Y&NGJ^*M(5U3D=:VI,
M$J",CYT G"<DCI.5R8C4I4V 0C143/.(CB(XB.(D.[XU#&WCK:;07K$0J4M-
MHUU> %E&PH)-\+;=5;%JNT:=.?%$T+@%QK=HIXC!@1)RRDH)5-@HE0G7VYC"
M#[^TY'2&IP.A]-ZKTI5II0E6]2Z]J&N@9$V\P^8("Z<!@@(4XJ[%CQ(JR$QB
M B1,S$B18N'W'$QHT=C#;2$24>(GQ$AH\P.GB"T&&4%%(4H<3&$8K,T>1'S6
M%QID&=#DH<CRX<N,ZY'DQGVW&7V7%M.H4A:DY1(JT!ID)U\U%3M/5LC,*@Z8
MR7CCILZ/#B25L%K"6L&6<QH#3,-AJ&X6<AQFV&D(3&89QE/J]7$28N(GYG'G
MC.,>7GG'[OV<1*R=8>N;_74+L*&3V$0VC8ME;%)[%L=R,UL-7#$N;-%" 0\2
M]'!*P,P(K( $'K-5'P(@T:!K @4&@P&T1%OR$2SG$1Q$K9KSKJW1=^[AW]+V
M!8;,8VN JM317)8FMB0M;KE1,VH^)AH6$&0I)N;"GW(U%A%9ZFY> ZV&"F3!
MC,X]/1+)\1'$2IC/46IQNXBNYK%ZV&N[R=7&=33J=-)")U(S624BF3(D46P^
M&R=#0!I.HO'TAH9KY7(LUB.'?;L2IY!$]$MGQ$<1*J;:ZK!-L;ZT=OF3<CE:
M-Z3=EJ@P0(P"S-.PY,UD@\%=MJX.;,+KIE]AF+<*_%G/![4)8CP9,*'(:^8*
M1+5\1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$@GLSJ0CO716Q-4"28@41MXJ%'BO6*
M ^5K,YP::&&\@;6,BO,22%2LZ!BZY:H3#F'I5>*DF6TN*7AM:)[>L^HI^@NO
MNG-*E+.Y<R.L->UFES+.Y'<AH+R 8UF&X_$A/2);T(:WEOVPJ$[*DNQ!K,2,
MX^ZMI3BD2<>(D/\ 8+4\/>VC=MZ:GR/9Q]F:^M=,Q+5)*1F(DDZ'EP84F;D/
M,@3I8UB8ZPZ3%IDIC&!Z9(D@U)'S949Y$S6B5UZH4>FU.1*;FOU>J5VNOS6D
M*::EO!!$,:Y*;:6I2VVY"XRG4(6I2D)7A*E9SC.<HF5\1*S]PM,VOL'UUV)I
M^DRM=C[+<XX2*-*[3JF+S3@KHZR"#.3<BI/-OCC1H,D=DE563<,F BVB*'(G
M0IT5#EA9Z)+^KZCG7^M-=T-7M/52:+4JBKV#Q*3!\ZV 'AL^RD&)$LN_$\X7
M][O%9<HDZSZ%SI#TI3KBD3.>(E7>YFA"/9SKAL?2(I.O\S;S A#VG=F5XE9:
MU"PT3B27"C,,21'385D$-LJ*5$VC,Y .S0Q1-T;.;C*9RB3Q1*]+J-'IM4(%
M$FY]8JE>KTTTB'@<@O+"B(8V242/Q(EX@I(/1ERTP\2I.(N'L,8D/>CXBD3*
MN(E1^\76VS=M>M]]T15]G2=5R+K!D1)YEH4LM",0TC2.(E=-M12 HHT!D'G
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MAWX16.S+;1/6%T5I6N/ORP6IM<B9DI@;%ESH5-K[$^9'#K'.BVILY,#$N8F
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5B(XB.(CB(XB.(CB(XB.(CB(XB?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g766269g58d70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g58d70.jpg
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M)5;4.7B!H;+_Q  = 0$  @(# 0$             " D&!P$$!0(#_\0 5Q$
M 0," @$-"0L+ @0& P    $#! (%!A$'"!(3%R$Q-C=1=9&TM4%6<71VI;+1
MU105(C5AA92AL;/P%A@T4U2!E;;!TM-5U",RDY8D4E=EX?$E0J+_V@ , P$
M A$#$0 _ (N<5,XW'B*;OM,33---+GD6FFFF>6FFG^1)]&FFO4T%E&BM$VN\
M'[B?$D7N)R5%=FD]5VP,6;J_'$CN_)25_P#9S_'&^LS]XS_).1.A# \UY5Z5
M'9S_ !QOK,_>&2<B="#->5>E1V<_QQOK,_>&2<B="#->5>E1V<_QQOK,_>&2
M<B="#->5>E1V<_QQOK,_>&2<B="#->5>E1V<_P <;ZS/WADG(G0@S7E7I4=G
M/\<;ZS/WADG(G0@S7E7I4=G/\<;ZS/WADG(G0@S7E7I4=G/\<;ZS/WADG(G0
M@S7E7I4=G/\ '&^LS]X9)R)T(,UY5Z5'9S_'&^LS]X9)R)T(,UY5Z5/>U7 )
M/<-GUS4D14),)7:,[B5=QG)V6G(FK&031_;XVS9.2PHE4:D0:.+DFU6*2TRC
M,A/V0W$@W+'0O+H76X1K/:[E=Y=-:Q;7 F7&2C-%-;JQX,=R2\C5"U4)6YL;
M56LI6JE*JLD6I$7-.]:X$F[W*WVJ(M'NJYSHEOC;+6M#2/S'VX[*N5HE2TM[
M(Y3KZDIJ6FG-4I54R65.X+8Q+MN4:E+Y*=R&T.8O<.?BXR_5I5^X-EFEJ)'G
M%X[1N2+*#$-Z-UP.8%VAVD@*.T).:2DJK)45CD1GAIBN'L=1,1R8K$7#>,(;
M$R.LIBYW3#S\*U5L[#L[=:3JG*VE20WK?<ZIFCRU4I2OPD4R>_8)EX>CR7I6
M(<)RWHCZ1G[=;;^Q,NE#VS; Y0L&FBEU*F*]=[H2K6JTE-6N1%I5"#/9S_'&
M^LS]XSG).1.A#"LUY5Z5'9S_ !QOK,_>&2<B="#->5>E1V<_QQOK,_>&2<B=
M"#->5>E1V<_QQOK,_>&2<B="#->5>E20FWG;_)MQ*NX4<?DK8P9TWM]M;<*\
M9O&C@;B[L%3M*9W=6%MT1%FZX/#H4IQ*;S578T6!F.6JDTO'J:C'L0X@C8=I
MLU4B,[(2]8AM.'649V--AD79ZIEJ0[KU3-EI:55Q*<ZU1?@HJGOV"PR<05W>
MB/(:86T6&Z7]W9MD5'6+4U2ZZPWK$JR==2K)M:D2A%_YE1#QEJ5B[U.NAR!Q
MFE?S#.9UW$K(3'UQ-V^:)&)%+TARM-&)4I;->L8IRS8DZE2.,*>JK:33$^N>
M9I*@@TSNVJZ-7:B8XW"N$-(5QEVVJFY0G(5;]<.M**I46EW=?@O*N<:53\!Y
M$JR1%I5$Z=SMKMKKB4.3($M9EOB7&FJW36YE#%$NA:Z8TJIK<8FLY92(U7PV
ME6G-52JE5Y=V<_QQOK,_>/4R3D3H0\S->5>E1V<_QQOK,_>&2<B="#->5>E2
M:U#[&;:O"M5MU.,_IB@Z6(D1D/;;6W%61I7$2E4O((T4JXU#BT[7(9%)W) G
MU[*N,:F!0W).QJ2CEV)Z)<4FPF_8ZM-CN5%E;@7J_P!ZJCI,=M.'+;[Y2XL.
MJK6T29BU.QXT5MRK<;1V12Y7G2J-K36VM696/!-UO5NKO+DZSV*S4R%B-W7$
M%Q][XDJ72FNKC1$I:D2)+E%*YUJU'J;HRJ2IQ*J*TIY_N7VK7!M5?8LVV+G&
MGR-V#'])965G5Q*T4XJZS(SH;@0<\PJ7MFN*9R)2*#"B5R-4G0.R'Y0C/5MY
M*1Q;E"OT<,XKL^*X\IVW)*8DV^1[DN=KN42N#=;9*R6JEF=#=^$U572BJW73
M4XRYK:Z:'*JVG::.AB/#%VPN_&:N"QGX\]CW5;;E;I5$VV7*,BI34]"EMY4N
M4T5*B.454MNMZZBJMNFEQNJN-/9S_'&^LS]XR7).1.A#',UY5Z5&AQ^O\-#3
M===?X:::&9_Q_P#V&2<B="#->5>E2RPKA=WP@8F@R?6_M;IZS)%$L9M']OUO
MWZQP6[G)@4-ACPVGJHXXHLX[%E;LV%9JT+?-I9&5N..!I2XA$>F5E$:T72E8
M7)#R0+/BJ\6R/+]Q2,0V>P/S[&W(I<1EVFB2W6DB52RZJ4..0HDFC=2JBJNF
MJBJK8R:,[XVPTL^[89M%RD1?=C%ANU]8@WIQA6U>;JKCN4>YXM3K:+70W-E1
MJ\D5*Z:*J:TIK5S-489Y89'9ZZX998ZZX']DPUUQUUTUUQ,+SRPSQZNG^7/#
M++#+3J98Y:Z:Z:C92)2J(N6_N[J9+^]%1%3P*F:=TUTJU(JIGO;FXN:?N5%5
M%\*+DO</_/9S_'&^LS]XYR3D3H0XS7E7I4]Q85>6'5$AQB=CQM\ATDR9V&08
MLSV7DF7:LLH:$;_'W+0K0S/_ (5V9EZ-Q1Y]7_43*"L^IIU>IIT;?<;?=H_N
MNVR6)D;9I$?9F%2JC9HKU<>0UGDGPF7FZVZT[E5*H=V?;Y]KD)%N$9Z)(5EB
M0C+R+37L,EJA^.YEG_RNLUT.4+W::D4\/V<_QQOK,_>.]DG(G0ATLUY5Z5'9
MS_'&^LS]X9)R)T(,UY5Z5'9S_'&^LS]X9)R)T(,UY5Z5'9S_ !QOK,_>&2<B
M="#->5>E25^V7:-8VZ5NM5]BL\J>O(O3#+&WZ?2ZYI[K (JT-\L>C(\RYY/9
MS:XH\,U+O@6ATT5YI,-3U20DLPPT_ L8GB;%UNPLY:F)4"[7&5>GI,>WP[+
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MHJJ5$7=8()DW
M
M
M
M
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M#Y
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M?5*TNCW$H@78DWFQ4(AK\\1J,EMZ!5AB0&?_ ,KW5_'U[Y,P#@
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MR;</=C5V=FUYQ%81&MAK@1DRKV;=KV3.G6_\JY[EE@U>2F
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MSC6NE;@K\Y0_1?),:D[C8I\F[SZ<(T:"-)9P
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ML-QGK[8+1>'H[555;3#MRM\>8XRW57\.IMNIY:**JOA+2B+5NYGOAYYD0
M !F*XAW+!MWZH!^F$+$J-&_ NS?./:LXJDU2O'7C/P8<_E2QD+!G!HH "Q3A
M?<I[#F]EOXS.-:Z5N"OSE#]%\DQJ3N-BGR;O/IPC1H(TEG
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M<Q![6L35)VM.]Q.:-#,[EI'F./C2],KPE3JF5V1+.J@<#STBXA*.#M
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MN&",0RHU0 !:3PG/#O/N:1RZ8PP:HTO\'K?SRSU&<2VU'?&#B/R-D]MV,O\
MQ'8L:     (&<2?DGS'TAA/25 -@Z,.%\+Q:=U5PCQJI.)Z]<YV'M1@S5"3Y
M5L   &MK;/R<Z%YFZSZ&LPAYBCA+B'GNZ]>?+D]%?%EH\\B,+=B03MP\(ST
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M.#10 %BG"^Y3V'-[+?QF<:UTK<%?G*'Z+Y)C4G<;%/DW>?3A&C01I+.
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M&5&J  +2>$YX=Y]S2.73&&#5&E_@];^>6>HSB6VH[XP<1^1LGMNQE_XCL6-
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MD@5J   !L3K7P=0'T*BOY$@$+;G\97#QZ7UAPNSPOP9P[S%:.SXY[4=$]T
M   RJ;S^5+=OIJJ_M$8EM@C@G8O$:/3K*AM.?&WCSGUW[A@C$,J-4  6D\)S
MP[S[FD<NF,,&J-+_  >M_/+/49Q+;4=\8.(_(V3VW8R_\1V+&@    "!G$GY
M)\Q](83TE0#8.C#A?"\6G=5<(\:J3B>O7.=A[48,U0D^5;   !K:VS\G.A>9
MNL^AK,(>8HX2XAY[NO7GRY/17Q9://(C"W8D$[</",]     ,Q7$.Y8-N_5
M/TPA8E1HWX%V;YQ[5G%4FJ5XZ\9^##G\J6,A8,X-%  6*<+[E/8<WLM_&9QK
M72MP5^<H?HODF-2=QL4^3=Y].$:-!&DLX       JLXLW@5KGG1)Z)R4;:T0
M?'MRYIJZY%(B:L;@)AGRM;['NI04)#%=0 'W3Z=/KT_J!RF^GA3[3:.(/EYX
M      &1O<7R@[VYY+/Z;/@F+AK@YA_F2U=08*9M)G&1I!\M\5]O3SC8]LP@
M "X/A&?S7=GH]#?S)^&F-,?Z'8O&9OW4<FKJ,OCG'?-EDZU/+Q1H8GV
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MQD+!G!HH "Q3A?<I[#F]EOXS.-:Z5N"OSE#]%\DQJ3N-BGR;O/IPC1H(TEG
M      %5G%F\"M<\Z)/1.2C;6B#X]N7--77(I$35C<!,,^5K?8]U*"A(8KJ
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MX8(Q#*C5  %I/"<\.\^YI'+IC#!JC2_P>M_/+/49Q+;4=\8.(_(V3VW8R_\
M$=BQH     @9Q)^2?,?2&$])4 V#HPX7PO%IW57"/&JDXGKUSG8>U&#-4)/E
M6P   :VML_)SH7F;K/H:S"'F*.$N(>>[KUY\N3T5\66CSR(PMV)!.W#PC/0
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M9A  %P?",_FN[/1Z&_F3\-,:8_T.Q>,S?NHY-749?'..^;+)UJ>7BC0Q/L
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M[YLLG6IY>*-#$^P    "M7BI<FUCYV(QT<F0VAHDX3R.9Y76H)%K5=\5UO\
M+&U=EWPSPB2!6H   &Q.M?!U ?0J*_D2 0MN?QE</'I?6'"[/"_!G#O,5H[/
MCGM1T3W0    #*IO/Y4MV^FJK^T1B6V"."=B\1H].LJ&TY\;>/.?7?N&",0R
MHU0 !:3PG/#O/N:1RZ8PP:HTO\'K?SRSU&<2VU'?&#B/R-D]MV,O_$=BQH
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M=)5%H?'[0D$TC<0<)5(DQY*1I+6KJ]EQZC'+$W-(WM)JP['0O,O3(<$H
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M:D *BHB+W%SR_=EZSY0NZVL]PSD\,D2:[$BS\U0^$V2G8;-@3[ G=_K"R39
M1 K%CZ1Y*QU6QR2*8K(4FB<[)+)&%8VY(Y6P,"I6WDJP5%3ZT_>F^27 X
M    CSNEG5Y5W2TFD.W"H%%VW!F>T,\4AQ;M%FE(AR>7-.WN,S=L9=,("VO;
M7"6TY5)%$33RZ/.4N,;R8VB?6#)SS?VL<IDJ[JY)^_\ HB_85T5E5EHU5(*0
MW&-FW+<W,9=%Y#N.9=QK59#OMNQO^VY5N C%(K\]PS,UP^]7>I-(\QN5(1"I
M6:!H9S&W*$U]BE:8[%S8U$4ISF.5RW4S3N*F6>6YGN;J(O=Y#IS;MON1'M!H
MF#+8B5C96.]RLMSD]AZ-]8%6%?L,OW^E;J9]'>W>K@2RO'S5162.3,JRCZU>
M2]&1@S"+XN^*ANQ4CC/=_=E__.7UG]>YV*7?;-]4NFBM#6VW/--;C:?E<8M8
MZV82Z[5'^E4KU&G2W9-852N<[2N"JTFR(K+#A]9$Z4^ZSN'V7A!YQ$+ 0QC5
MZ7M@Y3++=7?1=S+=SR7+=RWL\E7=+1 /D      "K*\E&X"U]U#-!)_M?OA^
MVB5-,:RED165B_[>#HS>5GM:I@F#38%OG3&^H18#-55&2TM$O9:Q98,YN4TG
M,5[L7T]V8V>.1%W'TF66>N3/)=S*K/DR3),MU.4\C3M)WLA>-HM#R.H)%&HO
ML_W'W1<+_>R]_@"N"V1#%L*W(02J4T!2M,P<;"-FDV2WPPO<[1R:$QY!%M8M
M/F=0Z.7;.(N,B#--W=SS1$^5-[?W-W>R^7?.E2+;#=D]9>(U"6*0,]3%[D-T
M=:RN(RJ1,YTS99E2[9M/V85I9;&K9(A.8?)FANG2JK+1J5P/+D<5E;6A-72!
MAS3=EC[T<"JGP>[E2J+X==4O]47D/=;!:BO^G(O>[+>^E:D923<A:TU@B.M8
M>NB#5G%Y$^&*2'@E JLFQ<$;&]%8I#XS'LSVUVC+<3FW/.KBHR+.)'"Y;F7(
MGV$]P.     #CNX&9VE7M-S^84G4ZF\;79F;'."58ED<>B6LK?UBY&W)BE<A
ME+HS,K:U-6"PQ]><SW$A4>T-:U*U8J'8]"F.'*99[JY)R[_X_&\565_5-VQY
MUJ/<H\;>MQLONR$7X_6'N1^<-5MQ99Y;[?8U 3BGL7BC(O"]PT]@D:A=)'*X
M8S12KWV=1]T2UYK*5R5RG]E.CTZ3 <KENHBIDJ;F_N;O=S1%SW-W).3DW.LJ
M-O-TO.R^PH^I@1[5:MP;O$VXLRL#GZ*GN,'BDCWKQ&W\8^[OB-\41 ^2QVK6
M@I[FI+#('9I,EY;\V1IUDF&C:N<PSW? BI]2_P!3_3=U3TUF-QN#[36W2W6G
M< YD46BK[=]#+F:HO6C*SPN=.;R[-UM1'YV(\\+X[!FI_FG;6$FU3/4-H,TS
M-8D.2D]4Y8QT$7Y4[NXJ?8N2Y9\N:9?N+6 /D      "K+>"HW 6?<373#IM
M?OB?;-V9MC,KG3C2[_MXT<-P\LT<<G$FJY;\Y]]59(8;3,4,0-R^=MK6SN3O
M<2Q47$E+@Q5^V21LL@?5.62KFB5=S//+>WTR1=WDWLM_P>1;:2O8MT8=MAM0
M2,J(L/$2FN\0_<68_P  RKM75<@W%S?=VW,Z)$7,#+,SL7*8RQ)2"N.*($E;
MRFE"YRS*091[)O[8OQ^/QW!FF_G_ /JB9?+DE*]S+>S7[3WUX4+N DFO$D,K
M! M9'B]:EIF+U0]-LI98VZR8Z.PV6LM@LD;?<E9IT'DRIM=E$>CDJ?$S8C9I
M [MK\2KQ2MRA:F'"9;GAW?!N'H=BE73>L9+:;8R5U>=)[6TL$I&+TK3FX:V2
M[:F<9F\1)L)!9[M$%.5M78LA=7+8LHI^,L,1.GG:W*1PZ6/T>BK$TNQ;O+.$
M\&7X_'XWRKX%7=W43+^B%C@Y.     #G5N2B;0FL)[+:VKA=;]@1Z+/#I"ZO
M;9 PQ-9/),E1F9LT9+D\G4I&&/ENB[0E.H>',[5.WILCE6A"HPO!*<"='R\A
M4!$ZGW"/R)@W$SG;Q?3MN@A.XBF;QMPF=+]NT?26E"&&'W/6&%,[:V.&[B+%
M88U#-O\ 'KDEDSA4=LN2Q9QF,F6.#\Z2M[F\V>U;>/M<MY%3+++<UVYO+FN=
M*;^66Y_0ZU+*%NRQ=FW$OZVLW6-VAO-=KDF5;4T]O<,[J&1.KVZ5CM[@;+(W
M5KDKG!&F1S)/4:6:N*5/+EC<Q&S+M8[.I;BB<\"1QGNT_)E]N:_:2LW!UK.;
MJM[;? S6+/3;_"I>KO\ M]_.7M>*.33*I53*JH*J>U&JW)Y6$F68ZI+L<7+1
MKT:$1U),3.J<,C9)BB,'"+DB\N]Z_5^\E\!P      !6'OF4[A+$F;%M_:=N
M=Z3S:5)(9J\7S,:)D="HYE:W;!S<VH[;>5I:MY5&\0.$.S.BP<K7F;(0ZO<H
MC#ZE@$35QXQ?)) @'U3EOYHB]S/7=.XB_N^OY>7OU)WDHULO;HST7)TT-N#>
MY1FZ%GNO1[K)- H'5,8L*A;IG$<E363.<ILCM"*O-3R2LX@PQ>(2*.J]72OY
M(CD_:)+*=(R&:;^]E2J9;N:YHJ9[V7=S7=Y?DSDQ8=27.NO[=Q/:\98\G-L#
M895%3U'(IAHS.D-775%YKO!>\F>41TTQ<O41]J,LROG!_P!7)DS9W9L>U")*
M8XGIG1(E#-,J47N5*JI\BI3ZE.&</:A)S45CRET)J&[ZDK4[;Q25</*7<K:,
M3MVPW>TZY<YEUZ*M7V/V3::F+TU%6&0JTZ:&M[S$:I3/[U\OJ*M8PF/EZU[?
MC\=T*N?=3/-5W$Y<O!_7PELX'R
M                                                        ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g766269g59x67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g59x67.jpg
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M P 8 , /U,O_ *E/_P#/_IGSJO\ 5/\ 9^\AV1^L7[?W&/RYV'4, & # !@
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M*2-EB;+HV];8MLG"0D9 [KT](.J)=";#AG!7CZ_MAC+!3860EZ-:DFC-)O\
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MR39_)*,'-GC6H8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
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M@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
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M # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
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M 8 , & # !@ P \'M&HIW_6U^HZL3 SJ=OI]BK9X6T+RK6NRH3,2Z8=[YMY
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M)9]$-)4[M"->+!VKEFFBLI_&<<#@>FP 8 , & # !@ P 8 , & # !@ P 8
M, & # !@ P Z:QS'V=KT[8.]DK-=XX:4F.\T$T[OFY;O8Q7>][(9CVB7=DJ_
M[#N6/:=JGW0[511[0G7ZP &O?"_Q(L>)*O7&89QE89JTJSQ59D75&OA-EU!P
M\F*)4+\5@UMA:W4C_:*!8W!E$7"O+0B2U=G&ZK,7CY,Z:X@_/TC9W !@!5#X
MN_.<WE[QK%_5CDP<%\%*#DR-_ *?-,_E6Q_SGL_MS&QW1<^<VK[M[7_70&8Q
MI:X*)Y4A_9R1L_L2_*LOFO<=8KA8NR,HLT# !@ P 8 , & # !@ P 8 , &
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MC%,F/*G0\2R*UAR/$8AH3$;JZJ4E!MQTH0I1/2WC-9EK&2B3GDDAO/FOQO\
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MUX(%RC'1NLY9^BV0:V-U;F0IL]M5 6,C/U2$@9]89QO69>:6KTN1H'.6S/\
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M*&/(8<6R\P_;US3S+K:C2MIUIR0E:'&U$:5(6DE(41D9$9#+U/AM!*V*NO\
M7[?5REEI5,DJ?6?L<O6S/J[17ZM4)(P<<SA%A[B@1/4:@W[$B!6[4D1&-4!1
M2 $C_F_ G14$Y)A2X[9J)!+?C/-(-1D9DDE.(2DU&23,BSS,B,\MAC]X-_16
MCRH]9=5-C(2V;RF(-E#EO):2I*%.J:CO.+)M*G$)-9IU24M*3/-1$>9L^0>L
M,1<0/D%W;[HMD_)LUGM8;X14'+57UY@87I(\G>/>9>*?<<X5%,F<*8Q8!Z)S
MR"WWWNRGR;2LCEIBX0UW(S77IPL<[#OR=XAYZ3/<=")1\U():!@ P 8 , &
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M*1_8NH>R\!^4M,A%/_KTWZW)^V6+NJ#Q%2\DUW4V1ZC/D'K!@ P 8 , & #
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M#7<C-=>G"QSL._)WB'GI,]QT(E'S4@EH& # !@ P 8 , & # !@ P 8 , &
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MLR5Z;T^:</9^94/W3L)_.1U?@[%+2;9F#:*BXB1EEV<5"M6\&Q<(PL= QT*
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MV7@/REID(I_]>F_6Y/VRQ=U0>(J7DFNZFR/49\@]8, & # !@ P 8 , & #
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MV7@/REID(I_]>F_6Y/VRQ=U0>(J7DFNZFR/49\@]8, & # !@ P 8 , & #
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M04C^Q=0]EX#\I:9"*?\ UZ;];D_;+%W5!XBI>2:[J;(]1GR#U@P 8 , & #
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M_) BOX7(*1_8NH>R\!^4M,A%/_KTWZW)^V6+NJ#Q%2\DUW4V1ZC/D'K!@ P
M8 08=+C_ &XTW[*6?\WC\D!H9\7W?UR)]BX*_P#LS/'^".1[7KL819T'^W=*
M]K:Y^<,\VW9>+I_U*5]@X(DX;X14'+57UY@7&\A(+M@P JJ\:'G3;M]M'/\
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MW_/-?JY&T61#$>_Y>)/H?=A"2<>8YM1[(*4I7K8QC&-39D"E*4%1$3"(@
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M-..X5P@33:W#+$$HS)"%+,B[FN;3))'D0@G[1/\ WA/^(O\ WR0>[-?WK?\
MOI_S%??:DKT:1_P7/NBX!K"7B2ZUUX4TI'%,6C5(IBF>M@$HA 1X" @*O,!
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M$&LKG;F-]5MTNVNE5LVP:IQ-V#5D?:[K$Q$)=X765@-;H%W&*5>-L][<QT\
MS=F7E"+ S+_$S_=E^P;Z:$^WI=24UOLJOL:O:V#62BSPC%LS8E;5V)FY.,I"
M[Z,CK!:XZ'G)&D-*])V*#C;-/QT'/O)*(82[]HR1<J!U/YAV>YP<FU+LE-G1
M;%L]TO2K&V0UW4K(C3K)=E746Y;DK,/;'$Y6TJT\F!5[B+.#.QIXLJQWB3@%
M42$. OSG^3_<(R-;Z+W9%6/7K]36ERA9 \OIF=JLB5]4H*F</1&'$SM?9'$[
M1J[ ,MA3;ZNT&Y:4L]8U13FD SFE+S%QU>:V*,K"$""<"'8S+Z=\OIV%MWN/
M;]/M&7F?"],2M+T_K:PTJ0DDZWQ6;JO+[8EQM2ESNM+TZTWW?=OU1.,N-BL,
MY;Y.5VZ$7J^FR@*R#J7:T2>L[B3>14U"L&IP9[=GG(B/V9"27 ZC2KCCJ=FO
MNMZ_2JMJ:V;(D+'8GL<K9:S*PZ)M-,GE8G8UWM-K6YJ]T9I;KO!-Y!1'5S15
MRNA6KZZAKRJYCCUA [D.2W_S_(C_ &_,-6+5P[[LMM7XGH!O4-D0D_;-2<93
M![:6VR$*W);GO%SVZWNO!RA%62K7QO.K?=IK*/?4&:+:35B&AX:QIZZ5&<J1
MI5HR#DC+9])?/ELR/V_,,YPFL]PM>/6T[-7KM@#7+\LA'-[ N\KP0:E,<Z<U
M8Q8$0FTK:O;'"33:=;LS6/TZYHS2MQ<C(VG;XV=*4GF,;-!QL_/T_GC$A.!P
M& # !@!I%QFU*SWI+5]6K.IKI=#2<U,EEMGU27A2N=%Q"7>([NVU6LS=]IR#
M_<DL7E%:JNI&S[[KNI;+>=ZJ**= V2')?GY_F^CCX_\ $M:6G#QNJ8I&]HAQ
M4-@5NTO:%&A)2S38R<$7=N_X3:FQK*TV-".JQ>R.!@G%<D(!5RC;RP364K4G
M2M=S,.JPUF%<KH<[-GT[=GFV?]_V^T;0U>F7%/C4L-]8:YL55H+C5%VKUMM,
MB>LM8^[796S:B7I$T1Y%; LDY=6OV8@[5'59C-U*I?=0WCK2V3 3;**BL'7_
M +?G]@W2P BTXDM8;4V'N^VNZ1IO8D-&UVOQ"KO8\':JXD^XA(]U#Q:5VTXQ
MEI#9C!YKO684,]BKT/6E(*&:6KB!E(^_OG5$C:@K<MDAR7'GM_.1[Q_^/I'K
MJ7IS;L0&G+?5:M+UB2J=]XIEZI0+?>I%A2Z-K:\,MIOM/UVXU:KV*;KZ<6$T
MZHJ3)O 0T_8-;51RQIT*E&1T"YBDP9[_ -!?X9?RSS&6>"N@[LUO0-@0&]&S
M;[4.]QW:QL)IOL62V0-JC;$E#R3VS=\)*ITTT"UE[,K/NH^JLH5C%P#(Z+")
MC(:+19134!_G\YF-Q,#@0@KZ0W)8JW;; GPW;8J439FNPF4!H-&[4PKVH[!<
MT%_#Z0W=.W97;\L6W;60FE)]]M+:1IL)BO7&SZYDX@+:;5*^W)$.V]YR/V_3
MEO;Q_P L]F8V7VAP]VR69;YC[ QV[:X6^V#APM7;TF6J-U?3%FI*RKVX'C*=
MN2UEJ\=0N^45 MY^E,VC)@XA5UR0$"NZ,[<I@(\LN/;Q\1<6WC&\&G6UK9:C
MU8SOD#!56\--<TAM<JQ5R(IUJN6I"LQB5A@:\FW?RJ"<'$2Q'<?$IH2DFB1@
MW0*E(/4P*Y5#J?YS'EN) DFKI2\I0NJ)7>,LJUB$H[5,596M2^V+M2Q1!$&,
MY./9B%:I4QH<P2M^CUEY$)VD,+!!%K-P/)%J<T :"Z9T%MZ!O^M2SU5V3UF]
MI1DUMGOIF!J3.D:/?:-V'7+7HV-@:_LRQS]5B6F])LMCHE)A']E80=7E-7R_
MVRF)O5';P(=L_P#M\^TMIYEQ?1O;=_;VE>UUQ746Q\,<1"5ZPOZ7K!\[;A%2
M\Q&7"/=FNN[[!7;]8]GVR<V?'VY*5UYPS/#2FHI)HA?#SUDMEJ8VN/=S3& 8
MN@X\WY_9_CO_ +!*M@<#2'C!J5GO$KIJO5O4MTMY%[!).YK:]5EX0%=(Q$=*
M4Z0<R]:K$U?J@F[VS:^Y2PM O:3&2/K&%1OLZ#M8SPFO]DAR7'^3_P"W_CYR
MUIK_  \;JD:+LR*D*AL"MV@M7T4>:?M]C)PJ>YN(:D;7V#/;&VRP4K%[*+^N
MV6O2U:DU@N18T+)!_9.FS->)]VK*"B Y,^+Y_9LV;WY//Z3W2U[IU*,XD]S;
MD/3(^FM',' :^JJL<$>@YOZD@5E?-C;-G0BG!C/AE9UY6J%"-;,@6:@E]9VF
M6C 2A[YVKX.N>S+_ ,>P;18 17[YU?M&^;WV),5+2VPX.#A6-,0E+=$VBMBO
MQ,UD\KJ>2VCKIO)/]FM7-)H8:MKMJU]3:(YA*_&V/<%@LMZE'M':E6L^Q [%
ME\WLWM_YLM_+YQVT%I#<<?#5.R5ZKW6&EXVD\;\#5Z*[VDYK<;3ZSL&^35EX
M=*<HPB;/+56J2S6 7@86,G("*DG^MX>.C*L1\C%UEBSP.,_9L\Q<6W\YC-7
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MX5/A)]-7CX)?_7S=O@_:1O1:KI5G[HC)X6^AWTV_Z"?^*'A4^$GTU>/@E_\
M7QX/VD;T6JZ59^Z'A;Z'?3;_ *"?^*'A4^$GTU>/@E_]?'@_:1O1:KI5G[H>
M%OH=]-O^@G_BAX5/A)]-7CX)?_7QX/VD;T6JZ59^Z'A;Z'?3;_H)_P"*'A4^
M$GTU>/@E_P#7QX/VD;T6JZ59^Z'A;Z'?3;_H)_XH>%3X2?35X^"7_P!?'@_:
M1O1:KI5G[H>%OH=]-O\ H)_XH>%3X2?35X^"7_U\>#]I&]%JNE6?NAX6^AWT
MV_Z"?^*'A4^$GTU>/@E_]?'@_:1O1:KI5G[H>%OH=]-O^@G_ (H>%3X2?35X
M^"7_ -?'@_:1O1:KI5G[H>%OH=]-O^@G_BAX5/A)]-7CX)?_ %\>#]I&]%JN
ME6?NAX6^AWTV_P"@G_BAX5/A)]-7CX)?_7QX/VD;T6JZ59^Z'A;Z'?3;_H)_
MXH>%3X2?35X^"7_U\>#]I&]%JNE6?NAX6^AWTV_Z"?\ BAX5/A)]-7CX)?\
MU\>#]I&]%JNE6?NAX6^AWTV_Z"?^*'A4^$GTU>/@E_\ 7QX/VD;T6JZ59^Z'
MA;Z'?3;_ *"?^*'A4^$GTU>/@E_]?'@_:1O1:KI5G[H>%OH=]-O^@G_BAX5/
MA)]-7CX)?_7QX/VD;T6JZ59^Z'A;Z'?3;_H)_P"*'A4^$GTU>/@E_P#7QX/V
MD;T6JZ59^Z'A;Z'?3;_H)_XH>%3X2?35X^"7_P!?'@_:1O1:KI5G[H>%OH=]
M-O\ H)_XH>%3X2?35X^"7_U\>#]I&]%JNE6?NAX6^AWTV_Z"?^*'A4^$GTU>
M/@E_]?'@_:1O1:KI5G[H>%OH=]-O^@G_ (H>%3X2?35X^"7_ -?'@_:1O1:K
MI5G[H>%OH=]-O^@G_BAX5/A)]-7CX)?_ %\>#]I&]%JNE6?NAX6^AWTV_P"@
MG_BAX5/A)]-7CX)?_7QX/VD;T6JZ59^Z'A;Z'?3;_H)_XH>%3X2?35X^"7_U
M\>#]I&]%JNE6?NAX6^AWTV_Z"?\ BC<S3>X:7O:AQVQ]?KR#FLRKN39-%91@
MI&/#+Q+U:/> =HJ8YR%*Y04!,PC_ !D #AXAS6.)L-6F$K=^DN$,MSX[;#CJ
M6'DOMDF0RA]K)Q)$1F;:TF9>8]@W?@G&E'I P]%Q/AUR2Y52WI3#*Y<=45\W
M(;ZXSVLRHU&DB=;423S^461^<>RMMFBZ55;-<IPZR<)4J_,V:84;(F<."1<#
M'.960.@W*(&76*T:K"DB40,J<"D 0$W//,KH,BTL(-9$)*I5C,BP8Q+42$'(
MEOHCLDM9[$)-QQ)*4>Q)9GYA[=Q:1*.IM+J>I:8-/73;2:II!N.)B5\9V7)4
MVV61N+)EE9H01D:U9)+?&@/A4^$GTU>/@E_]?-P^#]I&]%JNE6?NB.OA;Z'?
M3;_H)_XH>%3X2?35X^"7_P!?'@_:1O1:KI5G[H>%OH=]-O\ H)_XH>%3X2?3
M5X^"7_U\>#]I&]%JNE6?NAX6^AWTV_Z"?^*'A4^$GTU>/@E_]?'@_:1O1:KI
M5G[H>%OH=]-O^@G_ (H>%3X2?35X^"7_ -?'@_:1O1:KI5G[H>%OH=]-O^@G
M_BAX5/A)]-7CX)?_ %\>#]I&]%JNE6?NAX6^AWTV_P"@G_BAX5/A)]-7CX)?
M_7QX/VD;T6JZ59^Z'A;Z'?3;_H)_XH>%3X2?35X^"7_U\>#]I&]%JNE6?NAX
M6^AWTV_Z"?\ BAX5/A)]-7CX)?\ U\>#]I&]%JNE6?NAX6^AWTV_Z"?^*'A4
M^$GTU>/@E_\ 7QX/VD;T6JZ59^Z'A;Z'?3;_ *"?^*'A4^$GTU>/@E_]?'@_
M:1O1:KI5G[H>%OH=]-O^@G_BAX5/A)]-7CX)?_7QX/VD;T6JZ59^Z'A;Z'?3
M;_H)_P"*'A4^$GTU>/@E_P#7QX/VD;T6JZ59^Z'A;Z'?3;_H)_XH>%3X2?35
MX^"7_P!?'@_:1O1:KI5G[H>%OH=]-O\ H)_XH>%3X2?35X^"7_U\>#]I&]%J
MNE6?NAX6^AWTV_Z"?^*'A4^$GTU>/@E_]?'@_:1O1:KI5G[H>%OH=]-O^@G_
M (H>%3X2?35X^"7_ -?'@_:1O1:KI5G[H>%OH=]-O^@G_BAX5/A)]-7CX)?_
M %\>#]I&]%JNE6?NAX6^AWTV_P"@G_BAX5/A)]-7CX)?_7QX/VD;T6JZ59^Z
M'A;Z'?3;_H)_XH>%3X2?35X^"7_U\>#]I&]%JNE6?NAX6^AWTV_Z"?\ BAX5
M/A)]-7CX)?\ U\>#]I&]%JNE6?NAX6^AWTV_Z"?^*'A4^$GTU>/@E_\ 7QX/
MVD;T6JZ59^Z'A;Z'?3;_ *"?^*'A4^$GTU>/@E_]?'@_:1O1:KI5G[H>%OH=
M]-O^@G_BAX5/A)]-7CX)?_7QX/VD;T6JZ59^Z'A;Z'?3;_H)_P"*-[->WNO[
M.I-9V!55'2U<ML2WFH=5ZV,S=G8N@$43+M3B8Z"@@ ]9,PB)?[\U+<U,RAM9
M]/8);3-KI"XLE+3A.MDZV>2B0X61+3Q*+?$@,-X@KL5455B.H4ZNLN(;4Z$I
M]HV'E,/$9H-QI1F;:MFU)F9D-?=[<:VC.'.X,*/LN0L;2>DJZSM#9.(KKJ6;
M#$OI&6BVYSN45"$(N+N%? 9$0$Q2%3.(\E  ,RPEHMQ9C:M>MJ)B$Y#8FNP'
M%29K<992&F(\A9$A9&9IW.4T9*WC,U%_9&N-(&G3 .C.ZCT&*)%HU82JUBV:
M3"K7)C1PY$F9$;-3J%I(G#>@OD:,LR2259_*&%?"I\)/IJ\?!+_Z^91X/VD;
MT6JZ59^Z,&\+?0[Z;?\ 03_Q0\*GPD^FKQ\$O_KX\'[2-Z+5=*L_=#PM]#OI
MM_T$_P#%#PJ?"3Z:O'P2_P#KX\'[2-Z+5=*L_=#PM]#OIM_T$_\ %#PJ?"3Z
M:O'P2_\ KX\'[2-Z+5=*L_=#PM]#OIM_T$_\4/"I\)/IJ\?!+_Z^/!^TC>BU
M72K/W0\+?0[Z;?\ 03_Q0\*GPD^FKQ\$O_KX\'[2-Z+5=*L_=#PM]#OIM_T$
M_P#%#PJ?"3Z:O'P2_P#KX\'[2-Z+5=*L_=#PM]#OIM_T$_\ %#PJ?"3Z:O'P
M2_\ KX\'[2-Z+5=*L_=#PM]#OIM_T$_\4/"I\)/IJ\?!+_Z^/!^TC>BU72K/
MW0\+?0[Z;?\ 03_Q0\*GPD^FKQ\$O_KX\'[2-Z+5=*L_=#PM]#OIM_T$_P#%
M#PJ?"3Z:O'P2_P#KX\'[2-Z+5=*L_=#PM]#OIM_T$_\ %#PJ?"3Z:O'P2_\
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M+5=*L_=#PM]#OIM_T$_\4/"I\)/IJ\?!+_Z^/!^TC>BU72K/W0\+?0[Z;?\
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M5:F'%L;Z/)O$:*7:2YLJ!A23L,6X=Q5-FPF4L7K;"J>3/@QDS)R>VI50]"7
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MJZKKB=11K1JK46JM1$E2DY&6JI1$1&HLC,B(C/(B'&"JA0  4.      <P
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M*,]1)J,THUCS5JD9Y)UCVGEEF>T]H=LKS >U4Y@)1 >N;F D+U"" \_YE)_
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MR&#<4;*'7$H0XZEO/42XXAMM*UDDE*2VA*C,DI(N+M5>?/M%.?,IN?7-SZQ
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BZ=[[J[=^;5?-$=D5Y/VN<%;U>>)4]AYY6I'-&YZ[4C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g766269g66i18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g66i18.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[23"4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      $5    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    9 $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,0 S
M "  5 !H &4 ( !" &4 <P!T       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $
M 0/      0 !.$))300F       .             #^    X0DE-! T
M  0    >.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             &%@  !U,          0
M                       !              =3   &%@
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   &%@    !29VAT;&]N
M9P  !U,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P  !A8     4F=H=&QO;F<   =3     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
M !J'     0   *    "%   !X   ^6   !IK !@  ?_8_^T #$%D;V)E7T--
M  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+
M"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# S_P  1" "% * # 2(  A$! Q$!_]T !  *_\0!
M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M   !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H # ,!  (1 Q$ /P#6RKK/MV3NL?(NL$%Q_?=YJ==SO]([_./]Z[1S
M6EQEH)GN FVL_=;_ )H4ON^'XL_OZ?+^+R9MN])_I6?I=KO3W$D;X_1[O<WV
M[T 9?UD #&8U#C[9N-\ ZN]3]#O]OM#/SO9_PJ[/8S]QO^:/[DME?[C?\T)I
MG?1:<M]/Q>39F_64,).#CO>!/])V[C!]K1N?M]VWZ3TK,KZQM?61CT6,<QOJ
ML];9M>7NW[+=[W6>G3Z?L]'9^?ZG^ 76>FP\,:?[(_N2].O]QO\ FA#B1[GA
M^+Q=>?UYU[:[\-E;(8ZRP7RT!QVV5UN:=MMM;??_ .K%8MM=_I'?YQ_O76;*
M_P!QO^:/[DMC/W6_YH_N1&2NB1FKI?U>)LN=_I'?YQ_O6C]5;7NZJ]N]SF^@
MXD$DCZ5>U=+M9^ZW[A_<B5 !Q@ :=@ B<E@BMTRS7$CAW\7B_KE;8WKC6^H]
MK?L["T!S@/IV[ML>U9^/<Z1-KX[^X_WKT.V-P!:':=P#_P!4J61E,INKQA47
M66!SFN#9 :.=[@I8\UPP$>"Z%;_^@M&7+\4C+CJ_!XW!RNL&VMM];/3<_P!]
MHM(VM_.#:VOL=9[OYI_^C_GJZG_HE9Q\OZQ[6 XM#W0"][[]@W:[V-8Q]_T?
M\'9O^A^DL_2/]&GJKLBFHUUO9-N22*ZFM!>=HWW;=Q8WV-4,A]CJW,HQ7L>X
M%H?MKEI(TC]*F'-?0_;_ .@KQBKJ/L_]"<*KJ'UF<QCF],I$B7,LR0#K]!I]
MWZ)U?^&_G/\ @_\ @IG-^LP8=^!C.<&S(R0W<=?:UFY^W\WZ=G_GS]#=Z5EU
M-H-;7#.<RPM>ZO98&$:>@Y_J;FV?R;$2SZQ=!I<]E]V/3;62VRM]F.US2W1S
M7M-WM<F>X;Z_:NX!X?R_PG$R,GZQ@,L;3CNBL&S']4AQL+KO;7?O]-M==3<7
M<]W\YOLV*D_+^L/N]2BB3J"V\@ 1]"-UCG>[\]=,SZT?5QV@R:)\ ^@G_HVI
MZ^J=-ZAD,^QY0W8P-MN/7L.]A+6?I!6Y^W;N_/3AEKH?M_\ 05IQ7U'V?^A/
M+'(R#4TWN-=I'O8RQSF@S^:Z?W4/"OL_:F$&VO).32(#G=WMGO\ NKOR^HM#
MFM$$ B&@<_$(E987PR"01, 2)_-4HYK2N#I7S?\ H*S[MK?'UO;_ -"?_]#T
MX\GXJ!>0[;MTB94SR?BH6!SF$-C=VGQ24Q]8FTU[=NT3N=HIAT]BWN)[A <R
MRL&XG?80 YND*=<;6V.F>[7#C\$E-;(QVW=4HKL?;Z;Z+":V6/K <RREK+!Z
M#ZOIMR'^IO\ ]'6H]&O>_I^.'EUCW-W.+B29<2YS-SW/=LIG97O=9^A5:G-Q
M&9F3:_*IJLJVX]+;'M:Z&.=9D/;ZGYOKN]#_ -!47I=]9-^-CVLM]&QSZG,<
MUS37<770US9;^BM==3_UM&CV31IOW66,+-NUH=W<>44D P>?! 92S>=Y]0@R
M!/![\_NH.#1732YGK.R#O+M]IES9]VW\[Z/TT$-U3K^E\D-KFN$CA$K^E\DE
M,;"/5@<D:A"=LM:YI)\F@ZF-=/WD6P1=N&LCA!+&CWV$2PRTDP->)24Y/40S
M_G)]7V'43F!L<'] WS6U:6-<WTQ+I&X@;H ^EW]JYGZT=19TSK'0LZRM]K*G
M9<,9]-V^EC&QNC]Y#J_QAX320,)[7.DES[&-,_R_W4E/2TX^-3=<VIC*F L?
M[&@22';G^WZ3W?O+R/ZP8/3C]9,G)8YNXYV0,MKH.NYQJ>S<?I;_ &6L_P"+
M7IW0NNU=8&3D4U&OTW,8?<U^NW=N86_UEY']8L6\]?ZSEU@%E>=?/C]+\W1%
M#+)S\&C.%YIWOKK-1<P;6V-#MS+-QVN_J6?Z/_BEL_4')ZAU'KCZZ[&5O&+N
MM(D2T6T;]_[W\EBYG$M?M<^P%U]0+L;<WW0UOT6Z;K&_G;/?_A/],NE_Q<9+
M.G]7L?;C;1DT.:US=" ;:6^FRMQ<_8QR"7TN[[>+*C6]K:ZWCU'.&KF=PS^4
MIM#:[6P"W>\1WG7S4+LXL?4P5O+;GAC'M:2!/YSY_-1MUAL8)VPX ^>J2G__
MT?3CR?BHN!+8$Z\QS\E(\GXH&;6Z['=4RYV.Y\18SZ0@_P#?DE+FNQX-8<=A
MX<.52ZEU!W3L5[B\!^TLH!@F?SKMOYS*6[[/_ TL_%LLH;BT9!K=8073I,'4
M.<P-2LZ1CY&-51E?IK:F[/4T#Q'TN=S=NO\ A66>Q)(\7ABYS]\,!+A()^DU
MK/W73^XW:_\ ?5_HV>W ZB'L<XT$D$D;7%A ]26#?M?M9ZO]>BMG^$6Y_P V
M>E^JYLOVCC2OD?\ 65%OU;P&9E;@YQI8#ZM1#9=/;U*V5[6[?I*>66!B8T=F
M>6:!B8T=O]YT;LS)LHO&"TOR,:P5F1WGW.KGVV>W]Y2I/4*L,;ZFNRWMW;08
M]_[KBWVJP]ME?Z2LAS6_0;VU4AZNCR-P</H=A(4#794>KZ+#<UM=I:#8QIEH
M=^=M1J_I?)#;HT#R1*_I?))2UH]\CDC54LIN6^VM];F?9P"VRLB23^8]C]%=
MM^ES&B&:R?SC!G32-4E/&?XQ18QO271M+'7Z@:"65^*XQSW.<7.,N/)T7H>=
M]5/JRPUU9;LES2++6,LR+K6,;6 ;[?TS[/3:UKJV_P"D54_5+ZF-'Z5EV.^
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M4_4+/3]-OID>G V;8VQVV;?;M4M/%?+B22GZCT\?P3MC<->Z^6TDE/\ _]D
M.$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $,
M4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0   1H
M!0    $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R
M 3(  @   !0   "0AVD !     $   "D    T  MQL   "<0 "W&P   )Q!!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C$P.C(Y(#$R.C S
M.C S   #H $  P    '__P  H ( !     $   =3H , !     $   86
M      8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
M     0 "   " 0 $     0   2X" @ $     0              2     $
M  !(     3A"24T#_0      "      !    _^$!,$U- "H    (  <!$@ #
M     0     !&@ %     0   &(!&P %     0   &H!*  #     0 "   !
M,0 "    '@   '(!,@ "    %    )"':0 $     0   *0   #0   #P
M  $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ
M,3 Z,CD@,3(Z,#,Z,#,   .@ 0 #     ?__  "@ @ $     0  !U.@ P $
M     0  !A8         !@$#  ,    !  8   $:  4    !   !'@$;  4
M   !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'S E@# 1$  A$! Q$!_\0 'P
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MRVS<!6[820,ZBB/?*'AMFQFB8+FS$K4VH!K4TP.@_P#IG3C]72L!@6/\4P]
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MTGY(]WAQ+7E>#QK*J!'G_EV2[QL/\IY^07POLF%_H\G^K1](1V9LW^@8,_\
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M_:<C,A_W.64,:^T/GT43 7.;,X+6M:MZB#D%@_W0Q:G96S"!_N?@_P#1I/\
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MJJFN'3]=TY<?'&5?9[8(=MC;+&G\2PXJVO=C-\Z5B]&WMMEWVOM&G^>3\_\
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M3*DHFD@DK 7O#>4FS%OA ^(Z5#V'&HES<29\[")PLG#2L1O)F%>(2E9(*YB
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M+Q6S5X1 EHF2IDI7VB;N$E<OO$S$[C*0N5,W2X+D1"MN;:SV@,F=H'9DV?\
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M8;S-9FT+VIL65M6;B)>,*@K#[-[C'S-DHQ?<34"5]K0-GXPF7-7(*E]W,F?
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M]/:O80OBI@'_ $?$/_\ IG.*3V6VT_\ :R/](D?[0>G*(^Y))*7$D'/B(_\
MB:0#KU0Q>GM?L$$?QJ8&_P UQ#-G_<_",Z^R>W5.V%1R^TX>O_YFO+C$?<QL
MVH(B2 GAXB'^27H<=>:77KC2CMGV> _MN9Q_BN)_V3> BA79#;YH,)+;CB<-
MY?M8C;JG*F4WMRG)TU[\8QT'S)S\.?NU([;]FQ?&3!1O[4Q7#_BHSJ[&=H2[
M827FSXK"W/\ VMGY^<1MU1=8J"824Q-C?A>/7#_Y$.^_/&E/;OLR 'QTQQ_F
M>+U?*3%![$=H_P"AR_\ 2\+\YL1IWES7BU^SI2:'6^K,X>Z]A[N'3RTH_2!V
M6%\=-X'[%C#_ /!]UB@]ANTI_O*5_I>$T/\ QNK1&7>4V8ZQ3=G2$P-[B%V]
MN7]J_P!:8U(_2+V32P5CYS\,#C2*.*_L-#&978'M026P,KA_'<)\YS5]ZQ%W
M626::HCV='2H\1U3*'S/;]W/&A/Z2>R '^^$VO\ F.-XD?WO>K1G5^CWM40?
MXA*>M\;@\^/?1&G.06;ZE]RB94;_ -W#KU5[[Z6Q<C])?8X7VC.__#\>,S?^
M+OU;RC.K]'7:PVV?*_T[!>G??/YO'76SCG0K<24)*#IH':--?>N'U;O#&I'Z
M3^QB;[2G#+_>['WI5AA[>,9E?HU[7D$?J^27K_;^!R=G_;TB,/-F#/183B2@
M)(=[A^>8AX<77T/3&I'Z5.Q"6!VI/I7_ 'MVA>_]&;SNV44*_1EVQ)_WMDD
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M) >_="UKB \K7  ^0#U$W4^GU\AIF6B.^=.C5?*C^_(($!$V_4T1UL(;A;
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MD$UC)/WK555,4BGPB&H<[_5M/6&%$OP#AG\/?&)0G3<*DF1(C! I$RE(0NX
MV*4+%"X@(C8 XB(B/'#8:MT-^=!<<.=(COG0>?UAAJ6"C&T0[D4&1/68I$\@
MU(0I %==L0Q@:'N)0.1\7>:&)<-5@.005!,P(AAGR(K>A_)V+"&%$TI?C^/G
M]6;P7: K3[;\BI(7,PP6?R#<@Q(J4T5- JA$I8WKH$.HNX.9BB+$[HHN$E#"
M((E,H"MEPY?EGRAO6A&E7KH0/'G2IBJ95:Q30CS\C)!TGZTU;N#(^RP!BV<+
M%2<2CD%'R8BRCTS"Z=E1!1P*"9^R244 "X&%21Y>]+-6&[E@1^#MQ^661@I"
M!(5BY0J%&.<5"G(.#2BS%NHDR7!903QZS%)PHLJ1F,<""1 $Y@!9%P!A%8BH
MBP!9V;A^5 ,[-F\(DCC1ZT^G"E_*)<,!#@%_44/]F7\/KQPR ,]:=?IJ!:$%
MJ.0]]8Q.^IA2=GY:&8KECJ<>>SW"CB,%PSFV4A%O14F7#1\!SH%CY,46,45J
M5$IC.2S;DQE"_86BS^OA$[9\N+V]T$3[\AHD U=2?CZRE][>V);H:E@!R?FU
M,KGG4TKWS^'I[XQ9O\NXE\R=LQD9QL#INJW%PSD$V[I#MB"056ZY6P&26(!M
MY-0!N4X (!@W;UM6I'#I35W=K0]\^N1XUN<[^L>D1%P[>..VD4D?6(,@M9)T
MX$H"L5JB4Q))4YM2D=MP*[.(B/9F.HF)C"03#'GEIGR]F).;C0$!O'KH'CC1
MGIM 5)5F8TR[H>I)JGJ28'"*A&T)).XU%XV:G.4TFX(T62*LN^7%18JARB8C
M8S=(!LF(F&!N'B4.^SKG]-TWF1&(9@U%+SU*3^["R!IV1=2*<0LZ53!G+(^M
M**]B#=P!".CDL'JBJQC7[, P01V@+ PQBE,#-N8#% Q3%(42F*( ("!K" @(
M" @-]0$![\289D>[?77@Y:*RI60M2M],OEG"^P(<>#% ? A>/$. :A\QTP,*
MU]/.]-6S(%X-Y68:W!Q8BOMJPOL"'_J*'7] FGP^KZ#A,->-OQS]W@WE::@4
M/OEI6D4_D_$7&S% 0$-/L6U\;"'A8,,!\\OF/8:#?+9/XZY/1J7BH("''_@*
M'^S /F4,&Z+N0.7M^@K 5D:>^1,+^3\/_44/]0OX8&''A1W?WSK80M\\//ZP
M@T_$?U%'@(?H%&W0;;NM\ 3?SU?YZ9%_-[YX>^OOT3\GX@1_440X#?LRV'C?
MEIX<> \<1:O'\6@WC>AX/;ZY5%*'G"A3\2/%DW'P(%[AY:_08EN-HP=V;)S3
MV_" KT%>.GC[O"_D_#_U%#_4+^& I S\CGY^(KXPM\Z#S^L(-/Q _P# 40[P
M(7\/K7AS"EG]Z.^E^)]8-\\/ _6->=IC,*+R:RX=S$<R:FJ69<%AJ;*JW*JD
MD^62.JJ^4((;ADV+9)58"''=.L*1!OO"48G(</4/Y6IGY222:O33W[X-'/;+
M+:SKEK7%/C7SUE+TBX>D9S39*'8-UTFSO\QZZ@JV1(IVC)0Y''9W$%4R'2L!
MCE.4B<=BDH.%62363:-SIK$352.4@6,FH4#D-J7]$2C<+AKXCB3<:EF:M_8]
MVK*BYT#UY:=>=W:/3\GXB_Z@A;77<#KTW #CW\.%P' P=GS\/+IE7A!O'7T\
M+NPUUH8\EX6$;HK.%6C9-%!,ZJJAP(0B9$BF.<YCC8"E* 7,(VL&HC8,)A73
MBWF,\_=( HEAF6JV3^%JO:(''2[%5B@O,TS&P;\R?;.8QS4,(*S0ITE7*(+B
MLHV43.=B0'ADU$4S))[^\6R9C8/(L]P?D.FL2<_)PDT]7LT28L> @ A28& 0
M$0$'T8(& =2B @I8=. ZZ=;Z#&E+\1[]VH86]Q'@>OOZ5\H)NWDS2:,G32,*
M]CGZB";0SIN],ZCCE*9E)E413(0J;LO:%[,.T[)9!9$5#'(:PS^_=JN>4!54
M5H1=J?7I1LWB0A3\3_28H"/^C+^ </X=,/=\V9B,WUO[K"W]/._EX#SUB8TP
MV1:G730(5,O9$^R4+%N!N( &@81!#?C\_?S:"[^77+RCTG_UM+^[EZ6_G5/G
MPPTW_!_>G6!>777QZ7,,0AQZ6'3CKK?3O_$.>):4%C2MZGI6C/PRI6+CH'=J
M4]&](+ /A[[CI;J/#GT'S 9VI1K@7/.^;%VMD;,%N?@UWT%\N%M2X=/AKQ .
M%KVZCW=V$"/O,S:-:UJ9,'MH-!CK],S=V?3G> ;V'SX '3H;CJ-_+CU+@WJ<
MM:.&I5_(4S@S'3/Z6H&^6@%N5NE@L'#\.?PPQ?)^@9F<ZTJX# L>J+Y\W+G*
MGX>!A0'SUMH'#2^M^ZWOM@&C7)J*%Q6KT?.[0$>F9!>K4;W1X._J'E?KP"_P
M_ %Q<4H]7+<+T('E>H.&AZMI<MY_5 'GRZV#CQ'ARTMPU'"=P<QP9[ G+(YM
MF]P(9'CHYM84-7J[9#* =;:>%P\.&M].?GY#NU &+LP%CX\SPM0F 4>O-CSO
M1JY=.H AR ?*W'[^E^%^>![ECF^CGQO07&1@(.9'5[?+5KME"VMP#K]>?/RT
MQ(BE.+<\Q4 ZU?)VA/\ +R]&R8:P?OTZ]>O/3[N&%X6K;XGO7@;U8 <:'X5T
MTTRK\[P@ /#QU$ Z] TUY?&^(AZBA?E0^V;)VXP/7\3T\,V;@T+Q&UM+>7'A
M;#(#\QH&<TTM1_$B"P=\^MO?SM!KW=.MKVXZA]6' _*I-7!9Z-Q;,94,%..N
MCWX'V\)<  .5K7'6VG'7GH \>FO+ 6%#4L+&S4T^K4#,!#8DG.^CUS\QXN(.
M%POTL \N&MQO?SZ8;]7MK<5<W%JG2S P:%M;9FK!@S6RU> 0"VN@!\/ 0L(>
M6!0'0'PIEJ337B80)XE_/F*O &NNO#B(C;3ST\;7ZX0)UZOH-+\R.>KLT+<J
M !Z]*\K6BKG\?KZ^_#I8TL7ID2,_G5W!>T1R\O?OY0EOQT_=QL&G?@HY)<EG
M>H%].%-08?Y5_&U:\(00[^0!RX7Y@.FO#AS'R1KPL&)KJ[=:-T&4-^&9/Y$:
M7-<AU!* CPZ\Q#ITTOW\<,BK,]Z#1VUSS-QG0- "6OPR-.OY0O"P=>?NXCA4
MME7B7 X$"OK2P$+Y>[>?C"7X7OU^ZP[OB'PP]'<$7-,^3Z\+N:L(;79CE^-?
M=VI""-PX@ CQY#:_T%QX#PXX3O:CTNU [ CE3,6K>!F-B1R<.WNF8O:"_+EU
M#D&G  #770.@^[")<,PU>W"C7;*]O ;/R(-36[NU*GAXPMM?Z0\KC;F =+=.
M[4<,O=E/F>?%J9#2X;599:M7*GS>"W+6P=XAJ/A8!#7RP[/<"Y=PS\ 0^G#U
M?',N<C05SKEU'6 0N.HCI[A\/#X![\)JA]ZO"N=F=FIXY0 L[ 5URX$YN!;P
MT@TN//S\=-T-!'3GK;GIA9'URM0;IO7,\ZU$%:96];N;=*<(3GS#G:X=WG?4
M-!'\,-ZW.M6JSL"!F]&_!@VRT=CJ=>M0'?Q-0>-PY=?N[^73 #345#D<F/X'
M0.U&1Y-[\=/.$"VMK\=>\=!N'+AP$-.[##U9W=\F?7\;&AM9G)VM]0WUSI>%
ML'0 UOP .'$?W_QPLB*6<9OD6Z@UNU100J\\L\\OP_&)['_J+3^[I?L!B$7B
M+S!!%A*?J#G^P'[9<$(V/(^D06_S#D/0/X?#CBP$L:-I0LQN'XY6O3)J6^>8
MX^_.T( C?\;=1Z>7P\TY)'JU>+99-7A:\!%/IR'KTL>EL[;(O&RS5R7?1<IG
M15)U*H42C81T P"("4>)3!<+V"R+V+MS?YWX.\2&;-0._KQMF .A)>,1$S-&
M2=LW]-S0K1CYQ'%?G/$)HS"#8"BC*M"KRB:W8.R& ?SB8&!4BI> 7P.0&:MB
M"1Q(^];TZL89 =P;V%>&E?G#=*3KH7CL9" EF,-3\>2=.Y7-''3EY AU08Q;
M0&SUP!EVZB8.!(L)"^L&9"%A^V")H[EAX4RMDY/NH!H02:?ZQJ?BY_1HPQ3F
M9M32;/V\=--@YFC Z48.VB)W,60ETV\2L;?/NJ,"E,DX #B O!<J!;M!*6!6
M03TJ:EZ?6U'UBS=!'+($BF9T]>,9QHVI1J..63>]D9\W$Q'1"E I%45?T%"I
M!<-TUQ3.4+@(A<=#@(S2O>!</U9G;UU B"DD9MH.0.9.5;VYAH8FOY1*3JK.
M"00;H4Y(I13R4F$E564W N&)GB;2/.T7(J$K"/#HLU5UR"EV?K!=P5%0!$%Z
M5J17BX;)LX'I5[;U.#<32S"PSAZJES5;*"D7#.1I>,> D4&SZ13?F;(JF4(4
M?S?K"9E5C)B<K9$A@%1P*06-^B+-GHW!ZMH]<\OE"!!8589,+9O2G.I\8>J<
MBPCV0*'2,DY=E(=1-4=Y1JW(7=:,MZP#_)T=5_\ C'JKIP( *Q@P]WA=^) \
MJZTSUI"47-[6:E=<\[<'K$A[A"][^%@^@\\2)# ',4Y9#,Z58UM2(\=&\_9O
MYQ JXJ,T(Q*1J<"OW0B1N(6$4K?SJPE&X'[,!W" );=H<#:F2TJ4IKW\#U]?
MG%J 2XN.-J9OE:VN@,:\U)4DPLV=JR#TR\6\8.8FHD%2I DX@W9%"+F6$"!]
MAJ"ISG&_YMLLZ$!N:V( DYZ"OGT:UK<XDWU]]7CDAF51"]!5:_@[BO'&L_@W
MA1 Z;Z'<F,9HL14@B10R8 9NL8HB JI&&UC!B=X(E61.5SC-.OH^'537+ 1@
M!,5.Z2 2F1AVBJ8*()J6L5P_6,DR;CQ*985;&!(0P01V/!PJ4"D2.=!%(B:*
M""2ARIH()$*DB@F&]<"))D(F4!UL4+XJ)T)&M]==+9M6D$7<'7+R.FW$&K$O
M7\<2-&16FB/6)46+SM@(6-41=.$EC*+-@,[[0F\FD0I0,%U0Q-"FH[\03UN-
M*.-1UBI+M[_&)Z_J=_'GC5%*<?\ LYV\3;2$D9]%%;PS51-022#E,CM9=9$5
MP1;G*B0!3[;M3F*1(PXF]+-\O7B+ZQ'='5R:^ENMN+,8D#8Z3\"NTQ!5LHF'
MJIKCN'2'45;?9_G!MNW#0A2B 6-ABIMT/YCP\H#07S!+.]=.CYU-SD?91 "E
M!1$H HF.];7\X4+@=,0O8=X+VX_; HWTP$6U'R.=N6;ZEQ"<NQL?0VOS'TCS
M?RL=%QKJ8D7:+*+9-5'SQZX.";=LT13%95PL<="III@)SFX  "/(<2=A2W(T
M-+D#AE8\+18VS]Z>_*+1*I(!9--9*8CSI*D(HF<KI(2G3.4#D.4=[4#%, AU
M <&^AF<9MUTH=?P:#=5H8N(B9BY^/;2T*^;R<8[!46SYHH"K9?L5E&ZO9J!H
M;LUT54C6X'(8.0X3Z%VM2AKT+O0WSXP%)%VY9^4.0<NGC^\;Z?+OT %=+/0Y
MBUWTK05J(#GKR_ -7UX5 #CW_'3GAD,XHU""<[\W.E-<BQ'MP\JDTBD0N-A#
M3AH-@ >/+7STT&UNIF 12@9Q=CQSR-(>3O7B*FK9TZ5M>E,'9_493N8M#C1$
MZ#U-[4,@5"FGS.*=2RD5/-6KMVV?K)LDU%$&1$4%T'2QS(I"1P#<RH*KI@:)
M+ZN39A1O/@WB]XF'&C:@ZLU\^>6D:543L=M<O*FBJVKRH5JAINFW2<FZAHZC
M)[MGJZ*A08E5 WK &:)NS)+NR=D;>02.4PD3$QRIFN#Z1)WH"'Z'YQU#243.
M0ADS%$ABE,2UK;HZE O@7@ \N@<&XRNQKU8-G;KTI%1!SH/G2I',U:UN?KRT
MT\OQ^O'$\G2S< UN=R;"AO?,K.M??#Y<J1'GPC)/T8DOZJW!)[+#KNF)O"+-
MB(7M_*52=LL!K@#5 Q+%%P4Q8'2N3Y!WSR%1KX"D3LYN;"SGD<SE07+%X\7I
M:06<+&?MX-=R8VZX.Y9-%ECF(D9L *J'2,<QBMSG;_:$;(G.E;<,)<#H!;>%
MZO1K:,;/PX0@%9 ZAE4^A$2!LNW<HE4;*)JHC]DIT_T!W=! +  !8>0<,-)!
MLVCT OPL=+EQ"(4+^H/"OIIE#1,)G:G0FT"[QV(&3?IE 1,XB5!*9P!0#4RS
M0Q2O$0^T)@261(&\N&Z$9D-6H&8H:<NO-@(8.5>%<Z^OO6'@'"(@4P*%$JA"
MJ)B4=X#D.%P.6P"(E&X6'ATZ8-YF&0;BQN_CY4A;I+,*U?+1N#YZUB14ZH0[
MAR!37'L2#:PAIOVOJ 7U]V(F]"XY-[]M$T!K^K_EXU\()^_K25N/JY?#^<5Z
M=]KA?AA@$NWA6O#V82[A[>=;^5CK#$%^7QOII8.>O#7K>_?AC)M269VR\?*Q
M.IA].!>KGU\F@$+7'3E;3F 6L'W=._";C1G'.X!O<5:U2W%@GU?2NM/$Z9B#
M]X6'B//CX ''S&^&,J-<<RQOY-1SQ:#\"XX4]7J[69A"^'QUZ?=P\N'###U(
MU9C?B:EB2+ME8B%S\N7UOUO"".G#W#Q[K_ ;@ <N_!<-F#XO6CNUG+C(@W,,
M7OXW'%O,,3K /< 7MTX?YHZ].E\*V0Z!VH&:HS\ZP#G0\376PS]O!Q^/&X=W
MD-]/?;#R!JW,-D QR+WIKRA5]@'CU&>EN$ :6OH%N'$>0:\>H6M;PP@X(=QO
M!N(RNWND,U=M<J!F?Y'+KJH^X-+B.O"WS#GJ 6P^(HVH<Y%ZC)ZW:]7JOQS]
M>60S@MX\?E\OA?"^'B0;"OL9<2X- X@\+<,_7S:$UOQN'0+<.\;WZ#X:"&"Y
M8O?)F8MFYX%JMRL\N.I?PLVO6QI!H%@#OL&NNG4;_##I4 MSK2GN[%JN+*I<
MMUT\->,*'(.G4-= XA^-L*F9-*=!1@:=:.<JW-=3Q]?I2#3W=?WZ\N/NPQXJ
M&9LVM7H#HW"#YZ?04S^L)K_#W\QM\-<#YN2^0%VR?KI47T@_&_S KYTA?#ER
M#Z^&G' 6N!:FAI2K@ZC.M'&4+V(2W,0#6W"_?QZA:W( Q&]3G3.K>9RTJ<FB
M7+)[M2UGS?(5$'?IK:VO&W=U#[N6"ATR#A_ AJDW>Q:D'"M'>EGXZ'YYP %A
MTMY>/NTT#KU'JP*W8$N&ZTK3G3A2Q#:K^P.M:F[:#1;^?U^&OROA@UI4 #,"
MG"QIQ)H[UB/OWZ>K0@B']+N[@N/3AP'W:#QX(G47/))YM>^M*<7D <N/EPK?
MSM:Z]_D.G3X^'</##NQ&3 T?/0,6HX]!6%[<'W[SA.-]1Y!\;<.0Z<>'/K@#
M$9V O8OSIDWBU##LULS;)@6?.AM?R@Z".FG -=>>MN7*PA?I@M<==#J;=-T@
MGC>%J!].6?J*0:#PUM;CUMH/RUTOUTMA4:E6868DUTK?E0-6':]'?U8^R_+.
M#SX>[F'CQ#F(^_@9"M0X:EF.FK7>@-\X1Y7_  .GH!X0:6[A'J(<=0M<>6GQ
MMTP4 >KN'RI>GA3EE##]6R /"K#GY/"\_/3OT^%A^/3!5ZV=^)W1P'TKI>%E
MK\J^;^^"!8+!?CPOTZ<?=]^&[!M;.UQKY7+"@L(+O2U_KKE7Y/!QUZVM;6P_
M$-+<?'S6GD1?>MJU6OUU,.U-'O2GK5S3E"WO?B'B&EOE;#! <$,S.6?H6'GG
M>AA,S6/(U?U>#G?Z\!^KA?H."QJ]N0R)!#4#ME5\W@R;WS'MBVH@&W,?CYAI
M]<.>&PU=P]VX@@ <S:]=8![TK0N?#QRA+==;@(:>.O.^GC8.6NF(EJWT)#5.
M="Y%6!:GH6^E&(->5,FKR<YTK!QM</OUU^07Y6UTP'B-6];AGK>C.Y!:%9V/
MRT]2W'6)]'_J+3^[I?L!B!BX6'*+S!#BPE/U!S_8#]LN 7$(V/SC%\PZ,T9G
M(C]IX\-ZFQ3!0Q3*.G & @[X (IE1*!W"J@%'<22.8+B6PR-.H9C6AJ<@WXG
M,16!O?D!T&ODT,\33!HN-91QJDJ5\=HW21,]>20+N7!R  '66540.<YSGN([
MYC" ?9$PVN*=LR^KT9OR^8#0[U89T:IN:V:F8KP-H<O8A@#_ '9G!ZCZ\GR[
MQ;Z:^0 %L,C0DL+\*BG#6K:UI$7#_=&37]GYQB:OZGD<GLOZXEFP3-4/8]C(
MST(>0<'?NMYXNDDLW65$H"#&%<+D>B0H62C3]F4ED1$P:.XN[$CSOY>S*BFT
MS%+M]*:TIJ.'C[-',UTY]?-7E6JNR/B2A"+5#*J,SNTG'K92*LS.Q;';J*@)
M#MQ2%'LS"3<W0MB,61TGI&II:4B:7G34O-)(UC%EE'[5)%(/8<FFV3.J9R5=
M=N8C>3^SZOV93G,J3M5")F5.8:R 7J*,.0M7CD,]:L8;M[]^[T<1L!22TO'-
M5)9E3L^X>R+AM%LRD2:E2:H.W1$#RKV[\I_4FJ@@JN*9%%A;H.#(D.<"VD@-
M8^'*M81^)G;P&7#YY1GUG&%8LDVK9=>Z1!LJH8IC*K&'M%%UK%N<ZZHF45-?
M>,8QA ;V'%N[2CTZU;)NE=/*K><AVTS&>8=M=;QS.DMJ.N]HW-.LLG,A%\C&
M<=1"<Z<7V9T?/5U456U+0]0,X:9-2E+4M75!'A$8*46558R[R3DW#LT8NY39
MLT%$%#\R5M-,_:LS92<-B").&,Z9BRA2</WN^A/<HWD_M%;LP*4H*W15("B#
M'*3M1*MIS=GRI$T]UAU35XA0*9)F)F2T_9TE20%**9@7O!3!B!O5*<WP"6WK
M)-P,_P P-E>%*BB@"KV8R-S/2;*N3*&1.W(JSVEW!3N" 3ME2@1),H*%(4=X
M#%+UU!*$DJ/PV<N'UO1WZOE&[O4O\0* 6<DI2D.:!]XOKE2A8VE1::VY%$2N
M"YT[&1FZAQ!-<F2F;QDCB740*H&T9N',&Z(B!3#:UAO8<5A06G>2-Y)LI+$-
MP4 0:T_&+$JE*JF:A0U"DMI=R+]=(A=697;;$T9LHOGAL:-'*1;IB?)K-QMV
MB#@?S>I]H183$,H6Z.ZF &$QP*<0L&(+W!1;H5< D"AH/O!_K2KQ+OI:**FR
MA:BEI&=RY-2:>40J4V=-N.2;+1"^=FQR*<DB9NY0-D[FZ519BL4Q7*9$QSR/
MV@+H@=$_V0#LS',4Y3@6S$MOW5GH,JN/AO6VF=HEWB6??0W-_GE>W@SP[QF4
M>UW23)89#./81;PU.QA# I)9&YG]C"M""*;M9=1;:$:(L6)"D;H$.J?L2%2_
M01.)Q4 4.4_>(NEZW9R!45<-72(B;+42!-EOH%I<#(D$O?ESM"LW.T<JJ#2*
MVE_1WE</-Y#U>,RJS 36=D%,XG0$K;:8[18 )O*;NZ82B3M W=T1">XW]S4.
M2:'R'%LZ\HEO ?OIR=U#G099-D1D885J7VOBO=Y+:>V#A:@@L MU<L\S$E#.
M!.7L3#;:#7.!-T#IG$%?LZ634']'GG';.!(5C<*&)2WVF0""DFC%3[P-_;YO
MUC@<\=@GL1]JDT+L:[_1F%<XOH>D=KABV=MV&TOL,KRLJL+85RY9YFG<&=/U
M-T2-C)[0N]ZR< (U:IE;B8$4RD(&\41&0Q^SU$)1C,,25!"0G$R22M18("4J
M?>)+  N2;:L8[!*4 ,;@U.H) &(DDE9+!(&^74] +DY/'I,92[<L=&/WD[M'
M;'<?$MVZIY)Y(Y9YP,V+9N%B**.7+C/U-%NF43 45%#D!,PE'> ;!C9N$"H7
MR-FY[KG0ZQH"TFRD:"M="+\J9VXQZPM4;3D;&HLGNUQZ/=PJV1 AG!J%S!5.
MJFD0 ]97$-I%H4JBH667 B14RJ*'$AMT2XD 6^XL\:MF,DZ&M>D(E)(.^G+,
M ^^M/5T5K+:243M_C9^CY*50MP.% 9@AO)B;=,8IO\9D0$!'[("&E]+WX5F=
M(!8K2%!Q_*(!=Z @U&8.9U+Q6)DL%N^DO_RTN&X/?F*<(9Y6J=HR2:$9!M;^
MCP! YR&,D-"UZ4CCLA 46YRCM*+@H@98I#*%M<W9E3$#E,8N(]])--]%6#!:
M7+^9?Z1(3)0J)TH_]=+>1OTSM$&$^TT(C?;5V!"C<="T[F&%AN-P H;10;MA
M"U@ +6MH 6Q/<-V7X?#4#5)?VUXMWT?SD_\ B$/$36NTI3"*C FU3L!RC<X@
MY(HTHJM%@(LH:RY/SNTPP AEALNH( ??7466,/:*&,>Z7+&[4J279B]6I1AE
M4EZC*E\\R:RF"=]LTE+/2[WHSY1*F69.T8[2$ZNU5Z/V/$#;O9/:%K@JIM+[
MX CM/J$W=;7W[W = "PBUI"30%3W(<9/>IRM:A@EK"R=YD,U"4G3IZVTA'^8
M&TT5-(8S:S]'(LJ*R8*@_H_,5JF5L.]VITCM]I!X8ZY;%%-,Z9$S_:WE26"\
M#7]U70<?KYQ8-W-:&_Y0O].L>$9F%M0F05/-[5_HX&ZQ3E%).(I/,=\F=(&Z
M)E-]1WM&1YBJ@Y]83(4J9RF0*BJ8Q%%#I)(NQ^!5*[M6:G#04#-RR/AJRDFC
M_>#^''5PS9AXC<?GMGU2L1(YG5[FOL8UTPA6CI1]EO0[B<HJNUZ>9K=N^>4S
M+U#G!6\(M.K-DQ=H0,A%M"2BC9LQ]MLC"DIC/AIDV?*3,FX6;A9A*DB7,*5J
M"060IT@-O@.UTVJ ":</.7-DIF399PZR5/*40HL^ZDD) ("PQW6)JU8VUJJN
M&%24Y3J\"N+F(JJ#BZE;N=PR9'<3+-4WL9^;/J!7""Q%U"&N(?9(:Y@L$YA8
M-9[BO/Z:_(:D@5.AOGI]0. YF,'1%0$BIAU!&=.$7$.DSD&3Q4JQ&I6#QP9)
MB@=^I9N9Z@LD= $.T[8[<J"ARG,<YA@78&O$<1GHSAZ]+Q+\?R]ZQMY$5*TE
MH1%_ZZU:+JME .90Y!3073 4U%1()R;R)5BB;], $F@'T$0N!<7(-C6EJDBI
MK>M6(&45[K$,'SJ]:V>PIXFXM#%"/GC"G'P/GC:4J5 ZB\I(,D/56TB=T8OJ
M\LT:]LOV++U,42(I LJ5MV)D>T4W!543T-*\M<^)&3<<XDQ<?S;>&77.[M$(
M$1,8QA$1,8;B(C<1$>8^(W'Q$<4DV/$W+OS;/1F8-P,2B9TC)&;*.FZQBD9
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M;TXU\*,]M1FPU'XT>FE\M2=&A>_[^GUK[ATPP:.[5\VXU/(G(!X7OQ]T\80
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MWAB)()$WE!&P"/ "D3$+&.JH<0(B4H[ZB@E*34<6.&))<W:O&CW-_D[5$*N
M,B6/X6'%A3G'PX>CE@X^5]++FHUIUW5#2II!?:C=5 V=0BTFW;N_RJ6%BW@6
M0KH%E$E4Q$SLZ:B"1=U,QA  WL=;!SY.&F(G8G#HQ4H!E2ED!)44EC4$,#5L
MZ1S\?)G3Y"Y4B<J0O?!3,0"I0"35+#,^ #FK5^Z:G*$IUI'P3I] 0*D^R12=
MN)1M&MT5CS"S(C5_(D4!,JP.'10,550YC*B0=PQC6OCG3IQ5-F*0!+0I:BE
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M:00XTRDB\&?2F5'A#(^HHL1;IM#E^UZP#PZG\H(</L=EV5BB GWQ 0+BV0K
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MU72>-'B"3EHX;&2'MDG+=8JB*R)R7 Z:J9B"6X&*)1U,N08%NM:G4 'C1V>
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MQB-OGZ'Y^Z0O'P^A ;WM]:X3/<T #C(4O0]0U^$%O?CETX$&#P^NZUPUU_'
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M-[-YIDU/ZPDW6W!>,0]8;]H5-;L\&Z6I2F3L[WSRL>M"(L!2L,"-YOB3<GB
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M@F4DFV;()N2&*5DF\CU 64; HLJ005$"K."B5%14BB8)%4;J":<V4$B44J4
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MM*L:O'[*PZD=TD8'$2T'N</+9*!+E+2H;B&8$G<^\H^Z[:_I"E=O,=L69B,
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ME8CO'O90H4-!IF3-;_.,&\%KB!@*/ 1Q%FL6(RZO;DQOU,1OE<Y95%36A:U
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M=:Q>S"Q 3 S@R93$"PI;Y1*4Y2WT 1Q/<%V+WJ]M:GY1#>JV3M[&>A;3B(Y
M;963M9H9E_E5%LIVJ(VHFB*909,G<DI$KQZ1$O503:I*G09N$1([;[Q2@"RC
MI,PB<MS'#W>_*)WB3;$>4=7,ZW6K:?92U.P[3M(9!O(M7C [J47(BX:.'#5P
MDEVC)(X W164*!!?N$BHB*A!L7+=<O?6 E@\=<T()'L4_64FYW %_/'1]931
M.H(7$4R&7,8I+\ N(\N6'NC,5KR+-]+:W9HKW_ ZBW@1^3%X:*I:/B1[)K3A
MV3:HA?(^PUGJ+A=FV[/604=)HK)KF:C'F=$7$JJ8J*+))[PJ&3NR*MF_E?\
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MH3''EI%0J-+Y]+MZ'6))MQ%,GR\J4\,HA9#&*<IDQ$#@8HDMQWK_ &;=1OP
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M!J:^I%+!^C<#%:E.Y%\LZ!G<GV:-$I<1+ J*HI-4$SBF<+E3*7>*)! Y#"4
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M0[4B^Z5TDF8AE6IED0$H'O@+,0*EZ,,Z5H;'2Q=@*0)+$/1[DTUY#37G6/!
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M>@L=95$J:9FZ;0FZ)DA,8%*FIHW*K:LU.?*$; #PXL./RH08NOREA &_KQ+
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MV!F"A3-_6UGF^DF@;?A=I8G9J\7N2T=_/DJPQ[Z6E?<#?&^H2YB2!.&X4I)
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M3!3L;F$JBI 1#\XHF!I%+^7EZUY&IK"C;U^T6BFB;<^[VKPQC+*)F Q>S1,
M%;E/I?[8=J<-+_F^1;"B"!X FUC1_G0Z00Q@-O+F _CTYC?EY!#ESXU8T;6C
M,*6-!4A9:!/,%;223IBT<+IF2<E>+F1]8,@($(Z3LFIO=H0"D5$; 91,Q@$3
M&'$B' )+%JOPO3Q\A#!;)Z_7ZGJQUC).3L(O%2<PHJ[8.058()E!FX,L8MG&
M]O' R2>Z40L :B-[A:W"20 _FWOP.8@)<O;WPC*4_JZ2_NY?^M4^>H7]V+!8
MC7QX< ]GXUI%2[CZ4]C2WS8K>/OZ"%A\?N[\.X&3-5QJW0_("(ORUMJ+#ETK
MPA1[N/(.%^[4/KCB3ZT(<C4FK<PU-80]\.-(/A<>8AIR[^[W^6$,Q9^0\N=
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MS_D;9_1[0B0,Q^=OKRCL!4C5F=FH9VLFU2MVH.%;B5!9,GZ9@* F$BJ8=B<
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M8Q5FR_KIJE(A)G+!1OK>S?:S$[!"\.N4G%X"8HS.Y*^[7*F$ *F29FZL,I(
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M"S.3R:'3/2C7.F7F!XF)]'_J+3^[I?L!B$7"+S!!#=+G*2-=G.(%*5,!$1X
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M66&U06^?ES@^S8O^>L-_E'SKE$8+LOYE(E G^)-F78N@;\/"":VN@F%4-X0
M; (_:M8+\Q?VG $MWDDG_FR<GT;('/Y0^YQ?^$70?S];9WXF[YQ4&S+F2/\
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MWN"Q5-X=X1M6L9]#P]^ZQ-)I07U\>O*QI2T8W23.L=-%$HG54,5),A>)C*"
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M[8C=N+ >=6U-<QJ',/(WS+?CP>N=W:A@#CX::\1X:AW</&_O8/2G5RU;U=N
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MJSW/2N5:C4!N-G.>1&A>OYO:J(D %$0-OICO[O:'$#@&ADQ QA#4HB)1#@<
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MX &GAP\//$P&(8<W%>F3:FK/<O")>]#R]GUZ0O'G8.7O&X@/@'70-<1TT/\
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M"T4B@C2R"0HM_P"4>MJ-3W[(BE^GV9G]C)FRNWB>S6"[08;%CL1MHSU[7Q&
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MV+F)3,Q>)*%*2E2@-Q"REED[T=/9.PA@)\[:&+QDW:>UL4CNY^-FH3*")*5
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M=B8592@6&\O$*6IAFI1YQGJ0V5Z[JNL]D/,3,;.I&LJUV9Y+,>3J2:)EZQ@
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MAQZ^=_,!);/,]&-!Q%M2> @;7RUYVYWR'(&P<M1[OB/GB.IT;("]:Y-3J]X
MYSH./D.D)KKK?YZ<K ''S\NK<A@[@T(:HU#>-_E#I2C6Y5S>%Y#\OGUX\^/7
MC@XD]#3-B!;B],\[PO8-N5>$'[N?U^_@.'7,5H];FPH.=A=N#0O?OWQ'$'WB
M'UQMTY<^%M0P$UMJ 1JYS#E^#9DPQ[MRL2-?I8PG?J&G#R[^?#CT[QP9O9\L
MWZT>NM:V+B!]6^E7RRO;Y"#7P#H(:AIP"WB-[#I:P6#7"RNUPQ_!WN:^ $/S
M.K\;GP#.*NY<T@"VFG#@-[\[>-NO(+^YN*"E,[YEAR;GI0P%ZUO<,V3\GTS+
M>(/#G?SY#YAPX#X6UMA5;-\A6E[7J.-1Y@%\FZ9CH;W'-Z/!P >[SOIX7L'#
MK8,%*U8^.3'I7FPU$#N?PJ*Y![F_,P:WMKQ -./B.NFO'3AUY&?45TJYX TJ
MX>E0*P49Z6)K;D*5I:M],UU^O#R]WQOAA[N"ST8L7]7I3EF85/?/KX^307UY
M>\>O2W+KUT&UL#D&_J:DV !L+ M>EX&IGX<'O3PTL^:=->OAISUN/#733F.F
M(@Y UJ]*,!YT&8SUAM>EFISRI2_(Y<(GT?\ J+3^[I?L!B,7"PB\P0182GZ@
MY_L!^V7 (1L>1](@O=SM<>'\./CBRAH2;&C<ZZ UO;6L4\>-+Y>=*:0@6UTU
MX_HB'=STUM^. 6X_>L:\O $9/PLR^M/^4_IHY\?%>@\..GCK\^?XX1#:UX!K
M5-RUGIE9X6HO:O*GIE](7#!'$D6+&Q<]7'X!JE0EM.6G#CITUX^.!C:E.9(#
M&A;+@(;US8W^?#E"#<0$.'3F/QM\\(@D:OQ)US-+&O+@688$&^N0\G](6]O/
M3Y_ASTPRPR:A >W-F)O3\(C /S^8VM?[[^'=A4IF^0<.Y#/IU<U>Y<,>GH'=
MODW/C!H'UX!^%O=AT (J.%;4<F[>MK@U*GWS/U?QA?KZ' >>K,"&UZL7-K5N
M87OV(, 8&W AM ]-:UO9J6,$)]<_G]#\,#E[FE &?QI8L]'.EH?O+T]CSA+@
M <.&M@ ?AIK@?@;"WB"[9W)85&<#$F]]3ZW,+R^KV\P^'D& BCO<TIU!L[ :
M/!G[9^A\^I@#OX_0V_?SM@%3EI9QGQ&3"U6I0&#W\O>CPN&2S$5Z/?CS];0H
MI$ ,%A_ ?$.G,._7EA$./(4)5?/-K^O"&"07'X<HJQ+HW2N='!NP+<QRA0GR
ML-\1.8)L.(S87->=@[O!ZT@Z!Q'ZXX--;6R9@#<59['P$/4V'NT&M_X_A;\.
MHWP5<CB]-;@YUHQR'$5@HWY?5_KH&A<2 >XS.6M;Y7\KPHI'O\M1YZ:AP&W?
MIB!.1<M;+(5-/;FMHD+AKU?I6G/Q$ 7"W,.H=.O'Y:C?NU*L,TO6G!CS#9^.
M4!8OD=./X^76E73Z]^&0S!^ <:ZCH,@YKD8CK[\(2X!]? +\^[#<.7+.U&SY
M$'3)N(>'7PT_#UA MQL&NM]-;\PY]+^[$7 #L.HJ0:4#UI>PT@K:MK:-J.%?
M=(4;\K>>'4UT-"11F\>.AO>D XNW"$[K:6"P\0UTM_#C[\)VXT<5I_-9B^I_
M"'Q>KL18TJ_XFW2%^ ]=/K7ZL.'G=KA\GH_4L][-^]"]M[T]N(+!T#C]#XX-
M';*@%.!I?.EFT,'4V]]&'E (Z@'4==.X1ZZ:AW\>_ 2S: AJ,#0UIJ<M,C:#
M7R'4?(^4)SMXCRO?2UO(;:] PN7%@"'&=""7H&KX6$#4?B-6XOX9:GHH];?P
MYV\>6)&C,*CJ0 ,VU%AYZ T]OD\(&M_PM8/=J.FNORQ&]>+5'5GN33.EP]89
MHWU=SXT%:4]8D%/_ ,^XT_WDO[?#RPE94:E]??XYQ-&=<_9ZQ14 V=)#Q_DY
M?^L4P)+59VM\^/R$"@Y M?VWTOTABO\ /2X#I?YZ^%KV&W##<9YNSN['C;/5
MM38I@VFE6(R]]6<:P!I?@'NX< $;<O'AX!@!9[,_D1P>@ Z<:@AJV?UN;Y\K
MTS@"_/NT[[B.@]W,..F"]ZUH'IK=SD_&T!X<:\" *B]<C:N62\0X:VX7Y]+^
M(6'3[\-G+M8=':W0AF+AFR8%6-_++7Z0@Z]]QMR#CXAQ#6P!<;\>Y58OGE^#
M5;@:4!M#Z"SYFW(FAU+!K<:55"I)G4/^B0HF-X!X]<"B*MZT-W-M?DS0@"X\
MO7+V,XT%J_TBF3-%574-'S-.YB$EJ;E7D,^,A"PBK959DL=(7#58:D(99FY
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M;SIVG@#_ .R\? >_$?["O; %SB-AW_IN+Y4 P%:4_,PQ^EWLK_@-L?Z+AO\
MYMH<$O2L;/2P!NTYFAK>V]3\ 4/ 0_*T>0\^>ML5J_0OVO KB-B-6V,Q5?#
M5X$]8D/TM]E_\!M@?]UPX_\ \M_#QAQ2]*-D$K;<IW,RW,30,"'3_P#6D>5_
MEBL_H=[6)O/V)UQ>*+FP/]H]/6)#]+'9<_WOM@#_ *+AN/\ GG3AQAQ2])CD
M4L "6 S'#I>#@_+_ -Z4VO[^6*E?HB[5B\_8S?\ 2\2?7!/X=,XL'Z5>S.4C
M:P?7#2+9VQ>?6EHOT_209)J6W(#,'Q&'A_\ [XQZZ7T#%?\ 8F[4#^[;'>O]
M]XE[F_\ $_/E6)_V4>S1KW.U?]%PXST^TT_/6'!/TA^3*UMV"K[D(",1$?=4
M/#$#^BGM.%.9VR7_ .E8FO'^T\[?*)C])O9QJ2MJ5R^S2+9?WR:^Q#@CM^Y0
MK6W8.N0\8J)X_P#Q>^(VY>43^BWM,D5G;)#EZ8K$4+C_ #.O*ORB0_25V=)I
M*VGDSX>17K]J(T](<";=F5*GZ,)6NO\ G1D67Y3@]WOQ6?T8]I+=]LHWMBL3
MI_T3\#Q,6C](NP#7N=IC_N\@^7VFOSB_3VV,LE;"6&K +\C1T98+::6F>(A\
MPX<!K/Z->T0KWVR\O[YGY?\ =*9T#/6C1,?I#V":"3M*G^;R'KK_ !EN1TRB
M^3VR<N51#<AZLZZQ\=WWU]L!;SN&G#3%9_1QV@3>=LV_])Q%<W_M7Z'UA_V0
M=A?X+:/]1(Z6Q)TKZEZ7B>UWE^8 W8:J> \64< B(#;_ )5Y\],1_L>[> _E
M=FT;^^)]<_Z-]#2L3_A]L,DGNMHW_P #(_\ F/PR>+HFUA0A^$14_P#\)Q^M
MO_6@CKQX\O?$_H_VZ+S=F\!W\X^N&)Z\A#';S8A_N6T"?^8DC_\ R".'YAK@
MNU10YM0BJC#Q9,?ND[_0XC_ ';O^%V=HW?SK?Z-T_&L2_AUL3_!8^_\ @97^
MW_&/<-J&B3!I%5%_\*,K_P#QQPCV"VY_A-G#_O$X:6_B_P N-X?\.-B_X/'_
M -3*SM_=N(YY<*PVG:,_Y)J+_P"%&7WR.$>P>V_\+L^F?VB>?/[.?*SF'_#?
M8W^"Q_\ 4R1_\;Y13_C044%[Q51:?]#9^?\ W1P?P"VW;O=G5_SB=J[?VO[Y
MM"_AQL6O[+:%+CN)7C_+>3<8\3;4M$%U&*J+O_DC+RXR0!SY^_A>7\ =NN#W
MFSM/Y><W_N_& ]N=B_X/:%*_R$K/_MJ</QCQ-M6T*2UXBIO)DP\O^Z8!PO\
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MW'^<Y:U-[PW*>D)R<2$1/!5X(!TB(@;=?_>@#C8/#ARQ8/T5=IW_ );9!/\
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M[]7[5PTQ1:3.5]FGEZ=W-(2%$Z(F;DPG(),>J[([3_5FV\'-4K=D8@_8\0]
M)<\I2E1-6$N<F5--SNI.L<(&A   [@#Z]_3D./KI-SS/SC[VLT.IIXWA@K;-
MC+C*?\D1S$JEG2Q:ZJR,H>E3O6\@LE+53,=I[-BBJL6;M-D=SV2G\KD3-&"0
M%$SAVD&HX,1B9&&[LSY@E]]-3)054WIJW9-+.QJ6%*M&.?C,+@A(.*G)D_:9
MZ,-(W@HB9/6^Y+!2E022Q.\HI2&J8D^7N;>6V8T[7],T553*?G<K:@+2U?,&
MS:10&FZ@,=XE[+<N'K-JT=+D5CWJ2AHUP\125;*)*J$/8HTHQ4C$3)TN5-2M
M6'5N3DA_V:ZT-!_-.99C:T.3CL+BIN*E8><F;,P4T2<2A(5^RFN1N**DI!4"
ME7W"1\*@2(R#5=<4CEW%,YNLYE""B7L_3=+M7BZ#UR56>JZ=CZ9IR.!)BV=+
ME4E)V48QZ2QDRMD%7)%7:[=N518A-G2Y"-^:H(3O(0Y?[TQ:4(% 35:DBV<5
M8B?*D([R<ONT&9*E!1"B-^;,3*EI^$$_'-F)0[,"STK$RH:JJ>KB 95/3#Y1
M_"2#B1:LW;B/DHI59Q$R;V'D$Q8S#./D4NQD8YX@!EFB9'!$@<MC+-5D5U*T
MS$S$A222"5"H*:I)21NJ (8@CB "*5-:9R)LL3)1)2HJ )2M!="BA?PK"5!E
M)(J [ APT2FBZJIRL8YU*TX^._9L9R=IMRLM'R469.9IJ8=0,RT*A+,V+A4C
M659.6R;U%([!^4A',>Y=-%DEU*>\$Q]UV2I2"X(^)"BE5[L00"'!N"08H1-1
M,"E()*4+6A192?CEK5+4EE $@+20X^$L""4EXEDU.0M)0$[5%1/TXR"IB$E*
MCGY Z:RX1T)"L5Y*4D%&[5)=VJFU9-5US)MD%EU 3$B*2J@D(-:UI0DJ40 D
M%1?("I/2_3A%4V8F6A<V861+0I:C5@E*742P)H YI$@IB9AJIIZ"JJGWJ<C3
M]20L74$))$(L@B_AIIDA(Q;XJ;I)!RD1VR<H+E2<HHKD!0"+))J <@4A86E*
MPK>2H!23D0JH(YQ0)@F(2M)WD+2%I(>J5 *26O5)%+C.KQ33M;T94E75M0D+
M.MY"K\MU*:2K:#(W>HN( ]7PYYZG"K+.&J+-T$K$)*O4ACW#LJ1"&3="@N44
M@@)J"M4L*&^C=WAF-X.DG1Q8T%#H8J[U*U3$(6@KE$)FH2H&9+*D!:=]-TA2
M2Z5-NJ(4$J*DJ R&1L74/LZ"!!L(#81 /LC;@80$+ (7U#NP;_OV1\^L#'6G
M!S7P+'F'B/U=4E/4+2\]653OCQ].4U%.IR:?(,9*76:Q;)(RSARG&PS.0E7H
MD3*8Q4(]DZ<K" E114/]G",P .;"[#\3Z=(" &J*D"[W('\W4WYQY5#/TU3%
M-3-85)-QD!2U/0;RI9Z?F7:49%PM/Q[)22?2\HZ>BBG'L&;!%5VZ7="F1!%)
M0RHEW38?>H""M1"$I25*4J@"0"2238 !R2S9PE+$M"IBU)3+0E4Q:U'=2E"1
MO*6I18 ;H)))+ &S10V<LI)DRD6#A-TQDF3>08KD$0!RQ=I$7;N4P.!5 352
M43.&\4!#> #  CNXL!< BH+$<7M%J%!8!&8!\?K?\C#>Y1*41"Y=;@ 7"XZ"
M;@.MP* CW %^'":5Y$V\J'J_._K>E3WO^'Y^[,#DA W?M%LK^A]H+'N B&[K
M]JX7'2^FH7XXMBY*LC0W!?UX:ZO9ZQ&7B1 $Q;E_1WN(7 M[7M?0MP$+CI<+
M#?='%R2XXYQ<E3,<C?WPB*O"%(!Q,)0W1U$1  "^@7$= Y6YC< \;DGT\*MY
MT+Y5U,: 6K>E=*T^EN48%J+.S*J!JIQ1$O5S5E5+:HZ&I%>(/'S*BJ=19EMI
M5W0\8+A&-59BI/-X24417*Y%HT*T.$DNS,HB"D%8F0A9E*FI$P*E(*2[[T[>
M[H6;X]Q39!JM$/M^$ES#AYDX)G"9AY.YNKWN]Q6_]G22$D S1+6079("MXI>
MLM=D#[0!P_2#7D.EPZ]P_?C:@N+OUJWOR:.C<>S;*MZ\G'C$6=IV$P?=P$/F
M-L6HN8K%%TM;QRZ&,Q;,^7*F8N<E+QYD1581#DL[(")+EW6*J0M$S:"%SO3H
M&$IM#)HJ]+8XO:;'?8]DSTI41-Q?\5EL:@3 3-5P_9)4E\BH/'G.V.T_U=L+
M$I2HB=CB,%*8U"9J5=^JE@)"5I?)2T:Q])T2P3C8]HS3*!2H(ID H    E*
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MA[S%['Q$P*QFSU*JDE@K%8,J($O%!(2"#^SQ"4B7-96Y.E>/[8=B\!VKPW>
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MY>5E'S,R;9DBX?ZQL+'2\3,5*1)P^_M7%XT8E$T%9E8G9TZ1+>6$AE2,3,)
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M1D5E)E>G3-$4;53"NVS.IYC)Z-V;)7*=2GJMCYB%D*H<31*R<%D91A#U3 T
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M.Y_&$XQ +$=V5[W=SPF6EXSXGM!L=,[:0ESES,.=H;;F+P\K!G[/MZ3CM].
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M1A,/.Q,S[DB6N:K(D(23NCBH@)'$B,F.Q,K!87$8R<?V>'E+FK:Y"$%6Z/\
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MU32VS/FQ44+1D!)U30+R(),R!<P(.%S<B<HI525!G1"PTO)L74N2L582FO\
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M'CY_(LT(@9-LRDA<1T9FT)Z,04("52DXJ9+6%$;PER\$C$D2]V7>JE,HK*E
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MT#GC>IH]6M%-/>?E\GU>$&_N^.E]-0XCI81Y8*T^[H ]Z#2[\2Q>"GOGGTS
MO"Z].8_7G\L#FCCC4\:4+#AQM1Q!3C[ZP>.@=;AW?PPWL]&-*CA>QMP=C7-S
ME4Z,>/YP@!8+!K<1&_CK?6]QOP\L %&%B2']":'CHSO#>M:,&;R;)AKU@M<-
MT=0M;6VOC;"L"]G<U%>;/F-;\GA<10\'I[K^4:SY\[/--YL0CHBK-,DD4@G;
M.4R%*LDL &W3D/;>*("/$!UN(" @(@.[9FU,?L7&R=H;.GJD8B4JBA5$R6XW
MY,U'W9LJ8P"D*#*8*3NJ2E2<FTMG8';&"FX#:$E$Z1-%4JHJ6L A$Z2O[TN:
MAR4+3\0<@NE1!XBY@97U+E;4"\-.-%00[4X,W_9F!%RF!A +C^B18 "YB7L/
MZ1+A<"_IGLIVQP':G"LG=PVTY"0<9@5*<V ^T88JK,PRC3^?)41+FC^3F3/S
MKVG[)XWLUB05;V(V;-6V%QH3342,0$AI>( !/\R<D%<JRT2VF.-H'X<M+>86
MMX8]/-'R\_AX:ZZ5:D>=ELY'UJ::\WSL*PWYFU!*4OEC7E1PCD&<O"4G-R<:
MZ%)%<&[QFQ56;+"BX(JW5W%" .XLF=,W Q1 ;8\WVCQ4_ [#VKC,,ON\1AL#
MB)TA>ZE>[,1*6I)W5A25,0"R@0<WCT6P<+)QNV-E83$)WY&)QV&DS4;Q3O2Y
MDQ*5IWDD*#@D?"00UXUMI;:2KMO4L K4+E5Q 451M:L\R8QM&,$G<[7=%1%6
M2C\S1<S5,6V^RBX1V0K-5NR(>1_.)@D!RA\WPW:S:?VO#*Q2RK#8#9^T96UI
M*94M*\3M/9\C'39A0KNQN RI.&6!+4B6DS:I"00GZ!B>RVS3A,2,*@)Q&/QV
M F[)FKG3#+P^S-H3L%*E;Z=\[S+G8A!,P+F$2OA)+$[#4YM-SDT6$B6F6AT*
MLG:C]CQS28G9BG::68)T>K6CB1)/3]$QTB9=%D@K'>J!39FRS\".&TBO&JH.
MU.M*[4SL2)$I&RRC&8C$F3+1/GSL-AE2Q@CC531B<1@)4TJ2A*I7=_9=U4P!
M2)JI2DK/'F]EY&'[^:K:>_A)&'[U:I$B3B<2F8<8,$F6</A\?-E;JIBDS O[
M3OB6Z5RTS0I 8<L=IBK@@X%Q.(+U=4514QE"TB63I]#T]!.:LS&JZM(,CM^^
M8T\LYAV:;>#14?N2A+(G!!LA'13=RLJHXY. [28LR,.J>E6+Q.)PNRDRD*7)
MP\A6*Q^,QL@+F+1A]^4D)DIWU?M00E*9<I*B2KJX[L[A!/Q"<.4X3#X?%;47
M,6E$Z?.3A<!A,).*4(7B F:HJFJ$M)$M0WB9DU24@#*<EM+533U1-O6*21?/
MG-(T8F-%QU=TU)0"53U/G(ZRS%1O5D73KY955(0165[==)%!,!8/H6-E$':Q
M;,3M[$R9XW\*DJ5AL*#A)>,P\V0,1/VJK9Y*<1+DJ)((!)4I( ^!<I"PHBJ1
ML'#SL.Z<4I*1B\2V+F8.?+G'#R-E)V@ K#3)TM(!^)/P@DGXT3IDLI$7M2;:
MKZD*><R+W+9DZGJ<E\P8VM*>95=+R!V*.752L*:DY*$<Q- RBKB+?+OB+-IN
MJV-&P+91/V>YE0?KMD5<N*[3+D22I>"09TF;C)>)DHQ,Q>Y]CQ"9"URC+PBU
M*EJ*@1,GIPTH$;A7O$ Z<+V:1.FI2C&J$F?)P<S#3UX>7+"_MDA4]")J5XI
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MZ7=H/AW8]%+#D=0.=/K' FM7G3GG\XB7J;V3=HL6#95V\=*@D@W1()E%#FT
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MXZ<D#%8U20E:['NI(.\96'2H B6"=X@+F$J;=Z!(-TFJ1$4"%33( %*4I0
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MGHUG;B+TZL*'5Q'S&I<M=OGUOT\H4=/+7J(\1&P=1M\1P$'-G&;\SEKEZ6,
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ME2C]]V9LS [&PB,'@I7=RTU6HLJ;.F$,J=/6PWYBFO1*0 B6E,M*4IVD H%
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M#/6@HBWOPKY&EZPG3KSZ7$/X\[?##%ZWXVK5K&[LV5<R##UTRU8'\LG\X
MOR#A]7^'GB(:IRT\]>@.N58"26S-_;>?2%^.OX>^W7KB0J7)<T;QS-0'-JGE
ME"/+W\N7*$$>G'I]_+YV\QPJ!V-"]#FVC'2@K6T'/Q'S_)QR#1C/,'*JELR&
MR;6HF*+LB9@.0%4R'W3A<-XN^ CO6$VO01UM@29B"\M2D*J'0HI)%B'!!9P[
M< <GB^7/7).]+F+EJ/P[R%*0=TL6)012@=.HM&&/\3W*C_D5N'/0I>7=N!PX
M::AW#B7?8G^D333_  BW8_\ 7Z5?)QK=]NQ7]*Q _P"VFYY/O?A"_P")_E4
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M#U5"_P"*-EAI_D[4.>\-^/\ 9X#\N?/"[R?7]M,_\2G''[WG9X7VS$?TF?\
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MU_# 2[NV=.#6S>OF/  -&!/2GS]Y:KQ^^WROI@US<U"> KH=.9IG!;Y/ZM6
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M3EJ,J5TTKGQI$4D!R<SEU+9BOO6( U]''"1F56;.6$7F6_2)7D5LVLJ:J-:
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M. *UI6MB<N8'OD*Z:Y^0J_A0#IXWX#QXZ>/4.NEL(4?2H+-H<KY/;5F%RU?
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M^1/I?.W!^3>D(/U]D1\.'0?AQY#AEW+M5LKMP<$L:<JF#W<#GXCSMF(GT?\
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MX_VA'[\7)L.0_#P>-:*$#V6'OZB\1-^7>/N@43&,.Z4I0$QC#R*!0 1$1'D
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M5\NO7(:/>L :@(7'3O'F'"^G#QOPX8;%C7,N*ESH32_TNX@.K /P^1?\:\8
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MG SP 9ID+/[LX;H)TWP2CQ4.4>CPO:/96*('?_9YBF&YBD]VQ)JTSXI+95F
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MGI"!H'RMTMI\ [_'##!ZU#MGGEF.3V+OF"Y]7US\S"ZW[N7PT^>!S?J]"PN
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MG,5#-71FT:K.7A=?>GA /GY>[CW7OW6OAEG:H;++1^# O3K40#IU\?-FZMG
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M1$J@G.FF(@54Y"F*F82E.)3#; #>K]2YL&=AQ'!WRAD%A0Z>I/'V8]W;YLR
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MPT\N6H^/"_6W3"?(#S<7H/,"Y&8K6 Y%[UZYT'*[:/K&J==9".(&GLQ:ERF
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M/)A&_+2_._[NGNU'#OH":.^M@P<"@SB(;.K9-^.OC00<O=8+C;3AKW]1T'3
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M#PS\((,&@SOHV=>#%O&YI!!@K4DL"UK7895IGQ\"#!ZW+#,OST:[6HT$&'Y
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M4-:5E%T33T&G+L*>9&DI)K(R!G4M/R956<4P:L(IXH*@H.5W+D6[)JW5<.2
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MQ6,T-,Q!9!K2%$M) L4XJN?76<M0*P*_[1$C2-!_*K%;.EDF)DD1,*>%\)L
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M.UKF[2=21C*=IQ[5N;#ELSRWI%]'2"+EB\8Q=-R5!3T8T>(KI)'I21;;MBF
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MQVS;5M,+(9+9/99Q8U''GS8:HGA5H][#T]%(%AJ+F3S\BG42ZJJAW2GK*+M
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M()9TH)2C^:D[H9XV71XCPX!W\!#[_CY8VAQ^+#Z6RSC@*=@,O.QS]:#U;WL
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M3SL#F1%C%NR4K3@M* :+F]B3[IB#=%G3Q83UMNFY5*9"%4(VDB)78DW9$!G
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M#TMUR\=+9NYI7+!@O3F./&HZZ5%*00H!<0#J(![\1-B34B[9;I!H".-7MU,
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MX32!4!,.\L0-: 6M7(/II0G.P\Z"0[6O:UO$B@CY^:=V8-N>0V\Z\C*30B:
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MW:D JXC.R]IB](Q%-7MU&943+D(:PFD/0@A_75N+BS,7BI34;3+DX]]8RB/
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M&U,3MO:NT-KXP@XK:6,GXR?N_=$R?,5,4E+UW4ONI<DL Y)K&6<:&<'+\N1
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M7\ V5>=H,O=VMY]#;6*L-GJVM176C7I:SWM>%"#SUU\>FO0>O0;Z81J3Z \
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M ]UQY=.?3Y=^&  X/ NX;)],Z:M;BK_3/7(>^ @ =1Z!H/0!TTOYA8+!SXZ
M"!K6P>E&:U->6?6&U/;M6K?GES@&^G77NOI>VM[!IT'$=&XVH7OZVU@&>E/5
MGI7/40<;?&P^(=-0O?$M&ZD6 T;,4?-SS$%G\G'$<:%FZ=(- TXATX_?RL.G
M7ATP4L*UIZVSW6/ OQJ7K:GCY5=_"^L+;KUOT\/'^&$UG:I_/H?#H83Z:-KS
MY?G""'"^HZ7&WC[O$.?=AD!@XK4%K4!TS-+^#0P;]6#\O'D;PH< Y>.O#3N_
M## <'(-9@20/="U^-2C<Y\J>_=82X#P'CII\^H<!"_7"-0XY$#C4MGK>G*&S
M7:E:^FAN"1I!<+6$>Z_?;7P]^G"^&]P#<WJ:T!X\14\;L!C=J7RM[X<6: .
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E_9E_#! PT'@(]4FR"(B9%%-,3!81(0"B(!J "(!J%\$-FM'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g766269g73c53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g73c53.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ R@(Z P$1  (1 0,1 ?_$ !\  0 " @(# 0$            )"@<(
M!08#! L" ?_$ $D0   & @$ !0<(" 0$!@,    " P0%!@$'" D3.%?5$1(4
M&7>6MA46%S=V>+6W(315=)27L]$8(C'6-E%ULB0RDY74US,UDO_$ !T! 0 "
M @,! 0             '" 4& 0($ PG_Q !5$0  !@ " PH(" P% @8# 0
M 0(#! 4&$0<2(1,4,34V5G65M-05&$%1572SM51S=I.4L=+3"!87(C,T-V%Q
MD;+P(W*!H<,RT2124Y+!PH+5X2;_V@ , P$  A$#$0 _ +_    (0NF)_7./
M?[MM+^KKT5#_  IOTN!_B\1_U48OK^!/^@TD_&X2_HQ((5!4L7K
M                                               %P3CIV?-$^QO6
M'P3!C]1\#<B<'_);#_NF(/Q6TF?M(T@_+?%?OZ>,R#:1I             J8
M<R^U-O3V@S/_ ')#\T-*W[1\8]-RO_J/V-T(_LDT?_)J!_0H:S"/A*8
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MT[/FB?8WK#X)@Q^H^!N1.#_DMA_W3$'XK:3/VD:0?EOBOW]/&9!M(T@
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M^JC%]?P)_P!!I)^-PE_1B00J"I8O6
M                         +@G'3L^:)]C>L/@F#'ZCX&Y$X/^2V'_ '3$
M'XK:3/VD:0?EOBOW]/&9!M(T@            5,.9?:FWI[09G_N2'YH:5OV
MCXQZ;E?_ %'[&Z$?V2:/_DU _H4-9A'PE,
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MX#QT[WF)4]<S.Y!ZG^D]]=I]THGQ8/%=I^=EEU;%[P'CIWO,2IZYF=R#U/\
M2>^NT^Z43XL'BNT_.RRZMB]X#QT[WF)4]<S.Y"5Z@5-&A42E45L\5D6]+J5<
MJ;>072(@L^1KD.SATGBR*9CIHJNB,RKJ)$.<B9SY(4QL8QG-DZ6M134]33MN
MJ?155D"M0^M)(6\B#%:BI=4A)F25.$T2U)(S))F9$9D68I]B.X7B+$-[B!UA
M$9V]N;2X<C-K-Q$==G.?FK80XHDJ6AI3YMI6I*342249$9Y#MHR8PP
M      BYVYT8=3VSLNZ[)>;8L4,ZN<Z[G5XMK6HUVW8J.\ER9NBY5DDE%B$\
MW]!SID-GR_I+@5VQ/^#U68FQ!;7[V)9\5VVF.S%QFX$=QME3F6:$K4^E2B++
MA-)&?F%M,&_A7W&#L+46%V<'5LYJCKF*]N6[:RF7)"&",B<6TB*M*%*(]J4K
M41>0QCKU/])[Z[3[I1/BPP7BNT_.RRZMB]X&S>.G>\Q*GKF9W(/4_P!)[Z[3
M[I1/BP>*[3\[++JV+W@/'3O>8E3US,[D'J?Z3WUVGW2B?%@\5VGYV675L7O
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M1&GORUN+;A389,J;=CM)2DTS5.&LE&9&V2<LE&9;X"917H
M
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M/YUY8KI.W*JS6ZKC&ZO2V"2/UA>"U*4U+F9BIS.:3.ZNL<[%WA&(P^V>DO\
M(B4!!6<.<BU3/,\R\G\3_O@S\V7E&I&P^F1VQK;0.G=[VGCY4H",LS3EA8ME
M-GECODU#(&XR\FL:.QI76UGJ]'EH^2W!;JF2;V"PEKDG6:FJSI,^H@SS&*O7
M=:#G5+;M/R9%_$N$_P!V>S9GP\/!GN+RIY\77C_R*C-6U_7%5LFOZ=!\2;1N
MJPS=CF8RW$A>9'*R2XGT-/6<0QAGL5)2-)L4+)W2V(SS]NE+POH<)$&92*YW
MR8<$69?^[+_\4ZQYE^_81?Z^;(2@ .H
M                                   _"BJ:6"Y54(G@YR)$RH<I,&44
M-@B:9<FSCSCJ&S@I"8\IC&SC!<9SGR  %53,=1,JA#*)>9UJ93ER=/S\9R3K
M"XSDQ//QC.2>=C'G8QG./+C  /V
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MB\IF9$0Y3*CJ,DHD,*4K824NMFH]F61$2C,S,MF1</E&[X\@^P
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MD>1&>WS< GG =
M           !"WTZ?9*U[]X:J?ESM839H'Y76/R=E^\JD:'I#XFC=),]FEBJ
M&+:"&P       !MCP1[9?&3VST3\<:C4<?<BL4="S_8*&8P]QY4=(1?;)%Z\
M4-%B
M      !@;DIR'I?%O4TSN*_QEFF*S!R$)&NV-09Q;^<47GI-O%,SMVTS,0+
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M%OIT^R5KW[PU4_+G:PFS0/RNL?D[+]Y5(T/2'Q-&Z29[-+%4,6T$-@
M #;'@CVR^,GMGHGXXU&HX^Y%8HZ%G^P4,QA[CRHZ0B^V2+UXH:+$
M                                                      "+SIB>
MPGL/[5ZW^,XH2GH:Y>UWJEGV)X:CCCD[*^.B]H0*<0N:(-  %F'H$?J_Y&?;
M&@_@EA%8M/\ QCAOU*?[>.)7T<?JUI\?&]FZ)_Q7P22
M                                       (6^G3[)6O?O#53\N=K";-
M _*ZQ^3LOWE4C0](?$T;I)GLTL50Q;00V        -L>"/;+XR>V>B?CC4:C
MC[D5BCH6?[!0S&'N/*CI"+[9(O7BAHL0
M                                  (O.F)[">P_M7K?XSBA*>AKE[7>
MJ6?8GAJ...3LKXZ+VA IQ"YH@T  68>@1^K_ )&?;&@_@EA%8M/_ !CAOU*?
M[>.)7T<?JUI\?&]FZ)_Q7P22
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M^CC]6M/CXWLW1/\ BO@DD
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M>"/;+XR>V>B?CC4:CC[D5BCH6?[!0S&'N/*CI"+[9(O7BAHL0
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M7)AN0YJUQ7W8ZU()C44IE:FU*3K/$>J9I,RS(CRX2(QC_P!>_P =^Y_='_\
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M8\$>V7QD]L]$_'&HU''W(K%'0L_V"AF,/<>5'2$7VR1>O%#18@
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MAZ!'ZO\ D9]L:#^"6$5BT_\ &.&_4I_MXXE?1Q^K6GQ\;V;HG_%?!)(
M                                                   A;Z=/LE:]
M^\-5/RYVL)LT#\KK'Y.R_>52-#TA\31NDF>S2Q5#%M!#8        VQX(]LO
MC)[9Z)^.-1J./N16*.A9_L%#,8>X\J.D(OMDB]>*&BQ
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MM/\ QCAOU*?[>.)7T<?JUI\?&]FZ)_Q7P22
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M=V6O$+Z0./&^CX_MI(AU$RC1P !?OXQ=FOCU[#M3? 4 /S\Q1RFQ%T[;^\)
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M8GL)[#^U>M_C.*$IZ&N7M=ZI9]B>&HXXY.ROCHO:$"G$+FB#0 !9AZ!'ZO\
MD9]L:#^"6$5BT_\ &.&_4I_MXXE?1Q^K6GQ\;V;HG_%?!)(            T
M'Z4'L'<A_L_5_P P:B) T6<OL.>L2_=TP:WB_DY9_%L=J8%)<7@$!@
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MF!27%X! 8        ]EE^N-/WE#^J0='/T;G^17])CE/"7\2^L?17'YQ"SX
M     BRZ9'L,W7[:ZY^)FPE;0QR[A>HV79E#3\=<GG_6(OM2%.P7*$'@
M   #+_'OZ_-'^U_6GQI"C#8CY/7W0UIV%\>VMXQ@>NQ?;MCZ (_/@63
M $+?3I]DK7OWAJI^7.UA-F@?E=8_)V7[RJ1H>D/B:-TDSV:6*H8MH(;
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M7VR1>O%#18@    >L]_4W?[LO_2..R/^M/\ F3]9#A7 ?\#^H?.H'Z/"L
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M<       !ZCN/9/L$P\:H.<)9-E/"R95/,R?S?.\WSL9\GG>:7R^3_7R8_Y
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MU^874M5^MLY9Y'9=70=2OF5*:4LP=3RU2/RF?[^ N'//9F9^;@RV\)"3,!U
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MGZ,U0IME7ECV*K))P,K'IEY'51$1GE_9Y;2+]Q'L+/;Y]HWJ <
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MQSIN[*)K5*"Y [5C=R;'-9K=+NKE#UEI4HTD).6!]*UZMM(=HF3&$:I$NV\
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M(4I"$+@I"%Q@I2E+C&"E*7&,8*4N,8QC&,8QC&,8QCR  _0
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LK/1UCID,JAUQ<$5ZE0Q<G2ZTF,%4\S)?/+C!3>7&,8 !Y0         ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g766269g95i46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g766269g95i46.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2CT4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $4< 5H  QLE1QP"   "   < E  %4UI8W)O<V]F="!/9F9I8V4@57-E
M<AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX .$))300E       0W%\@
M)OL>CT)BMG1P^1W!03A"24T$.@      ]0   !     !       +<')I;G1/
M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4    "0!" %< ( !$ %0 4  @ #(       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              -W   '/P
M   !                          $             !S\   -W
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   -W     %)G
M:'1L;VYG   '/P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   #=P    !29VAT;&]N9P  !S\    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     8X0DE-
M! P     'F0    !    H    $T   '@  "08   'D@ &  !_]C_X@Q824-#
M7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3
M+4A0("
M         !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B
M:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0
M !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #
MU    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER
M:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M       2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q
M.38V+3(N,0
M                6%E:(        /-1  $    !%LQ865H@
M         %A96B        !OH@  ./4   .06%E:(        &*9  "WA0
M&-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                          !D
M97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(
M9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$
M '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M $P)5@!0    5Q_G;65A<P         !                         H\
M   "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H
M "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4
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M_G/0?5D9@Z<1F>J+/5?M]?=NVZ1_.^_:M9 PMOV.C8]UC/39ML?])PVB'O\
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MR>LLIN&/AT?;>H&18]X+FL>/IUU,9]/T_P ]S/3K_P"&43D?6XN%OLT!BO\
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M5O?3X:#U'UD?NVL9M_D6*M]6^I69_1L#.L<7Y%3CB7O/+MNC'N/YSG-])_\
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M:-_2_HV^QN35_P"A%2C9_C$%5CJ'8-QL:T0T.&XN/QKW>GM_.])="X5^L[[
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M0__9.$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @
M $, 4P V     0 X0DE-!"(      5)-30 J    "  ( 1(  P    $  0
M 1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X
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M   " 0 $     0   5(" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!5$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    %@   +"':0 $     0   ,@   #T
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,C Z,#$Z,#D@,C,Z,S8Z-3( 36EC<F]S;V9T($]F9FEC92!5<V5R
M  .@ 0 #     ?__  "@ @ $     0  !S^@ P $     0   W<
M!@$#  ,    !  8   $:  4    !   !0@$;  4    !   !2@$H  ,    !
M  (   (!  0    !   !4@("  0    !              /      0   \
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M 0$! 0$! 0$! ?_  !$( 1P"4@,!$0 "$0$#$0'_Q  ?  $  00# 0$!
M        !P4&" D#! H! @O_Q !E$  !! (! @0#!0,&!@P&# \% @,$!@$'
M  @1$A,A,0D40146(E%A<8&1%R,R0J&Q&"0E,]'P"ADF-%)88G*6P=35)U>2
ME.'Q*#5#1$955G2$E[+%-CAS=7:"A8>3E:.FM</$_\0 '@$!   ' 0$!
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M[XPK./7'?'OCO^SOV_+FSV/&/^Q_=66B_1^W]]:Q]*_$IMZ(]+SO.OUFM24
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ME*E*M[JKEP;V8JN"K.^G5LLT',DBM>*@JZ4L5?649+AJV<(Q6V#^1CXU*")
M4U+'Q<SHL?YAP@R0@P5*Q%,=;6S*K10ABP:) D[QL#6VM-H:DJ=-VC+)CKH*
MO6RM4ZT+5HJ<.Z]K;U4ME;+;BI;T9K(HV#.M$LY;-#_DIV&%*NR?ULQRVO\
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M2/*0Y,^$Z+Z@+P.V5N&*J-*EO-9^^]]$C+5/>\'S$$O B2 KPS#*$XR$=W<
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M=50;Z$=$,_YJ)9V_^9:#"?[I6.5UZ<T!/JZ-IB_*RM__ $=3C1],7MI]D/\
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M:(ZTN94JC#-YZ4-3JR+#[?U>5)W5#KE.'#K]59LZUH8F%A[RJY$C%7)!O#)
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M 2+7I,URJ#'2:IIF,A=H$1.T9C,I$R4RP[';5)B^>I5WE-CZ\!I++-WRF!T
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ML[DDGOV'8 "QFZ,Z2N)6GGZ<T669\;Y)-/MF=]HP-S&/)P/,\UV/]KXZ+/\
MBZ:[_P#,9W_;^2?G[6O]U=0_[[F_Y_EY53_D-T=_O8T/W_ZFVOE_VNF?A\=%
MN??ITUWG_P"@SOI_]/Y#\^ZUYZKJ![][N8]^3^G4#T+T:>_2^A'MWTVU/;D?
MVOR/;W4_VOCHM_XNFN__ #&;_P!OY'\^ZU_NKJ'G_LN?S[_IT_D+T;G/\E]"
MSQS^;;7/'(_M?D>1[J^_[7QT6Y]^G37?_F,[_M_'Y]UK&/SKJ&./]ES^7;].
MH_R&Z-SG^2^AY]_YMM<_^3KY_M?'19_Q=-=_^8SO^W\?GW6N/]%=0X((Q=SC
M!!R,8?\ ';M0]#=&D$'IC0\'@_Z&VOG_ -KKM1^@;HZALXCQ= 46.QA;SF&6
M6B;;>%R'ER'U80DEA.%.ONN/.9QC\3BU*SZYSGFJWFB:1J-U->W^F65Y>7+^
M)<75S;Q33S/@#=++(K/(V !EB> !V K++HFD(B1QZ;91QQHL:)';QH%15"J@
M"J,*%  ';%<_^ =T@_\ B&I7_D%?^\^6O\E^G!G&A:2,]_[!MN?G]'4WYGTK
MM^;K/_O>(GYDE<D^>3SGG-??\!#I#_\ $/2__)+?]Y\'I;IL]]"TH_.QM\_?
MLS0Z/I1_Z'6?S]7CS]^W/VY]WN%?/\ _I"_\0U*_\DK_ -Y\'I;IL_\ 0+2?
M/_8-N/K=^T?GY^^GYFTKST^T/Q,",?O()^5<2.@CH]0^Y)3H2EXD.MH:6[G[
M84O+3:G%MM8RHIGP-I6ZXK"$>%.%+4KMWSG/*<_2/2]RJ)<=/Z/,L98HLFGV
MS!2^-Q ,?<[1D]^*VOIOJ+7NC?6_Y)ZQJ737K_@^N_F.\GTOULVZLL!N/4WA
M\8Q*[!#)N(#'FN;_  $>D3_Q$4O^!;]O_P 9_GZ\M_Y#=&_[U]#_ .3;7RP1
M_:_> ?L'NK:?\UKTH?\ PA=9?^$6J_\ K5??\!+I$_\ $33/X%O^\^0_D+T9
M_O7T+_DRU]V/[G[N/EQVJ!]+/I//?T@]8G((YZBU4\$8(YNNQ'<=CYU\_P !
M#I#]?_ 33?7W[9,8QG]V"G(_R'Z.'^UC0^<D_P"AUKY]_P"U^?G4/\UCTG__
M  @]9>?^V/5O/ /^RO/ S[\5]_P$>D3V_D(IG[\%L_WD_7C^0W1O^]?0^.W^
MAMKQ_P#9U$>EGTGCMZ0>LN>__LBU7GYGUKFKYUUTN=/^I;*FX:YU;6ZG9T#Y
M8I!D<F<J8@?/4PJ9%0J5,D(0W(S%8\SPHPK.&\8\6,95C-_IO373^CSM<Z5H
MVG:=.\9B>6SM8K=VC+!BC&-5RNY0<'W5AM;ZWZQZEMH[+J'JG7]<M(IA<16V
MJZM>W\$<ZH\8F2*YFD1) DCH'4!MK,,X)J?.9NM7IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*@GJ8Z?JAU2Z.OVAKV0.":Q?X(R--*5N4S$-#I00Z*LP>="<E1Y
M<1S,4R%'O/Q)<9^+-C(>B/H\MY2L*5\Z9NGVH=+.CZ'H>B$#I:LT*$2CPREE
ME,S#1&4:.$[&6FS'(L>)$:^9+EYSK$2'%8BPXZFHK+?@:PI2E75NK77\K^G=
MJZHP7^P,[,US=:#@[F#]I_8WWOKA$!]J_9OS<#Y_[/\ M#YKY+YZ'\SY7D_-
M,>/S4CSQ2L<=B='#%[K-\ -WA@._>3N\S3Y)-31*<C?RSZ4*:>^7>;2=B+G?
M=YN=$-Y>7(9^U6QK KRQZ<-3F5*ZNR.B]J_*V_AF_-@F-J_?;"6&JFB4V 1;
M^ED#TTI2E*3T1!#[-0#1;<?@@IDMNHK_ (8Z6,%G%*I1WHI+76'L%VZ[0%.G
MMCC;J#+S*CKQ5:"P1%DZ?\Z$$_9H*9<K [@D)@*78Y\V66DH*/98!QHPD; A
MK;4JZI/3+L'-QB[3@[0IC6RXMH!V;#L_5Q:?0W'(>G)^H3$;%7QLR,;8<F19
MN#0HBS;\2Q>6Y(=_[2@%)JLJ53:!T5C->PJJ/&7AR:S5;EHFU1Y,RML(G2F-
M*:\30\"UO,%D-QT6#+DTFRJ.RF* 9FNBH\&:SW?6I5VV#IG*F]I'+<U>QL6D
M6S;>KMVV2LO4QR7</OIJ:LUBM@(%?O>+1&B!JF032:Q.+C'Z@3(N9^] ^,78
MAVEU(Y_5^KFE55/3R2@=-^LM&!+K!CF]68TA+"W(G5WR L@7TG<J9<Q[I2JQ
M;(,EJ&GI5/;@SH46T1I42-/<<CD%NL(\Q2H[O'1;$O%;* I-]4+DDY/4>065
M%UV1$D)([ZV77]E0UK7"LT(BN'5)M:&B9T=@K$F64<WC#!*NO-L.,J4!](9H
M$;H=B$WP+73X"Y3K1<;-7X&X)5LN0XO/JKEBJDRP7G?=V<) K:%IX@$<BWF+
M>(P[,:)8*=%K%D&CR<=^/Q^JE7=TS=+K?3P%*!W+.Q;GG:52-=B[ ]_*,X>S
M4M?M6-FO0S'WVVKL$*SB-]XYLED;1@U$KT6=++/Q@R(T^)!$J5!<'X>S@S1C
MFA86VDYJ[-+V+7!$Z91\2BT MM71!K4EQ*39V;4B6<'.60U*O84:4D/$ T%Y
M5#8.K 0 #@=2KMW?T5V/:T3=(FO[FE46O[M+V6?80$('96(#3![1>L=+0_F'
MJ9L:AD#K]?;U[.-PQ)N9+HAANUR!MII1U80.1:4K]W?HOL%P-V8I'VVJLBYM
MZJ^QZW4:Z/V,'K<:X 2)=XA83J16XH!B&;L(DS)@&)VJ"VIV"AO&+D?@G#2L
MHPI5]:PZ7B&L+W2K/7[<# @J[5Y8&SUJI!=@PL;!<DJL4UG%HD7#;][&D8XJ
MPV298Q!HB$([#AR4+#IO6:V0)B):E1_L7H8C7RZ&K:]>67HEI?V9 M%4,1=C
M1JZ6J6RY]+GS@LEG7.WM:RR+D552<BRV3THS73L0FVF=76GQ420M2N,OT4VT
M_<+W>#>\996QEA-I;UT4)UZS%%T&R.;DJ&Z-8G<ARFRYM3S!UL9H]=!.UZC5
MO74.Z!Q^9%AD+*S94O+\?CW\TK[7^@X+5+9730FVQBX06%UB@D"N$78A%B=<
MM8BI4"'=4B*WMNHT4A./$'D6(LQ<*3;7FSSQF=&(8P:<9B/Q^.?\M*D<%TR'
MQ^@;3I0ELE$U1 \.-T>:D$?(UC742N3*H8JM.'@KA?+7:3U%'GJK\]-KQS8#
MV7!)LG4@DZO5F*"'B5*I5NZ9]F;"ONNKM<]T#G8M*/Z]M,NHUFI76LU62;H>
MPSMS>DC $?;\D"Z[919$(!(S[V(OY 7)K+1NLOA'3,Z$RI5 A=&$VOC=3.5;
M88B#9=.T'IRJ==F%*&LA7"Q;0D+;0J28L-?A6T1*E0K>.VX8=CC8AR)+K)T<
M..-%R[K>8W%*I-AZ&Y-GL6S#YG80R<]LP8?G/Y4$V3'CU/8-DZ>6>GPC:*C5
M8VZV]<18& R))"'%-4@Y9H0TH2JZ+@Y%^S"(Q2LC=D:;G6RJZL%U2PB:N?T]
M<*K<ZE+*UA=@JTB96J\9JBAIFKP3M;D/#)(2P$LP4CSP]\,8:$%8[C_V;B+(
M4K&BT="<NW/[@=,[&%RE[9J]]C_,J!;*0W3+SL/0^=''+-5ZDG=W\FS(UN$^
M0(08,VD3++'#$7:EFXNM,1#+"E24]TMG&-FB-B -BPZ_(B;-)WDG,@5RQ1K2
M1K9ERGK-ZV=)0-A0:L5JMA:J+,<FS;Z3:L0'I*#=89 6.!#+-J5W=E])H79F
MU+!?"-ID#JY:=;%JL9ID,.POS-@RJG<M<!]KQS#LWRT&Q.M-A6RGNCWQ,E!"
M/]W)*YT?%?9C2%*B<KT06VV!K;'NFX@DX[;!L@4X0KVLY8(5 C9Z9-C].$/+
M F;L$]*>=;9OJ+E+6Z8QB1+'R T=$.+-CRQRE7#?.BI5HLY"VAM@_8DZ3;1%
M@BBL0[V&#(&1-* --$@TQ_66TM:V5]R9&KT0O$E1K#"A1HJY%?G""D1_,M"E
M5_\ P32H6I72MZ_V.BBN6_9>NKL\X$#6H3'16*!I+6.FV]>.%*UL>N[#9$2T
M:Y:L,4L&V"&-Q/G&0,V67'),+/*5950Z([!4D40(UM<).J-> ]+8JT19&MI2
M[4=F=*]JF72KS -J?OTE-<C68X_':.Q20>U2V!;4J./)M39\@AQ2N37_ $+1
M:);J!8'+TW:!M4!::C%1!J-L>&Q)LVEP. (*R@!-=VZ$H\-<IMB!/:BW"E7M
MX.19GR(D]YLFJ/$4J2MD=-=BN-[M%U [!"@\&36E;N*%&:/+L30^^Z4./31,
M@F_'N8%HQ430>2[!F@&X0TT.,HAV(9:F7(3(_*E5P?T[R&=11M<$+A%DF)&[
MQ.]#]A@5G[,$R[ SU&#NH8T'#5G)N:L,(G$(DBM#U/FRTZ''?09)2#9+YOYU
M2HCD]&5I+[2);)LVZYUARZ<S.$0)X6SR7!P5KJ7U-U!"@+<<CL<C4!$<&+U7
M!UM$<I%,IJ"D1^/;K/'/'XS^)BE="M=",:NW8%:'KZBPC(TRK$3@$M'V3 B/
M$Z1M.^;/K!0(.JFWZW4DSATVZMLQ\W6IWJ- *A6CP^-'R2GC'%*ECIWZ<K#I
M,DF8=O@&X1A&F=3Z+JT<+0G*;(BU#4$NYN@25AEN6VS).60G'MZT%I$", #M
MOP_-&AH2)+S?%*ROXI3BE.*5H:^.)U?=0G2Y7.GV!H78$K73]],; D68L,%
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MW-^94J3Z[JS6]2G#R]=HU6%G1E>&U.)9& D!=HQ7 \&(-&AY%G>8=/S846#
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MM4DP;*V:8Q2":(JB,00KJ1[3)W#L""2>>W?'6^C9M!B)&JWD5N)XWMY_%D9
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MT.V>79/..1$N 2PBLV>E.UVQA(I+$>H_7C#/!!9RW$;Q2J?!CD<D2@#($8+
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MMRD\K_\ 9 T)GQ^+_P""IIS&._U_]M$=_?T[8Q]?3UYG;;T*K;@#^41;&/\
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M"GCHL9J:_:ZL*K&*9(:/./35D'8-G:3$E#X4P2*@Q"LH,+J7#6#PQ&WCFBN
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M&)N(R3]41?G"2X95[[\PQJN]P74YVD#!JJ\H>;Q&'T,:VV\8RSNEI&BL3@X
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MR.3D8')^'S^ZI/Q]]??$G_A8]/3WQQD>\>ZE?,*3GUPI.<>_IG&> P(!!!!
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M./$;7XW4X\&>^/7';.<8^F._?/K^F,>_OCUY0DFV<>8[GOY'Y#XG^-6[R#)
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M7I4,='=:F#C%M"DXJH#W,^M?2IH?2RRV5OG5=:Y0VMHX$=DP["\GPZQMW]E
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MQ*@6^!5)92TYA&QLD>7D?<T2SU %ZC=Y8=_ >7\KL:LZ'>*UL"'6;L,.=:X
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M?:TXSXG7&D94F/"L/;Q+;E?S<<LYE3!'*7W4$F-BU71EN?[(MML5TO<_568
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M&D<!5WLVTN20/:))W'DDGD]5M++3;.%8K&T@@CCPF5B52V//D9]WZN_>LEF
MD%E.&X\2,VG'IA#,=O&,=OIA*4>G[,?PYE2W8'>20.Y). >V22<#G SCY5<&
M1PV5;';ZN !]@P/P*C/6VC*/JR":B@QC;\^S&IY^P&I\=I9(K/GS),K"'G,H
M_FX,#$A<<=":\+$9KQN9PY+E2Y$C6>FND],Z7AO5L8)99;^\DO)]48K'<LSN
MS"#<A\00H6*JBLJGN>3FL7H^CV6C+-ZFOT]S/-/<3\EW,S/(RLYSD MA0,#
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MOUYAM7DV1.RGD(W'F< G@9[\8QCN<#GOT[HO3_6[Z"+'\]X2*Q&=F\JH.2.
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M&"%CJ[4%+=>&I0MB5#2I58/4'X>&Q11EQT((>A:D9BZ6ME!HQK8E3?>KE!V
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MI;QHVF=KBWCDER88XHV19&8*P1"Q#@A1P+VZ0]9"MP;\!T<R>L5:CMU:PVZ
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M49[]N_Y?M_#GU[\UW6$PCD+@!6/ QC@G/N_K[=Z[)Z/YU-_!&6$8?P8B20H
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M^JEH@YE6<Y[81G/OZ\U2W;PM6M&./;>2,C..)(9D'/D<[?@.3BL-"WAW]O\
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MH6\EUQ.>W96%]_KR4G!)SP!Y?,Y_9C/&*5XS?BR[$C7SK.MHR"[E<76E/IE
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MDEO"DX<4/)Q8DQ+><^%Q3&$*[ISGG6-0M4U"QNK.09CN[>2%N"<;@,.![T8
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MU3J^EZGJ6DB73[BTB];ETEW6[N! L5R8K6W6*1Y)Y9%!10[K#NP,BIGQ??B
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MA"4IRF.QA79B''1W5AI'B[9SG.?Q/.Y[*<7G.<X2G"4)ID]B<8]V>^<_'&<
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M9;XQ((^QI#>NS>GB[LW[6%@4'+^6U%-")V%RJY;Q+3V'TAK(,2MKYEE*O-S
M*LOQBX1Q^3]DS6FYQ&+.AU3TAIG4\!68+%>*H%O=I&JOQN(2>; 9H5W$K&6V
MY9C[.>;CT/\ ILZF]$FJ>+9.=4T*ZD/YSZ>O9YDLIPVQ7NK=U):SO4"+ME@
M6<(L=VDT:1!/29TO_$HT?OUD97K,0B:GVA)RS'73[43CM#34Y?X,XI=H<;B#
M+*AYS_>XY*8-C0U_.S@4)&4J7YQZAZ1UOIV5X[VP,EJH/AW]NSM =I(5BRC9
MG')C)![9XQ7U$]''ICZ$])MDDF@ZLBZOM0W6BZA-;6>HP94%REEO1IE5L@2P
M1O _]K;.0-E@JPDAOA=$E76$J_'V9>PN,Y[?B6PKQ,.]\8QWRIO/;Z=O3FKA
M7Y*J648R<\#]?^3]O5 K-G:K$COA23CWG ^K_?=OC5[1]JV)A/9](R3C&/\
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M_M0I$BCOM@;,QC$VMTC,)JN9;1@R;79IWV8U7]\-S8V;1MHT\5_<2P1^LZH
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MCBCBM)&*R+)/&A=7FA(&Q78K$X$I3QPOA^QM&]+G7'6?2\4VN:-9].-?QA?
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MI K#G'B3DK+(3W(VQJ.  <5C7$B3",V$-&PYI(F3E,P!@P;$E$29*?)5X(T
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M5MWBPRJ(U8-(8BK[BF!?SW2ITRW&F=0FCLQ62(W=ELL=ZW,,'V=6+<DSL$G
M.D<NSX[V35='D9HF-)&CT98B---+Q#;PVI?>6W(58(TE5ULK@3PXVD[AJ$FI
MIXG&&47C2D# S&JKGV2:QKV\@CDN'BE$5^DD/B,#L8+81Z9*L9\B+>-5."?;
M+,1[6*@^[_#OZ*8^U(FWK+DX&N%$/S-X3IKNW;" AC93FY+-O5VT6""@Q"'Q
MJO"V%/M)%*I28PKY94B-(4^NOA'1%,M%:QS,;A8XX+=VN7F&XQV\GKV&W#!
M*W5\FXY(4*,^R2;F&RO[UX%MK*XN6O+N*TM([:&21[N^6.S1;.V1%/BW!6&S
ME,,7B3NY1A'[8W016/AN?"^D!*].KCH(\,&W.[;$18(>[IA5TC\H%UT.V9&F
ME0]A^SYP%T71]>/WV4ORBKLJ'%L5E/+-'2LLI-'>VJF.5+RW<)"TD31NK1[+
M-X[B?#*[J8X&\"0KR$<L!M#FKZ_Z;ZEL9;FUU'0-9LYXYK.WNH;K3;ZTEMYM
M1BN([&VFM[FTBEBGU)8KCU**8127(ADDM_&V;!N/%':\:EDQ(PR+(SPOR:#
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MT'^C?TCRR7/4&@PPZK.&5M;T@)INIDD$!Y3;+';71!8D+<0NA))8=JU*;/\
M@A=3]84^K75RU3MT5GS?$B;+-ZPL3C:\*QAA@*0CW$$YG*<Y0MU^Z0O?MAKP
M9RM/1]-],HMFAEO]**7,+Q2P7%LX+1RQNK%DC82*=R[E8.6&W(&"<UY?U_\
M(ED@N3<]'=<)&T<ADMK7J/3FMQ$5):/.HV<K)(VX*#BR& =V&['5MU#=!'55
MTTA7;IM33IVM411.,-3:4&*G91$29,\>(T:?)J5A//CFY2T>1#FF(PR._)<9
MA(4N:XAMST5T9Z4NF>MI7L["9[75(8Q)+IUPH625&&3+:.<),J<M)&I:6,<N
M-O(Z-;=(]<]/:1!_+"'39KF,F(ZAHT\LU@\4.T*[":*&59Y 23&$6+<,(WM
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MBE.*5"G4CJN1O+0.X].16Z6^_L_7-LHR(^Q@!FT4.4FR!Y0MR); 5=L=0L!
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MM['XT/(4I*TYQG&>WICT_I]S975E;3:>T363Q*;<PJHC6-1A4"  1^&!M,>
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MF]D98\GC-4[&V$6TQH 8R"H! 4\Y&1CL3DXSGDD]SBE:^^%Q#'ZTW52+MO\
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M_5E_A:N(NN1XR(&Q9-1+,TF:N3,2J'&1&LJQC_S$M*HK/@\R0A;2%ISL,$
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M5)H4R1CW>2^[XJ?>:XX].!*SZQL^_P#PD_EWQ_4^G(F"+(]D>[R]Q/NH(D+
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C.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
